FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Anderson, KC AF Anderson, K. C. TI Novel strategies for treating myeloma SO CLINICAL & EXPERIMENTAL METASTASIS LA English DT Meeting Abstract C1 [Anderson, K. C.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0262-0898 J9 CLIN EXP METASTAS JI Clin. Exp. Metastasis PY 2008 VL 25 SU S BP 17 EP 18 PG 2 WC Oncology SC Oncology GA 338GK UT WOS:000258494200017 ER PT J AU Smith, MR AF Smith, M. R. TI New agents for treatment and prevention of bone metastases from prostate cancer SO CLINICAL & EXPERIMENTAL METASTASIS LA English DT Meeting Abstract C1 [Smith, M. R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0262-0898 J9 CLIN EXP METASTAS JI Clin. Exp. Metastasis PY 2008 VL 25 SU S BP 18 EP 18 PG 1 WC Oncology SC Oncology GA 338GK UT WOS:000258494200018 ER PT J AU Liu, JC Jones, M Schoonmaker, J Mulay, S Wixted, JJ Bouxsein, M Scadden, DT Stein, GS Mukherjee, S Lian, JB AF Liu, J. C. Jones, M. Schoonmaker, J. Mulay, S. Wixted, J. J. Bouxsein, M. Scadden, D. T. Stein, G. S. Mukherjee, S. Lian, J. B. TI The proteasome inhibitor bortezomib reduces mammary fat pad tumor growth and prevents metastatic breast cancer osteolysis in mice SO CLINICAL & EXPERIMENTAL METASTASIS LA English DT Meeting Abstract C1 [Jones, M.; Wixted, J. J.] Univ Massachusetts, Sch Med, Dept Orthoped & Phys Rehabil, Worcester, MA USA. [Schoonmaker, J.; Mulay, S.; Bouxsein, M.; Scadden, D. T.; Mukherjee, S.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Schoonmaker, J.; Mulay, S.; Bouxsein, M.; Scadden, D. T.; Mukherjee, S.] Harvard Univ, Sch Med, Boston, MA USA. [Liu, J. C.; Stein, G. S.; Lian, J. B.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0262-0898 J9 CLIN EXP METASTAS JI Clin. Exp. Metastasis PY 2008 VL 25 SU S BP 42 EP 43 PG 2 WC Oncology SC Oncology GA 338GK UT WOS:000258494200070 ER PT J AU Agyemang, A Tsiftsoglou, S Alimzhanov, M Alicot, E Imanishi-Kari, T Carroll, M AF Agyemang, Amma Tsiftsoglou, Stefanos Alimzhanov, Marat Alicot, Elisabeth Imanishi-Kari, Thereza Carroll, Michael TI Role of complement C4 in the regulation of self-reactive B cells SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Agyemang, Amma; Carroll, Michael] Harvard Univ, Sch Med, Boston, MA USA. [Tsiftsoglou, Stefanos; Alimzhanov, Marat; Alicot, Elisabeth] Immune Dis Inst, Boston, MA USA. [Imanishi-Kari, Thereza] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Imanishi-Kari, Thereza] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S27 EP S28 DI 10.1016/j.clim.2008.03.462 PG 2 WC Immunology SC Immunology GA 296HD UT WOS:000255533200074 ER PT J AU Alessandrini, A de Haseth, S Fray, M Williams, W Cosimi, AB Benichou, G AF Alessandrini, Alessandro de Haseth, Stephanie Fray, Michael Williams, Winfred Cosimi, A. Benedict Benichou, Gilles TI GM-CSF induced maturation of dendritic cells is associated with GSK-3beta inhibition SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Alessandrini, Alessandro; de Haseth, Stephanie; Fray, Michael; Williams, Winfred; Cosimi, A. Benedict; Benichou, Gilles] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S76 EP S76 DI 10.1016/j.clim.2008.03.212 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200218 ER PT J AU Andersson, A Buttan, A Batra, R Zhu, L Dubinett, S Sharmax, S AF Andersson, Asa Buttan, Anshu Batra, Raj Zhu, Li Dubinett, Steven Sharmax, Sherven TI IL-7/IL-7R alpha-Fc immune therapy for non small cell lung cancer SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Andersson, Asa; Buttan, Anshu; Zhu, Li; Dubinett, Steven; Sharmax, Sherven] Univ Calif Los Angeles, Los Angeles, CA USA. [Batra, Raj] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S36 EP S36 DI 10.1016/j.clim.2008.03.095 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200099 ER PT J AU Astier, A Beriou, G Eisenhoure, T Hafler, D Hacohen, N AF Astier, Anne Beriou, Gaelle Eisenhoure, Thomas Hafler, David Hacohen, Nir TI FIt3, a new regulator of IL-10 production by human T cells, identified using an RNAi library SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Astier, Anne; Beriou, Gaelle; Hafler, David] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. [Eisenhoure, Thomas; Hacohen, Nir] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S29 EP S29 DI 10.1016/j.clim.2008.03.074 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200078 ER PT J AU Bradshaw, E Kent, S Greer, A Elyaman, W Raddassi, K Love, JC Orban, T Hafler, D AF Bradshaw, Elizabeth Kent, Sally Greer, Allison Elyaman, Wassim Raddassi, Khadir Love, J. Christopher Orban, Tihamer Hafler, David TI Ex vivo activated state of type 1 diabetic monocytes SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Bradshaw, Elizabeth; Kent, Sally; Greer, Allison; Elyaman, Wassim; Raddassi, Khadir; Hafler, David] Brigham & Womens Hosp, Boston, MA 02115 USA. [Love, J. Christopher] MIT, Cambridge, MA 02139 USA. [Orban, Tihamer] Joslin Diabet Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S106 EP S106 DI 10.1016/j.clim.2008.03.298 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200303 ER PT J AU Chiu, I Chen, A Zheng, Y Kosaras, B Tsiftsoglou, S Vartanian, T Brown, R Carroll, M AF Chiu, Isaac Chen, Adam Zheng, Yi Kosaras, Belo Tsiftsoglou, Stefanos Vartanian, Timothy Brown, Robert Carroll, Michael TI T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Chiu, Isaac; Zheng, Yi; Tsiftsoglou, Stefanos; Carroll, Michael] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA. [Kosaras, Belo; Vartanian, Timothy] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA. [Chen, Adam; Brown, Robert] Massachusetts Gen Hosp, Day Neuromuscular Res Ctr, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S78 EP S79 DI 10.1016/j.clim.2008.03.220 PG 2 WC Immunology SC Immunology GA 296HD UT WOS:000255533200226 ER PT J AU Cobb, B Kaufman, K Wang, Y Kelly, J Jonsson, R Bolstad, AI Brun, J Rischmueller, M Lester, S Witte, T Mariette, X Kimberly, R Edberg, J Bae, SC Jacob, C Alarcon-Riquelme, M Vyse, T Gilkeson, G Kamen, D Moser, K Gaffney, P Merrill, J James, J Harley, J AF Cobb, Beth Kaufman, Ken Wang, Yukun Kelly, Jennifer Jonsson, Roland Bolstad, Anne Isine Brun, Johan Rischmueller, Maureen Lester, Sue Witte, Torsten Mariette, Xavier Kimberly, Robert Edberg, Jeffrey Bae, Sang-Cheol Jacob, Chaim Alarcon-Riquelme, Marta Vyse, Timothy Gilkeson, Gary Kamen, Diane Moser, Kathy Gaffney, Patrick Merrill, Joan James, Judith Harley, John TI Association of Sjogren's syndrome (SS) and systemic lupus erythematosus (SLE) with BLK SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Cobb, Beth; Wang, Yukun; Kelly, Jennifer; Moser, Kathy; Gaffney, Patrick; Merrill, Joan; James, Judith; Harley, John] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Kaufman, Ken] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Jonsson, Roland; Bolstad, Anne Isine; Brun, Johan] Univ Bergen, Bergen, Norway. [Rischmueller, Maureen] Queen Elizabeth Hosp, Woodville, SA 5011, Australia. [Lester, Sue] Hanson Inst, Adelaide, SA, Australia. [Witte, Torsten] Hannover Med Sch, D-3000 Hannover, Germany. [Mariette, Xavier] Univ Paris 11, Le Kremlin Bicetre, France. [Kimberly, Robert; Edberg, Jeffrey] Univ Alabama, Birmingham, AL USA. [Bae, Sang-Cheol] Hanyang Univ, Seoul 133791, South Korea. [Jacob, Chaim] Univ So Calif, Los Angeles, CA USA. [Alarcon-Riquelme, Marta] Uppsala Univ, Uppsala, Sweden. [Vyse, Timothy] Univ London Imperial Coll Sci Technol & Med, London, England. [Gilkeson, Gary; Kamen, Diane] Med Univ S Carolina, Charleston, SC 29425 USA. RI Vyse, Tim/G-3887-2011; Witte, Torsten/B-5783-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S41 EP S41 DI 10.1016/j.clim.2008.03.111 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200115 ER PT J AU Collier, AR Reynosa, E Tjota, M Turley, S AF Collier, Ai-Ris Reynosa, Erika Tjota, Melissa Turley, Shannon TI Antigen presentation by lymph node stroma: Potential for tolerogenic immunotherapy SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Collier, Ai-Ris] Harvard Univ, Sch Med, Boston, MA USA. [Reynosa, Erika; Tjota, Melissa; Turley, Shannon] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S105 EP S105 DI 10.1016/j.clim.2008.03.296 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200301 ER PT J AU De Jager, P Baecher-Allan, C Maier, L Sawcer, S Goris, A Saarela, J Barcellos, L Dubois, B Peltonen, L Palotie, A Weiner, H Booth, D Stewart, G Pericak-Vance, M Haines, J Rioux, J Hauser, S Daly, M Waliszewska, A Oksenberg, J Hafler, D AF De Jager, Philip Baecher-Allan, Clare Maier, Lisa Sawcer, Stephen Goris, An Saarela, Janna Barcellos, Lisa Dubois, Benedicte Peltonen, Leena Palotie, Aarno Weiner, Howard Booth, David Stewart, Graeme Pericak-Vance, Maragaret Haines, Jonathan Rioux, John Hauser, Stephen Daly, Mark Waliszewska, Alicja Oksenberg, Jorge Hafler, David TI The CD58 pathway is implicated in MS susceptibility SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [De Jager, Philip; Baecher-Allan, Clare; Maier, Lisa; Weiner, Howard; Waliszewska, Alicja; Hafler, David] Brigham & Womens Hosp, Boston, MA 02115 USA. [Haines, Jonathan] Vanderbilt Univ, Nashville, TN USA. [Sawcer, Stephen] Univ Cambridge, Cambridge, England. [Goris, An; Dubois, Benedicte] Univ Leuven, Louvain, Belgium. [Saarela, Janna; Peltonen, Leena; Palotie, Aarno] Univ Helsinki, Helsinki, Finland. [Barcellos, Lisa] Univ Calif Berkeley, Berkeley, CA USA. [Booth, David; Stewart, Graeme] Univ Sydney, Sydney, NT, Australia. [Pericak-Vance, Maragaret] Univ Miami, Miami, FL 33152 USA. [Rioux, John] Univ Montreal, Montreal, PQ, Canada. [Hauser, Stephen] UCSF, San Francisco, CA USA. [Daly, Mark] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Rioux, John D./A-9599-2015 OI Rioux, John D./0000-0001-7560-8326 NR 0 TC 0 Z9 0 U1 1 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S40 EP S41 DI 10.1016/j.clim.2008.03.109 PG 2 WC Immunology SC Immunology GA 296HD UT WOS:000255533200113 ER PT J AU Degauque, N Galante, N Mariat, C Kenny, J Gao, WD Zheng, XX Strom, T AF Degauque, Nicolas Galante, Nelson Mariat, Christophe Kenny, James Gao, Wenda Zheng, Xin Xiao Strom, Terry TI Following interaction with TIM-4, regulatory T cells lack immunoregulatory function SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Degauque, Nicolas; Galante, Nelson; Mariat, Christophe; Kenny, James; Gao, Wenda; Zheng, Xin Xiao; Strom, Terry] BIDMC, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S16 EP S16 DI 10.1016/j.clim.2008.03.504 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200042 ER PT J AU Gibbons, C Haspot, F Sykes, M AF Gibbons, Carrie Haspot, Fabienne Sykes, Megan TI Overcoming CD8 T cell-mediated resistance to engraftment of allogeneic bone marrow cells SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Gibbons, Carrie; Haspot, Fabienne; Sykes, Megan] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S74 EP S74 DI 10.1016/j.clim.2008.03.206 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200212 ER PT J AU Haas, M Zheng, Y Schuerpf, F Alicot, E Carroll, M AF Haas, Michael Zheng, Yi Schuerpf, Franziska Alicot, Elisabeth Carroll, Michael TI Human natural IgM mediates injury in a murine model of myocardial infarction SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Haas, Michael; Schuerpf, Franziska; Alicot, Elisabeth] DecImmune Therapeut Inc, Boston, MA USA. [Zheng, Yi] Immune Dis Inst, Boston, MA USA. [Carroll, Michael] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S78 EP S78 DI 10.1016/j.clim.2008.03.218 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200224 ER PT J AU Haspot, F Fehr, T Gibbons, C Sykes, M AF Haspot, Fabienne Fehr, Thomas Gibbons, Carrie Sykes, Megan TI Critical role of recipient B cells for CD8 T cell tolerance required to permit engraftment of allogeneic bone marrow cells SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Haspot, Fabienne; Gibbons, Carrie; Sykes, Megan] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Fehr, Thomas] Univ Hosp, Zurich Med Sch, Zurich, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S27 EP S27 DI 10.1016/j.clim.2008.03.072 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200073 ER PT J AU Hu, D Liu, X Zeng, W Ritz, J AF Hu, Dan Liu, Xia Zeng, Wanyong Ritz, Jerome TI A clonal model. for human CD8 regulatory T cells: Unrestricted contact-dependent killing of activated CD4 T cells SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Hu, Dan; Liu, Xia; Zeng, Wanyong; Ritz, Jerome] Dana Farber Canc Inst, Boston, MA 02115 USA. RI Hu, Dan/D-9642-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S144 EP S144 DI 10.1016/j.clim.2008.03.413 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200417 ER PT J AU McLaughlin, K Chitnis, T Banwel, B Bar-Or, A Kuhle, J Kappos, L Rostasy, K Pohl, D Wong, S Tavakoli, N Tenembaum, S Franz, B O'Connor, K Hafler, D Wucherpfennig, K AF McLaughlin, Katherine Chitnis, Tanuja Banwel, Brenda Bar-Or, Amit Kuhle, Jens Kappos, Ludwig Rostasy, Kevin Pohl, Daniela Wong, Susan Tavakoli, Norma Tenembaum, Silvia Franz, Bettina O'Connor, Kevin Hafler, David Wucherpfennig, Kai TI Autoantibodies to myelin oligodendrocyte glycoprotein in pediatric MS SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [McLaughlin, Katherine; Franz, Bettina; Wucherpfennig, Kai] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chitnis, Tanuja; O'Connor, Kevin; Hafler, David] Brigham & Womens Hosp, Boston, MA 02115 USA. [Banwel, Brenda] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Bar-Or, Amit] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada. [Kuhle, Jens; Kappos, Ludwig] Univ Basel Hosp, CH-4031 Basel, Switzerland. [Rostasy, Kevin; Pohl, Daniela] Univ Gottingen, Gottingen, Germany. [Wong, Susan; Tavakoli, Norma] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA. [Tenembaum, Silvia] Dr JP Garrahan Natl Pediat Hosp, Buenos Aires, DF, Argentina. RI Bar-Or, Amit/C-4213-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S47 EP S48 DI 10.1016/j.clim.2008.03.126 PG 2 WC Immunology SC Immunology GA 296HD UT WOS:000255533200132 ER PT J AU Means, T Luster, A El Khoury, J AF Means, Terry Luster, Andrew El Khoury, Joseph TI The scavenger receptor CD36 mediates macrophage recognition of the pathogenic yeast C. neoformans SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Means, Terry; Luster, Andrew; El Khoury, Joseph] Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S29 EP S30 DI 10.1016/j.clim.2008.03.076 PG 2 WC Immunology SC Immunology GA 296HD UT WOS:000255533200080 ER PT J AU Mirshohidi, S Kramer, V Whitney, J Dranoff, G Anderson, K Ruprecht, R AF Mirshohidi, Saied Kramer, Victor Whitney, James Dranoff, Glenn Anderson, Karen Ruprecht, Ruth TI Using overlapping synthetic peptides from tumor-associated protein antigens for breast cancer vaccine development SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Mirshohidi, Saied; Kramer, Victor; Whitney, James; Dranoff, Glenn; Anderson, Karen; Ruprecht, Ruth] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S144 EP S145 DI 10.1016/j.clim.2008.03.414 PG 2 WC Immunology SC Immunology GA 296HD UT WOS:000255533200418 ER PT J AU Ottoboni, L Young, E Yelensky, R Hafler, D Daly, M De Jager, P AF Ottoboni, Linda Young, Erica Yelensky, Roman Hafler, David Daly, Mark De Jager, Philip TI Genetic variants that control the expression of MHC genes do not affect susceptibility to multiple sclerosis SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Ottoboni, Linda; Young, Erica; Hafler, David; De Jager, Philip] Brigham & Womens Hosp, Boston, MA 02115 USA. [Yelensky, Roman; Daly, Mark] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S53 EP S54 DI 10.1016/j.clim.2008.03.145 PG 2 WC Immunology SC Immunology GA 296HD UT WOS:000255533200151 ER PT J AU Patel, N Chinen, J Rosenblatt, H Hanson, IC Brown, B Ritz, J Shearer, W AF Patel, Niraj Chinen, Javier Rosenblatt, Howard Hanson, Imelda C. Brown, Betty Ritz, Jerome Shearer, William TI Outcomes of 20 patients treated with anti-CD6-T-cell depleted, non-conditioned hematopoietic stem cell transplantation for severe combined immunodeficiency (SCID) including Omenn syndrome SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Patel, Niraj; Chinen, Javier; Rosenblatt, Howard; Hanson, Imelda C.; Brown, Betty; Shearer, William] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA. [Ritz, Jerome] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S23 EP S23 DI 10.1016/j.clim.2008.03.060 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200061 ER PT J AU Sham, C Chen, L Wu, Y Sharpe, A Freeman, G Braun, J Gordon, L AF Sham, Caroline Chen, Ling Wu, Yin Sharpe, Arlene Freeman, Gordon Braun, Jonathan Gordon, Lynn TI Programmed cell death-1 regulates neuronal cell death in the developing mouse retina SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Gordon, Lynn] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA. [Wu, Yin; Sharpe, Arlene] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Freeman, Gordon] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S141 EP S142 DI 10.1016/j.clim.2008.03.405 PG 2 WC Immunology SC Immunology GA 296HD UT WOS:000255533200409 ER PT J AU Sinha, S Burrows, G Vandenbark, A Offner, H AF Sinha, Sushmita Burrows, Gregory Vandenbark, Arthur Offner, Halina TI Inhibition of autoimmune response to multiple antigens in EAE by a single recombinant TCR ligand (RTL) SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Sinha, Sushmita; Vandenbark, Arthur; Offner, Halina] Portland VA Med Ctr, Portland, OR USA. [Burrows, Gregory] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S47 EP S47 DI 10.1016/j.clim.2008.03.125 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200131 ER PT J AU Tocco, G Kant, C Kim, P Yun, S Lin, C Benichou, G AF Tocco, Georges Kant, Cavit Kim, Pilhan Yun, Seok Lin, Charles Benichou, Gilles TI Cellular trafficking in transplantation revisited through in vivo microscopy SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Tocco, Georges; Kant, Cavit; Kim, Pilhan; Yun, Seok; Lin, Charles; Benichou, Gilles] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S77 EP S77 DI 10.1016/j.clim.2008.03.215 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200221 ER PT J AU Turley, S AF Turley, Shannon TI The role of lymph node stromal cells in regulating T cell responses SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 8th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 05-09, 2008 CL Boston, MA SP Federat Clinical Immunol Soc C1 [Turley, Shannon] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2008 VL 127 SU S BP S11 EP S11 DI 10.1016/j.clim.2008.03.027 PG 1 WC Immunology SC Immunology GA 296HD UT WOS:000255533200026 ER PT J AU Jones, KL Muellegger, RR Means, TK Lee, M Glickstein, LJ Damle, N Sikand, VK Luster, AD Steere, AC AF Jones, Kathryn L. Muellegger, Robert R. Means, Terry K. Lee, Marshall Glickstein, Lisa J. Damle, Nitin Sikand, Vijay K. Luster, Andrew D. Steere, Allen C. TI Higher mRNA levels of chemokines and cytokines associated with macrophage activation in erythema migrans skin lesions in patients from the United States than in patients from Austria with Lyme borreliosis SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID BURGDORFERI SENSU-LATO; SURFACE PROTEIN-A; CEREBROSPINAL-FLUID; DISEASE; IDENTIFICATION; EXPRESSION; AFZELII; PCR; GARINII; CELLS AB Background. Erythema migrans (EM) is caused primarily by Borrelia afzelii in Europe and solely by Borrelia burgdorferi in the United States. B. burgdorferi infection in the United States has previously been associated with faster expansion of EM lesions and with more associated symptoms, compared with B. afzelii infection in Europe. However, reasons for these differences are not yet known. Methods. We determined the Borrelia species infecting 67 US or Austrian patients with EM. The clinical pictures and chemokine and cytokine mRNA levels in lesional skin were then compared in the 19 B. burgdorferi-infected US patients and the 37 B. afzelii-infected Austrian patients, the 2 largest groups. Results. The 19 B. burgdoiferi-infected US patients had faster-expanding EM lesions and a median of 4 associated signs and symptoms, whereas the 37 B. afzelii-infected Austrian patients had slower-expanding lesions and usually did not experience associated symptoms. Compared with the EM lesions of B. afzelii-infected Austrian patients, those of B. burgdorferi-infected US patients had significantly higher mRNA levels of chemokines associated with activation of macrophages, including chemoattractants for neutrophils (CXCL1), macrophages (CCL3 and CCL4), and T helper I cells (CXCL9, CXCL10, and CXCL11). In addition, compared with the EM lesions of Austrian patients., the EM lesions of US patients tended to have higher mRNA levels of the macrophage-associated proinflammatory cytokines interleukin 10 and tumor necrosis factor alpha, and they had significantly higher mRNA expression of the antiinflammatory cytokines interleukin 10 and transforming growth factor beta. Conclusions. The EM lesions of B. burgdorferi-infected US patients expanded faster, were associated with more symptoms, and had higher mRNA levels of macro phage-associated chemokines and cytokines than did the EM lesions of B. afzelii-infected Austrian patients. C1 [Jones, Kathryn L.; Means, Terry K.; Lee, Marshall; Glickstein, Lisa J.; Damle, Nitin; Sikand, Vijay K.; Luster, Andrew D.; Steere, Allen C.] Massachusetts Gen Hosp, Harvard Med Sch, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Boston, MA USA. [Muellegger, Robert R.] Med Univ Graz, Dept Dermatol, Graz, Austria. RP Jones, KL (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM k1jones@partners.org FU NCI NIH HHS [CA-69212]; NIAMS NIH HHS [AR-007258, AR-20358]; PHS HHS [CCU110 291] NR 40 TC 30 Z9 30 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2008 VL 46 IS 1 BP 85 EP 92 DI 10.1086/524022 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 245JP UT WOS:000251931200013 PM 18171218 ER PT J AU Hersch, EC Merriam, GR AF Hersch, Elizabeth C. Merriam, George R. TI Growth hormone (GH)-releasing hormone and GH secretagogues in normal aging: Fountain of Youth or Pool of Tantalus? SO CLINICAL INTERVENTIONS IN AGING LA English DT Review DE growth hormone; growth hormone-releasing hormone; growth hormone secretagogues; aging; sarcopenia; frailty AB Although growth hormone (GH) is primarily associated with linear growth in childhood, it continues to have important metabolic functions in adult life. Adult GH deficiency (AGHD) is a distinct clinical entity, and GH replacement in AGHD can improve body composition, strength, aerobic capacity, and mood, and may reduce vascular disease risk. While there are some hormone-related side effects, the balance of benefits and risks is generally favorable, and several countries have approved GH for clinical use in AGHD. GH secretion declines progressively and markedly with aging, and many age-related changes resemble those of partial AGHD. This suggests that replacing GH, or stimulating GH with GH-releasing hormone or a GH secretagogue could confer benefits in normal aging similar to those observed in AGHD - in particular, could reduce the loss of muscle mass, strength, and exercise capacity leading to frailty, thereby prolonging the ability to live independently. However, while most GH studies have shown body composition effects similar to those in AGHD, functional changes have been much less inconsistent, and older adults are more sensitive to GH side effects. Preliminary reports of improved cognition are encouraging, but the overall balance of benefits and risks of GH supplementation in normal aging remains uncertain. C1 VA Puget Sound Hlth Care Syst, Tacoma, WA USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Sch Med, Tacoma, WA USA. Univ Washington, Sch Med, Seattle, WA USA. RP Merriam, GR (reprint author), A 151 VA Puget Sound Hlth Care Syst, Res Serv, 9600 Vet Dr SW, Tacoma, WA 98493 USA. EM herschec@yahoo.com NR 26 TC 15 Z9 15 U1 0 U2 0 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1176-9092 J9 CLIN INTERV AGING JI Clin. Interv. Aging PY 2008 VL 3 IS 1 BP 121 EP 129 PG 9 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA V21WW UT WOS:000208238700013 PM 18488883 ER PT J AU Iqbal, N Rubenstein, AH AF Iqbal, Nayyar Rubenstein, Arthur H. TI Does lowering of blood glucose improve cardiovascular morbidity and mortality? SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID DEPENDENT DIABETES-MELLITUS; LONG-TERM COMPLICATIONS; CORONARY-HEART-DISEASE; MICROVASCULAR COMPLICATIONS; 10-YEAR INCIDENCE; RISK-FACTORS; PROGRESSION; RETINOPATHY; THERAPY; ROSIGLITAZONE C1 [Iqbal, Nayyar] Philadelphia Vet Affairs Med Ctr, Endocrinol Sect, Philadelphia, PA USA. [Iqbal, Nayyar; Rubenstein, Arthur H.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Iqbal, N (reprint author), 1 Maloney,3400 Spruce St, Philadelphia, PA 19104 USA. EM nayyar.iqbal2@med.va.gov NR 26 TC 3 Z9 3 U1 0 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JAN PY 2008 VL 3 IS 1 BP 163 EP 167 DI 10.2215/CJN.05041107 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 250IK UT WOS:000252293000024 PM 18178783 ER PT J AU van Wijngaarden, RAFDL van Rijn, L Hagen, EC Watts, RA Gregorini, G Tervaert, JWC Mahr, AD Niles, JL de Heer, E Bruijn, JA Bajema, IM AF van Wijngaarden, Robert A. F. de Lind van Rijn, Leendert Hagen, E. Christiaan Watts, Richard A. Gregorini, Gina Tervaert, Jan Willem Cohen Mahr, Alfred D. Niles, John L. de Heer, Emile Bruijn, Jan A. Bajema, Ingeborg M. TI Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody-associated vasculitis: The cause is hidden, but the result is known SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Review ID PARVOVIRUS B19 INFECTION; ANCA-ASSOCIATED VASCULITIS; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; SUBACUTE BACTERIAL-ENDOCARDITIS; POSITIVE SYSTEMIC VASCULITIS; NECROSIS-FACTOR-ALPHA; DIFFUSE PULMONARY HEMORRHAGE; SMALL-VESSEL VASCULITIDES; PRIMARY RENAL VASCULITIS; CHURG-STRAUSS-SYNDROME AB The first description of what is now known as antineutrophil cytoplasmic autoantibody-associated necrotizing vasculitis appeared more than 140 yr ago. Since then, many aspects of the pathogenic pathway have been elucidated, indicating the involvement of antineutrophil cytoplasmic autoantibodies, but why antineutrophil cytoplasmic autoantibodies are produced in the first place remains unknown. Over the years, many hypotheses have emerged addressing the etiology of antineutrophil cytoplasmic antibody production, but no exclusive factor or set of factors can so far be held responsible. Herein is reviewed the most influential hypotheses regarding the causes of antineutrophil cytoplasmic antibody-associated vasculitis with the aim of placing in an epidemiologic background the different hypotheses that are centered on environmental and genetic influences. C1 [van Wijngaarden, Robert A. F. de Lind; van Rijn, Leendert; de Heer, Emile; Bruijn, Jan A.; Bajema, Ingeborg M.] Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands. [Hagen, E. Christiaan] Meander Med Ctr, Dept Internal Med, Amersfoort, Netherlands. [Watts, Richard A.] Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England. [Gregorini, Gina] Univ Brescia, Dept Nephrol, Spedali Civili, I-25121 Brescia, Italy. [Tervaert, Jan Willem Cohen] Univ Hosp Maastricht, Dept Clin & Expt Immunol, Maastricht, Netherlands. [Mahr, Alfred D.] Hop Cochin, Dept Internal Med, F-75674 Paris, France. [Niles, John L.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP van Wijngaarden, RAFDL (reprint author), Leiden Univ, Med Ctr, Dept Pathol, Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands. EM R.A.F.de_Lind_van_Wijngaarden@lumc.nl RI De Heer, Emile/C-1110-2009 NR 238 TC 34 Z9 36 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JAN PY 2008 VL 3 IS 1 BP 237 EP 252 DI 10.2215/CJN.03550807 PG 16 WC Urology & Nephrology SC Urology & Nephrology GA 250IK UT WOS:000252293000033 ER PT J AU Weisbord, SD Palevsky, PM AF Weisbord, Steven D. Palevsky, Paul M. TI Prevention of contrast-induced nephropathy with volume expansion SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACUTE-RENAL-FAILURE; RANDOMIZED CONTROLLED-TRIAL; WATER DIURESIS; RADIOCONTRAST NEPHROPATHY; CORONARY INTERVENTION; MEDULLARY CIRCULATION; SODIUM-BICARBONATE; MAJOR ANGIOGRAPHY; SALINE HYDRATION; N-ACETYLCYSTEINE AB Background and objectives: Contrast-induced nephropathy is one of the few preventable forms of acute kidney injury. Several pharmacologic agents have been evaluated for the prevention of contrast-induced nephropathy, yet disappointingly, few have been shown conclusively to reduce the risk for this condition. A series of studies have demonstrated that volume expansion, particularly with intravenous fluids, is an effective intervention to reduce the risk for contrast-induced nephropathy. Design, setting, participants, & measurements: This article reviews the clinical trials that have assessed the role of volume expansion for the prevention of contrast-induced nephropathy. Results: The administration of isotonic sodium chloride before and after radiocontrast injection seems to be more protective than equivalent volumes of hypotonic saline and, when feasible, should be administered over a sustained period of time. Recent clinical trials suggested that an abbreviated regimen of intravenous sodium bicarbonate may be superior to a comparable protocol of sodium chloride. Although a small number of studies have found that volume supplementation by mouth may be effective in preventing contrast-induced nephropathy, the routine use of enteral fluids or solute in lieu of intravenous fluids in high-risk patients cannot be recommended at this time. Rather, liberal oral fluid and solute intake should complement intravenous fluid administration to minimize risk. Conclusions: Future studies will be required to define clearly the optimal prophylactic intravenous fluid regimen for contrast-induced nephropathy and further delineate the independent role of oral volume expansion for the prevention of this condition. C1 [Weisbord, Steven D.; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Weisbord, SD (reprint author), Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Mail Stop 111F-U,7E Room 120, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 40 TC 64 Z9 77 U1 1 U2 6 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JAN PY 2008 VL 3 IS 1 BP 273 EP 280 DI 10.2215/CJN.02580607 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 250IK UT WOS:000252293000037 PM 17989201 ER PT J AU Goral, M Libben, G Obler, LK Jarema, G Ohayon, K AF Goral, Mira Libben, Gary Obler, Loraine K. Jarema, Gonia Ohayon, Keren TI Lexical attrition in younger and older bilingual adults SO CLINICAL LINGUISTICS & PHONETICS LA English DT Article DE ageing; bilingual; lexical attrition; compound words; lexical decision ID SEMANTIC TRANSPARENCY; AGE-DIFFERENCES; RETRIEVAL; REPRESENTATION; METAANALYSIS; PERFORMANCE; ABILITY; DECLINE; SPANISH; MEMORY AB Healthy monolingual older adults experience changes in their lexical abilities. Bilingual individuals immersed in an environment in which their second language is dominant experience lexical changes, or attrition, in their first language. Changes in lexical skills in the first language of older individuals who are bilinguals, therefore, can be attributed to the typical processes accompanying older age, the typical processes accompanying first-language attrition in bilingual contexts, or both. The challenge, then, in understanding how lexical skills change in bilingual older individuals, lies in dissociating these processes. This paper addresses the difficulty of teasing apart the effects of ageing and attrition in older bilinguals and proposes some solutions. It presents preliminary results from a study of lexical processing in bilingual younger and older individuals. Processing differences were found for the older bilingual participants in their first language (L1), but not in their second language (L2). It is concluded that the lexical behaviour found for older bilinguals in this study can be attributed to L1 attrition and not to processes of ageing. These findings are discussed in the context of previous reports concerning changes in lexical skills associated with typical ageing and those associated with bilingual L1 attrition. C1 [Goral, Mira] CUNY Herbert H Lehman Coll, Bronx, NY 10468 USA. [Goral, Mira; Obler, Loraine K.] CUNY, Grad Sch, New York, NY USA. [Goral, Mira; Obler, Loraine K.] CUNY, Grad Sch, Univ Ctr, New York, NY USA. [Goral, Mira; Obler, Loraine K.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Goral, Mira; Obler, Loraine K.] Boston VA Healthcare Syst, Boston, MA 02118 USA. [Libben, Gary] Univ Alberta, Edmonton, AB T6G 2M7, Canada. [Jarema, Gonia] Univ Montreal, Montreal, PQ, Canada. [Jarema, Gonia] Inst Univ Geriatr Montreal, Montreal, PQ, Canada. RP Goral, M (reprint author), CUNY Herbert H Lehman Coll, 250 Bedford Pk Blvd, Bronx, NY 10468 USA. EM mira.goral@lehman.cuny.edu FU NIA NIH HHS [R03 AG027532, R03 AG027532-03] NR 59 TC 4 Z9 5 U1 2 U2 12 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9206 J9 CLIN LINGUIST PHONET JI Clin. Linguist. Phon. PY 2008 VL 22 IS 7 BP 509 EP 522 DI 10.1080/02699200801912237 PG 14 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA 318ME UT WOS:000257095100002 PM 18568793 ER PT J AU Kharrazi, FD Busfield, BT Khorshad, DS Hornicek, FJ Mankin, HJ AF Kharrazi, F. Daniel Busfield, Benjamin T. Khorshad, Daniel S. Hornicek, Francis J. Mankin, Henry J. TI Osteoarticular and total elbow allograft reconstruction with severe bone loss SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH LA English DT Article ID DISTAL HUMERAL PROSTHESIS; FOLLOW-UP; MUSCULOSKELETAL TUMOR; PROXIMAL PART; END; ARTHROPLASTY; REPLACEMENT; FRACTURES; RESECTION; EXPERIENCE AB Osteoarticular allograft reconstruction is an option in patients with massive periarticular elbow bone loss secondary to tumor surgery or trauma. Our consecutive series consisted of 18 patients with tumors and one patient with trauma. Reconstruction consisted of 16 hemiarticular allografts and three total elbow osteoarticular allografts; patients had a minimum followup of 2 years (mean, 9.9 years; range, 2-12 years). For patients who had hemiarticular allografts, 14 of 16 were able to return to their preoperative level of occupational function, with one patient experiencing failure of the allograft from infection. For the three patients who had total elbow allograft reconstructions, all had degenerative changes develop after surgery and two of the allografts failed. Complications occurred in six of 19 patients. Hemiarticular elbow allograft reconstruction is useful for limb salvage with massive bone loss. Total elbow allograft reconstructions have a high failure rate in the mid-term. C1 [Kharrazi, F. Daniel; Busfield, Benjamin T.; Khorshad, Daniel S.] Kerland Jobe Orthopaed Clin, Los Angeles, CA 90045 USA. [Hornicek, Francis J.; Mankin, Henry J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Orthoped Surg,Orthoped Oncol Unit, Boston, MA 02115 USA. RP Kharrazi, FD (reprint author), Kerland Jobe Orthopaed Clin, 6801 Pk Terrace Dr, Los Angeles, CA 90045 USA. EM fdkharrazi@aol.com NR 36 TC 11 Z9 14 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0009-921X J9 CLIN ORTHOP RELAT R JI Clin. Orthop. Rel. Res. PD JAN PY 2008 VL 466 IS 1 BP 205 EP 209 DI 10.1007/s11999-007-0011-8 PG 5 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 262QV UT WOS:000253164000043 PM 18196394 ER PT J AU Pulsifer, MB Butz, AM Foran, MO Belcher, HME AF Pulsifer, Margaret B. Butz, Arlene M. Foran, Megan O'Reilly Belcher, Harolyn M. E. TI Prenatal drug exposure: Effects on cognitive functioning at 5 years of age SO CLINICAL PEDIATRICS LA English DT Article DE prenatal drug exposure; intelligence; impulsivity; attention ID UTERO COCAINE EXPOSURE; IN-UTERO; PRESCHOOL-CHILDREN; SCHOOL READINESS; IMPULSE CONTROL; ATTENTION; INTELLIGENCE; OUTCOMES AB The goal of this cross-sectional study was to compare cognitive functioning at age 5 years in prenatal drug-exposed children with nondrug-exposed children from a comparable inner-city environment. Children with prenatal drug exposure scored significantly lower on measures of language, school readiness skills, impulse control, and visual attention span/sequencing than controls matched for age and socioeconomic status. Intelligence, visual-motor, manual dexterity, and sustained attention scores were not significantly different between groups. The total sample scored significantly below the normative mean on standardized measures of intelligence, language, school readiness, visual-motor skills, impulse control, and sustained attention, with 40% scoring at least I standard deviation below the mean (IQ < 85) on a measure of intelligence. Findings suggest that children with prenatal drug exposure are at increased risk for learning and attention problems and are in need of close developmental surveillance and possible intervention to support school success and improve behavioral outcome. C1 [Pulsifer, Margaret B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Psychol Assessment Ctr, Boston, MA 02114 USA. [Butz, Arlene M.; Belcher, Harolyn M. E.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA. [Foran, Megan O'Reilly] Prince Georges Cty Publ Sch, Upper Marlboro, MD USA. [Belcher, Harolyn M. E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. [Belcher, Harolyn M. E.] Kennedy Krieger Inst, Dept Neurol & Dev Med, Baltimore, MD USA. RP Pulsifer, MB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Psychol Assessment Ctr, 1 Bowdoin Pl,7th Floor, Boston, MA 02114 USA. EM mpulsifer@partners.org FU NCRR NIH HHS [M01 RR000052, M01 RR000052-38S10615]; NINR NIH HHS [NR03442, R01 NR003442] NR 37 TC 15 Z9 15 U1 5 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0009-9228 J9 CLIN PEDIATR JI Clin. Pediatr. PD JAN PY 2008 VL 47 IS 1 BP 58 EP 65 DI 10.1117/0009922807305872 PG 8 WC Pediatrics SC Pediatrics GA 242VH UT WOS:000251753800007 PM 17766581 ER PT J AU Greene, MF AF Greene, M. F. TI Emergency contraception: A reasonable personal choice or a destructive societal influence? SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Editorial Material ID LEVONORGESTREL; PILLS; KNOWLEDGE; ATTITUDES; ABORTION; RATES AB A 2003 petition to the US Food and Drug Administration by the manufacturer to move levonorgestrel emergency contraception from prescription status to over-the-counter sale embroiled the Agency in politics and remains controversial in some circles. This essay addresses the current remaining main points of contoversy about the medication and the Agency's decision. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA 02115 USA. RP Greene, MF (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA 02115 USA. EM mfgreene@partners.org NR 17 TC 2 Z9 2 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0009-9236 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD JAN PY 2008 VL 83 IS 1 BP 17 EP 19 DI 10.1038/sj.clpt.6100433 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 254KD UT WOS:000252584600008 PM 18165824 ER PT J AU Sims, K Poleitei, J Banikazemi, M Lee, P AF Sims, K. Poleitei, J. Banikazemi, M. Lee, P. CA Fabry Registry TI STROKES IN PATIENTS WITH FABRY DISEASE FREQUENTLY OCCUR BEFORE DIAGNOSIS AND IN THE ABSENCE OF OTHER CLINICAL EVENTS: NATURAL HISTORY DATA FROM THE FABRY REGISTRY SO CLINICAL THERAPEUTICS LA English DT Meeting Abstract CT 5th Symposium on Lysosomal Storage Disorders CY APR 10-12, 2008 CL Paris, FRANCE C1 [Sims, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA USA. [Sims, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA. [Poleitei, J.] Hosp Fernandez, Dept Neurol, Buenos Aires, DF, Argentina. [Banikazemi, M.] NYU, Sch Med, Dept Neurol, New York, NY USA. [Banikazemi, M.] NYU, Sch Med, Dept Pediat, New York, NY USA. [Lee, P.] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 J9 CLIN THER JI Clin. Ther. PY 2008 VL 30 SU C BP S105 EP S105 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 373AI UT WOS:000260943000040 ER PT J AU Zimran, A Cappellini, MD Cox, T Giannini, EH Grabowski, GA Hwu, WL Mankin, H Martins, AM Sawyers, C vom Dahl, S Weinreb, N Yeh, M AF Zimran, A. Cappellini, M. D. Cox, T. Giannini, E. H. Grabowski, G. A. Hwu, W. L. Mankin, H. Martins, A. M. Sawyers, C. vom Dahl, S. Weinreb, N. Yeh, M. TI DEVELOPMENT OF A DISEASE SEVERITY SCORING SYSTEM FOR TYPE 1 GAUCHER DISEASE SO CLINICAL THERAPEUTICS LA English DT Meeting Abstract CT 5th Symposium on Lysosomal Storage Disorders CY APR 10-12, 2008 CL Paris, FRANCE C1 [Zimran, A.] Shaare Zedek Med Ctr, Jerusalem, Israel. [Cappellini, M. D.] Univ Milan, Policlin Fdn IRCCS, Milan, Italy. [Cox, T.] Univ Cambridge, Cambridge, England. [Giannini, E. H.; Grabowski, G. A.] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA. [Hwu, W. L.] Natl Taiwan Univ Hosp, Taipei, Taiwan. [Mankin, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Martins, A. M.] Univ Fed Sao Paulo, Sao Paulo, Brazil. [Sawyers, C.; Yeh, M.] Genzyme Corp, Cambridge, MA USA. [vom Dahl, S.] St Franziskus Hosp, Cologne, Germany. [Weinreb, N.] Univ Res Fdn Lysosomal Storage Disorders, Coral Springs, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 J9 CLIN THER JI Clin. Ther. PY 2008 VL 30 SU C BP S95 EP S95 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 373AI UT WOS:000260943000014 ER PT J AU Lo, B Kriegstein, A Grady, D AF Lo, Bernard Kriegstein, Arnold Grady, Deborah TI Clinical trials in stem cell transplantation: guidelines for scientific and ethical review SO CLINICAL TRIALS LA English DT Article ID PARKINSONS-DISEASE; INFORMED-CONSENT; DRUG; ROFECOXIB; TGN1412; EVENTS; CANCER; ISSUES; ERA AB Background Transplantation of cells derived through the manipulation of pluripotent stem cells may involve great uncertainty and the possibility of serious risks. Purpose To develop guidelines for the ethical conduct of clinical trials using such stem cells. Methods Review of literature on clinical trials ethics and clinical applications of stem cells; critical deliberation on potential guidelines. Results Such transplantation should be allowed in clinical practice only after clinical trials demonstrate efficacy and safety. These clinical trials should follow ethical principles that guide all clinical research. Additional requirements to strengthen trial design, coordinate scientific and ethics review, verify that participants understand key features of the trial, and ensure publication of findings are also warranted because of the highly innovative nature of the intervention, limited experience in humans, and the high hopes of patients who have no alternative effective treatments. Limitations These recommendations will need to be modified in light of actual experience with stem cell clinical trials. Conclusions These recommendations will help guarantee that the efficacy and safety of innovative stem cell interventions will be rigorously established, while also protecting study participants. Clinical Trials 2008; 5: 517-522. http:// ctj.sagepub.com C1 [Lo, Bernard] Univ Calif San Francisco, Program Med Eth, San Francisco, CA 94143 USA. [Lo, Bernard] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Kriegstein, Arnold] Univ Calif San Francisco, Program Dev & Stem Cell Biol, San Francisco, CA 94143 USA. [Kriegstein, Arnold] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Grady, Deborah] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Lo, B (reprint author), Univ Calif San Francisco, Program Med Eth, 521 Parnassus Ave,Room C126, San Francisco, CA 94143 USA. EM bernie@medicine.ucsf.edu FU National Center for Research Resources (NCRR); NIH [RR024131-01]; Greenwall Foundation FX Supported by National Institutes of Health (NIH) Grant Number 1 UL1 RR024131-01 from the National Center for Research Resources (NCRR) and NIH Roadmap for Medical Research and by the Greenwall Foundation. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR of NIH. NR 45 TC 24 Z9 26 U1 0 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 J9 CLIN TRIALS JI Clin. Trials PY 2008 VL 5 IS 5 BP 517 EP 522 DI 10.1177/1740774508096705 PG 6 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 367RN UT WOS:000260570100006 PM 18827044 ER PT J AU Miller, FG Joffe, S AF Miller, Franklin G. Joffe, Steven TI Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? SO CLINICAL TRIALS LA English DT Article ID METASTATIC COLORECTAL-CANCER; SURROGATE END-POINTS; CLINICAL-TRIALS; 1ST-LINE CHEMOTHERAPY; SURVIVAL; RISKS; PARTICIPATION; METAANALYSIS; PROGRESSION; CONSENT AB Novel treatments for cancer are tested initially in phase I trials enrolling patients with advanced disease who have exhausted standard treatment options. Although these trials are designed to evaluate safety and to define dosing for future efficacy trials, most patients volunteer with the hope of obtaining medical benefit. Do phase I oncology trials promote a 'therapeutic misconception' among eligible patients about the personal meaning of trial participation, or do they offer them a reasonable prospect of direct medical benefit as compared with available alternatives? Recent evidence on outcomes of phase 1 oncology trials is examined systematically, with the aim of accurately assessing the prospect of direct medical benefit for participants and drawing implications for informed consent. We argue that, in view of important uncertainties, aggregate data from phase 1 trials relating to the surrogate outcomes of tumor shrinkage and stable disease do not permit any definitive estimate of a 'clinical benefit rate.' Nevertheless, these trials do offer participants a prospect of direct medical benefit. As a result, accurately informed patients may reasonably decide to enroll in phase 1 oncology trials in hopes of obtaining benefit, after considering the anticipated risks and available clinical alternatives. Motivation to enroll in these studies to receive personal benefit does not, in itself, compromise informed consent. Clinical Trials 2008; 5: 617-623. http://ctj.sagepub.com C1 [Miller, Franklin G.] NIH, Ctr Clin, Dept Bioeth, Bethesda, MD 20892 USA. [Joffe, Steven] Childrens Hosp, Dept Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. RP Miller, FG (reprint author), NIH, Ctr Clin, Dept Bioeth, Bldg 10,Room 1C118, Bethesda, MD 20892 USA. EM fmiller@nih.gov OI Joffe, Steven/0000-0002-0667-7384 NR 29 TC 36 Z9 36 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 J9 CLIN TRIALS JI Clin. Trials PY 2008 VL 5 IS 6 BP 617 EP 623 DI 10.1177/1740774508097576 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 385KA UT WOS:000261811900006 PM 19029210 ER PT J AU Wortzel, HS Oster, TJ Anderson, CA Arciniegas, DB AF Wortzel, Hal S. Oster, Timothy J. Anderson, C. Alan Arciniegas, David B. TI Pathological laughing and crying - Epidemiology, pathophysiology and treatment SO CNS DRUGS LA English DT Review ID SEROTONIN REUPTAKE INHIBITORS; TRAUMATIC BRAIN-INJURY; EMOTIONAL EXPRESSION DISORDER; PSEUDOBULBAR AFFECT; ANTIDEPRESSANT ACTION; CITALOPRAM TREATMENT; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; CONTROLLED-TRIAL; SIGMA-RECEPTORS AB Pathological laughing and crying (PLC) is characterized by frequent, brief, intense paroxysms of uncontrollable crying and/or laughing due to a neurological disorder. When sufficiently frequent and severe, PLC may interfere with the performance of activities of daily living, interpersonal functioning, or both, and is a source of distress for affected patients and their families. PLC is also often misunderstood by patients and their families, and is under-recognized by the clinicians caring for patients with this disorder. However, this syndrome is easily recognized when understood properly and is highly responsive to treatment with a variety of pharmacological agents. This review aims to facilitate the diagnosis and treatment of patients with PLC, and begins by providing definitions of mood and affect that will help clinicians distinguish between mood disorders, such as major depression and mania, and disorders of affect, such as PLC. In addition, the various terms used to describe this syndrome are reviewed and a recommendation for the use of the term PLC is made. The core clinical features of PLC are also presented and the epidemiology of this syndrome is reviewed. A discussion of the pathophysiology of PLC, including the neuroanatomic and neurochemical bases, is provided. Finally, the evaluation and treatment of patients with PLC is described. Based on the pathophysiology of PLC and on a detailed review of published treatment studies, SSRIs are recommended as first-line pharmacotherapy for this disorder. When SSRIs are ineffective or poorly tolerated, other treatment options, including TCAs, noradrenergic reuptake inhibitors, novel antidepressants, dopaminergic agents and uncompetitive NMDA receptor antagonists may be useful second-line treatments. C1 [Wortzel, Hal S.; Oster, Timothy J.; Anderson, C. Alan; Arciniegas, David B.] Univ Colorado, Sch Med, Neurobehav Disorders Program, Dept Psychiat, Denver, CO 80262 USA. [Wortzel, Hal S.; Arciniegas, David B.] HealthONE Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Aurora, CO USA. [Wortzel, Hal S.; Anderson, C. Alan; Arciniegas, David B.] Denver Vet Affairs Med Ctr, VISN MIRECC 19, Denver, CO USA. [Oster, Timothy J.; Anderson, C. Alan; Arciniegas, David B.] Univ Colorado, Sch Med, Dept Neurol, Behav Neurol Sect, Denver, CO 80262 USA. RP Arciniegas, DB (reprint author), Univ Colorado, Sch Med, Neurobehav Disorders Program, Dept Psychiat, 4200 E Ninth Ave,Campus Box C268-25, Denver, CO 80262 USA. EM David.Arciniegas@UCHSC.edu RI Arciniegas, David/A-3792-2009 NR 110 TC 48 Z9 51 U1 4 U2 20 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1172-7047 J9 CNS DRUGS JI CNS Drugs PY 2008 VL 22 IS 7 BP 531 EP 545 DI 10.2165/00023210-200822070-00001 PG 15 WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 322AT UT WOS:000257348300001 PM 18547124 ER PT J AU Sano, M Grossman, H Van Dyk, K AF Sano, Mary Grossman, Hillel Van Dyk, Kathleen TI Preventing Alzheimer's Disease Separating Fact From Fiction SO CNS DRUGS LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; MILD COGNITIVE IMPAIRMENT; LIPID-LOWERING AGENTS; AMYLOID PRECURSOR PROTEIN; MRC/BHF HEART PROTECTION; BETA IMMUNIZATION AN1792; HEALTH INITIATIVE MEMORY; ESTROGEN PLUS PROGESTIN; HIGH-RISK INDIVIDUALS AB Alzheimer's disease is an ever-increasing health concern among the aging population, and as we research new and existing treatments for this disease we begin to uncover possibilities for its prevention. Observational studies and animal models have provided promising findings and generated excitement, but placebo-controlled clinical trials are required to demonstrate true efficacy for these treatments. In the past two decades, clinical trials have led to the approval of symptomatic treatments for Alzheimer's disease, including cholinesterase inhibitors and, more recently, an NMDA receptor antagonist. Clinical trials have also examined antioxidants, NSAIDs, hormone replacement, nutritional supplements and non-pharmacological interventions for the treatment and prevention of Alzheimer's disease. While the results of many of these trials have been disappointing, new mechanisms targeting the hallmark pathology of Alzheimer's disease are currently under investigation, including immunotherapy and secretase modulation, targeted at reducing the amyloid burden, for which we await the results. We review the evidence from completed trials, support for ongoing studies and propose directions for future research. C1 [Sano, Mary; Grossman, Hillel; Van Dyk, Kathleen] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, Bronx, NY 10468 USA. [Sano, Mary; Grossman, Hillel; Van Dyk, Kathleen] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Sano, M (reprint author), Mt Sinai Sch Med, Alzheimers Dis Res Ctr, Rm 1F01,130 Kingsbridge Rd, Bronx, NY 10468 USA. EM mary.sano@mssm.edu FU Eisai Pharmaceuticals, Humanetics and Elan; [AG05138]; [AG10483]; [AG15922] FX The authors' work is supported by AG05138, AG10483 and AG15922. Dr Mary Sano has been a consultant to the following companies, which are involved in drug development for Alzheimer's disease: Aventis, Bayer, Forest, Glaxo-SmithKline, Janssen, Ortho-McNeil, Novartis, Pfizer, Bristol-Meyers Squibb, Takeda, Voyager Pharmaceuticals, Medication and Neurochem. These consultancies have been in reference to clinical trial design. Dr Hillel Grossman has been a consultant for the following companies, which are involved in drug development for Alzheimer's disease: Forest Industries and Dainippon America. These consultancies have been in reference to clinical trial design and clinical application. Additionally, Dr Grossman has received research funding from Eisai Pharmaceuticals, Humanetics and Elan. Kathleen van Dyk has no conflicts of interest that are directly relevant to the content of this review. NR 144 TC 14 Z9 14 U1 1 U2 2 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1172-7047 J9 CNS DRUGS JI CNS Drugs PY 2008 VL 22 IS 11 BP 887 EP 902 DI 10.2165/00023210-200822110-00001 PG 16 WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 367RK UT WOS:000260569800001 PM 18840031 ER PT J AU Smelson, DA Dixon, L Craig, T Remolina, S Batki, SL Niv, N Owen, R AF Smelson, David A. Dixon, Lisa Craig, Thomas Remolina, Stephen Batki, Steven L. Niv, Noosha Owen, Richard TI Pharmacological Treatment of Schizophrenia and Co-Occurring Substance Use Disorders SO CNS DRUGS LA English DT Review ID PERSISTENT MENTAL-ILLNESS; COCAINE DEPENDENCE; DRUG-ABUSE; ANTIPSYCHOTIC MEDICATIONS; CLINICAL-TRIAL; ALCOHOL-USE; CLOZAPINE; OLANZAPINE; RISPERIDONE; INDIVIDUALS AB Substance abuse among individuals with schizophrenia is common and is often associated with poor clinical outcomes. Comprehensive, integrated pharmacological and psychosocial treatments have been shown to improve these outcomes. While a growing number of studies suggest that second-generation antipsychotic medications may have beneficial effects on the treatment of co-occurring substance use disorders, this review suggests that the literature is still in its infancy. Few existing well controlled trials support greater efficacy of second-generation antipsychotics compared with first-generation antipsychotics or any particular second-generation antipsychotic. This article focuses on and reviews studies involving US FDA-approved medications for co-occurring substance abuse problems among individuals with schizophrenia. Comprehensive treatment for individuals with schizophrenia and co-occurring substance use disorders must include specialized, integrated psychosocial intervention. Most approaches use some combination of cognitive-behavioural therapy, motivational enhancement therapy and assertive case management. The research on antipsychotic and other pharmacological treatments is also reviewed, as well as psychosocial treatments for individuals with schizophrenia and co-occurring substance use disorders, and clinical recommendations to optimize care for this population are offered. C1 [Smelson, David A.] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA. [Smelson, David A.] Edith Nourse Rogers Mem Vet Adm Hosp, Dept Vet Affairs, Bedford, MA 01730 USA. [Dixon, Lisa] VISN 4 MIRECC, Dept Vet Affairs, Pittsburgh, PA USA. [Dixon, Lisa] Univ Maryland, Baltimore, MD 21201 USA. [Craig, Thomas] Amer Psychiat Assoc, Arlington, VA USA. [Remolina, Stephen] New Jersey Hlth Care Syst, Dept Vet Affairs, Lyons, NJ USA. [Batki, Steven L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Batki, Steven L.] SUNY Upstate Med Univ, Syracuse, NY USA. [Niv, Noosha] Univ Calif Los Angeles, Los Angeles, CA USA. [Owen, Richard] Cent Arkansas Vet Hlth Care Syst, Ctr Mental Healthcare & Outcomes Res, N Little Rock, AR USA. RP Smelson, DA (reprint author), Univ Massachusetts, Sch Med, Dept Psychiat, 55 Lake Ave N, Worcester, MA 01655 USA. EM David.Smelson@umassmed.edu FU Alkermes, Inc.,; Cephalon, Inc. FX No sources of funding were used to assist in the preparation of this review. Dr David Smelson has received honoraria for consulting for Eli Lilly. Dr Batki has received honoraria and research funding from Alkermes, Inc., and Cephalon, Inc. Neither of these two companies had any input into the preparation of this review, nor did they have a role in reviewing or approving the manuscript. All other authors have no conflicts of interest that are directly relevant to the content of this review. NR 89 TC 11 Z9 12 U1 3 U2 7 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1172-7047 EI 1179-1934 J9 CNS DRUGS JI CNS Drugs PY 2008 VL 22 IS 11 BP 903 EP 916 DI 10.2165/00023210-200822110-00002 PG 14 WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 367RK UT WOS:000260569800002 PM 18840032 ER PT J AU Targum, SD Pollack, MH Fava, M AF Targum, Steven D. Pollack, Mark H. Fava, Maurizio TI Redefining affective disorders: Relevance for drug development SO CNS NEUROSCIENCE & THERAPEUTICS LA English DT Article DE clinical trials; drug development; valid patient criteria ID GENERALIZED ANXIETY DISORDER; STAR-ASTERISK-D; MAJOR DEPRESSIVE DISORDER; VENLAFAXINE-XR; SYMPTOMS; EFFICACY; ANTIDEPRESSANTS; AUGMENTATION; OUTPATIENTS; SERTRALINE AB The evaluation of new drug entities with specific modes of action may be hampered by rigid diagnostic classification systems and patient selection processes that do not focus on the anticipated symptomatic, behavioral, and functional outcomes to be achieved. Patients enrolled in central nervous system (CNS) clinical trials may present with a heterogeneous group of symptoms representing several syndromes or subtypes, subsumed under the same diagnosis in the DSM-IV classification system. As a result, enrolled patients may not have the valid illness characteristics of interest to the particular study. We propose that clinical drug development needs to focus on the primary nosological entity likely to be affected by a new drug entity's mode of action. Ideally, a valid patient will have the acute primary symptoms that the novel drug is supposed to influence. In this article, we propose operational criteria to delineate a more symptom-specific and ecologically valid approach to the identification of the valid patient for clinical trials. C1 [Targum, Steven D.] Massachusetts Gen Hosp, Dept Psychiat, Clin Trials Network & Inst, Boston, MA 02114 USA. RP Targum, SD (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Clin Trials Network & Inst, Bulfinch 351,55 Fruit St, Boston, MA 02114 USA. EM sdtargum@yahoo.com NR 28 TC 31 Z9 31 U1 1 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1755-5930 J9 CNS NEUROSCI THER JI CNS Neurosci. Ther. PY 2008 VL 14 IS 1 BP 2 EP 9 DI 10.1111/j.1527-3458.2008.00038.x PG 8 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 305RV UT WOS:000256196400002 PM 18482094 ER PT J AU Hoge, EA Pollack, MH Kaufman, RE Zak, PJ Simon, NM AF Hoge, Elizabeth A. Pollack, Mark H. Kaufman, Rebecca E. Zak, Paul J. Simon, Naomi M. TI Oxytocin levels in social anxiety disorder SO CNS NEUROSCIENCE & THERAPEUTICS LA English DT Article DE oxytocin; social anxiety; social phobia; trust ID VOLES MICROTUS-OCHROGASTER; PLASMA OXYTOCIN; CEREBROSPINAL-FLUID; VASOPRESSIN; WOMEN; DEPRESSION; BEHAVIOR; PARTURITION; RESPONSES; STRESSOR AB Oxytocin is a neuropeptide recently associated with social behavior in animals and humans, but the study of its function in populations with social deficits such as autism, schizophrenia, and social anxiety disorder has only recently begun. We measured plasma oxytocin in 24 patients with Generalized Social Anxiety Disorder (GSAD) and 22 healthy controls using an enzyme-linked immunosorbent assay. There were no significant differences in oxytocin level (pg/mL) between patients (M = 163.0, SD = 109.4) and controls (M = 145.0, SD = 52.9, z = 0.21, P = 0.8). Within the GSAD sample, however, higher social anxiety symptom severity adjusted for age and gender was associated with higher oxytocin level (R(2) = 0.21, beta = 0.014, SE = 0.006, t = 2.18, P = 0.04). In addition, dissatisfaction with social relationships was associated with higher oxytocin levels (R(2) = 0.18, beta = -0.20, SE = 0.10, t = -2.01, P = 0.05). Our data provide preliminary support for a link between social anxiety severity and plasma oxytocin. These findings may suggest a possible role for oxytocin as a facilitator of social behavior, an effect which may not be fully utilized in individuals with severe social anxiety. C1 [Hoge, Elizabeth A.; Pollack, Mark H.; Kaufman, Rebecca E.; Simon, Naomi M.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Hoge, Elizabeth A.; Zak, Paul J.] Claremont Univ, Dept Econ, Claremont, CA USA. RP Hoge, EA (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Simches Res Bldg,185 Cambridge St,Suite 2200,2nd, Boston, MA 02114 USA. EM ehoge@partners.org RI Hoge, Elizabeth/H-5879-2012; OI Hoge, Elizabeth/0000-0002-5513-2292; Sripada, Rebecca/0000-0002-2844-3458 NR 41 TC 86 Z9 90 U1 6 U2 41 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1755-5930 J9 CNS NEUROSCI THER JI CNS Neurosci. Ther. PY 2008 VL 14 IS 3 BP 165 EP 170 DI 10.1111/j.1755-5949.2008.00051.x PG 6 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 336YF UT WOS:000258402000001 PM 18801109 ER PT J AU Dording, CM Fisher, L Papakostas, G Farabaugh, A Sonawalla, S Fava, M Mischoulon, D AF Dording, Christina M. Fisher, Lauren Papakostas, George Farabaugh, Amy Sonawalla, Shamsah Fava, Maurizio Mischoulon, David TI A double-blind, randomized, pilot dose-finding study of maca root (L. Meyenii) for the management of SSRI-Induced sexual dysfunction SO CNS NEUROSCIENCE & THERAPEUTICS LA English DT Article DE L . meyenii; maca; natural remedies; sexual dysfunction; side effects; SSRI ID ADULT HEALTHY-MEN; LEPIDIUM-MEYENII; MALE RATS; ERECTILE DYSFUNCTION; CONTROLLED TRIAL; SILDENAFIL; MICE; SPERMATOGENESIS; QUESTIONNAIRE; TESTOSTERONE AB We sought to determine whether maca, a Peruvian plant, is effective for selective-serotonin reuptake inhibitor (SSRI)-induced sexual dysfunction. We conducted a double-blind, randomized, parallel group dose-finding pilot study comparing a low-dose (1.5 g/day) to a high-dose (3.0 g/day) maca regimen in 20 remitted depressed outpatients (mean age 36 +/- 13 years; 17 women) with SSRI-induced sexual dysfunction. The Arizona Sexual Experience Scale (ASEX) and the Massachusetts General Hospital Sexual Function Questionnaire (MGH-SFQ) were used to measure sexual dysfunction. Ten subjects completed the study, and 16 subjects (9 on 3.0 g/day; 7 on 1.5 g/day) were eligible for intent-to-treat (ITT) analyses on the basis of having had at least one postbaseline visit. ITT subjects on 3.0 g/day maca had a significant improvement in ASEX (from 22.8 +/- 3.8 to 16.9 +/- 6.2; z = -2.20, P = 0.028) and in MGH-SFQ scores (from 24.1 +/- 1.9 to 17.0 +/- 5.7; z = -2.39, P = 0.017), but subjects on 1.5 g/day maca did not. Libido improved significantly (P < 0.05) for the ITT and completer groups based on ASEX item #1, but not by dosing groups. Maca was well tolerated. Maca root may alleviate SSRI-induced sexual dysfunction, and there may be a dose-related effect. Maca may also have a beneficial effect on libido. C1 [Dording, Christina M.; Fisher, Lauren; Papakostas, George; Farabaugh, Amy; Sonawalla, Shamsah; Fava, Maurizio; Mischoulon, David] Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, Boston, MA 02114 USA. RP Dording, CM (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, 50 Staniford St,401, Boston, MA 02114 USA. EM cdording@partners.org RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 FU National Institutes of Health FX Dr. Dording was supported by the Loan Repayment Program of the National Institutes of Health. NR 29 TC 27 Z9 30 U1 1 U2 22 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1755-5930 J9 CNS NEUROSCI THER JI CNS Neurosci. Ther. PY 2008 VL 14 IS 3 BP 182 EP 191 DI 10.1111/j.1755-5949.2008.00052.x PG 10 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 336YF UT WOS:000258402000003 PM 18801111 ER PT J AU Iosifescu, DV AF Iosifescu, Dan V. TI Prediction of Response to Antidepressants: Is Quantitative EEG (QEEG) an Alternative ? SO CNS NEUROSCIENCE & THERAPEUTICS LA English DT Editorial Material DE Antidepressant; Major depressive disorder; Predictor; Quantitative EEG (QEEG); Response ID MAJOR DEPRESSIVE DISORDER; STAR-ASTERISK-D; CITALOPRAM; DEPENDENCE; OUTCOMES; PLACEBO AB Selecting the most effective antidepressant for depressed subjects having failed previous treatments is difficult; the rates of success are relatively low. There is a clear need for objective biomarkers which could assist and optimize such treatment selection. We review here the current literature and recent developments on the role of quantitative EEG (QEEG) predictors of treatment outcome in major depressive disorder. C1 [Iosifescu, Dan V.] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. [Iosifescu, Dan V.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Iosifescu, DV (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, 50 Staniford St,Suite 401, Boston, MA 02114 USA. EM diosifescu@partners.org NR 24 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1755-5930 J9 CNS NEUROSCI THER JI CNS Neurosci. Ther. PY 2008 VL 14 IS 4 BP 263 EP 265 DI 10.1111/j.1755-5949.2008.00063.x PG 3 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 370EU UT WOS:000260746300001 PM 19040551 ER PT J AU Seijffers, R Benowitz, L AF Seijffers, Rhona Benowitz, Larry BE Kordower, JH Tuszynski, MH TI INTRINSIC DETERMINANTS OF AXON REGENERATION SO CNS REGENERATION: BASIC SCIENCE AND CLINICAL ADVANCES, 2ND EDITION LA English DT Article; Book Chapter ID RETINAL GANGLION-CELLS; ADULT SENSORY NEURONS; DORSAL-ROOT GANGLIA; CILIARY NEUROTROPHIC FACTOR; NERVE GROWTH-FACTOR; INJURED SPINAL-CORD; ACTIVATED PROTEIN-KINASE; RAT SCIATIC-NERVE; MYELIN-ASSOCIATED GLYCOPROTEIN; PROMOTES NEURITE OUTGROWTH AB In the peripheral nervous system (PNS), neurons spontaneously regenerate injured axons to reinnervate skin, muscle, and other targets. In contrast, neurons cannot generally regenerate injured axons within the central nervous system (CNS: brain, spinal cord, eye). While most research in the field has tended to ascribe these differences to cell-extrinsic inhibitors of growth, recent evidence suggests that intrinsic factors are at least as important in governing a neuron's ability to regenerate its axon. Following peripheral nerve injury, dorsal root ganglion (DRG) neurons undergo striking changes in the expression of genes required for cell survival and axon outgrowth, enabling them to regenerate both their peripheral axon branch and their centrally directed axon branch into the CNS. In contrast, following injury to the optic nerve, retinal ganglion cells (RGCs), the projection neurons of the eye, show only modest changes in gene expression and modest levels of terminal sprouting, but no long-distance regeneration. In response to growth factors released by macrophages, however, RGCs undergo changes in gene expression similar to those seen in regenerating DRG neurons and extend lengthy axons through the optic nerve. Here, we discuss what is known about the inductive signals for axon regeneration in DRG neurons and RGCs, the signal transduction pathways and transcription factors involved, and the use of combinatorial treatments to overcome cell-extrinsic growth-inhibitory signals while also activating neurons' intrinsic growth state. A greater understanding of the molecular events that accompany axon regeneration in the CNS and PNS is likely to help us achieve better outcome after neural injury in the clinical setting. C1 [Seijffers, Rhona] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, Charlestown, MA 02129 USA. [Seijffers, Rhona] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Benowitz, Larry] Harvard Univ, Childrens Hosp, Sch Med, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA. [Benowitz, Larry] Harvard Univ, Childrens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA. [Benowitz, Larry] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. [Benowitz, Larry] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA. RP Seijffers, R (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, Charlestown, MA 02129 USA. NR 266 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055698-7 PY 2008 BP 1 EP 39 DI 10.1016/B978-012373994-0.50003-8 PG 39 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA BGE45 UT WOS:000322549700002 ER PT J AU Mulrow, CD Chiquette, E Angel, L Grimm, R Cornell, J Summerbell, CD Anagnostelis, BB Brand, M AF Mulrow, Cynthia D. Chiquette, Elaine Angel, L. Grimm, Richard Cornell, John Summerbell, Carolyn D. Anagnostelis, Betsy B. Brand, M. TI Dieting to reduce body weight for controlling hypertension in adults (Withdrawn Paper. 2008, art.no. CD000484) SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Correction C1 [Mulrow, Cynthia D.] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. [Chiquette, Elaine] Univ Texas Austin, Coll Pharm, PHR 5 112, Austin, TX 78712 USA. [Angel, L.; Grimm, Richard; Brand, M.] Shapiro Ctr Evidenced Based Med, Minneapolis, MN USA. [Summerbell, Carolyn D.] Univ Teesside, Sch Hlth & Social Care, Middlesbrough, Cleveland, England. [Anagnostelis, Betsy B.] UCL, Royal Free & Univ Coll Med Sch, Med Lib, London, England. RP Mulrow, CD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem Vet Hosp, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. EM mulrowc@uthscsa.edu RI Anagnostelis, Betsy/C-5271-2008 NR 1 TC 5 Z9 5 U1 2 U2 6 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2008 IS 4 AR CD000484 DI 10.1002/14651858.CD000484.pub2 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 358CU UT WOS:000259895000142 PM 18843609 ER PT J AU Bonneh, YS Belmonte, MK Pei, F Iversen, PE Kenet, T Akshoomoff, N Adini, Y Simon, HJ Moore, CI Houde, JF Merzenich, MM AF Bonneh, Yoram S. Belmonte, Matthew K. Pei, Francesca Iversen, Portia E. Kenet, Tal Akshoomoff, Natacha Adini, Yael Simon, Helen J. Moore, Christopher I. Houde, John F. Merzenich, Michael M. TI Cross-modal extinction in a boy with severely autistic behaviour and high verbal intelligence SO COGNITIVE NEUROPSYCHOLOGY LA English DT Article DE autism; extinction; perception; attention; cross-modal; multimodal; auditory; visual; tactile ID AUDIOVISUAL SPEECH; SPECTRUM DISORDER; ATTENTION; NEGLECT; ABNORMALITIES; INDIVIDUALS; DYSFUNCTION; INTEGRATION; MECHANISMS; DOMINANCE AB Anecdotal reports from individuals with autism suggest a loss of awareness to stimuli from one modality in the presence of stimuli from another. Here we document such a case in a detailed study of A.M., a 13-year-old boy with autism in whom significant autistic behaviours are combined with an uneven IQ profile of superior verbal and low performance abilities. Although A.M.'s speech is often unintelligible, and his behaviour is dominated by motor stereotypies and impulsivity, he can communicate by typing or pointing independently within a letter board. A series of experiments using simple and highly salient visual, auditory, and tactile stimuli demonstrated a hierarchy of cross-modal extinction, in which auditory information extinguished other modalities at various levels of processing. A.M. also showed deficits in shifting and sustaining attention. These results provide evidence for monochannel perception in autism and suggest a general pattern of winner-takes-all processing in which a stronger stimulus-driven representation dominates behaviour, extinguishing weaker representations. C1 [Bonneh, Yoram S.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel. [Bonneh, Yoram S.] Univ Haifa, Fac Sci, IL-31999 Haifa, Israel. [Belmonte, Matthew K.] Cornell Univ, Dept Human Dev, Ithaca, NY USA. [Pei, Francesca] Italian Assoc Vis Sci AISV, Cascina, PI, Italy. [Iversen, Portia E.] Cure Autism Now, Los Angeles, CA USA. [Kenet, Tal] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Akshoomoff, Natacha] Univ Calif San Diego, Dept Psychiat, Sch Med, San Diego, CA 92103 USA. [Simon, Helen J.] Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA. [Moore, Christopher I.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [Houde, John F.] Univ Calif San Francisco, Dept Otolaryngol, San Francisco, CA 94143 USA. [Merzenich, Michael M.] Univ Calif San Francisco, Keck Ctr Integrat Neurosci, San Francisco, CA 94143 USA. RP Bonneh, YS (reprint author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel. EM Yoram.Bonneh@weizmann.ac.il RI Moore, Christopher/C-5588-2009; OI Belmonte, Matthew/0000-0002-4633-9400 FU Cure Autism Now; National Institute for Psychobiology in Israel FX We thank William Hirstein, Stefano Baldassi, Russ Hamer, David Blake, and Tony Norcia for valuable consultation. We thank Dorit Ben Shalom for helpful comments. We thank the Smith-Kettlewell Eye Research Institute for hosting most of the testing. We acknowledge the contribution of the written evaluation of A. M. as severely autistic by Lorna Wing, Judith Gold, and Beate Hermelin. The study was supported by Cure Autism Now and by a grant from the National Institute for Psychobiology in Israel to the first author. Special thanks to our participant and his mother for their enormous effort and collaboration. NR 58 TC 8 Z9 8 U1 1 U2 5 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0264-3294 J9 COGN NEUROPSYCHOL JI Cogn. Neuropsychol. PY 2008 VL 25 IS 5 BP 635 EP 652 DI 10.1080/02643290802106415 PG 18 WC Psychology; Psychology, Experimental SC Psychology GA 341AT UT WOS:000258687300001 PM 18651259 ER PT J AU Moo, LR Emerton, BC Slotnick, SD AF Moo, Lauren R. Emerton, Britt C. Slotnick, Scott D. TI Functional MT plus lesion impairs contralateral motion processing SO COGNITIVE NEUROPSYCHOLOGY LA English DT Article DE functional magnetic resonance imaging; vision; epilepsy; attention; perception ID ATTENTIONAL INHIBITION; SPATIAL ATTENTION; CEREBRAL-LESIONS; 2ND-ORDER MOTION; VISUAL-ATTENTION; BRAIN-DAMAGE; PERCEPTION; FMRI; STIMULATION; HUMANS AB Human motion processing region MT+ is retinotopically organized with perception of and attention to motion in the right visual field preferentially associated with left MT+ activity and vice versa. However, the degree to which MT+ is crucial for motion processing is uncertain. We report an epilepsy patient with visual symptoms early in his seizure evolution and a left temporal-occipital seizure onset electrographically in whom we hypothesized a functional left MT+ lesion. The patient was impaired in his right but not left visual field on a hemifield motion attention task and demonstrated worse performance on a hemifield picture identification task when pictures implying motion were presented in the right as opposed to the left visual field. Functional MRI (fMRI) during a full-field motion detection task activated right MT+ but failed to activate left MT+ despite activating both left and right MT+ in each of 10 controls. Furthermore, fMRI during a hemifield motion attention task also showed a lack of left MT+ attention effects in the patient. Together these results suggest that MT+ is necessary for normal motion processing. C1 [Moo, Lauren R.; Emerton, Britt C.] Massachusetts Gen Hosp, Dept Neurol, Neuropsychol Lab, Boston, MA 02114 USA. [Emerton, Britt C.] Suffolk Univ, Boston, MA 02114 USA. [Slotnick, Scott D.] Boston Coll, Dept Psychol, Chestnut Hill, MA 02167 USA. RP Moo, LR (reprint author), Massachusetts Gen Hosp, Dept Neurol, Neuropsychol Lab, 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM lmoo@partners.org FU National Institute for Deafness and Communication Disorders [DC005068] FX This work was supported by Grant DC005068 from the National Institute for Deafness and Communication Disorders (to L.R.M.). NR 37 TC 3 Z9 3 U1 0 U2 2 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0264-3294 J9 COGN NEUROPSYCHOL JI Cogn. Neuropsychol. PY 2008 VL 25 IS 5 BP 677 EP 689 DI 10.1080/02643290802271599 PG 13 WC Psychology; Psychology, Experimental SC Psychology GA 341AT UT WOS:000258687300003 PM 18651258 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI The communication of palliative care SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Article; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP 1 EP 19 PG 19 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100003 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI Communication as Comfort Preface SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Editorial Material; Book Chapter ID BREAKING BAD-NEWS; OF-LIFE CARE; TERMINALLY-ILL PATIENTS; PALLIATIVE CARE; CANCER-PATIENTS; SERIOUSLY ILL; CONTROLLED-TRIAL; PATIENTS PERSPECTIVES; MEDICAL-EDUCATION; INCURABLE CANCER C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP VIII EP + PG 16 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100001 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI Communication as Comfort Foreword SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Editorial Material; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP X EP XI PG 2 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100002 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI The history and practice of palliative care SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Article; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP 20 EP 33 PG 14 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100004 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI The patient's perspective SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Article; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP 34 EP 56 PG 23 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100005 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI The medical perspective SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Article; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP 57 EP 86 PG 30 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100006 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI The family/caregiver perspective SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Article; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP 87 EP 107 PG 21 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100007 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI The health care team's perspective SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Article; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP 108 EP 129 PG 22 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100008 ER PT J AU Ragan, SL Wittenberg-Lyles, EM Goldsmith, J Sanchez-Reilly, S AF Ragan, Sandra L. Wittenberg-Lyles, Elaine M. Goldsmith, Joy Sanchez-Reilly, Sandra BA Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S BF Ragan, SL WittenbergLyles, E Glodsmith, J SanchezReilly, S TI The authors' voices SO COMMUNICATION AS COMFORT: MULTIPLE VOICES IN PALLIATIVE CARE SE LEAs Communication Series LA English DT Article; Book Chapter C1 [Ragan, Sandra L.] Univ Oklahoma, Norman, OK 73019 USA. [Wittenberg-Lyles, Elaine M.] Univ N Texas, Denton, TX 76203 USA. [Goldsmith, Joy] Young Harris Coll, Young Harris, GA USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Palliat Care Program, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] GRECC S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. RP Ragan, SL (reprint author), Univ Oklahoma, Norman, OK 73019 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-93867-6 J9 LEA COMMUN SER PY 2008 BP 130 EP 148 PG 19 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BNT21 UT WOS:000275478100009 ER PT J AU Wang, ML Hanfelt, JJ AF Wang, Molin Hanfelt, John J. TI Orthogonal locally ancillary estimating functions with application to stratified clustered data SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS LA English DT Article DE ancillarity; bias correction; clustered data; estimating function; nuisance parameter; orthogonality; sparse data ID NUISANCE PARAMETERS; ESTIMATING EQUATIONS; MODELS; SENSITIVITY; ERRORS AB We propose an orthogonal locally ancillary estimating function that provides first-order bias correction of inferences. It requires the specification of merely the first two moments of the observations when applying to analysis of stratified clustered (continuous or binary) data with the parameters of interest in both the first and second joint moments of dependent data. Simulation results confirm that the estimators obtained using the proposed method are substantially improved over those using regular profile estimating functions. C1 [Wang, Molin] Harvard Univ, Dept Biostat, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. [Hanfelt, John J.] Emory Univ, Dept Biostat, Atlanta, GA 30322 USA. RP Wang, ML (reprint author), Harvard Univ, Dept Biostat, Boston, MA 02115 USA. EM mwang@jimmy.harvard.edu NR 19 TC 0 Z9 0 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0361-0926 J9 COMMUN STAT-THEOR M JI Commun. Stat.-Theory Methods PY 2008 VL 37 IS 18 BP 2836 EP 2853 DI 10.1080/03610920802017777 PG 18 WC Statistics & Probability SC Mathematics GA 332KD UT WOS:000258081000003 ER PT J AU Foglia, MB Pearlman, RA AF Foglia, Mary Beth Pearlman, Robert A. BE Ford, PJ Dudzinski, DM TI It's not my responsibility SO COMPLEX ETHICS CONSULTATIONS: CASES THAT HAUNT US LA English DT Article; Book Chapter C1 [Pearlman, Robert A.] Univ Washington, Seattle, WA 98195 USA. [Pearlman, Robert A.] VA Puget Sound Hlth Care Syst, Eth Program, Seattle, WA USA. NR 13 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69715-6 PY 2008 BP 197 EP 204 PG 8 WC Ethics; Medical Ethics SC Social Sciences - Other Topics; Medical Ethics GA BAN43 UT WOS:000304829400027 ER PT J AU Centorrino, F Cincotta, SL Talamo, A Fogarty, KV Guzzetta, F Saadeh, MG Salvatore, P Baldessarini, RJ AF Centorrino, Franca Cincotta, Stephanie L. Talamo, Alessandra Fogarty, Kate V. Guzzetta, Francesca Saadeh, Mark G. Salvatore, Paola Baldessarini, Ross J. TI Hospital use of antipsychotic drugs: polytherapy SO COMPREHENSIVE PSYCHIATRY LA English DT Article ID COMBINATION THERAPY AB Objective: Growing acceptance of new psychotropic drugs encouraged a survey of current use of antipsychotic drugs alone and in combinations, with comparisons with previous findings. Method: Records from a random sample of McLean Hospital (Belmont, Mass) inpatients treated with an antipsychotic from March to May 2004 were reviewed for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, discharge diagnosis; all current psychotropic drug treatments; initial, peak, and final chlorpromazine-equivalent milligram-per-day dose of antipsychotics (APD); initial, peak, and final lithium-equivalent dose (milligram per day) of mood stabilizers (MS); weight change; clinical status at admission and discharge; and days of hospitalization. Results: In the 305 inpatients sampled (n = 184 women, 60.3%), Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, clinical conditions ranked as follows: major affective (n = 161, 52.8%), psychotic (n 99, 32.5%), and other disorders (n = 45, 14.8%). Modern drugs comprised 92% of antipsychotic prescriptions, and quetiapine (Usually at low doses) was most frequently prescribed. "Polytherapy" (simultaneous treatment with >= 2 psychotropic agents) at discharge was identified in 80% of antipsychotic-treated patients. Use of at least 2 antipsychotics (in 23% of cases) was associated with a 2.8-fold increase in total dose vs monotherapy (651 +/- 403 vs 232 +/- 205 mg/d). Total antipsychotic doses also were higher with mood stabilizer (most often divalproex) or sedative (usually high-potency benzodiazepine) cotreatment, use of older neuroleptics, psychotic-disorder diagnoses, and substance use comorbidity. Polytherapy was not associated with superior clinical improvement or shorter hospitalization but was associated with higher body weight. Conclusions: Polytherapy involving antipsychotic drugs continues to increase despite limited empirical evidence for greater effectiveness or of safety of such combinations. (c) 2008 Elsevier Inc. All rights reserved. C1 [Centorrino, Franca; Cincotta, Stephanie L.; Talamo, Alessandra; Fogarty, Kate V.; Guzzetta, Francesca; Saadeh, Mark G.; Salvatore, Paola; Baldessarini, Ross J.] Massachusetts Gen Hosp, McLean Div, Schizophrenia Bipolar Disorder & Psychopharmacol, Belmont, MA 02478 USA. [Centorrino, Franca; Talamo, Alessandra; Salvatore, Paola; Baldessarini, Ross J.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Centorrino, Franca; Talamo, Alessandra; Salvatore, Paola; Baldessarini, Ross J.] Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA. [Salvatore, Paola] Univ Parma, Dept Neurosci, Sect Psychiat, I-43100 Parma, Italy. RP Centorrino, F (reprint author), Massachusetts Gen Hosp, McLean Div, Schizophrenia Bipolar Disorder & Psychopharmacol, Belmont, MA 02478 USA. EM fcentorrino@mclean.harvard.edu OI Talamo, Alessandra/0000-0001-7321-9247 NR 10 TC 18 Z9 18 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0010-440X J9 COMPR PSYCHIAT JI Compr. Psychiat. PD JAN-FEB PY 2008 VL 49 IS 1 BP 65 EP 69 DI 10.1016/j.comppsych.2007.08.002 PG 5 WC Psychiatry SC Psychiatry GA 243OL UT WOS:000251807100010 PM 18063043 ER PT J AU Friedman, SH Sorrentino, RM Stankowski, JE Holden, CE Resnick, PJ AF Friedman, Susan H. Sorrentino, Renee M. Stankowski, Joy E. Holden, Carol E. Resnick, Phillip J. TI Psychiatrists' knowledge about maternal filicidal thoughts SO COMPREHENSIVE PSYCHIATRY LA English DT Article; Proceedings Paper CT 159th Annual Meeting of the American-Psychiatric-Association CY MAY 20-25, 2006 CL Toronto, CANADA SP Amer Psychiat Assoc ID MENTALLY-ILL MOTHERS; CHILD MURDER; DISORDERS AB Objective: Child murder by mentally ill mothers is an important public health and psychiatric concern. However, the authors' clinical and forensic experience has been that psychiatrists often do not inquire about maternal thoughts of harming their children. This study sought to elucidate the perceptions of psychiatrists and psychiatric residents regarding the frequency of such thoughts, and to clarify whether they inquire specifically about maternal filicidal thoughts. Psychiatrists were expected to underestimate the prevalence maternal thoughts of harming their children. It was hypothesized that psychiatrists often do not ask their patients about these thoughts. Methods: This study surveyed psychiatrists and psychiatric residents at 2 academic institutions. Respondents were asked whether they routinely query women about motherhood, to estimate the frequency of thoughts of child harm, and whether they inquire about filicidal thoughts in psychotic or suicidal mothers. Results: Two hundred twenty surveys (67%) were returned. Most psychiatrists underestimated the frequency of depressed mothers who experienced thoughts of harming their young children. Almost one half indicated that they do not ask specifically about filicidal ideation but rather ask about general homicidal thoughts only. Conclusions: Psychiatrists should have further education about the prevalence of filicidal thoughts and more frequently inquire about them. (c) 2008 Elsevier Inc. All rights reserved. C1 [Friedman, Susan H.; Stankowski, Joy E.; Resnick, Phillip J.] Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Cleveland, OH 44106 USA. [Friedman, Susan H.; Sorrentino, Renee M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Holden, Carol E.] Michigan Ctr Forensic Psychiat, Ann Arbor, MI 48106 USA. RP Friedman, SH (reprint author), Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, 11100 Euclid Ave, Cleveland, OH 44106 USA. EM susan.hatters-friedman@uhhs.com NR 18 TC 12 Z9 12 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0010-440X J9 COMPR PSYCHIAT JI Compr. Psychiat. PD JAN-FEB PY 2008 VL 49 IS 1 BP 106 EP 110 DI 10.1016/j.comppsych.2007.07.001 PG 5 WC Psychiatry SC Psychiatry GA 243OL UT WOS:000251807100016 PM 18063049 ER PT B AU Soltesz, I Staley, K AF Soltesz, Ivan Staley, Kevin BE Soltesz, I Staley, K TI INTRODUCTION APPLICATIONS AND EMERGING CONCEPTS OF COMPUTATIONAL NEUROSCIENCE IN EPILEPSY RESEARCH SO COMPUTATIONAL NEUROSCIENCE IN EPILEPSY LA English DT Editorial Material; Book Chapter C1 [Soltesz, Ivan] Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA. [Staley, Kevin] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Soltesz, I (reprint author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055953-7; 978-0-12-373649-9 PY 2008 BP XV EP XIX DI 10.1016/B978-012373649-9.50003-X PG 5 WC Mathematical & Computational Biology; Clinical Neurology; Neurosciences SC Mathematical & Computational Biology; Neurosciences & Neurology GA BHP85 UT WOS:000326273800002 ER PT B AU Staley, K Swiercz, W Cios, KJ AF Staley, Kevin Swiercz, Waldemar Cios, Krzysztof J. BE Soltesz, I Staley, K TI VALIDATING MODELS OF EPILEPSY SO COMPUTATIONAL NEUROSCIENCE IN EPILEPSY LA English DT Article; Book Chapter ID CA3 NETWORK ACTIVITY; EPILEPTOGENESIS; HIPPOCAMPUS; CELLS AB Epilepsy has many etiologies that occur in a complex network. In contrast to the diversity of etiologies and the complexity of the network, the output of interest, seizures, is very simple. The simplicity of the output and the small numbers of measured parameters makes model validation difficult. Thus, it is not easy to determine the biological relevance of the manipulations used to generate the seizure output in realistic computer models with many necessary degrees of freedom. There are several ways to address this issue. The realism of the model can be increased by constraining the underlying cortical model to measured parameters. In addition, the output can be required to fit a more complex dataset by including measurements of as many parameters as possible, for example measures of network output that include temporal and physical dimensions. Measuring these parameters under as many experimental conditions as is feasible provides opportunities for additional tests of model accuracy. These constraints are likely to be the most practical approach to model validation in the near future. However, both model realism and model constraints are currently limited by the amount of experimental data available. C1 [Staley, Kevin] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Swiercz, Waldemar] Dept Neurol, Boston, MA USA. [Cios, Krzysztof J.] Univ Colorado Denver, Hlth Sci Ctr, Denver, CO USA. RP Staley, K (reprint author), Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 24 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055953-7; 978-0-12-373649-9 PY 2008 BP 43 EP 47 DI 10.1016/B978-012373649-9.50007-7 PG 5 WC Mathematical & Computational Biology; Clinical Neurology; Neurosciences SC Mathematical & Computational Biology; Neurosciences & Neurology GA BHP85 UT WOS:000326273800006 ER PT J AU Yang, E Maguire, TJ Yarmush, ML Berthiaume, F Androulakis, IP AF Yang, E. Maguire, T. J. Yarmush, M. L. Berthiaume, F. Androulakis, I. P. TI Identification of regulatory mechanisms of the hepatic response to thermal injury SO COMPUTERS & CHEMICAL ENGINEERING LA English DT Article; Proceedings Paper CT Process Systems Engineering Conference/16th European Symposium on Computer Aided Process Engineering (ESCAPE-16) CY 2006 CL Garmisch Partenkirchen, GERMANY DE gene expression; burn; inflammation; transcritpion factors ID GENE-EXPRESSION DATA; NETWORKS; INFLAMMATION; ACTIVATION; GENOMICS; LIVER; SHOCK; RATS AB The purpose of this paper is to evaluate the hypothesis that a systems biology approach can be developed such that a set of transcription factors, relevant to burn-induced inflammatory response can be identified and modulated to control the host response. We explore a novel method for identifying coherent and informative expression motifs and we subsequently determine conserved transcription factor binding sites for the sub-sets of co-expressed genes. The responses are rationalized in the context of burn-induced inflammation and the putative transcription factors are rationalized in the context of intervention targets for controlling gene expression. (c) 2007 Published by Elsevier Ltd. C1 [Yang, E.; Maguire, T. J.; Yarmush, M. L.; Androulakis, I. P.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08855 USA. [Berthiaume, F.] Shriners Hosp Children, Boston, MA USA. [Berthiaume, F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med,Surg Serv, Boston, MA USA. RP Androulakis, IP (reprint author), Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08855 USA. EM Yannis@rci.rutgers.edu NR 39 TC 2 Z9 2 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0098-1354 J9 COMPUT CHEM ENG JI Comput. Chem. Eng. PD JAN-FEB PY 2008 VL 32 IS 1-2 BP 356 EP 369 DI 10.1016/j.compchemeng.2007.02.009 PG 14 WC Computer Science, Interdisciplinary Applications; Engineering, Chemical SC Computer Science; Engineering GA 241DC UT WOS:000251636100029 ER PT B AU Indic, P Salisbury, EB Paydarfar, D Brown, EN Barbieri, R AF Indic, P. Salisbury, E. B. Paydarfar, D. Brown, E. N. Barbieri, R. GP IEEE TI Interaction between Heart Rate Variability and Respiration in Preterm Infants SO COMPUTERS IN CARDIOLOGY 2008, VOLS 1 AND 2 LA English DT Proceedings Paper CT 35th Annual Conference on Computers in Cardiology CY SEP 14-17, 2008 CL Bologna, ITALY ID SURROGATE DATA AB Several studies have focused attention on cardiorespiratory function as an important indicator of development in infants. In the preterm infant, however, it remains unclear whether respiratory activity already affects heart beat variations at such an early development stage. In this work we investigate the presence of cardiorespiratory coupling in preterm infants by quantifying the interaction between heart rate variability and respiration using multivariate autoregressive analysis. We evaluated the frequency domain indices using standard methods. Results show a significantly higher coupling, as confirmed by surrogate data analysis, in the frequency range associated with regular breathing compared to other ranges. These observations indicate a mild, but present, respiratory sinus arrhythmia in preterm infants. C1 [Indic, P.; Brown, E. N.; Barbieri, R.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA USA. [Indic, P.; Salisbury, E. B.; Paydarfar, D.] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01656 USA. [Brown, E. N.; Barbieri, R.] MIT, Dept Brain & Cognit Sci, Cambridge, MA USA. RP Indic, P (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA USA. EM Premananda.Indic@umassmed.edu OI Barbieri, Riccardo/0000-0001-9381-3833; Salisbury, Elisabeth/0000-0002-7708-3428 FU CIMIT under U.S. Army Medical Research Acquisition Activity Cooperative Agreement [W81XWH-07-2-0011 (R.B.)]; National Institutes of Health (NIH) [R01-HL084502 (R.B), R01-DA015644 (E.N.B), DP1-OD003646 (E.N.B), R01-HL49848 (D.P.), R01-HL071884 (D.P.)]; American Heart Association Scientist Development Grant (E.B.S.); Clinical and Translational Science Pilot Project Program of the University of Massachusetts Medical FX This work was supported by CIMIT under U.S. Army Medical Research Acquisition Activity Cooperative Agreement W81XWH-07-2-0011 (R.B.), by National Institutes of Health (NIH) Grants R01-HL084502 (R.B), R01-DA015644 (E.N.B), DP1-OD003646 (E.N.B), R01-HL49848 (D.P.), R01-HL071884 (D.P.), by American Heart Association Scientist Development Grant (E.B.S.), and the Clinical and Translational Science Pilot Project Program of the University of Massachusetts Medical NR 10 TC 1 Z9 1 U1 0 U2 0 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA BN 978-1-4244-3706-1 PY 2008 BP 57 EP + DI 10.1109/CIC.2008.4748976 PG 2 WC Computer Science, Information Systems; Engineering, Biomedical; Medical Informatics SC Computer Science; Engineering; Medical Informatics GA BIZ28 UT WOS:000263940800015 ER PT B AU Syed, Z Scirica, BM Stultz, CM Guttag, JV AF Syed, Z. Scirica, B. M. Stultz, C. M. Guttag, J. V. GP IEEE TI Comparing Symbolic Representations of Cardiac Activity to Identify Patient Populations with Similar Risk Profiles SO COMPUTERS IN CARDIOLOGY 2008, VOLS 1 AND 2 LA English DT Proceedings Paper CT 35th Annual Conference on Computers in Cardiology CY SEP 14-17, 2008 CL Bologna, ITALY AB This paper proposes electrocardiographic mismatch (ECGM) to quantify differences in the long-term ECG signals for two patients. ECGM compares the symbolic distributions of ECG signals and measures how different patients are electrocardiographically. Using ECGM, we propose a hierarchical clustering scheme that can identify patients in a population with anomalous ECG characteristics. When applied to a population of 686 patients suffering non-ST-elevation ACS, our approach was able to identify patients at an increased risk of death and myocardial infarction (HR 2.8, p=0.003) over a 90 day follow-up period. C1 [Syed, Z.; Stultz, C. M.; Guttag, J. V.] MIT, 32 Vassar St, 32G-91, Cambridge, MA 02139 USA. [Scirica, B. M.] Brigham Womens Hosp, TIMI Study Grp, Boston, MA USA. RP Syed, Z (reprint author), 32 Vassar St,32G-916, Cambridge, MA 02139 USA. EM zhs@csail.mit.edu FU Center for Integration of Medicine and Innovative Technology (CIMIT); Harvard-MIT Division of Health Sciences and Technology (HST); Industrial Technology Research Institute (ITRI); AstraZeneca (AZ) FX This work was supported by the Center for Integration of Medicine and Innovative Technology (CIMIT), the Harvard-MIT Division of Health Sciences and Technology (HST) and the Industrial Technology Research Institute (ITRI). The DISPERSE2 trial was supported by AstraZeneca (AZ). NR 6 TC 0 Z9 0 U1 0 U2 0 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA BN 978-1-4244-3706-1 PY 2008 BP 85 EP + DI 10.1109/CIC.2008.4748983 PG 2 WC Computer Science, Information Systems; Engineering, Biomedical; Medical Informatics SC Computer Science; Engineering; Medical Informatics GA BIZ28 UT WOS:000263940800022 ER PT B AU Chen, Z Brown, EN Barbieri, R AF Chen, Z. Brown, E. N. Barbieri, R. GP IEEE TI A Point Process Approach to Assess Dynamic Baroreflex Gain SO COMPUTERS IN CARDIOLOGY 2008, VOLS 1 AND 2 LA English DT Proceedings Paper CT 35th Annual Conference on Computers in Cardiology CY SEP 14-17, 2008 CL Bologna, ITALY ID HEART-RATE AB Evaluation of arterial baroreflex in cardiovascular control is an important topic in cardiology and clinical medicine. In this paper we present a point process approach to estimate the dynamic baroreflex gain in a closed-loop model of the cardiovascular system. Specifically, the inverse Gaussian probability distribution is used to model the heartbeat interval, whereas the instantaneous mean is modulated by a bivariate autoregressive model that contains the previous R-R intervals and systolic blood pressure (SBP) measures. The instantaneous baroreflex gain is estimated in the feedback loop with a point process filter while the RR -> SBP feedforward frequency response gain can be estimated by a Kalman filter The proposed estimation approach provides a quantitative assessment of interacting heartbeat dynamics and hemodynamics. We validate our approach with real physiological signals and evaluate the proposed model with established goodness-of-fit tests. C1 [Chen, Z.; Brown, E. N.; Barbieri, R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Harvard MIT Div Hlth Sci & Technol,Neurosci Stat, Cambridge, MA 02139 USA. RP Chen, Z (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Harvard MIT Div Hlth Sci & Technol,Neurosci Stat, 43 Vassar St,Rm 46-6057, Cambridge, MA 02139 USA. EM zhechen@mit.edu OI Barbieri, Riccardo/0000-0001-9381-3833; Chen, Zhe/0000-0002-6483-6056 NR 12 TC 2 Z9 2 U1 0 U2 0 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA BN 978-1-4244-3706-1 PY 2008 BP 805 EP 808 DI 10.1109/CIC.2008.4749164 PG 4 WC Computer Science, Information Systems; Engineering, Biomedical; Medical Informatics SC Computer Science; Engineering; Medical Informatics GA BIZ28 UT WOS:000263940800203 ER PT S AU Maherali, N Hochedlinger, K AF Maherali, N. Hochedlinger, K. BE Stillman, B Stewart, S Grodzicker, T TI Induced Pluripotency of Mouse and Human Somatic Cells SO CONTROL AND REGULATION OF STEM CELLS SE COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY SERIES LA English DT Proceedings Paper CT 73rd Cold Spring Harbor Symposium on Quantitative Biology CY MAY 28-JUN 02, 2008 CL Cold Spring Harbor, NY SP Natl Cancer Inst, Agilent Technol, Appl Biosyst, AstraZeneca, Bio Ventures, Bristol Myers Squibb Co, Genentech, Hoffmann La Roche, Invitrogen Co, IRX Therapeut, Kyowa Hakko Kogyo, New England BioLabs, OSI Pharmaceut, Sanofi Aventis, Schering Plough Res Inst ID EMBRYONIC STEM-CELLS; PANCREATIC BETA-CELLS; ES CELLS; NUCLEAR TRANSPLANTATION; DEFINED FACTORS; FIBROBLASTS; GENERATION; DIFFERENTIATION; EXPRESSION; DISEASE AB The identification of transcription factors to induce pluripotency directly in somatic cells has given researchers a unique platform oil which to dissect the mechanisms underlying epigenetic reprogramming. In addition, induced pluripotent stem (iPS) cells have enabled the derivation of patient-specific cells for the study and potential treatment of a variety of diseases. Here, we discuss recent discoveries in the reprogramming field including work from our own laboratory. C1 [Maherali, N.; Hochedlinger, K.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. RP Maherali, N (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. NR 50 TC 19 Z9 19 U1 1 U2 1 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 USA SN 0091-7451 BN 978-0-87969-862-1 J9 COLD SH Q B PY 2008 VL 73 BP 157 EP 162 DI 10.1101/sqb.2008.73.017 PG 6 WC Oncology; Cell Biology SC Oncology; Cell Biology GA BJT56 UT WOS:000267135700019 PM 19022751 ER PT S AU Orkin, SH Wang, J Kim, J Chu, J Rao, S Theunissen, TW Shen, X Levasseur, DN AF Orkin, S. H. Wang, J. Kim, J. Chu, J. Rao, S. Theunissen, T. W. Shen, X. Levasseur, D. N. BE Stillman, B Stewart, S Grodzicker, T TI The Transcriptional Network Controlling Pluripotency in ES Cells SO CONTROL AND REGULATION OF STEM CELLS SE COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY SERIES LA English DT Proceedings Paper CT 73rd Cold Spring Harbor Symposium on Quantitative Biology CY MAY 28-JUN 02, 2008 CL Cold Spring Harbor, NY SP Natl Cancer Inst, Agilent Technol, Appl Biosyst, AstraZeneca, Bio Ventures, Bristol Myers Squibb Co, Genentech, Hoffmann La Roche, Invitrogen Co, IRX Therapeut, Kyowa Hakko Kogyo, New England BioLabs, OSI Pharmaceut, Sanofi Aventis, Schering Plough Res Inst ID EMBRYONIC STEM-CELLS; SELF-RENEWAL; MOUSE EMBRYOS; NANOG; COMPLEXES; OCT4 AB Embryonic stem (ES) cells are capable of continuous self-renewal and pluripotential differentiation. A "core" set of transcription factors, Oct4, Sox2, and Nanog, maintains the ES cell state, whereas various combinations of factors, invariably including Oct4 and Sox2, reprogram somatic cells to pluripotency. We have sought to define the transcriptional network controlling pluripotency in mouse ES cells through combined proteomic and genomic approaches. We constructed a protein interaction network surrounding Nanog and determined gene targets of the core and reprogramming factors, plus others. The expanded transcriptional network we have constructed forms the basis for further studies of directed differentiation and lineage reprogramming, and a paradigm for comprehensive elucidation of regulatory pathways in other stem cells. C1 [Orkin, S. H.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. RP Orkin, SH (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. OI Theunissen, Thorold/0000-0001-6943-7858 FU Howard Hughes Medical Institute NR 26 TC 40 Z9 42 U1 0 U2 7 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 USA SN 0091-7451 BN 978-0-87969-862-1 J9 COLD SH Q B PY 2008 VL 73 BP 195 EP 202 DI 10.1101/sqb.2008.72.001 PG 8 WC Oncology; Cell Biology SC Oncology; Cell Biology GA BJT56 UT WOS:000267135700024 PM 19478325 ER PT S AU Cerletti, M Shadrach, JL Jurga, S Sherwood, R Wagers, AJ AF Cerletti, M. Shadrach, J. L. Jurga, S. Sherwood, R. Wagers, A. J. BE Stillman, B Stewart, S Grodzicker, T TI Regulation and Function of Skeletal Muscle Stem Cells SO CONTROL AND REGULATION OF STEM CELLS SE COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY SERIES LA English DT Proceedings Paper CT 73rd Cold Spring Harbor Symposium on Quantitative Biology CY MAY 28-JUN 02, 2008 CL Cold Spring Harbor, NY SP Natl Cancer Inst, Agilent Technol, Appl Biosyst, AstraZeneca, Bio Ventures, Bristol Myers Squibb Co, Genentech, Hoffmann La Roche, Invitrogen Co, IRX Therapeut, Kyowa Hakko Kogyo, New England BioLabs, OSI Pharmaceut, Sanofi Aventis, Schering Plough Res Inst ID GIRDLE MUSCULAR-DYSTROPHY; MYOGENIC SATELLITE CELLS; PROGENITOR CELLS; HEMATOPOIETIC STEM; SELF-RENEWAL; MEMBRANE REPAIR; MDX MICE; MOUSE; DYSFERLIN; REGENERATION AB Skeletal muscle satellite cells, which reside beneath the basal lamina of mature muscle fibers, function as myogenic precursors and are required for normal muscle growth and repair. Satellite cells share a common anatomical localization, yet they exhibit substantial phenotypic and functional heterogeneity. Recent efforts ill the field of adult myogenesis have been aimed at dissecting this heterogeneity and reveal the presence of discrete cell lineages within the muscle that function independently and interactively to maintain muscle homeostasis and to determine the outcome of muscle damage. Normal developmental regulation of the frequency and function of these distinct tissue and pathological deregulation of their activity, may have an important role in age- and disease-dependent loss of muscle regenerative activity. C1 [Cerletti, M.; Shadrach, J. L.; Jurga, S.; Wagers, A. J.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, Boston, MA 02215 USA. RP Cerletti, M (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, Boston, MA 02215 USA. NR 65 TC 23 Z9 23 U1 0 U2 4 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 USA SN 0091-7451 BN 978-0-87969-862-1 J9 COLD SH Q B PY 2008 VL 73 BP 317 EP 322 DI 10.1101/sqb.2008.73.054 PG 6 WC Oncology; Cell Biology SC Oncology; Cell Biology GA BJT56 UT WOS:000267135700038 PM 19204065 ER PT B AU Pacholczyk, T AF Pacholczyk, Tadeusz BE Kleinman, DL CloudHansen, KA Matta, C Handelsman, J TI The Catholic Church and Stem Cell Research SO CONTROVERSIES IN SCIENCE & TECHNOLOGY, VOL 2: FROM CLIMATE TO CHROMOSOMES LA English DT Article; Book Chapter ID UMBILICAL-CORD BLOOD; BONE-MARROW; MOUSE EMBRYOS; PLURIPOTENCY; POPULATION; CULTURE C1 [Pacholczyk, Tadeusz] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. NR 27 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT INC PI LARCHMONT PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA BN 978-0-913113-42-4 PY 2008 BP 69 EP 79 PG 11 WC History & Philosophy Of Science; Multidisciplinary Sciences SC History & Philosophy of Science; Science & Technology - Other Topics GA BOE17 UT WOS:000276362800004 ER PT B AU Meigs, JB AF Meigs, James B. BE LeRoith, D Vinik, AI TI Metabolic Syndrome Is There Treatment that Works? SO CONTROVERSIES IN TREATING DIABETES: CLINICAL AND RESEARCH ASPECTS SE Contemporary Endocrinology LA English DT Article; Book Chapter DE metabolic syndrome; type 2 diabetes; cardiovascular disease; prevention ID TYPE-2 DIABETES-MELLITUS; INSULIN-RESISTANCE SYNDROME; CORONARY-HEART-DISEASE; TREATMENT PANEL-III; CARDIOVASCULAR RISK-FACTORS; LIFE-STYLE INTERVENTION; ALL-CAUSE MORTALITY; ENDOTHELIAL DYSFUNCTION; CARDIORESPIRATORY FITNESS; OVERWEIGHT PATIENTS AB "Metabolic syndrome" refers to the phenomenon of risk factor clustering and is presumed to reflect a unifying underlying pathophysiology. Clustering commonly occurs in the setting of obesity, insulin resistance and a sedentary lifestyle. Currently there are five different criteria for metabolic syndrome, all of which are associated with increased risk of diabetes or cardiovascular disease. Therapeutic lifestyle change that focuses on obesity and physical inactivity to reduce disease risk has a good evidence base. There is no specific drug therapy recommended for metabolic syndrome beyond medications that lower levels of its component risk factors, especially hypertension and dyslipidemia. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Gen Med Div, Boston, MA 02115 USA. RP Meigs, JB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Gen Med Div, Boston, MA 02115 USA. NR 85 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-708-2 J9 CONTEMP ENDOCRINOL S PY 2008 BP 33 EP 50 DI 10.1007/978-1-59745-572-5_3 D2 10.1007/978-1-59745-572-5 PG 18 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BJO77 UT WOS:000266928900003 ER PT J AU Celi, LA Hinske, LC Alterovitz, G Szolovits, P AF Celi, Leo Anthony Hinske, L. Christian Alterovitz, Gil Szolovits, Peter TI An artificial intelligence tool to predict fluid requirement in the intensive care unit: a proof-of-concept study SO CRITICAL CARE LA English DT Article ID CARDIAC-SURGERY; DECISION-SUPPORT; MORBIDITY; THERAPY; MODELS; SYSTEM AB Introduction The goal of personalised medicine in the intensive care unit (ICU) is to predict which diagnostic tests, monitoring interventions and treatments translate to improved outcomes given the variation between patients. Unfortunately, processes such as gene transcription and drug metabolism are dynamic in the critically ill; that is, information obtained during static non-diseased conditions may have limited applicability. We propose an alternative way of personalising medicine in the ICU on a real-time basis using information derived from the application of artificial intelligence on a high-resolution database. Calculation of maintenance fluid requirement at the height of systemic inflammatory response was selected to investigate the feasibility of this approach. Methods The Multi-parameter Intelligent Monitoring for Intensive Care II (MIMIC II) is a database of patients admitted to the Beth Israel Deaconess Medical Center ICU in Boston. Patients who were on vasopressors for more than six hours during the first 24 hours of admission were identified from the database. Demographic and physiological variables that might affect fluid requirement or reflect the intravascular volume during the first 24 hours in the ICU were extracted from the database. The outcome to be predicted is the total amount of fluid given during the second 24 hours in the ICU, including all the fluid boluses administered. Results We represented the variables by learning a Bayesian network from the underlying data. Using 10-fold cross-validation repeated 100 times, the accuracy of the model in predicting the outcome is 77.8%. The network generated has a threshold Bayes factor of seven representing the posterior probability of the model given the observed data. This Bayes factor translates into p < 0.05 assuming a Gaussian distribution of the variables. Conclusions Based on the model, the probability that a patient would require a certain range of fluid on day two can be predicted. In the presence of a larger database, analysis may be limited to patients with identical clinical presentation, demographic factors, co-morbidities, current physiological data and those who did not develop complications as a result of fluid administration. By better predicting maintenance fluid requirements based on the previous day's physiological variables, one might be able to prevent hypotensive episodes requiring fluid boluses during the course of the following day. C1 [Celi, Leo Anthony] Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. [Hinske, L. Christian] Decis Syst Grp, Boston, MA 02215 USA. [Alterovitz, Gil] Childrens Hosp, Informat Program, Boston, MA 02115 USA. [Szolovits, Peter] Stata Ctr, Cambridge, MA 02139 USA. RP Celi, LA (reprint author), Massachusetts Gen Hosp, Comp Sci Lab, 50 Staniford St,7th Floor, Boston, MA 02114 USA. EM lceli@mit.edu OI Hinske, Ludwig Christian/0000-0001-7273-5899 FU National Library of Medicine [2T15LM007092-16] FX This work has been supported in part by National Library of Medicine Training Grant # 2T15LM007092-16. The authors would like to thank Professor Roger Mark, Mauro Villaroel, Gari Clifford and Li-Wei Lehman for their assistance in using the MIMIC II database. NR 13 TC 9 Z9 9 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1466-609X J9 CRIT CARE JI Crit. Care PY 2008 VL 12 IS 6 AR R151 DI 10.1186/cc7140 PG 7 WC Critical Care Medicine SC General & Internal Medicine GA 415QK UT WOS:000263949200018 PM 19046450 ER PT J AU Kimberly, HH Noble, VE AF Kimberly, Heidi Harbison Noble, Vicki E. TI Using MRI of the optic nerve sheath to detect elevated intracranial pressure SO CRITICAL CARE LA English DT Editorial Material ID DIAMETER; SONOGRAPHY; ULTRASOUND; SEQUENCES; INJURY AB The current gold standard for the diagnosis of elevated intracranial pressure (ICP) remains invasive monitoring. Given that invasive monitoring is not always available or clinically feasible, there is growing interest in non-invasive methods of assessing ICP using diagnostic modalities such as ultrasound or magnetic resonance imaging (MRI). Increased ICP is transmitted through the cerebrospinal fluid surrounding the optic nerve, causing distention of the optic nerve sheath diameter (ONSD). In this issue of Critical Care, Geeraerts and colleagues describe a non-invasive method of diagnosing elevated ICP using MRI to measure the ONSD. They report a positive correlation between measurements of the ONSD on MRI and invasive ICP measurements. If the findings of this study can be replicated in larger populations, this technique may be a useful non-invasive screening test for elevated ICP in select populations. C1 [Kimberly, Heidi Harbison; Noble, Vicki E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Kimberly, HH (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. EM hkimberly@partners.org; vnoble@partners.org NR 15 TC 26 Z9 27 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1466-609X J9 CRIT CARE JI Crit. Care PY 2008 VL 12 IS 5 AR 181 DI 10.1186/cc7008 PG 2 WC Critical Care Medicine SC General & Internal Medicine GA 381UJ UT WOS:000261561100028 PM 18831721 ER PT J AU Li, LF Liao, SK Huang, CC Hung, MJ Quinn, DA AF Li, Li-Fu Liao, Shuen-Kuei Huang, Chung-Chi Hung, Ming-Jui Quinn, Deborah A. TI Serine/threonine kinase-protein kinase B and extracellular signal-regulated kinase regulate ventilator-induced pulmonary fibrosis after bleomycin-induced acute lung injury: a prospective, controlled animal experiment SO CRITICAL CARE LA English DT Article ID INDUCED NEUTROPHIL INFILTRATION; RESPIRATORY-DISTRESS-SYNDROME; GROWTH-FACTOR; CHEMOKINE; INHIBITION; PATHWAY; HYALURONAN; ACTIVATION; EXPRESSION; HYPEROXIA AB Introduction Lung fibrosis, reduced lung compliance, and severe hypoxemia found in patients with acute lung injury often result in a need for the support of mechanical ventilation. Hightidal-volume mechanical ventilation can increase lung damage and fibrogeneic activity but the mechanisms regulating the interaction between high tidal volume and lung fibrosis are unclear. We hypothesized that high-tidal-volume ventilation increased pulmonary fibrosis in acute lung injury via the serine/threonine kinase-protein kinase B (Akt) and mitogen-activated protein kinase pathways. Methods After 5 days of bleomycin administration to simulate acute lung injury, male C57BL/6 mice, weighing 20 to 25 g, were exposed to either high-tidal-volume mechanical ventilation (30 ml/kg) or low-tidal-volume mechanical ventilation (6 ml/kg) with room air for 1 to 5 hours. Results High-tidal-volume ventilation induced type I and type III procollagen mRNA expression, microvascular permeability, hydroxyproline content, Masson's trichrome staining, S100A4/fibroblast specific protein-1 staining, activation of Akt and extracellular signal-regulated kinase (ERK) 1/2, and production of macrophage inflammatory protein-2 and 10 kDa IFN gamma-inducible protein in a dose-dependent manner. High-tidal-volume ventilation-induced lung fibrosis was attenuated in Akt-deficient mice and in mice with pharmacologic inhibition of ERK1/2 activity by PD98059. Conclusion We conclude that high-tidal-volume ventilation-induced microvascular permeability, lung fibrosis, and chemokine production were dependent, in part, on activation of the Akt and ERK1/2 pathways. C1 [Quinn, Deborah A.] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA. [Li, Li-Fu; Huang, Chung-Chi] Chang Gung Mem Hosp, Div Pulm & Crit Care Med, Tao Yuan 333, Taiwan. [Liao, Shuen-Kuei; Hung, Ming-Jui] Chang Gung Univ, Grad Inst Clin Med Sci, Tao Yuan 333, Taiwan. [Li, Li-Fu; Huang, Chung-Chi] Chang Gung Mem Hosp, Dept Resp Therapy, Tao Yuan 333, Taiwan. [Hung, Ming-Jui] Chang Gung Mem Hosp, Dept Med, Cardiol Sect, Chilung 204, Taiwan. [Quinn, Deborah A.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Quinn, Deborah A.] Novartis Inst Biomed Res, Cambridge, MA 02140 USA. RP Quinn, DA (reprint author), Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, 55 Fruit St,Bulfinch 148, Boston, MA 02114 USA. EM dquinn1@partners.org NR 38 TC 28 Z9 33 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1466-609X J9 CRIT CARE JI Crit. Care PY 2008 VL 12 IS 4 AR R103 DI 10.1186/cc6983 PG 14 WC Critical Care Medicine SC General & Internal Medicine GA 360UF UT WOS:000260082700019 PM 18691424 ER PT J AU Liu, YY Lee, CH Dedaj, R Zhao, H Mrabat, H Sheidlin, A Syrkina, O Huang, PM Garg, HG Hales, CA Quinn, DA AF Liu, Yung-Yang Lee, Cheng-Hung Dedaj, Rejmon Zhao, Hang Mrabat, Hicham Sheidlin, Aviva Syrkina, Olga Huang, Pei-Ming Garg, Hari G. Hales, Charles A. Quinn, Deborah A. TI High-molecular-weight hyaluronan - a possible new treatment for sepsis-induced lung injury: a preclinical study in mechanically ventilated rats SO CRITICAL CARE LA English DT Article ID GENE-EXPRESSION; PERITONEAL PERMEABILITY; INFLAMMATION; ENDOTOXIN; TRANSCRIPTION; MACROPHAGES; RECEPTORS; CYTOKINES; REPAIR; MODEL AB Introduction Mechanical ventilation with even moderate-sized tidal volumes synergistically increases lung injury in sepsis and has been associated with proinflammatory low-molecular-weight hyaluronan production. High-molecular-weight hyaluronan (HMW HA), in contrast, has been found to be anti-inflammatory. We hypothesized that HMW HA would inhibit lung injury associated with sepsis and mechanical ventilation. Methods Sprague-Dawley rats were randomly divided into four groups: nonventilated control rats; mechanical ventilation plus lipopolysaccharide (LPS) infusion as a model of sepsis; mechanical ventilation plus LPS with HMW HA (1,600 kDa) pretreatment; and mechanical ventilation plus LPS with low-molecular-weight hyaluronan (35 kDa) pretreatment. Rats were mechanically ventilated with low (7 ml/kg) tidal volumes. LPS (1 or 3 mg/kg) or normal saline was infused 1 hour prior to mechanical ventilation. Animals received HMW HA or low-molecular-weight hyaluronan via the intraperitoneal route 18 hours prior to the study or received HMW HA (0.025%, 0.05% or 0.1%) intravenously 1 hour after injection of LPS. After 4 hours of ventilation, animals were sacrificed and the lung neutrophil and monocyte infiltration, the cytokine production, and the lung pathology score were measured. Results LPS induced lung neutrophil infiltration, macrophage inflammatory protein-2 and TNF alpha mRNA and protein, which were decreased in the presence of both 1,600 kDa and 35 kDa hyaluronan pretreatment. Only 1,600 kDa hyaluronan completely blocked both monocyte and neutrophil infiltration and decreased the lung injury. When infused intravenously 1 hour after LPS, 1,600 kDa hyaluronan inhibited lung neutrophil infiltration, macrophage inflammatory protein-2 mRNA expression and lung injury in a dose-dependent manner. The beneficial effects of hyaluronan were partially dependent on the positive charge of the compound. Conclusions HMW HA may prove to be an effective treatment strategy for sepsis-induced lung injury with mechanical ventilation. C1 [Liu, Yung-Yang; Lee, Cheng-Hung; Dedaj, Rejmon; Zhao, Hang; Mrabat, Hicham; Syrkina, Olga; Huang, Pei-Ming; Garg, Hari G.; Hales, Charles A.; Quinn, Deborah A.] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA. [Liu, Yung-Yang; Lee, Cheng-Hung; Dedaj, Rejmon; Zhao, Hang; Mrabat, Hicham; Syrkina, Olga; Huang, Pei-Ming; Garg, Hari G.; Hales, Charles A.; Quinn, Deborah A.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Liu, Yung-Yang] Taipei Vet Gen Hosp, Chest Dept, Taipei 11217, Taiwan. [Liu, Yung-Yang] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan. [Lee, Cheng-Hung] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan 70428, Taiwan. [Sheidlin, Aviva] Genzyme Corp, Cambridge, MA 02142 USA. [Syrkina, Olga] Shriners Burn Hosp, Boston, MA 02114 USA. [Huang, Pei-Ming] Natl Taiwan Univ Hosp, Dept Traumatol & Surg, Taipei 100, Taiwan. RP Quinn, DA (reprint author), Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, 55 Fruit St, Boston, MA 02114 USA. EM dquinn1@partners.org OI HUANG, PEI-MING/0000-0001-5493-7673 FU Genzyme Corporation; [AHA EIA 0440146N]; [NHLBI HL39150]; [T32 HL007874-11] FX The authors thank Susannah Wood for her generous support and encouragement, and thank John Beagle and Lunyin Yu for their expert technical assistance. The present work was supported by an unrestricted grant from the Genzyme Corporation, by the Susannah Wood Fund, and by AHA EIA 0440146N (to DAQ), by NHLBI HL39150 (to CAH), and by T32 HL007874-11 (to HZ). NR 40 TC 36 Z9 36 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1466-609X J9 CRIT CARE JI Crit. Care PY 2008 VL 12 IS 4 AR R102 DI 10.1186/cc6982 PG 11 WC Critical Care Medicine SC General & Internal Medicine GA 360UF UT WOS:000260082700018 PM 18691420 ER PT J AU Stelfox, HT Crimi, C Berra, L Noto, A Schmidt, U Bigatello, LM Hess, D AF Stelfox, Henry Thomas Crimi, Claudia Berra, Lorenzo Noto, Alberto Schmidt, Ulrich Bigatello, Luca M. Hess, Dean TI Determinants of tracheostomy decannulation: an international survey SO CRITICAL CARE LA English DT Article ID INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; CRITICALLY-ILL PATIENTS; SURGICAL TRACHEOSTOMY; RESPIRATORY-FAILURE; DECISION; OUTCOMES; COMPLICATIONS; METAANALYSIS; PERCEPTIONS AB Background Although tracheostomy is probably the most common surgical procedure performed on critically ill patients, it is unknown when a tracheostomy tube can be safely removed. Methods We performed a cross- sectional survey of physicians and respiratory therapists with expertise in the management of tracheostomized patients at 118 medical centers to characterize contemporary opinions about tracheostomy decannulation practice and to define factors that influence these practices. Results We surveyed 309 clinicians, of whom 225 responded ( 73%). Clinicians rated patient level of consciousness, ability to tolerate tracheostomy tube capping, cough effectiveness, and secretions as the most important factors in the decision to decannulate a patient. Decannulation failure was defined as the need to reinsert an artificial airway within 48 hours ( 45% of respondents) to 96 hours ( 20% of respondents) of tracheostomy removal, and 2% to 5% was the most frequent recommendation for an acceptable recannulation rate ( 44% of respondents). In clinical scenarios, clinicians who worked in chronic care facilities ( 30%) were less likely to recommend decannulation than clinicians who worked in weaning ( 47%), rehabilitation ( 53%), or acute care ( 55%) facilities ( p = 0.015). Patients were most likely to be recommended for decannulation if they were alert and interactive ( odds ratio [ OR] 4.76, 95% confidence interval [ CI] 3.27 to 6.90; p < 0.001), had a strong cough ( OR 3.84, 95% CI 2.66 to 5.54; p < 0.001), had scant thin secretions ( OR 2.23, 95% CI 1.56 to 3.19; p < 0.001), and required minimal supplemental oxygen ( OR 2.04, 95% CI 1.45 to 2.86; p < 0.001). Conclusion Patient level of consciousness, cough effectiveness, secretions, and oxygenation are important determinants of clinicians' tracheostomy decannulation opinions. Most surveyed clinicians defined decannulation failure as the need to reinsert an artificial airway within 48 to 96 hours of planned tracheostomy removal. C1 [Stelfox, Henry Thomas] Univ Calgary, Foothills Med Ctr, Dept Crit Care Med, Calgary, AB T2N 2T9, Canada. [Crimi, Claudia; Berra, Lorenzo; Schmidt, Ulrich; Bigatello, Luca M.; Hess, Dean] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. [Noto, Alberto] Univ Messina, Policlin Univ G Martino, Dept Anesthesia & Crit Care, Messina, Italy. RP Stelfox, HT (reprint author), Univ Calgary, Foothills Med Ctr, Dept Crit Care Med, EG23A,1403-29 St NW, Calgary, AB T2N 2T9, Canada. EM tom.stelfox@calgaryhealthregion.ca RI Noto, Alberto/G-6468-2012 NR 29 TC 43 Z9 48 U1 2 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1466-609X J9 CRIT CARE JI Crit. Care PY 2008 VL 12 IS 1 AR R26 DI 10.1186/cc6802 PG 9 WC Critical Care Medicine SC General & Internal Medicine GA 285YQ UT WOS:000254812500066 PM 18302759 ER PT J AU Tobin, MJ Jubran, A AF Tobin, Martin J. Jubran, Arnal TI Meta-analysis under the spotlight: Focused on a meta-analysis of ventilator weaning SO CRITICAL CARE MEDICINE LA English DT Article DE meta-analysis; clinical practice guidelines; mechanical ventilation; weaning; systematic error; random error ID PRESSURE SUPPORT VENTILATION; SHALLOW-BREATHING INDEX; MECHANICAL VENTILATION; INSPIRATORY PRESSURE; T-PIECE; SYSTEMATIC REVIEWS; OCCLUSION PRESSURE; ENDOTRACHEAL-TUBE; CLINICAL-TRIALS; EXTUBATION AB Objective. Because the results of a meta-analysis are used to formulate the highest level recommendation in clinical practice guidelines, clinicians should be mindful of problems inherent in this technique. Rather than reviewing meta-analysis in abstract, general terms, we believe readers can gain a more concrete understanding of the problems through a detailed examination of one meta-analysis. The meta-analysis on which we focus is that conducted by an American College of Chest Physicians/American Association for Respiratory Care/American College of Critical Care Medicine Task Force on ventilator weaning. Data Source: Two authors extracted data from all studies included in the Task Force's meta-analysis. Data Synthesis and Overview: The major obstacle to reliable internal validity and, thus, reliable external validity (generalizability) in biological research is systematic error, not random error. If systematic errors are present, averaging (as with a meta-analysis) does not decrease them-instead, it reinforces them, producing artifact. The Task Force's meta-analysis commits several examples of the three main types of systematic error: selection bias (test-referral bias, spectrum bias), misclassification bias (categorizing reintubation as weaning failure, etc.), and confounding (pressure support treated as unassisted breathing). Several additional interpretative errors are present. Conclusions. An increase in study size, as achieved through the pooling of data in a meta-analysis, is mistakenly thought to increase external validity. On the contrary, combining heterogeneous studies poses considerable risk of systematic error, which impairs internal validity and, thus, external validity. The strength of recommendations in clinical practice guidelines is based on a misperception of the relative importance of systematic vs. random error in science. C1 [Tobin, Martin J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA. Loyola Univ, Stritch Sch Med, Hines, IL USA. RP Tobin, MJ (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. EM mtobin2@lumc.edu FU NINR NIH HHS [R01 NR008782] NR 70 TC 47 Z9 48 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD JAN PY 2008 VL 36 IS 1 BP 1 EP 7 DI 10.1097/01.CCM.0000297883.04634.11 PG 7 WC Critical Care Medicine SC General & Internal Medicine GA 291YA UT WOS:000255232100001 PM 18007269 ER PT J AU Huang, YQ Sauthoff, H Herscovici, P Pipiya, T Cheng, J Heitner, S Szentirmai, O Carter, B Hay, JG AF Huang, Yao Qi Sauthoff, Harald Herscovici, Pablo Pipiya, Teona Cheng, Jin Heitner, Sheila Szentirmai, Oskar Carter, Bob Hay, John G. TI Angiopoietin-1 increases survival and reduces the development of lung edema induced by endotoxin administration in a murine model of acute lung injury SO CRITICAL CARE MEDICINE LA English DT Article DE acute respiratory distress syndrome; adenovirus; endotoxin; angiopoietin-1 ID RESPIRATORY-DISTRESS-SYNDROME; ESCHERICHIA-COLI; ENDOTHELIAL-CELL; MEDICAL PROGRESS; PLASMA LEAKAGE; SEPSIS; MECHANISMS; OUTCOMES; PATHOPHYSIOLOGY; ANGIOGENESIS AB Objective: To evaluate the effect of angiopoietin-1, an angiogenic growth factor, on lung capillary leakage and survival in a murine model of acute lung injury. Design: Laboratory investigation. Setting. Research laboratory at New York University School of Medicine and Department of Veterans Affairs, NY Harbor Healthcare System. Subjects: C57BL/6 mice weighing 18-20 g, susceptible to endotoxin-induced acute lung injury. Interventions: Acute lung injury was induced in C57BU6 mice by the intraperitoneal administration of endotoxin. The effects of angiopoietin-1, expressed from a nonreplicating E1a-deleted adenovirus containing the angiopoietin-1 complementary DNA (AdAng1), on survival and lung injury were evaluated. An E1a-deleted adenovirus that does not contain a transgene (Ad312) and phosphate-buffered saline were used as controls. Measurements and Main Results. Angiopoietin-1 protein was detected by immunoblotting in the serum of mice that received an intraperitoneal injection of AdAng1 but not in mice that received the control virus Ad312. When compared with control groups, mice that received AdAng1 5 days before endotoxin administration had improved survival and significantly less protein leakage from the circulation into the lungs, as detected by quantitative spectrophotometric measurements of Evans blue dye. Furthermore, when compared with controls, histopathology and immunostaining of lungs against CD31 and smooth muscle actin suggested preservation of vascular integrity and decreased tissue damage in mice pretreated with AdAng1. When endotoxin administration preceded infection with AdAng1 by 3 hrs, no benefit was observed. Conclusions: These data show that adenoviral mediated expression of angiopoietin-1 can protect against the development of lung capillary protein leak and decrease the mortality induced by endotoxin. However, the timing of AdAng1 administration in relation to the onset of lung injury may be critical. C1 [Huang, Yao Qi; Sauthoff, Harald; Herscovici, Pablo; Pipiya, Teona; Cheng, Jin; Heitner, Sheila; Hay, John G.] NYU, Sch Med, Div Pulm & Crit Care Med, New York, NY 10003 USA. [Huang, Yao Qi; Sauthoff, Harald; Herscovici, Pablo; Pipiya, Teona; Cheng, Jin; Heitner, Sheila; Hay, John G.] NYU, Sch Med, Dept Med, New York, NY 10003 USA. [Hay, John G.] NYU, Sch Med, Dept Pathol, New York, NY 10003 USA. [Hay, John G.] NYU, Sch Med, Inst Canc, New York, NY 10003 USA. [Sauthoff, Harald; Hay, John G.] New York Harbor Healthcare Syst, New York, NY USA. [Szentirmai, Oskar; Carter, Bob] Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02114 USA. RP Hay, JG (reprint author), NYU, Sch Med, Div Pulm & Crit Care Med, New York Campus, New York, NY 10003 USA. EM john.hay@med.nyu.edu OI Hay, John/0000-0003-3807-4075; Sauthoff, Harald/0000-0001-9258-4135 FU NCI NIH HHS [R01CA102053]; NCRR NIH HHS [M01RR-00096] NR 41 TC 26 Z9 31 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD JAN PY 2008 VL 36 IS 1 BP 262 EP 267 DI 10.1097/01.CCM.0000297955.02633.A4 PG 6 WC Critical Care Medicine SC General & Internal Medicine GA 291YA UT WOS:000255232100037 PM 18007265 ER PT J AU Dellinger, RP Levy, MM Carlet, JM Bion, J Parker, MM Jaeschke, R Reinhart, K Angus, DC Brun-Buisson, C Beale, R Calandra, T Dhainaut, JF Gerlach, H Harvey, M Marini, JJ Marshall, J Ranieri, M Ramsay, G Sevransky, J Thompson, BT Townsend, S Vender, JS Zimmerman, JL Vincent, JL AF Dellinger, R. Phillip Levy, Mitchell M. Carlet, Jean M. Bion, Julian Parker, Margaret M. Jaeschke, Roman Reinhart, Konrad Angus, Derek C. Brun-Buisson, Christian Beale, Richard Calandra, Thierty Dhainaut, Jean-Francois Gerlach, Herwig Harvey, Maurene Marini, John J. Marshall, John Ranieri, Marco Ramsay, Graham Sevransky, Jonathan Thompson, B. Taylor Townsend, Sean Vender, Jeffrey S. Zimmerman, Janice L. Vincent, Jean-Louis CA Int Surviving Sepsis Campai TI Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 SO CRITICAL CARE MEDICINE LA English DT Review DE sepsis; severe sepsis; septic shock; sepsis syndrome; infection; Grades of Recommendation; Assessment Development and Evaluation criteria; GRADE; guidelines; evidence-based medicine; Surviving Sepsis Campaign; sepsis bundles ID RESPIRATORY-DISTRESS-SYNDROME; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; ACUTE-RENAL-FAILURE; RANDOMIZED CONTROLLED-TRIAL; ACUTE LUNG INJURY; MECHANICALLY VENTILATED PATIENTS; DEEP-VEIN THROMBOSIS; LOW-DOSE HEPARIN; STRESS-ULCER PROPHYLAXIS AB Objective., To provide an update to the original Surviving Sepsis Campaign clinical management guidelines, "Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock," published in 2004. Design. Modified Delphi method with a consensus conference Of 55 international experts, several subsequent meetings of subgroups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee. This process was conducted independently of any industry funding. Methods, We used the Grades of Recommendation, Assessment Development and Evaluation (GRADE) system to guide assessment of quality of evidence from high (A) to very low (D) and to determine the strength of recommendations. A strong recommendation (1) indicates that an intervention's desirable effects clearly outweigh its undesirable effects (risk, burden, cost) or clearly do not. Weak recommendations (2) indicate that the tradeoff between desirable and undesirable effects is less clear. The grade of strong or weak is considered of greater clinical importance than a difference in letter level of quality of evidence. In areas without complete agreement, a formal process of resolution was developed and applied. Recommendations are grouped into those directly targeting severe sepsis, recommendations targeting general care of the critically ill patient that are considered high priority in severe sepsis, and pediatric considerations. Results: Key recommendations, listed by category, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition (1Q, blood cultures before antibiotic therapy (1Q imaging studies performed promptly to confirm potential source of infection (IC); administration of broad-spectrum antibiotic therapy within I hr of diagnosis of septic shock (113) and severe sepsis without septic shock (11 D); reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate (1C); a usual 7-10 days of antibiotic therapy guided by clinical response (1 D); source control with attention to the balance of risks and benefits of the chosen method (1Q administration of either crystalloid or colloid fluid resuscitation (1113); fluid challenge to restore mean circulating filling pressure (I Q reduction in rate of fluid administration with rising filing pressures and no improvement in tissue perfusion (0); vasopressor preference for norepinephrine or dopamine to maintain an initial target of mean arterial pressure >= 65 mm Hg (1C); dobutamine inotropic therapy when cardiac output remains low despite fluid resuscitation and combined inotropic/vasopressor therapy (1Q stress-dose steroid therapy given only in septic shock after blood pressure is identified to be poorly responsive to fluid and vasopressor therapy (2C); recombinant activated protein C in patients with severe sepsis and clinical assessment of high risk for death (2B except 2C for postoperative patients). In the absence of tissue hypoperfusion, coronary artery disease, or acute hemorrhage, target a hemoglobin of 7-9 g/dL (11B); a low tidal volume (1B) and limitation of inspiratory plateau pressure strategy (1 C) for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS); application of at least a minimal amount of positive end-expiratory pressure in acute lung injury (1 Q head of bed elevation in mechanically ventilated patients unless contraindicated (1 B); avoiding routine use of pulmonary artery catheters in ALYARDS (1A); to decrease days of mechanical ventilation and ICU length of stay, a conservative fluid strategy for patients with established ALI/ARDS who are not in shock (1C); protocols for weaning and sedation/analgesia (10); using either intermittent bolus sedation or continuous infusion sedation with daily interruptions or lightening (1B); avoidance of neuromuscular blockers, if at all possible (1B); institution of glycemic control (1B), targeting a blood glucose <150 mg/dL after initial stabilization (2C); equivalency of continuous veno-veno hernofiltration or intermittent hemodialysis (2B); prophylaxis for deep vein thrombosis (1A); use of stress ulcer prophylaxis to prevent upper gastrointestinal bleeding using H2 blockers (1A) or proton pump inhibitors (1B); and consideration of limitation of support where appropriate (11)). Recommendations specific to pediatric severe sepsis include greater use of physical examination therapeutic end points (2C); dopamine as the first drug of choice for hypotension (2C); steroids only in children with suspected or proven adrenal insufficiency (2C); and a recommendation against the use of recombinant activated protein C in children (1B). Conclusions. There was strong agreement among a large cohort of international experts regarding many level 1 recommendations for the best current care of patients with severe sepsis. Evidenced-based recommendations regarding the acute management of sepsis and septic shock are the first step toward improved outcomes for this important group of critically ill patients. C1 [Dellinger, R. Phillip] Cooper Univ Hosp, Camden, NJ 08103 USA. [Levy, Mitchell M.; Townsend, Sean] Brown Univ, Rhode Isl Hosp, Providence, RI 02903 USA. [Carlet, Jean M.] St Joseph Hosp, Paris, France. [Bion, Julian] Univ Birmingham, Birmingham, W Midlands, England. [Parker, Margaret M.] SUNY Stony Brook, Stony Brook, NY 11794 USA. [Jaeschke, Roman] McMaster Univ, Hamilton, ON, Canada. [Reinhart, Konrad] Univ Jena, Jena, Germany. [Angus, Derek C.] Univ Pittsburgh, Pittsburgh, PA USA. [Brun-Buisson, Christian] Univ Paris 12, Hop Henri Mondor, F-94010 Creteil, France. [Beale, Richard] Guys & St Thomas Hosp Trust, London, England. [Calandra, Thierty] CHU Vaudois, Lausanne, Switzerland. [Dhainaut, Jean-Francois] French Agcy Evaluat Res & Higher Educ, Paris, France. [Gerlach, Herwig] Vivantes Klinikum Neukoelin, Berlin, Germany. [Harvey, Maurene] Crit Care Inc, Glenbrook, NV USA. [Marini, John J.] Univ Minnesota, St Paul, MN 55108 USA. [Marshall, John] Univ Toronto, St Michaels Hosp, Toronto, ON M5B 1W8, Canada. [Ranieri, Marco] Univ Turin, Turin, Italy. [Ramsay, Graham] W Hertfordshire Hlth Trust, Hemel Hempstead, England. [Sevransky, Jonathan] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Thompson, B. Taylor] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Vender, Jeffrey S.] Evanston Northwestern Healthcare, Evanston, IL USA. [Zimmerman, Janice L.] Baylor Univ, Methodist Hosp, Houston, TX 77030 USA. [Vincent, Jean-Louis] Erasme Univ Hosp, B-1070 Brussels, Belgium. RP Dellinger, RP (reprint author), Cooper Univ Hosp, Camden, NJ 08103 USA. EM Dellinger-Phil@CooperHealth.edu RI Beale, Richard/J-7831-2013; Angus, Derek/E-9671-2012; Calandra, Thierry/D-9017-2015 OI Calandra, Thierry/0000-0003-3051-1285 FU NIGMS NIH HHS [K23 GM071399-03] NR 335 TC 2527 Z9 2915 U1 119 U2 520 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD JAN PY 2008 VL 36 IS 1 BP 296 EP 327 DI 10.1097/01.CCM.0000298158.12101.41 PG 32 WC Critical Care Medicine SC General & Internal Medicine GA 291YA UT WOS:000255232100042 PM 18158437 ER PT J AU Greer, D AF Greer, David TI Can cytokine removal in brain-dead patients improve transplant organ survival? SO CRITICAL CARE MEDICINE LA English DT Editorial Material ID DONORS; THERAPY C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Greer, D (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD JAN PY 2008 VL 36 IS 1 BP 362 EP 363 DI 10.1097/01.CCM.0000295264.34469.E5 PG 2 WC Critical Care Medicine SC General & Internal Medicine GA 291YA UT WOS:000255232100066 PM 18158461 ER PT J AU Ng, K Zhu, AX AF Ng, Kimmie Zhu, Andrew X. TI Targeting the epidermal growth factor receptor in metastatic colorectal cancer SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY LA English DT Review DE colorectal cancer; cetuximab (Erbitux (TM)); panitumumab (Vectibix (TM)); gefitinib; erlotinib (Tarceva (TM)); EGFR inhibition; clinical trial ID TYROSINE-KINASE-INHIBITOR; PHASE-II TRIAL; PREVIOUSLY TREATED PATIENTS; COLON-CARCINOMA CELLS; AMERICAN JOINT COMMITTEE; HUMAN TUMOR XENOGRAFTS; MONOCLONAL-ANTIBODY; LUNG-CANCER; IN-VIVO; ANTITUMOR-ACTIVITY AB Although significant advances have been made in the treatment of metastatic colorectal cancer (CRC), prognosis remains poor, with a 5-year survival of less than 10%. Monoclonal antibodies that target the epidermal growth factor receptor (EGFR) have shown clinical benefit as single agents and in combination with standard chemotherapy in the refractory setting, with tolerable toxicity. This article will discuss the role of the EGFR pathway in the pathogenesis of CRC, the data supporting the current use of cetuximab and panitumumab in the treatment of CRC, and clinical trials of EGFR tyrosine kinase inhibitors in CRC. Novel strategies of targeting the EGFR pathway to improve efficacy, as well as ongoing research in identifying molecular predictors of response to anti-EGFR agents, will also be reviewed. (c) 2007 Elsevier Ireland Ltd. All rights reserved. C1 [Ng, Kimmie; Zhu, Andrew X.] Massachusetts Gen Hosp, Ctr Canc, Tucker Gosnell Ctr Gastrointestinal Canc, Boston, MA 02114 USA. [Ng, Kimmie] Dana Farber Canc Inst, Boston, MA USA. [Ng, Kimmie; Zhu, Andrew X.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Zhu, AX (reprint author), Massachusetts Gen Hosp, Ctr Canc, Tucker Gosnell Ctr Gastrointestinal Canc, Lawrence House,POB 232-55 Fruit St, Boston, MA 02114 USA. EM azhu@partners.org FU NCI NIH HHS [T32 CA009172] NR 97 TC 31 Z9 32 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1040-8428 J9 CRIT REV ONCOL HEMAT JI Crit. Rev. Oncol./Hematol. PD JAN PY 2008 VL 65 IS 1 BP 8 EP 20 DI 10.1016/j.critrevonc.2007.09.006 PG 13 WC Oncology; Hematology SC Oncology; Hematology GA 256LM UT WOS:000252730300002 PM 18006328 ER PT J AU Stark, M AF Stark, Martha TI Hormesis, adaptation, and the sandpile model SO CRITICAL REVIEWS IN TOXICOLOGY LA English DT Review DE adaptation; chaos theory; extracellular matrix; hormesis; nonmonotonic dose-response curve; sandpile model; stress AB Hormesis, characterized by stimulation (or inhibition) along some portion of the dose-response curve followed by its opposing action along some other portion of that curve, speaks to all those dose-response relationships characterized by a change in sign and reversal in direction of the curve as it progresses along the x axis (a nonmonotonic dose-response curve). Although this is better known in toxicology than in pharmacology, it behooves all clinicians to appreciate that if a particular dose of a medication is not efficacious, it does not necessarily follow that a higher dose will be more efficacious. The point of maximum stimulation (variable from individual to individual and variable within an individual over time) might be such that a lower dose of the medication would prove more therapeutic. Calabrese's hypothesis is that hormesis is a manifestation of the body's adaptive response to stress. This commentary emphasizes the importance of recognizing that such adaptations are always accomplished at some cost to the system in terms of its adaptation (nutrient and energetic) reserves. There is no gain without pain. Finally, the sandpile, a complex adaptive system whose evolution is characterized by iterative cycles of collapse and recovery, disruption and repair, challenge and adaptive reconstitution, may be a useful model for the cumulative impact over time of stress on the body, highlighting the complex nature of the body's responsiveness to varying degrees of stress. C1 [Stark, Martha] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Continuing Educ Program, Boston, MA USA. [Stark, Martha] Harvard Univ, Sch Med, Ctr Psychoanalyt Studies, Continuing Educ Program,Massachusetts Gen Hosp, Boston, MA USA. RP Stark, M (reprint author), 3 Ripley St, Newton, MA 02459 USA. EM marthastarkmd@hms.harvard.edu NR 19 TC 9 Z9 9 U1 1 U2 6 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1040-8444 J9 CRIT REV TOXICOL JI Crit. Rev. Toxicol. PY 2008 VL 38 IS 7 BP 641 EP 644 DI 10.1080/10408440802026422 PG 4 WC Toxicology SC Toxicology GA 338IJ UT WOS:000258500400008 PM 18709573 ER PT J AU Azar, D Casanova, FH Mimura, T Jain, S Chang, JH AF Azar, Dimitri T. Casanova, Fabio H. Mimura, Tatsuya Jain, Sandeep Chang, Jin-Hong TI Effect of MT1-MMP Deficiency and Overexpression in Corneal Keratocytes on Vascular Endothelial Cell Migration and Proliferation SO CURRENT EYE RESEARCH LA English DT Article DE angiogenesis; gene; expression; keratocyte; keratocyte-derived MT1-MMP; metalloproteinases; MT1-MMP ID MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; PRO-MMP-2 ACTIVATION; MICE; COLLAGEN; ANGIOGENESIS; CLEAVAGE; SURFACE; EXPRESSION; GENERATION; MATRILYSIN AB Purpose: To determine the effect of keratocyte-derived MT1-MMP on calf pulmonary artery endothelial cell (CPAE) proliferation and migration. Methods: Keratocyte lines were generated from MT1-MMP knockout (KO) and wild type (WT) mice. WT keratocytes were transfected with WT or mutant MT1-MMP DNAs (TC or E240A). The effect of keratocyte-conditioned media on CPAE proliferation and migration was assayed. Results: KO keratocyte conditioned media resulted in the greatest increase of CPAE cell proliferation (190.5 6.0%; p 0.01). WT keratocyte conditioned media showed higher CPAE proliferation (155.4 3.6%) than WT/MT1-MMP-transfected keratocytes (119.7 2.2%; p 0.001). Migration assays confirmed these findings. Conclusions: Keratocyte-derived MT1-MMP has anti-angiogenic effects in CPAE cells. C1 [Azar, Dimitri T.; Mimura, Tatsuya; Jain, Sandeep; Chang, Jin-Hong] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA. [Azar, Dimitri T.; Casanova, Fabio H.; Jain, Sandeep; Chang, Jin-Hong] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. [Azar, Dimitri T.; Mimura, Tatsuya; Chang, Jin-Hong] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA. RP Azar, D (reprint author), Univ Illinois, Dept Ophthalmol & Visual Sci, 1855 W Taylor St, Chicago, IL 60612 USA. EM dazar@uic.edu FU Research to Prevent Blindness, New York (NY); National Institutes of Health [EY10101, EY001792, EY14048] FX This work was supported by an unrestricted departmental grant from Research to Prevent Blindness, New York (NY) and National Institutes of Health Grants EY10101 (DTA), EY001792 (DTA), and EY14048 (JHC). NR 24 TC 14 Z9 14 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0271-3683 J9 CURR EYE RES JI Curr. Eye Res. PY 2008 VL 33 IS 11-12 BP 954 EP 962 AR PII 906653352 DI 10.1080/02713680802461106 PG 9 WC Ophthalmology SC Ophthalmology GA 383DC UT WOS:000261653300007 PM 19085378 ER PT J AU Altfeld, M Markowitz, M AF Altfeld, Marcus Markowitz, Martin TI Acute HIV-1 infection: past lessons, current thinking, future goals SO CURRENT OPINION IN HIV AND AIDS LA English DT Editorial Material C1 [Markowitz, Martin] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA. [Altfeld, Marcus] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partners AIDS Res Ctr, Boston, MA USA. [Altfeld, Marcus] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Infect Dis Unit, Boston, MA USA. [Altfeld, Marcus] Harvard Univ, Sch Med, Div Aids, Boston, MA USA. RP Markowitz, M (reprint author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave,7th Floor, New York, NY 10016 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1746-630X J9 CURR OPIN HIV AIDS JI Curr. Opin. HIV AIDS PD JAN PY 2008 VL 3 IS 1 BP 1 EP 3 DI 10.1097/COH.0b013e3282f331c5 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA V24NX UT WOS:000208418200001 PM 19372936 ER PT J AU Streeck, H van Bockel, D Kelleher, A AF Streeck, Hendrik van Bockel, David Kelleher, Anthony TI T-cell responses in primary HIV-1 infection SO CURRENT OPINION IN HIV AND AIDS LA English DT Article DE CD4; CD8; dysfunction; human leukocyte antigen; primary HIV infection; T cell AB Purpose of review Important immunological events, especially involving T cells, occur during primary HIV-1 infection. The qualitative nature of the primary immune response to the virus may determine long-term outcome. Whereas CD4 T cells are being rapidly depleted, CD8 T cells play an important role in the initial control of viral replication. There is significant individual variability in the extent of viral control. Understanding the mechanisms underlying these differences and the causes of the development of dysfunctional T-cell responses will allow the identification of opportunities for therapeutic intervention that might change the long-term outcome. Recent findings Recent studies have revealed early dysfunction of T cells demonstrating increased expression of PD-1, CTLA-4 and reduced expression of CD127. Those studies suggest disruption of the interaction between CD4 and CD8 T cells. In addition, a few regions, mainly within the Gag protein, have been highlighted as potentially important targets for effective immune responses inducing viral control. Summary Despite recent studies emphasizing the critical nature of acute HIV-1 infection, current intervention strategies have failed to influence disease progression. Recent findings have indicated potential new strategies to re-enable functional properties of T cells and direct these responses towards critical regions of the virus. C1 [van Bockel, David; Kelleher, Anthony] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia. [Streeck, Hendrik] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partners AIDS Res Ctr,Infect Dis Unit, Boston, MA USA. [Streeck, Hendrik] Harvard Univ, Sch Med, Div Aids, Boston, MA USA. RP Kelleher, A (reprint author), St Vincents Hosp, Immunovirol & Pathogenesis Program, NCHECR, UNSW,Ctr Immunol, Cnr W & Boundary St, Darlinghurst, NSW 2010, Australia. EM t.kelleher@cfi.unsw.edu.au FU National Centre in HIV Epidemiology and Clinical Research; Commonwealth Department of Health and Ageing through the Australian National Council on AIDS, Hepatitis C and Related Diseases; Dora Lush postgraduate scholarship; NHMRC (Australia); Deutscher Akademischer Austauschdiensts FX Sponsorship: The National Centre in HIV Epidemiology and Clinical Research is supported by the Commonwealth Department of Health and Ageing through the Australian National Council on AIDS, Hepatitis C and Related Diseases. D.vB. is the recipient of a Dora Lush postgraduate scholarship and A. D. K. is supported by a practitioner fellowship both awarded by NHMRC (Australia). H. S. is supported by the Deutscher Akademischer Austauschdiensts. NR 86 TC 3 Z9 3 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1746-630X J9 CURR OPIN HIV AIDS JI Curr. Opin. HIV AIDS PD JAN PY 2008 VL 3 IS 1 BP 52 EP 59 DI 10.1097/COH.0b013e3282f269d6 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA V24NX UT WOS:000208418200009 PM 19372944 ER PT J AU Mullins, JI Rolland, M Allen, TM AF Mullins, James I. Rolland, Morgane Allen, Todd M. TI Viral evolution and escape during primary human immunodeficiency virus-1 infection: implications for vaccine design SO CURRENT OPINION IN HIV AND AIDS LA English DT Article DE evolution; HIV; T lymphocyte; viral proteins AB Purpose of review The ability of human immunodeficiency virus to mutate rapidly to evade host immune pressures is a key hurdle limiting the control of human immunodeficiency virus-1 by cellular immune responses. Viral escape from CD8(+) T-cell recognition continues to be studied extensively, and emerging data provide greater appreciation of the affect of these mutations on the virus. These data may help identify key immune responses capable of suppressing viral replication. This goal remains critical, as current vaccines are unlikely to produce protective T-cell immunity. Recent findings Recent studies provide greater understanding of the propensity for transmitted mutations to revert, and of the ability of CD8(+) T-cell escape mutations to impact viral replication capacity and protein structure. These observations reveal important constraints on virus evolution and sequence diversity. Data are also accumulating for the ability of the immune system to mount de-novo CD8(+) T-cell responses against escape variants, revealing an underappreciated complexity of the process of viral escape. Summary Understanding the limits of sequence variation and the impact of immune escape mutations on viral fitness, particularly during acute infection, will be critical to guide the design of contemporary vaccines or therapeutics attempting to force human immunodeficiency viruses to become less fit. C1 [Allen, Todd M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partners AIDS Res Ctr, Boston, MA USA. [Mullins, James I.; Rolland, Morgane] Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA. [Mullins, James I.; Rolland, Morgane] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Allen, TM (reprint author), Massachusetts Gen Hosp, 149 13th St, Charlestown, MA 02129 USA. EM tallen2@partners.org RI Allen, Todd/F-5473-2011 FU National Institutes of Health [R01-AI054178, R21-AI067078, P01-AI57005 P30-AI27757, 1R01 AI058894]; Boeing Corporation FX We thank Arne Schneidewind for his critical review of this manuscript and Brad Loetel for preparation of the figure. Supported by the National Institutes of Health grants R01-AI054178 (T. M. Allen), R21-AI067078 (T. M. Allen), P01-AI57005 P30-AI27757, 1R01 AI058894 (J.I. Mullins), and by an unrestricted gift from the Boeing Corporation (J.I. Mullins). NR 72 TC 5 Z9 5 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1746-630X J9 CURR OPIN HIV AIDS JI Curr. Opin. HIV AIDS PD JAN PY 2008 VL 3 IS 1 BP 60 EP 66 DI 10.1097/COH.0b013e3282f233d9 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA V24NX UT WOS:000208418200010 PM 19372945 ER PT J AU Ziegler, DS Kung, AL AF Ziegler, David S. Kung, Andrew L. TI Therapeutic targeting of apoptosis pathways in cancer SO CURRENT OPINION IN ONCOLOGY LA English DT Review DE apoptosis; Bcl-2; cancer; death receptors; inhibitor of apoptosis proteins ID TUMOR-NECROSIS-FACTOR; BH3 MIMETIC ABT-737; BCL-2 ANTISENSE OLIGONUCLEOTIDE; CHRONIC LYMPHOCYTIC-LEUKEMIA; SMALL-MOLECULE ANTAGONISTS; ACUTE MYELOID-LEUKEMIA; IN-VIVO; MULTIPLE-MYELOMA; MDM2 ANTAGONISTS; ANTITUMOR-ACTIVITY AB Purpose of review Anti-apoptotic mechanisms contribute to the development of cancer and the resistance of cancer cells to antitumor therapies. This review focuses on the progress towards clinical application of therapies that directly modulate the apoptosis pathways. Recent findings A growing understanding of the mechanisms that control apoptosis has generated a number of strategies for modulating apoptotic pathways, including activation of death receptors and neutralization of anti-apoptotic proteins. Striking antitumor efficacy has been achieved in preclinical cancer models. To date, early-phase testing has not yet established the clinical utility of these strategies. Summary There is every reason to be optimistic that the wealth of knowledge about the molecular controls of apoptosis will eventually be translated into new clinical therapies for cancer. It is likely that the optimum utility of these pro-apoptotic therapies will be in combination with other treatment modalities, and careful patient selection will be necessary. C1 [Ziegler, David S.; Kung, Andrew L.] Childrens Hosp, Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA. RP Kung, AL (reprint author), 44 Binney St, Boston, MA 02115 USA. EM andrew_kung@dfci.harvard.edu OI Kung, Andrew/0000-0002-9091-488X NR 75 TC 59 Z9 69 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8746 J9 CURR OPIN ONCOL JI Curr. Opin. Oncol. PD JAN PY 2008 VL 20 IS 1 BP 97 EP 103 PG 7 WC Oncology SC Oncology GA 242DQ UT WOS:000251705100014 PM 18043263 ER PT J AU Murdoch, D Sager, J AF Murdoch, David Sager, Jason TI Will targeted therapy hold its promise? An evidence-based review SO CURRENT OPINION IN ONCOLOGY LA English DT Review ID RENAL-CELL CARCINOMA; METASTATIC COLORECTAL-CANCER; PHASE-III TRIAL; QUALITY-OF-LIFE; LUNG-CANCER; FOLLICULAR LYMPHOMA; INTERFERON-ALPHA; FRONT-LINE; LOW-GRADE; RITUXIMAB AB Key points (1) Many of the significant advances in cancer management in recent years have centered on the development and introduction of molecularly targeted therapies, such as monoclonal antibodies and tyrosine kinase inhibitors. (2) Despite targeted therapy that has clearly benefited and even cured certain patients (eg, imatinib, trastuzumab), the ultimate goal of curing cancer, and the more immediate goal of replacing non-targeted chemotherapies with less toxic, targeted agents has yet to be achieved for most cancer patients. (3) Based on a systematic review of randomized controlled trials, examples of significant benefits in selected cancers are provided: (a) Non-Hodgkin's lymphoma (NHL) - A large meta-analysis and several individual randomised, controlled trials (RCTs) report that rituximab plus chemotherapy has a major survival advantage over chemotherapy alone in patients with NHL; an overview of six clinical trials supports the survival benefit of rituximab plus chemotherapy. (b) Renal cell carcinoma (RCC) - Temsirolimus or sunitinib has a significant survival benefit relative to interferon-alpha, and sorafenib carries such a benefit in patients resistant to standard therapy. (c) Colorectal cancer (CRC) - An overview of three RCTs in metastatic CRC revealed that bevacizumab plus 5-fluorouracil/leucovorin possesses a significant survival advantage over 5-fluorouracil/leucovorin and irinotecan/5-fluorouracil/leucovorin. (d) Non-small-cell lung cancer (NSCLC) - In refractory NSCLC, erlotinib significantly prolongs survival, particularly in nonsmokers, and gefitinib may have some utility in patients of Asian ethnicity. (e) Head and neck squamous-cell carcinoma (HNSCC) - Cetuximab plus radiotherapy (versus radiotherapy alone) significantly improves locoregional control and survival (hazard ratio [HR] 0.68; p = 0.005) without worsening radiotherapy-related toxicity. C1 [Murdoch, David] Wolters Kluwer Hlth, Auckland, New Zealand. [Sager, Jason] Novartis Pharmaceut, Cambridge, MA USA. [Sager, Jason] Dana Farber Canc Inst, Cambridge, MA USA. RP Murdoch, D (reprint author), Wolters Kluwer Hlth, Auckland, New Zealand. NR 38 TC 36 Z9 38 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8746 J9 CURR OPIN ONCOL JI Curr. Opin. Oncol. PD JAN PY 2008 VL 20 IS 1 BP 104 EP 111 PG 8 WC Oncology SC Oncology GA 242DQ UT WOS:000251705100015 PM 18043264 ER PT J AU Rowe, BH Camargo, CA AF Rowe, Brian H. Camargo, Carlos A., Jr. TI The role of magnesium sulfate in the acute and chronic management of asthma SO CURRENT OPINION IN PULMONARY MEDICINE LA English DT Article DE asthma; bronchodilation; emergency medicine; magnesium sulfate; systematic reviews ID PLACEBO-CONTROLLED TRIAL; INTRAVENOUS MAGNESIUM; ORAL MAGNESIUM; METAANALYSIS; FLOW AB Evidence suggests that intravenous MgSO4 is beneficial in acute asthma, while the evidence for inhaled MgSO4 is less convincing. Moreover, the role of replacement therapy with oral magnesium remains to be clarified. The use of intravenous MgSO4 remains uncommon, with emergency physicians appropriately restricting its use to patients with severe exacerbations. C1 [Rowe, Brian H.] Univ Alberta, Dept Emergency Med, Edmonton, AB T6G 2B7, Canada. [Rowe, Brian H.] Capital Hlth, Edmonton, AB, Canada. [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Harvard Med Sch, Dept Emergency Med, Boston, MA USA. RP Rowe, BH (reprint author), Univ Alberta, Dept Emergency Med, 1G1-43 WMC,8440-112th St, Edmonton, AB T6G 2B7, Canada. EM brian.rowe@ualberta.ca FU NHLBI NIH HHS [HL-84401] NR 37 TC 33 Z9 35 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1070-5287 J9 CURR OPIN PULM MED JI Curr. Opin. Pulm. Med. PD JAN PY 2008 VL 14 IS 1 BP 70 EP 76 DI 10.1097/MCP.0b013e3282f19867 PG 7 WC Respiratory System SC Respiratory System GA 242AU UT WOS:000251697700011 PM 18043278 ER PT J AU Leaf, A Kang, JX Xiao, YF AF Leaf, Alexander Kang, Jing X. Xiao, Yong-Fu TI Fish oil fatty acids as cardiovascular drugs SO CURRENT VASCULAR PHARMACOLOGY LA English DT Article ID RAT CARDIAC MYOCYTES; SODIUM-CHANNEL INACTIVATION; VENTRICULAR-FIBRILLATION; MYOCARDIAL-INFARCTION; SUDDEN-DEATH; LONG-CHAIN; EICOSAPENTAENOIC ACID; CONTROLLED-TRIAL; NA+ CHANNELS; PREVENTION AB Starting in the 1970s the hypothesis that the low mortality from coronary heart disease among the Greenland Eskimos was due to their high consumption of n-3 fish oil fatty acids, initiated many studies to find if the n-3 polyunsaturated fatty acids in fish oils (PUFAs) could prevent cardiac atherosclerosis. To date this possibility has not achieved clinical recognition. The recent literature shows an increase of intervention studies to learn if the fish oil fatty acids can reduce mortality from sudden cardiac death, and the mechanism(s) of such a protective effect. Indeed the most definite beneficial cardiac action of these n-3 PUFAs seems now to be their ability in the short term to prevent sudden cardiac death. It is apparent that over long periods of time the n-3 fish oil fatty acids also prevent atherosclerosis. Definition of the fatty acids to which I will be referring in the text: n-6 (omega-6) polyunsaturated fatty acids; linoleic acid (18: 2n-6, LA); arachidonic acid (C20:4n-6, AA). n-3 (omega-3) fatty acids; linolenic acid (18:3n-3, ALA); eicosapentaenoic acid (20:5n-3, EPA); docosahexaenoic acid (C22:6n-3, DHA). The bold, underlined abbreviation will appear in the text to identify the fatty acid being discussed. C1 [Leaf, Alexander; Kang, Jing X.] Massachusetts Gen Hosp, Dept Med, Charlestown, MA 02129 USA. [Xiao, Yong-Fu] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Xiao, Yong-Fu] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Leaf, A (reprint author), Massachusetts Gen Hosp, Dept Med, E 149,13th St, Charlestown, MA 02129 USA. EM aleaf@partners.org NR 43 TC 36 Z9 38 U1 1 U2 7 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1570-1611 J9 CURR VASC PHARMACOL JI Current Vascular Pharmacology PD JAN PY 2008 VL 6 IS 1 BP 1 EP 12 DI 10.2174/157016108783331286 PG 12 WC Pharmacology & Pharmacy; Peripheral Vascular Disease SC Pharmacology & Pharmacy; Cardiovascular System & Cardiology GA 275ID UT WOS:000254064200001 PM 18220934 ER PT J AU Quintero-Rivera, F Abreu-E-Lima, P Zhang, IH Bieber, F Parast, MM AF Quintero-Rivera, F. Abreu-E-Lima, P. Zhang, I. H. Bieber, F. Parast, M. M. TI Concurrent homozygous alpha-thalassemia and trisomy 7 mosaicism: Case report of a liveborn male infant SO CYTOGENETIC AND GENOME RESEARCH LA English DT Meeting Abstract CT 40th Biennial American Cytogenetics Conference CY APR 10-13, 2008 CL Monterey, CA SP Genetix Appl Imaging Corp & Genzyme Genet C1 [Quintero-Rivera, F.; Bieber, F.] Brigham & Womens Hosp, Dept Pathol, Cytogenet Div, Boston, MA 02115 USA. [Abreu-E-Lima, P.; Bieber, F.; Parast, M. M.] Dana Farber Canc Inst, Dept Pathol, Div Womens & Perinatal Pathol, Boston, MA 02115 USA. [Zhang, I. H.] Dana Farber Canc Inst, Dept Pediat, Div Pediat Hematol Oncol, Boston, MA 02115 USA. [Quintero-Rivera, F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1424-8581 J9 CYTOGENET GENOME RES JI Cytogenet. Genome Res. PY 2008 VL 121 IS 1 MA 56 PG 1 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA 315KZ UT WOS:000256880200069 ER PT J AU Baloch, ZW Cibas, ES Clark, DP Layfield, LJ Ljung, BM Pitman, MB Abati, A AF Baloch, Zubair W. Cibas, Edmund S. Clark, Douglas P. Layfield, Lester J. Ljung, Britt-Marie Pitman, Martha Bishop Abati, Andrea TI The National Cancer Institute Thyroid fine needle aspiration state of the science conference: a summation SO CYTOJOURNAL LA English DT Review ID PARATHYROID-HORMONE ASSAY; TRANSCRIPTION FACTOR-I; HURTHLE CELL LESIONS; MONOCLONAL-ANTIBODIES; DIAGNOSTIC-ACCURACY; SUPPRESSIVE THERAPY; MEDULLARY CARCINOMA; PAPILLARY CARCINOMA; ADEQUACY ASSESSMENT; FOLLICULAR VARIANT C1 [Abati, Andrea] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA. [Baloch, Zubair W.] Univ Penn, Med Ctr, Dept Pathol, Philadelphia, PA 19104 USA. [Cibas, Edmund S.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Cibas, Edmund S.] Harvard Univ, Sch Med, Boston, MA USA. [Clark, Douglas P.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. [Layfield, Lester J.] Univ Utah Hosp & Clin, Dept Pathol, Salt Lake City, UT USA. [Ljung, Britt-Marie] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA. [Pitman, Martha Bishop] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA. RP Abati, A (reprint author), NCI, Pathol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA. EM baloch@mail.med.upenn.edu; ECIBAS@PARTNERS.ORG; dpclark@jhmi.edu; LAYFIEL@aruplab.com; britt-marie.ljung@ucsf.edu; MPITMAN@PARTNERS.ORG; abatia@mail.nih.gov FU American Cancer Society; College of American Pathologists; American Society for Clinical Pathology; American Society of Clinical Oncology; La Societe Francaise de Cytologie Clinique; American Society of Cytopathology; Papanicolaou Society of Cytopathology; American Association of Clinical Endocrinologists; American Association of Endocrine Surgeons; American Thyroid Association; Society of Radiologists in Ultrasound; American College of Radiology; National Comprehensive Cancer Network; American College of Endocrinology FX The following medical societies are co-sponsors of the NCI Thyroid Fine Needle Aspiration State of the Science Conference and Website:; The American Cancer Society; College of American Pathologists; The American Society for Clinical Pathology; The American Society of Clinical Oncology; La Societe Francaise de Cytologie Clinique; The American Society of Cytopathology; The Papanicolaou Society of Cytopathology; The American Association of Clinical Endocrinologists; The American Association of Endocrine Surgeons; The American Thyroid Association; The Society of Radiologists in Ultrasound; The American College of Radiology; National Comprehensive Cancer Network; The American College of Endocrinology NR 134 TC 189 Z9 196 U1 0 U2 5 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 0974-5963 EI 1742-6413 J9 CYTOJOURNAL JI CytoJournal PY 2008 VL 5 AR 6 DI 10.1186/1742-6413-5-6 PG 17 WC Pathology SC Pathology GA V17PI UT WOS:000207948700006 PM 18394201 ER PT J AU Zhu, CW Leibman, C McLaughlin, T Zbrozek, AS Scarmeas, N Albert, M Brandt, J Blacker, D Sano, M Stern, Y AF Zhu, Carolyn W. Leibman, Christopher McLaughlin, Trent Zbrozek, Arthur S. Scarmeas, Nikolaos Albert, Marilyn Brandt, Jason Blacker, Deborah Sano, Mary Stern, Yaakov TI Patient Dependence and Longitudinal Changes in Costs of Care in Alzheimer's Disease SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE Alzheimer's disease; Patient dependence; Costs of care, longitudinal changes ID PREDICTORS; MULTICENTER; DEMENTIAS; SEVERITY AB Background/Aims: To examine the incremental effect of patients' dependence on others, on cost of medical and non-medical care, and on informal caregiving hours over time. Methods: Data are obtained from 172 patients from the Predictors Study, a large, multicenter cohort of patients with probable Alzheimer disease (AD) followed annually for 4 years in 3 University-based AD centers in the USA. Enrollment required a modified Mini-Mental State Examination score >= 30. We examined the effects of patient dependence (measured by the Dependence Scale, DS) and function (measured by the Blessed Dementia Rating Scale, BDRS) on medical care cost, nonmedical care cost, and informal caregiving time using random effects regression models. Results: A one-point increase in DS score was associated with a 5.7% increase in medical cost, a 10.5% increase in nonmedical cost, and a 4.1% increase in caregiving time. A one-point increase in BDRS score was associated with a 7.6% increase in medical cost, a 3.9% increase in nonmedical cost and an 8.7% increase in caregiving time. Conclusions: Both functional impairment and patient dependence were associated with higher costs of care and caregiving time. Measures of functional impairment and patient dependence provide unique and incremental information on the overall impact of AD on patients and their caregivers. Copyright (C) 2008 S. Karger AG, Basel C1 [Zhu, Carolyn W.; Sano, Mary] James J Peters VA Med Ctr, GRECC, Bronx, NY 10468 USA. [Zhu, Carolyn W.; Sano, Mary] James J Peters VA Med Ctr, Res Enhancement Awards Program, Bronx, NY 10468 USA. [Zhu, Carolyn W.] Mt Sinai Sch Med, Brookdale Dept Geriatr, New York, NY USA. [Sano, Mary] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Scarmeas, Nikolaos; Stern, Yaakov] Taub Inst Res Alzheimers Dis & Aging Brain, Cognit Neurosci Div, New York, NY USA. [Scarmeas, Nikolaos; Stern, Yaakov] Columbia Univ, Med Ctr, Gertrude H Sergievsky Ctr, New York, NY USA. [Scarmeas, Nikolaos; Stern, Yaakov] Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA. [Leibman, Christopher; McLaughlin, Trent] Elan Pharmaceut Inc, San Francisco, CA USA. [Zbrozek, Arthur S.] Wyeth Pharmaceut, Collegeville, PA USA. [Albert, Marilyn; Brandt, Jason] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD USA. [Blacker, Deborah] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA. RP Zhu, CW (reprint author), James J Peters VA Med Ctr, GRECC, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM carolyn.zhu@mssm.edu OI Brandt, Jason/0000-0001-7381-6244 FU Elan Pharmaceuticals, Inc.; Wyeth Pharmaceuticals; Department of Veterans Affairs, Veterans Health Administration; [R01 AG07370]; [M01 RR000645]; [U01AG010483] FX The Predictors Study is supported by Federal grants R01 AG07370, M01 RR000645, and U01AG010483. Funding for this analysis was also partially provided by Elan Pharmaceuticals, Inc., and Wyeth Pharmaceuticals. Drs. Zhu and Sano are supported by the Department of Veterans Affairs, Veterans Health Administration. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 31 TC 42 Z9 42 U1 1 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2008 VL 26 IS 5 BP 416 EP 423 DI 10.1159/000164797 PG 8 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 369GW UT WOS:000260683600004 PM 18946219 ER PT J AU Pekkala, S Albert, ML Spiro, A Erkinjuntti, T AF Pekkala, S. Albert, M. L. Spiro, A., III Erkinjuntti, T. TI Perseveration in Alzheimer's disease SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE recurrent perseveration; stuck-in-set perseveration; continuous perseveration; semantic verbal fluency task; Alzheimer's disease ID TRAUMATIC BRAIN INJURY; HUNTINGTONS-DISEASE; VASCULAR DEMENTIA; CATEGORY FLUENCY; WORKING-MEMORY; VERBAL FLUENCY; FRONTAL LOBES; APHASIA; VARIETIES; RETRIEVAL AB Background/Aims and Methods: Perseveration is common in Alzheimer's disease (AD). We document the type and quantitative burden of perseveration as cognitive decline progresses from normal aging (n = 30) through mild AD (n = 20) to moderate AD (n = 20) by administering a semantic verbal fluency task. Results: We found perseveration to increase significantly with increasing severity of AD and different types of perseveration that distinguish the subject groups in a statistically significant manner. Recurrent and continuous perseverations appear early in AD. As the disease progresses in severity into moderate stage, the number of recurrent and continuous perseverations increases, and stuck-in-set perseverations emerge. Conclusion: The different types of perseveration are likely to reflect the progressive deterioration of different brain regions in AD. Copyright (C) 2007 S. Karger AG, Basel. C1 [Pekkala, S.; Albert, M. L.] VA Boston Healthcare Syst, Language Aging Brain Lab, Med Res Serv, Boston, MA 02130 USA. [Pekkala, S.] Univ Helsinki, Dept Speech Sci, Helsinki, Finland. [Erkinjuntti, T.] Univ Helsinki, Dept Neurol, Helsinki, Finland. [Spiro, A., III] VA Boston Healthcare Syst, Normat Aging Study, Boston, MA 02130 USA. [Albert, M. L.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Spiro, A., III] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. RP Pekkala, S (reprint author), VA Boston Healthcare Syst, Language Aging Brain Lab, Med Res Serv, 12D,Room 91,150 S Huntington Ave, Boston, MA 02130 USA. EM seija.pekkala@helsinki.fi FU NIA NIH HHS [AG 14345] NR 37 TC 23 Z9 23 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2008 VL 25 IS 2 BP 109 EP 114 DI 10.1159/000112476 PG 6 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 254MW UT WOS:000252591700003 PM 18075249 ER PT J AU Mendez, MF Shapira, JS Woods, RJ Licht, EA Saul, RE AF Mendez, Mario F. Shapira, Jill S. Woods, Rochelle J. Licht, Eliot A. Saul, Ronald E. TI Psychotic symptoms in frontotemporal dementia: Prevalence and review SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE frontotemporal dementia; psychosis; delusions; hallucinations; paranoia; Alzheimer's disease ID FRONTAL-LOBE DEGENERATION; NON-ALZHEIMER TYPE; PICKS-DISEASE; NEUROPSYCHIATRIC FEATURES; SPECT CHARACTERISTICS; TEMPORAL VARIANTS; CLINICAL PICTURE; WORK GROUP; SCHIZOPHRENIA; DIAGNOSIS AB Background/Aims: Although most patients with frontotemporal dementia (FTD) present with neuropsychiatric symptoms, the frequency of psychotic symptoms is unclear. This study aims to determine the prevalence of psychotic symptoms in a large cohort of well-diagnosed and followed FTD patients compared to age-matched patients with Alzheimer's disease (AD) and to further review the literature on psychosis in FTD. Methods: Delusions, hallucinations and paranoia were evaluated among 86 patients who met consensus criteria for FTD, had frontotemporal changes on functional neuroimaging and were followed for 2 years. They were compared to 23 patients with early-onset AD on a caregiver-administered psychiatric questionnaire. Results: Among the FTD patients, only 2 (2.3%) had delusions, 1 of whom had paranoid ideation; no FTD patient had hallucinations. This was significantly less than the AD patients, 4 (17.4%) of whom had delusions and paranoia. Other investigations fail to establish a significant association of psychosis with FTD. Conclusions: These findings, and a literature review, indicate that psychotic symptoms are rare in FTD, possibly due to limited temporal-limbic involvement in this disorder. Copyright (c) 2008 S. Karger AG, Basel. C1 [Mendez, Mario F.; Woods, Rochelle J.; Licht, Eliot A.; Saul, Ronald E.] VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA 90073 USA. [Mendez, Mario F.; Shapira, Jill S.; Woods, Rochelle J.; Licht, Eliot A.; Saul, Ronald E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, 116AF,Bldg 500,3S,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu NR 48 TC 44 Z9 46 U1 2 U2 6 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2008 VL 25 IS 3 BP 206 EP 211 DI 10.1159/000113418 PG 6 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 271GS UT WOS:000253777500002 PM 18204254 ER PT J AU Ringman, JM Romano, JD Medina, LD Rodriguez-Agudelo, Y Schaffer, B Varpetian, A Ortiz, F Fitten, LJ Cummings, JL Baloh, RW AF Ringman, John M. Romano, Joseph D. Medina, Luis D. Rodriguez-Agudelo, Yaneth Schaffer, Barbara Varpetian, Arousiak Ortiz, Freddy Fitten, L. Jamie Cummings, Jeffrey L. Baloh, Robert W. TI Increased prevalence of significant recurrent headache in preclinical familial Alzheimer's disease mutation carriers SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE familial Alzheimer's disease; headache; migraine; presenilin-1; amyloid precursor protein; Notch3; amyloid angiopathy ID CEREBRAL AMYLOID ANGIOPATHY; PRECURSOR PROTEIN GENE; PRESENILIN-1 MUTATION; SPASTIC PARAPARESIS; PS-1 MUTATIONS; SPECTRUM; DEPOSITION; MIGRAINE; FEATURES AB Background/Aims: A previous study found a high prevalence of headaches in persons with familial Alzheimer's disease (FAD) due to a PSEN1 mutation. In our study we compared the prevalence of headaches between nondemented FAD mutation carriers (MCs) and non-mutation-carrying controls (NCs). Methods: A headache questionnaire that assessed the prevalence of significant headaches and diagnosis of migraine and aura by ICHD-2 criteria was administered to 27 individuals at risk for FAD. Frequency of significant headaches, migraine, and aura were compared between MCs and NCs by chi(2) or Fisher's exact tests. Results: Twenty-three subjects were at risk for PSEN1 mutations and 4 for an APP substitution. The majority of subjects were female (23/27). MCs were more likely to report significant recurrent headache than NCs (67 vs. 25%, p = 0.031). Forty percent of MCs had headaches that met criteria for migraine whereas 17% of NCs met such criteria. The tendency for a higher prevalence of headaches in MCs held for different PSEN1 and APP mutations but was not significant unless all families were combined. Conclusions: In this population, headache was more common in nondemented FAD MCs than NCs. Possible mechanisms for this include cerebral inflammation, aberrant processing of Notch3, or disrupted intracellular calcium regulation. Copyright (C) 2008 S. Karger AG, Basel. C1 [Ringman, John M.; Medina, Luis D.; Schaffer, Barbara; Ortiz, Freddy; Fitten, L. Jamie; Cummings, Jeffrey L.] Univ Calif Los Angeles, Alzheimers Dis Res Ctr, Dept Neurol, Los Angeles, CA 90095 USA. [Ortiz, Freddy; Fitten, L. Jamie] Univ Calif Los Angeles, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90095 USA. [Cummings, Jeffrey L.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Varpetian, Arousiak] USC, Rancho Los Amigos Natl Rehabilitat Ctr, Keck Sch Med, Dept Neurol, Downey, CA USA. [Ortiz, Freddy; Fitten, L. Jamie] Olive View UCLA Med Ctr, Neuropsychiat Res Memory Clin, Sylmar, CA 91342 USA. [Romano, Joseph D.] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA. [Rodriguez-Agudelo, Yaneth] Natl Inst Neurol & Neurosurg, Dept Neuropsychol, Mexico City, DF, Mexico. RP Ringman, JM (reprint author), Univ Calif Los Angeles, Alzheimers Dis Res Ctr, Dept Neurol, 10911 Weyburn Ave,Suite 200, Los Angeles, CA 90095 USA. EM jringman@mednet.ucla.edu FU NCRR NIH HHS [M01-RR00865]; NIA NIH HHS [K08 AG-22228, R01 AG-21055, P50 AG-16570] NR 28 TC 8 Z9 8 U1 0 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2008 VL 25 IS 4 BP 380 EP 384 DI 10.1159/000121986 PG 5 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 289UD UT WOS:000255078500013 PM 18376127 ER PT J AU Beeri, MS Silverman, JM Schmeidler, J Wysocki, M Grossman, HZ Purohit, DP Perl, DP Haroutunian, V AF Beeri, Michal Schnaider Silverman, Jeremy M. Schmeidler, James Wysocki, Michael Grossman, Hillel Z. Purohit, Dushyant P. Perl, Daniel P. Haroutunian, Vahram TI Clinical dementia rating performed several years prior to death predicts regional Alzheimer's neuropathology SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE dementia severity; Alzheimer's disease; neuropathology; neuritic plaques; neurofibrillary tangles ID MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLES; ENTORHINAL CORTEX; SENILE PLAQUES; DISEASE; RELIABILITY; DECLINE; CA1 AB Aims: To assess the relationships between early and late antemortem measures of dementia severity and Alzheimer disease ( AD) neuropathology severity. Methods: 40 residents of a nursing home, average age at death 82.0, participated in this longitudinal cohort study with postmortem assessment. Severity of dementia was measured by Clinical Dementia Rating ( CDR) at two time points, averaging 4.5 and 1.0 years before death. Densities of postmortem neuritic plaques ( NPs) and neurofibrillary tangles ( NFTs) were measured in the cerebral cortex, hippocampus, and entorhinal cortex. Results: For most brain areas, both early and late CDRs were significantly associated with NPs and NFTs. CDRs assessed proximal to death predicted NFTs beyond the contribution of early CDRs. NPs were predicted by both early and late CDRs. NPs were predictive of both early and late CDRs after controlling for NFTs. NFTs were only associated significantly with late CDR in the cerebral cortex after controlling for NPs. Conclusions: Even if assessed several years before death, dementia severity is associated with AD neuropathology. NPs are more strongly associated with dementia severity than NFTs. NFTs consistently associate better with late than early CDR, suggesting that these neuropathological changes may occur relatively later in the course of the disease. Copyright (c) 2008 S. Karger AG, Basel. C1 [Beeri, Michal Schnaider; Silverman, Jeremy M.; Schmeidler, James; Wysocki, Michael; Grossman, Hillel Z.; Haroutunian, Vahram] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Purohit, Dushyant P.; Perl, Daniel P.] Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA. [Haroutunian, Vahram] James J Peters Vet Affairs Med Ctr, Psychiat Serv, Bronx, NY USA. RP Beeri, MS (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave Levy Pl,Box 1230, New York, NY 10029 USA. EM michal.beeri@mssm.edu NR 28 TC 3 Z9 3 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2008 VL 25 IS 5 BP 392 EP 398 DI 10.1159/000122586 PG 7 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 289UG UT WOS:000255078800002 ER PT J AU Gershuny, BS Baer, L Parker, H Gentes, EL Infield, AL Jenike, MA AF Gershuny, Beth S. Baer, Lee Parker, Holly Gentes, Emily L. Infield, Alison L. Jenike, Michael A. TI Trauma and posttraumatic stress disorder in treatment-resistant obsessive-compulsive disorder SO DEPRESSION AND ANXIETY LA English DT Article DE obsessive-compulsive disorder; posttraumatic stress disorder; prevalence; treatment-resistant ID POPULATION; SYMPTOMS; EVENTS AB Prior research has indicated a seemingly unique relation between obsessive-compulsive disorder (OCD) and posttraumatic stress disorder (PTSD) that appears to relate to negative treatment outcome for OCD. However, to date, the prevalence of trauma and PTSD in individuals seeking treatment for OCD is unclear. To begin to address this gap, this study assessed history of traumatic experiences and current PTSD in individuals seeking treatment for treatment-resistant OCD. Trauma predictors of PTSD severity also were examined in this sample. Participants included 104 individuals diagnosed with treatment resistant OCD who sought treatment over the course of 1 year from OCD specialty treatment facilities. Data were collected via naturalistic retrospective chart reviews of pre-treatment clinical intake files. Findings revealed that 82% of participants reported a history of trauma. Over 39% of the overall sample met criteria for PTSD, whereas almost 50% of individuals with a trauma history met criteria for PTSD. Interpersonal traumas and greater frequency of traumas were most predictive of PTSD severity, and individuals diagnosed with OCD and additional major depressive disorder (MDD) or borderline personality disorder (BPD) appeared at particular risk for a comorbid PTSD diagnosis. PTSD may be relatively common in individuals diagnosed with treatment-resistant OCD; and interpersonal traumas, MDD, and BPD may play a relatively strong predictive role in PTSD diagnosis and severity in such OCD patients. C1 [Gershuny, Beth S.; Gentes, Emily L.; Infield, Alison L.] Skidmore Coll, Dept Psychol, Saratoga Springs, NY 12866 USA. [Baer, Lee; Jenike, Michael A.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. [Baer, Lee; Jenike, Michael A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Parker, Holly] Harvard Univ, Sch Med, Dept Health Care Policy, Boston, MA 02115 USA. RP Gershuny, BS (reprint author), Skidmore Coll, Dept Psychol, 815 N Broadway, Saratoga Springs, NY 12866 USA. EM gershuny@skidmore.edu NR 17 TC 25 Z9 25 U1 1 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2008 VL 25 IS 1 BP 69 EP 71 DI 10.1002/da.20284 PG 3 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 258MH UT WOS:000252871500009 PM 17318836 ER PT J AU Olatunji, BO Feldman, G Smits, JAJ Christian, KM Zalta, AK Pollack, MH Simon, NM AF Olatunji, Bunmi O. Feldman, Greg Smits, Jasper A. J. Christian, Kelly M. Zalta, Alyson K. Pollack, Mark H. Simon, Naomi M. TI Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: Impact of anxiety senstivity on response to pharmacotherapy SO DEPRESSION AND ANXIETY LA English DT Article DE anxiety; depression; anxiety sensitivity; generalized anxiety disorder; fluoxetine ID PANIC DISORDER; HIERARCHICAL STRUCTURE; SENSITIVITY INDEX; MAJOR DEPRESSION; COMORBIDITY; MODEL AB Pharmacotherapy is an effective treatment for generalized anxiety disorder (GAD), but few studies have examined the nature of decline of anxiety and depression during pharmacotherapy for GAD and even fewer studies have examined predictors of symptom decline. This study examined the decline in symptoms of anxiety and depression in patients with GAD during a 6-week open trial of fluoxetine. Growth curve analyses indicated that pharmacotherapy with fluoxetine led to significant declines in symptoms of anxiety and depression over the 6 weeks of treatment. However, the decay slope observed for anxiety symptoms was significantly greater than that for depressive symptoms. Further analyses revealed that the decline in anxiety remained significant after accounting for the changes in symptoms of depression. However, the effect of treatment on depression was no longer significant after controlling for the reduction in anxiety symptoms. Overall anxiety sensitivity (AS) did not moderate the level of reduction in symptoms of anxiety or depression during pharmacotherapy. However, AS specific to physical concerns demonstated a marginal negative association with decline in anxiety and depression. AS specific to social concerns also demonstrated a marginal negative association with decline in anxiety symptoms. These findings suggest that the decline in anxiety symptoms is independent of the decline in symptoms of depression during pharmacotherapy for GAD and specific AS dimensions may predict symptom change in GAD. C1 [Olatunji, Bunmi O.] Vanderbilt Univ, Dept Psychol, Nashville, TN 37203 USA. [Feldman, Greg] Simmons Coll, Dept Psychol, Boston, MA 02115 USA. [Feldman, Greg; Christian, Kelly M.; Zalta, Alyson K.; Pollack, Mark H.; Simon, Naomi M.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Smits, Jasper A. J.] So Methodist Univ, Dept Psychol, Dallas, TX 75275 USA. RP Olatunji, BO (reprint author), Vanderbilt Univ, Dept Psychol, 301 Wilson Hall,111 21st Ave S, Nashville, TN 37203 USA. EM olubunmi.o.olatunji@vanderbilt.edu RI Smits, Jasper/A-4350-2008 OI Smits, Jasper/0000-0001-7128-9807 NR 27 TC 8 Z9 8 U1 3 U2 6 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2008 VL 25 IS 2 BP 167 EP 171 DI 10.1002/da.20283 PG 5 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 268GB UT WOS:000253566100010 PM 17335002 ER PT J AU Cullen, B Samuels, JE Pinto, A Fyer, AJ McCracken, JT Rauch, SL Murphy, DL Greenberg, BD Knowles, JA Placentini, J Bienvenu, OJ Grados, MA Riddle, MA Rasmussen, SA Pauls, DL Willour, VL Shugart, YY Liang, KY Hoehn-Sanic, R Nestadt, G AF Cullen, Bernadette Samuels, Jack E. Pinto, Anthony Fyer, Abby J. McCracken, James T. Rauch, Scott L. Murphy, Dennis L. Greenberg, Benjamin D. Knowles, James A. Placentini, John Bienvenu, O. Joseph, III Grados, Marco A. Riddle, Mark A. Rasmussen, Steven A. Pauls, David L. Willour, Virginia L. Shugart, Yin Y. Liang, Kung-Yee Hoehn-Sanic, Rudolf Nestadt, Gerald TI Demographic and clinical characteristics associated with treatment status in family members with obsessive-compulsive disorder SO DEPRESSION AND ANXIETY LA English DT Article DE OCD; treatment; clinical characteristics ID MENTAL-HEALTH-SERVICES; PSYCHIATRIC-DISORDERS; HELP-SEEKING; ANXIETY; PREDICTORS; PEOPLE; ACCESS; ONSET; MOOD AB This study investigated the demographic and clinical factors that influence treatment status in family members with obsessive-compulsive disorder (OCD). Six hundred and two subjects from the OCD Collaborative Genetics Study were interviewed using the Structured Clinical Interview for DSM-IV (SCID) to diagnose Axis I disorders, and the Yak-Brown Obsessive Compulsive Scale (Y-BOCS) for assessment of OCD symptoms. The demographic and clinical data were compared between subjects who bad received treatment and those who had not. A precipitous onset of symptoms, severe illness, multiple obsessions and compulsions, and co-morbid affective disorders were all positively associated with receiving treatment. Older age and the presence of obsessive compulsive personality disorder (OCPD) or OCPD traits were negatively associated with treatment. Gender and age at onset of symptoms did not predict treatment history. The mean duration from onset of symptoms to receiving treatment was 13.8 +/- SD 11.9 years, but there was a direct relationship between current age and time to treatment, with younger subjects receiving treatment sooner. Clinical factors are predominant in predicting treatment status in family members with OCD. Although the mean duration from onset of symptoms to treatment was long, younger family members appear to receive treatment sooner. C1 [Cullen, Bernadette; Samuels, Jack E.; Bienvenu, O. Joseph, III; Grados, Marco A.; Riddle, Mark A.; Willour, Virginia L.; Hoehn-Sanic, Rudolf; Nestadt, Gerald] Johns Hopkins Univ Hosp, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21287 USA. [Pinto, Anthony; Greenberg, Benjamin D.; Rasmussen, Steven A.] Butler Hosp, Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI 02906 USA. [Fyer, Abby J.; Knowles, James A.] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, New York, NY 10032 USA. [Fyer, Abby J.; Knowles, James A.] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA. [McCracken, James T.] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA USA. [Rauch, Scott L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Rauch, Scott L.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Murphy, Dennis L.] NIMH, NIH, Clin Sci Lab, Bethesda, MD 20892 USA. [Pauls, David L.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Shugart, Yin Y.] Johns Hopkins Univ, Sch Publ Hlth, Dept Epidemiol Bloomberg, Baltimore, MD USA. [Liang, Kung-Yee] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA. RP Cullen, B (reprint author), Johns Hopkins Univ Hosp, Sch Med, Dept Psychiat & Behav Sci, Meyer 144,600 N Wolfe St, Baltimore, MD 21287 USA. EM bcullen@jhmi.edu RI Liang, Kung-Yee/F-8299-2011; Pinto, Anthony/D-2718-2017; OI Pinto, Anthony/0000-0002-6078-7242; Samuels, Jack/0000-0002-6715-7905 FU NCRR NIH HHS [RR00052]; NIMH NIH HHS [K23-MH64543, R01 MH50214] NR 30 TC 13 Z9 14 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2008 VL 25 IS 3 BP 218 EP 224 DI 10.1002/da.20293 PG 7 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 282SV UT WOS:000254588400006 PM 17345603 ER PT J AU Hirshfeld-Becker, DR Micco, J Henin, A Bloomfield, A Biederman, J Rosenbaum, J AF Hirshfeld-Becker, Dina R. Micco, Jamie Henin, Aude Bloomfield, Alison Biederman, Joseph Rosenbaum, Jerrold TI Behavioral inhibition SO DEPRESSION AND ANXIETY LA English DT Article DE behavioral inhibition; childhood anxiety disorders; social anxiety disorders; temperament ID AGE 3 YEARS; ANXIETY DISORDERS; PANIC DISORDER; SOCIAL-ANXIETY; PSYCHIATRIC-DISORDERS; LONGITUDINAL EVIDENCE; UNINHIBITED BEHAVIOR; PARENTING BEHAVIORS; INFANT TEMPERAMENT; PRESCHOOL-CHILDREN AB Over the past 25 years, our understanding of the risks conferred by "behavioral inhibition to the unfamiliar" (BI) has grown tremendously, yet many questions remain. BI represents the persistent tendency to show extreme reticence, fearfulness, or avoidance in novel situations or with unfamiliar people. Prospective studies of high-risk offspring, selected community children, and unselected epidemiologic samples converge to suggest that BI confers specific risk for social anxiety disorder in early and middle childhood and adolescence. Later outcomes are less clear, with some studies suggesting associations with depression or panic disorder. Studies that find broad associations between BI and anxiety proneness in general may be limited by the absence of information about parental psychopathology (an important potential confound associated with both BI and anxiety disorders in offspring). A critical area for further inquiry is the degree to which BI confers risk for social anxiety disorder in the absence of family history of anxiety disorders. Additionally, although progress has been made in identifying risk factors, protective factors, and treatments that may influence the course of BI and associated anxiety, more work is needed. Also, several exciting inroads have been made into the genetic and neurobiologic underpinnings of BI, and future studies promise greater elucidation of these areas. For now, the clinical take-home message is that preschool-age children presenting with extreme and persistent BI are at elevated risk for social anxiety disorder and possibly for other future disorders; preliminary evidence suggests that these children may be helped by early cognitive-behavioral intervention. C1 [Hirshfeld-Becker, Dina R.; Micco, Jamie; Henin, Aude; Bloomfield, Alison; Biederman, Joseph; Rosenbaum, Jerrold] Massachusetts Gen Hosp, Dept Psychiat, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA. RP Hirshfeld-Becker, DR (reprint author), 185 Alewife Brook Pkway,Suite 2000, Cambridge, MA 02461 USA. NR 90 TC 53 Z9 54 U1 6 U2 20 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2008 VL 25 IS 4 BP 357 EP 367 DI 10.1002/da.20490 PG 11 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 291ZN UT WOS:000255236200010 PM 18412062 ER PT J AU Smoller, JW Gardner-Schuster, E Misiaszek, M AF Smoller, Jordan W. Gardner-Schuster, Erica Misiaszek, Mirella TI Genetics of anxiety: would the genome recognize the DSM? SO DEPRESSION AND ANXIETY LA English DT Review DE genetic; anxiety; disorder; nosology; DSM ID OBSESSIVE-COMPULSIVE DISORDER; CATECHOL-O-METHYLTRANSFERASE; POSTTRAUMATIC-STRESS-DISORDER; SEROTONIN TRANSPORTER GENE; ENVIRONMENTAL RISK-FACTORS; GENERALIZED SOCIAL PHOBIA; WIDE LINKAGE ANALYSIS; PANIC DISORDER; MAJOR DEPRESSION; HUMAN AMYGDALA AB The nosology of anxiety disorders has undergone substantial evolution over the past several decades. The modern classification of these disorders dates to the publication of Diagnostic and Statistical Manual-III (DSM-III) in 1980, but the validity of the current diagnostic categories has been the subject of controversy. Genetic research can help clarify the boundaries of diagnostic categories by examining the etiologic relationships among them. The question posed in the title of this article asks to what degree the DSM-IV definitions of the anxiety disorders are supported by the evolving body of research on the genetic basis of pathologic anxiety. With DSM-V on the horizon, there is a renewed imperative to examine the structure of these disorders. In this article, we address this issue by, first, providing a brief update about the current status of genetic research on anxiety disorders and then considering whether the evidence suggests that genetic influences conform to or transcend DSM definitions. Finally, we discuss future directions for the genetic dissection of anxiety disorders. C1 [Smoller, Jordan W.; Gardner-Schuster, Erica; Misiaszek, Mirella] Massachusetts Gen Hosp, Ctr Human Genet Res, Dept Psychiat, Psychiat Genet Program Mood & Anxiety Disorders, Boston, MA 02114 USA. [Smoller, Jordan W.; Gardner-Schuster, Erica; Misiaszek, Mirella] Massachusetts Gen Hosp, Ctr Human Genet Res, Neurodev Genet Unit, Psychiat Genet Program Mood & Anxiety Disorders, Boston, MA 02114 USA. RP Smoller, JW (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Dept Psychiat, Psychiat Genet Program Mood & Anxiety Disorders, Simches Res Bldg,185 Cambridge St, Boston, MA 02114 USA. EM jsmoller@hms.harvard.edu NR 121 TC 25 Z9 26 U1 5 U2 10 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2008 VL 25 IS 4 BP 368 EP 377 DI 10.1002/da.20492 PG 10 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 291ZN UT WOS:000255236200011 PM 18412063 ER PT J AU Pollack, MH Otto, MW Roy-Byrne, PP Coplan, JD Rothbaum, BO Simon, NM Gorman, JM AF Pollack, Mark H. Otto, Michael W. Roy-Byrne, Peter P. Coplan, Jeremy D. Rothbaum, Barbara O. Simon, Naomi M. Gorman, Jack M. TI Novel treatment approaches for refractory anxiety disorders SO DEPRESSION AND ANXIETY LA English DT Review DE anxiety disorder; treatment failure; drug therapy; behavior therapy; cognitive ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIOR THERAPY; PLACEBO-CONTROLLED TRIAL; SEROTONIN REUPTAKE INHIBITORS; GENERALIZED SOCIAL PHOBIA; RESISTANT PANIC DISORDER; EXPOSURE-BASED TREATMENT; DOUBLE-BLIND; OPEN-LABEL; D-CYCLOSERINE AB The Anxiety Disorders Association of America convened a conference of experts to address treatment-resistant anxiety disorders and review promising novel approaches to the treatment of refractory anxiety disorders. Workgroup leaders and other participants reviewed the literature and considered the presentations and discussions from the conference. Authors placed the emerging literature on new therapeutic approaches into clinical perspective and identified unmet needs and priority areas for future research. There is a relative paucity of efforts addressing inadequate response to anxiety disorder treatment. Systematic efforts to exhaust all therapeutic options and overcome barriers to effective treatment delivery are needed before patients can be considered treatment refractory. Cognitive behavioral therapy, especially in combination with pharmacotherapy, must be tailored to accommodate the effects of clinical context on treatment response. The literature on pharmacologic treatment of refractory anxiety disorders is small but growing and includes studies of augmentation strategies and non-traditional anxiolytics. Research efforts to discover new pharmacologic targets are focusing on neuronal systems that mediate responses to stress and fear. A number of clinical and basic science studies were proposed that would advance the research agenda and improve treatment of patients with anxiety disorders. Significant advances have been made in the development of psychotherapeutic and pharmacologic treatments for anxiety disorders. Unfortunately, many patients remain symptomatic and functionally impaired. Progress in the development of new treatments has great promise, but will only succeed through a concerted research effort that systematically evaluates potential areas of importance,and properly uses scarce resources. C1 [Pollack, Mark H.; Simon, Naomi M.] Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Related Disorders, Boston, MA 02114 USA. [Pollack, Mark H.; Simon, Naomi M.] Harvard Univ, Sch Med, Boston, MA USA. [Otto, Michael W.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Otto, Michael W.] Boston Univ, Ctr Anxiety & Related Disorders, Boston, MA 02215 USA. [Roy-Byrne, Peter P.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Coplan, Jeremy D.] Suny Downstate Med Ctr, Dept Psychiat, Dept Neuropsychopharmacol, Brooklyn, NY 11203 USA. [Rothbaum, Barbara O.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Trauma & Anxiety Recovery Program, Atlanta, GA USA. [Gorman, Jack M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Gorman, Jack M.] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA. RP Pollack, MH (reprint author), Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Related Disorders, Simches Res Bldg,185 Cambridge St,Suite 2200,2nd, Boston, MA 02114 USA. EM mpollack@partners.org NR 89 TC 23 Z9 26 U1 3 U2 8 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2008 VL 25 IS 6 BP 467 EP 476 DI 10.1002/da.20329 PG 10 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 317JV UT WOS:000257017000001 PM 17437259 ER PT J AU Hinton, DE Chong, R Pollack, MH Barlow, DH McNally, RJ AF Hinton, Devon E. Chong, Roberto Pollack, Mark H. Barlow, David H. McNally, Richard J. TI Ataque de nervios: Relationship to anxiety sensitivity and dissociation predisposition SO DEPRESSION AND ANXIETY LA English DT Article DE Anxiety Sensitivity Index; Dissociation Experiences Scale; Puerto Rican; Hispanic; ataque de nervios; panic attacks ID TRAUMATIZED CAMBODIAN REFUGEES; COGNITIVE-BEHAVIOR THERAPY; PANIC DISORDER; DE-NERVIOS; ATTACKS; PREDICTION; VALIDITY; SCALE; INDEX AB We investigated the relative importance of "fear of arousal symptoms" (i.e., anxiety sensitivity) and "dissociation tendency" in generating ataque de nervios. Puerto Rican patients attending an outpatient psychiatric clinic were assessed for ataque de nervios frequency in the previous month, and they completed the Anxiety Sensitivity Index (ASI) and the Dissociation Experiences Scale (DES). ASI scores were especially high in the ataque-positive group (M = 41.6, SD = 12.8) as compared with the ataque-negative group (M = 27.2, SD = 11.7), t(2, 68) = 4.6, P < .001. Among the whole sample (N = 70), in a logistic regression analysis, the ASI significantly predicted (odds ratio = 2.6) the presence of ataque de nervios, but the DES did not. In a linear regression analysis, ataque severity was significantly predicted by both the ASI (beta =.46) and the DES (beta =.29). The theoretical and clinical implications of the strong relationship of the ASI to ataque severity are discussed. C1 [Hinton, Devon E.; Pollack, Mark H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Hinton, Devon E.; Chong, Roberto] Arbour Counseling Ctr, SE Asian Clin, Lowell, MA USA. [Barlow, David H.] Boston Univ, Ctr Anxiety & Related Disorders, Boston, MA 02215 USA. [McNally, Richard J.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA. RP Hinton, DE (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St,WACC 812, Boston, MA 02114 USA. EM devon_hinton@hms.harvard.edu NR 24 TC 26 Z9 26 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2008 VL 25 IS 6 BP 489 EP 495 DI 10.1002/da.20309 PG 7 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 317JV UT WOS:000257017000004 PM 17570492 ER PT J AU Kelly, MM Tyrka, AR Price, LH Carpenter, LL AF Kelly, Megan M. Tyrka, Audrey R. Price, Lawrence H. Carpenter, Linda L. TI Sex differences in the use of coping strategies: Predictors of anxiety and depressive symptoms SO DEPRESSION AND ANXIETY LA English DT Article DE coping; depression; anxiety; sex differences; emotion regulation ID COGNITIVE EMOTION REGULATION; BREAST-CANCER PATIENTS; GENDER-DIFFERENCES; UNIPOLAR DEPRESSION; SYMPTOMATOLOGY IDS; STRESS; DISTRESS; DYSPHORIA; INVENTORY; DISORDER AB This study examined sex differences in the use of coping strategies and their relationship to depression and anxiety-related psychopathology. Responses on measures of coping strategies, depression, and anxiety were obtained from a carefully screened nonclinical sample (N = 107). The results demonstrated that women who used less positive reframing bad higher levels of depressive symptoms compared with women who used more positive reframing and to men irrespective of their use of more or less positive reframing. In addition, women who reported the use of more self-blame had elevated levels of trait anxiety, although a similar effect was not found for men. The observed sex differences in the use of coping strategies and their association with depression and anxiety-related problems underscores differences in the clinical presentation of anxiety and depression between women and men. C1 [Kelly, Megan M.; Tyrka, Audrey R.; Price, Lawrence H.; Carpenter, Linda L.] Butler Hosp, Mood Disorders Res Program, Providence, RI 02906 USA. [Kelly, Megan M.; Tyrka, Audrey R.; Price, Lawrence H.; Carpenter, Linda L.] Butler Hosp, Lab Clin Neurosci, Providence, RI 02906 USA. [Kelly, Megan M.; Tyrka, Audrey R.; Price, Lawrence H.; Carpenter, Linda L.] Brown Univ, Sch Med, Dept Psychiat & Human Behav, Providence, RI 02912 USA. RP Kelly, MM (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B 5, 150 S Huntington Ave, Boston, MA 02130 USA. EM Megan.Kelly@va.gov RI Tyrka, Audrey/L-2504-2014 FU Pfizer/Society for Women's Health Research (SWHR); National Institute of Mental Health [MH0687670-01]; Pfizer Pharmaceutical, Inc; UCB Pharma, Inc FX Contract grant sponsor: Pfizer/Society for Women's Health Research (SWHR) 2004 Research Scholar Award; Contract grant sponsor: National Institute of Mental Health; Contract grant number: MH0687670-01; Contract grant sponsor: Investigator-Initiated Awards from Pfizer Pharmaceutical, Inc. and UCB Pharma, Inc. NR 39 TC 26 Z9 28 U1 2 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2008 VL 25 IS 10 BP 839 EP 846 DI 10.1002/da.20341 PG 8 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 357VW UT WOS:000259876300004 PM 17603810 ER PT J AU Dombrovski, AY Cyranowski, JM Mulsant, BH Houck, PR Buysse, DJ Andreescu, C Thase, ME Mallinger, AG Frank, E AF Dombrovski, Alexandre Y. Cyranowski, Jill M. Mulsant, Benoit H. Houck, Patricia R. Buysse, Daniel J. Andreescu, Carmen Thase, Michael E. Mallinger, Alan G. Frank, Ellen TI WHICH SYMPTOMS PREDICT RECURRENCE OF DEPRESSION IN WOMEN TREATED WITH MAINTENANCE INTERPERSONAL PSYCHOTHERAPY? SO DEPRESSION AND ANXIETY LA English DT Article DE depressive disorder; depressive symptoms; sleep initiation and maintenance disorders; sleep; anxiety; recurrence ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; CHRONIC PRIMARY INSOMNIA; MAJOR DEPRESSION; RESIDUAL SYMPTOMS; SECONDARY INSOMNIA; SLEEP DISTURBANCE; ELDERLY-PATIENTS; DOUBLE-BLIND; RISK-FACTOR AB Background: Even low levels of residual symptoms are known to increase the risk of relapse and early recurrence of major depression. It is not known if ongoing psychotherapy lessens this risk. We therefore examined the impact of persistent symptoms, including mood, insomnia, and anxiety symptoms, on time to recurrence in women receiving maintenance interpersonal psychotherapy (IPT-M) for recurrent depression. Methods: We analyzed data on 131 women aged 20-60 from a 2-year randomized trial of weekly versus twice-monthly versus monthly IPT-M. Participants achieved remission with IPT alone (n = 99) or IPT plus sequential antidepressant medication (n = 32). Medications were tapered before starting maintenance treatment. Residual symptoms were assessed with the Hamilton Rating Scale for Depression (HRSD; total score and subscales); insomnia was also assessed in 76 women with the Pittsburgh Sleep Quality Index (PSQI). Data analyses used Cox proportional hazards regression models. Results: Neither overall burden of residual symptoms (HRSD total score), nor HRSD mood and anxiety subscale scores predicted recurrence during ongoing IPT-M. In contrast, persistent insomnia measured both by the HRSD-17 insomnia subscale and the PSQI predicted recurrence. Women with persistent insomnia who required sequential pharamacotherapy had the highest recurrence rate (65%) compared to women requiring sequential treatment without insomnia (13%), or women who had recovered with IPT alone but had persistent insomnia (21%) or no insomnia. (18%). Conclusions: Persistent insomnia following the recovery from an episode of recurrent major depression is associated with increased risk of recurrence despite maintenance psychotherapy, particularly for those withdrawn from antidepressant medication. Depression and Anxiety 25:1060-1066, 2008. (C) 2008 Wiley-Liss, Inc. C1 [Dombrovski, Alexandre Y.; Cyranowski, Jill M.; Mulsant, Benoit H.; Houck, Patricia R.; Buysse, Daniel J.; Andreescu, Carmen; Thase, Michael E.; Mallinger, Alan G.; Frank, Ellen] Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Mulsant, Benoit H.] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON M5S 1A1, Canada. [Thase, Michael E.] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A1, Canada. [Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Mallinger, Alan G.] Natl Inst Hlth Intramural Res Program, Mood & Anxiety Disorders Program, Bethesda, MD USA. RP Cyranowski, JM (reprint author), 100 N Bellefield St,852 Bellefield Towers, Pittsburgh, PA 15213 USA. EM cyranowskijm@upmc.edu OI Dombrovski, Alexandre/0000-0002-2054-4772 FU NIMH NIH HHS [MH049115, MH030915, P30 MH030915, R01 MH049115-08, R01 MH49115] NR 57 TC 38 Z9 42 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2008 VL 25 IS 12 BP 1060 EP 1066 DI 10.1002/da.20467 PG 7 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 382HO UT WOS:000261597000010 PM 18781665 ER PT J AU El Tal, AK Tannous, Z AF El Tal, Abdel Kader Tannous, Zeina TI Cutaneous vascular disorders associated with internal malignancy SO DERMATOLOGIC CLINICS LA English DT Review ID ROTHMUND-THOMSON SYNDROME; IDIOPATHIC THROMBOCYTOPENIC PURPURA; HAIRY-CELL LEUKEMIA; MEDULLARY-THYROID CARCINOMA; DEEP-VEIN THROMBOSIS; ATAXIA-TELANGIECTASIA; TROUSSEAUS-SYNDROME; HARLEQUIN-SYNDROME; MONDORS-DISEASE; BREAST-CANCER AB This article provides a detailed review of the vascular manifestations affecting the skin in relationship to internal malignancies. Vascular abnormalities heralding internal malignancies can be divided into three main categories, consisting of disorders related to vascular dilatation (flushing, palmar erythema, and telangiaectasia), and disoders related to vascular occlusion or hypercoagulability states (purpura, cutaneous ischemia, and thrombophlebitis). Entities are discussed according to etiology. The treatment of these entities is mostly related to treating the underlying malignancy. The goal of this article is to enlighten the practicing dermatologist about the association of these vascular manifestations with internal malignancy, thus leading to prompt initiation of the proper workup and management. C1 [El Tal, Abdel Kader] Massachusetts Gen Hosp, Harvard Med Sch, Dept Dermatol, Boston, MA 02114 USA. [Tannous, Zeina] Wayne State Univ, Oakwood Hosp, Canc Ctr Clin, Dept Dermatol, Dearborn, MI 48123 USA. [Tannous, Zeina] Boston Vet Affairs Hlth Care Syst, Dept Dermatol, Boston, MA 02130 USA. RP Tannous, Z (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Dept Dermatol, 50 Staniford St,2nd Floor, Boston, MA 02114 USA. EM ztannous@partners.org OI El Tal, Abdel Kader/0000-0003-2017-5310 NR 113 TC 9 Z9 9 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8635 J9 DERMATOL CLIN JI Dermatol. Clin. PD JAN PY 2008 VL 26 IS 1 BP 45 EP + DI 10.1016/j.det.2007.08.001 PG 14 WC Dermatology SC Dermatology GA 244QV UT WOS:000251881300005 PM 18023770 ER PT J AU Somoano, B Tsao, H AF Somoano, Brian Tsao, Hensin TI Genodermatoses with cutaneous tumors and internal malignancies SO DERMATOLOGIC CLINICS LA English DT Review ID HOGG-DUBE-SYNDROME; FAMILIAL ADENOMATOUS POLYPOSIS; TUBEROUS SCLEROSIS COMPLEX; CELL CARCINOMA SYNDROME; MUIR-TORRE-SYNDROME; GENOTYPE-PHENOTYPE CORRELATIONS; NONPOLYPOSIS COLORECTAL-CANCER; OF-THE-LITERATURE; RILEY-RUVALCABA-SYNDROME; NONMELANOMA SKIN-CANCER AB The genodermatoses reflect a diverse group of disorders characterized by cutaneous findings associated with an underlying genetic defect. A subset of these conditions are known to confer a susceptibility to the development of cutaneous and internal tumors. Powerful genetic technologies are continuously advancing our understanding of the molecular basis of these familial cancer syndromes. This article reviews those genodermatoses with cutaneous and extracutaneous tumors, focusing on recent insight into their clinical presentation and molecular etiology, because familiarity with these may facilitate early diagnosis and minimize morbidity from their associated malignancies. C1 [Somoano, Brian] Stanford Univ, Med Ctr, Dept Dermatol, Stanford, CA 94305 USA. [Tsao, Hensin] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. RP Tsao, H (reprint author), Stanford Univ, Med Ctr, Dept Dermatol, 900 Blake Wilbur Dr, Stanford, CA 94305 USA. EM tsao.hensin@mgh.harvard.edu NR 159 TC 5 Z9 5 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8635 EI 1558-0520 J9 DERMATOL CLIN JI Dermatol. Clin. PD JAN PY 2008 VL 26 IS 1 BP 69 EP + DI 10.1016/j.det.2007.08.011 PG 20 WC Dermatology SC Dermatology GA 244QV UT WOS:000251881300007 PM 18023772 ER PT J AU Moon, NS Dyson, N AF Moon, Nam-Sung Dyson, Nicholas TI E2F7 and E2F8 keep the E2F family in balance SO DEVELOPMENTAL CELL LA English DT Editorial Material ID TRANSCRIPTION; APOPTOSIS; PROLIFERATION AB An article by Li and colleagues (in this issue of Developmental Cell) shows that the atypical E2Fs, E2F7 and E2F8, are critical for mouse development. One of the important functions of these family members stems from a negative feedback loop in which E2F7 and E2F8 limit the expression of E2F1 and prevent E2F1-dependent apoptosis. C1 [Moon, Nam-Sung; Dyson, Nicholas] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA. RP Dyson, N (reprint author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA. EM dyson@helix.mgh.harvard.edu NR 10 TC 18 Z9 19 U1 0 U2 3 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1534-5807 J9 DEV CELL JI Dev. Cell PD JAN PY 2008 VL 14 IS 1 BP 1 EP 3 DI 10.1016/j.devcel.2007.12.017 PG 3 WC Cell Biology; Developmental Biology SC Cell Biology; Developmental Biology GA 252RO UT WOS:000252464500001 PM 18194644 ER PT J AU Biederman, J Petty, CR Doyle, AE Spencer, T Henderson, CS Marion, B Fried, R Faraone, SV AF Biederman, Joseph Petty, Carter R. Doyle, Alysa E. Spencer, Thomas Henderson, Carly S. Marion, Bryan Fried, Ronna Faraone, Stephen V. TI Stability of executive function deficits in girls with ADHD: A prospective longitudinal Followup study into adolescence SO DEVELOPMENTAL NEUROPSYCHOLOGY LA English DT Article ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; OSTERRIETH COMPLEX FIGURE; HYPERACTIVITY DISORDER; NEUROPSYCHOLOGICAL PERFORMANCE; LEARNING-DISABILITIES; SUSTAINED ATTENTION; PREADOLESCENT GIRLS; CHILDREN; ADULTS; IMPACT AB Neuropsychological deficits in the executive system are major sources of morbidity in individuals with attention-deficit/hyperactivity disorder (ADHD). We conducted a 5-year longitudinal study of girls with (N = 140) and without (N = 122) ADHD, aged 6-18 years at baseline. Neuropsychological functioning was assessed using standard neuropsychological testing assessing executive functions (EFs). Girls with ADHD were significantly more impaired than controls in all neuropsychological domains except set shifting. Despite variability in the stability of individual domains of EFs, the majority (79%) of girls with ADHD that met the categorical definition of executive function deficits (EFDs, defined as two or more EF tasks impaired) at baseline continued to have EFDs at the five-year followup. These findings document the stability of EFDs in girls with ADHD from childhood into adolescence. C1 [Biederman, Joseph; Petty, Carter R.; Doyle, Alysa E.; Spencer, Thomas; Henderson, Carly S.; Marion, Bryan; Fried, Ronna] Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Dept Psychiat, Pediat Psychopharmacol Program, Boston, MA 02114 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat & Behav Sci, Syracuse, NY USA. RP Biederman, J (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Dept Psychiat, Pediat Psychopharmacol Program, 55 Fruit St,Warren 705, Boston, MA 02114 USA. EM jbiederman@partners.org OI Faraone, Stephen/0000-0002-9217-3982 FU NICHD NIH HHS [5R01 HD-36317-07] NR 55 TC 42 Z9 42 U1 1 U2 13 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 8756-5641 J9 DEV NEUROPSYCHOL JI Dev. Neuropsychol. PD JAN-FEB PY 2008 VL 33 IS 1 BP 44 EP 61 DI 10.1080/87565640701729755 PG 18 WC Psychology, Developmental; Psychology; Psychology, Experimental SC Psychology GA 255ON UT WOS:000252667400003 PM 18443969 ER PT J AU Kuhlthau, K Hill, K Fluet, C Meara, E Yucel, RM AF Kuhlthau, Karen Hill, Kristen Fluet, Christina Meara, Ellen Yucel, Recai M. TI Correlates of therapy use and expenditures in children in the United States SO DEVELOPMENTAL NEUROREHABILITATION LA English DT Article DE Specialized therapy; children; expenditures; therapy; paediatric AB Introduction: This paper describes correlates of use and expenditures for therapies (physical, occupational, speech or home health services) among children in the US. Methods: It examined data from the Medical Expenditure Panel Survey, a nationally-representative US sample. The characteristics of users and described patterns of expenditures were examined. Results: Use is quite low, only 3.8% of children use services or 4.3% once the use that occurs in the special education system is included. Children more likely to use therapy include those with presumably greater need: children with chronic conditions, functional limitations and/or a history of hospitalizations or injuries. There is a significant interaction of minority status and having a functional limitation. Expenditures are low when examined across the child population. Among a small proportion of high users, therapy expenditures account for a large proportion of overall health expenditures. Conclusions: The educational system adds only slightly to the overall rate of use. In general use appears to be related to the need for such services. Some children, likely including racial/ethnic minority children, may under-use services. Lack of insurance is not related to less use, perhaps because there are other ways to get some services (family care or services provided through the public health system) or because not all insurers cover therapy services. Therapy expenditures account for a high proportion of overall expenditures among the high users of therapy whereas, for the entire child population, therapy expenditures account for a very small part of overall health expenditures. C1 [Kuhlthau, Karen; Hill, Kristen; Fluet, Christina] Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Policy, MassGen Hosp Children, Boston, MA 02114 USA. [Kuhlthau, Karen] Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA. [Meara, Ellen] Harvard Univ, Sch Med, Dept Hlth Care Policy, Cambridge, MA 02138 USA. [Meara, Ellen] Natl Bur Econ Res, Cambridge, MA 02138 USA. [Yucel, Recai M.] Univ Massachusetts Amherst, Sch Publ Hlth & Hlth Sci, Dept Biostat & Epidemiol, Amherst, MA USA. RP Kuhlthau, K (reprint author), Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Policy, MassGen Hosp Children, 50 Staniford St,Suite 901, Boston, MA 02114 USA. EM kkuhlthau@partners.org FU Agency for Healthcare Research and Quality [1 R03 HS013757] FX This project was supported by grant number 1 R03 HS013757 from the Agency for Healthcare Research and Quality. The authors would like to thank Tara C. Alexander, Alexy Arauz, MD, James M. Caruso, Bill Dubbs, Timothy Ferris, Maureen Thompson and Susan Villageliu. NR 28 TC 1 Z9 1 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1751-8423 EI 1751-8431 J9 DEV NEUROREHABIL JI Dev. Neurorehabil. PY 2008 VL 11 IS 2 BP 115 EP 123 DI 10.1080/17518420701605627 PG 9 WC Clinical Neurology; Pediatrics; Rehabilitation SC Neurosciences & Neurology; Pediatrics; Rehabilitation GA V15FF UT WOS:000207787200003 PM 17952754 ER PT J AU Caviness, VS Bhide, PG Nowakowski, RS AF Caviness, V. S. Bhide, P. G. Nowakowski, R. S. TI Histogenetic processes leading to the laminated neocortex: Migration is only a part of the story SO DEVELOPMENTAL NEUROSCIENCE LA English DT Review DE neocortical histogenesis; neuronal migration; cell position; cortical pattern cell death ID REELER MUTANT MOUSE; MURINE CEREBRAL WALL; CELL-CYCLE; NEURONAL MIGRATION; OCULAR DOMINANCE; PROLIFERATIVE EPITHELIUM; NERVOUS SYSTEM; VISUAL-SYSTEM; CORTEX; MICE AB The principal events of neocortical histogenesis were anticipated by work published prior to the 20th century. These were neuronal proliferation and migration and the complex events of cortical pattern formation leading to a laminated architecture where each layer is dominated by a principal neuronal class. Work that has followed has extended the knowledge of the workings of the proliferative epithelium, cellular mechanisms of migration and events through which cells are winnowed and then differentiate once their postmigratory positions are established. Work yet ahead will emphasize mechanisms that coordinate the molecular events that integrate proliferation and cell class specification in relation to the final neocortical neural system map. Copyright (c) 2008 S. Karger AG, Basel. C1 [Caviness, V. S.; Bhide, P. G.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Nowakowski, R. S.] UMDNJ RWJ Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ USA. RP Caviness, VS (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St,VBK-901, Boston, MA 02114 USA. EM caviness@helix.mgh.harvard.edu RI Nowakowski, Richard/C-3217-2016; OI Nowakowski, Richard/0000-0002-5006-3670 FU NEI NIH HHS [R01 EY015647, EY15647]; NIDA NIH HHS [DA020796, R01 DA020796-03, R01 DA020796]; NINDS NIH HHS [NS43246, R01 NS049445, R01 NS043426-05, NS49445, R01 NS012005, R01 NS043426, R01 NS043246] NR 85 TC 26 Z9 27 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0378-5866 J9 DEV NEUROSCI-BASEL JI Dev. Neurosci. PY 2008 VL 30 IS 1-3 BP 82 EP 95 DI 10.1159/000109854 PG 14 WC Developmental Biology; Neurosciences SC Developmental Biology; Neurosciences & Neurology GA 241MT UT WOS:000251661200009 PM 18075257 ER PT J AU D'Arceuil, H Liu, C Levitt, P Thompson, B Kosofsky, B de Crespigny, A AF D'Arceuil, Helen Liu, Christina Levitt, Pat Thompson, Barbara Kosofsky, Barry de Crespigny, Alex TI Three-dimensional high-resolution diffusion tensor imaging and tractography of the developing rabbit brain SO DEVELOPMENTAL NEUROSCIENCE LA English DT Article DE three-dimensional high-resolution diffusion tensor imaging, rabbit brain; tractography, rabbit brain; developmental changes in regional diffusion anisotropy ID WHITE-MATTER DEVELOPMENT; ANISOTROPIC WATER DIFFUSION; WEIGHTED MR-IMAGES; CORPUS-CALLOSUM; ACALLOSAL MOUSE; CEREBRAL-CORTEX; CORTICOSPINAL TRACT; INITIAL EXPERIENCE; FIBER TRACTOGRAPHY; PREMATURE-INFANTS AB Diffusion tensor imaging (DTI) is sensitive to structural ordering in brain tissue particularly in the white matter tracts. Diffusion anisotropy changes with disease and also with neural development. We used high-resolution DTI of fixed rabbit brains to study developmental changes in regional diffusion anisotropy and white matter fiber tract development. Imaging was performed on a 4.7-tesla Bruker Biospec Avance scanner using custom-built solenoid coils and DTI was performed at various postnatal ages. Trace apparent diffusion coefficient, fractional diffusion anisotropy maps and fiber tracts were generated and compared across the ages. The brain was highly anisotropic at birth and white matter anisotropy increased with age. Regional DTI tractography of the internal capsule showed refinement in regional tract architecture with maturation. Interestingly, brains with congenital deficiencies of the callosal commissure showed selectively strikingly different fiber architecture compared to age-matched brains. There was also some evidence of subcortical to cortical fiber connectivity. DTI tractography of the anterior and posterior limbs of the internal capsule showed reproducibly coherent fiber tracts corresponding to known corticospinal and corticobulbar tract anatomy. There was some minor interanimal tract variability, but there was remarkable similarity between the tracts in all animals. Therefore, ex vivo DTI tractography is a potentially powerful tool for neuroscience investigations and may also reveal effects (such as fiber tract pruning during development) which may be important targets for in vivo human studies. Copyright (c) 2007 S. Karger AG, Basel. C1 [D'Arceuil, Helen; Liu, Christina; de Crespigny, Alex] Massachusetts Gen Hosp, Dept Radiol, Athinous Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [D'Arceuil, Helen; de Crespigny, Alex] Massachusetts Gen Hosp, Neuroradiol Sect, Boston, MA 02114 USA. [Kosofsky, Barry] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Child Neurol, New York, NY USA. [Levitt, Pat; Thompson, Barbara] Vanderbilt Univ, Kennedy Ctr Res Human Dev, Nashville, TN USA. RP D'Arceuil, H (reprint author), MGH NMR Ctr, Rm 2301,Bldg 149,13th St, Charlestown, MA 02129 USA. EM helen@nmr.mgh.harvard.edu OI Liu, Christina/0000-0002-5723-177X FU NCRR NIH HHS [1S10RR016811, P41RR14075]; NHLBI NIH HHS [HL071635]; NIBIB NIH HHS [EB00790]; NINDS NIH HHS [NS051188, NS053684] NR 66 TC 27 Z9 27 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0378-5866 J9 DEV NEUROSCI-BASEL JI Dev. Neurosci. PY 2008 VL 30 IS 4 BP 262 EP 275 DI 10.1159/000110503 PG 14 WC Developmental Biology; Neurosciences SC Developmental Biology; Neurosciences & Neurology GA 297AF UT WOS:000255586600006 PM 17962716 ER PT J AU Lauritzen, HPMM Ploug, T Ai, H Donsmark, M Prats, C Galbo, H AF Lauritzen, Hans P. M. Mortensen Ploug, Thorkil Ai, Hua Donsmark, Morten Prats, Clara Galbo, Henrik TI Denervation and high-fat diet reduce insulin signaling in T-tubules in skeletal muscle of living mice SO DIABETES LA English DT Article ID STIMULATED GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSVERSE TUBULES; VACUOLE FORMATION; PLASMA-MEMBRANE; GLUT4 PROTEIN; RAT HINDLIMB; IN-VIVO; TRANSLOCATION; FIBERS AB OBJECTIVE-Insulin stimulates muscle glucose transport by translocation of GLUT4 to sarcolemma and T-tubules. Despite muscle glucose uptake playing a major role in insulin resistance and type 2 diabetes, the temporal and spatial changes in insulin signaling and GLUT4 translocation during these conditions are not well described. RESEARCH DESIGN AND METHODS-We used time-lapse confocal imaging of green fluorescent protein (GFP) ADP-ribosylation factor nucleotide-binding site opener (ARNO) (evaluation of phosphatidylinositide 3-kinase activation) and GLUT4-GFP-transfected quadriceps muscle in living, anesthetized mice either muscle denervated or high-fat fed. T-tubules were visualized with sulforhodamine B dye. In incubated muscle, glucose transport was measured by 2-deoxy-D-[H-3]-glucose uptake, and functional detubulation was carried out by osmotic shock. Muscle fibers were immumostained for insulin receptors. RESULTS-Denervation and high-fat diet reduced insulin-mediated glucose transport. In denervated muscle, insulin-stimulated phosphatidylinositol 3,4,5 P-3 (PIP3) production was abolished in T-tubules, while PIP3 production at sarcolemma was increased 2.6-fold. Correspondingly, GLUT4-GFP translocation to T-tubules was abolished, while translocation to sarcolemma was increased 2.3-fold. In high fat-fed mice, a similar to 65% reduction in both insulin-induced T-tubular PIP3 production and GLUT4-GFP translocation was seen. Sarcolemma was less affected, with reductions of similar to 40% in PIP3 production and similar to 15% in GLUT4-GFP translocation. Access to T-tubules was not compromised, and insulin receptor distribution in sarcolemma and T-tubules was unaffected by denervation or high-fat feeding. Detubulation of normal muscle reduced basal and abolished insulin-induced glucose transport. CONCLUSIONS-Our findings demonstrate, for the first time, that impaired insulin signaling and GLUT4 translocation is compartmentalized in muscle and primarily localized to T-tubules and not sarcolemma during insulin resistance. C1 [Lauritzen, Hans P. M. Mortensen] Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA. [Ploug, Thorkil; Ai, Hua; Donsmark, Morten; Prats, Clara] Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark. [Galbo, Henrik] Bispebjerg Hosp, Dept Rheumatol, DK-2400 Copenhagen, Denmark. RP Lauritzen, HPMM (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA. EM hans.lauritzen@joslin.harvard.edu RI Prats, Clara/F-5993-2014 NR 40 TC 27 Z9 27 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD JAN PY 2008 VL 57 IS 1 BP 13 EP 23 DI 10.2337/db07-0516 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 248TP UT WOS:000252178800004 PM 17914033 ER PT J AU Utzschneider, KM Tong, J Montgomery, B Udayasankar, J Gerchman, F Marcovina, SM Watson, CE Ligueros-Saylan, MA Foley, JE Holst, JJ Deacon, CF Kahn, SE AF Utzschneider, Kristina M. Tong, Jenny Montgomery, Brenda Udayasankar, Jayalakshmi Gerchman, Fernando Marcovina, Santica M. Watson, Catherine E. Ligueros-Saylan, Monica A. Foley, James E. Holst, Jens J. Deacon, Carolyn F. Kahn, Steven E. TI The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose SO DIABETES CARE LA English DT Article ID GLUCAGON-LIKE PEPTIDE-1; IV INHIBITOR; GLYCEMIC CONTROL; TYPE-2; TOLERANCE; INCREASES; LAF237; MODEL AB OBJECTIVE - To evaluate the effect of treatment with the dipeptidyl peptidase (DPP)-4 inhibitor vildagliptin on insulin sensitivity and beta-cell function in subjects with impaired fasting glucose (IFG). RESEARCH DESIGN AND METHODS - A total of 22 subjects with IFG (11 female and 11 male, mean +/- SD age 59.6 +/- 11.5 years) were treated orally with 100 mg vildagliptin once daily in a single-blind study. Subjects received placebo for 2 weeks (run-in) followed by vildagliptin for 6 weeks (treatment) and then placebo for 2 weeks (washout). A frequently sampled intravenous glucose tolerance test (FSIGT), followed by a 2-h meal tolerance test (MTT), was performed at 2, 8, and 10 weeks. From the FSIGT, the acute insulin response to glucose (AIR(g)) and insulin sensitivity index (S) were determined and used to compute the disposition index (AIRg X S,) as a measure of beta-cell function. RESULTS - Fasting plasma glucose did not change after 6 weeks of vildagliptin treatment. With treatment, mean +/- SEM AIR(g) increased from 224 +/- 44 to 286 +/- 52 pmol/1(P < 0.05), and S, improved from 2.8 +/- 0.5 to 3.5 0.5 X 10(-5) - min(-1). pmol(-1) center dot 1 (P < 0.01), resulting in an increase in the disposition index from 688 +/- 180 to 1,164 +/- 318 X 10(-5)/min (P < 0.05). These effects were not sustained after washout. During the MTT, the incremental area under the glucose curve was significantly decreased after treatment (240 +/- 15 vs. 191 +/- 14 mmol center dot 1(-1) min-1; P = 0.002), but this effect was not sustained after washout. CONCLUSIONS - The DPP-4 inhibitor vildagliptin improves insulin sensitivity and P-cell function, leading to improved postprandial glycemia in subjects with IFG, who are known to have beta-cell dysfunction. Thus, vildagliptin may prevent progression to diabetes in high-risk subjects. C1 [Utzschneider, Kristina M.; Tong, Jenny; Montgomery, Brenda; Udayasankar, Jayalakshmi; Gerchman, Fernando; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Utzschneider, Kristina M.; Tong, Jenny; Montgomery, Brenda; Udayasankar, Jayalakshmi; Gerchman, Fernando; Kahn, Steven E.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Marcovina, Santica M.] Univ Washington, NW Lipid Metab & Diabet Res Labs, Seattle, WA 98195 USA. [Watson, Catherine E.] Novartis Inst Biomed Res, Cambridge, MA USA. [Ligueros-Saylan, Monica A.; Foley, James E.] Novartis Pharmaceut, E Hanover, NJ USA. [Holst, Jens J.; Deacon, Carolyn F.] Univ Copenhagen, Panum Inst, Dept Biomed Sci, DK-2200 Copenhagen, Denmark. RP Utzschneider, KM (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM kutzschn@u.washington.edu OI Holst, Jens Juul/0000-0001-6853-3805 FU NIDDK NIH HHS [DK-17047] NR 20 TC 75 Z9 79 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2008 VL 31 IS 1 BP 108 EP 113 DI 10.2337/dc07-1441 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 248TQ UT WOS:000252178900026 PM 17909087 ER PT J AU Nathan, DM Buse, JB Davidson, MB Ferrannini, E Holman, RR Sherwin, R Zinman, B AF Nathan, David M. Buse, John B. Davidson, Mayer B. Ferrannini, Ele Holman, Rury R. Sherwin, Robert Zinman, Bernard TI Management of Hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy - Update regarding thiazolidinediones: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes SO DIABETES CARE LA English DT Article ID CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; ROSIGLITAZONE; RISK; METAANALYSIS; TRIALS; DEATH C1 [Nathan, David M.] Harvard Univ, Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA. [Nathan, David M.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Buse, John B.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Davidson, Mayer B.] Charles R Drew Univ Med & Sci, Los Angeles, CA 90059 USA. [Ferrannini, Ele] Univ Pisa, Dept Internal Med, Pisa, Italy. [Holman, Rury R.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Diabet Trials Unit, Oxford, England. [Sherwin, Robert] Yale Univ, Sch Med, New Haven, CT USA. [Zinman, Bernard] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. RP Nathan, DM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA. EM dnathan@partners.org RI Zinman, Bernard/E-7266-2013 NR 17 TC 140 Z9 148 U1 0 U2 8 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2008 VL 31 IS 1 BP 173 EP 175 DI 10.2337/dc08-9016 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 248TQ UT WOS:000252178900039 PM 18165348 ER PT J AU Funnell, MM Brown, TL Childs, BP Haas, LB Hosey, GM Jensen, B Maryniuk, M Peyrot, M Piette, JD Reader, D Siminerio, LM Weinger, K Weiss, MA AF Funnell, Martha M. Brown, Tammy L. Childs, Belinda P. Haas, Linda B. Hosey, Gwen M. Jensen, Brian Maryniuk, Melinda Peyrot, Mark Piette, John D. Reader, Diane Siminerio, Linda M. Weinger, Katie Weiss, Michael A. TI National standards for diabetes self-management education SO DIABETES CARE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; CHRONIC DISEASE MANAGEMENT; IMPROVE GLYCEMIC CONTROL; PRIMARY-CARE PATIENTS; HEALTH-CARE; COMPLICATIONS TRIAL; PATIENT EDUCATION; AFRICAN-AMERICAN; COMMUNITY-HEALTH; CHRONIC ILLNESS C1 [Funnell, Martha M.] Univ Michigan, Ctr Diabet Res & Training, Dept Med Educ, Ann Arbor, MI 48109 USA. [Brown, Tammy L.] Indian Hlth Serv, Albuquerque, NM USA. [Childs, Belinda P.] MidAmer Diabet Associat, Wichita, KS USA. [Haas, Linda B.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Hosey, Gwen M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30333 USA. [Jensen, Brian] Lakeshore Apothacare, Two Rivers, WI USA. [Maryniuk, Melinda; Weinger, Katie] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. [Peyrot, Mark] Loyola Coll, Baltimore, MD 21210 USA. [Piette, John D.] VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA. [Piette, John D.] Univ Michigan, Ctr Diabet Res & Training, Dept Internal Med, Ann Arbor, MI 48109 USA. [Reader, Diane] Int Diabet Ctr, Minneapolis, MN USA. [Siminerio, Linda M.] Univ Pittsburgh, Med Ctr, Inst Diabet, Pittsburgh, PA USA. [Weiss, Michael A.] Patient Centered Solut, Pittsburgh, PA USA. RP Funnell, MM (reprint author), Univ Michigan, Ctr Diabet Res & Training, Dept Med Educ, 300 N Ingalls,3D06,Box0489, Ann Arbor, MI 48109 USA. EM mfunnell@umich.edu RI McDowell, Joan/H-3159-2014 FU NIDDK NIH HHS [5P60 DK20572]; PHS HHS [1 R18 0K062323] NR 164 TC 70 Z9 78 U1 3 U2 11 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2008 VL 31 SU 1 BP S97 EP S104 DI 10.2337/dc08-S097 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 250WR UT WOS:000252332500010 PM 18165344 ER PT B AU Prakash, M Sun, JK King, GL AF Prakash, Manvi Sun, Jennifer K. King, George L. BE Duh, EJ TI The Role of Protein Kinase C in Diabetic Retinopathy SO DIABETES RETINOPATHY SE Contemporary Diabetes LA English DT Article; Book Chapter DE Protein kinase C; diacylglycerol; diabetes; diabetic retinopathy; retinal blood flow; vascular permeability; angiogenesis; ruboxistaurin ID ENDOTHELIAL GROWTH-FACTOR; RETINAL BLOOD-FLOW; MESANGIAL CELLS; HIGH GLUCOSE; ALBUMIN PERMEABILITY; NITRIC-OXIDE; VITAMIN-E; PKC-BETA; IN-VIVO; ACTIVATION AB The protein kinase C (PKC) Molecule is part of a serine/threonine kinase family that catalyzes phosphorylation of key proteins involved in signal transduction. Conventional and novel PKC isoforms are upregulated by diacylglycerol (DAG), which in turn is increased by the hyperglycemia of diabetes. PKC isoforms are differentially expressed and activated in tissues throughout the body, including the aorta, kidney, heart, monocytes, and retina, but not in the brain or peripheral nerves. In the retina, PKC activation is associated with changes in retinal blood flow, possibly through effects on retinal pericytes, the expression of endothelium-derived growth factors, and/or leukostasis. The activation of PKC may also lead to basement membrane and extracellular matrix alterations within the retinal vasculature. Increases in retinal vascular permeability and angiogenesis are seen with PKC activation related to its actions on vascular endothelial growth factor. Inhibition of PKC, particularly PKC-beta isoforms, appears to ameliorate many of these effects on the retinal vasculature. Ruboxistaurin is a PKC inhibitor with a high affinity for PKC-beta isoforms. Human clinical studies with this drug are ongoing, but trials have already demonstrated its efficacy in preventing vision loss, decreasing the need for laser treatment, and decreasing the progression of macular edema in patients with diabetes. C1 [Prakash, Manvi; Sun, Jennifer K.; King, George L.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. RP Prakash, M (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. NR 68 TC 0 Z9 0 U1 1 U2 3 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-934115-83-1 J9 CONTEMP DIABETES PY 2008 BP 207 EP 216 DI 10.1007/978-1-59745-563-3_8 D2 10.1007/978-1-59745-563-3 PG 10 WC Endocrinology & Metabolism; Medicine, General & Internal; Ophthalmology SC Endocrinology & Metabolism; General & Internal Medicine; Ophthalmology GA BJU35 UT WOS:000267166700008 ER PT B AU Sun, JK Hamam, R Aiello, LP AF Sun, Jennifer K. Hamam, Rola Aiello, Lloyd P. BE Duh, EJ TI Clinical Trials in Protein Kinase C-beta Inhibition in Diabetic Retinopathy SO DIABETES RETINOPATHY SE Contemporary Diabetes LA English DT Article; Book Chapter DE Diabetes; Diabetic retinopathy; Macular edema; Protein kinase c; LY333531; Ruboxistaurin; Clinical trials ID PKC-BETA; PERIPHERAL NEUROPATHY; MACULAR EDEMA; VISUAL-LOSS; RUBOXISTAURIN; DIACYLGLYCEROL; COMPLICATIONS; RATS; ACTIVATION; GLUCOSE AB Protein kinase C (PKC) activation plays a key role in the development of microvascular complications in diabetes, including diabetic retinopathy. Vision loss in patients with diabetes stems from the development of ocular complications that include diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR). Even with timely intervention, a large number of patients lose vision from diabetic eye disease each year, necessitating an ongoing effort toward exploring new and more effective approaches for the prevention and treatment of diabetic retinopathy (DR). Clinical trials of PKC inhibition for diabetic retinopathy have focused largely on the oral PKC-beta inhibitor, ruboxistaurin (RBX). Preclinical studies of RBX in animal models demonstrated amelioration of diabetes-induced abnormalities in retinal circulation, vascular permeability, and leukocyte adhesion. Subsequent clinical studies, consisting of multiple multicenter, double-masked, randomized, placebo-control led trials have consistently demonstrated that RBX reduces long-term visual loss, increases visual gain, slows progression of diabetic macular edema, and reduces the need for initial macular laser photocoagulation in patients with advanced nonproliferative DR (NPDR). However, RBX does not halt the progression of diabetic retinopathy. RBX has been well-tolerated with a favorable safety profile. Additional studies with this drug are currently ongoing to provide additional supporting data on its beneficial effects in diabetic macular edema and vision loss. C1 [Sun, Jennifer K.; Hamam, Rola; Aiello, Lloyd P.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. RP Sun, JK (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. NR 42 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-934115-83-1 J9 CONTEMP DIABETES PY 2008 BP 423 EP 434 DI 10.1007/978-1-59745-563-3_18 D2 10.1007/978-1-59745-563-3 PG 12 WC Endocrinology & Metabolism; Medicine, General & Internal; Ophthalmology SC Endocrinology & Metabolism; General & Internal Medicine; Ophthalmology GA BJU35 UT WOS:000267166700018 ER PT J AU Nathan, DM Buse, JB Davidson, MB Ferrannini, E Holman, RR Sherwin, R Zinman, B AF Nathan, D. M. Buse, J. B. Davidson, M. B. Ferrannini, E. Holman, R. R. Sherwin, R. Zinman, B. TI Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy - Update regarding the thiazolidinediones SO DIABETOLOGIA LA English DT Editorial Material ID CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; ROSIGLITAZONE; RISK; METAANALYSIS; ASSOCIATION; STATEMENT; TRIALS; DEATH C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA. Univ N Carolina, Sch Med, Chapel Hill, NC USA. Univ Pisa, Dept Internal Med, Pisa, Italy. Univ Oxford, Oxford Ctr Endocrinol & Metab, Diabet Trials Unit, Oxford, England. Yale Univ, Sch Med, New Haven, CT USA. Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. RP Nathan, DM (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA. EM dnathan@partners.org RI Zinman, Bernard/E-7266-2013 NR 17 TC 60 Z9 62 U1 0 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD JAN PY 2008 VL 51 IS 1 BP 8 EP 11 DI 10.1007/s00125-007-0873-z PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 236RK UT WOS:000251320900003 PM 18026926 ER PT B AU Gejman, R Hedley-Whyte, ET AF Gejman, Roger Hedley-Whyte, E. Tessa BA Biller, BMK BF Biller, BMK BE Swearingen, B TI Pathology of Pituitary Adenomas SO DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS SE Contemporary Endocrinology LA English DT Article; Book Chapter DE Pituitary adenomas; Pathology; Chromophobe; Basophil ID SPINDLE-CELL-ONCOCYTOMA; MIXED GANGLIOCYTOMA-ADENOMA; ADENOHYPOPHYSIS; EXPRESSION; TUMOR; INDEX; GLAND; SELLA AB Pituitary adenomas are the most common tumors of the sella and are manifest by either symptoms of mass effect or symptoms of hormone overproduction or underproduction. The histological and functional classification of pituitary adenomas is reviewed in relation to their clinical presentation and potential therapies. The pathological classification of pituitary tumors is complex. The role of immunohistochemical markers is discussed, but their value remains controversial. The pathological characteristics of other sellar lesions that enter into the differential diagnosis of pituitary tumors are described. C1 [Hedley-Whyte, E. Tessa] Harvard Univ, Sch Med, Boston, MA USA. [Hedley-Whyte, E. Tessa] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 34 TC 1 Z9 1 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-922-2 J9 CONTEMP ENDOCRINOL S PY 2008 BP 17 EP + DI 10.1007/978-1-59745-264-9_2 D2 10.1007/978-1-59745-264-9 PG 23 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BJO83 UT WOS:000266930700002 ER PT B AU Lysack, JT Schaefer, PW AF Lysack, John T. Schaefer, Pamela W. BA Biller, BMK BF Biller, BMK BE Swearingen, B TI Imaging of the Pituitary Gland, Sella, and Parasellar Region SO DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS SE Contemporary Endocrinology LA English DT Article; Book Chapter DE magnetic resonance imaging; pituitary adenoma ID LANGERHANS CELL HISTIOCYTOSIS; CAVERNOUS SINUS INVASION; CENTRAL-NERVOUS-SYSTEM; TOLOSA-HUNT-SYNDROME; RATHKE CLEFT CYSTS; SKULL-BASE; SIGNAL INTENSITY; ENHANCED MR; RADIOLOGICAL FEATURES; POSTERIOR PITUITARY AB This chapter discusses the anatomy of the sellar region, Lis well Lis the optimal imaging techniques and radiographic findings typical of sellar disease. Based on the imaging characteristics, a practical differential diagnosis can be constructed to guide appropriate therapy. C1 [Lysack, John T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MRI, Boston, MA 02115 USA. [Schaefer, Pamela W.] Harvard Univ, Sch Med, Boston, MA USA. RP Lysack, JT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, MRI, Boston, MA 02115 USA. NR 78 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-922-2 J9 CONTEMP ENDOCRINOL S PY 2008 BP 45 EP 91 DI 10.1007/978-1-59745-264-9_4 D2 10.1007/978-1-59745-264-9 PG 47 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BJO83 UT WOS:000266930700004 ER PT B AU Cestari, DM Rizzo, JF AF Cestari, Dean M. Rizzo, Joseph F., III BA Biller, BMK BF Biller, BMK BE Swearingen, B TI Neuro-ophthalmology of Sellar Disease SO DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS SE Contemporary Endocrinology LA English DT Article; Book Chapter DE vision; Visual field; chiasm ID AFFERENT PUPILLARY DEFECT; VISUAL-FIELD DEFECTS; OPTIC NEUROPATHY; PITUITARY-ADENOMA; LESIONS; COMPRESSION; CHIASM AB The degree to which a patient with sellar pathology has been neurologically affected by the lesion can be best determined with a neuro-ophthalmic examination, which traditionally includes a detailed historical assessment and physical examination. With lesions in the sellar region, the clinical neuro-ophthalmologic examination often reveals neural dysfunction because several important afferent and efferent visual pathways course near this area. The combination of neuroradiological, neuroendocrinological, and neuro-ophthalmological assessment is needed to properly manage the typical patient with a parasellar lesion. This chapter will provide an overview of the relevant anatomy and clinical neuro-ophthalmic features of lesions that affect the sellar region. C1 [Cestari, Dean M.; Rizzo, Joseph F., III] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02115 USA. RP Cestari, DM (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02115 USA. NR 39 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-922-2 J9 CONTEMP ENDOCRINOL S PY 2008 BP 93 EP 124 DI 10.1007/978-1-59745-264-9_5 D2 10.1007/978-1-59745-264-9 PG 32 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BJO83 UT WOS:000266930700005 ER PT B AU Shih, HA Loeffler, JS AF Shih, Helen A. Loeffler, Jay S. BA Biller, BMK BF Biller, BMK BE Swearingen, B TI Radiation Therapy for Pituitary Adenomas SO DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS SE Contemporary Endocrinology LA English DT Article; Book Chapter DE Pituitary adenoma; Radiation therapy; Radiosurgery; Proton beam; LINAC; Gamma knife ID GAMMA-KNIFE RADIOSURGERY; TERM-FOLLOW-UP; GROWTH-FACTOR-I; STEREOTACTIC RADIOSURGERY; CUSHINGS-DISEASE; POSTOPERATIVE RADIOTHERAPY; TRANSSPHENOIDAL SURGERY; FRACTIONATED RADIOTHERAPY; CONFORMAL RADIOTHERAPY; BEAM IRRADIATION AB Radiation therapy offers another means of therapy for pituitary adenomas when roles for medical therapy and surgery have been exhausted. Technological advancements in medical physics have revolutionized modern day radiotherapy for pituitary adenomas. A variety of treatment modalities now exist, all of which offer higher degree of accuracy and safety ill radiation delivery. Very high tumor local control rates and reasonably high hormonal response rates to radiation therapy call now be achieved with fairly low rates of treatment-related adverse effects. The exception to this remains radiation-induced hypopituitarism which remains an inherent limitation of irradiating the pituitary. C1 [Shih, Helen A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA. [Loeffler, Jay S.] Harvard Univ, Sch Med, Boston, MA USA. RP Shih, HA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA. NR 56 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-922-2 J9 CONTEMP ENDOCRINOL S PY 2008 BP 321 EP 338 DI 10.1007/978-1-59745-264-9_17 D2 10.1007/978-1-59745-264-9 PG 18 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BJO83 UT WOS:000266930700017 ER PT B AU Ulmer, S Byrne, TN AF Ulmer, Stephan Byrne, Thomas N. BA Biller, BMK BF Biller, BMK BE Swearingen, B TI Lymphocytic Hypophysitis and Inflammatory Disease of the Pituitary SO DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS SE Contemporary Endocrinology LA English DT Article; Book Chapter DE Lymphocytic hypophysitis; Autoimmune ID CENTRAL DIABETES-INSIPIDUS; LANGERHANS CELL HISTIOCYTOSIS; EMPTY SELLA SYNDROME; CAVERNOUS SINUS; ANTIBODIES; INVOLVEMENT; SARCOIDOSIS; INFUNDIBULONEUROHYPOPHYSITIS; AUTOIMMUNE; AUTOANTIBODIES AB The most common form of primary hypophysitis is lymphocytic hypophysitis (LH), which is a rare inflammatory disorder of the pituitary that may present both as a sellar mass extending into the suprasellar space and as hypopituitarism. It is often confused radiographically with pituitary tumors. It usually presents in the peripartum period and may be associated with autoimmune diseases. The clinical context is usually quite important in raising the clinical Suspicion of this disorder. This chapter discusses the epidemiology, pathogenesis, clinical presentation, imaging, differential diagnosis, and management of LH. C1 [Ulmer, Stephan] Univ Hosp Schleswig Holstein, Inst Neuroradiol, Kiel, Germany. [Byrne, Thomas N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Ulmer, S (reprint author), Univ Hosp Schleswig Holstein, Inst Neuroradiol, Kiel, Germany. NR 47 TC 1 Z9 1 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-922-2 J9 CONTEMP ENDOCRINOL S PY 2008 BP 339 EP 351 DI 10.1007/978-1-59745-264-9_18 D2 10.1007/978-1-59745-264-9 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BJO83 UT WOS:000266930700018 ER PT B AU Russell, SJ Miller, KK AF Russell, Steven J. Miller, Karen Klahr BA Biller, BMK BF Biller, BMK BE Swearingen, B TI Pituitary Apoplexy SO DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS SE Contemporary Endocrinology LA English DT Article; Book Chapter DE Pituitary apoplexy ID GONADOTROPIN-RELEASING-HORMONE; RATHKES CLEFT CYST; CONSERVATIVE MANAGEMENT; TRANSSPHENOIDAL SURGERY; CLINICAL-SIGNIFICANCE; COMPUTED-TOMOGRAPHY; SURGICAL-TREATMENT; CUSHINGS-DISEASE; ARTERY ANEURYSM; AGONIST THERAPY AB Pituitary apoplexy (apoplexy-to disable by a stroke) is a clinical syndrome characterized by the abrupt onset of characteristic signs and symptoms, most commonly headache, nausea, visual disturbance, and ophthalmoplegia, in association with hemorrhage or infarction within the pituitary fossa. Because pituitary apoplexy is rare, and because most cases Occur suddenly in the absence of prior suspicion for pituitary pathology, it has been a difficult condition to study. Regardless, if apoplexy is diagnosed in a timely fashion and managed appropriately, death should be rare and permanent neurologic complication of the acute event should be uncommon. This chapter will review what is known of the epidemiology of pituitary apoplexy as well as its clinical presentation, management, and prognosis. C1 [Russell, Steven J.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Miller, Karen Klahr] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroendocrine Unit, Boston, MA USA. RP Russell, SJ (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 108 TC 3 Z9 3 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-922-2 J9 CONTEMP ENDOCRINOL S PY 2008 BP 353 EP 375 DI 10.1007/978-1-59745-264-9_19 D2 10.1007/978-1-59745-264-9 PG 23 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BJO83 UT WOS:000266930700019 ER PT B AU Stanley, T Prabhakaran, R Misra, M AF Stanley, Takara Prabhakaran, Rajani Misra, Madhusmita BA Biller, BMK BF Biller, BMK BE Swearingen, B TI Sellar and Pituitary Tumors in Children SO DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS SE Contemporary Endocrinology LA English DT Article; Book Chapter DE Pediatric pituitary adenomas; Craniopharyngiomas ID GERM-CELL TUMORS; SALIVARY CORTISOL MEASUREMENT; DEPENDENT CUSHINGS-SYNDROME; GROWTH-HORMONE TREATMENT; PINEAL REGION TUMORS; RATHKES CLEFT CYSTS; QUALITY-OF-LIFE; CHILDHOOD CRANIOPHARYNGIOMA; PEDIATRIC CRANIOPHARYNGIOMAS; TRANSSPHENOIDAL SURGERY AB Sellar and parasellar tumors are rare in children and adolescents, but can be associated with significant morbidity. In addition to clinical features resulting from mass effect, and hormonal insufficiencies and excess depending on the nature of the tumor, children with these tumors often present with a slowing of growth velocity and pubertal delay, features unique to children and adolescents. Craniopharyngiomas are the most common sellar/pituitary tumors in children, accounting for 80-90% of these tumors, followed by pituitary adenomas. As in adults, prolactinomas are the most common pituitary adenomas seen in children and adolescents, followed by ACTH secreting adenomas. Suprasellar germinomas in children present classically with diabetes insipidus with or without other pituitary hormone deficiencies and visual field deficits. Treatment for pituitary tumors is typically surgery, with the exception of prolactinomas, treated effectively in most instances with dopamine agonist therapy. Germinomas are very sensitive to chemotherapy and radiotherapy, but use of radiotherapy in children is otherwise limited to tumor recurrence after surgery or tumor occurrence in surgically inaccessible areas. C1 [Misra, Madhusmita] MassGen Hosp Children, Endocrinol Unit, Boston, MA USA. [Misra, Madhusmita] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. [Misra, Madhusmita] Harvard Univ, Sch Med, Boston, MA USA. NR 117 TC 2 Z9 2 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-922-2 J9 CONTEMP ENDOCRINOL S PY 2008 BP 411 EP 444 DI 10.1007/978-1-59745-264-9_22 D2 10.1007/978-1-59745-264-9 PG 34 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BJO83 UT WOS:000266930700022 ER PT B AU Boucher, HW Patterson, TF AF Boucher, Helen W. Patterson, Thomas F. BE Hospenthal, DR Rinaldi, MG TI Aspergillosis SO DIAGNOSIS AND TREATMENT OF HUMAN MYCOSES SE Infectious Disease LA English DT Article; Book Chapter ID INVASIVE PULMONARY ASPERGILLOSIS; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; LIPOSOMAL AMPHOTERICIN-B; CELL TRANSPLANT RECIPIENTS; POLYMERASE-CHAIN-REACTION; GUINEA-PIG MODEL; BETA-D-GLUCAN; FUNGAL-INFECTIONS; ANTIFUNGAL THERAPY; IN-VITRO C1 [Boucher, Helen W.] Tufts Univ, New England Med Ctr, Dept Med, Div Infect Dis, Boston, MA 02111 USA. [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. [Patterson, Thomas F.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Boucher, HW (reprint author), Tufts Univ, New England Med Ctr, Dept Med, Div Infect Dis, Boston, MA 02111 USA. NR 84 TC 1 Z9 1 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-822-5 J9 INFECT DIS PY 2008 BP 181 EP 199 DI 10.1007/978-1-59745-325-7_9 D2 10.1007/978-1-59745-325-7 PG 19 WC Immunology; Infectious Diseases; Mycology; Virology SC Immunology; Infectious Diseases; Mycology; Virology GA BKK77 UT WOS:000268394800009 ER PT J AU El-Serag, HB AF El-Serag, Hashem B. TI Epidemiology of non-erosive reflux disease SO DIGESTION LA English DT Article; Proceedings Paper CT Nerd Task Force - Overview and Consensus Meeting CY NOV 30-DEC 02, 2007 CL Vevey, SWITZERLAND DE non-erosive reflux disease, epidemiology; gastroesophageal reflux disease; epidemiological studies; temporal trends ID GASTROESOPHAGEAL-REFLUX; EROSIVE ESOPHAGITIS; RISK-FACTORS; PREVALENCE; POPULATION; SYMPTOMS AB Non-erosive reflux disease (NERD) is a relatively new entity, the definition of which has been evolving and involves the use of symptoms, endoscopy, and objective evidence of reflux or reflux-related damage. The closest entity to NERD that is examined by available epidemiologic studies is defined by the presence of gastroesophageal reflux disease (GERD) symptoms in the absence of esophageal erosions or Barrett's esophagus. In this review, I identified two populationbased studies, one non-community study, and several endoscopy-based studies that provided information on several aspects of NERD. Most of GERD is NERD (50-85%), and therefore one can estimate 11-12% of the general pop ulation and considerably higher proportions of patients presenting to endoscopy (37-87%) may have NERD. Risk factors for NERD including absence of hiatus hernia, low BMI, and presence of Helicobacter pylori indicate that it is a 'milder' part of the GERD spectrum. Other associations of NERD include younger age, female sex, and psychological comorbidities that resemble those of functional gut disorders. The temporal trends in NERD are unclear, and are probably increasing because GERD symptom prevalence has increased. Copyright (C) 2008 S. Karger AG, Basel. C1 [El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [El-Serag, Hashem B.] Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Houston VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.edu NR 13 TC 34 Z9 36 U1 1 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0012-2823 J9 DIGESTION JI Digestion PY 2008 VL 78 SU 1 BP 6 EP 10 DI 10.1159/000151249 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 356WK UT WOS:000259808100002 PM 18832834 ER PT S AU Smith, AP Rafferty, EA Niklason, L AF Smith, Andrew P. Rafferty, Elizabeth A. Niklason, Loren BE Krupinski, EA TI Clinical performance of breast tomosynthesis as a function of radiologist experience level SO DIGITAL MAMMOGRAPHY, PROCEEDINGS SE Lecture Notes in Computer Science LA English DT Proceedings Paper CT 9th International Workshop on Digital Mammography CY JUL 20-23, 2008 CL Tucson, AZ DE breast tomosynthesis; digital mammography; ROC curve AB This study reports the performance of breast tomosynthesis (3D images) combined with digital mammography (2D images). compared to digital mammography alone, as a function of the experience of the radiologist. In this trial, twelve readers analyzed 316 image sets, giving BIRADS (and other) scores first for the digital mammograms, and subsequently for the combined datasets of tomosynthesis and digital mammograms. Clinical performance was measured using two metrics, area under the ROC curve (AUROC) and recall rate, and was analyzed as a function of the experience level. The study found that all radiologists AUROC improved when using 3D+2D compared to 2D imaging showed a mean decrease in recall rate of 39.2% for the most experienced and a decrease of 39.6% for the least experienced, again with no correlation found with experience level. In summary, radiologists with a range of experience demonstrated improved performance using tomosynthesis in combination with digital mammography (3d+2D), as measured using recall rate reduction and AUROC metrics. C1 [Smith, Andrew P.; Niklason, Loren] Hologic Inc, 35 Crosby Dr, Bedford, MA 01730 USA. [Rafferty, Elizabeth A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Smith, AP (reprint author), Hologic Inc, 35 Crosby Dr, Bedford, MA 01730 USA. EM Andrew.smith@hologic.com NR 3 TC 19 Z9 19 U1 0 U2 2 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 978-3-540-70537-6 J9 LECT NOTES COMPUT SC PY 2008 VL 5116 BP 61 EP + PG 2 WC Computer Science, Artificial Intelligence; Computer Science, Theory & Methods; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA BID15 UT WOS:000258502700009 ER PT J AU Faraone, SV Adamson, JJ Wilens, TE Monuteaux, MC Biederman, J AF Faraone, Stephen V. Adamson, Joel J. Wilens, Timothy E. Monuteaux, Michael C. Biederman, Joseph TI Familial transmission of derived phenotypes for molecular genetic studies of substance use disorders SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE factor analysis; substance use disorders; genetic studies ID DEFICIT HYPERACTIVITY DISORDER; PSYCHIATRIC COMORBIDITY; BEHAVIORAL-INHIBITION; ANXIETY DISORDERS; BIPOLAR DISORDER; ASSOCIATION; ALCOHOLISM; CHILDREN; COCAINE; TWINS AB Although family, twin, and adoption studies indicate that genes play a significant etiologic role in the development of substance use disorders (SUDs), detecting specific genes has been difficult due to uncertainties about how to define SUDs, genetic heterogeneity and variable phenotypic expression of SUD genotypes. We used data from families recruited into six contemporaneous studies of children and adults to derive candidate SUD phenotypes using principle factors factor analysis with varimax rotation. We previously found evidence of two SUD phenotypes in offspring: a psychopathology dimension and a cognitive impairment dimension. We found evidence for one SUD-related phenotype in adults that we term Psychopathology and Cognitive Impairment. Parental factor scores significantly predicted both offspring phenotypes, as well as parental SUD (OR = 1.41, p < 0.001) and offspring SUD (mother's phenotype: OR = 1.34, p = 0.04; father's phenotype: OR = 1.33, p = 0.01). Offspring phenotype predicted offspring SUD (psychopathology phenotype: OR = 2.96, p < 0.001; cognitive impairment: OR = 1.33, p = 0.04); in offspring, baseline psychopathology predicted SUD at follow-up assessments (OR = 1.55, p = 0.01). Results suggest that these candidate SUD phenotypes may be useful for genetic studies of SUD. (C) 2007 Elsevier Ireland Ltd. All rights reserved. C1 [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA. [Adamson, Joel J.; Wilens, Timothy E.; Monuteaux, Michael C.; Biederman, Joseph] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Pediat Psychopharmacol Unit, Yawkey Ctr Outpatient Care,Dept Psychiat, Boston, MA 02114 USA. RP Faraone, SV (reprint author), SUNY Upstate Med Univ, Dept Psychiat, 750 E Adams St, Syracuse, NY 13210 USA. EM faraones@upstate.edu OI Adamson, Joel/0000-0002-1399-5786; Faraone, Stephen/0000-0002-9217-3982 FU NICHD NIH HHS [R01 HD037694, R01 HD037694-01, R01 HD037694-02, R01 HD037694-03, R01 HD037694-04, R01 HD037694-05, R01 HD037999, R01 HD037999-01, R01 HD037999-02, R01 HD037999-03, R01 HD037999-04, R01 HD037999-05]; NIDA NIH HHS [R01 DA018659, R01 DA018659-01, R01 DA018659-02, R01 DA018659-03, R01 DA018659-04]; NIMH NIH HHS [R01 MH062873-05, R01 MH057934, R01 MH057934-02, R01 MH057934-03, R01 MH057934-04, R01 MH057934-05, R01 MH062873, R01 MH062873-01A1, R01 MH062873-02, R01 MH062873-03, R01 MH062873-04, R01 MH062873-05S1, R01 MH066877, R01 MH066877-01, R01 MH066877-02, R01 MH066877-03, R01 MH066877-04, R01 MH066877-05A1, R01 MH066877-06, R01 MH081803, R01 MH081803-01, R01MH57934, R13 MH059126, R13 MH059126-01, R13 MH059126-02, R13 MH059126-03, R13 MH059126-03S1, R13 MH059126-04, R13 MH059126-05, R13 MH059126-06A1, R13 MH059126-07, R13 MH059126-08, R21 MH066191, R21 MH066191-01, R21 MH066191-02, R21 MH066191-03, R21 MH066191-04] NR 49 TC 7 Z9 7 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD JAN 1 PY 2008 VL 92 IS 1-3 BP 100 EP 107 DI 10.1016/j.drugalcdep.2007.07.002 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 256DF UT WOS:000252707200014 PM 17766060 ER PT J AU Graham, DY Lu, H Yamaoka, Y AF Graham, David Y. Lu, Hong Yamaoka, Yoshio TI Therapy for Helicobacter pylori infection can be improved - Sequential therapy and beyond SO DRUGS LA English DT Article ID PROTON-PUMP INHIBITOR; 7-DAY TRIPLE-THERAPY; QUADRUPLE THERAPY; DUAL THERAPY; DOUBLE-BLIND; ANTIBIOTIC-RESISTANCE; UNITED-STATES; CURE RATE; ANTIMICROBIAL SUSCEPTIBILITY; CYP2C19 POLYMORPHISM AB As with other bacterial infections, successful treatment of Helicobacter pylori infections depends on the use of antibacterial agents to which the organism is susceptible. In this article, we use the proposed report card grading scheme (i.e. grade A, B, C, D, F) for the outcome of clinical trials, where intention-to-treat cure rates > 95% = A, 90-95% = B, 85-89% = C, 81-84% = D and < 81% = F. The goal of therapy is to consistently cure >95% of patients (e.g. provide grade A results). Like tuberculosis, H. pylori infections are difficult to cure and successful treatment generally requires the administration of several antibacterial agents simultaneously. Duration of therapy is also important and depends upon whether resistance is present; 14 days is often best. With few exceptions, worldwide increasing macrolide resistance now undermines the effectiveness of the legacy triple therapy (e.g. a proton pump inhibitor [PPI], clarithromycin and amoxicillin) and, in most areas, cure rates have declined to unacceptable levels (e.g. grade F). The development of sequential therapy was one response to this problem. Sequential therapy has repeatedly been shown in head-to-head studies to be superior to legacy triple therapy. Sequential therapy, as originally described, is the sequential administration of a dual therapy (a PPI plus amoxicillin) followed by a Bazzoli-type triple therapy (a PPI plus clarithromycin and tinidazole) and has been shown to be especially useful where there is clarithromycin resistance. However, the cure rates of the original sequential treatment are grade B and can probably be further improved by changes in dose, duration or administration, such as by continuing the amoxicillin into the triple therapy arm. The sequential approach may also be more complicated than necessary, based on the fact that the same four drugs have also been given concomitantly (at least nine publications with > 700 patients) as a quadruple therapy with excellent success. This article discusses the approach to therapy in the modem era where antimicrobial resistance is an increasing problem and legacy triple therapy is no longer an acceptable initial choice. Methods to achieve acceptable eradication rates (e.g. grade A or B results) are discussed and, specifically, sequential therapy is considered both conceptually and practically. Suggestions are provided regarding how sequential therapy might be improved to become a grade A therapy as well as how to identify situations where it can be expected to yield unacceptable results. New uses for current drugs are discussed and suggestions for subsequent randomized comparisons to overcome phenotypic and genotypic resistance are given. We propose a change in focus from comparative studies (designed to prove that a new therapy is superior to a known inferior therapy) to demanding that efficacious therapies meet or exceed a pre-specified level of success (i.e. grade A or B result). To do so, coupled with less concern about the effect of recommendations on the pharmaceutical industry, should provide clinicians with much higher quality information, and improve the quality of medical care and recommendations regarding treatment. Ultimately, there is little or no justification for comparative testing that includes an arm with known unacceptably low results. H. pylori gastritis is an infectious disease and should be approached and treated as such. C1 [Graham, David Y.; Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. [Graham, David Y.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Lu, Hong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Digest Dis, Renji Hosp,Dept Gastroenterol, Shanghai 200030, Peoples R China. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, RM 3A-320,111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu FU NIDDK NIH HHS [DK56338] NR 80 TC 58 Z9 62 U1 0 U2 3 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 0012-6667 J9 DRUGS JI Drugs PY 2008 VL 68 IS 6 BP 725 EP 736 DI 10.2165/00003495-200868060-00001 PG 12 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 296GQ UT WOS:000255531900001 PM 18416582 ER PT J AU Kovacs, TOG Jensen, DM AF Kovacs, Thomas O. G. Jensen, Dennis M. TI The Short-Term Medical Management of Non-Variceal Upper Gastrointestinal Bleeding SO DRUGS LA English DT Article ID PROTON-PUMP INHIBITORS; CONTINUOUS INTRAVENOUS-INFUSION; PEPTIC-ULCER HEMORRHAGE; INTRAGASTRIC PH; HIGH-RISK; ENDOSCOPIC HEMOSTASIS; ADHERENT CLOTS; LANSOPRAZOLE REGIMENS; COST-EFFECTIVENESS; RANDOMIZED-TRIAL AB Upper gastrointestinal (UGI) bleeding occurs frequently and results in substantial patient morbidity, mortality and medical expense. After initial resuscitation to stabilize the patient, carefully performed endoscopy provides an accurate diagnosis and can identify high-risk subgroups in ulcer patients who are likely to rebleed with medical therapy alone and would benefit most from endoscopic haemostasis. Several different pharmacological therapies have been used for patients with bleeding ulcers, including intravenous histamine H(2)-receptor antagonists, proton pump inhibitors, somatostatin and octreotide, and tranexamic acid. The results of several studies and meta-analyses favour high-dose, intravenous proton pump inhibitors, such as omeprazole or pantoprazole, after successful endoscopic haemostasis. For patients with ulcer bleeding and low-risk endoscopic stigmata, high-dose oral proton pump inhibitor therapy is suggested. Medical management with proton pump inhibitors is not a substitute for appropriate endoscopic therapy for patients with UGI bleeding and high-risk ulcer stigmata. C1 [Kovacs, Thomas O. G.; Jensen, Dennis M.] VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. RP Kovacs, TOG (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Bldg 115,Room 212,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM tkovacs@mednet.ucla.edu NR 48 TC 6 Z9 7 U1 1 U2 2 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 0012-6667 J9 DRUGS JI Drugs PY 2008 VL 68 IS 15 BP 2105 EP 2111 DI 10.2165/00003495-200868150-00003 PG 7 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 373IK UT WOS:000260965100003 PM 18840002 ER PT J AU Hughes, KS AF Hughes, Kevin S. TI Why do we believe that breast cancer in the elderly is the same as breast cancer in young women? SO DRUGS & AGING LA English DT Editorial Material C1 Massachusetts Gen Hosp, Avon Comprehens Breast Evaluat Ctr, Boston, MA 02114 USA. RP Hughes, KS (reprint author), Massachusetts Gen Hosp, Avon Comprehens Breast Evaluat Ctr, Yawkey 7,55 Fruit St, Boston, MA 02114 USA. EM kshughes@partners.org OI Hughes, Kevin/0000-0003-4084-6484 NR 2 TC 2 Z9 2 U1 0 U2 0 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1170-229X J9 DRUG AGING JI Drugs Aging PY 2008 VL 25 IS 1 BP 47 EP 48 PG 2 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 261IE UT WOS:000253071500005 PM 18184028 ER PT J AU Kasckow, JW Zisook, S AF Kasckow, John W. Zisook, Sidney TI Co-occurring depressive symptoms in the older patient with schizophrenia SO DRUGS & AGING LA English DT Review ID INTENSIVE CASE-MANAGEMENT; QUALITY-OF-LIFE; ELDERLY-PATIENTS; ATYPICAL ANTIPSYCHOTICS; PSYCHOTIC DEPRESSION; DOUBLE-BLIND; SCHIZOAFFECTIVE DISORDER; MAJOR DEPRESSION; BIPOLAR DISORDER; LONG-TERM AB Clinicians treating older patients with schizophrenia are often challenged by patients presenting with both depressive and psychotic features. The presence of co-morbid depression impacts negatively on quality of life, functioning, overall psychopathology and the severity of co-morbid medical conditions. Depressive symptoms in patients with schizophrenia include major depressive episodes (MDEs) that do not meet criteria for schizoaffective disorder, MDEs that occur in the context of schizoaffective disorder and subthreshold depressive symptoms that do not meet criteria for MDE. Pharmacological treatment of patients with schizophrenia and depression involves augmenting antipsychotic medications with anti depressants. Recent surveys suggest that clinicians prescribe antidepressants to 30% of inpatients and 43% of outpatients with schizophrenia and depression at all ages. Recent trials addressing the efficacy of this practice have evaluated selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, sertraline, fluvoxamine and citalopram. These trials have included only a small number of Subjects and few older Subjects participated; furthermore. the efficacy results have been mixed. Although no published controlled psychotherapeutic studies have specifically targeted major depression or depressive symptoms in older patients with schizophrenia, psychosocial interventions likely play a role in any comprehensive management plan in this population of patients. Our recommendations for treating the older patient with schizophrenia and major depression involve a stepwise approach. First, a careful diagnostic assessment to rule out medical or medication causes is important as well as checking whether patients are adherent to treatments. Clinicians should also consider switching patients to an atypical antipsychotic if they are not taking one already. In addition, dose optimization needs to be targeted towards depressive as well as positive and negative psychotic symptoms. If major depression persists, adding an SSRI is a reasonable next step; one needs to start with a low dose and then cautiously titrate upward to reduce depressive symptoms. If remission is not achieved after an adequate treatment duration (8-12 weeks) or with an adequate close (similar to that used for major depression without schizophrenia), switching to another agent or adding augmenting therapy is recommended. We recommend treating an acute first episode of depression for at least 6-9 months and consideration of longer treatment for patients with residual symptoms, very severe or highly co-morbid major depression, ongoing episodes or recurrent episodes. Psychosocial interventions aimed at improving adherence, quality of life and function are also recommended. For patients with schizophrenia and subsyndromal depression, a similar approach is recommended. Psychosis accompanying major depression in patients without schizophrenia is common in elderly patients and is considered a primary mood disorder; for these reasons, it is an important syndrome to consider in the differential diagnosis of older patients with mood and thought disturbance. Treatment for this condition has involved electroconvulsive therapy (ECT) as well as combinations of antidepressant and antipsychotic medications. Recent evidence suggests that combination treatment may not be any more effective than antidepressant treatment alone and ECT may be more efficacious overall. C1 [Kasckow, John W.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA 15206 USA. [Kasckow, John W.] Univ Pittsburgh, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Zisook, Sidney] VA San Diego Healthcare Syst, San Diego, CA USA. RP Kasckow, JW (reprint author), VA Pittsburgh Hlth Care Syst, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM kasckowjw@upmc.edu FU Mental Illness Research, Education and Clinical Centers; University of California; San Diego Center; Aspect Medical Systems; PamLab; National Institute of Mental Health; [MH063931]; [MH6398]; [VISN 222] FX This work was supported by MH063931 (SZ), MH6398 (JK), the Veterans Integrated Services Network (VISN) 4 (JK) and VISN 222 (SZ) Mental Illness Research, Education and Clinical Centers. and the University of California, San Diego Center for Community-based Research in Older People with Psychoses (SZ). John Kasckow has acted as a consultant for. received honoraria from. and been a recipient of grant Support from Forest, Pfizer, AstraZeneca. Lilly, Bristol-Myers Squibb, and Johnson and Johnson. Sidney Zisook is a consultant for GlaxoSmithKline, has received honoraria from GlaxoSmith Kline, Forest, Pfizer. Wyeth and Eli Lilly, and has received grant support from Aspect Medical Systems, PamLab and the National Institute of Mental Health. NR 115 TC 20 Z9 22 U1 4 U2 14 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1170-229X J9 DRUG AGING JI Drugs Aging PY 2008 VL 25 IS 8 BP 631 EP 647 PG 17 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 342BE UT WOS:000258758800002 PM 18665657 ER PT J AU Rosowski, JJ Nakajima, HH Merchant, SN AF Rosowski, John J. Nakajima, Hideko H. Merchant, Sauntil N. TI Clinical utility of laser-Doppler vibrometer measurements in live normal and pathologic human ears SO EAR AND HEARING LA English DT Review ID SEMICIRCULAR CANAL DEHISCENCE; CONDUCTIVE HEARING-LOSS; VESTIBULAR AQUEDUCT SYNDROME; MIDDLE-EAR; TYMPANIC MEMBRANE; ACOUSTIC REFLEX; SUPERIOR; BONE; CAT; REFLECTANCE AB The laser-Doppler vibrometer (LDV) is a research tool that can be used to quickly measure the sound-induced velocity of the tympanic membrane near the umbo (the inferior tip of the malleus) in live human subjects and patients. In this manuscript we demonstrate the LDV to be a sensitive and selective tool for the diagnosis and differentiation of various ossicular disorders in patients with intact tympanic membranes and aerated middle ears. Patients with partial or total ossicular interruption or malleus fixation are readily separated from normal-hearing subjects with the LDV. The combination of LDV measurements and air-bone gap can distinguish patients with fixed stapes from those with normal ears. LDV measurements can also help differentiate air-bone gaps produced by ossicular pathologies from those associated with pathologies of inner-ear sound conduction such as a superior semicircular canal dehiscence. C1 [Rosowski, John J.; Nakajima, Hideko H.; Merchant, Sauntil N.] Harvard Univ, Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. [Rosowski, John J.; Nakajima, Hideko H.; Merchant, Sauntil N.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Rosowski, John J.; Merchant, Sauntil N.] Harvard Mit Div Hlth Sci & Technol, Speech & Hearing Biosci & Technol Program, Cambridge, MA 02139 USA. RP Rosowski, JJ (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA. EM John-Rosowski@meei.harvard.edu FU NIDCD NIH HHS [T32 DC000020, T32 DC 000020, R01 DC004798-07, R01 DC004798, R01 DC 004798] NR 58 TC 60 Z9 63 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0196-0202 J9 EAR HEARING JI Ear Hear. PD JAN PY 2008 VL 29 IS 1 BP 3 EP 19 PG 17 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 249OL UT WOS:000252238200002 PM 18091103 ER PT J AU Demetri, GD Joensuu, H AF Demetri, George D. Joensuu, Heikki TI Systemic treatment of patients with gastrointestinal stromal tumor: Current status and future opportunities SO EJC SUPPLEMENTS LA English DT Article DE gastrointestinal stromal tumor; outcome; mutational status; tyrosine kinase inhibitor; imatinib; sunitinib; nilotinib; adjuvant therapy; neoadjuvant therapy ID TYROSINE KINASE INHIBITOR; POPULATION-BASED INCIDENCE; RENAL-CELL CARCINOMA; TERM-FOLLOW-UP; IMATINIB MESYLATE; C-KIT; FREE SURVIVAL; SARCOMA GROUP; PHASE-II; GIST AB Imatinib mesylate is considered the standard first-line systemic treatment for patients with advanced gastrointestinal stromal tumor (GIST). Results from recent research have expanded the knowledge of tyrosine kinase inhibitors in management of GIST. In the setting of unresectable and metastatic GIST, long-term follow-up of the B2222 study showed that imatinib 400 and 600mg/d produced objective responses in 68% of patients and clinical benefit in 84%; it also extended median survival from 19 months in historical controls to 57 months. The MetaGIST analysis in two large phase 3 trials consisting of more than 1600 patients with metastatic and/or unresectable GIST showed that imatinib 800 mg/d compared with the standard 400-mg/d dose conferred a progression-free survival advantage in patients with KIT exon 9 mutations but not in other subpopulations. The higher starting dose does not significantly improve overall survival. The BFR14 trial demonstrated that interrupting imatinib is associated with a high risk of rapid disease progression. For patients with imatinib-intolerant or imatinib-resistant GIST, sunitinib or a variety of investigational agents, including the next-generation kinase inhibitor nilotinib, may be viable options for achieving disease control. In the setting of primary localized GIST, function-sparing surgical resection is the standard treatment approach, but some patients may be at substantial risk of disease recurrence and metastasis depending on tumor size, mitotic count, and possibly other factors. Initial results from ACOSOG Z9001 indicate that adjuvant imatinib for 1 year prolongs recurrence-free survival following surgical resection of larger (at least 3 cm) KIT-expressing GIST. Other ongoing studies are further exploring the role of imatinib in both adjuvant and neoadjuvant therapy. Recent updates to clinical practice guidelines and recommendations now incorporate some of these new findings. (c) 2008 Elsevier Ltd. All rights reserved. C1 [Demetri, George D.] Dana Farber Harvard Univ, Ludwig Ctr, Boston, MA USA. [Joensuu, Heikki] Univ Helsinki, Cent Hosp, Helsinki, Finland. RP Demetri, GD (reprint author), Dana Farber Canc Inst, Ludwig Ctr, 44 Binney St,Dana Bldg D1212, Boston, MA 02115 USA. EM gdemetri@partners.org NR 61 TC 6 Z9 6 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD JAN PY 2008 VL 6 IS 1 BP 1 EP 14 DI 10.1016/S1359-6349(08)70003-X PG 14 WC Oncology SC Oncology GA 265ZR UT WOS:000253401100001 ER PT J AU McDonnell, AM Churchill, WW Cotugno, M Cooley, T Silverman, J Bartel, SB AF McDonnell, Anne M. Churchill, William W. Cotugno, Michael Cooley, Thomas Silverman, Jon Bartel, Sylvia B. TI The use of medication safety technology to deliver safe use of medication SO EJHP PRACTICE LA English DT Article ID PHYSICIAN ORDER ENTRY; ADVERSE DRUG EVENTS; PREVENTION; ERRORS AB Brigham and Women's Hospital (BWH) has invested substantial time and resources into computerised physician order entry (CPOE), bar code scanning, chemotherapy order templates for high-risk protocols and clinical trials, smart infusion pump technology and medications reconciliation systems. C1 [McDonnell, Anne M.; Churchill, William W.; Cotugno, Michael; Cooley, Thomas; Silverman, Jon] Brigham & Womens Hosp, Dept Pharm, Boston, MA 02115 USA. [Bartel, Sylvia B.] Dana Farber Canc Inst, Dept Pharm, Boston, MA 02115 USA. RP McDonnell, AM (reprint author), Brigham & Womens Hosp, Dept Pharm, 75 Francis St,L2, Boston, MA 02115 USA. EM amcdonnell@partners.org NR 8 TC 0 Z9 0 U1 2 U2 3 PU PHARMA PUBLISHING & MEDIA EUROPE-PPM EUROPE PI MOL PA POSTBUS 10001, MOL, B-2400, BELGIUM SN 1781-9989 J9 EJHP PRACT JI EJHP Pract. PY 2008 VL 14 IS 4 BP 26 EP 28 PG 3 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 354ZO UT WOS:000259678600024 ER PT J AU Yoshida, S Pellman, D AF Yoshida, Satoshi Pellman, David TI Plugging the GAP between cell polarity and cell cycle SO EMBO REPORTS LA English DT Article ID CANDIDA-ALBICANS; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; GROWTH; PHOSPHORYLATION; MORPHOGENESIS; PROTEIN; ACTIVATION; GTPASE; CDC42P C1 [Yoshida, Satoshi; Pellman, David] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. RP Pellman, D (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA. EM david_pellman@dfci.harvard.edu RI Yoshida, Satoshi/C-5016-2011 NR 16 TC 8 Z9 8 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1469-221X J9 EMBO REP JI EMBO Rep. PD JAN PY 2008 VL 9 IS 1 BP 39 EP 41 DI 10.1038/sj.embor.7401142 PG 3 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 247QY UT WOS:000252095600012 PM 18174895 ER PT J AU Cline, D Thomas, SH AF Cline, David Thomas, Stephen H. BE Thomas, SH TI Chronic pain SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID LOW-BACK-PAIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; EFFICACY; THERAPY; TRIALS C1 [Cline, David] Wake Forest Univ, Baptist Med Ctr, Dept Emergency Med, Winston Salem, NC 27109 USA. [Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. RP Cline, D (reprint author), Wake Forest Univ, Baptist Med Ctr, Dept Emergency Med, Winston Salem, NC 27109 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 52 EP 60 DI 10.1017/CBO9780511544835.008 D2 10.1017/CBO9780511544835 PG 9 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500008 ER PT J AU White, BA Thomas, SH AF White, Benjamin A. Thomas, Stephen H. BE Thomas, SH TI NSAIDs and opioids SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACUTE PAIN; CONTROLLED-TRIAL; INTRAVENOUS MORPHINE; CHILDREN; HYDROMORPHONE; IBUPROFEN; EFFICACY; OSTEOARTHRITIS; COMPLICATIONS C1 [White, Benjamin A.] Brigham & Womens Hosp, Boston, MA 02115 USA. [White, Benjamin A.; Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. RP White, BA (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 22 TC 0 Z9 0 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 61 EP 69 DI 10.1017/CBO9780511544835.009 D2 10.1017/CBO9780511544835 PG 9 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500009 ER PT J AU Rosen, P Thomas, SH AF Rosen, Peter Thomas, Stephen H. BE Thomas, SH TI Reflections on analgesia in emergency departments SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter C1 [Rosen, Peter; Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Rosen, P (reprint author), Harvard Univ, Sch Med, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 77 EP 83 DI 10.1017/CBO9780511544835.011 D2 10.1017/CBO9780511544835 PG 7 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500011 ER PT J AU Listwa, TM Thomas, SH AF Listwa, Todd M. Thomas, Stephen H. BE Thomas, SH TI Arthritis SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACUTE GOUTY-ARTHRITIS; PLACEBO-CONTROLLED TRIAL; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; KNEE OSTEOARTHRITIS; CARDIOVASCULAR EVENTS; CLINICAL-TRIALS; ADRENOCORTICOTROPIC HORMONE; INTRAARTICULAR INJECTION C1 [Listwa, Todd M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Listwa, Todd M.; Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. RP Listwa, TM (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 69 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 94 EP 110 DI 10.1017/CBO9780511544835.014 D2 10.1017/CBO9780511544835 PG 17 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500014 ER PT J AU Thomas, SH Ilgen, JS AF Thomas, Stephen H. Ilgen, Jonathan S. BE Thomas, SH TI Biliary tract pain SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID DOUBLE-BLIND; SYMPTOMATIC TREATMENT; ODDI DYSFUNCTION; COLIC PAIN; BILE-DUCT; SPHINCTER; MEPERIDINE; KETOROLAC; PENTAZOCINE; DICLOFENAC C1 [Thomas, Stephen H.; Ilgen, Jonathan S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. [Ilgen, Jonathan S.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Thomas, SH (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 26 TC 1 Z9 1 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 111 EP 116 DI 10.1017/CBO9780511544835.015 D2 10.1017/CBO9780511544835 PG 6 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500015 ER PT J AU Thomas, SH Browne, CJ AF Thomas, Stephen H. Browne, Ciaran J. BE Thomas, SH TI Bites and stings - marine SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID JELLYFISH CHIRONEX-FLECKERI; BOX-JELLYFISH; IRUKANDJI-SYNDROME; 1ST AID; ENVENOMATION; AUSTRALIA; MANAGEMENT; FAILURE; HAND C1 [Thomas, Stephen H.; Browne, Ciaran J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. [Browne, Ciaran J.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Thomas, SH (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 34 TC 0 Z9 0 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 117 EP 123 DI 10.1017/CBO9780511544835.016 D2 10.1017/CBO9780511544835 PG 7 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500016 ER PT J AU Lovecchio, F Thomas, SH AF Lovecchio, Frank Thomas, Stephen H. BE Thomas, SH TI Bites and stings - terrestrial SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID FIRE ANT STINGS; WIDOW SPIDER ENVENOMATION; BIERS BLOCK TECHNIQUE; CONTROLLED-TRIAL; CENTIPEDE BITES; ANTIVENOM SERUM; SAUDI-ARABIA; BLACK; CATERPILLAR; MANAGEMENT C1 [Lovecchio, Frank] Arizona Coll Osteopath Med, Phoenix, AZ 85036 USA. [Lovecchio, Frank] Maricopa Cty Gen Hosp, Dept Emergency Med, Phoenix, AZ USA. [Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. RP Lovecchio, F (reprint author), Arizona Coll Osteopath Med, Phoenix, AZ 85036 USA. NR 62 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 124 EP 132 DI 10.1017/CBO9780511544835.017 D2 10.1017/CBO9780511544835 PG 9 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500017 ER PT J AU Walta, M Thomas, SH AF Walta, Michael Thomas, Stephen H. BE Thomas, SH TI Cancer and tumor pain SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID DOUBLE-BLIND; ADJUVANT ANALGESICS; INTRAVENOUS LIDOCAINE; MORPHINE THERAPY; CONTROLLED-TRIAL; ORAL MORPHINE; MANAGEMENT; KETAMINE; CALCITONIN; ACETAMINOPHEN C1 [Walta, Michael] Brigham & Womens Hosp, Boston, MA 02115 USA. [Walta, Michael; Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. RP Walta, M (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 40 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 151 EP 161 DI 10.1017/CBO9780511544835.021 D2 10.1017/CBO9780511544835 PG 11 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500021 ER PT J AU White, BA Thomas, SH AF White, Benjamin A. Thomas, Stephen H. BE Thomas, SH TI Cystitis, urethritis, and prostatitis SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID THE-COUNTER PHENAZOPYRIDINE; URINARY-TRACT-INFECTION; PELVIC PAIN SYNDROME; INTERSTITIAL CYSTITIS; DISCOMFORT; PYRIDIUM C1 [White, Benjamin A.] Brigham & Womens Hosp, Boston, MA 02115 USA. [White, Benjamin A.; Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. RP White, BA (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 23 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 188 EP 192 DI 10.1017/CBO9780511544835.027 D2 10.1017/CBO9780511544835 PG 5 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500027 ER PT J AU White, BA Thomas, SH AF White, Benjamin A. Thomas, Stephen H. BE Thomas, SH TI Dysmenorrhea SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC EFFICACY; MEFENAMIC-ACID; PAIN STATES; INHIBITOR; VALDECOXIB; ETORICOXIB C1 [White, Benjamin A.] Brigham & Womens Hosp, Boston, MA 02115 USA. [White, Benjamin A.; Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. RP White, BA (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 20 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 193 EP 196 DI 10.1017/CBO9780511544835.028 D2 10.1017/CBO9780511544835 PG 4 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500028 ER PT J AU Walta, M Thomas, SH AF Walta, Michael Thomas, Stephen H. BE Thomas, SH TI Fibromyalgia SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID PLACEBO-CONTROLLED TRIAL; MAJOR DEPRESSIVE DISORDER; CHRONIC NONCANCER PAIN; CONTROLLED CROSSOVER TRIAL; DOUBLE-BLIND; PRIMARY FIBROSITIS; ANTIDEPRESSANTS; AMITRIPTYLINE; METAANALYSIS; FLUOXETINE C1 [Walta, Michael] Brigham & Womens Hosp, Boston, MA 02115 USA. [Walta, Michael; Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. RP Walta, M (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 42 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 204 EP 212 DI 10.1017/CBO9780511544835.031 D2 10.1017/CBO9780511544835 PG 9 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500031 ER PT J AU Fix, ML Thomas, SH AF Fix, Megan L. Thomas, Stephen H. BE Thomas, SH TI Gastritis and peptic ulcer disease SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID PROTON-PUMP INHIBITORS; ERADICATING HELICOBACTER-PYLORI; DOUBLE-BLIND; NONULCER DYSPEPSIA; FUNCTIONAL DYSPEPSIA; GI COCKTAIL; H-2-RECEPTOR ANTAGONISTS; COMPARATIVE TRIAL; CLINICAL-TRIAL; PRIMARY-CARE C1 [Fix, Megan L.] Maine Med Ctr, Dept Emergency Med, Portland, ME 04102 USA. [Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. RP Fix, ML (reprint author), Maine Med Ctr, Dept Emergency Med, Portland, ME 04102 USA. NR 48 TC 0 Z9 0 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 213 EP 224 DI 10.1017/CBO9780511544835.032 D2 10.1017/CBO9780511544835 PG 12 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500032 ER PT J AU White, BA Thomas, SH AF White, Benjamin A. Thomas, Stephen H. BE Thomas, SH TI Hemorrhoids and perianal pain SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID CHRONIC ANAL-FISSURE; GLYCERYL TRINITRATE OINTMENT; PLACEBO-CONTROLLED TRIAL; CONSERVATIVE TREATMENT; POSTOPERATIVE PAIN; TOPICAL NIFEDIPINE; CROHNS-DISEASE; DOUBLE-BLIND; SITZ-BATH; NITROGLYCERIN C1 [White, Benjamin A.] Brigham & Womens Hosp, Boston, MA 02115 USA. [White, Benjamin A.; Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. RP White, BA (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 47 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 232 EP 242 DI 10.1017/CBO9780511544835.034 D2 10.1017/CBO9780511544835 PG 11 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500034 ER PT J AU Levine, A Thomas, SH AF Levine, Adam Thomas, Stephen H. BE Thomas, SH TI Neck and back pain - radicular syndromes SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID RANDOMIZED CONTROLLED-TRIAL; ACUTE SCIATICA; ACUTE LUMBAGO; INDOMETHACIN; MULTICENTER; DIPYRONE; PLACEBO; PHENYLBUTAZONE; DIFLUNISAL; DICLOFENAC C1 [Levine, Adam] Brigham & Womens Hosp, Boston, MA 02115 USA. [Levine, Adam; Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. RP Levine, A (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 21 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 268 EP 272 DI 10.1017/CBO9780511544835.038 D2 10.1017/CBO9780511544835 PG 5 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500038 ER PT J AU Walta, M Thomas, SH AF Walta, Michael Thomas, Stephen H. BE Thomas, SH TI Neck and back pain - spinal spondylitic syndromes SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DOUBLE-BLIND; CERVICAL MYELOPATHY; MUSCLE SPASM; CYCLOBENZAPRINE; EFFICACY; TRIAL; OSTEOARTHRITIS; AMITRIPTYLINE; MULTICENTER C1 [Walta, Michael] Brigham & Womens Hosp, Boston, MA 02115 USA. [Walta, Michael; Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. RP Walta, M (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 20 TC 1 Z9 1 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 273 EP 276 DI 10.1017/CBO9780511544835.039 D2 10.1017/CBO9780511544835 PG 4 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500039 ER PT J AU Cline, D Thomas, SH AF Cline, David Thomas, Stephen H. BE Thomas, SH TI Neuropathy - HIV related SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID PLACEBO-CONTROLLED TRIAL; PERIPHERAL NEUROPATHY; SENSORY NEUROPATHIES; GABAPENTIN; CANNABIS; PAIN C1 [Cline, David] Wake Forest Univ, Baptist Med Ctr, Dept Emergency Med, Winston Salem, NC 27109 USA. [Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. RP Cline, D (reprint author), Wake Forest Univ, Baptist Med Ctr, Dept Emergency Med, Winston Salem, NC 27109 USA. NR 17 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 285 EP 288 DI 10.1017/CBO9780511544835.042 D2 10.1017/CBO9780511544835 PG 4 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500042 ER PT J AU Thomas, SH AF Thomas, Stephen H. BE Thomas, SH TI Ocular inflammation SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID TRAUMATIC CORNEAL ABRASIONS; ALLERGIC CONJUNCTIVITIS; OPHTHALMIC SOLUTION; INDOMETHACIN SOLUTION; TOPICAL INDOMETHACIN; KETOTIFEN FUMARATE; CLINICAL-TRIAL; EFFICACY; SAFETY; 0.1-PERCENT C1 [Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. RP Thomas, SH (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 44 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 306 EP 313 DI 10.1017/CBO9780511544835.045 D2 10.1017/CBO9780511544835 PG 8 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500045 ER PT J AU Wilcox, SR Thomas, SH AF Wilcox, Susan R. Thomas, Stephen H. BE Thomas, SH TI Osteoporotic vertebral compression fracture SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID SALMON-CALCITONIN; DOUBLE-BLIND; NASAL SPRAY; ACUTE PAIN; PAMIDRONATE C1 [Wilcox, Susan R.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Wilcox, Susan R.; Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. RP Wilcox, SR (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 331 EP 334 DI 10.1017/CBO9780511544835.048 D2 10.1017/CBO9780511544835 PG 4 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500048 ER PT J AU Thomas, SH Ilgen, JS AF Thomas, Stephen H. Ilgen, Jonathan S. BE Thomas, SH TI Pancreatitis SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID DOUBLE-BLIND TRIAL; SPHINCTER; BUPRENORPHINE; MANAGEMENT; TRAMADOL; ODDI; PAIN C1 [Thomas, Stephen H.; Ilgen, Jonathan S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. [Ilgen, Jonathan S.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Thomas, SH (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 23 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 339 EP 343 DI 10.1017/CBO9780511544835.050 D2 10.1017/CBO9780511544835 PG 5 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500050 ER PT J AU LoVecchio, F Thomas, SH AF LoVecchio, Frank Thomas, Stephen H. BE Thomas, SH TI Undifferentiated abdominal pain SO EMERGENCY DEPARTMENT ANALGESIA: AN EVIDENCE-BASED GUIDE LA English DT Article; Book Chapter ID RANDOMIZED CLINICAL-TRIAL; INTRAVENOUS MORPHINE; DIAGNOSTIC-ACCURACY; ANALGESIA; FENTANYL; CHILDREN; RELIEF; APPENDICITIS; EMERGENCY; SAFETY C1 [LoVecchio, Frank] Maricopa Cty Gen Hosp, Dept Emergency Med, Phoenix, AZ USA. [Thomas, Stephen H.] Harvard Univ, Sch Med, Boston, MA USA. [Thomas, Stephen H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 29 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69601-2 PY 2008 BP 392 EP 397 DI 10.1017/CBO9780511544835.060 D2 10.1017/CBO9780511544835 PG 6 WC Emergency Medicine SC Emergency Medicine GA BCK42 UT WOS:000310449500060 ER PT J AU Lee, HJ Teixeira, J AF Lee, Ho-Joon Teixeira, Jose TI Evidence of a role for androgens in embryonic stem cell function and differentiation SO ENDOCRINOLOGY LA English DT Article ID INSULIN-SECRETING CELLS; IN-VITRO; CARDIOMYOCYTES; EXPRESSION; RECEPTOR; MICE C1 [Teixeira, Jose] Massachusetts Gen Hosp, Vincent Reprod Biol, Boston, MA 02114 USA. [Lee, Ho-Joon; Teixeira, Jose] Massachusetts Gen Hosp, Harvard Med Sch, Vincent Ctr Reprod Biol, Boston, MA 02114 USA. RP Teixeira, J (reprint author), Massachusetts Gen Hosp, Vincent Reprod Biol, Thier 913,55 Fruit St, Boston, MA 02114 USA. EM teixeira@helix.mgh.harvard.edu OI Teixeira, Jose/0000-0002-6438-5064 NR 16 TC 12 Z9 12 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD JAN PY 2008 VL 149 IS 1 BP 3 EP 4 DI 10.1210/en.2007-1417 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 243LF UT WOS:000251797500002 PM 18096671 ER PT J AU Renlund, N Pieretti-Vanmarcke, R O'Neill, FH Zhang, LH Donahoe, PK Teixeira, J AF Renlund, Nina Pieretti-Vanmarcke, Rafael O'Neill, Francis H. Zhang, LiHua Donahoe, Patricia K. Teixeira, Jose TI c-Jun N-terminal kinase inhibitor II (SP600125) activates mullerian inhibiting substance type II receptor-mediated signal transduction SO ENDOCRINOLOGY LA English DT Article ID PROSTATE-CANCER CELLS; OVARIAN-CANCER; INDEPENDENT MECHANISM; SEXUAL DEVELOPMENT; DUCT REGRESSION; PROTEIN-KINASE; TUMOR-GROWTH; EXPRESSION; JNK; PATHWAY AB Mullerian inhibiting substance (MIS), the hormone required for Mullerian duct regression in fetal males, is also expressed in both adult males and females, but its physiological role in these settings is not clear. The expression of the MIS type II receptor (MISRII) in ovarian cancer cells and the ability of MIS to inhibit proliferation of these cells suggest that MIS might be a promising therapeutic for recurrent ovarian cancer. Using an MISRII-dependent activity assay in a small-molecule screen for MIS-mimetic compounds, we have identified the c-Jun N-terminal kinase inhibitor SP600125 as an activator of the MIS signal transduction pathway. SP600125 increased the activity of a bone morphogenetic protein-responsive reporter gene in a dose-dependent manner and exerted a synergistic effect when used in combination with MIS. This effect was specific for the MISRII and was not seen with other receptors of the TGF beta family. Moreover, treatment of mouse ovarian cancer cells with a combination of SP600125 and paclitaxel, an established chemotherapeutic agent used in the treatment of ovarian cancer, or with MIS enabled inhibition of cell proliferation at a lower dose than with each treatment alone. These results offer a strong rationale for testing the therapeutic potential of SP600125, alone or in combination with already established drugs, in the treatment of recurrent ovarian cancer with a much-needed decrease in the toxic side effects of currently employed therapeutic agents. C1 [Renlund, Nina; Zhang, LiHua; Teixeira, Jose] Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Boston, MA 02114 USA. [Pieretti-Vanmarcke, Rafael; O'Neill, Francis H.; Donahoe, Patricia K.] Massachusetts Gen Hosp, Harvard Med Sch, Pediat Surg Res Labs, Boston, MA 02114 USA. RP Teixeira, J (reprint author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, 55 Fruit St, Boston, MA 02114 USA. EM Teixeira@helix.mgh.harvard.edu OI Teixeira, Jose/0000-0002-6438-5064 FU NCI NIH HHS [CA17393, R01 CA017393] NR 47 TC 14 Z9 17 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD JAN PY 2008 VL 149 IS 1 BP 108 EP 115 DI 10.1210/en.2007-0529 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 243LF UT WOS:000251797500015 PM 17947357 ER PT J AU Delgado-Escueta, AV Bourgeois, BFD AF Delgado-Escueta, Antonio V. Bourgeois, Blaise F. D. TI Debate: Does genetic information in humans help us treat patients? SO EPILEPSIA LA English DT Article ID SEVERE MYOCLONIC EPILEPSY; FEBRILE SEIZURES PLUS; UNVERRICHT-LUNDBORG-DISEASE; CHILDHOOD ABSENCE EPILEPSY; TONIC-CLONIC SEIZURES; CHANNEL ALPHA-1-SUBUNIT MUTATIONS; NEURONAL SODIUM-CHANNEL; OF-FUNCTION MUTATION; DE-NOVO MUTATIONS; CYSTATIN-B GENE AB In the past decade, genotyping has started to help the neurologic practitioner treat patients with three types of epilepsy causing mutations, namely ( 1) SCNIA, a sodium channel gene mutated in Dravet's sporadic severe myoclonic epilepsy of infancy (SMEI and SMEB); ( 2) laforin ( dual specificity protein phosphatase) and malin ( ubiquitin E3 ligase) in Lafora progressive myoclonic epilepsy ( PME); and ( 3) cystatin B in Unverricht-Lundborg type of PME. Laforin, malin, and cystatin B are non-ion channel gene mutations that cause PME. Genotyping ensures accurate diagnosis, helps treatment and genetic counseling, psychological and social help for patients and families, and directs families to organizations devoted to finding cures for specific epilepsy diseases. In SCN1A and cystatin B mutations, treatment with sodium channel blockers ( phenytoin, carbamazepine, oxcarbazepine, lamotrigine) should be avoided. Because of early and correct diagnosis by genotyping of SCN1A mutations, the avoidance of sodium channel blockers, and aggressive treatment of prolonged convulsive status, there is hope that Dravet's syndrome may not be as severe as observed in all past reports. Genotyping also identifies nonsense mutations in Lafora PME. Nonsense mutations can be corrected by premature stop codon readthrough drugs such as gentamicin. The community practitioner together with epilepsy specialists in PME can work together and acquire gentamicin (Barton-Davis et al., 1999) for compassionate use'' in Lafora PME, a generalized lysosome multiorgan storage disorder that is invariably fatal. In Unverricht-Lundborg PME, new cohorts with genotyped cystatin B mutations have led to the chronic use of antioxidant N-acetylcysteine and combination valproate clobazam or clonazepam plus antimyoclonic drugs topiramate, zonisamide, piracetam, levetiracetam, or brivaracetam. These cohorts have minimal ataxia and no dementia, questioning whether the syndrome is truly progressive. In conclusion, not only is genotyping a prerequisite in the diagnosis of Dravet's syndrome and the progressive myoclonus epilepsies, but it also helps us choose the correct antiepileptic drugs to treat seizures in Dravet's syndrome and Unverricht-Lundborg PME. Genotyping also portends a brighter future, helping us to reassess the true course, severity, and progressive nature of Dravet's syndrome and Unverricht-Lundborg PME and helping us craft a future curative treatment for Dravet's syndrome and Lafora disease. Without the genotyping diagnosis of epilepsy causing mutations we are stuck with imprecise diagnosis and symptomatic treatment of seizures. C1 [Delgado-Escueta, Antonio V.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Epilepsy Genet Genom Labs, Los Angeles, CA 90073 USA. [Bourgeois, Blaise F. D.] Harvard Univ, Sch Med, Boston, MA USA. [Bourgeois, Blaise F. D.] Childrens Hosp, Div Epilepsy & Clin Neurophysiol, Boston, MA 02115 USA. RP Delgado-Escueta, AV (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Epilepsy Genet Genom Labs, Los Angeles, CA 90073 USA. EM escueta@ucla.edu FU NINDS NIH HHS [R01 NS055057] NR 90 TC 23 Z9 24 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 13 EP 24 DI 10.1111/j.1528-1167.2008.01922.x PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA 392DK UT WOS:000262282900004 PM 19087113 ER PT J AU Hoef, LV AF Hoef, Lawrence Ver TI EFFECT OF SPIKE DETECTION PARAMETERS ON THE EFFECTIVENESS OF SPIKE DETECTION SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Hoef, Lawrence Ver] Univ Alabama, UAB Epilepsy Ctr, Birmingham, AL USA. [Hoef, Lawrence Ver] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 26 EP 26 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600058 ER PT J AU Cole, AJ Wiebe, S AF Cole, Andrew J. Wiebe, Samuel TI Debate: Should antiepileptic drugs be stopped after successful epilepsy surgery? SO EPILEPSIA LA English DT Article DE Epilepsy surgery; Outcome; Anticonvulsant Drugs; Discontinuation; Evidence-based medicine; Risk stratification ID QUALITY-STANDARDS-SUBCOMMITTEE; TEMPORAL-LOBE EPILEPSY; TECHNOLOGY-ASSESSMENT SUBCOMMITTEE; ACADEMY-OF-NEUROLOGY; AMERICAN-ACADEMY; PRACTICE PARAMETER; SOCIETY; REDUCTION; LOBECTOMY; SEIZURES AB There is no consensus on whether or when to stop anticonvulsant drug treatment in patients after apparently successful epilepsy surgery. Although there are compelling reasons to consider antiepileptic drug (AED) discontinuation, there are relatively few data, and no class 1 data, to guide patient and physician decision-making on this topic. This debate lays out a conceptual framework for considering the issue of AED discontinuation, and reviews and critiques the avaialble data. The goal is to provide physicians with the best available data, a context in which to consider it, and a full understanding of its limitations. This article also highlights an area that is ripe for further prospective study. C1 [Cole, Andrew J.] Massachusetts Gen Hosp, Epilepsy Serv, Boston, MA 02114 USA. [Wiebe, Samuel] Univ Calgary, Calgary, AB, Canada. RP Cole, AJ (reprint author), Massachusetts Gen Hosp, Epilepsy Serv, WAC 739 L,Fruit St, Boston, MA 02114 USA. EM cole.andrew@.mgh.harvard.edu RI shengkun, yu/B-8440-2012 NR 24 TC 12 Z9 12 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 29 EP 34 DI 10.1111/j.1528-1167.2008.01924.x PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 392DK UT WOS:000262282900006 PM 19087115 ER PT J AU Pfeifer, HH Lyczkowski, DA Thiele, EA AF Pfeifer, Heidi H. Lyczkowski, David A. Thiele, Elizabeth A. TI Low glycemic index treatment: Implementation and new insights into efficacy SO EPILEPSIA LA English DT Article DE Glycemic index; Low glycemic index treatment; Refractory epilepsy; Dietary therapy ID KETOGENIC DIET; SEIZURE SUSCEPTIBILITY; GLUCOSE; EPILEPSY; METABOLISM; THRESHOLD; KETOSIS; FOODS AB Despite the substantial efficacy of the ketogenic diet (KD) in treating refractory epilepsy, use of the KD remains limited because of difficulties in implementation and tolerability. An effective alternative dietary approach is a low glycemic index treatment (LGIT), which liberalizes the extreme carbohydrate restriction of the KD but restricts the type of carbohydrate-containing foods to those that produce relatively small changes in blood glucose. Foods with a "glycemic index" of less than 50 produce less than half the area-under-the-curve elevation of blood glucose compared to a reference food. The LGIT approach produces comparable efficacy to the classic KD, but tolerability is improved and implementation is much simpler. The LGIT appears to be a viable first-line dietary therapy for epilepsy. C1 [Pfeifer, Heidi H.; Lyczkowski, David A.; Thiele, Elizabeth A.] Massachusetts Gen Hosp, Pediat Epilepsy Program, Boston, MA 02114 USA. RP Pfeifer, HH (reprint author), Massachusetts Gen Hosp, Pediat Epilepsy Program, 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM hpfeifer@partners.org NR 20 TC 19 Z9 20 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 SU 8 BP 42 EP 45 DI 10.1111/j.1528-1167.2008.01832.x PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 374QW UT WOS:000261059800013 PM 19049585 ER PT J AU Nguyen, VHV Dergalust, S AF Nguyen, Viet-Huong V. Dergalust, S. TI RETROSPECTIVE CHART REVIEW OF ANTIEPILEPTIC DRUG (AED) MONOTHERAPY IN VETERAN PATIENTS WITH EPILEPSY SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Nguyen, Viet-Huong V.; Dergalust, S.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 54 EP 54 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600125 ER PT J AU Shareef, AH Patil, VK AF Shareef, Aisha H. Patil, Vijaya K. TI LEVETIRACETAM MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES: A RETROSPECTIVE ANALYSIS OF A VA POPULATION SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Shareef, Aisha H.; Patil, Vijaya K.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Shareef, Aisha H.; Patil, Vijaya K.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 65 EP 65 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600149 ER PT J AU Van Cott, AC Cramer, J Dersh, JJ Zeber, J Mortensen, E Copeland, LA Steinman, M Glickman, M Pugh, M AF Van Cott, Anne C. Cramer, Joyce Dersh, J. J. Zeber, John Mortensen, E. Copeland, Laurel A. Steinman, M. Glickman, M. Pugh, M. TI SUICIDE IN OLDER VETERANS TREATED WITH ANTIEPILEPTIC DRUGS SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Van Cott, Anne C.] VA Pittsburgh Healthcare Syst, Div Neurol, Pittsburgh, PA USA. [Van Cott, Anne C.] Univ Pittsburgh, Pittsburgh, PA USA. [Cramer, Joyce] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Dersh, J. J.] S Texas Vet Hlth Care Syst, Spinal Cord Injury Unit, Dept Vet Affairs, San Antonio, TX USA. [Zeber, John; Mortensen, E.; Copeland, Laurel A.; Pugh, M.] S Texas Vet Hlth Care Syst, VERDICT HSR& D, Dept Vet Affairs, San Antonio, TX USA. [Zeber, John; Copeland, Laurel A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Mortensen, E.; Pugh, M.] Univ Texas Hlth Sci Ctr San Antonio, Div Med, San Antonio, TX 78229 USA. [Steinman, M.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Steinman, M.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Glickman, M.] Edith Nourse Rogers Mem Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. [Glickman, M.] Boston Univ, Sch Publ Hlth, Dept Hlth Serv, Bedford, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 69 EP 69 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600160 ER PT J AU Chu-Shore, C Major, P Montenegro, M Thiele, E AF Chu-Shore, Catherine Major, Philippe Montenegro, M. Thiele, E. TI CYSTIC CORTICAL TUBERS ARE PREDICTIVE OF THE DEVELOPMENT OF EPILEPSY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Chu-Shore, Catherine; Montenegro, M.; Thiele, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Major, Philippe] CHU St Justine, Serv Neurol, Montreal, PQ, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 75 EP 75 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600175 ER PT J AU Major, P Camposano, SE Muzykewicz, D Chu-Shore, C Thiele, EA AF Major, Philippe Camposano, Susana E. Muzykewicz, D. Chu-Shore, Catherine Thiele, E. A. TI THE NATURAL HISTORY OF EPILEPSY IN TUBEROUS SCLEROSIS COMPLEX SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Major, Philippe; Camposano, Susana E.; Muzykewicz, D.; Chu-Shore, Catherine; Thiele, E. A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 82 EP 82 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600190 ER PT J AU Bruno, PL Numis, AL Pfeifer, HH Thiele, EA AF Bruno, Patricia L. Numis, A. L. Pfeifer, Heidi H. Thiele, E. A. TI THE KETOGENIC DIET IN THE TREATMENT OF INFANTILE SPASMS SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Bruno, Patricia L.; Numis, A. L.; Pfeifer, Heidi H.; Thiele, E. A.] Massachusetts Gen Hosp, Pediat Epilepsy Program, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 120 EP 120 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600274 ER PT J AU Leeman, BA Moo, LR Leveroni, CL Cole, AJ Schachter, SC Hoch, DB AF Leeman, Beth A. Moo, L. R. Leveroni, C. L. Cole, A. J. Schachter, S. C. Hoch, Daniel B. TI COGNITIVE EFFECTS OF TREATMENT OF FOCAL INTERICTAL DISCHARGES WITH LEVETIRACETAM SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Leeman, Beth A.; Schachter, S. C.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA. [Leeman, Beth A.; Moo, L. R.; Leveroni, C. L.; Cole, A. J.; Hoch, Daniel B.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 136 EP 137 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600312 ER PT J AU Salinsky, MC Munoz, S Storzbach, D AF Salinsky, Martin C. Munoz, S. Storzbach, D. TI PREGABALIN EFFECTS ON THE EEG AND COGNITION: A RANDOMIZED, DOUBLE-BLIND STUDY IN HEALTHY VOLUNTEERS SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Salinsky, Martin C.; Munoz, S.; Storzbach, D.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Salinsky, Martin C.; Munoz, S.; Storzbach, D.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 139 EP 140 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600319 ER PT J AU Hamiwka, L Keller, A Stufflebeam, S Hader, WH Sherman, E AF Hamiwka, Lorie Keller, A. Stufflebeam, S. Hader, W. H. Sherman, Elisabeth TI TEMPORAL LOBE CORTICAL THICKNESS AND HIPPOCAMPAL VOLUMES: CORRELATION WITH MEMORY ABNORMALITIES IN CHILDREN WHO ARE MEDICALLY REFRACTORY SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Hamiwka, Lorie; Keller, A.; Hader, W. H.; Sherman, Elisabeth] Alberta Childrens Prov Gen Hosp, Calgary, AB T2T 5C7, Canada. [Stufflebeam, S.] Massachusetts Gen Hosp, Athinoula A Martins Ctr Biomed Imaging, Charlestown, MA USA. RI Hamiwka, Lorie/C-5585-2008 OI Hamiwka, Lorie/0000-0002-6946-4028 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 149 EP 150 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600342 ER PT J AU Glykys, J Staley, KJ AF Glykys, Joseph Staley, K. J. TI DIFFERENCES IN CORTICAL VS. SUBCORTICAL GABA EFFECTS: A MECHANISM FOR ELECTROCLINICAL DISSOCIATION OF NEONATAL SEIZURES SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Glykys, Joseph; Staley, K. J.] Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 170 EP 170 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600391 ER PT J AU Wyeth, MS Zhang, N Huang, CS Houser, CR AF Wyeth, Megan S. Zhang, N. Huang, C. S. Houser, C. R. TI SELECTIVE LOSS OF CHOLECYSTOKININ INNERVATION OF PYRAMIDAL CELL BODIES IN A MODEL OF SPONTANEOUS SEIZURES SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Wyeth, Megan S.; Zhang, N.; Huang, C. S.; Houser, C. R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Huang, C. S.; Houser, C. R.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 170 EP 171 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600393 ER PT J AU Shapiro, MJ Chaippa, KH AF Shapiro, Michelle J. Chaippa, K. H. TI CORRELATION OF SOMATOSENSORY EVOKED POTENTIALS AND ELECTROENCEPHALOGRAPHIC RESULTS IN PATIENTS WITH ANOXIC BRAIN INJURY SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Shapiro, Michelle J.; Chaippa, K. H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 192 EP 192 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600450 ER PT J AU Spencer, DC Snodgrass, M Salinsky, M AF Spencer, David C. Snodgrass, M. Salinsky, M. TI SURFACE EEG IN PURE MEDIAL TEMPORAL EPILEPSY SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Spencer, David C.; Snodgrass, M.; Salinsky, M.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Spencer, David C.; Salinsky, M.] Portland VA Med Ctr, Dept Neurol, Portland, OR USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 192 EP 193 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600451 ER PT J AU Thibert, RL Thiele, EA AF Thibert, Ronald L. Thiele, E. A. TI THE SIGNIFICANCE OF EEG FINDINGS IN ANGELMAN SYNDROME SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Thibert, Ronald L.; Thiele, E. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 193 EP 194 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600453 ER PT J AU Camposano, SE Major, P Ahlfors, SP Thiele, EA AF Camposano, Susana E. Major, Philippe Ahlfors, S. P. Thiele, E. A. TI LOCALIZATION OF PRIMARY CORTICES IN TUBEROUS SCLEROSIS COMPLEX (TSC): A MAGNETOENCEPHALOGRAPHY (MEG) STUDY SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Ahlfors, S. P.] Massachusetts Gen Hosp, Martinos Ctr Radiol, Boston, MA 02114 USA. RI Ahlfors, Seppo/P-3644-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 197 EP 197 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600458 ER PT J AU Tanaka, N Tanaka, N Liu, H Mori, N Madsen, J Bourgeois, B Hamalainen, M Stufflebeam, S AF Tanaka, Naoaki Tanaka, Naoaki Liu, H. Mori, N. Madsen, J. Bourgeois, B. Hamalainen, M. Stufflebeam, S. TI SPATIOTEMPORAL SOURCE RECONSTRUCTION OF MAGNETOENCEPHALOGRAPHIC AND ELECTROENCEPHALOGRAPHIC SPIKES IN PATIENTS WITH TEMPORAL LOBE EPILEPSY: COMPARISON WITH INTRACRANIAL ELECTROENCEPHALOGRAM SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Tanaka, Naoaki; Tanaka, Naoaki; Liu, H.; Mori, N.; Hamalainen, M.; Stufflebeam, S.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Madsen, J.] Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA. [Bourgeois, B.] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA. RI Hamalainen, Matti/C-8507-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 202 EP 202 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600470 ER PT J AU Carmant, L Wheless, JW Bebin, M Conry, JA Chiron, C Elterman, RD Frost, M Paolicchi, JM Shields, WD Thiele, E Zupanc, ML Collins, S AF Carmant, Lionel Wheless, James W. Bebin, Martina Conry, J. A. Chiron, C. Elterman, Roy D. Frost, M. Paolicchi, Juliann M. Shields, W. D. Thiele, E. Zupanc, Mary L. Collins, S. TI MAGNETIC RESONANCE IMAGING ABNORMALITIES IN INFANTS TREATED WITH VIGABATRIN FOR INFANTILE SPASMS SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Carmant, Lionel] CHU St Justine, Montreal, PQ, Canada. [Wheless, James W.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. [Wheless, James W.] LeBonheur Neurosci Inst, Memphis, TN USA. [Bebin, Martina] Univ Alabama, Birmingham, AL USA. [Conry, J. A.] Childrens Natl Med Ctr, Washington, DC USA. [Chiron, C.] Hop Necker Enfants Malad, Paris, France. [Elterman, Roy D.] Dallas Pediat Neurol Associates, Dallas, TX USA. [Frost, M.] Minnesota Epilepsy Grp, St Paul, MN USA. [Paolicchi, Juliann M.] Monroe Carrell Jr Childrens Hosp Vanderbilt, Nashville, TN USA. [Shields, W. D.] Univ Calif Los Angeles, Mattel Childrens Hosp, Los Angeles, CA USA. [Thiele, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Zupanc, Mary L.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA. [Collins, S.] Ovat Pharmaceut Inc, Deerfield, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 211 EP 211 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600493 ER PT J AU Numis, AL Staley, BA Thibert, RL Thiele, EA AF Numis, Adam L. Staley, B. A. Thibert, Ronald L. Thiele, E. A. TI SLEEP DISORDERS IN EPILEPSY AND TUBEROUS SCLEROSIS COMPLEX SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Numis, Adam L.; Thiele, E. A.] Harvard Univ, Sch Med, Boston, MA USA. [Staley, B. A.; Thibert, Ronald L.; Thiele, E. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 268 EP 268 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600637 ER PT J AU Dyhrfjeld-Johnsen, J Sabolek, H Staley, KJ AF Dyhrfjeld-Johnsen, Jonas Sabolek, H. Staley, K. J. TI LONG LASTING POSTICTAL DEPRESSION OF SEPSC AMPLITUDES IN CA3 PYRAMIDAL CELLS FROM ORGANOTYPIC SLICE CULTURES SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Dyhrfjeld-Johnsen, Jonas; Sabolek, H.; Staley, K. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Dyhrfjeld-Johnsen, Jonas; Sabolek, H.; Staley, K. J.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 333 EP 334 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600800 ER PT J AU Berdichevsky, Y Sabolek, HR Yarmush, M Staley, KJ AF Berdichevsky, Yevgeny Sabolek, Helen R. Yarmush, M. Staley, K. J. TI LONG-TERM RECORDING OF EPILEPTIFORM ACTIVITY IN ORGANOTYPIC HIPPOCAMPUS SLICES SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Berdichevsky, Yevgeny; Sabolek, Helen R.; Yarmush, M.; Staley, K. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Berdichevsky, Yevgeny; Sabolek, Helen R.; Yarmush, M.; Staley, K. J.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 338 EP 339 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600812 ER PT J AU Li, Y Peng, ZC Houser, CR AF Li, Yi Peng, Z. C. Houser, C. R. TI ALTERED GABA(A) RECEPTOR delta SUBUNIT EXPRESSION EXTENDS BEYOND THE DENTATE GYRUS IN A MOUSE MODEL OF TEMPORAL LOBE EPILEPSY SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society/2nd Biennial North American Regional Epilepsy Congress CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Li, Yi; Peng, Z. C.; Houser, C. R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Houser, C. R.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 SU 7 BP 346 EP 346 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306600830 ER PT J AU Lee, JW Drappatz, J Norden, A Wen, P Bromfield, EB AF Lee, Jong Woo Drappatz, J. Norden, A. Wen, P. Bromfield, E. B. TI USE OF LEVETIRACETAM REDUCES CHEMOTHERAPY-ASSOCIATED NAUSEA IN BRAIN TUMOR PATIENTS SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Lee, Jong Woo; Drappatz, J.; Norden, A.; Wen, P.; Bromfield, E. B.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Drappatz, J.; Norden, A.; Wen, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 440 EP 440 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306601032 ER PT J AU Niquet, J Lopez-Meraz, M Wasterlain, C AF Niquet, Jerome Lopez-Meraz, M. Wasterlain, C. TI EXPERIMENTAL STATUS EPILEPTICUS INDUCES CASPASE-8 UPREGULATON AND NECROSIS IN CA1 PYRAMIDS, BUT CASPASE-9 ACTIVATION AND APOPTOSIS IN DENTATE GRANULE CELLS SO EPILEPSIA LA English DT Meeting Abstract CT 62nd Annual Meeting of the American-Epilepsy-Society CY DEC 05-09, 2008 CL Seattle, WA SP Amer Epilepsy Soc C1 [Niquet, Jerome; Lopez-Meraz, M.; Wasterlain, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Niquet, Jerome; Lopez-Meraz, M.; Wasterlain, C.] VA Greater Los Angeles Healthcare Syst, Epilepsy Res Lab, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2008 VL 49 BP 471 EP 471 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 363ZS UT WOS:000260306601099 ER PT J AU Korbey, SM Heinrichs, SC Leussis, MP AF Korbey, Samantha M. Heinrichs, Stephen C. Leussis, Melanie P. TI Seizure susceptibility and locus ceruleus activation are reduced following environmental enrichment in an animal model of epilepsy SO EPILEPSY & BEHAVIOR LA English DT Article DE cFos; E1 mouse; environment; immediate-early gene; locus ceruleus; stress ID CORTICOTROPIN-RELEASING-FACTOR; GLUCOCORTICOID-RECEPTOR EXPRESSION; PRONE EL MICE; AUDIOGENIC-SEIZURES; SOCIAL-ISOLATION; GENE-EXPRESSION; FOS EXPRESSION; BRAIN; STRESS; RATS AB Alterations in the complexity of social and physical housing environments modulate seizure susceptibility in animal models of epilepsy. The studies described here tested the hypothesis that environmental enrichment would delay seizure onset in the epileptic (E1) mouse. Neural activation measured via cFos expression, accumulation of the stress neuropeptide corticotropin-releasing factor (CRF), and behavioral seizure susceptibility were quantified in E1 mice to better understand the mechanisms of ictogenesis. Enrichment housing of E1 mice from Postnatal Days 21 to 49 produced a 100% decrease in seizure susceptibility relative to E1 controls. cFos expression increased in the primary motor cortex, locus ceruleus, and hippocampus of E1 mice relative to ddY controls, an effect attenuated by enrichment housing. CRF levels were elevated by enrichment in the hippocampus of ddY mice only. This study provides evidence that enrichment housing delays the onset of seizure susceptibility in E1 mice while altering the neuronal and stress-related responses in seizure-associated regions of the E1 brain. (C) 2007 Elsevier Inc. All rights reserved. C1 [Korbey, Samantha M.; Heinrichs, Stephen C.; Leussis, Melanie P.] Boston Coll, Dept Psychol, Chestnut Hill, MA 02467 USA. RP Leussis, MP (reprint author), Harvard Univ, Sch Med, Ctr Human Genet Res, Massachusetts Gen Hosp,Dept Psychiat, 185 Cambridge St,6th Floor, Boston, MA 02114 USA. EM mleussis@chgr.mgh.harvard.edu NR 53 TC 15 Z9 16 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD JAN PY 2008 VL 12 IS 1 BP 30 EP 38 DI 10.1016/j.yebeh.2007.09.013 PG 9 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 252RU UT WOS:000252465100004 PM 17983840 ER PT B AU Berka, C Levendowski, DJ Davis, G Zivkovic, VT Cvetinovic, MM Olmstead, RE AF Berka, Chris Levendowski, Daniel J. Davis, Gene Zivkovic, Vladimir T. Cvetinovic, Milenko M. Olmstead, Richard E. BE Chebykin, OY Bedny, GZ Karwowski, W TI The New Interface of Brain, Mind, and Machine: Will the Emergent Whole Be Greater than the Sum of the Parts? SO ERGONOMICS AND PSYCHOLOGY: DEVELOPMENTS IN THEORY AND PRACTICE SE Ergonomics Design and Management Theory and Applications LA English DT Article; Book Chapter ID SLEEP-DEPRIVATION; COMPUTER INTERFACE; EEG SPECTRUM; PERFORMANCE; ALERTNESS; TASK; DISORDERS; INDEXES; WORKERS C1 [Berka, Chris; Levendowski, Daniel J.; Davis, Gene; Zivkovic, Vladimir T.; Cvetinovic, Milenko M.] Adv Brain Monitoring, Carlsbad, CA USA. [Olmstead, Richard E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Berka, C (reprint author), Adv Brain Monitoring, Carlsbad, CA USA. NR 69 TC 0 Z9 0 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4200-6700-2 J9 ERGON DES MANAG THEO PY 2008 BP 167 EP 188 D2 10.1201/9781420067019 PG 22 WC Ergonomics; Psychology, Applied SC Engineering; Psychology GA BJY89 UT WOS:000267470200009 ER PT B AU Ellenbogen, JM AF Ellenbogen, Jeffrey M. BE Chebykin, OY Bedny, GZ Karwowski, W TI The Interaction of Sleep and Memory SO ERGONOMICS AND PSYCHOLOGY: DEVELOPMENTS IN THEORY AND PRACTICE SE Ergonomics Design and Management Theory and Applications LA English DT Article; Book Chapter ID SLOW-WAVE SLEEP; COMPLEMENTARY LEARNING-SYSTEMS; DECLARATIVE MEMORY; REM-SLEEP; PROCEDURAL MEMORY; AWAKE STATE; CONSOLIDATION; TIME; HIPPOCAMPUS; CELLS C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Sleep Med Program, Boston, MA 02115 USA. RP Ellenbogen, JM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Sleep Med Program, Boston, MA 02115 USA. NR 55 TC 0 Z9 0 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4200-6700-2 J9 ERGON DES MANAG THEO PY 2008 BP 189 EP 202 D2 10.1201/9781420067019 PG 14 WC Ergonomics; Psychology, Applied SC Engineering; Psychology GA BJY89 UT WOS:000267470200010 ER PT J AU Williams, ES Shah, SJ Ali, S Na, BY Schiller, NB Whooley, MA AF Williams, Eric S. Shah, Sanjiv J. Ali, Sadia Na, Bee Ya Schiller, Nelson B. Whooley, Mary A. TI C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE C-reactive protein; coronary heart disease; heart failure; diastolic dysfunction; inflammation; echocardiography ID TARGETED ANTICYTOKINE THERAPY; INDEPENDENT PROGNOSTIC VALUE; LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; NECROSIS-FACTOR-ALPHA; CARDIOVASCULAR-DISEASE; DEPRESSIVE SYMPTOMS; INFLAMMATION; MARKERS; INTERLEUKIN-6 AB Background: High-sensitivity C-reactive protein (CRP) is an inflammatory marker that predicts coronary heart disease (CHD) and, in recent studies, incident heart failure (HF). Whether the association of inflammation with incident HF is explained by worse baseline left ventricular dysfunction or by underlying CHD is unknown. Methods and results: Serum CRP was measured in a cohort of 985 outpatients with established CHD from the Heart and Soul Study. During 3 years of follow-up, 15% of the participants with elevated CRP levels (>3 mg/L) were hospitalised for HF, compared with 7% of those with CRP <= 3 mg/L. In multivariate analysis, elevated CRP was associated with HF after adjustment for traditional risk factors, baseline CHD severity and interim MI (adjusted HR 2.1, 95% CI, 1.2-3.6; p=0.009). However, elevated CRP was no longer associated with HF after further adjustment for the presence of diastolic dysfunction on echocardiography (adjusted HR 1.6, 95% CI, 0.8-3.2; p=0.1). Conclusions: Among outpatients with stable CHD, elevated CRP levels predict hospitalisation for heart failure, independent of baseline heart failure, medication use, CHD severity, and subsequent MI events. This relationship appears to be at least partly explained by abnormal diastolic function in patients with elevated CRP levels. (c) 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved. C1 [Williams, Eric S.; Shah, Sanjiv J.; Ali, Sadia; Na, Bee Ya; Schiller, Nelson B.; Whooley, Mary A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Williams, Eric S.; Shah, Sanjiv J.; Ali, Sadia; Na, Bee Ya; Schiller, Nelson B.; Whooley, Mary A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Williams, ES (reprint author), 4150 Clement St,Box 1211, San Francisco, CA 94143 USA. EM eric.williams@ucsf.edu FU NHLBI NIH HHS [R01 HL079235, R01 HL079235-01A1] NR 46 TC 33 Z9 33 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1388-9842 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD JAN PY 2008 VL 10 IS 1 BP 63 EP 69 DI 10.1016/j.ejheart.2007.11.003 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 260VP UT WOS:000253038800010 PM 18160340 ER PT J AU Engert, JC Lemire, M Faith, J Brisson, D Fujiwara, TM Roslin, NM Brewer, CG Montpetit, A Darmond-Zwaig, C Renaud, Y Dore, C Bailey, SD Verner, A Tremblay, G St-Pierre, J Betard, C Platko, J Rioux, JD Morgan, K Hudson, TJ Gaudet, D AF Engert, James C. Lemire, Mathieu Faith, Janet Brisson, Diane Fujiwara, T. Mary Roslin, Nicole M. Brewer, Carl G. Montpetit, Alexandre Darmond-Zwaig, Corinne Renaud, Yannick Dore, Carole Bailey, Swneke D. Verner, Andrei Tremblay, Gerald St-Pierre, Julie Betard, Christine Platko, Jill Rioux, John D. Morgan, Kenneth Hudson, Thomas J. Gaudet, Daniel TI Identification of a chromosome 8p locus for early-onset coronary heart disease in a French Canadian population SO EUROPEAN JOURNAL OF HUMAN GENETICS LA English DT Article DE atherosclerosis; stenosis; linkage; genes; genetics; French Canadian ID MACROPHAGE SCAVENGER RECEPTORS; LIPOPROTEIN-LIPASE DEFICIENCY; SQUALENE SYNTHASE INHIBITOR; CHOLESTEROL-LOWERING AGENT; LOW-DENSITY-LIPOPROTEIN; PROSTATE-CANCER RISK; GENOME-WIDE LINKAGE; FAMILY-BASED TESTS; ARTERY-DISEASE; SUSCEPTIBILITY LOCUS AB Susceptibility to coronary heart disease (CHD) has long been known to exhibit familial aggregation, with heritability estimated to be greater than 50%. The French Canadian population of the Saguenay-Lac-Saint-Jean region of Quebec, Canada is descended from a founder population that settled this region 300-400 years ago and this may provide increased power to detect genes contributing to complex traits such as CHD. Probands with early-onset CHD, defined by angiographically determined coronary stenosis, and their relatives were recruited from this population ( average sibship size of 6.4). Linkage analysis was performed following a genome-wide microsatellite marker scan on 42 families with 284 individuals. Nonparametric linkage (NPL) analysis provided suggestive evidence for a CHD susceptibility locus on chromosome 8 with an NPL score of 3.14 (P=0.001) at D8S1106. Linkage to this locus was verified by fine mapping in an enlarged sample of 50 families with 320 individuals. This analysis provided evidence of linkage at D8S552 (NPL score=3.53, P=0.0003), a marker that maps to the same location as D8S1106. Candidate genes in this region, including macrophage scavenger receptor 1, farnesyl-diphosphate farnesyltransferase 1, fibrinogen-like 1, and GATA-binding protein 4, were resequenced in all coding exons in both affected and unaffected individuals. Association studies with variants in these and five other genes did not identify a disease-associated mutation. In conclusion, a genome-wide scan and additional fine mapping provide evidence for a locus on chromosome 8 that contributes to CHD in a French Canadian population. C1 [Engert, James C.; Roslin, Nicole M.; Brewer, Carl G.; Betard, Christine; Morgan, Kenneth; Hudson, Thomas J.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. [Engert, James C.; Fujiwara, T. Mary; Bailey, Swneke D.; Morgan, Kenneth; Hudson, Thomas J.] McGill Univ, Dept Human Genet, Montreal, PQ, Canada. [Engert, James C.; Fujiwara, T. Mary; Morgan, Kenneth; Hudson, Thomas J.] McGill Univ, Dept Med, Montreal, PQ, Canada. [Lemire, Mathieu; Faith, Janet; Montpetit, Alexandre; Darmond-Zwaig, Corinne; Renaud, Yannick; Dore, Carole; Verner, Andrei; Morgan, Kenneth; Hudson, Thomas J.] McGill Univ, Genome Quebec Innovat Ctr, Montreal, PQ, Canada. [Brisson, Diane; Tremblay, Gerald; St-Pierre, Julie; Gaudet, Daniel] Univ Montreal, Chicoutimi Hosp, Montreal Univ Commun Genom Res Ctr, Dept Med Lipid Diabetes & Atherosclerosis Res Grp, Chicoutimi, PQ, Canada. [Platko, Jill; Rioux, John D.; Hudson, Thomas J.] MIT, Whitehead Inst Biomed Res, Cambridge, MA USA. [Platko, Jill] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rioux, John D.] MIT & Harvard, Broad Inst, Cambridge, MA USA. [Rioux, John D.] Univ Montreal, Montreal, PQ, Canada. [Rioux, John D.] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada. RP Engert, JC (reprint author), McGill Univ, Royal Victoria Hosp, Dept Med & Human Genet, H730,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada. EM jamie.engert@mcgill.ca RI Rioux, John/A-9599-2015 OI Rioux, John/0000-0001-7560-8326 NR 77 TC 10 Z9 11 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1018-4813 J9 EUR J HUM GENET JI Eur. J. Hum. Genet. PD JAN PY 2008 VL 16 IS 1 BP 105 EP 114 DI 10.1038/sj.ejhg.5201920 PG 10 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 240UP UT WOS:000251614000015 PM 17805225 ER PT J AU Brown, RE McKenna, JT Winston, S Basheer, R Yanagawa, Y Thakkar, MM McCarley, RW AF Brown, Ritchie E. McKenna, James T. Winston, Stuart Basheer, Radhika Yanagawa, Yuchio Thakkar, Mahesh M. McCarley, Robert W. TI Characterization of GABAergic neurons in rapid-eye-movement sleep controlling regions of the brainstem reticular formation in GAD67-green fluorescent protein knock-in mice SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE carbachol; orexin; REM sleep; subcoeruleus; whole cell ID GLUTAMIC-ACID DECARBOXYLASE; DORSAL RAPHE NUCLEUS; PEDUNCULOPONTINE TEGMENTAL NUCLEI; GAMMA-AMINOBUTYRIC-ACID; INDUCED ACTIVE SLEEP; C-FOS EXPRESSION; REM-SLEEP; PARADOXICAL SLEEP; PONTIS ORALIS; PONTOMESENCEPHALIC TEGMENTUM AB Recent experiments suggest that brainstem GABAergic neurons may control rapid-eye-movement (REM) sleep. However, understanding their pharmacology/physiology has been hindered by difficulty in identification. Here we report that mice expressing green fluorescent protein (GFP) under the control of the GAD67 promoter (GAD67-GFP knock-in mice) exhibit numerous GFP-positive neurons in the central gray and reticular formation, allowing on-line identification in vitro. Small (10-15 mu m) or medium-sized (15-25 mu m) GFP-positive perikarya surrounded larger serotonergic, noradrenergic, cholinergic and reticular neurons, and > 96% of neurons were double-labeled for GFP and GABA, confirming that GFP-positive neurons are GABAergic. Whole-cell recordings in brainstem regions important for promoting REM sleep [subcoeruleus (SubC) or pontine nucleus oralis (PnO) regions] revealed that GFP-positive neurons were spontaneously active at 3-12 Hz, fired tonically, and possessed a medium-sized depolarizing sag during hyperpolarizing steps. Many neurons also exhibited a small, low-threshold calcium spike. GFP-positive neurons were tested with pharmacological agents known to promote (carbachol) or inhibit (orexin A) REM sleep. SubC GFP-positive neurons were excited by the cholinergic agonist carbachol, whereas those in the PnO were either inhibited or excited. GFP-positive neurons in both areas were excited by orexins/hypocretins. These data are congruent with the hypothesis that carbachol-inhibited GABAergic PnO neurons project to, and inhibit, REM-on SubC reticular neurons during waking, whereas carbachol-excited SubC and PnO GABAergic neurons are involved in silencing locus coeruleus and dorsal raphe aminergic neurons during REM sleep. Orexinergic suppression of REM during waking is probably mediated in part via excitation of acetylcholine-inhibited GABAergic neurons. C1 [Brown, Ritchie E.; McKenna, James T.; Winston, Stuart; Basheer, Radhika; Thakkar, Mahesh M.; McCarley, Robert W.] Harvard Univ, Sch Med, In Vitro Neurophysiol Sect, Neurosci Lab, Brockton, MA 02301 USA. [Brown, Ritchie E.; McKenna, James T.; Winston, Stuart; Basheer, Radhika; Thakkar, Mahesh M.; McCarley, Robert W.] VA Boston Healthcare Syst, Brockton, MA 02301 USA. [Yanagawa, Yuchio] Gunma Univ, Grad Sch Med & SORST, JST, Dept Genet & Behav Neurosci, Maebashi, Gumma 371, Japan. RP Brown, RE (reprint author), Harvard Univ, Sch Med, In Vitro Neurophysiol Sect, Neurosci Lab, 940 Belmont St,Res 151-C, Brockton, MA 02301 USA. EM Ritchie_Brown@hms.harvard.edu RI McCarley, Robert/N-5562-2014; OI McCarley, Robert/0000-0001-5705-7495; Brown, Ritchie/0000-0002-7164-4132 FU BLRD VA [I01 BX001356]; NIMH NIH HHS [R01 MH062522, R01 MH062522-01, R37 MH039683] NR 65 TC 55 Z9 56 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD JAN PY 2008 VL 27 IS 2 BP 352 EP 363 DI 10.1111/j.1460-9568.2008.06024.x PG 12 WC Neurosciences SC Neurosciences & Neurology GA 253CG UT WOS:000252495700010 PM 18215233 ER PT J AU Furtado, AD Smith, WS Koroshetz, W Dillon, WP Furie, KL Lev, MH Vittinghoff, E Schaeffer, S Biagini, T Hazarika, O Wintermark, M AF Furtado, A. D. Smith, W. S. Koroshetz, W. Dillon, W. P. Furie, K. L. Lev, M. H. Vittinghoff, E. Schaeffer, S. Biagini, T. Hazarika, O. Wintermark, M. TI Perfusion CT imaging follows clinical severity in left hemispheric strokes SO EUROPEAN NEUROLOGY LA English DT Article DE perfusion CT, stroke; noncontrast CT, stroke; clinical severity, stroke; left hemispheric stroke ID ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; OF-HEALTH STROKE; BLOOD-VOLUME MEASUREMENTS; DIFFUSION-WEIGHTED MRI; MEAN TRANSIT-TIME; COMPUTED-TOMOGRAPHY; THROMBOLYTIC THERAPY; CEREBRAL INFARCTION; HYPERACUTE STROKE AB Objective: The purpose of this study was to assess how imaging findings on admission perfusion CT (PCT) and follow-up noncontrast CT (NCT), and their changes over time, correlate with clinical scores of stroke severity measured on admission, at discharge and at 6-month follow-up. Methods: Fifty-two patients with suspected hemispheric acute ischemic stroke underwent a PCT within the first 24 h of symptom onset and a follow-up NCT of the brain between 24 h and 3 months after the initial stroke CT study. NIH Stroke Scale (NIHSS) scores were recorded for each patient at admission, discharge and 6 months; modified Rankin scores were determined at discharge and 6 months. Baseline PCT and follow-up NCT were analyzed quantitatively (volume of ischemic/infarcted tissue) and semiquantitatively (anatomical grading score derived from the Alberta Stroke Program Early CT Score). The correlation between imaging volumes/scores and clinical scores was assessed. Analysis was performed for all patients considered together and separately for those with right and left hemispheric strokes. Results: Significant correlations were found between clinical scores and both quantitative and semiquantitative imaging. The volume of the acute PCT mean transit time lesion showed best correlation with admission NIHSS scores (R(2) = 0.61, p < 0.001). This association was significantly better for left hemispheric strokes (R(2) = 0.80, p < 0.001) than for right hemispheric strokes (R(2) = 0.39, p = 0.131). Correlation between imaging and NIHSS scores was better than correlation between imaging and modified Rankin scores (p = 0.047). The correlation with discharge clinical scores was better than that with 6-month clinical scores (p = 0.012). Conclusions: Baseline PCT and follow-up NCT volumes predict stroke severity at baseline, discharge and, to a lesser extent, 6 months. The correlation is stronger for left-sided infarctions. This finding supports the use of PCT as a surrogate stroke outcome measure. Copyright (C) 2008 S. Karger AG, Basel. C1 [Furtado, A. D.; Dillon, W. P.; Schaeffer, S.; Wintermark, M.] Univ Calif San Francisco, Dept Radiol, Neuroradiol Sect, San Francisco, CA 94143 USA. [Smith, W. S.; Biagini, T.; Hazarika, O.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Vittinghoff, E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Koroshetz, W.; Furie, K. L.] Massachusetts Gen Hosp, Stroke Serv, Boston, MA 02114 USA. [Lev, M. H.] Massachusetts Gen Hosp, Dept Radiol, Neuroradiol Sect, Boston, MA 02114 USA. RP Wintermark, M (reprint author), Univ Calif San Francisco, Dept Radiol, Neuroradiol Sect, 505 Parnassus Ave,Box 0628, San Francisco, CA 94143 USA. EM Max.Wintermark@radiology.ucsf.edu OI Wintermark, Max/0000-0002-6726-3951 FU DHHS-AHRQ [RO1-HS011392-01A1]; National Center for Research Resources [KL2 RR024130]; GE Healthcare and Philips Medical Systems FX The present research was a substudy of the STOP Stroke Study, which was supported by DHHS-AHRQ (RO1-HS011392-01A1). M. W. receives funding from the National Center for Research Resources, grant KL2 RR024130, GE Healthcare and Philips Medical Systems. NR 45 TC 6 Z9 7 U1 1 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0014-3022 J9 EUR NEUROL JI Eur. Neurol. PY 2008 VL 60 IS 5 BP 244 EP 252 DI 10.1159/000151700 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 355RC UT WOS:000259725000005 PM 18756089 ER PT J AU McMurtray, AM Licht, E Yeo, T Krisztal, E Saul, RE Mendez, MF AF McMurtray, Aaron M. Licht, Eliot Yeo, Tuty Krisztal, Erica Saul, Ronald E. Mendez, Mario F. TI Positron emission tomography facilitates diagnosis of early-onset Alzheimer's disease SO EUROPEAN NEUROLOGY LA English DT Article DE positron emission tomography; sensitivity; dementia; Alzheimer's disease ID MILD COGNITIVE IMPAIRMENT; REGIONAL CEREBRAL METABOLISM; ACADEMY-OF-NEUROLOGY; FDG-PET; GLUCOSE-METABOLISM; EARLY DEMENTIA; ASYMMETRIES; PREVALENCE; PARAMETER; PATTERNS AB Background: Clinical positron emission tomography (PET) may help in the evaluation of presenile patients with memory complaints for the presence of Alzheimer's disease (AD). Methods: Clinical PET scans from 27 patients with clinically probable AD and early ages of onset (< 65 years) were compared to PET scans from 27 age-matched controls presenting with memory complaints, but without dementia or mild cognitive impairment. Results: Compared to controls, the AD patients had significant frontal, temporal and parietal hypometabolism bilaterally, and AD diagnosis correlated with left temporal and right temporoparietal hypometabolism. The sensitivity of temporoparietal hypometabolism for AD was 92.6%, the specificity 85.2%. Conclusion: Clinical PET imaging helps distinguish early-onset AD from patients with memory complaints not meeting criteria for dementia or mild cognitive impairment. Copyright (C) 2007 S. Karger AG, Basel. C1 Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA USA. Va Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu NR 31 TC 20 Z9 20 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0014-3022 J9 EUR NEUROL JI Eur. Neurol. PY 2008 VL 59 IS 1-2 BP 31 EP 37 DI 10.1159/000109258 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 238GV UT WOS:000251436400005 PM 17917455 ER PT J AU Hamidi, SA Prabhakar, S Said, SI AF Hamidi, S. A. Prabhakar, S. Said, S. I. TI Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article DE gene expression and regulation; pulmonary hypertension; quantitative PCR; right heart failure ID VASOACTIVE-INTESTINAL-PEPTIDE; ARTERIAL-HYPERTENSION; SMOOTH-MUSCLE; MICE LACKING; EXPRESSION; LUNGS; CELLS; TETRAHYDROBIOPTERIN; SYNTHASE; PATHWAY AB The pathogenesis of idiopathic pulmonary arterial hypertension (PAH) remains poorly understood. The present authors recently reported that mice with vasoactive intestinal peptide (VIP) gene disruption show a spontaneous phenotype of PAH, with pulmonary vascular remodelling and lung inflammation. To explore the underlying molecular mechanisms in this model, it was examined whether absence of the VIP gene might alter the expression of additional genes involved in the pathogenesis of PAH, as single-gene deletions, in the absence of hypoxia, rarely result in significant pulmonary vascular remodelling. Lung tissue from mice with targeted disruption of the vasoactive intestinal peptide gene (VIP-/- mice) and from control mice was subjected to whole-genome gene microarray analysis, and the results validated with quantitative, real-time PCR. Lungs from VIP-/- mice showed a wide range of significant gene expression alterations, including overexpression of genes that promote pulmonary vascular smooth muscle cell proliferation, underexpression of antiproliferative genes and upregulation of pro-inflammatory genes. In conclusion, vasoactive intestinal peptide is a pivotal modulator of genes controlling the pulmonary vasculature, its deficiency alone resulting in gene expression alterations that can readily explain both the vascular remodelling and associated inflammatory response in pulmonary arterial hypertension. The present findings shed more light on the molecular mechanisms of pulmonary arterial hypertension, and could lead to better understanding of the pathogenesis of human pulmonary arterial hypertension, and hence to improved therapy. C1 [Hamidi, S. A.; Said, S. I.] SUNY Hlth Sci Ctr, Stony Brook, NY 11784 USA. [Hamidi, S. A.; Said, S. I.] US Dept Vet Affairs, Med Ctr, Northport, NY USA. [Prabhakar, S.] SuperArray Biosci Corp, Frederick, MD USA. RP Said, SI (reprint author), SUNY Hlth Sci Ctr, T-17-040, Stony Brook, NY 11784 USA. EM sami.i.said@stonybrook.edu FU NHLBI NIH HHS [HL-70212, HL-68188] NR 27 TC 36 Z9 38 U1 0 U2 2 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND SN 0903-1936 J9 EUR RESPIR J JI Eur. Resp. J. PD JAN PY 2008 VL 31 IS 1 BP 135 EP 139 DI 10.1183/09031936.00105807 PG 5 WC Respiratory System SC Respiratory System GA 251RG UT WOS:000252390800022 PM 18166594 ER PT J AU Kelly, JF Yeterian, JD AF Kelly, John F. Yeterian, Julie D. BE ODonohue, WT Cummings, NA TI MUTUAL-HELP GROUPS SO EVIDENCE-BASED ADJUNCTIVE TREATMENTS SE Practical Resources for the Mental Health Professional LA English DT Article; Book Chapter ID SUBSTANCE-USE DISORDERS; SEVERE MENTAL-ILLNESS; NATIONAL COMORBIDITY SURVEY; MULTIVARIATE PROCESS MODEL; SELF-HELP; OUTPATIENT TREATMENT; GROUP PARTICIPATION; SOCIAL NETWORKS; ABUSE PATIENTS; FRIENDSHIP NETWORKS C1 [Kelly, John F.; Yeterian, Julie D.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, Boston, MA 02114 USA. [Kelly, John F.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Kelly, JF (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, Boston, MA 02114 USA. NR 94 TC 30 Z9 30 U1 1 U2 3 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055750-2 J9 PRACT RESOUR MENT PY 2008 BP 61 EP 105 DI 10.1016/B978-012088520-6.50005-6 PG 45 WC Psychology, Clinical SC Psychology GA BEO15 UT WOS:000317523100004 ER PT J AU Gottlieb, JD Mueser, KT AF Gottlieb, Jennifer D. Mueser, Kim T. BE ODonohue, WT Cummings, NA TI ADJUNCTIVE TREATMENTS FOR SEVERE MENTAL ILLNESS (SCHIZOPHRENIA) SO EVIDENCE-BASED ADJUNCTIVE TREATMENTS SE Practical Resources for the Mental Health Professional LA English DT Article; Book Chapter ID ASSERTIVE COMMUNITY TREATMENT; SUBSTANCE USE DISORDERS; SUPPORTED EMPLOYMENT PROGRAMS; RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIOR THERAPY; MULTIPLE-FAMILY GROUPS; PERSONAL THERAPY; DUAL DISORDERS; 3-YEAR TRIALS; PEOPLE C1 [Gottlieb, Jennifer D.] Massachusetts Gen Hosp, Schizophrenia Program, Boston, MA 02114 USA. [Gottlieb, Jennifer D.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. [Gottlieb, Jennifer D.; Mueser, Kim T.] New Hampshire Dartmouth Psychiat Res Ctr, Dept Psychiat, Concord, NH 03301 USA. [Mueser, Kim T.] New Hampshire Dartmouth Psychiat Res Ctr, Dept Community & Family Med, Concord, NH 03301 USA. RP Gottlieb, JD (reprint author), Massachusetts Gen Hosp, Schizophrenia Program, Boston, MA 02114 USA. NR 79 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055750-2 J9 PRACT RESOUR MENT PY 2008 BP 339 EP 364 DI 10.1016/B978-012088520-6.50017-2 PG 26 WC Psychology, Clinical SC Psychology GA BEO15 UT WOS:000317523100016 ER PT J AU Pierce, ML Weston, MD Fritzsch, B Gabel, HW Ruvkun, G Soukup, GA AF Pierce, Marsha L. Weston, Michael D. Fritzsch, Bernd Gabel, Harrison W. Ruvkun, Gary Soukup, Garrett A. TI MicroRNA-183 family conservation and ciliated neurosensory organ expression SO EVOLUTION & DEVELOPMENT LA English DT Article ID EAR SENSORY EPITHELIA; INNER-EAR; PRONEURAL GENE; MYOSIN-VIIA; PAX GENES; EMBRYONIC-DEVELOPMENT; NERVOUS-SYSTEM; VERTEBRATE EAR; SEA-URCHIN; NULL MICE AB MicroRNAs (miRNAs) are an integral component of the metazoan genome and affect posttranscriptional repression of target messenger RNAs. The extreme phylogenetic conservation of certain miRNAs suggests their ancient origin and crucial function in conserved developmental processes. We demonstrate that highly conserved miRNA-183 orthologs exist in both deuterostomes and protostomes and their expression is predominant in ciliated ectodermal cells and organs. The miRNA-183 family members are expressed in vertebrate sensory hair cells, in innervated regions of invertebrate deuterostomes, and in sensilla of Drosophila and C. elegans. Thus, miRNA-183 family member expression is conserved in possibly homologous but morphologically distinct sensory cells and organs. The results suggest that miR-183 family members contribute specifically to neurosensory development or function, and that extant metazoan sensory organs are derived from cells that share genetic programs of common evolutionary origin. C1 [Pierce, Marsha L.; Weston, Michael D.; Fritzsch, Bernd; Soukup, Garrett A.] Creighton Univ, Sch Med, Dept Biomed Sci, Omaha, NE 68178 USA. [Gabel, Harrison W.; Ruvkun, Gary] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA. [Gabel, Harrison W.; Ruvkun, Gary] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. RP Soukup, GA (reprint author), Creighton Univ, Sch Med, Dept Biomed Sci, Omaha, NE 68178 USA. EM gasoukup@creighton.edu OI Fritzsch, Bernd/0000-0002-4882-8398 FU NCRR NIH HHS [C06 RR017417, C06RR017417, P20 RR018788, P20RR018788]; NIDCD NIH HHS [R01 DC005590, R01 DC005590-06, R01DC005590] NR 57 TC 82 Z9 92 U1 0 U2 8 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1520-541X J9 EVOL DEV JI Evol. Dev. PD JAN-FEB PY 2008 VL 10 IS 1 BP 106 EP 113 PG 8 WC Evolutionary Biology; Developmental Biology; Genetics & Heredity SC Evolutionary Biology; Developmental Biology; Genetics & Heredity GA 247ZD UT WOS:000252120200011 PM 18184361 ER PT J AU Obidi, CS Pugeda, JP Fan, XD Dimaculangan, CM Singh, SP Chalisa, N Perlmuter, LC AF Obidi, Chinye S. Pugeda, James P. Fan, Xiaoduo Dimaculangan, Carissa M. Singh, Sant P. Chalisa, Nuzhat Perlmuter, Lawrence C. TI Race moderates age-related cognitive decline in type 2 diabetes SO EXPERIMENTAL AGING RESEARCH LA English DT Article; Proceedings Paper CT 65th Annual Meeting of the American-Diabetes-Association CY JUN 10-14, 2005 CL San Diego, CA SP Amer Diabet Assoc ID RACIAL-DIFFERENCES; AFRICAN-AMERICANS; OLDER-ADULTS; EDUCATION; ALCOHOL; HEALTH; RISK; MELLITUS AB The age-related rate of cognitive decline in patients with diabetes mellitus has received relatively little attention. In this cross-sectional study, Caucasian (N=145) and African American (N=25) males with diabetes mellitus were recruited to examine age-related changes in cognitive performance. It is known that African Americans with diabetes mellitus are at increased risk for more frequent and more severe diabetes-related complications. It was hypothesized that such complications may accelerate age-related cognitive decline in African Americans. Three timed tests varying in complexity assessed attention, mental flexibility, and learning. Advancing age was uniformly associated with decreasing cognitive performance but only on more complex tasks did race moderate this relationship. A steeper age-related decline was observed in African Americans on more complex cognitive tests. Diabetes may be an accelerated form of aging that impacts cognition and race appears to differentially moderate this relationship. C1 [Obidi, Chinye S.; Pugeda, James P.; Perlmuter, Lawrence C.] Rosalind Franklin Univ Med & Sci, Dept Psychol, Chicago Med Sch, N Chicago, IL 60064 USA. [Fan, Xiaoduo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA. [Singh, Sant P.] Rosalind Franklin Univ Med & Sci, Dept Med, N Chicago, IL 60064 USA. [Singh, Sant P.; Chalisa, Nuzhat] N Chicago Vet Affairs Med Ctr, N Chicago, IL USA. [Perlmuter, Lawrence C.] Rosalind Franklin Univ, Dept Psychol, N Chicago, IL USA. RP Perlmuter, LC (reprint author), Rosalind Franklin Univ Med & Sci, Dept Psychol, Chicago Med Sch, 3333 Green Bay Rd, N Chicago, IL 60064 USA. EM lawrence.perlmuter@RosalindFranklin.edu NR 25 TC 5 Z9 5 U1 0 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0361-073X J9 EXP AGING RES JI Exp. Aging Res. PY 2008 VL 34 IS 2 BP 114 EP 125 DI 10.1080/03610730701876938 PG 12 WC Geriatrics & Gerontology; Psychology SC Geriatrics & Gerontology; Psychology GA 277LO UT WOS:000254214300002 PM 18351498 ER PT J AU Fan, XD O'Donnell, A Singh, SP Pungan, R Perlmuter, LC AF Fan, Xiaoduo O'Donnell, Amy Singh, Sant P. Pungan, Ramona Perlmuter, Lawrence C. TI Light to moderate alcohol drinking is associated with higher cognitive function in males with type 2 diabetes SO EXPERIMENTAL AGING RESEARCH LA English DT Article ID CORONARY-HEART-DISEASE; BLOOD-PRESSURE; RISK-FACTORS; GLYCEMIC CONTROL; CONSUMPTION; PERFORMANCE; MELLITUS; MORTALITY; WOMEN; IMPAIRMENT AB This study examined cognitive function in males with type 2 diabetes who drank light to moderate levels of alcohol in comparison to abstainers. Patients who abstained from alcohol use (Abstainer; N=99) were compared to patients who were current drinkers (Drinker; N=20) with respect to demographic, clinical, and cognitive variables. There were no significant differences between the Drinker and Abstainer groups in demographic and general clinical variables (p values.05). After controlling for various potential confounding variables including age, education level, number of years diagnosed with diabetes, hemoglobin A1c (HbA1c), hypertension status, and depression, multivariate analysis of covariance (MANCOVA) showed that the Drinker group performed significantly better than the Abstainer group, specifically on three of five cognitive tests - Digit Span Backward, Digit Symbol, and Trail Making B (p values.05). Our findings suggest that light to moderate alcohol consumption, up to two drinks per day, is associated with relatively higher cognitive function in males with type 2 diabetes. C1 [Perlmuter, Lawrence C.] Rosalind Franklin Univ Med & Sci, Dept Psychol, N Chicago, IL 60064 USA. [Singh, Sant P.; Perlmuter, Lawrence C.] Rosalind Franklin Univ Med & Sci, Dept Med, N Chicago, IL 60064 USA. [Fan, Xiaoduo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA. [O'Donnell, Amy] VA Western New York Healthcare Syst, Dept Med, New York, NY USA. [Singh, Sant P.; Pungan, Ramona] N Chicago Vet Affairs Med Ctr, N Chicago, IL USA. RP Perlmuter, LC (reprint author), Rosalind Franklin Univ Med & Sci, Dept Psychol, 3333 Green Bay Rd, N Chicago, IL 60064 USA. EM lawrence.perlmuter@rosalindfranklin.edu NR 31 TC 4 Z9 4 U1 1 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0361-073X J9 EXP AGING RES JI Exp. Aging Res. PY 2008 VL 34 IS 2 BP 126 EP 137 DI 10.1080/03610730701876953 PG 12 WC Geriatrics & Gerontology; Psychology SC Geriatrics & Gerontology; Psychology GA 277LO UT WOS:000254214300003 PM 18351499 ER PT J AU Chen, HC Vaid, J Bortfeld, H Boas, DA AF Chen, Hsin-Chin Vaid, Jyotsna Bortfeld, Heather Boas, David A. TI Optical imaging of phonological processing in two distinct orthographies SO EXPERIMENTAL BRAIN RESEARCH LA English DT Article DE near infrared spectroscopy; optical imaging; phonological processing; homophone judgment; word recognition; writing system ID EVENT-RELATED FMRI; WRITING SYSTEMS; TIME-COURSE; CHINESE; DESIGNS; BRAINS; WORDS; MODEL AB Recent fMRI studies comparing the processing of alphabetic versus logographic scripts provide evidence for shared and orthography-specific regions of neural activity. The present study used near-infrared spectroscopy to compare (within and across brain regions) the time course of neural activation for these two distinct orthographies. Native readers of English and of Chinese were tested on a homophone judgment task. Differences across groups were obtained in the time course of hemodynamic change for the left middle frontal, left superior temporal, and left supramarginal gyri. Results thus support previous findings using fMRI and suggest that different neural mappings arise depending on whether an individual has learned to process written language using an alphabetic or logographic script. C1 [Chen, Hsin-Chin] Natl Chung Cheng Univ, Dept Psychol, Chiayi, Taiwan. [Vaid, Jyotsna; Bortfeld, Heather] Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA. [Boas, David A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Anthinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Chen, HC (reprint author), Natl Chung Cheng Univ, Dept Psychol, 168 Univ Rd, Chiayi, Taiwan. EM psyhcc@ccu.edu.tw OI Bortfeld, Heather/0000-0002-3545-5449 FU NICHD NIH HHS [R03 HD046533-02, R03 HD046533-01, R03 HD046533] NR 19 TC 11 Z9 11 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0014-4819 J9 EXP BRAIN RES JI Exp. Brain Res. PD JAN PY 2008 VL 184 IS 3 BP 427 EP 433 DI 10.1007/s00221-007-1200-0 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 241FL UT WOS:000251642200013 PM 17999056 ER PT J AU Jinnah, HA Richter, A Mink, JW Caldwell, GA Caldwell, KA Gonzalez-Alegre, P Cookson, MR Breakefield, XO Delong, MR Hess, EJ AF Jinnah, H. A. Richter, Angelika Mink, Jonathon W. Caldwell, Guy A. Caldwell, Kim A. Gonzalez-Alegre, Pedro Cookson, Mark R. Breakefield, Xandra O. Delong, Mahlon R. Hess, Ellen J. TI Animal models for drug discovery in dystonia SO EXPERT OPINION ON DRUG DISCOVERY LA English DT Review DE animal model; Caenorhabditis elegans; dystonia; experimental therapeutics; hamster; mouse; primate; rat ID INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; IDIOPATHIC DYSTONIA; PARKINSONS-DISEASE; CALCIUM-CHANNEL; DYT1 DYSTONIA; INTRATHECAL BACLOFEN; PAROXYSMAL DYSTONIA; MOUSE MUTANT; PATHOPHYSIOLOGY; DEGENERATION AB Dystonia is a neurological disorder characterized by involuntary twisting movements and unnatural postures. There are many different forms of dystonia, which affect over three million people worldwide. Effective treatments are available only for a minority of patients, so new treatments are sorely needed. Several animal species have been used to develop models for different forms of dystonia, each with differing strengths and weaknesses. This review outlines the strategies that have been used to exploit these models for drug discovery. Some have been used to dissect the pathogenesis of dystonia for the identification of molecular targets for intervention. Others have been used for the empirical identification of candidate drugs. Therefore, the animal models provide promising new tools for developing better treatments for dystonia. C1 [Jinnah, H. A.; Hess, Ellen J.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA. [Richter, Angelika] Free Univ Berlin, Inst Pharmacol & Toxicol, Dept Vet Med, D-14195 Berlin, Germany. [Mink, Jonathon W.] Univ Rochester, Dept Neurol Neurobiol & Anat, Rochester, NY 14642 USA. [Caldwell, Guy A.; Caldwell, Kim A.] Univ Alabama, Dept Biol Sci, Tuscaloosa, AL 35487 USA. [Gonzalez-Alegre, Pedro] Univ Iowa, Carver Coll Med, Dept Neurol, Iowa City, IA 52242 USA. [Cookson, Mark R.] NIA, Cell Biol & Gene Express Unit, Neurogenet Lab, Bethesda, MD 20892 USA. [Breakefield, Xandra O.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA. [Delong, Mahlon R.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. RP Jinnah, HA (reprint author), Johns Hopkins Univ, Dept Neurol, Meyer Room 6-181, Baltimore, MD 21287 USA. FU Bachmann-Strauss Dystonia and Parkinson Foundation; Dystonia Medical Research Foundation; [NS28384]; [NS40470] FX This review was derived in part from workshops sponsored by the Bachmann-Strauss Dystonia and Parkinson Foundation and the Dystonia Medical Research Foundation. Additional support was obtained from NS28384, NS40470 and the Jack Fasciana Fund for Dystonia Research.; Guy A Caldwell and Kim A Caldwell are scientific advisors for QRxPharma, Ltd., and receive consulting fees and research support from this company. The other authors state no conflict of interest and have received no payment in preparation of this manuscript. NR 79 TC 13 Z9 13 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1746-0441 J9 EXPERT OPIN DRUG DIS JI Expert. Opin. Drug Discov. PD JAN PY 2008 VL 3 IS 1 BP 83 EP 97 DI 10.1517/17460441.3.1.83 PG 15 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 362BU UT WOS:000260174000006 PM 23480141 ER PT J AU Blackman, SC Evenson, AR Voss, SD Barnewolt, CE Puder, M AF Blackman, Samuel C. Evenson, Amy R. Voss, Stephan D. Barnewolt, Carol E. Puder, Mark TI Prenatal diagnosis and subsequent treatment of an intermediate-risk paraspinal neuroblastoma: Case report and review of the literature SO FETAL DIAGNOSIS AND THERAPY LA English DT Review DE neuroblastoma, paraspinal; prenatal diagnosis; perinatal management; MRI ID INTRASPINAL NEUROBLASTOMA; NEONATAL NEUROBLASTOMA; PEDIATRIC-ONCOLOGY; CANCER; EXPERIENCE; CHILDREN; TRENDS; US AB Objectives: Neuroblastoma is the most common extracranial solid tumor of childhood, and the most common malignancy diagnosed during infancy. In comparison, neonatal neuroblastoma is relatively rare. Improvements in prenatal imaging and widespread use of fetal ultrasonography have led to an increased rate of prenatal diagnoses. Methods: Case report and literature review. Results: We report a case of an intermediate-risk neuroblastoma, diagnosed at 36 weeks' gestation by ultrasound and subsequently visualized by fetal MRI, that resulted in spinal cord compression and decreased fetal movement. A multidisciplinary team approach resulted in rapid delivery, evaluation, biopsy, staging, and treatment implementation in a successful effort to preserve lower extremity function. Conclusion: Prenatal diagnosis of neuroblastoma, management and outcomes are reviewed. Prompt diagnosis can strongly influence perinatal management and improve prognosis. Copyright (C) 2008 S. Karger AG, Basel. C1 [Blackman, Samuel C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Evenson, Amy R.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg, Boston, MA 02215 USA. [Voss, Stephan D.; Barnewolt, Carol E.] Harvard Univ, Childrens Hosp, Dept Radiol, Sch Med, Boston, MA 02115 USA. [Puder, Mark] Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Boston, MA 02115 USA. RP Puder, M (reprint author), Childrens Hosp, Dept Surg Fegan 3, 300 Longwood Ave, Boston, MA 02115 USA. EM mark.puder@childrens.harvard.edu NR 24 TC 5 Z9 6 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1015-3837 J9 FETAL DIAGN THER JI Fetal Diagn. Ther. PY 2008 VL 24 IS 2 BP 119 EP 125 DI 10.1159/000142141 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 345XT UT WOS:000259031800010 PM 18648212 ER PT J AU Deliyski, DD Petrushev, PP Bonilha, HS Gerlach, TT Martin-Harris, B Hillman, RE AF Deliyski, Dimitar D. Petrushev, Pencho P. Bonilha, Heather Shaw Gerlach, Terri Treman Martin-Harris, Bonnie Hillman, Robert E. TI Clinical implementation of laryngeal high-speed videoendoscopy: Challenges and evolution SO FOLIA PHONIATRICA ET LOGOPAEDICA LA English DT Article; Proceedings Paper CT 7th International Conference on Advances in Quantitative Laryngology, Voice and Speech Research CY OCT, 2006 CL Groningen, NETHERLANDS DE voice assessment; high-speed videoendoscopy; stroboscopy; kymography; vocal fold vibration ID VOCAL-FOLD VIBRATIONS; RECORDINGS; IMAGES; MOTION AB High-speed videoendoscopy (HSV) captures the true intra-cycle vibratory behavior of the vocal folds, which allows for overcoming the limitations of videostroboscopy for more accurate objective quantification methods. However, the commercial HSV systems have not gained widespread clinical adoption because of remaining technical and methodological limitations and an associated lack of information regarding the validity, practicality, and clinical relevance of HSV. The purpose of this article is to summarize the practical, technological and methodological challenges we have faced, to delineate the advances we have made, and to share our current vision of the necessary steps towards developing HSV into a robust tool. This tool will provide further insights into the biomechanics of laryngeal sound production, as well as enable more accurate functional assessment of the pathophysiology of voice disorders leading to refinements in the diagnosis and management of vocal fold pathology. The original contributions of this paper are the descriptions of our color high-resolution HSV integration, the methods for facilitative playback and HSV dynamic segmentation, and the ongoing efforts for implementing HSV in phonomicrosurgery, as well as the analysis of the challenges and prospects for the clinical implementation of HSV, additionally supported by references to previously reported data. Copyright (c) 2007 S. Karger AG, Basel. C1 [Deliyski, Dimitar D.; Petrushev, Pencho P.; Bonilha, Heather Shaw] Univ S Carolina, Dept Math, Columbia, SC 29208 USA. [Gerlach, Terri Treman] Charlotte Eye Ear Nose & Throat Assoicates, Voice & Swallowing Ctr, Charlotte, NC USA. [Martin-Harris, Bonnie] Med Univ S Carolina, Evelyn Trammell Inst Voice & Swallowing, Charleston, SC 29425 USA. [Hillman, Robert E.] Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, Boston, MA 02114 USA. RP Deliyski, DD (reprint author), Univ S Carolina, Dept Math, 1621 Greene St,6th Floor, Columbia, SC 29208 USA. EM ddeliyski@sc.edu FU NIDCD NIH HHS [R01 DC007640] NR 26 TC 67 Z9 67 U1 0 U2 6 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1021-7762 J9 FOLIA PHONIATR LOGO JI Folia Phoniatr. Logop. PY 2008 VL 60 IS 1 BP 33 EP 44 DI 10.1159/000111802 PG 12 WC Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation SC Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation GA 263WW UT WOS:000253248200006 PM 18057909 ER PT J AU Ledoux, W AF Ledoux, William BE Harris, GF Smith, PA Marks, RM TI The Biomechanics of the Diabetic Foot SO FOOT AND ANKLE MOTION ANALYSIS: CLINICAL TREATMENT AND TECHNOLOGY SE Biomedical Engineering Series LA English DT Article; Book Chapter ID LIMITED JOINT MOBILITY; SHOE PLANTAR SHEAR; PERIPHERAL NEUROPATHY; TOE DEFORMITY; HIGH-RISK; FAT-PAD; PRESSURE DISTRIBUTION; GAIT CHARACTERISTICS; HEEL-PAD; WALKING C1 Univ Washington, Dept Mech Engn, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Ledoux, W (reprint author), Univ Washington, Dept Mech Engn, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 82 TC 1 Z9 1 U1 0 U2 0 PU BUTTERWORTH-HEINEMANN PI WOBORN PA 225 WILDWOOD AVE, WOBORN, MA 01801 USA J9 BIOMED ENG SER PY 2008 BP 317 EP 345 PG 29 WC Orthopedics SC Orthopedics GA BKX81 UT WOS:000269556400021 ER PT J AU Turner, EH AF Turner, Erick H. TI Publication bias, the first or the final nail into the coffin of evidence-based medicine? SO FORSCHENDE KOMPLEMENTARMEDIZIN LA German DT Editorial Material C1 Portland VA Med Ctr, Portland, OR 97239 USA. RP Turner, EH (reprint author), Portland VA Med Ctr, P3MHDC,3710 SW,US Vet Hosp Rd, Portland, OR 97239 USA. EM turnere@ohsu.edu NR 4 TC 0 Z9 0 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1021-7096 J9 FORSCH KOMPLEMENTMED JI Forsch. Komplement.med. PY 2008 VL 15 IS 2 BP 110 EP 112 PG 3 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 324KZ UT WOS:000257518800012 ER PT J AU Fiorito, C Rienzo, M Crimi, E Rossiello, R Balestrieri, ML Casamassimi, A Muto, F Grimaldi, V Giovane, A Farzati, B Mancini, FP Napoli, C AF Fiorito, Carmela Rienzo, Monica Crimi, Ettore Rossiello, Raffaele Balestrieri, Maria Luisa Casamassimi, Amelia Muto, Francesco Grimaldi, Vincenzo Giovane, Alfonso Farzati, Bartolomeo Mancini, Francesco P. Napoli, Claudio TI Antioxidants increase number of progenitor endothelial cells through multiple gene expression pathways SO FREE RADICAL RESEARCH LA English DT Article DE antioxidants; vitamins; endothelial progenitor cells; VEGF; microarray ID BONE-MARROW-CELLS; HYPERCHOLESTEROLEMIC MICE; VASCULAR COMPLICATIONS; CARDIOVASCULAR-DISEASE; NITRIC-OXIDE; RED WINE; DYSFUNCTION; REPAIR; ATHEROSCLEROSIS; MOBILIZATION AB To date, there is no report on the effect of antioxidants on endothelial progenitor cells (EPCs). This study shows that in vitro incubation of EPCs with vitamin C and E reverted the already well documented lowering effect of TNF-alpha on EPC number and increased p-p38 expression levels. In order to document major changes of gene expression levels and gain insight into signalling pathways, microarray analysis was performed and a significant variation of the expression of 5389 genes in EPCs following antioxidant treatment was detected. Also in vivo evidence is provided about the positive effect of antioxidant vitamins on EPCs, since vitamin C and E supplementation potentiated the physical training-induced increase of EPC number and VEGF levels. Together, these data indicate that antioxidant treatment ameliorates EPC number and causes major changes of gene expression within these cells in vitro. Furthermore, concomitant antioxidant supplementation and physical training in vivo raised the levels of circulating EPCs and serum VEGF more than physical training alone. C1 [Rossiello, Raffaele; Balestrieri, Maria Luisa; Giovane, Alfonso] Univ Naples 2, Dept Biochem & Biophys, Sch Med 1, I-80138 Naples, Italy. [Fiorito, Carmela; Rienzo, Monica; Casamassimi, Amelia; Muto, Francesco; Grimaldi, Vincenzo; Farzati, Bartolomeo; Napoli, Claudio] Univ Naples 2, Dept Gen Pathol, I-80138 Naples, Italy. [Fiorito, Carmela; Rienzo, Monica; Casamassimi, Amelia; Muto, Francesco; Grimaldi, Vincenzo; Farzati, Bartolomeo; Napoli, Claudio] Univ Naples 2, Excellence Res Ctr Cardiovasc Dis, Div Clin Pathol, I-80138 Naples, Italy. [Fiorito, Carmela] IRCCS Multimedia, Milan, Italy. [Crimi, Ettore] Univ Novara, Dept Anesthesiol, Novara, Italy. [Crimi, Ettore] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02115 USA. [Rossiello, Raffaele; Balestrieri, Maria Luisa; Giovane, Alfonso] Univ Naples 2, Sch Med 1, Dept Biochem & Biophys, Naples, Italy. [Mancini, Francesco P.] Univ Sannio, Dept Biol & Environm Sci, Benevento, Italy. RP Balestrieri, ML (reprint author), Univ Naples 2, Dept Biochem & Biophys, Sch Med 1, Complesso S Andrea Dame,Via L Crecchio 7, I-80138 Naples, Italy. EM marialuisa.balestrieri@unina2.it OI Giovane, Alfonso/0000-0002-2508-2597; Napoli, Claudio/0000-0002-5455-555X FU Meccanismi fisiopatologici di danno vascolare/trombotico e angiogenesis [PRIN MIUR 2006 0622153_002]; Fondation Jerome Lejeune; British Heart Foundation [PG/07/075/23478]; Effetti in vivo ed in vitro dei polifenoli del vino rosso da diverse viticolture sull'espressione genica endoteliale durante lo shear stress perturbato e loro relazione con i processi biotecnologici della produzione del vino [BRC1498] FX This work was supported in part by PRIN MIUR 2006 code 0622153_002 'Meccanismi fisiopatologici di danno vascolare/trombotico e angiogenesis' (C.N), by Fondation Jerome Lejeune (C.N.), by British Heart Foundation PG/07/075/23478 and by a grant from Regione Campania legge 5 2006 code BRC1498 'Effetti in vivo ed in vitro dei polifenoli del vino rosso da diverse viticolture sull'espressione genica endoteliale durante lo shear stress perturbato e loro relazione con i processi biotecnologici della produzione del vino' (M.L.B. and C.N.). NR 46 TC 28 Z9 30 U1 0 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1071-5762 J9 FREE RADICAL RES JI Free Radic. Res. PY 2008 VL 42 IS 8 BP 754 EP 762 DI 10.1080/10715760802357057 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 340CX UT WOS:000258624800007 PM 18712633 ER PT J AU Schinzel, AC Hahn, WC AF Schinzel, Anna C. Hahn, William C. TI Oncogenic transformation and experimental models of human cancer SO FRONTIERS IN BIOSCIENCE-LANDMARK LA English DT Review DE immortalization; transformation; senescence; cancer; viral oncoproteins; RNAi; Genomics; telomerase; review ID MAMMARY EPITHELIAL-CELLS; TELOMERASE REVERSE-TRANSCRIPTASE; HUMAN-DIPLOID FIBROBLASTS; RESOLUTION GENOMIC PROFILES; HUMAN CELLULAR SENESCENCE; REPLICATIVE LIFE-SPAN; HUMAN TUMOR-CELLS; CATALYTIC SUBUNIT; COSTELLO-SYNDROME; GENETIC SCREEN AB Tumorigenesis occurs when cells undergo a series of genetic and epigenetic events that upset the balance of cell death, proliferation and differentiation. In a few cases, alterations in key regulatory steps have been identified, facilitating the design of rational cancer therapies. However, the karyotypic complexity exhibited by most solid tumors makes it challenging to identify the lesions underlying specific tumor phenotypes in most cancers. Work from many laboratories indicates that the acquisition of the tumorigenic phenotype requires several cooperating events and that a finite set of genetic alterations suffices to transform cells derived from numerous different lineages. Experimental models derived from the manipulation of oncogenes, tumor suppressor genes and telomerase provide useful platforms to delineate pathways involved in cell transformation, to connect specific cancer-associated mutations with particular cancer phenotypes and to discover and validate new targets for therapeutic development. Here we review the development of such experimental models and recent work combining such model systems with increasingly powerful genetic and chemical tools to identify and validate genes involved in malignant transformation. C1 [Schinzel, Anna C.; Hahn, William C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Schinzel, Anna C.; Hahn, William C.] Harvard & MIT, Broad Inst, Cambridge, MA 02142 USA. RP Hahn, WC (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Dana 1538, Boston, MA 02115 USA. EM william_hahn@dfci.harvard.edu NR 155 TC 28 Z9 29 U1 0 U2 10 PU FRONTIERS IN BIOSCIENCE INC PI IRVINE PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA SN 1093-9946 EI 1093-4715 J9 FRONT BIOSCI-LANDMRK JI Front. Biosci. PD JAN 1 PY 2008 VL 13 BP 71 EP 84 DI 10.2741/2661 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 299SQ UT WOS:000255775700005 PM 17981529 ER PT J AU Shacka, JJ Roth, KA Zhang, JH AF Shacka, John J. Roth, Kevin A. Zhang, Jianhua TI The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy SO FRONTIERS IN BIOSCIENCE-LANDMARK LA English DT Review DE macroautophagy; chaperone-mediated autophagy; lysosome; aging; Alzheimer's disease; Parkinson's disease; neurodegeneration; therapeutics; review ID AMYLOID PRECURSOR PROTEIN; CHAPERONE-MEDIATED AUTOPHAGY; APOPTOTIC CELL-DEATH; AGE-RELATED-CHANGES; SPORADIC ALZHEIMERS-DISEASE; GENOME-WIDE ASSOCIATION; CATHEPSIN-D ACTIVITY; PARKINSONS-DISEASE; GRANULOVACUOLAR DEGENERATION; ALPHA-SYNUCLEIN AB Alterations in the autophagy-lysosomal degradation pathway have been described in normal brain aging and in age-related neurodegenerative diseases including Alzheimer's (AD) and Parkinson's (PD). An improper clearance of proteins in AD and PD may result either from a compromise in the autophagy-lysosomal degradation pathway or induce alterations in this pathway, and may result in neuron dysfunction and neuron loss. This review provides an overview of AD and PD with a specific focus on macroautophagy, chaperone-mediated autophagy and lysosome function in human and experimental models of AD and PD. Potential therapies for AD and PD are also discussed that may promote survival by regulating the autophagy and lysosomal degradation pathway. C1 [Shacka, John J.; Roth, Kevin A.; Zhang, Jianhua] Univ Alabama, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA. [Shacka, John J.] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35294 USA. RP Shacka, JJ (reprint author), Univ Alabama, Dept Pathol, Div Neuropathol, SC 930, Birmingham, AL 35294 USA. EM shacka@uab.edu RI zhang, jianhua/D-3404-2009; OI Roth, Kevin/0000-0002-0643-995X FU NINDS NIH HHS [NS35107, NS41962, NS47466, NS57098] NR 181 TC 77 Z9 83 U1 1 U2 20 PU FRONTIERS IN BIOSCIENCE INC PI IRVINE PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA SN 1093-9946 EI 1093-4715 J9 FRONT BIOSCI-LANDMRK JI Front. Biosci. PD JAN 1 PY 2008 VL 13 BP 718 EP 736 DI 10.2741/2714 PG 19 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 299SQ UT WOS:000255775700058 PM 17981582 ER PT J AU Meeran, SM Katiyar, SK AF Meeran, Syed Musthapa Katiyar, Santosh Kumar TI Proanthocyanidins inhibit mitogenic and survival-signaling in vitro and tumor growth in vivo SO FRONTIERS IN BIOSCIENCE-LANDMARK LA English DT Article DE grape seed proanthocyanidins; mitogen-activated protein kinases; nuclear factor-kappaB; tumor xenograft; phosphatidylinositol 3-kinase ID NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; GRAPE SEEDS; INDUCE APOPTOSIS; CARCINOMA-CELLS; CANCER-CELLS; PATHWAY; TRANSDUCTION; PHOTOCARCINOGENESIS; INVASIVENESS AB We have previously shown that treatment of human epidermoid carcinoma A431 cells with grape seed proanthocyanidins (GSPs) induces apoptosis of A431 cells. Here, we report that treatment of A431 cells with GSPs inhibits constitutive as well as EGF-induced higher levels of phosphorylated proteins of MAPK family in a dose-dependent manner. This effect is associated with the reactivation of MAP kinase phosphatases. Western blot analysis reveals that GSPs decrease: (i) the levels of phosphatidylinositol 3-kinase (PI3K) and the phosphorylation of Akt at ser(473), and (ii) the constitutive activation of NF-kappaB/p65. As NF-kappaB-targeted genes play crucial roles in tumor cell proliferation and differentiation, we assessed the effect of GSPs on proteins encoded by these genes. Treatment with GSPs results in inhibition of the expression of COX-2, iNOS, PCNA, cyclin D1 and MMP-9 in A431 cells compared with non-GSPs-treated controls. Treatment of athymic nude mice with GSPs by oral gavage (50 or 100 mg/kg body weight/mouse) reduces the growth of A431-xenografts in mice, which is associated with the inhibition of tumor cell proliferation in xenografts as indicated by the inhibition of mRNA expression of PCNA and cyclin D1, and of NF-kappaB activity. Together, the data suggest that GSPs might be effective in the treatment of skin cancers. C1 [Meeran, Syed Musthapa; Katiyar, Santosh Kumar] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh Kumar] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Meeran, SM (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU NCI NIH HHS [CA104428-01] NR 37 TC 13 Z9 17 U1 1 U2 5 PU FRONTIERS IN BIOSCIENCE INC PI IRVINE PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA SN 1093-9946 EI 1093-4715 J9 FRONT BIOSCI-LANDMRK JI Front. Biosci. PD JAN 1 PY 2008 VL 13 BP 887 EP 897 DI 10.2741/2729 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 299SQ UT WOS:000255775700073 PM 17981597 ER PT J AU Pryor, HI Vacanti, JP AF Pryor, Howard I., II Vacanti, Joseph P. TI The promise of artificial liver replacement SO FRONTIERS IN BIOSCIENCE-LANDMARK LA English DT Review DE bioartificial liver; acute liver failure; liver dialysis; hemofiltration; hemodiafiltration; hemoperfusion; hemodiadsoprtion; Hepatassist 2000; extracorporeal liver assist device; bioartificial liver support system; TECA-HybridArtificial liver support system; academic medical center bioartifical liver; modular extracorporeal liver system; radial flow bioreactor; hybrid liver; ELAD; TECA-HALSS; AMC-BAL; MELS; (134) ID FULMINANT HEPATIC-FAILURE; AMC-BIOARTIFICIAL LIVER; ADSORBENT RECIRCULATING SYSTEM; HIGH-VOLUME PLASMAPHERESIS; I CLINICAL-TRIAL; SUPPORT-SYSTEM; PLASMA-EXCHANGE; ASSIST DEVICE; PHASE-I; CHARCOAL HEMOPERFUSION AB One of the most challenging clinical syndromes in medicine is that of acute liver failure (ALF). Many devices and systems have been devised to support ALF patients. This manuscript reviews the significant clinical findings of ALF, as well as, the non-biologic liver support systems and the bioartificial liver devices that have been clinically tested to support patients with this disease. Finally, we identify several improvements critical to the future of the field of bioartificial liver replacement therapy. C1 [Pryor, Howard I., II; Vacanti, Joseph P.] Massachusetts Gen Hosp, Tissue Engn & Organ Fabricat Lab, Boston, MA 02446 USA. RP Vacanti, JP (reprint author), Massachusetts Gen Hosp, Lab Tissue Engn & Organ Fabricat, 55 Fruit St,WRN 11, Boston, MA 02114 USA. EM jvacanti@partners.org NR 142 TC 8 Z9 12 U1 2 U2 11 PU FRONTIERS IN BIOSCIENCE INC PI IRVINE PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA SN 1093-9946 EI 1093-4715 J9 FRONT BIOSCI-LANDMRK JI Front. Biosci. PD JAN 1 PY 2008 VL 13 BP 2140 EP 2159 DI 10.2741/2830 PG 20 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 299SQ UT WOS:000255775700174 PM 17981698 ER PT J AU Meeran, SM Katiyar, SK AF Meeran, Syed Musthapa Katiyar, Santosh Kumar TI Cell cycle control as a basis for cancer chemoprevention through dietary agents SO FRONTIERS IN BIOSCIENCE-LANDMARK LA English DT Review DE cell cycle; cyclins; cyclin dependent kinases; Cip1/p21; Kip1/p27; apigenin; curcumin; epigallocatechin-3-gallate; grape seed proanthocyanidins; genistein; resveratrol; silymarin; review ID DEPENDENT KINASE INHIBITOR; S-PHASE CHECKPOINT; CARCINOMA A431 CELLS; PROSTATE-CANCER; DNA-DAMAGE; BREAST-CANCER; PANCREATIC-CANCER; INK4 INHIBITORS; CDK INHIBITORS; GRAPE SEEDS AB The development of cancer is associated with disorders in the regulation of the cell cycle. The purpose of this review is to briefly summarize the known sequence of events that regulate cell cycle progression with an emphasis on the checkpoints and the mechanisms cell employ to insure DNA stability in the face of genotoxic stress. Key transitions in the cell cycle are regulated by the activities of various protein kinase complexes composed of cyclin and cyclin-dependent kinases ( CDK) molecules. The cyclins are CDK binding partners which are required for kinase activity and their protein levels are intimately linked to the cell cycle stage. CDK activity can be regulated by other mechanisms, such as phosphorylation events, that may contribute to deregulation of cell cycle and the development of cancer. While fruits and vegetables are recommended for prevention of cancer, their active ingredients and mechanisms of action are less well understood. Here, we briefly present evidence that dietary agents identified from fruits and vegetables can act to modulate the effects of deregulated cell cycle checkpoints, and that this may contribute to the prevention of cancer. The agents include apigenin ( celery, parsley), curcumin ( turmeric), (-)-epigallocatechin-3-gallate ( green tea), resveratrol ( red grape, peanuts and berries), genistein ( soybean), and silymarin ( milk thistle). The teachings of Hippocrates are still true "let food be thy medicine and medicine be thy food". C1 [Meeran, Syed Musthapa; Katiyar, Santosh Kumar] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh Kumar] Univ Alabama, Clin Nutr Res Ctr, Birmingham, AL 35294 USA. [Katiyar, Santosh Kumar] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh Kumar] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU NCCIH NIH HHS [R01 AT002536, AT002536, R01 AT002536-01A2, R01 AT002536-02]; NCI NIH HHS [CA104428, R21 CA104428, R21 CA104428-01A2, R21 CA104428-02] NR 103 TC 112 Z9 120 U1 1 U2 8 PU FRONTIERS IN BIOSCIENCE INC PI IRVINE PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA SN 1093-9946 EI 1093-4715 J9 FRONT BIOSCI-LANDMRK JI Front. Biosci. PD JAN 1 PY 2008 VL 13 BP 2191 EP 2202 DI 10.2741/2834 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 299SQ UT WOS:000255775700178 PM 17981702 ER PT J AU Brass, SD Zivadinov, R Bakshi, R AF Brass, Steven David Zivadinov, Robert Bakshi, Rohit TI Acute demyelinating optic neuritis: a review SO FRONTIERS IN BIOSCIENCE-LANDMARK LA English DT Review DE optic neuritis; multiple sclerosis; clinically isolated syndrome; optic neuritis; treatment trial; review ID CLINICALLY ISOLATED SYNDROMES; DEFINITE MULTIPLE-SCLEROSIS; CONTRAST LETTER ACUITY; NEUROMYELITIS-OPTICA; TREATMENT TRIAL; DIAGNOSTIC-CRITERIA; NERVE ATROPHY; VISUAL DYSFUNCTION; RANDOMIZED-TRIAL; SUSACS-SYNDROME AB Acute demyelinating optic neuritis ( ON) is a leading consideration in the differential diagnosis for young adults presenting with sudden onset of painful unilateral visual loss. Multiple sclerosis ( MS) is believed to be the most common etiology for ON. Nearly 50% of MS patients will develop ON, and in 15-20% of cases, ON will be the initial manifestation of the illness. Conventional and emerging magnetic resonance imaging (MRI) techniques have provided greater insight into the pathophysiology of ON, and conventional MRI has also allowed clinicians to better estimate the future risk of MS. At 10 years after ON, patients with zero, one, or two or more brain lesions on T2-weighted MRI sequences demonstrated a 22%, 52%, and 56% risk of developing MS, respectively. Treatment with high dose intravenous methylprednisolone may accelerate visual recovery in patients with acute ON, but has little impact on long term visual outcome. Disease modifying therapies in patients with acute demyelinating ON should be considered as a treatment option at the time of initial presentation in those patients whose initial brain MRI shows demyelinating lesions as these therapies have been shown in to be effective at reducing the future risk of MS. C1 [Brass, Steven David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA. [Brass, Steven David; Bakshi, Rohit] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol,Partners Multiple Sclerosis Ctr, Boston, MA 02114 USA. [Zivadinov, Robert] SUNY Buffalo, Jacobs Neurol Inst, Buffalo Neuroimaging Anal Ctr, Dept Neurol, Buffalo, NY 14260 USA. [Bakshi, Rohit] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Imaging,Dept Radiol, Boston, MA 02114 USA. RP Brass, SD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, 55 Fruit St,Wang ACC Suite 835, Boston, MA 02114 USA. EM sbrass@partners.org FU NINDS NIH HHS [1R01NS055083-01] NR 107 TC 5 Z9 5 U1 0 U2 0 PU FRONTIERS IN BIOSCIENCE INC PI IRVINE PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA SN 1093-9946 EI 1093-4715 J9 FRONT BIOSCI-LANDMRK JI Front. Biosci. PD JAN 1 PY 2008 VL 13 BP 2376 EP 2390 DI 10.2741/2851 PG 15 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 299SQ UT WOS:000255775700195 PM 17981719 ER PT J AU Weiss, MJ Madsen, JC Rosengard, BR Allan, JS AF Weiss, Matthew J. Madsen, Joren C. Rosengard, Bruce R. Allan, James S. TI Mechanisms of chronic rejection in cardiothoracic transplantation SO FRONTIERS IN BIOSCIENCE-LANDMARK LA English DT Article DE transplantation; chronic rejection; heart; lung; review ID BRONCHIOLITIS OBLITERANS SYNDROME; CARDIAC ALLOGRAFT VASCULOPATHY; CORONARY-ARTERY-DISEASE; DONOR BRAIN-DEATH; LUNG-TRANSPLANTATION; RISK-FACTORS; INTRAVASCULAR ULTRASOUND; HEART-TRANSPLANTATION; INDIRECT ALLORECOGNITION; INDIRECT RECOGNITION AB Despite significant improvements in early post-transplantation survival rates, long-term patient and graft survival have remained poor, due in large part to the vexing problem of chronic allograft rejection. Attempts to combat this problem with intensification of immunosuppression have led to concomitant increases in the rates of fatal malignancies and infections. In cardiac transplantation, chronic rejection is manifested primarily by a disease entity known as cardiac allograft vasculopathy, an occlusive narrowing of the coronary vessels. In lung transplantation, chronic rejection is typified by obliterative bronchiolitis, an airflow limiting narrowing of the bronchioles. From an immunologic standpoint, chronic rejection is believed to be the end result of repeated immune and non-immune insults to the graft. This review examines the pathophysiology of heart and lung chronic, with emphasis on both immune and non-immune causes. C1 [Allan, James S.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Div Cardiovasc Surg, Boston, MA 02114 USA. [Allan, James S.] Massachusetts Gen Hosp, Div Thorac Surg, Dept Surg, Boston, MA 02114 USA. RP Allan, JS (reprint author), Massachusetts Gen Hosp, Transplantat Biol Res Ctr, 55 Fruit St,Blake 1570, Boston, MA 02114 USA. EM jallan@partners.org FU NHLBI NIH HHS [P01HL8646, R01HL054211, R01HL67110, R01HL071932, R01 HL071932, R01 HL067110, R01 HL067110-04, R01 HL054211]; NIAID NIH HHS [U19 AI066705-050003, U19AI066705] NR 76 TC 27 Z9 29 U1 0 U2 2 PU FRONTIERS IN BIOSCIENCE INC PI IRVINE PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA SN 1093-9946 EI 1093-4715 J9 FRONT BIOSCI-LANDMRK JI Front. Biosci. PD JAN 1 PY 2008 VL 13 BP 2980 EP 2988 DI 10.2741/2903 PG 9 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 299SQ UT WOS:000255775700247 PM 17981771 ER PT J AU Chan, AT Giovannucci, EL Meyerhardt, JA Schernhammer, ES Wu, K Fuchs, CS AF Chan, Andrew T. Giovannucci, Edward L. Meyerhardt, Jeffrey A. Schernhammer, Eva S. Wu, Kana Fuchs, Charles S. TI Aspirin dose and duration of use and risk of colorectal cancer in men SO GASTROENTEROLOGY LA English DT Article; Proceedings Paper CT Digestive Disease Week Meeting/108th Annual Meeting of the American-Gastroenterological-Association CY MAY 19-24, 2007 CL Washington, DC SP Amer Gastroenterol Assoc, Amer Assoc Study Liver Dis, Amer Soc Gastrointestinal Endoscopy, Soc Surg Alimentary Tract ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MALE HEALTH-PROFESSIONALS; LONG-TERM USE; NF-KAPPA-B; COLON-CANCER; RANDOMIZED-TRIAL; LARGE-BOWEL; PRIMARY PREVENTION; FAMILY-HISTORY; WOMENS HEALTH AB Background & Aims: Long-term data on the risk of colorectal cancer according to dose, duration, and consistency of aspirin therapy are limited. Methods: We conducted a prospective study of 47,363 male health professionals who were ages 40-75 years at enrollment in 1986. Biennially, we collected data on aspirin use, other risk factors, and diagnoses of colorectal cancer. We confirmed all reports of colorectal cancer through 2004 by review of medical records. Results: During 18 years of follow-up, we documented 975 cases of colorectal cancer over 761,757 person-years. After adjustment for risk factors, men who regularly used aspirin ( >= 2 times per week) had a multivariate relative risk (RR) for colorectal cancer of 0.79 (95% confidence interval, [CI], 0.69-0.90) compared with nonregular users. However, significant risk reduction required at least 6-10 years of use (P for trend =.008) and was no longer evident within 4 years of discontinuing use (multivariate RR, 1.00; CI, 0.72-1.39). The benefit appeared related to increasing cumulative average dose: compared with men who denied any aspirin use, the multivariate RRs for cancer were 0.94 (CI, 0.75-1.18) for men who used 0.5-1.5 standard aspirin tablets per week, 0.80 (CI, 0.63-1.01) for 2-5 aspirin tablets per week, 0.72 (CI, 0.56-0.92) for 6-14 aspirin tablets per week, and 0.30 (CI, 0.11-0.81) for > 14 aspirin tablets per week (P for trend =.004). Conclusions: Regular, long-term aspirin use reduces risk of colorectal cancer among men. However, the benefit of aspirin necessitates at least 6 years of consistent use, with maximal risk reduction at doses greater than 14 tablets per week. The potential hazards associated with long-term use of such doses should be carefully considered. C1 [Chan, Andrew T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Chan, Andrew T.; Giovannucci, Edward L.; Schernhammer, Eva S.; Fuchs, Charles S.] Harvard Univ, Sch Med, Boston, MA USA. [Chan, Andrew T.; Giovannucci, Edward L.; Schernhammer, Eva S.; Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA. [Chan, Andrew T.; Giovannucci, Edward L.; Meyerhardt, Jeffrey A.; Fuchs, Charles S.] Dana Farber & Harvard Canc Ctr, Canc Epidemiol Program, Boston, MA USA. [Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Giovannucci, Edward L.; Wu, Kana] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Meyerhardt, Jeffrey A.; Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Chan, AT (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St,GRJ 728A, Boston, MA 02114 USA. EM achan@partners.org FU NCI NIH HHS [K07 CA107412-03, CA10741, CA55075, K07 CA107412, P01 CA055075, P01 CA055075-170002, P50 CA127003, P50 CA127003-02] NR 55 TC 126 Z9 135 U1 1 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JAN PY 2008 VL 134 IS 1 BP 21 EP 28 DI 10.1053/j.gastro.2007.09.035 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 247GO UT WOS:000252066400008 PM 18005960 ER PT J AU Balaguer, F Balmana, J Castellvi-Bel, S Steyerberg, EW Andreu, M Llor, X Jover, R Syngal, S Castells, A AF Balaguer, Francesc Balmana, Judith Castellvi-Bel, Sergi Steyerberg, Ewout W. Andreu, Montserrat Llor, Xavier Jover, Rodrigo Syngal, Sapna Castells, Antoni CA Gastrointestinal Oncology Grp Span TI Validation and extension of the PREMM1,2 model in a population- based cohort of colorectal cancer patients SO GASTROENTEROLOGY LA English DT Article ID REVISED BETHESDA GUIDELINES; LYNCH-SYNDROME; MICROSATELLITE INSTABILITY; AMSTERDAM CRITERIA; BREAST-CANCER; BRAF MUTATION; IDENTIFICATION; PREDICTION; IMMUNOHISTOCHEMISTRY; SUSCEPTIBILITY AB Background & Aims: Early recognition of patients at risk for Lynch syndrome is critical but often difficult. Recently, a predictive algorithm-the PREMM1,2 model-has been developed to quantify the risk of carrying a germline mutation in the mismatch repair (MMR) genes MLH1 and MSH2. However, the model's performance in an unselected, population-based colorectal cancer population as well as its performance in combination with tumor MMR testing are unknown. Methods: We included all colorectal cancer cases from the EPICOLON study, a prospective, multicenter, population-based cohort (n = 1222). All patients underwent tumor microsatellite instability analysis and immunostaining for MLH1 and MSH2, and those with MMR deficiency (n = 91) underwent tumor BRAF V600E mutation analysis and MLH1/MSH2 germline testing. Results: The PREMM1,2 model with a 5% cut-off had a sensitivity, specificity, and positive predictive value (PPV) of 100%, 68%, and 2%, respectively. The use of a higher PREMM1,2 cut-off provided a higher specificity and PPV, at expense of a lower sensitivity. The combination of a :5% cut-off with tumor MMR testing maintained 100% sensitivity with an increased specificity (97%) and PPV (21%). The PPV of a PREMM1,2 score >= 20% alone (16%) approached the PPV obtained with PREMM1,2 score :5% combined with tumor MMR testing. In addition, a PREMM1,2 score of <5% was associated with a high likelihood of a BRAF V600E mutation. Conclusions: The PREMM1,2 model is useful to identify MLH1/MSH2 mutation carriers among unselected colorectal cancer patients. Quantitative assessment of the genetic risk might be useful to decide on subsequent tumor MMR and germline testing. C1 [Balaguer, Francesc; Castellvi-Bel, Sergi; Castells, Antoni] Univ Barcelona, Dept Gastroenterol, Inst Malalties Digest & Metab,Inst Invest Biomed, Hosp Clin,Ctr Invest Biomed & Red Enfermedades He, E-08036 Barcelona, Catalonia, Spain. [Balmana, Judith] Hosp Valle De Hebron, Dept Med Oncol, Barcelona, Catalonia, Spain. [Steyerberg, Ewout W.] Univ MC Rotterdam, Erasmus Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands. [Andreu, Montserrat] Hosp Mar, Dept Gastroenterol, Barcelona, Catalonia, Spain. [Llor, Xavier] Hosp Badalona Germans Trias & Pujol, Dept Gastroenterol, Barcelona, Catalonia, Spain. [Jover, Rodrigo] Gen Hosp Univ Alicante, Dept Gastroenterol, E-03080 Alicante, Spain. [Syngal, Sapna] Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA. [Syngal, Sapna; Gastrointestinal Oncology Grp Span] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA. RP Castells, A (reprint author), Univ Barcelona, Dept Gastroenterol, Inst Malalties Digest & Metab,Inst Invest Biomed, Hosp Clin,Ctr Invest Biomed & Red Enfermedades He, Villarroel 170, E-08036 Barcelona, Catalonia, Spain. EM castells@clinic.ub.es RI Andreu, Montserrat/D-9911-2015; BALAGUER, FRANCESC/G-2389-2016 OI Castells, Antoni/0000-0001-8431-2033; Andreu, Montserrat/0000-0003-4286-1098; Steyerberg, Ewout/0000-0002-7787-0122; FU NCI NIH HHS [CA 113433, K24 CA113433, K24 CA113433-01, K24 CA113433-02, K24 CA113433-03] NR 28 TC 40 Z9 41 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD JAN PY 2008 VL 134 IS 1 BP 39 EP 46 DI 10.1053/j.gastro.2007.10.042 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 247GO UT WOS:000252066400011 PM 18061181 ER PT J AU Kunzli, BM Nuhn, P Enjyoji, K Banz, Y Smith, RN Csizmadia, E Schuppan, D Berberat, PO Friess, H Robson, SC AF Kuenzli, Beat M. Nuhn, Philipp Enjyoji, Keiichi Banz, Yara Smith, Rex N. Csizmadia, Eva Schuppan, Detlef Berberat, Pascal O. Friess, Helmut Robson, Simon C. TI Disordered pancreatic inflammatory responses and inhibition of fibrosis in CD39-null mice SO GASTROENTEROLOGY LA English DT Article ID STELLATE CELLS; P2 RECEPTORS; CD39; DIPHOSPHOHYDROLASE; EXPRESSION; RAT; THROMBOREGULATION; ECTONUCLEOTIDASES; TRANSPLANTATION; IDENTIFICATION AB Background & Aims: Extracellular nucleotides are released from injured cells and bind purinergic-type 2 receptors (P2-Rs) that modulate inflammatory responses. Ectonucleotidases, such as CD39/nucleoside triphosphate diphosphohydrolase-1, hydrolyze extracellular nucleotides to integrate purinergic signaling responses. Because the role of extracellular nucleotides and CD39 in mediating inflammation and fibrosis are understood poorly, we studied the impact of CD39 gene deletion in a model of pancreatic disease. Methods: Pancreatitis was induced by cyclosporine pretreatment, followed by cerulein injections (50 mu g/kg, 6 intraperitoneal injections/day, 3 times/wk); Mice were killed at day 2, week 3, and week 6. Experimental parameters were correlated with cytokine levels in blood, RNA, and protein expression of purinergic and fibrosis markers in tissues. Immunohistochemistry and pancreatic morphometry of fibrosis were performed m wild-type and CD39-null mice. Effects of CD39 deletion on proliferation of primary pancreatic stellate cells (PSCs) were investigated in vitro. Results: Wild-type mice developed morphologic features of pancreatitis with the anticipated development of parenchymal atrophy and fibrosis. CD39 and P2-R became over-expressed in vascular and adventitious wild-type tissues. In contrast, CD39-null mice had inflammatory reactions but developed only minor pancreatic atrophy and limited fibrosis. Interferon-gamma became significantly increased in tissues and plasma of CD39-null mice. Wild-type PSCs expressed high levels of CD39 and P2-R CD39-null PSCs showed decreased rates of proliferation and the expression of procollagen-alpha 1 was inhibited significantly in vitro (P < .03). Conclusions: CD39 deletion decreases fibrogenesis in experimental pancreatitis. Our data implicate extracellular nucleotides as modulators of PSC proliferation and collagen production in pancreatitis. C1 [Kuenzli, Beat M.; Enjyoji, Keiichi; Banz, Yara; Csizmadia, Eva; Schuppan, Detlef; Robson, Simon C.] Harvard Univ, Beth Israel Deaconess Med Ctr, Massachusetts Gen Hosp, Dept Med,Div Gastroenterol, Boston, MA 02215 USA. [Smith, Rex N.] Harvard Univ, Beth Israel Deaconess Med Ctr, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02215 USA. [Kuenzli, Beat M.; Nuhn, Philipp; Berberat, Pascal O.; Friess, Helmut] Tech Univ Munich, Dept Surg, Munich, Germany. RP Robson, SC (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Gastroenterol, Res North,Room 301,99 Brookline Ave, Boston, MA 02215 USA. EM srobson@bidmc.harvard.edu FU NHLBI NIH HHS [P01 HL076540, HL63972, P01 HL076540-019001, R01 HL063972, P01 HL076540-010003, R01 HL063972-06, HL076540] NR 29 TC 26 Z9 26 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JAN PY 2008 VL 134 IS 1 BP 292 EP 305 DI 10.1053/j.gastro.2007.10.030 PG 14 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 247GO UT WOS:000252066400035 PM 18036594 ER PT J AU da Silveira, E Barkun, AN AF da Silveira, Eduardo Barkun, Alan N. TI Self-expandable metal stents in acute malignant colonic obstruction: shall you cross this bridge? SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material ID VS. EMERGENCY-SURGERY; DECISION-MAKING; CANCER; MANAGEMENT; RESECTION C1 [da Silveira, Eduardo] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. [Barkun, Alan N.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. RP da Silveira, E (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. NR 23 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 2008 VL 67 IS 1 BP 74 EP 76 DI 10.1016/j.gie.2007.06.062 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 252AW UT WOS:000252418200014 PM 18054009 ER PT J AU Adams, GB Scadden, DT AF Adams, G. B. Scadden, D. T. TI A niche opportunity for stem cell therapeutics SO GENE THERAPY LA English DT Review DE hematopoietic stem cells; niche microenvironment; stem cell therapy; stem cell engraftment; stem cell homing ID HEMATOPOIETIC STEM; HUMAN OSTEOBLASTS; PROGENITOR CELLS; ENGRAFTMENT; MICROENVIRONMENT; GERMLINE; THERAPY; MOUSE; CD44 AB The success of hematopoietic stem cell (HSC)-based therapies relies on the ability of the stem cells to both engraft and self-renew sufficiently in the bone marrow microenvironment. Previous studies identified that a number of components of bone contribute to the regulation of HSCs indicating that they participate in a stem cell 'niche'. This niche is a dynamic microenvironment that changes during development and with varying physiologic states. Components of it, such as the osteoblast, can be modulated through pharmacological treatment. Reasoning that the stem cell niche may be manipulated to augment the effectiveness of stem cell therapies, we demonstrated that daily treatment with parathyroid hormone ( a clinically approved method for increasing osteoblast function) resulted in therapeutic benefit in three clinically relevant models of stem cell therapy. These results suggest that the niche may be a pharmacological target for altering stem cell function in settings of regenerative medicine. C1 [Scadden, D. T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA USA. [Adams, G. B.] Univ So Calif, Keck Sch Med, Ctr Stem Cell & Regenerat Med, Los Angeles, CA USA. [Scadden, D. T.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA USA. RP Scadden, DT (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Regenerat Med, 185 Cambridge St CPZN-4265A, Boston, MA USA. EM scadden.david@mgh.harvard.edu NR 29 TC 29 Z9 30 U1 5 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0969-7128 J9 GENE THER JI Gene Ther. PD JAN PY 2008 VL 15 IS 2 BP 96 EP 99 DI 10.1038/sj.gt.3303063 PG 4 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 247QQ UT WOS:000252094800005 PM 18004404 ER PT J AU Boudreaux, ED Clark, S Camargo, CA AF Boudreaux, Edwin D. Clark, Sunday Camargo, Carlos A., Jr. TI Mood disorder screening among adult emergency department patients: a multicenter study of prevalence, associations and interest in treatment SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE depression; bipolar disorder; emergency medicine; screening; psychiatry ID CONTROLLED TRIAL; REGULAR SOURCE; DEPRESSION; HEALTH; CARE; QUESTIONNAIRE; VALIDITY; INTERVENTION; INSTRUMENT; SERVICES AB Objective: Planning for emergency department (ED)-initiated interventions for mood disorders requires confirmation of prevalence data, identification of predictors, and an assessment of patient interest in such interventions. Method: For two 24-h periods, consecutive patients aged 18+ years presenting to four Boston EDs were enrolled. We collected data on demographics, medical history, psychiatric history, healthcare utilization, depressive symptoms, manic symptoms and interest in hypothetical ED-initiated interventions. Patients with severe illness, altered mental status or severe emotional disturbance were excluded. Results: Of 476 screened patients, 152 (32%; 95% CI, 28-36%) screened positive for depression and 17 (4%; 95% CI, 2-6%) for mania. Depressed patients were more likely than nondepressed patients (all P<01) to have income <20,000/year (43% vs. 25%), a substance abuse history (19% vs. 5%), a chronic medical condition (67% vs. 53%), use tobacco (42% vs. 22%), have at least one ED visit in the past 6 months (76% vs. 56%) and have at least one hospitalization for substance abuse in the past 6 months (5% vs. 1%). About 50% of patients who screened positive for any mood disorder were interested in at least one ED-based intervention. Conclusion: ED patients screening positive for mood disorder symptoms are likely to have complex psychiatric, medical and social histories, which will be necessary to take into account when designing ED-initiated interventions. (c) 2008 Elsevier Inc. All rights reserved. C1 [Boudreaux, Edwin D.] Cooper Univ Hosp, Camden, NJ 08103 USA. [Boudreaux, Edwin D.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Emergency Med, Camden, NJ 08103 USA. [Boudreaux, Edwin D.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Camden, NJ 08103 USA. [Clark, Sunday; Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA 02114 USA. RP Boudreaux, ED (reprint author), Cooper Univ Hosp, 1 Cooper Plaza, Camden, NJ 08103 USA. EM boudreaux-edwin@cooperhealth.edu OI Boudreaux, Edwin/0000-0002-3223-6371 FU NIDA NIH HHS [DA-16698] NR 33 TC 18 Z9 19 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD JAN-FEB PY 2008 VL 30 IS 1 BP 4 EP 13 DI 10.1016/j.genhosppsych.2007.09.006 PG 10 WC Psychiatry SC Psychiatry GA 250NK UT WOS:000252306800002 PM 18164934 ER PT J AU Antipova, AA Stockwell, BR Golub, TR AF Antipova, Alena A. Stockwell, Brent R. Golub, Todd R. TI Gene expression-based screening for inhibitors of PDGFR signaling SO GENOME BIOLOGY LA English DT Article ID AURIN TRICARBOXYLIC-ACID; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLONY-STIMULATING FACTOR; AURINTRICARBOXYLIC ACID; GROWTH-FACTOR; POTENT INHIBITOR; RECEPTOR; ACTIVATION; PROTEIN; MECHANISM AB Here we describe a proof-of-concept experiment designed to explore the possibility of using gene expression-based high-throughput screening (GE-HTS) to find inhibitors of a signaling cascade, using platelet derived growth factor receptor (PDGFR) signaling as the example. The previously unrecognized ability of aurintricarboxylic acid to inhibit PDGFR signaling, discovered through a screen of 1,739 compounds, demonstrates the feasibility and generalizability of GE-HTS for the discovery of small molecule modulators of any signaling pathway of interest. C1 [Antipova, Alena A.; Golub, Todd R.] MIT, Broad Inst, Canc Program, Cambridge, MA 02142 USA. [Antipova, Alena A.; Golub, Todd R.] Harvard Univ, Cambridge Ctr, Cambridge, MA 02142 USA. [Antipova, Alena A.; Golub, Todd R.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Antipova, Alena A.; Golub, Todd R.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Antipova, Alena A.] MIT, Dept Chem, Cambridge, MA 02139 USA. [Stockwell, Brent R.] Columbia Univ, Dept Biol Sci, Fairchild Ctr MC 2406, New York, NY 10027 USA. [Stockwell, Brent R.] Columbia Univ, Dept Chem, Fairchild Ctr MC 2406, New York, NY 10027 USA. [Golub, Todd R.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. RP Golub, TR (reprint author), MIT, Broad Inst, Canc Program, Cambridge, MA 02142 USA. EM golub@broad.harvard.edu FU Howard Hughes Medical Institute; NCI NIH HHS [CA97061, R01 CA097061] NR 53 TC 16 Z9 16 U1 1 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2008 VL 9 IS 3 AR R47 DI 10.1186/gb-2008-9-3-r47 PG 14 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 283TN UT WOS:000254659500017 PM 18312689 ER PT J AU Garneski, KM DeCaprio, JA Nghiem, P AF Garneski, Kelly M. DeCaprio, James A. Nghiem, Paul TI Does a new polyomavirus contribute to Merkel cell carcinoma? SO GENOME BIOLOGY LA English DT Review ID VACUOLATING VIRUS; HIV-INFECTION; DNA-SEQUENCES; IDENTIFICATION; REPLICATION; SV40; AMPLIFICATION; INDUCTION; GENOME AB A new technique designed to hunt for non-human transcripts has identified a novel SV40-like virus present in the majority of Merkel cell carcinomas. Here we examine what it will take to determine whether or not this virus contributes to carcinogenesis. C1 [Garneski, Kelly M.; Nghiem, Paul] Univ Washington, Dept Med, Seattle, WA 98109 USA. [Garneski, Kelly M.; Nghiem, Paul] Univ Washington, Dept Dermatol & Pathol, Seattle, WA 98109 USA. [DeCaprio, James A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [DeCaprio, James A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [DeCaprio, James A.] Harvard Univ, Boston, MA 02115 USA. [Nghiem, Paul] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. RP Nghiem, P (reprint author), Univ Washington, Dept Med, Seattle, WA 98109 USA. EM pnghiem@u.washington.edu RI Paulson, Kelly/E-5761-2010; Nghiem, Paul/A-9210-2011 OI Paulson, Kelly/0000-0002-0033-3708; Nghiem, Paul/0000-0003-2784-963X FU NCI NIH HHS [T32 CA080416] NR 23 TC 14 Z9 15 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2008 VL 9 IS 6 AR 228 DI 10.1186/gb-2008-9-6-228 PG 4 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 324DN UT WOS:000257498000005 PM 18598371 ER PT J AU Hughes, TR Roth, FP AF Hughes, Timothy R. Roth, Frederick P. TI A race through the maze of genomic evidence Introduction SO GENOME BIOLOGY LA English DT Editorial Material ID YEAST GENES; MOUSE; RESOURCE C1 [Hughes, Timothy R.] Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada. [Hughes, Timothy R.] Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5S 3E1, Canada. [Roth, Frederick P.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Roth, Frederick P.] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA. RP Hughes, TR (reprint author), Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada. EM t.hughes@utoronto.ca; fritz_roth@hms.harvard.edu RI Roth, Frederick/H-6308-2011 FU NHGRI NIH HHS [P50 HG004233] NR 20 TC 8 Z9 8 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2008 VL 9 SU 1 AR S1 DI 10.1186/gb-2008-9-s1-s1 PG 3 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 602XX UT WOS:000278173500001 PM 18613945 ER PT J AU Ketteler, R Sun, ZR Kovacs, KF He, WW Seed, B AF Ketteler, Robin Sun, Zairen Kovacs, Karl F. He, Wei-Wu Seed, Brian TI A pathway sensor for genome-wide screens of intracellular proteolytic cleavage SO GENOME BIOLOGY LA English DT Article ID MAMMALIAN-CELLS; GAUSSIA LUCIFERASE; IN-VIVO; BIOLUMINESCENT REPORTER; SECRETED LUCIFERASE; PLASMA-MEMBRANE; GENE-EXPRESSION; CDNA CLONING; DEATH; AUTOPHAGY AB Protein cleavage is a central event in many regulated biological processes. We describe a system for detecting intracellular proteolysis based on non-conventional secretion of Gaussia luciferase ( GLUC). GLUC exits the cell without benefit of a secretory leader peptide, but can be anchored in the cell by fusion to beta-actin. By including protease cleavage sites between GLUC and beta-actin, proteolytic cleavage can be detected. Using this assay, we have identified regulators of autophagy, apoptosis and beta-actin cleavage. C1 [Ketteler, Robin; Seed, Brian] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. [Ketteler, Robin; Seed, Brian] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA. [Sun, Zairen; Kovacs, Karl F.; He, Wei-Wu] Origene Technol Inc, Rockville, MD 20850 USA. RP Seed, B (reprint author), Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Cambridge St, Boston, MA 02114 USA. EM bseed@ccib.mgh.harvard.edu OI Ketteler, Robin/0000-0002-2786-7291 NR 43 TC 21 Z9 21 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2008 VL 9 IS 4 AR R64 DI 10.1186/gb-2008-9-4-r64 PG 11 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 311BK UT WOS:000256574800008 PM 18387192 ER PT J AU Pena-Castillo, L Tasan, M Myers, CL Lee, H Joshi, T Zhang, C Guan, YF Leone, M Pagnani, A Kim, WK Krumpelman, C Tian, WD Obozinski, G Qi, YJ Mostafavi, S Lin, GN Berriz, GF Gibbons, FD Lanckriet, G Qiu, J Grant, C Barutcuoglu, Z Hill, DP Warde-Farley, D Grouios, C Ray, D Blake, JA Deng, MH Jordan, MI Noble, WS Morris, Q Klein-Seetharaman, J Bar-Joseph, Z Chen, T Sun, FZ Troyanskaya, OG Marcotte, EM Xu, D Hughes, TR Roth, FP AF Pena-Castillo, Lourdes Tasan, Murat Myers, Chad L. Lee, Hyunju Joshi, Trupti Zhang, Chao Guan, Yuanfang Leone, Michele Pagnani, Andrea Kim, Wan Kyu Krumpelman, Chase Tian, Weidong Obozinski, Guillaume Qi, Yanjun Mostafavi, Sara Lin, Guan Ning Berriz, Gabriel F. Gibbons, Francis D. Lanckriet, Gert Qiu, Jian Grant, Charles Barutcuoglu, Zafer Hill, David P. Warde-Farley, David Grouios, Chris Ray, Debajyoti Blake, Judith A. Deng, Minghua Jordan, Michael I. Noble, William S. Morris, Quaid Klein-Seetharaman, Judith Bar-Joseph, Ziv Chen, Ting Sun, Fengzhu Troyanskaya, Olga G. Marcotte, Edward M. Xu, Dong Hughes, Timothy R. Roth, Frederick P. TI A critical assessment of Mus musculus gene function prediction using integrated genomic evidence SO GENOME BIOLOGY LA English DT Article ID YEAST SACCHAROMYCES-CEREVISIAE; PROTEIN FUNCTION PREDICTION; HETEROGENEOUS DATA; DATA FUSION; MOUSE; NETWORKS; SCALE; ANNOTATION; EXPRESSION; DATABASE AB Background: Several years after sequencing the human genome and the mouse genome, much remains to be discovered about the functions of most human and mouse genes. Computational prediction of gene function promises to help focus limited experimental resources on the most likely hypotheses. Several algorithms using diverse genomic data have been applied to this task in model organisms; however, the performance of such approaches in mammals has not yet been evaluated. Results: In this study, a standardized collection of mouse functional genomic data was assembled; nine bioinformatics teams used this data set to independently train classifiers and generate predictions of function, as defined by Gene Ontology (GO) terms, for 21,603 mouse genes; and the best performing submissions were combined in a single set of predictions. We identified strengths and weaknesses of current functional genomic data sets and compared the performance of function prediction algorithms. This analysis inferred functions for 76% of mouse genes, including 5,000 currently uncharacterized genes. At a recall rate of 20%, a unified set of predictions averaged 41% precision, with 26% of GO terms achieving a precision better than 90%. Conclusion: We performed a systematic evaluation of diverse, independently developed computational approaches for predicting gene function from heterogeneous data sources in mammals. The results show that currently available data for mammals allows predictions with both breadth and accuracy. Importantly, many highly novel predictions emerge for the 38% of mouse genes that remain uncharacterized. C1 [Pena-Castillo, Lourdes; Grouios, Chris; Morris, Quaid; Hughes, Timothy R.] Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada. [Tasan, Murat; Tian, Weidong; Berriz, Gabriel F.; Gibbons, Francis D.; Roth, Frederick P.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Myers, Chad L.; Guan, Yuanfang; Troyanskaya, Olga G.] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA. [Myers, Chad L.; Guan, Yuanfang; Troyanskaya, Olga G.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA. [Lee, Hyunju] Gwangju Inst Sci & Technol, Dept Informat & Commun, Kwangju 500712, South Korea. [Joshi, Trupti; Zhang, Chao; Lin, Guan Ning; Xu, Dong] Univ Missouri, Dept Comp Sci, Digital Biol Lab, Columbia, MO 65211 USA. [Joshi, Trupti; Zhang, Chao; Lin, Guan Ning; Xu, Dong] Univ Missouri, Christopher S Bond Life Sci Ctr, Columbia, MO 65211 USA. [Leone, Michele; Pagnani, Andrea] ISI Fdn, I-10133 Turin, Italy. [Kim, Wan Kyu; Marcotte, Edward M.] Univ Texas Austin, Inst Cellular & Mol Biol, Ctr Syst & Synthet Biol, Austin, TX 78712 USA. [Krumpelman, Chase] Univ Texas Austin, Inst Cellular & Mol Biol, Dept Elect & Comp Engn, Austin, TX 78712 USA. [Obozinski, Guillaume] UC Berkeley, Dept Stat, Berkeley, CA 94720 USA. [Qi, Yanjun; Bar-Joseph, Ziv] Carnegie Mellon Univ, Sch Comp Sci, Pittsburgh, PA 15213 USA. [Mostafavi, Sara; Warde-Farley, David; Morris, Quaid] Univ Toronto, Dept Comp Sci, Toronto, ON M5S 3G4, Canada. [Lanckriet, Gert] UC San Diego, Dept Elect & Comp Engn, La Jolla, CA 92093 USA. [Qiu, Jian; Grant, Charles; Noble, William S.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Barutcuoglu, Zafer] Princeton Univ, Dept Comp Sci, Princeton, NJ 08544 USA. [Hill, David P.; Blake, Judith A.] Jackson Lab, Bar Harbor, ME 04609 USA. [Ray, Debajyoti] Gatsby Computat Neurosci Unit, London WC1N 3AR, England. [Deng, Minghua] Peking Univ, Sch Math Sci, Beijing 100871, Peoples R China. [Deng, Minghua] Peking Univ, Ctr Theoret Biol, Beijing 100871, Peoples R China. [Jordan, Michael I.] UC Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA. [Jordan, Michael I.] UC Berkeley, Dept Stat, Berkeley, CA 94720 USA. [Noble, William S.] Univ Washington, Dept Comp Sci & Engn, Seattle, WA 98195 USA. [Morris, Quaid; Hughes, Timothy R.] Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5S 3E1, Canada. [Klein-Seetharaman, Judith] Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA. [Chen, Ting; Sun, Fengzhu] Univ So Calif, Dept Biol Sci, Mol & Computat Biol Program, Los Angeles, CA 90089 USA. [Roth, Frederick P.] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA. RP Hughes, TR (reprint author), Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada. EM t.hughes@utoronto.ca; fritz_roth@hms.harvard.edu RI Sun, Fengzhu /G-4373-2010; Deng, Minghua/B-1316-2012; Roth, Frederick/H-6308-2011; Pagnani, Andrea/J-2363-2015; Deng, Minghua/B-5430-2012; OI Pagnani, Andrea/0000-0002-6509-0807; Deng, Minghua/0000-0002-9143-1898; Pena Castillo, Lourdes/0000-0002-0643-2547 FU NIH [R33 HG003070, P50 HG 002790, R01 GM071966, HG003224, HG0017115, HL81341, HG004233, HG004098, LM07994-01]; NIH/NSF [DMS-0241102]; Gwangju Institute of Science and Technology; National Natural Science Foundation of China [30570425]; National Key Basic Research Project of China [2003CB715903]; Microsoft Research Asia (MSRA); NSERC; Genome Canada; NSF [IIS-0513552, EIA0225656, EIA0225636, CAREER CC044917]; NIGMS [P50 GM071508]; Packard Foundation; USDA/CSREES [USDA/CSREES-2004-25604-14708]; Keck Foundation; CIHR; Welch Foundation; NSF/ITR [NSF/ITR-IIS-0407204]; [HG002273] FX Team A (GO, GL, JQ, CG, MJ, and WSN) was supported by NIH award R33 HG003070. Team B (HL, MD, TC, and FS) was supported by NIH/NSF joint mathematical biology initiative DMS-0241102 and NIH P50 HG 002790; HL is supported by the systems biology infrastructure establishment grant provided by Gwangju Institute of Science and Technology in 2008; MD is supported by the National Natural Science Foundation of China (No. 30570425), the National Key Basic Research Project of China (No. 2003CB715903), and Microsoft Research Asia (MSRA). Team C (SM, DW-F, CG, DR, QM) was supported by an NSERC operating grant to QM as well as a Genome Canada grant administered by the Ontario Genomics Institute. Team D (YG, CLM, ZB, and OGT) was partially supported by NIH grant R01 GM071966 and NSF grant IIS-0513552 to OGT and NIGMS Center of Excellence grant P50 GM071508. Team E (WKK, CK, and EMM) was supported by grants from the NIH, NSF, Packard and Welch Foundations. Team F (TJ, CZ, GNL, and DX) was supported by USDA/CSREES-2004-25604-14708 and NSF/ITR-IIS-0407204. Team G (MT, WT, FDG, GFB, and FPR) was supported by NIH grants (HG003224, HG0017115, HL81341, HG004233 and HG004098), by the Keck Foundation, and by NSF TeraGrid resources. Team H (YQ, JK, and ZB) was supported in part by National Science Foundation NSF grants EIA0225656, EIA0225636, CAREER CC044917 and National Institutes of Health NIH grant LM07994-01. Team I (ML and AP) warmly thanks A Vazquez for his support. DPH and JAB were supported by HG002273. LP-C and TRH were supported by a CIHR grant and thank O Meruvia for helping with the design of figures. NR 57 TC 116 Z9 120 U1 1 U2 14 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2008 VL 9 SU 1 AR S2 DI 10.1186/gb-2008-9-s1-s2 PG 19 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 602XX UT WOS:000278173500002 PM 18613946 ER PT J AU Tian, WD Zhang, LV Tasan, M Gibbons, FD King, OD Park, J Wunderlich, Z Cherry, JM Roth, FP AF Tian, Weidong Zhang, Lan V. Tasan, Murat Gibbons, Francis D. King, Oliver D. Park, Julie Wunderlich, Zeba Cherry, J. Michael Roth, Frederick P. TI Combining guilt-by-association and guilt-by-profiling to predict Saccharomyces cerevisiae gene function SO GENOME BIOLOGY LA English DT Article ID PROTEIN INTERACTION DATA; GENOME-WIDE ANALYSIS; MESSENGER-RNA; YEAST GENOME; GLOBAL ANALYSIS; CELL-GROWTH; COMPLEX; DATABASE; NETWORK; IDENTIFICATION AB Background: Learning the function of genes is a major goal of computational genomics. Methods for inferring gene function have typically fallen into two categories: 'guilt-by-profiling', which exploits correlation between function and other gene characteristics; and 'guilt-by-association', which transfers function from one gene to another via biological relationships. Results: We have developed a strategy ('Funckenstein') that performs guilt-by-profiling and guilt-by-association and combines the results. Using a benchmark set of functional categories and input data for protein-coding genes in Saccharomyces cerevisiae, Funckenstein was compared with a previous combined strategy. Subsequently, we applied Funckenstein to 2,455 Gene Ontology terms. In the process, we developed 2,455 guilt-by-profiling classifiers based on 8,848 gene characteristics and 12 functional linkage graphs based on 23 biological relationships. Conclusion: Funckenstein outperforms a previous combined strategy using a common benchmark dataset. The combination of 'guilt-by-profiling' and 'guilt-by-association' gave significant improvement over the component classifiers, showing the greatest synergy for the most specific functions. Performance was evaluated by cross-validation and by literature examination of the top-scoring novel predictions. These quantitative predictions should help prioritize experimental study of yeast gene functions. C1 [Tian, Weidong; Zhang, Lan V.; Tasan, Murat; Gibbons, Francis D.; King, Oliver D.; Wunderlich, Zeba; Roth, Frederick P.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Park, Julie; Cherry, J. Michael] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA. [Roth, Frederick P.] Dana Farber Canc Inst, CCSB, Boston, MA 02115 USA. [Zhang, Lan V.] McKinsey & Co Inc, Palo Alto, CA 94304 USA. [Gibbons, Francis D.] Merrimack Pharmaceut, Cambridge, MA 02139 USA. [King, Oliver D.] BBRI, Watertown, MA 02472 USA. [Wunderlich, Zeba] MIT, Cambridge, MA 02139 USA. RP Roth, FP (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Longwood Ave, Boston, MA 02115 USA. EM fritz_roth@hms.harvard.edu RI Roth, Frederick/H-6308-2011 FU West Quad Computing Group at Harvard Medical School; US National Institutes of Health (NIH) [HG003224, HG0017115, DK071507, F32 HG004098, F32 HG02552, HG001315]; Keck Foundation FX We thank the West Quad Computing Group at Harvard Medical School for computational resources and support. Computational resources were also provided by the National Science Foundation through the TeraGrid program. This work was supported by US National Institutes of Health (NIH) grants HG003224 (FR), HG0017115 (FR), DK071507 (WT), F32 HG004098 (MT), F32 HG02552 (ODK), HG001315 (JP and JMC), and the Keck Foundation (FR). ZW is a Howard Hughes Medical Institute Predoctoral Fellow. NR 77 TC 37 Z9 39 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2008 VL 9 SU 1 AR S7 DI 10.1186/gb-2008-9-s1-s7 PG 21 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 602XX UT WOS:000278173500007 PM 18613951 ER PT J AU Zhang, Q Menon, R Deutsch, EW Pitteri, SJ Faca, VM Wang, H Newcomb, LF DePinho, RA Bardeesy, N Dinulescu, D Hung, KE Kucherlapati, R Jacks, T Politi, K Aebersold, R Omenn, GS States, DJ Hanash, SM AF Zhang, Qing Menon, Rajasree Deutsch, Eric W. Pitteri, Sharon J. Faca, Vitor M. Wang, Hong Newcomb, Lisa F. DePinho, Ronald A. Bardeesy, Nabeel Dinulescu, Daniela Hung, Kenneth E. Kucherlapati, Raju Jacks, Tyler Politi, Katerina Aebersold, Ruedi Omenn, Gilbert S. States, David J. Hanash, Samir M. TI A mouse plasma peptide atlas as a resource for disease proteomics SO GENOME BIOLOGY LA English DT Article ID MASS-SPECTROMETRY; COMPARATIVE ONCOGENOMICS; CANCER BIOMARKERS; STATISTICAL-MODEL; GENE; GENOME; EXPRESSION; DISCOVERY; DATABASE; IDENTIFICATIONS AB We present an in-depth analysis of mouse plasma leading to the development of a publicly available repository composed of 568 liquid chromatography-tandem mass spectrometry runs. A total of 13,779 distinct peptides have been identified with high confidence. The corresponding approximately 3,000 proteins are estimated to span a 7 logarithmic range of abundance in plasma. A major finding from this study is the identification of novel isoforms and transcript variants not previously predicted from genome analysis. C1 [Zhang, Qing; Pitteri, Sharon J.; Faca, Vitor M.; Wang, Hong; Newcomb, Lisa F.; Hanash, Samir M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Menon, Rajasree; Omenn, Gilbert S.; States, David J.] Univ Michigan, Ctr Computat Med & Biol, Ann Arbor, MI 48109 USA. [Deutsch, Eric W.] Inst Syst Biol, Seattle, WA 98103 USA. [DePinho, Ronald A.] Harvard Univ, Ctr Canc, Dana Farber Canc Inst, Boston, MA 02115 USA. [DePinho, Ronald A.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Ctr Appl Canc Sci, Dept Med Oncol Med Genet,Belfer Inst Innovat Canc, Boston, MA 02114 USA. [Bardeesy, Nabeel; Hung, Kenneth E.; Kucherlapati, Raju] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Dinulescu, Daniela] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. [Jacks, Tyler] MIT, Ctr Canc Res, Cambridge, MA 02139 USA. [Politi, Katerina] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Zurich, Fac Sci, CH-8093 Zurich, Switzerland. Univ Zurich, ETH Zurich, Inst Mol Syst Biol, CH-8093 Zurich, Switzerland. RP Zhang, Q (reprint author), Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. EM qing@fhcrc.org RI Faca, Vitor/A-3989-2013; OI Omenn, Gilbert S./0000-0002-8976-6074; FACA, VITOR MARCEL/0000-0003-3205-7944; Pitteri, Sharon/0000-0002-3119-873X FU NHLBI NIH HHS [N01-HV-28179, N01HV28179] NR 38 TC 14 Z9 14 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2008 VL 9 IS 6 AR R93 DI 10.1186/gb-2008-9-6-r93 PG 10 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 324DN UT WOS:000257498000012 PM 18522751 ER PT J AU Zhang, Y Liu, T Meyer, CA Eeckhoute, J Johnson, DS Bernstein, BE Nussbaum, C Myers, RM Brown, M Li, W Liu, XS AF Zhang, Yong Liu, Tao Meyer, Clifford A. Eeckhoute, Jerome Johnson, David S. Bernstein, Bradley E. Nussbaum, Chad Myers, Richard M. Brown, Myles Li, Wei Liu, X. Shirley TI Model-based Analysis of ChIP-Seq (MACS) SO GENOME BIOLOGY LA English DT Article ID PROTEIN-DNA INTERACTIONS; GENOME-WIDE ANALYSIS; BINDING-SITES; TRANSCRIPTION; ARRAYS AB We present Model-based Analysis of ChIP-Seq data, MACS, which analyzes data generated by short read sequencers such as Solexa's Genome Analyzer. MACS empirically models the shift size of ChIP-Seq tags, and uses it to improve the spatial resolution of predicted binding sites. MACS also uses a dynamic Poisson distribution to effectively capture local biases in the genome, allowing for more robust predictions. MACS compares favorably to existing ChIP-Seq peak-finding algorithms, and is freely available. C1 [Li, Wei] Baylor Coll Med, Dept Mol & Cellular Biol, Dan L Duncan Canc Ctr, Div Biostat, Houston, TX 77030 USA. [Zhang, Yong; Liu, Tao; Meyer, Clifford A.; Liu, X. Shirley] Harvard Univ, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Sch Publ Hlth, Boston, MA 02115 USA. [Eeckhoute, Jerome; Brown, Myles] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Onocl, Boston, MA 02115 USA. [Eeckhoute, Jerome; Brown, Myles] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Eeckhoute, Jerome; Brown, Myles] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Johnson, David S.] Gene Secur Network Inc, Redwood City, CA 94063 USA. [Bernstein, Bradley E.] Harvard Univ, Sch Med, Dept Pathol, Charlestown, MA 02129 USA. [Bernstein, Bradley E.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA. [Bernstein, Bradley E.] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA. [Bernstein, Bradley E.; Nussbaum, Chad] Broad Inst Harvard, Cambridge, MA 02142 USA. [Bernstein, Bradley E.; Nussbaum, Chad] MIT, Cambridge, MA 02142 USA. [Myers, Richard M.] Stanford Univ, Med Ctr, Dept Genet, Stanford, CA 94305 USA. RP Li, W (reprint author), Baylor Coll Med, Dept Mol & Cellular Biol, Dan L Duncan Canc Ctr, Div Biostat, 1 Baylor Plaza, Houston, TX 77030 USA. EM wl1@bcm.edu; xsliu@jimmy.harvard.edu RI Li, Wei/A-8544-2009; Liu, Tao/G-3585-2010; Zhang, Yong/B-4838-2011 OI Brown, Myles/0000-0002-8213-1658; Liu, Tao/0000-0002-8818-8313; Eeckhoute, Jerome/0000-0002-7222-9264; Zhang, Yong/0000-0001-6316-2734 FU NIH [HG004069, HG004270, DK074967] FX We thank Barbara Wold, Ting Wang, Jason Lieb, Sevinc Ercan, Julie Ahringer, and Peter Park for their comments and insights. We also thank Jeremy Zhenhua Wu for proof reading the manuscript. The project was partially funded by NIH grants HG004069, HG004270 and DK074967. NR 13 TC 2290 Z9 2300 U1 25 U2 163 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2008 VL 9 IS 9 AR R137 DI 10.1186/gb-2008-9-9-r137 PG 9 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 367XW UT WOS:000260586900015 PM 18798982 ER PT J AU Bastepe, M AF Bastepe, Murat TI The GNAS locus and pseudohypoparathyroidism SO GENOMIC IMPRINTING SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Article ID STIMULATORY G-PROTEIN; ALBRIGHT HEREDITARY OSTEODYSTROPHY; GS-ALPHA GENE; PROGRESSIVE OSSEOUS HETEROPLASIA; NUCLEOTIDE REGULATORY PROTEIN; IMPRINTING CONTROL ELEMENT; PEPTIDE RECEPTOR GENE; PARATHYROID-HORMONE; BINDING PROTEIN; DEOXYRIBONUCLEIC-ACID AB Pseudohypoparathyroidism (PHP) is a disorder of end-organ resistance primarily affecting the actions of parathyroid hormone (PTH). Genetic defects associated with different forms of PHP involve the alpha-subunit of the stimulatory G protein (Gs alpha), a signaling protein essential for the actions of PTH and many other hormones. Heterozygous inactivating mutations within Gs alpha-encoding GNAS exons are found in patients with PHP-Ia, who also show resistance to other hormones and a constellation of physical features called Albright's hereditary osteodystrophy (AHO). Patients who exhibit AHO features without evidence for hormone resistance, who are said to have pseudopseudohypoparathyroidism (PPHP), also carry heterozygous inactivating Gs alpha mutations. Maternal inheritance of such a mutation leads to PHP-Ia, i.e., AHO plus hormone resistance, while paternal inheritance of the same mutation leads to PPHP, i.e., AHO only. This imprinted mode of inheritance for hormone resistance can be explained by the predominantly maternal expression of Gsa in certain tissues, including renal proximal tubules. Patients with PHP-Ib lack coding Gsa mutations but display epigenetic defects of the GNAS locus, with the most consistent defect being a loss of imprinting at the exon A/B differentially methylated region (DMR). This epigenetic defect presumably silences, in cis, Gsa expression in tissues where this protein is derived from the maternal allele only, leading to a marked reduction of Gsa levels. The familial form of PHP-Ib (AD-PHP-Ib) is typically associated with an isolated loss of imprinting at the exon A/B DMR. A unique 3-kb microdeletion that disrupts the neighboring STX16 locus has been identified in this disorder and appears to be the cause of the loss of imprinting. In addition, deletions removing the entire NESP55 DMR, located within GNAS, have been identified in some AD-PHP-Ib kindreds in whom affected individuals show loss of all the maternal GNAS imprints. Mutations identified in different forms of PHP-Ib thus point to different cis-acting elements that are apparently required for the proper imprinting of the GNAS locus. Most sporadic PHP-Ib cases also have imprinting abnormalities of GNAS that involve multiple DMRs, but the genetic lesion(s) responsible for these imprinting abnormalities remain to be discovered. C1 [Bastepe, Murat] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Bastepe, Murat] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Bastepe, M (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. EM bastepe@helix.mgh.harvard.edu NR 81 TC 61 Z9 61 U1 1 U2 2 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0065-2598 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2008 VL 626 BP 27 EP 40 PG 14 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA BHH46 UT WOS:000253296100003 PM 18372789 ER PT J AU Menotti-Raymond, M David, VA Pflueger, SM Lindblad-Toh, K Wade, CM O'Brien, SJ Johnson, WE AF Menotti-Raymond, Marilyn David, Victor A. Pflueger, Solveig M. Lindblad-Toh, Kerstin Wade, Claire M. O'Brien, Stephen J. Johnson, Warren E. TI Patterns of molecular genetic variation among cat breeds SO GENOMICS LA English DT Article DE domestic cat; cat breeds; STRUCTURE algorithm; STRs; SNPs; population subdivision ID ROD-CONE DEGENERATION; DOMESTIC CAT; LINKAGE DISEQUILIBRIUM; FELIS-CATUS; GENOME; TYROSINASE; MUTATIONS; PHENOTYPE; ALLELES; DISEASE AB Genetic variation in cat breeds was assessed utilizing a panel of short tandem repeat (STR) loci genotyped in 38 cat breeds and 284 single-nucleotide polymorphisms (SNPs) genotyped in 24 breeds. Population structure in cat breeds generally reflects their recent ancestry and absence of strong breed barriers between some breeds. There is a wide range in the robustness of population definition, from breeds demonstrating high definition to breeds with as little as a third of their genetic variation partitioning into a single population. Utilizing the STRUCTURE algorithm, there was no clear demarcation of the number of population subdivisions; 16 breeds could not be resolved into independent populations, the consequence of outcrossing in established breeds to recently developed breeds with common ancestry. These 16 breeds were divided into 6 populations. Ninety-six percent of cats in a sample set of 1040 were correctly assigned to their classified breed or breed group/population. Average breed STR heterozygosities ranged from moderate (0.53; Havana, Korat) to high (0.85; Norwegian Forest Cat, Manx). Most of the variation in cat breeds was observed within a breed population (83.7%), versus 16.3% of the variation observed between populations. The hierarchical relationships of cat breeds is poorly defined as demonstrated by phylogenetic trees generated from both STR and SNP data, though phylogeographic grouping of breeds derived completely or in part from Southeast Asian ancestors was apparent. (C) 2007 Elsevier Inc. All rights reserved. C1 [Menotti-Raymond, Marilyn; David, Victor A.; O'Brien, Stephen J.; Johnson, Warren E.] Natl Canc Inst Frederick, Lab Genome Divers, Frederick, MD 21702 USA. [Pflueger, Solveig M.] Baystate Med Ctr, Springfield, MA 01199 USA. [Lindblad-Toh, Kerstin; Wade, Claire M.] Broad Inst Harvard, Cambridge, MA 02141 USA. [Lindblad-Toh, Kerstin; Wade, Claire M.] MIT, Cambridge, MA 02141 USA. [Wade, Claire M.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. RP Menotti-Raymond, M (reprint author), Natl Canc Inst Frederick, Lab Genome Divers, Frederick, MD 21702 USA. EM raymond@ncifcrf.gov RI Johnson, Warren/D-4149-2016; OI Johnson, Warren/0000-0002-5954-186X; Wade, Claire/0000-0003-3413-4771 NR 28 TC 34 Z9 35 U1 1 U2 19 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0888-7543 J9 GENOMICS JI Genomics PD JAN PY 2008 VL 91 IS 1 BP 1 EP 11 DI 10.1016/j.ygeno.2007.08.008 PG 11 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 255MH UT WOS:000252661600001 PM 17964115 ER PT B AU Lee, DG Urbach, JM Wu, G Liberati, NT Feinbaum, RL Ausubel, FM AF Lee, Daniel G. Urbach, Jonathan M. Wu, Gang Liberati, Nicole T. Feinbaum, Rhonda L. Ausubel, Frederick M. BE Gustafson, JP Taylor, J Stacey, G TI Combining genomic tools to dissect multifactorial virulence in Pseudomonas aeruginosa SO GENOMICS OF DISEASE SE STADLER GENETICS SYMPOSIA SERIES LA English DT Proceedings Paper CT 24th Stadler Genetics Symposium CY OCT 02-04, 2006 CL Columbia, MO ID MICROBIAL GENE IDENTIFICATION; CAENORHABDITIS-ELEGANS; PATHOGENICITY ISLANDS; OPPORTUNISTIC PATHOGEN; NEGATIVE SELECTION; CYSTIC-FIBROSIS; MODEL; INFECTION; MUTANTS; STRAIN C1 [Lee, Daniel G.; Urbach, Jonathan M.; Wu, Gang; Liberati, Nicole T.; Feinbaum, Rhonda L.; Ausubel, Frederick M.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. RP Lee, DG (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. NR 40 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-76722-2 J9 STADLER GEN PY 2008 BP 127 EP 150 PG 24 WC Genetics & Heredity SC Genetics & Heredity GA BHO75 UT WOS:000254891400010 ER PT S AU Smagghe, BJ Halder, P Hargrove, MS AF Smagghe, Benoit J. Halder, Puspita Hargrove, Mark S. BE Poole, RK TI Measurement of distal histidine coordination equilibrium and kinetics in hexacoordinate hemoglobins SO GLOBINS AND OTHER NITRIC OXIDE-REACTIVE PROTEINS, PT A SE Methods in Enzymology LA English DT Review; Book Chapter ID SPERM WHALE MYOGLOBIN; LIGAND-BINDING; FLASH-PHOTOLYSIS; ACTIVE-SITE; NEUROGLOBIN; PROTEIN; LEGHEMOGLOBIN; PLANTS AB The kinetics of ligand binding to hemoglobins has been measured for decades. Initially, these studies were confined to readily available pentacoordinate oxygen transport proteins like myoglobin, leghemoglobin, and red blood cell hemoglobin. Bimolecular ligand binding to these proteins is relatively simple, as ligand association is largely unimpeded at the heme iron. Although many techniques have been used to examine these reactions in the past, stopped-flow rapid mixing and flash photolysis are the most common ways to measure rate constants for ligand association and dissociation. Expression of recombinant proteins has allowed for examination of many newly discovered hemoglobins. The hexacoordinate hemoglobins are one such group of proteins that exhibit more complex binding kinetics than pentacoordinate hemoglobins due to reversible intramolecular coordination by a histidine side chain. Here, we describe methods for characterizing the kinetics of ligand binding to hexacoordinate hemoglobins with a focus on measurement of histidine coordination and exogenous ligand binding in both the ferrous and the ferric oxidation states. C1 [Smagghe, Benoit J.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. [Halder, Puspita; Hargrove, Mark S.] Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA USA. RP Smagghe, BJ (reprint author), Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. NR 34 TC 6 Z9 6 U1 0 U2 5 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 978-0-12-374277-3 J9 METHOD ENZYMOL JI Methods Enzymol. PY 2008 VL 436 BP 359 EP 378 DI 10.1016/S0076-6879(08)36020-0 PG 20 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BHH44 UT WOS:000253294600020 PM 18237643 ER PT J AU Nagymanyoki, Z Callahan, MJ Parast, MM Berkowitz, RS Mok, SC Fulop, V AF Nagymanyoki, Zoltan Callahan, Michael J. Parast, Mana M. Berkowitz, Ross S. Mok, Samuel C. Fulop, Vilmos TI Overexpression of laminin receptor 1 on decidual cells in partial and complete mole SO GYNECOLOGIC ONCOLOGY LA English DT Article DE gestational trophoblastic disease; decidual stromal cells; laminin receptor 1 ID HUMAN CHORIONIC-GONADOTROPIN; KDA LAMININ RECEPTOR; GENE-PRODUCT P57(KIP2); BREAST-CANCER CELLS; HYDATIDIFORM MOLES; PROGNOSTIC-SIGNIFICANCE; BINDING PROTEIN; MESSENGER-RNA; EXPRESSION; METASTASIS AB Objectives. Laminin receptor 1 (LR1),. a non-integrin-type laminin receptor, has been described in several tumors and may play a role in tumor invasion. It is well known that LR1 can modify the conformation and degradation of laminin thus enhancing tumor cell invasion. LR1 may play a role in controlling trophoblast invasion in normal and molar pregnancies. Materials and methods. Real-time polymerase chain reaction (RT-PCR) was performed on total cDNA from 17 gestational age-controlled normal placentas, 10 complete moles (CM), and 4 partial moles (PM). Immunolocalization of LR1 was performed on paraffin sections prepared from 17 age-controlled placentas, 17 PM, and 19 CM. Results. RT-PCR demonstrated a 13-fold increase in LR1 mRNA expression in molar tissues (PM and CM combined) versus normal placentas (p=0.012). Immunohistochemical analysis revealed LR1 localized to the decidual cells. In normal placenta LR1 localized to the decidual cell membrane. However, in PM and CM, LR1 was additionally noted in the cytoplasm of decidual cells. Interestingly, with immunohistochemistry method, we found that PM demonstrated higher protein expression of LR1 than either normal placenta or CM (p=0.001 and p=0.024, respectively). Conclusion. LR1 is expressed in both the decidual cells of normal placenta and mole (CM and PM). Decidual cells in CM and PM express LR1 significantly greater than the decidual cells in placenta. The underlying mechanism of how molar tissue may be associated with enhanced expression of LR1 in the maternal endometrium is unclear. (c) 2007 Elsevier Inc. All rights reserved. C1 [Nagymanyoki, Zoltan; Callahan, Michael J.; Berkowitz, Ross S.; Mok, Samuel C.] Harvard Univ, Sch Med,Lab Gynecol Oncol,Div Gynecol Oncol,Dept, Brigham & Womens Hosp,New England Trophoblast Dis, Dana Farber Canc Inst,Donald P Goldstein MD Troph, Boston, MA 02115 USA. [Mok, Samuel C.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol,Div Womens & Perinatal Pathol, Boston, MA USA. [Nagymanyoki, Zoltan; Fulop, Vilmos] Natl Hlth Ctr, Dept Obstet & Gynecol, Budapest, Hungary. [Nagymanyoki, Zoltan; Fulop, Vilmos] Semmelweis Univ, H-1085 Budapest, Hungary. RP Berkowitz, RS (reprint author), Harvard Univ, Sch Med,Lab Gynecol Oncol,Div Gynecol Oncol,Dept, Brigham & Womens Hosp,New England Trophoblast Dis, Dana Farber Canc Inst,Donald P Goldstein MD Troph, Boston, MA 02115 USA. EM rberkowitz@partners.org NR 34 TC 3 Z9 4 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD JAN PY 2008 VL 108 IS 1 BP 121 EP 125 DI 10.1016/j.ygyno.2007.08.097 PG 5 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 254RH UT WOS:000252605200022 PM 17928039 ER PT J AU Vossough, A Lev, MH AF Vossough, Arastoo Lev, Michael H. BE Newton, HB Jolesz, FA TI CNS Infarction SO HANDBOOK OF NEURO-ONCOLOGY NEUROIMAGING LA English DT Article; Book Chapter ID ENHANCED MR-ANGIOGRAPHY; DIGITAL-SUBTRACTION-ANGIOGRAPHY; ATTENUATED INVERSION-RECOVERY; CAROTID-ARTERY STENOSIS; SPINAL-CORD INFARCTION; ACUTE STROKE; MAGNETIC-RESONANCE; CEREBRAL-ARTERY; INTRAARTERIAL THROMBOLYSIS; HEMORRHAGIC TRANSFORMATION C1 [Vossough, Arastoo] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Lev, Michael H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Vossough, A (reprint author), Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 55 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055629-1 PY 2008 BP 74 EP 82 DI 10.1016/B978-012370863-2.50013-0 PG 9 WC Oncology; Clinical Neurology; Neuroimaging SC Oncology; Neurosciences & Neurology GA BFF67 UT WOS:000319669900012 ER PT J AU Monje, M Wen, PY AF Monje, Michelle Wen, Patrick Y. BE Newton, HB Jolesz, FA TI Neurological Complications of Oncological Therapy SO HANDBOOK OF NEURO-ONCOLOGY NEUROIMAGING LA English DT Article; Book Chapter ID CENTRAL-NERVOUS-SYSTEM; ACUTE LYMPHOBLASTIC-LEUKEMIA; OF-THE-LITERATURE; RADIATION-INDUCED TELANGIECTASIA; ACUTE LYMPHOCYTIC-LEUKEMIA; DOSE CYTOSINE-ARABINOSIDE; WHOLE-BRAIN RADIOTHERAPY; MOTOR-NEURON SYNDROME; CRANIAL IRRADIATION; COGNITIVE FUNCTION C1 [Monje, Michelle] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. [Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA. RP Monje, M (reprint author), Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA. NR 134 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055629-1 PY 2008 BP 102 EP 115 DI 10.1016/B978-012370863-2.50017-8 PG 14 WC Oncology; Clinical Neurology; Neuroimaging SC Oncology; Neurosciences & Neurology GA BFF67 UT WOS:000319669900016 ER PT B AU Chen, CC Chapman, PH Bussiere, M Loeffler, JS AF Chen, Clark C. Chapman, Paul H. Bussiere, Marc Loeffler, Jay S. BE Newton, HB Jolesz, FA TI Stereotactic Radiosurgery: Basic Principles, Delivery Platforms and Clinical Applications SO HANDBOOK OF NEURO-ONCOLOGY NEUROIMAGING LA English DT Article; Book Chapter ID GAMMA-KNIFE RADIOSURGERY; HIGH-GRADE GLIOMAS; THERAPY ONCOLOGY GROUP; RECURSIVE PARTITIONING ANALYSIS; RECURRENT MALIGNANT GLIOMAS; JUGULAR FORAMEN SCHWANNOMAS; WHOLE-BRAIN RADIOTHERAPY; OF-FLORIDA EXPERIENCE; TERM FOLLOW-UP; RADIATION-THERAPY C1 [Chen, Clark C.; Chapman, Paul H.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Chapman, Paul H.; Bussiere, Marc] Harvard Univ, Sch Med, Boston, MA USA. [Bussiere, Marc] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Loeffler, Jay S.] Massachusetts Gen Hosp, Northeast Proton Therapy Ctr, Boston, MA 02114 USA. RP Chen, CC (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. NR 182 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055629-1; 978-0-12-370863-2 PY 2008 BP 192 EP 214 DI 10.1016/B978-012370863-2.50026-9 PG 23 WC Oncology; Clinical Neurology; Neuroimaging SC Oncology; Neurosciences & Neurology GA BFF67 UT WOS:000319669900025 ER PT J AU Cruz, LCH Domingues, RC Sorensen, AG AF Celso Hygino Cruz, L., Jr. Domingues, Romeu C. Sorensen, A. Gregory BE Newton, HB Jolesz, FA TI Diffusion Magnetic Resonance Imaging in Brain Tumors SO HANDBOOK OF NEURO-ONCOLOGY NEUROIMAGING LA English DT Article; Book Chapter ID GRADE CEREBRAL GLIOMAS; CENTRAL-NERVOUS-SYSTEM; WHITE-MATTER TRACTS; IN-VIVO; WEIGHTED MRI; GLIOBLASTOMA-MULTIFORME; CORTICOSPINAL TRACT; INTRACRANIAL TUMORS; MULTIPLE-SCLEROSIS; CANCER STATISTICS C1 [Celso Hygino Cruz, L., Jr.; Domingues, Romeu C.] CDPI, Ctr Med Barrashopping, Rio De Janeiro, Brazil. [Sorensen, A. Gregory] Massachusetts Gen Hosp, Dept Neuroradiol, Boston, MA 02114 USA. RP Cruz, LCH (reprint author), CDPI, Ctr Med Barrashopping, Rio De Janeiro, Brazil. NR 110 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055629-1 PY 2008 BP 215 EP 238 DI 10.1016/B978-012370863-2.50027-0 PG 24 WC Oncology; Clinical Neurology; Neuroimaging SC Oncology; Neurosciences & Neurology GA BFF67 UT WOS:000319669900026 ER PT J AU Vossough, A Gonzalez, RG Henson, JW Schaefer, PW AF Vossough, Arastoo Gonzalez, R. Gilberto Henson, John W. Schaefer, Pamela W. BE Newton, HB Jolesz, FA TI Intracranial Metastases SO HANDBOOK OF NEURO-ONCOLOGY NEUROIMAGING LA English DT Article; Book Chapter ID PROTON MR SPECTROSCOPY; NERVOUS-SYSTEM TUMORS; CONTRAST-ENHANCED MR; HIGH-GRADE GLIOMAS; BRAIN METASTASES; CEREBRAL METASTASES; FDG-PET; DIFFERENTIAL-DIAGNOSIS; GADOBENATE DIMEGLUMINE; MAGNETIZATION-TRANSFER C1 [Vossough, Arastoo] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Gonzalez, R. Gilberto] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Henson, John W.] Massachusetts Gen Hosp, Div Neuroradiol, Pappas Brain Tumor Imaging Res Program, Boston, MA 02114 USA. [Schaefer, Pamela W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Vossough, A (reprint author), Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 46 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055629-1 PY 2008 BP 485 EP 493 DI 10.1016/B978-012370863-2.50049-X PG 9 WC Oncology; Clinical Neurology; Neuroimaging SC Oncology; Neurosciences & Neurology GA BFF67 UT WOS:000319669900048 ER PT J AU Ulmer, S Harris, GJ Henson, JW AF Ulmer, Stephan Harris, Gordon J. Henson, John W. BE Newton, HB Jolesz, FA TI Neuroimaging Issues in Assessing Response to Brain Tumor Therapy SO HANDBOOK OF NEURO-ONCOLOGY NEUROIMAGING LA English DT Article; Book Chapter ID MAGNETIC-RESONANCE SPECTROSCOPY; CONTRAST-ENHANCED MR; HIGH-GRADE GLIOMAS; MALIGNANT GLIOMA; FINAL REPORT; RADIOTHERAPY; CRITERIA; CANCER; ASTROCYTOMA; PREDICTION C1 [Ulmer, Stephan] Massachusetts Gen Hosp, Dept Radiol, Imaging Serv 3D, Boston, MA 02114 USA. [Harris, Gordon J.] Massachusetts Gen Hosp, Ctr Canc, Ctr Neurooncol, Boston, MA USA. [Henson, John W.] Massachusetts Gen Hosp, Div Neuroradiol, Pappas Brain Tumor Imaging Res Program, Boston, MA 02114 USA. RP Ulmer, S (reprint author), Massachusetts Gen Hosp, Dept Radiol, Imaging Serv 3D, Boston, MA 02114 USA. NR 35 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-055629-1 PY 2008 BP 504 EP 514 DI 10.1016/B978-012370863-2.50051-8 PG 11 WC Oncology; Clinical Neurology; Neuroimaging SC Oncology; Neurosciences & Neurology GA BFF67 UT WOS:000319669900050 ER PT B AU Kogan, AN von Andrian, UH AF Kogan, Avi N. von Andrian, Ulrich H. BE Tuma, RF Duran, WN Ley, K TI Lymphocyte Trafficking SO HANDBOOK OF PHYSIOLOGY: MICROCIRCULATION, 2ND EDITION LA English DT Article; Book Chapter ID HIGH ENDOTHELIAL VENULES; CELL-ADHESION MOLECULE-1; THYMUS-EXPRESSED CHEMOKINE; HOMING T-CELLS; HEMATOPOIETIC STEM-CELLS; EPIDERMAL LANGERHANS CELLS; ANTIBODY-SECRETING CELLS; NONOBESE DIABETIC MICE; OMENTAL MILKY SPOTS; SPLENIC WHITE PULP C1 [Kogan, Avi N.; von Andrian, Ulrich H.] Immune Dis Inst, Boston, MA 02115 USA. [von Andrian, Ulrich H.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Kogan, AN (reprint author), Immune Dis Inst, Boston, MA 02115 USA. NR 334 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-056993-2; 978-0-12-374530-9 PY 2008 BP 449 EP 482 PG 34 WC Cardiac & Cardiovascular Systems; Physiology SC Cardiovascular System & Cardiology; Physiology GA BJP64 UT WOS:000329517700012 ER PT J AU Nykiel, SA Baldessarini, RJ Bower, MC Goodwin, J Salvatore, P AF Nykiel, Sherry A. Baldessarini, Ross J. Bower, Montgomery C. Goodwin, Jean Salvatore, Paola TI Psychosis NOS: Search for diagnostic clarity SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article ID ATAQUE-DE-NERVIOS; EPILEPSY; SYMPTOMS C1 [Nykiel, Sherry A.; Baldessarini, Ross J.; Bower, Montgomery C.; Salvatore, Paola] McLean Hosp, OPC, Belmont, MA 02478 USA. [Nykiel, Sherry A.; Baldessarini, Ross J.; Bower, Montgomery C.; Salvatore, Paola] Harvard Univ, Sch Med, Belmont, MA 02178 USA. [Nykiel, Sherry A.; Baldessarini, Ross J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Goodwin, Jean] Univ Texas Med Branch, Galveston, TX USA. [Goodwin, Jean] Houston Galveston Psychoanalyt Inst, Galveston, TX USA. RP Nykiel, SA (reprint author), McLean Hosp, OPC, 115 Mill St, Belmont, MA 02478 USA. EM snykiel@partners.org NR 37 TC 0 Z9 0 U1 1 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PY 2008 VL 16 IS 1 BP 55 EP 65 DI 10.1080/10673220801924274 PG 11 WC Psychiatry SC Psychiatry GA 269JB UT WOS:000253644200005 PM 18306099 ER PT J AU Hamoda, HM Osser, DN AF Hamoda, Hesham M. Osser, David N. TI The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on psychotic depression SO HARVARD REVIEW OF PSYCHIATRY LA English DT Review DE affective disorders; psychopharmacology; psychotic; psychotic depression ID SEROTONIN REUPTAKE INHIBITORS; NONPSYCHOTIC MAJOR DEPRESSION; RANDOMIZED CONTROLLED-TRIAL; TARDIVE-DYSKINESIA RATES; DELUSIONAL DEPRESSION; DOUBLE-BLIND; ELECTROCONVULSIVE-THERAPY; PHARMACOLOGICAL-TREATMENT; LITHIUM AUGMENTATION; UNIPOLAR DEPRESSION AB This new version of the psychotic depression algorithm has been developed by the Psychopharmacology Algorithm Project at the Harvard South Shore Program. The most effective treatment modality for inpatients with severe psychotic depression is electroconvulsive therapy. The first-line psychopharmacological treatment is a combination of an antidepressant (either a tricyclic or a selective serotonin reuptake inhibitor) and an antipsychotic. If one of these combinations has failed, consider switching to the other. If both combinations have failed, the next psychopharmacological option would be to augment the combination with lithium. Another option, though with limited evidence, is monotherapy with clozapine. If there is a good reason to avoid combination therapy with an antipsychotic, then a trial of monotherapy with a TCA or an SSRI can be supported. If that fails, adding an antipsychotic or ECT should be considered. C1 [Osser, David N.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA 02301 USA. Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. RP Osser, DN (reprint author), VA Boston Healthcare Syst, Brockton Div, 940 Belmont St, Brockton, MA 02301 USA. EM David.Osser@va.gov NR 100 TC 12 Z9 12 U1 5 U2 5 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PY 2008 VL 16 IS 4 BP 235 EP 247 DI 10.1080/10673220802277904 PG 13 WC Psychiatry SC Psychiatry GA 331GP UT WOS:000258001000003 PM 18661366 ER PT J AU La Flair, LN Franko, DL Herzog, DB AF La Flair, Lareina N. Franko, Debra L. Herzog, David B. TI Sexual assault and disordered eating in Asian women SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE Asian; cross-cultural psychiatry; eating disorders; sexual assault ID ANOREXIA-NERVOSA; HONG-KONG; BULIMIC PSYCHOPATHOLOGY; MEDIATING ROLE; ABUSE; CHILDHOOD; CULTURE; CHINESE; ETHNICITY; SYMPTOMS AB The link between sexual assault and disordered eating has yet to be clarified, especially for ethnic minority populations. Asian women, in particular, report low rates of both sexual assault and eating disorders compared to their Western counterparts, and studies suggest that these rates may be conservative. The literature indicates that there are cultural attitudes that contribute to non- and underreporting of sexual assault by Asian women and that these sociocultural factors may have an important role in the development of eating disorders as a response to sexual victimization. Research illustrates a relationship between sexual assault and eating disorders; eating disorders may serve as coping mechanisms for survivors of sexual assault by providing a mechanism for comfort, numbing, and distracting in an effort to rid the painful feelings in response to the assault. To stimulate future research, this article reviews the current literature on the development of eating disorders following a sexual assault and on the sociocultural factors linking both phenomena in Asian women, and offers avenues for investigation to increase our understanding of these relationships. C1 [La Flair, Lareina N.; Herzog, David B.] Massachusetts Gen Hosp, Harris Ctr Educ & Advocacy Eating Disorders, Dept Psychiat, Boston, MA 02114 USA. [La Flair, Lareina N.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21218 USA. [Franko, Debra L.] Northeastern Univ, Dept Counseling & Appl Educ Psychol, Boston, MA 02115 USA. [Herzog, David B.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP La Flair, LN (reprint author), Massachusetts Gen Hosp, Harris Ctr Educ & Advocacy Eating Disorders, Dept Psychiat, 2 Longfellow Pl,Suite 200, Boston, MA 02114 USA. EM llaflair@jhsph.edu NR 73 TC 4 Z9 4 U1 2 U2 7 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PY 2008 VL 16 IS 4 BP 248 EP 257 DI 10.1080/10673220802277896 PG 10 WC Psychiatry SC Psychiatry GA 331GP UT WOS:000258001000004 PM 18661367 ER PT J AU Trinh, NH Moore, D Brendel, DH AF Trinh, Nhi-Ha Moore, Derek Brendel, David H. TI Ethics Consultation to PACT Teams: Balancing Client Autonomy and Clinical Necessity SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE assertive community treatment; autonomy; beneficence; boundary crossings; ethics; informed consent; PACT; psychiatric advance directive ID PSYCHIATRIC ADVANCE DIRECTIVES; MENTAL-HOSPITAL TREATMENT AB The Program for Assertive Community Treatment (PACT) is a community-based treatment program for people with severe and persistent mental illness, who have been underserved by traditional levels of care and are thought to be at high risk for rehospitalization. Within this model can be found a number of nontraditional treatment practices, some of which challenge the balance between client autonomy and paternalism, and can lead to clinical impasses. In this article we present three clinical cases (with discussions) to illustrate the most common ethical dilemmas that our PACT team has faced in assisting clients with their finances, legal terms of probation, and personal safety. We describe our use of professional ethics consultation to help us manage these dilemmas, enhance client informed consent, and promote collaborative care within the PACT model. Such ethics consultation may be useful to other PACT teams struggling to resolve clinical and ethical dilemmas by respecting both the autonomy and best interests of their clients. (HARV REV PSYCHIATRY 2008;16:365-372.) C1 [Trinh, Nhi-Ha; Brendel, David H.] Harvard Univ, Sch Med, Boston, MA USA. [Trinh, Nhi-Ha] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Moore, Derek] N Suffolk Mental Hlth Ctr, Somerville, MA USA. [Brendel, David H.] McLean Hosp, Belmont, MA 02178 USA. RP Trinh, NH (reprint author), 50 Staniford St,Suite 401, Boston, MA 02114 USA. EM ntrinh@partners.org NR 16 TC 3 Z9 3 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PY 2008 VL 16 IS 6 BP 365 EP 372 DI 10.1080/10673220802564160 PG 8 WC Psychiatry SC Psychiatry GA 391YT UT WOS:000262270800005 PM 19085390 ER PT J AU Iezzoni, LI AF Iezzoni, Lisa I. TI Blocked SO HEALTH AFFAIRS LA English DT Editorial Material C1 Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA. [Iezzoni, Lisa I.] Harvard Univ, Sch Med, Boston, MA USA. RP Iezzoni, LI (reprint author), Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA. EM liezzoni@partners.org FU NCI NIH HHS [R21 CA122130] NR 0 TC 6 Z9 6 U1 0 U2 0 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN-FEB PY 2008 VL 27 IS 1 BP 203 EP 209 DI 10.1377/hlthaff.27.1.203 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 319TZ UT WOS:000257188400024 PM 18180496 ER PT J AU Saha, S Shipman, SA AF Saha, Somnath Shipman, Scott A. TI Race-neutral versus race-conscious workforce policy to improve access to care SO HEALTH AFFAIRS LA English DT Article ID MEDICAL-SCHOOLS; UNDERSERVED POPULATIONS; HEALTH-CARE; GENERALIST PHYSICIANS; AFFIRMATIVE-ACTION; MINORITY; QUALITY AB Access to care for racial and ethnic minority groups, low-income populations, and the un- and underinsured has been problematic despite expansion in the health workforce. Workforce policies that improve access to care are needed, as is funding to support them. Reviewing evidence related to providers' patterns of service to the underserved, this paper concludes that underrepresented minority health professionals have consistently been more likely than those from low socioeconomic backgrounds or the National Health Service Corps to deliver health care to the underserved. These findings have implications for policies and programs that might leverage the workforce to better meet the needs of disadvantaged patients. C1 [Saha, Somnath] Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR USA. [Shipman, Scott A.] Dartmouth Med Sch, Inst Hlth Policy & Clin Practice, Lebanon, NH USA. RP Saha, S (reprint author), Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR USA. EM sahas@ohsu.edu FU PHS HHS [03-BHPR-104] NR 25 TC 35 Z9 35 U1 1 U2 3 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN-FEB PY 2008 VL 27 IS 1 BP 234 EP 245 DI 10.1377/hlthaff.27.1.234 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 319TZ UT WOS:000257188400028 PM 18180500 ER PT J AU Culliton, BJ Roberts, T AF Culliton, Barbara J. Roberts, Thomas TI Promoting medical innovation while developing sound social and business policy: A conversation with Thomas G. Roberts SO HEALTH AFFAIRS LA English DT Editorial Material AB The development of "targeted biologics" as cancer therapy has made the field ripe for investment from the private sector and is changing the face of cancer medicine, while also raising important policy concerns about price, profit, and continued innovation. In this interview Barbara Culliton talks with Thomas Roberts, who sees this world from a unique perspective. Roberts, an oncologist, has practiced at the Massachusetts General Hospital and is currently thinking about innovation as a hedge fund manager. C1 [Roberts, Thomas] Noonday Global Management, Charlotte, NC USA. [Roberts, Thomas] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Roberts, Thomas] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. EM bculliton@projecthope.org; Troberts@noonday.com NR 0 TC 1 Z9 1 U1 2 U2 3 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN-FEB PY 2008 VL 27 IS 1 BP W34 EP W40 DI 10.1377/hlthaff.27.1.w34 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 319TZ UT WOS:000257188400052 ER PT J AU Sayers, SL Riegel, B Goldberg, LR Coyne, JC Samaha, FF AF Sayers, Steven L. Riegel, Barbara Goldberg, Lee R. Coyne, James C. Samaha, Frederick F. TI Clinical exacerbations as a surrogate end point in heart failure research SO HEART & LUNG LA English DT Article ID LEFT-VENTRICULAR DYSFUNCTION; ASSOCIATION; MORTALITY; SURVIVAL; HEALTH; BLACK; RACE AB BACKGROUND: We examined the utility of an index of clinical exacerbations of heart failure (HF) as a surrogate measure of outcome for use in modestly sized clinical trials and observational studies. METHODS: Electronic records of 189 outpatients with HF in a US Veterans Affairs Medical Center were examined over a 2- to 3-year period. Data collected included patient characteristics, clinical exacerbations of HF, hospitalizations, and deaths. Subsets of patient were also assessed for HF-related level of functioning. RESULTS: Episodes of clinical exacerbation could be detected reliably (kappa = .83). An index of episodes (number of episodes divided by the time in years) was associated with lower quality of life, higher functional class, increased rate of HF hospitalization, poorer exercise tolerance, and up to 30% increased risk of mortality across 2 years. CONCLUSIONS: The index of HF exacerbations is potentially a useful surrogate end point for use in clinical HF research. C1 [Sayers, Steven L.; Samaha, Frederick F.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Sayers, Steven L.; Coyne, James C.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Riegel, Barbara] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Goldberg, Lee R.; Samaha, Frederick F.] Univ Penn, Dept Internal Med, Div Cardiol, Philadelphia, PA 19104 USA. RP Sayers, SL (reprint author), Philadelphia Vet Affairs Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA. OI Goldberg, Lee/0000-0002-7906-9638 NR 25 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0147-9563 J9 HEART LUNG JI Heart Lung PD JAN-FEB PY 2008 VL 37 IS 1 BP 28 EP 35 DI 10.1016/j.hrtlng.2007.02.002 PG 8 WC Cardiac & Cardiovascular Systems; Nursing; Respiratory System SC Cardiovascular System & Cardiology; Nursing; Respiratory System GA 254TC UT WOS:000252609900004 PM 18206524 ER PT J AU Effinor, PT Nam, EG Shea, MA Milan, DJ Ruskin, JN MacRae, CA AF Effinor, Patrick T. Nam, Edwin G. Shea, Marisa A. Milan, David J. Ruskin, Jeremy N. MacRae, Caturn A. TI Cardiac sodium channel mutation in atrial fibrillation SO HEART RHYTHM LA English DT Article DE atrial fibrillation; arrhythmia; mutation; gene; sodium channel; SCN5a ID OF-FUNCTION MUTATION; LONG QT SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISMS; SICK SINUS SYNDROME; BRUGADA-SYNDROME; CONDUCTION DISEASE; SCN5A MUTATIONS; GENETIC-LOCUS; HEART-FAILURE; RISK-FACTOR AB BACKGROUND Mutations in the sodium channel SCN5A have been implicated in many cardiac disorders, including the tong QT syndrome, Brugada syndrome, conduction system disease, and dilated cardiomyopathy with atrial arrhythmias. OBJECTIVE In view of the pleiotropic effects of SCN5A mutations, the purpose of this study was to examine a cohort of patients with familial atrial fibrillation (AF) for mutations in the SCN5A gene. METHODS Probands with AF were enrolled in the study between June 1, 2001 and February 10, 2004. Each patient underwent a standardized evaluation, which included an interview, physical examination, ECG, echocardiogram, and blood sample for genetic analysis. Direct sequencing of the coding region of SCN5A was used to screen for mutations in genomic DNA. RESULTS One hundred eighty-nine patients with AF were enrolled during the study period. From this cohort, a subset of 57 probands with a family history of AF in at least one first-degree relative was studied. Forty-seven subjects were men (82%); 45 had paroxysmal AF (79%). Echocardiography revealed ejection fraction 62% +/- 6.4% and left atrial dimension 40 +/- 6.9 mm. A single mutation (N1986K) was observed in one family but was not present in more than 600 control chromosomes. Expression of the N1986K mutant in Xenopus oocytes revealed a hyperpolarizing shift in channel steady-state inactivation. CONCLUSION In a cohort with familial AF, a single SCN5A mutation causing the arrhythmia in one kindred was identified. These data extend the range of phenotypes observed with SCN5A mutations and suggest that variation in the SCN5A gene is not a major cause of familial AF. C1 [Effinor, Patrick T.; Nam, Edwin G.; Shea, Marisa A.; Milan, David J.; Ruskin, Jeremy N.; MacRae, Caturn A.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Effinor, Patrick T.; Nam, Edwin G.; Shea, Marisa A.; Milan, David J.; Ruskin, Jeremy N.; MacRae, Caturn A.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. RP Effinor, PT (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, 55 Fruit St,GRB 109, Boston, MA 02114 USA. EM pellinor@partners.org NR 47 TC 0 Z9 0 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1547-5271 J9 HEART RHYTHM JI Heart Rhythm PD JAN PY 2008 VL 5 IS 1 BP 99 EP 105 DI 10.1016/j.hrthm.2007.09.015 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 251NH UT WOS:000252379800018 ER PT B AU Naeim, F AF Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Structure and Function of Hematopoietic Tissues SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID MESENCHYMAL STEM-CELLS; SPLENIC MARGINAL ZONE; PERIPHERAL-BLOOD FILM; BONE-MARROW; T-CELL; PROGENITOR CELLS; DENDRITIC CELLS; MAST-CELLS; ERYTHROID-CELLS; FLOW-CYTOMETRY C1 [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 129 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 1 EP 26 PG 26 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800002 ER PT B AU Naeim, F Rao, PN Grody, WW AF Naeim, Faramarz Rao, P. Nagesh Grody, Wayne W. BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Hematopathology Morphology, Immunophenotype, Cytogenetics and Molecular Approaches Preface SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Editorial Material; Book Chapter C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP IX EP IX PG 1 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800001 ER PT B AU Naeim, F AF Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Principles of Immunophenotyping SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID ACUTE LYMPHOBLASTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; G-CSF-RECEPTOR; TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; NATURAL CYTOTOXICITY RECEPTORS; MULTIPARAMETER FLOW-CYTOMETRY; SURFACE ANTIGEN-EXPRESSION C1 [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 197 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5; 978-0-12-370607-2 PY 2008 BP 27 EP 55 DI 10.1016/B978-0-12-370607-2.00002-8 PG 29 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800003 ER PT B AU Grody, WW Rao, PN Naeim, F AF Grody, Wayne W. Rao, P. Nagesh Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Principles of Molecular Techniques SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID DNA-POLYMERASE; ARRAY CGH; AMPLIFICATION; CYTOGENETICS; MICROARRAYS; SEQUENCES; LEUKEMIA; FUSION C1 [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. [Rao, P. Nagesh; Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Grody, WW (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. NR 23 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5; 978-0-12-370607-2 PY 2008 BP 65 EP 79 DI 10.1016/B978-0-12-370607-2.00004-1 PG 15 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800005 ER PT B AU Naeim, F AF Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Morphology of Abnormal Bone Marrow SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID OF-THE-LITERATURE; SICKLE-CELL-DISEASE; GELATINOUS TRANSFORMATION; MULTIPLE-MYELOMA; AMYLOID DEPOSITS; BETA-FIBRILLOSES; AL AMYLOIDOSIS; BREAST-CANCER; STEM-CELLS; Q-FEVER C1 [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 73 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5; 978-0-12-370607-2 PY 2008 BP 81 EP 99 DI 10.1016/B978-0-12-370607-2.00005-3 PG 19 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800006 ER PT J AU Naeim, F AF Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Reactive Lymphadenopathies SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID ROSAI-DORFMAN DISEASE; CAT-SCRATCH DISEASE; LANGERHANS-CELL HISTIOCYTOSIS; LYMPH-NODE HYPERPLASIA; SINUS HISTIOCYTOSIS; MASSIVE LYMPHADENOPATHY; CASTLEMANS-DISEASE; HEMOPHAGOCYTIC SYNDROME; DERMATOPATHIC LYMPHADENOPATHY; TOXOPLASMIC LYMPHADENITIS C1 [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 61 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 101 EP 113 DI 10.1016/B978-0-12-370607-2.00006-5 PG 13 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800007 ER PT J AU Naeim, F Rao, PN Grody, WW AF Naeim, Faramarz Rao, P. Nagesh Grody, Wayne W. BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Bone Marrow Aplasia SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; SHWACHMAN-DIAMOND-SYNDROME; GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA; FANCONI-ANEMIA; DYSKERATOSIS-CONGENITA; FLOW-CYTOMETRY; CYTOGENETIC ABNORMALITIES; ANTITHYMOCYTE GLOBULIN; FAILURE SYNDROMES C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 115 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 115 EP 127 DI 10.1016/B978-0-12-370607-2.00007-7 PG 13 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800008 ER PT B AU Naeim, F Rao, PN Grody, WW AF Naeim, Faramarz Rao, P. Nagesh Grody, Wayne W. BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Myelodysplastic Syndromes SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID ACUTE MYELOID-LEUKEMIA; IN-SITU HYBRIDIZATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; INTERNATIONAL WORKING GROUP; BONE-MARROW; CLINICAL CHARACTERISTICS; RESPONSE CRITERIA; SCORING SYSTEM; FLOW-CYTOMETRY; SYNDROME MDS C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 97 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 129 EP 154 DI 10.1016/B978-0-12-370607-2.00008-9 PG 26 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800009 ER PT J AU Naeim, F Rao, PN Grody, WW AF Naeim, Faramarz Rao, P. Nagesh Grody, Wayne W. BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Chronic Myeloproliferative Diseases SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID CHRONIC NEUTROPHILIC LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; IDIOPATHIC-HYPEREOSINOPHILIC-SYNDROME; CHRONIC EOSINOPHILIC LEUKEMIA; IN-SITU HYBRIDIZATION; BONE-MARROW HISTOPATHOLOGY; TYROSINE KINASE MUTATION; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 135 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 155 EP 189 DI 10.1016/B978-0-12-370607-2.00009-0 PG 35 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800010 ER PT B AU Naeim, F Rao, PN AF Naeim, Faramarz Rao, P. Nagesh BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Myelodysplastic/Myeloproliferative Diseases SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID CHRONIC MYELOMONOCYTIC LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; PEDIATRIC MYELODYSPLASTIC SYNDROMES; CHRONIC MYELOGENOUS LEUKEMIA; MARROW MONOCYTIC NODULES; RETROSPECTIVE ANALYSIS; MYELOPROLIFERATIVE DISEASES; PTPN11 MUTATIONS; RECEPTOR-BETA; RAS C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 71 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 191 EP 205 DI 10.1016/B978-0-12-370607-2.00010-7 PG 15 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800011 ER PT J AU Naeim, F Rao, PN AF Naeim, Faramarz Rao, P. Nagesh BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Acute Myeloid Leukemia SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MEGAKARYOBLASTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; ACUTE BASOPHILIC LEUKEMIA; ACUTE MYELOBLASTIC-LEUKEMIA; OF-THE-LITERATURE; THERAPY-RELATED MYELODYSPLASIA; COOPERATIVE-ONCOLOGY-GROUP C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 260 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 207 EP 255 DI 10.1016/B978-0-12-370607-2.00011-9 PG 49 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800012 ER PT J AU Naeim, F Rao, PN Grody, WW AF Naeim, Faramarz Rao, P. Nagesh Grody, Wayne W. BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI The Neoplasms of Precursor Lymphoblasts SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID ACUTE LYMPHOCYTIC-LEUKEMIA; MINIMAL-RESIDUAL-DISEASE; POLYMERASE-CHAIN-REACTION; CHILDRENS CANCER GROUP; OF-THE-LITERATURE; CLINICAL-SIGNIFICANCE; GENE REARRANGEMENTS; MOLECULAR-GENETICS; FUSION GENE; PHILADELPHIA-CHROMOSOME C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 92 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 257 EP 277 DI 10.1016/B978-0-12-370607-2.00012-0 PG 21 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800013 ER PT B AU Naeim, F AF Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Acute Leukemias of Ambiguous Lineage SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID ACUTE LYMPHOBLASTIC-LEUKEMIA; BIPHENOTYPIC ACUTE-LEUKEMIA; ACUTE MYELOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ABERRANT EXPRESSION; SWITCH; T(4/11); CD79A; GENE; DIFFERENTIATION C1 [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 39 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 279 EP 286 DI 10.1016/B978-0-12-370607-2.00013-2 PG 8 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800014 ER PT B AU Naeim, F Rao, PN Grody, WW AF Naeim, Faramarz Rao, P. Nagesh Grody, Wayne W. BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Lymphoid Malignancies of Non-precursor Cells: General Considerations SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID NON-HODGKIN-LYMPHOMA; MOLECULAR PATHOGENESIS; HELICOBACTER-PYLORI; EPIDEMIOLOGY; P53; CLASSIFICATION; CYTOGENETICS; INFECTION; PATHWAYS; BIOLOGY C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 42 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 287 EP 296 DI 10.1016/B978-0-12-370607-2.00014-4 PG 10 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800015 ER PT J AU Naeim, F Rao, PN Grody, WW AF Naeim, Faramarz Rao, P. Nagesh Grody, Wayne W. BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Mature B-Cell Neoplasms SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID CHRONIC LYMPHOCYTIC-LEUKEMIA; MARGINAL-ZONE LYMPHOMA; MINIMAL RESIDUAL DISEASE; PRIMARY EFFUSION LYMPHOMA; POLYMERASE-CHAIN-REACTION; IN-SITU HYBRIDIZATION; C VIRUS-INFECTION; LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIA; CHRONIC LYMPHOPROLIFERATIVE DISORDERS; IMMUNOGLOBULIN GENE REARRANGEMENTS C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 331 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 297 EP 372 DI 10.1016/B978-0-12-370607-2.00015-6 PG 76 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800016 ER PT J AU Naeim, F Rao, PN Grody, WW AF Naeim, Faramarz Rao, P. Nagesh Grody, Wayne W. BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Plasma Cell Myeloma and Related Disorders SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID FAMILIAL MEDITERRANEAN FEVER; HEAVY-CHAIN DISEASE; OF-THE-LITERATURE; NONSECRETORY MULTIPLE-MYELOMA; SMALL-INTESTINAL DISEASE; IN-SITU HYBRIDIZATION; MONOCLONAL GAMMOPATHY; UNDETERMINED SIGNIFICANCE; EXTRAMEDULLARY PLASMACYTOMA; GENETIC EVENTS C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 100 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 373 EP 396 DI 10.1016/B978-0-12-370607-2.00016-8 PG 24 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800017 ER PT J AU Naeim, F Rao, PN Song, S Grody, WW AF Naeim, Faramarz Rao, P. Nagesh Song, Sophie Grody, Wayne W. BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Mature T-Cell and NK-Cell Neoplasms SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID GRANULAR LYMPHOCYTE LEUKEMIA; NON-HODGKINS-LYMPHOMA; EPSTEIN-BARR-VIRUS; OF-THE-LITERATURE; POLYMERASE-CHAIN-REACTION; IN-SITU HYBRIDIZATION; NATURAL-KILLER NK; MYCOSIS FUNGOIDES/SEZARY-SYNDROME; HTLV ENVELOPE SEROREACTIVITY; PRIMARY CUTANEOUS LYMPHOMAS C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Song, Sophie] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, UCLA Med Ctr, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 222 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 397 EP 440 DI 10.1016/B978-0-12-370607-2.00017-X PG 44 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800018 ER PT J AU Song, S Grody, WW Naeim, F AF Song, Sophie Grody, Wayne W. Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Hodgkin Lymphoma SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID REED-STERNBERG CELLS; EPSTEIN-BARR-VIRUS; CENTER B-CELLS; IMMUNOGLOBULIN GENE REARRANGEMENTS; CHILDHOOD SOCIAL-ENVIRONMENT; POLYMERASE-CHAIN-REACTION; EUROPEAN TASK-FORCE; NF-KAPPA-B; INFECTIOUS-MONONUCLEOSIS; DIFFERENTIAL-DIAGNOSIS C1 [Song, Sophie] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, UCLA Med Ctr, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Song, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, UCLA Med Ctr, Los Angeles, CA 90095 USA. NR 106 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 441 EP 454 DI 10.1016/B978-0-12-370607-2.00018-1 PG 14 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800019 ER PT J AU Naeim, F Rao, PN Grody, WW AF Naeim, Faramarz Rao, P. Nagesh Grody, Wayne W. BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Non-neoplastic and Borderline Lymphocytic Disorders SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID EPSTEIN-BARR-VIRUS; WISKOTT-ALDRICH-SYNDROME; LINKED LYMPHOPROLIFERATIVE-DISEASE; B-CELL LYMPHOCYTOSIS; SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW-TRANSPLANTATION; UNEXPLAINED OPPORTUNISTIC INFECTIONS; CD4+ T-LYMPHOCYTOPENIA; NON-HODGKIN-LYMPHOMA; MALIGNANT-LYMPHOMA C1 [Naeim, Faramarz; Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Rao, P. Nagesh] Univ Calif Los Angeles, David Geffen Sch Med, Clin & Mol Cytogenet Labs, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Grody, Wayne W.] Univ Calif Los Angeles, David Geffen Sch Med, Mol Pathol Labs, Los Angeles, CA 90095 USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 183 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 455 EP 476 DI 10.1016/B978-0-12-370607-2.00019-3 PG 22 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800020 ER PT B AU Naeim, F AF Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Mastocytosis SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID CELL PROLIFERATIVE DISORDERS; KIT MUTATION D816V; OF-THE-ART; MAST-CELL; SYSTEMIC MASTOCYTOSIS; C-KIT; PEDIATRIC MASTOCYTOSIS; CUTANEOUS MASTOCYTOSIS; SOLITARY MASTOCYTOMA; PERIPHERAL-BLOOD C1 [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 47 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 477 EP 488 DI 10.1016/B978-0-12-370607-2.00020-X PG 12 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800021 ER PT B AU Naeim, F AF Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Histiocytic and Dendritic Cell Disorders SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID NIEMANN-PICK-DISEASE; CHEDIAK-HIGASHI-SYNDROME; FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; EPSTEIN-BARR-VIRUS; OF-THE-LITERATURE; CD4(+)/CD56(+) HEMATODERMIC NEOPLASM; LYSOSOMAL STORAGE DISORDERS; GAUCHER-DISEASE; LANGERHANS CELLS; EOSINOPHILIC GRANULOMA C1 [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 153 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 489 EP 512 DI 10.1016/B978-0-12-370607-2.00021-1 PG 24 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800022 ER PT J AU Naeim, F AF Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Granulocytic Disorders SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID TRANSIENT MYELOPROLIFERATIVE DISORDER; HEREDITARY MYELOPEROXIDASE DEFICIENCY; CHRONIC IDIOPATHIC NEUTROPENIA; CHRONIC GRANULOMATOUS-DISEASE; SEVERE CONGENITAL NEUTROPENIA; CHEDIAK-HIGASHI-SYNDROME; ACUTE MYELOID-LEUKEMIA; PELGER-HUET; BONE-MARROW; DOWN-SYNDROME C1 [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 105 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5 PY 2008 BP 513 EP 527 DI 10.1016/B978-0-12-370607-2.00022-3 PG 15 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800023 ER PT B AU Naeim, F AF Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Disorder of Red Blood Cells: Anemias SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID CONGENITAL DYSERYTHROPOIETIC ANEMIA; DIAMOND-BLACKFAN ANEMIA; AUTOIMMUNE HEMOLYTIC-ANEMIA; PYRUVATE-KINASE DEFICIENCY; PREIMPLANTATION GENETIC DIAGNOSIS; TOTAL HOMOCYSTEINE CONCENTRATIONS; INTRINSIC-FACTOR DEFICIENCY; PARVOVIRUS B19 INFECTION; LONG-TERM OBSERVATION; CHRONIC-RENAL-FAILURE C1 [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Naeim, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 310 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5; 978-0-12-370607-2 PY 2008 BP 529 EP 565 DI 10.1016/B978-0-12-370607-2.00023-5 PG 37 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800024 ER PT B AU Howard, TE Naeim, F AF Howard, Tom E. Naeim, Faramarz BA Naeim, F Rao, PN Grody, WW BF Naeim, F Rao, PN Grody, WW TI Disorders of Megakaryocytes and Platelets SO HEMATOPATHOLOGY: MORPHOLOGY, IMMUNOPHENOTYPE, CYTOGENETICS AND MOLECULAR APPROACHES LA English DT Article; Book Chapter ID THROMBOTIC THROMBOCYTOPENIC PURPURA; HEMOLYTIC-UREMIC SYNDROME; WISKOTT-ALDRICH-SYNDROME; BERNARD-SOULIER-SYNDROME; CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA; INDUCED IMMUNE THROMBOCYTOPENIA; MEMBRANE GLYCOPROTEIN-IIIA; STORAGE POOL DEFICIENCY; IX-V COMPLEX; BONE-MARROW C1 [Howard, Tom E.] VA Greater Los Angeles Healthcare Syst, Hemostasis & Pharmacogenet Labs, Los Angeles, CA USA. [Howard, Tom E.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Naeim, Faramarz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Naeim, Faramarz] VA Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. RP Howard, TE (reprint author), VA Greater Los Angeles Healthcare Syst, Hemostasis & Pharmacogenet Labs, Los Angeles, CA USA. NR 165 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091948-5; 978-0-12-370607-2 PY 2008 BP 567 EP 582 DI 10.1016/B978-0-12-370607-2.00024-7 PG 16 WC Hematology; Pathology SC Hematology; Pathology GA BER05 UT WOS:000317820800025 ER PT J AU Weisbord, SD Kimmel, PL AF Weisbord, Steven D. Kimmel, Paul L. TI Health-related quality of life in the era of erythropoietin SO HEMODIALYSIS INTERNATIONAL LA English DT Review DE depression; renal transplantation; dialysis; hematocrit; hemoglobin; mortality ID STAGE RENAL-DISEASE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; SICKNESS IMPACT PROFILE; CHRONIC KIDNEY-DISEASE; PATIENTS RECEIVING HEMODIALYSIS; RANDOMIZED CONTROLLED-TRIAL; EXERCISE CAPACITY; DIALYSIS PATIENTS; PSYCHOSOCIAL FACTORS; COGNITIVE FUNCTION AB Patients with end-stage renal disease treated with maintenance hemodialysis suffer substantial impairments in health-related quality of life (HRQOL). Despite widespread efforts, there are few interventions that improve the overall well-being and quality of life of this patient population. The current review provides a description of HRQOL as an essential, yet arguably overlooked health-related domain in hemodialysis patients, and discusses interventions that have been evaluated to improve the functional status and well-being of this population, with a particular focus on therapy with recombinant human erythropoietin. We review the controversy surrounding recombinant human erythropoietin as it relates to HRQOL, and describe the delicate balance faced by renal providers who seek to reduce hemodialysis patients' morbidity and mortality while simultaneously striving to improve patients' HRQOL. C1 [Kimmel, Paul L.] George Washington Univ, Med Ctr, Sch Med, Div Renal Dis & Hypertens, Washington, DC 20037 USA. [Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. RP Kimmel, PL (reprint author), George Washington Univ, Med Ctr, Sch Med, Div Renal Dis & Hypertens, 2150 Pennsylvania Ave NW, Washington, DC 20037 USA. EM pkimmel@mfa.gwu.edu NR 62 TC 20 Z9 21 U1 1 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1492-7535 J9 HEMODIAL INT JI Hemodial. Int. PD JAN PY 2008 VL 12 IS 1 BP 6 EP 15 DI 10.1111/j.1542-4758.2008.00233.x PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 306TU UT WOS:000256271500002 PM 18271834 ER PT J AU Zhai, YA Shen, XD Gao, F Zhao, A Freitas, MC Lassman, C Luster, AD Busuttil, RW Kupiec-Weglinski, JW AF Zhai, Yuan Shen, Xiu-Da Gao, Feng Zhao, Alice Freitas, Maria Cecilia Lassman, Charles Luster, Andrew D. Busuttil, Ronald W. Kupiec-Weglinski, Jerzy W. TI CXCL10 regulates liver innate immune response against ischemia and reperfusion injury SO HEPATOLOGY LA English DT Article ID HEPATIC ISCHEMIA/REPERFUSION INJURY; ACUTE ALLOGRAFT-REJECTION; T-CELL; IFN-GAMMA; INDUCIBLE PROTEIN-10; CARDIAC ALLOGRAFTS; INTERLEUKIN-10; MICE; LYMPHOCYTES; RECRUITMENT AB We have shown that activation of toll-like receptor 4 (TLR4) and its interferon regulatory factor 3 (IRF3)-dependent downstream signaling pathway are required for the development of liver ischemia/reperfusion injury (IRI). This study focused on the role of TLR4-IRF3 activation pathway products, in particular, chemokine (C-X-C moo ligand 10 (CXCL10). The induction of CXCL10 by liver IR was rapid (I hour postreperfusion), restricted (ischemic lobes), and specific (no CXCL9 and CXCL11 induction). Functionally, CXCL10 was critical for IR-induced liver inflammation and hepatocellular injury. CXCL10 knockout (KO) mice were protected from IRI, as evidenced by reduced serum alanine aminotransferase (sALT) levels and preserved liver histological detail. The induction of pro-inflammatory genes, such as tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1 beta), IL-6, and IL-12 beta was diminished, whereas the induction of the IL-10 gene remained intact in CXCL10 KO mice, indicating an altered liver response against IR. This was accompanied by selective down-regulation of extracellular signal-regulated kinase (ERK), but intact Jun N-terminal kinase (JNK), activation in the KO IR livers. This altered liver inflammation response was (1) specific to IR, because lipopolysaccharide (LPS) induced a comparable pro-inflammatory response in CXCL10 KO and wild-type (WT) mice; and (2) responsible for liver cytoprotection from IR, because neutralization of IL-10 restored local inflammation and hepatocellular damage. Conclusion: CXCL10 regulates liver inflammation response against IRI and its deficiency protected livers from IRI by local IL-10-mediated cytoprotection. Targeting CXCL10 may provide a novel therapeutic means to ameliorate liver IRI in clinics. C1 [Zhai, Yuan; Shen, Xiu-Da; Gao, Feng; Zhao, Alice; Freitas, Maria Cecilia; Busuttil, Ronald W.; Kupiec-Weglinski, Jerzy W.] Dumont Univ Calif Los Angeles, Transplant Ctr, Dept Surg, Div Liver & Pancreas Transplantat, Los Angeles, CA 90095 USA. [Lassman, Charles; Kupiec-Weglinski, Jerzy W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA USA. [Luster, Andrew D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA USA. RP Kupiec-Weglinski, JW (reprint author), Dumont Univ Calif Los Angeles, Transplant Ctr, Dept Surg, Div Liver & Pancreas Transplantat, 77-120 CHS,10833 Conte Ave, Los Angeles, CA 90095 USA. EM JKUPIEC@MEDNET.UCLA.EDU FU NIAID NIH HHS [AI42223, R01 AI023847, R01 AI042223, AI23847]; NIDDK NIH HHS [R01 DK062357] NR 40 TC 71 Z9 80 U1 0 U2 8 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD JAN PY 2008 VL 47 IS 1 BP 207 EP 214 DI 10.1002/hep.21986 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 248HJ UT WOS:000252143200028 PM 18041715 ER PT S AU Geng, Y Lee, YM Welcker, M Swanger, J Zagozdzon, A Roberts, JM Kaldis, P Clurman, BE Sicinski, P AF Geng, Yan Lee, Youngmi Welcker, Markus Swanger, Jherek Zagozdzon, Agnieszka Roberts, James M. Kaldis, Philipp Clurman, Bruce E. Sicinski, Piotr BE Melmed, S Rochefort, H Chanson, P Christen, Y TI A novel function for cyclin E in cell cycle progression SO HORMONAL CONTROL OF CELL CYCLE SE Research and Perspectives in Endocrine Interactions LA English DT Proceedings Paper CT International Workshop on Hormonal Control of Cell Cycle CY DEC 04, 2006 CL Paris, FRANCE ID DNA-REPLICATION; CDK2; ACTIVATION; CHROMATIN; ROLES; CDC6; COMPLEXES; E-CDK2; MICE AB In this study we demonstrated the presence of a kinase-independent function for cyclin E. Specifically, we observed that a kinase-deficient cyclin E1 mutant can reconstitute cyclin E's function in cyclin E-null cells. Kinase-deficient cyclin E1 is loaded onto chromatin during G(0) -> S progression, it restores MCM incorporation and it facilitates S phase entry of cyclin E-null cells. We also observed that, in wild-type cells, cyclin E is loaded onto DNA during the G(0) -> S transition, and it co-localizes with MCM on chromatin. We demonstrated a physical interaction between cyclin E and MCM. We propose that the DNA-bound fraction of cyclin E facilitates MCM loading in a kinase-independent fashion. Our work indicates that, in addition to their well-established function as activators of cyclin-dependent kinases, E-cyclins play a kinase-independent function in cell cycle progression. C1 [Geng, Yan; Lee, Youngmi; Zagozdzon, Agnieszka; Sicinski, Piotr] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Roberts, James M.] Howard Hughes Med Inst, Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA. [Geng, Yan; Lee, Youngmi; Zagozdzon, Agnieszka; Sicinski, Piotr] Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA. [Welcker, Markus; Swanger, Jherek; Clurman, Bruce E.] Div Clin Res, Boston, MA 02115 USA. [Welcker, Markus; Swanger, Jherek; Clurman, Bruce E.] Div Human Biol, Boston, MA 02115 USA. [Kaldis, Philipp] NCI, Mouse Canc Genet Program, Frederick, MD 21702 USA. RP Geng, Y (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. EM peter_sicinski@dfci.harvard.edu RI Kaldis, Philipp/G-2714-2010 OI Kaldis, Philipp/0000-0002-7247-7591 NR 20 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 1861-2253 BN 978-3-540-73854-1 J9 RES PERSPECT END INT JI Res. Perspect. End. Int. PY 2008 BP 31 EP + DI 10.1007/978-3-540-73855-8_4 PG 2 WC Oncology; Cell Biology; Endocrinology & Metabolism SC Oncology; Cell Biology; Endocrinology & Metabolism GA BGY28 UT WOS:000251315500004 ER PT J AU Turan, S Bereket, A Guran, T Akcay, T Aydin, C Bastepe, M Juppner, H AF Turan, Serap Bereket, Abdullah Guran, Tulay Akcay, Teoman Aydin, Cumhur Bastepe, Murat Juppner, Harald TI Hypophosphatemic rickets: New and important roles for bone mineralization and phosphate homeostasis of Dentin matrix protein-1 SO HORMONE RESEARCH LA English DT Meeting Abstract C1 [Turan, Serap; Juppner, Harald] Marmara Univ, Massachusetts Gen Hosp, Endocrine Unit, Istanbul, Boston, Turkey. [Aydin, Cumhur] Gulhane Mil Med Acad, Ankara, Turkey. [Bastepe, Murat] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2008 VL 70 BP 14 EP 14 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 356NT UT WOS:000259785600043 ER PT J AU Jimenez-Chillaron, J Pentinat-Pelegrin, T Isganaitis, E Otis, J Faucette, R Gasa, R Diaz, R Patti, ME AF Jimenez-Chillaron, Josep Pentinat-Pelegrin, Thais Isganaitis, Elvira Otis, Jessica Faucette, Ryan Gasa, Rosa Diaz, Ruben Patti, Mary-Elizabeth TI Intergenerational programming of glucose intolerance by in utero undernutrition: Non-genomic dysregulation of beta-cell function SO HORMONE RESEARCH LA English DT Meeting Abstract C1 [Jimenez-Chillaron, Josep; Pentinat-Pelegrin, Thais; Diaz, Ruben] Hosp San Juan Dios, Barcelona, Spain. [Isganaitis, Elvira; Otis, Jessica; Faucette, Ryan; Patti, Mary-Elizabeth] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. [Gasa, Rosa] IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2008 VL 70 BP 26 EP 26 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 356NT UT WOS:000259785600084 ER PT J AU Jacobson-Dickman, E Thambundit, A Plummer, L Sidis, Y Raivio, T Dwyer, A Cole, L Schwartz, D Crowley, WF Boepple, PA Pitteloud, N AF Jacobson-Dickman, Elka Thambundit, Apisadaporn Plummer, Lacey Sidis, Yisrael Raivio, Taneli Dwyer, Andrew Cole, Lindsay Schwartz, David Crowley, William F., Jr. Boepple, Paul A. Pitteloud, Nelly TI FGFR1: A genetic etiology for delayed puberty SO HORMONE RESEARCH LA English DT Meeting Abstract C1 [Jacobson-Dickman, Elka; Thambundit, Apisadaporn; Plummer, Lacey; Sidis, Yisrael; Raivio, Taneli; Dwyer, Andrew; Cole, Lindsay; Crowley, William F., Jr.; Boepple, Paul A.; Pitteloud, Nelly] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA. [Schwartz, David] Univ S Carolina, Sch Med, Columbia, SC USA. RI Dwyer, Andrew/D-8099-2012; PITTELOUD, Nelly/K-2709-2014 OI Dwyer, Andrew/0000-0002-7023-6794; NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2008 VL 70 BP 40 EP 40 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 356NT UT WOS:000259785600126 ER PT J AU Turan, S Bereket, A Aydin, C Akcay, T Guran, T Yaralioglu, BA Bastepe, M Juppner, H AF Turan, Serap Bereket, Abdullah Aydin, Cumhur Akcay, Teoman Gueran, Tuelay Yaralioglu, Betuel Akmen Bastepe, Murat Jueppner, Harald TI Identification of a novel dentin matrix protein-1 (DMP-1) mutation in a kindred with autosomal recessive hypophosphatemia and dental anomalies SO HORMONE RESEARCH LA English DT Meeting Abstract C1 [Turan, Serap; Bereket, Abdullah; Akcay, Teoman; Gueran, Tuelay] Marmara Univ, Istanbul, Turkey. [Aydin, Cumhur] Gulhane Mil Med Acad, Ankara, Turkey. [Yaralioglu, Betuel Akmen] Dentaura Dent Clin, Istanbul, Turkey. [Bastepe, Murat; Jueppner, Harald] Harvard Univ, Sch Med, Endocrine Unit, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2008 VL 70 BP 184 EP 185 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 356NT UT WOS:000259785600605 ER PT J AU Saidman, SL AF Saidman, Susan L. TI CONVERSION OF LUMINEX DATA TO MESF UNITS USING QUANTIPLEX BEADS DOES NOT RESULT IN MORE CONSISTENT QUANTITATION SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract CT 34th Annual Meeting of the American-Society-for-Histocompatibility-and-Immunogenetics CY OCT 27-31, 2008 CL Toronto, CANADA SP Amer Soc Histocompatibil & Immunogenet C1 [Saidman, Susan L.] Massachusetts Gen Hosp, Histocompatibil Lab, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 2008 VL 69 BP S17 EP S17 PG 1 WC Immunology SC Immunology GA 364ZE UT WOS:000260373800035 ER PT J AU Robert, ME Lamps, L Lauwers, GY AF Robert, Marie E. Lamps, Laura Lauwers, Gregory Y. CA Assoc Directors Anatom TI Recommendations for the reporting of gastric carcinoma SO HUMAN PATHOLOGY LA English DT Article DE gastric carcinoma; gastric practice guidelines; ADASP ID FUNDIC GLAND POLYPS; HELICOBACTER-PYLORI; ADENOMATOUS POLYPOSIS; CANCER; DYSPLASIA; RISK; ADENOCARCINOMA; INFECTION; MUTATIONS; PATIENT AB It has been evident for decades that pathology reports vary between institutions and even within a single institution. Standardization of reporting is the best way to ensure that information necessary for patient management is included in pathology reports. Two societies, the Association of Directors of Anatomic and Surgical Pathology (ADASP) and the College of American Pathologists (CAP) have published guidelines for the reporting of common cancers. Although not identical, the basic content of the ADASP and CAP guidelines are similar. The American College of Surgery Commission on Cancer (COC) accredits cancer centers in the United States. The ADASP has updated all of its protocols to comply with COC requirements in the form of 37 uniform checklists. The checklists utilize criteria sited in the American Joint Committee on Cancer 2002 staging manual and are formatted for ease of use. They may be used as templates for uniform reporting and are designed be compatible with voice-activated transcription. (c) 2008 Elsevier Inc. All rights reserved. C1 [Robert, Marie E.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA. [Lamps, Laura] Univ Arkansas Med Sci Ctr, Dept Pathol, Little Rock, AR 72205 USA. [Lauwers, Gregory Y.] Massachusetts Gen Hosp, Harvard Med Sch, Dept Pathol, Boston, MA 02114 USA. RP Robert, ME (reprint author), Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA. EM marie.robert@yale.edu NR 30 TC 3 Z9 3 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0046-8177 J9 HUM PATHOL JI Hum. Pathol. PD JAN PY 2008 VL 39 IS 1 BP 9 EP 14 DI 10.1016/j.humpath.2007.05.024 PG 6 WC Pathology SC Pathology GA 244WH UT WOS:000251895500003 PM 17967475 ER PT J AU Kuohung, W Ram, K Cheng, DM Marcus, KJ Diller, LR Laufer, MR AF Kuohung, Wendy Ram, Katherine Cheng, Debbie M. Marcus, Karen J. Diller, Lisa R. Laufer, Marc R. TI Laparoscopic oophoropexy prior to radiation for pediatric brain tumor and subsequent ovarian function SO HUMAN REPRODUCTION LA English DT Article; Proceedings Paper CT 59th Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 11-15, 2003 CL SAN ANTONIO, TX SP Amer Soc Reprod Med DE brain tumor; children; laparoscopy; oophoropexy; radiation ID BONE-MARROW TRANSPLANTATION; HODGKINS-DISEASE; IRRADIATION; CHILDHOOD; PREGNANCY; TRANSPOSITION; MALIGNANCIES; CHILDREN; MEDULLOBLASTOMA; RADIOTHERAPY AB BACKGROUND: Ovarian failure has been reported to occur in female cancer survivors who had received spinal radiation as children. We aimed to determine whether laparoscopic unilateral oophoropexy prior to radiotherapy effectively preserves ovarian function. METHODS: In a retrospective analysis, the study group comprised girls, aged 18 and younger, who received spinal irradiation for a brain tumor. Ovarian dysfunction, the primary endpoint, was defined as an elevated follicle-stimulating hormone level or persistent amenorrhea. RESULTS: After applying exclusion criteria, 15 patients comprised the group that had undergone laparoscopic oophoropexy, and 11 patients comprised the comparison group that did not have oophoropexy. Mean age at diagnosis, length of follow-up, proportion of high-risk tumors and doses and duration of chemotherapy and radiation were not different between the two groups. Two of 15 patients (13%, 95% CI 0.2-40%) with oophoropexy had ovarian dysfunction compared with five of 11 (45%, 95% CI 17-77%) in the comparison group (P = 0.09). CONCLUSIONS: Oophoropexy may protect against radiation-induced ovarian failure in girls receiving spinal radiation. A high risk of ovarian dysfunction was seen in :patients who did not undergo oophoropexy. In girls who underwent oophoropexy, a lower rate of ovarian dysfunction was seen. C1 [Kuohung, Wendy] Boston Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02115 USA. [Kuohung, Wendy; Laufer, Marc R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA 02115 USA. [Ram, Katherine; Laufer, Marc R.] Harvard Univ, Childrens Hosp Boston, Sch Med, Div Gynecol, Boston, MA 02115 USA. [Cheng, Debbie M.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA. [Marcus, Karen J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Childrens Hosp Boston,Dept, Boston, MA 02115 USA. [Diller, Lisa R.] Harvard Univ, Childrens Hosp Boston, Sch Med, Dana Farber Canc Inst,Dept Pediat Oncol, Boston, MA 02115 USA. [Diller, Lisa R.] Harvard Univ, Childrens Hosp Boston, Sch Med, Dept Med, Boston, MA 02115 USA. RP Laufer, MR (reprint author), Boston Univ, Sch Med, Dept Obstet & Gynecol, 85 E Concord St,6th Flr, Boston, MA 02115 USA. EM marc.laufer@childrens.harvard.edu NR 20 TC 23 Z9 23 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 J9 HUM REPROD JI Hum. Reprod. PD JAN PY 2008 VL 23 IS 1 BP 117 EP 121 DI 10.1093/humrep/dem368 PG 5 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 258CZ UT WOS:000252847300018 PM 18003624 ER PT J AU Gallardo, TD John, GB Bradshaw, K Welt, C Reijo-Pera, R Vogt, PH Touraine, P Bione, S Toniolo, D Nelson, LM Zinn, AR Castrillon, DH AF Gallardo, Teresa D. John, George B. Bradshaw, Karen Welt, Corrine Reijo-Pera, Renee Vogt, Peter H. Touraine, Philippe Bione, Silvia Toniolo, Daniela Nelson, Lawrence M. Zinn, Andrew R. Castrillon, Diego H. TI Sequence variation at the human FOXO3 locus: a study of premature ovarian failure and primary amenorrhea SO HUMAN REPRODUCTION LA English DT Article DE FOXO3; female infertility; premature ovarian failure; primary amenorrhea; menopause ID FORKHEAD TRANSCRIPTION FACTOR; TUMOR SUPPRESSION; MENOPAUSE; GENE; MICE; POF; ASSOCIATION AB BACKGROUND: The forkhead transcription factor Foxo3 is a master regulator and potent suppressor of primordial follicle activation. Loss of Foxo3 function in the mouse leads to premature ovarian failure (POF) due to global follicle activation. METHODS and RESULTS: Here, we show that the mouse Foxo3 locus is haploinsufficient, and that Foxo3(-/+) females undergo early reproductive senescence consistent with an increased rate of primordial follicle utilization. Then, to determine if heterozygous or homozygous polymorphisms or mutations of the human orthologue FOXO3 contribute to POF or idiopathic primary amenorrhea (PA), we sequenced the exons and flanking splice sequences of the gene in a large number of women with idiopathic POF (n = 273) or PA (n = 29). A total of eight single-nucleotide polymorphisms (SNPs) were identified, revealing a substantial amount of genetic variation at this locus. Allelic frequencies in control samples excluded several of these variants as causal. For the remaining variants, site-directed mutagenesis was performed to assess their functional impact. However, these rare sequence variants were not associated with significant decreases in FOXO3 activity. CONCLUSIONS: Taken together, our findings suggest that, despite the potential for FOXO3 haploinsufficiency to cause ovarian failure, FOX03 mutations or common SNPs are not a common cause of either POF or PA. C1 [Gallardo, Teresa D.; John, George B.; Castrillon, Diego H.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX USA. [Bradshaw, Karen] Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Dallas, TX USA. [Welt, Corrine] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Reprod Endocrinol, Boston, MA USA. [Reijo-Pera, Renee] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Palo Alto, CA 94304 USA. [Vogt, Peter H.] Univ Heidelberg, Dept Gynecol Endocrinol & Reprod Med, D-6900 Heidelberg, Germany. [Touraine, Philippe] Hop La Pitie Salpetriere, Dept Endocrinol & Reprod Med, AP HP, Paris, France. [Bione, Silvia] Inst Mol Genet, Dept Human Genet & Genom, Pavia, Italy. [Toniolo, Daniela] Ist Sci San Raffaele, Dept Mol Biol & Genom, Milan, Italy. [Nelson, Lawrence M.] Natl Inst Hlth, NICHHD, Bethesda, MD USA. [Zinn, Andrew R.] Univ Texas SW Med Ctr Dallas, McDermott Ctr Human Growth & Dev, Dallas, TX USA. RP Castrillon, DH (reprint author), Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX USA. EM diego.castrillon@utsouthwestem.edu OI Bione, Silvia/0000-0002-3924-4606; Zinn, Andrew/0000-0002-4935-3291; Welt, Corrine/0000-0002-8219-5504; Reijo Pera, Renee/0000-0002-6487-1329 FU Intramural NIH HHS; NICHD NIH HHS [HD048690, R01 HD048690-01, R01 HD048690] NR 41 TC 20 Z9 21 U1 0 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 J9 HUM REPROD JI Hum. Reprod. PD JAN PY 2008 VL 23 IS 1 BP 216 EP 221 DI 10.1093/humrep/dem255 PG 6 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 258CZ UT WOS:000252847300031 PM 17959613 ER PT J AU Rana, S Rauh-Hain, A Karumanchi, A Thadhani, R AF Rana, Sarosh Rauh-Hain, Alejandro Karumanchi, Ananth Thadhani, Ravi TI Alterations in Levels of Angiogenic Proteins in First Trimester and Subsequent Risk of Developing Abruption SO HYPERTENSION IN PREGNANCY LA English DT Meeting Abstract C1 [Rana, Sarosh; Karumanchi, Ananth] BIDMC, Boston, MA USA. [Rauh-Hain, Alejandro; Thadhani, Ravi] MGH, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1064-1955 J9 HYPERTENS PREGNANCY JI Hypertens. Pregnancy PY 2008 VL 27 IS 4 BP 548 EP 548 PG 1 WC Obstetrics & Gynecology; Physiology; Peripheral Vascular Disease SC Obstetrics & Gynecology; Physiology; Cardiovascular System & Cardiology GA 371MC UT WOS:000260834400164 ER PT J AU Sogin, D Lim, KH Karumanchi, A Laird, D Sluss, P Pucci, D AF Sogin, David Lim, Kee-Hak Karumanchi, Ananth Laird, Don Sluss, Patrick Pucci, Dominick TI Diagnosing Preeclampsia Utilizing SFIT-1 and PlGF Levels Measured by the Abbott ARCHITECT SO HYPERTENSION IN PREGNANCY LA English DT Meeting Abstract C1 [Sogin, David; Laird, Don; Pucci, Dominick] Abbott Labs, Abbott Pk, IL 60064 USA. [Lim, Kee-Hak; Karumanchi, Ananth] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Sluss, Patrick] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1064-1955 J9 HYPERTENS PREGNANCY JI Hypertens. Pregnancy PY 2008 VL 27 IS 4 BP 624 EP 624 PG 1 WC Obstetrics & Gynecology; Physiology; Peripheral Vascular Disease SC Obstetrics & Gynecology; Physiology; Cardiovascular System & Cardiology GA 371MC UT WOS:000260834400270 ER PT J AU Carr, D Newton, K Utzschneider, K Faulenbach, M Kahn, S Easterling, T Heckbert, S AF Carr, Darcy Newton, Katherine Utzschneider, Kristina Faulenbach, Mirjam Kahn, Steven Easterling, Thomas Heckbert, Susan TI Gestational Diabetes or Lesser Degrees of Glucose Intolerance and Risk of Preeclampsia. SO HYPERTENSION IN PREGNANCY LA English DT Meeting Abstract C1 [Heckbert, Susan] Univ Washington, Grp Hlth Ctr Hlth Studies, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Utzschneider, Kristina; Faulenbach, Mirjam; Kahn, Steven] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1064-1955 J9 HYPERTENS PREGNANCY JI Hypertens. Pregnancy PY 2008 VL 27 IS 4 BP 639 EP 639 PG 1 WC Obstetrics & Gynecology; Physiology; Peripheral Vascular Disease SC Obstetrics & Gynecology; Physiology; Cardiovascular System & Cardiology GA 371MC UT WOS:000260834400292 ER PT B AU Sands, BE AF Sands, B. E. BE Tozun, N Dagli, U Mantzaris, G Scholmerich, J TI Fistulizing Crohn's disease: the aggressive approach SO IBD 2007 - ACHIEVEMENTS IN RESEARCH AND CLINICAL PRACTICE SE FALK SYMPOSIUM LA English DT Proceedings Paper CT Falk Symposium 159 on IBD 2007 - Achievements in Research and Clinical Practice CY MAY 04-05, 2007 CL Istanbul, TURKEY SP Falk Fdn ID PERIANAL FISTULAS; METRONIDAZOLE THERAPY; LONG-TERM; 6-MERCAPTOPURINE; AZATHIOPRINE; INFLIXIMAB; MAINTENANCE; TACROLIMUS; CIPROFLOXACIN; CYCLOSPORINE C1 Massachusetts Gen Hosp, Gastrointestinal Unit, MGH Crohns & Colitis Ctr, Boston, MA 02114 USA. RP Sands, BE (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, MGH Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. NR 41 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 978-1-4020-6986-4 J9 FALK SYMP PY 2008 VL 159 BP 249 EP 256 PG 8 WC Gastroenterology & Hepatology; Medicine, Research & Experimental SC Gastroenterology & Hepatology; Research & Experimental Medicine GA BHN82 UT WOS:000254615500025 ER PT J AU Veilleux, I Spencer, JA Biss, DP Cote, D Lin, CP AF Veilleux, Israel Spencer, Joel A. Biss, David P. Cote, Daniel Lin, Charles P. TI In vivo cell tracking with video rate multimodality laser scanning microscopy SO IEEE JOURNAL OF SELECTED TOPICS IN QUANTUM ELECTRONICS LA English DT Article DE blood flow; cell trafficking; endogenous; exogenous; in vivo microscopy; large-scale imaging; video microscopy ID RAMAN SCATTERING MICROSCOPY; LYMPHOCYTE TRAFFICKING; 2-PHOTON MICROSCOPY; HUMAN SKIN; TISSUE AB Studies of biological processes, such as disease progression and response to therapy, call for live imaging methods that allow continuous observation without terminating the study subject for histological tissue processing. Among all current imaging modalities, optical microscopy is the only method capable of probing live tissue with cellular and subcellular resolution. We present a video-rate (30 frames/s), multimodality imaging system that is designed specifically for live animal imaging and cell tracking. In vivo depth-sectioned, high-resolution images are obtained using confocal and nonlinear optical techniques that extract structural, functional, and molecular information by combining multiple contrast mechanisms, including back scattering, fluorescence (from single- and two-photon excitation), second harmonic generation, and coherent anti-Stokes Raman scattering. Simultaneous use of up to three modalities is possible and eliminates the need for coregistration, especially on large-scale images. A real-time movement correction algorithm was developed to extend integration times in cases where the image needs to be stabilized against subject movement. Finally, imaging of fast moving leukocytes in blood vessels is made possible with a modification that permits operation at 120 frames/s over a smaller area. Sample imagery obtained in vivo with the microscope is presented to illustrate the capabilities. C1 [Veilleux, Israel; Cote, Daniel] Univ Laval, Ctr Rech, Dept Phys, Quebec City, PQ G1J 2G3, Canada. [Veilleux, Israel; Spencer, Joel A.; Biss, David P.; Cote, Daniel; Lin, Charles P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Spencer, Joel A.] Tufts Univ, Sch Engn, Dept Biomed Engn, Medford, MA 02155 USA. [Biss, David P.] Schepens Eye Res Inst, Boston, MA 02114 USA. [Lin, Charles P.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. RP Veilleux, I (reprint author), Univ Laval, Ctr Rech, Dept Phys, Quebec City, PQ G1J 2G3, Canada. EM israel.veilleux@crulrg.ulaval.ca; jaspencer@partners.org; dbiss@partners.org; daniel.cote@crulrg.ulaval.ca; lin@helix.mgh.harvard.edu RI Cote, Daniel/D-5185-2011; Spencer, Joel/A-4590-2013 NR 21 TC 82 Z9 82 U1 1 U2 22 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 1077-260X J9 IEEE J SEL TOP QUANT JI IEEE J. Sel. Top. Quantum Electron. PD JAN-FEB PY 2008 VL 14 IS 1 BP 10 EP 18 DI 10.1109/.JSTQE.2008.912751 PG 9 WC Engineering, Electrical & Electronic; Optics; Physics, Applied SC Engineering; Optics; Physics GA 268DH UT WOS:000253558100003 ER PT J AU Dogan, M Yalcin, A Jain, S Goldberg, MB Swan, AK Unlu, MS Goldberg, BB AF Dogan, Mehmet Yalcin, Ayca Jain, Sumita Goldberg, Marcia B. Swan, Anna K. Unlu, M. Selim Goldberg, Bennett B. TI Spectral self-interference fluorescence microscopy for subcellular Imaging SO IEEE JOURNAL OF SELECTED TOPICS IN QUANTUM ELECTRONICS LA English DT Article DE fluorescence microscopy; localization; self-interference; subcellular imaging ID HAND-OVER-HAND; CONTRAST MICROSCOPY; OXIDIZED SILICON; STIMULATED-EMISSION; RESOLUTION; LIMIT AB Spectral self-interference fluorescence microscopy (SSFM) has been recently developed to determine the axial position of fluorescent emitters placed on reflecting dielectric structures. In this paper, we review SSFM with emphasis on its axial localization capabilities. We show that there is a tradeoff between the numerical aperture (NA) of the microscopy system and the axial localization fidelity. To use high-NA objectives for better lateral resolution, we describe and demonstrate a high-NA 4Pi microscopy system that performs spectral self-interference microscopy for axial localization of less than 2 nm. We demonstrate axial localization by using artificial samples. We also probe the membrane topography of a Shigella flexneri bacterium, several micrometers away from a solid support. C1 [Dogan, Mehmet; Goldberg, Bennett B.] Boston Univ, Dept Phys, Boston, MA 02215 USA. [Unlu, M. Selim] Boston Univ, Dept Elect & Comp Engn, Boston, MA 02215 USA. [Jain, Sumita; Goldberg, Marcia B.] Harvard Univ, Sch Med, Div Infect Dis, Cambridge, MA 02139 USA. [Jain, Sumita; Goldberg, Marcia B.] Massachusetts Gen Hosp, Dept Med, Cambridge, MA 02139 USA. RP Dogan, M (reprint author), Boston Univ, Dept Phys, 590 Commonwealth Ave, Boston, MA 02215 USA. EM mdogan@bu.edu; aycti@bu.edu; sumita@u.washington.edu; goldberg@bu.edu; swan@bu.edu; sefm@bu.edu RI Yalcin, Ayca/J-8195-2012; Unlu, Selim/B-4244-2013 NR 25 TC 9 Z9 9 U1 0 U2 5 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1077-260X J9 IEEE J SEL TOP QUANT JI IEEE J. Sel. Top. Quantum Electron. PD JAN-FEB PY 2008 VL 14 IS 1 BP 217 EP 225 DI 10.1109/JSTQE.2008.912901 PG 9 WC Engineering, Electrical & Electronic; Optics; Physics, Applied SC Engineering; Optics; Physics GA 268DH UT WOS:000253558100028 ER PT J AU Patel, S Hester, T Hughes, R Huggins, N Flaherty, A Standoert, D Growdon, J Bonoto, P AF Patel, Shyarrial Hester, Todd Hughes, Richard Huggins, Nancy Flaherty, Alice Standoert, David Growdon, John Bonoto, Paolo TI Processing wearable sensor data to optimize deep-brain stimulation SO IEEE PERVASIVE COMPUTING LA English DT Article ID PARKINSONS-DISEASE C1 [Patel, Shyarrial; Hester, Todd; Hughes, Richard; Growdon, John; Bonoto, Paolo] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Cambridge, MA 02138 USA. [Huggins, Nancy; Flaherty, Alice; Growdon, John] Harvard Univ, Dept Neurol, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. [Standoert, David] Univ Alabama, Birmingham, AL USA. RP Patel, S (reprint author), Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Cambridge, MA 02138 USA. EM spateil19@partners.org; todd.hester@gmail.com; rhughes1@partners.org; nhuggins@partners.org; aflaherty@partners.org; dstand@uab.edu; growdon@helix.mgh.harvard.edu; pbonato@partners.org RI Patel, Shyamal/K-3176-2012; OI Standaert, David/0000-0003-2921-8348 NR 6 TC 4 Z9 4 U1 0 U2 5 PU IEEE COMPUTER SOC PI LOS ALAMITOS PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1314 USA SN 1536-1268 J9 IEEE PERVAS COMPUT JI IEEE Pervasive Comput. PD JAN-MAR PY 2008 VL 7 IS 1 BP 56 EP 61 DI 10.1109/MPRV.2008.15 PG 6 WC Computer Science, Information Systems; Engineering, Electrical & Electronic; Telecommunications SC Computer Science; Engineering; Telecommunications GA 248VK UT WOS:000252184900010 ER PT J AU Westover, MB O'Sullivan, JA AF Westover, M. Brandon O'Sullivan, Joseph A. TI Achievable rates for pattern recognition SO IEEE TRANSACTIONS ON INFORMATION THEORY LA English DT Article; Proceedings Paper CT IEEE Information Theory Workshop CY MAR 13-17, 2006 CL Punta del Este, URUGUAY SP IEEE DE distributed source coding; multiterminal information theory; pattern recognition ID COMPRESSION; CLASSIFICATION; STATISTICS; MODEL AB Biological and machine pattern recognition systems face a common challenge: Given sensory data about an unknown pattern, classify the pattern by searching for the best match within a library of representations stored in memory. In many cases, the number of patterns to be discriminated and the richness of the raw data force recognition systems to internally represent memory and sensory information in a compressed format. However, these representations must preserve enough information to accommodate the variability and complexity of the environment, otherwise recognition will be unreliable. Thus, there is an intrinsic tradeoff between the amount of resources devoted to data representation and the complexity of the environment in which a recognition system may reliably operate. In this paper, we describe a mathematical model for pattern recognition systems subject to resource constraints, and show how the aforementioned resource-complexity tradeoff can be characterized in terms of three rates related to the number of bits available for representing memory and sensory data, and the number of patterns populating a given statistical environment. We prove single-letter information-theoretic bounds governing the achievable rates, and investigate in detail two illustrative cases where the pattern data is either binary or Gaussian. C1 [Westover, M. Brandon] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [O'Sullivan, Joseph A.] Washington Univ, Dept Elect Engn, St Louis, MO 63130 USA. RP Westover, MB (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. EM mb.westover@gmail.com; jao@ee.wustl.edu NR 49 TC 21 Z9 21 U1 0 U2 1 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 0018-9448 J9 IEEE T INFORM THEORY JI IEEE Trans. Inf. Theory PD JAN PY 2008 VL 54 IS 1 BP 299 EP 320 DI 10.1109/TIT.2007.911296 PG 22 WC Computer Science, Information Systems; Engineering, Electrical & Electronic SC Computer Science; Engineering GA 249VA UT WOS:000252256900020 ER PT J AU Sharp, GC Lee, SW Wehe, DK AF Sharp, Gregory C. Lee, Sang W. Wehe, David K. TI Maximum-likelihood registration of range images with missing data SO IEEE TRANSACTIONS ON PATTERN ANALYSIS AND MACHINE INTELLIGENCE LA English DT Article DE range data; registration; maximum-likelihood; pixel classification ID MULTIVIEW REGISTRATION; OBJECT RECOGNITION; 3D SCENES; REPRESENTATION; INTEGRATION; ALGORITHM; SURFACES; SHAPES; VIEWS; ERROR AB Missing data are common in range images, due to geometric occlusions, limitations in the sensor field of view, poor reflectivity, depth discontinuities, and cast shadows. Using registration to align these data often fails, because points without valid correspondences can be incorrectly matched. This paper presents a maximum-likelihood method for registration of scenes with unmatched or missing data. Using ray casting, correspondences are formed between valid and missing points in each view. These correspondences are used to classify points by their visibility properties, including occlusions, field of view, and shadow regions. The likelihood of each point match is then determined using statistical properties of the sensor, such as noise and outlier distributions. Experiments demonstrate high rates of convergence on complex scenes with varying degrees of overlap. C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Sogang Univ, Dept Media Technol, Seoul 121742, South Korea. Univ Michigan, Ann Arbor, MI 48109 USA. RP Sharp, GC (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St COX3, Boston, MA 02114 USA. EM gcsharp@partners.org; slee@sogang.ac.kr; dkw@umich.edu NR 33 TC 8 Z9 8 U1 0 U2 2 PU IEEE COMPUTER SOC PI LOS ALAMITOS PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1314 USA SN 0162-8828 EI 1939-3539 J9 IEEE T PATTERN ANAL JI IEEE Trans. Pattern Anal. Mach. Intell. PD JAN PY 2008 VL 30 IS 1 BP 120 EP 130 DI 10.1109/TPAMI.2007.1130 PG 11 WC Computer Science, Artificial Intelligence; Engineering, Electrical & Electronic SC Computer Science; Engineering GA 229YW UT WOS:000250843500010 PM 18000329 ER PT J AU Zinn, KR Chaudhuri, TR Szafran, AA O'Quinn, D Weaver, C Dugger, K Lamar, D Kesterson, RA Wang, XD Frank, SJ AF Zinn, Kurt R. Chaudhuri, Tandra R. Szafran, April Adams O'Quinn, Darrell Weaver, Casey Dugger, Kari Lamar, Dale Kesterson, Robert A. Wang, Xiangdong Frank, Stuart J. TI Noninvasive bioluminescence imaging in small animals SO ILAR JOURNAL LA English DT Article DE bioluminescence; imaging; luciferase; transgenic mice ID TRANSGENIC MOUSE MODEL; SIMPLEX-VIRUS TYPE-1; PATHOGEN CITROBACTER-RODENTIUM; PROTEIN-PROTEIN INTERACTIONS; REPORTER GENE-EXPRESSION; IN-VIVO; LIVING ANIMALS; THYMIDINE KINASE; MICE; ADENOVIRUS AB There has been a rapid growth of bioluminescence imaging applications in small animal models in recent years, propelled by the availability of instruments, analysis software, reagents, and creative approaches to apply the technology in molecular imaging. Advantages include the sensitivity of the technique as well as its efficiency, relatively low cost, and versatility. Bioluminescence imaging is accomplished by sensitive detection of light emitted following chemical reaction of the luciferase enzyme with its substrate. Most imaging systems provide 2-dimensional (2D) information in rodents, showing the locations and intensity of light emitted from the animal in pseudo-color scaling. A 3-dimensional (3D) capability for bioluminescence imaging is now available, but is more expensive and less efficient; other disadvantages include the requirement for genetically encoded luciferase, the injection of the substrate to enable light emission, and the dependence of light signal on tissue depth. All of these problems make it unlikely that the method will be extended to human studies. However, in small animal models, bioluminescence imaging is now routinely applied to serially detect the location and burden of xenografted tumors, or identify and measure the number of immune or stem cells after an adoptive transfer. Bioluminescence imaging also makes it possible to track the relative amounts and locations of bacteria, viruses, and other pathogens over time. Specialized applications of bioluminescence also follow tissue-specific luciferase expression in transgenic mice, and monitor biological processes such as signaling or protein interactions in real time. In summary, bioluminescence imaging has become an important component of biomedical research that will continue in the future. C1 [Zinn, Kurt R.] Univ Alabama Birmingham, Lab Multimodal Imaging, Birmingham, AL 35294 USA. [Chaudhuri, Tandra R.] UAB, Dept Radiol, Birmingham, AL USA. [Szafran, April Adams; Weaver, Casey; Dugger, Kari] UAB, Dept Pathol, Birmingham, AL USA. [Lamar, Dale; Kesterson, Robert A.] UAB, Dept Genet, Birmingham, AL USA. [Wang, Xiangdong] UAB, Dept Med, Birmingham, AL USA. [Frank, Stuart J.] Birmingham VA Med Ctr, Med Serv, Endocrinol Sect, Birmingham, AL USA. RP Zinn, KR (reprint author), Univ Alabama Birmingham, Lab Multimodal Imaging, 1530 3rd Ave S,BDB 802, Birmingham, AL 35294 USA. EM kurtzinn@uab.edu OI Weaver, Casey/0000-0002-2180-1793; Zinn, Kurt/0000-0001-7463-4741 FU NCI NIH HHS [P30 CA013148, 5P30CA013148-36, P30 CA013148-35, P30 CA013148-35S1, P30 CA013148-35S2, P30 CA013148-36, P30 CA013148-36S1, P30 CA013148-37, P30 CA013148-37S1, P30 CA013148-37S2, P30 CA13148]; NIAMS NIH HHS [P30 AR048311, P30 AR48311]; NIDDK NIH HHS [DK58259, R01 DK058259, R01 DK058259-01A1, R01 DK058259-02, R01 DK058259-03, R01 DK058259-04, R01 DK058259-04S1, R01 DK058259-05A1, R01 DK058259-06, R01 DK058259-07, R56 DK058259] NR 49 TC 67 Z9 68 U1 1 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1084-2020 EI 1930-6180 J9 ILAR J JI ILAR J. PY 2008 VL 49 IS 1 BP 103 EP 115 PG 13 WC Veterinary Sciences SC Veterinary Sciences GA 311UI UT WOS:000256625500010 PM 18172337 ER PT S AU Yoshida, H Dachman, AH AF Yoshida, Hiroyuki Dachman, Abraham H. BE Neri, E Caramella, D Bartolozzi, C TI Computer Aided Diagnosis: Clinical Applications in CT Colonography SO IMAGE PROCESSING IN RADIOLOGY: CURRENT APPLICATIONS SE Medical Radiology Diagnostic Imaging LA English DT Article; Book Chapter ID TOMOGRAPHIC VIRTUAL COLONOSCOPY; ASSISTED READER SOFTWARE; POLYP DETECTION; COLONIC POLYPS; FALSE POSITIVES; VOLUMETRIC FEATURES; IN-VITRO; SEGMENTATION; REDUCTION; CLASSIFICATION C1 [Yoshida, Hiroyuki] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. [Yoshida, Hiroyuki; Dachman, Abraham H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Yoshida, H (reprint author), Massachusetts Gen Hosp, Dept Radiol, 25 New Chardon St,Suite 400C, Boston, MA 02114 USA. NR 76 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0942-5373 BN 978-3-540-25915-2 J9 MED RADIOL DIAGN IMA PY 2008 BP 375 EP 391 DI 10.1007/978-3-540-49830-8_27 D2 10.1007/978-3-540-49830-8 PG 17 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA BJQ44 UT WOS:000266989500027 ER PT J AU Sundrud, MS Rao, A AF Sundrud, Mark S. Rao, Aniana TI Regulation of T helper 17 differentiation by orphan nuclear receptors: It's not just ROR gamma t anymore SO IMMUNITY LA English DT Editorial Material ID CELL-DIFFERENTIATION; ALPHA AB T cells that produce IL-17 (T helper 17 cells) are implicated in autoimmune pathogenesis. In this issue of Immunity, Yang et al. (2008) report that the closely related orphan nuclear receptors ROR alpha and ROR gamma t work together to regulate T helper (Th) 17 cell differentiation. C1 [Sundrud, Mark S.; Rao, Aniana] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Sundrud, Mark S.; Rao, Aniana] Immune Dis Inst, Boston, MA 02115 USA. RP Rao, A (reprint author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. EM arao@cbr.med.harvard.edu NR 10 TC 10 Z9 12 U1 0 U2 1 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1074-7613 J9 IMMUNITY JI Immunity PD JAN PY 2008 VL 28 IS 1 BP 5 EP 7 DI 10.1016/j.immuni.2007.12.006 PG 3 WC Immunology SC Immunology GA 254ZU UT WOS:000252627300002 PM 18199410 ER PT J AU Sun, ZYJ Oh, KJ Kim, MY Yu, J Brusic, V Song, LK Qiao, ZS Wang, JH Wagner, G Reinherz, EL AF Sun, Zhen-Yu J. Oh, Kyoung Joon Kim, Milkyung Yu, Jessica Brusic, Vladimir Song, Likai Qiao, Zhisong Wang, Jia-Huai Wagner, Gerhard Reinherz, Ellis L. TI HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane SO IMMUNITY LA English DT Article ID PROXIMAL EXTERNAL REGION; VIRUS TYPE-1 ANTIBODY; ENVELOPE GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; MEDIATED FUSION; AIDS VACCINE; 4E10; NMR; 2F5; TRYPTOPHAN AB Although rarely elicited during natural human infection, the most broadly neutralizing antibodies (BNAbs) against diverse human immunodeficiency virus (HIV)-1 strains target the membrane-proximal ectodomain region (MPER) of viral gp41. To gain insight into MPER antigenicity, immunogenicity, and viral function, we studied its structure in the lipid environment by a combination of nuclear magnetic resonance (NMR), electron paramagnetic resonance (EPR), and surface plasmon resonance (SPR) techniques. The analyses revealed a tilted N-terminal alpha helix (aa 664-672) connected via a short hinge to a flat C-terminal helical segment (675-683). This metastable L-shaped structure is immersed in viral membrane and, therefore, less accessible to immune attack. Nonetheless, the 4E10 BNAb extracts buried W672 and F673 after initial encounter with the surface-embedded MPER. The data suggest how BNAbs may perturb tryptophan residue-associated viral fusion involving the mobile N-terminal MPER segment and, given conservation of MPER sequences in HIV-1, HIV-2, and SIV, have important implications for structure-guided vaccine design. C1 [Oh, Kyoung Joon; Kim, Milkyung; Brusic, Vladimir; Song, Likai; Qiao, Zhisong; Reinherz, Ellis L.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Sun, Zhen-Yu J.; Wang, Jia-Huai; Wagner, Gerhard] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Wang, Jia-Huai] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Oh, Kyoung Joon; Brusic, Vladimir; Song, Likai; Reinherz, Ellis L.] Harvard Univ, Sch Med, Canc Vaccine Ctr, Boston, MA 02115 USA. [Kim, Milkyung; Yu, Jessica; Qiao, Zhisong; Wang, Jia-Huai; Reinherz, Ellis L.] Harvard Univ, Sch Med, Immunol Lab, Boston, MA 02115 USA. [Kim, Milkyung; Yu, Jessica; Qiao, Zhisong; Wang, Jia-Huai; Reinherz, Ellis L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Reinherz, EL (reprint author), Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. EM ellis_reinherz@dfci.harvard.edu FU NIAID NIH HHS [P30 AI060354, AI43649]; NIGMS NIH HHS [GM47467] NR 51 TC 185 Z9 186 U1 1 U2 21 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1074-7613 J9 IMMUNITY JI Immunity PD JAN PY 2008 VL 28 IS 1 BP 52 EP 63 DI 10.1016/j.immuni.2007.11.018 PG 12 WC Immunology SC Immunology GA 254ZU UT WOS:000252627300010 PM 18191596 ER PT J AU Zurawski, DV Mumy, KL Badea, L Prentice, JA Hartland, EL McCormick, BA Maurelli, AT AF Zurawski, Daniel V. Mumy, Karen L. Badea, Luminita Prentice, Julia A. Hartland, Elizabeth L. McCormick, Beth A. Maurelli, Anthony T. TI The NleE/OspZ family of effector proteins is required for polymorphonuclear transepithelial migration, a characteristic shared by enteropathogenic Escherichia coli and Shigella flexneri infections SO INFECTION AND IMMUNITY LA English DT Article ID INTESTINAL EPITHELIAL-CELLS; III SECRETION APPARATUS; INNATE IMMUNE-RESPONSES; NF-KAPPA-B; CITROBACTER-RODENTIUM; VIRULENCE PLASMID; HEPOXILIN A(3); SYSTEM; TRANSMIGRATION; ACTIVATION AB Enteropathogenic Escherichia coli (EPEC) and Shigella flexneri are human host-specific pathogens that infect intestinal epithelial cells. However, each bacterial species employs a different infection strategy within this environmental niche. EPEC attaches to the apical surface of small intestine enterocytes, causing microvillus effacement and rearrangement of the host cell cytoskeleton beneath adherent bacteria. In contrast, S.flexneri invades the large intestine epithelium at the basolateral membrane, replicates, and spreads cell to cell. Both EPEC and S.flexneri rely on type three secretion systems (T3SS) to secrete effectors into host cells, and both pathogens recruit polymorphonuclear leukocytes (PMNs) from the submucosa to the lumen of the intestine. In this report, we compared the virulence functions of the EPEC T3SS effector NleE and the homologous Shigella protein Orf212. We discovered that Orf212 was secreted by the S.flexneri T3SS and renamed this protein OspZ. Infection of polarized T84 intestinal epithelial cells with an ospZ deletion mutant of S. flexneri resulted in reduced PMN transepithelial migration compared to infection by the wild type. An nleE deletion mutant of EPEC showed a similar reduction of PMN migration. The ability to induce PMN migration was restored in both mutants when either ospZ or nleE was expressed from a plasmid. An infection of T84 cells with the Delta ospZ mutant resulted in reduced extracellular signal-related kinase phosphorylation and NF-kappa B activation compared to infection with the wild type. Therefore, we conclude that OspZ and NleE have similar roles in the upstream induction of host signaling pathways required for PMN transepithelial migration in Shigella and EPEC infections. C1 [Zurawski, Daniel V.; Maurelli, Anthony T.] Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA. [Mumy, Karen L.; McCormick, Beth A.] Massachusetts Gen Hosp, Mucosal Immunol Lab, Charlestown, MA USA. [Mumy, Karen L.; McCormick, Beth A.] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA. [Badea, Luminita; Prentice, Julia A.; Hartland, Elizabeth L.] Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia. [Hartland, Elizabeth L.] Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic, Australia. RP Maurelli, AT (reprint author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. EM amaurelli@usuhs.mil RI Zurawski, Daniel/B-6578-2009; Hartland, Elizabeth/O-2569-2014 OI Zurawski, Daniel/0000-0002-7920-5601; Hartland, Elizabeth/0000-0003-4254-2863 FU NIAID NIH HHS [AI24656, R01 AI024656]; NIDDK NIH HHS [DK56754, DK33506, P01 DK033506, R01 DK056754] NR 55 TC 32 Z9 32 U1 1 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD JAN PY 2008 VL 76 IS 1 BP 369 EP 379 DI 10.1128/IAI.00684-07 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 248BJ UT WOS:000252126000040 PM 17984206 ER PT J AU Martin, SI Fishman, JA AF Martin, Stanley I. Fishman, Jay A. TI Cryptococcal meningitis: Review of current disease management SO INFECTIONS IN MEDICINE LA English DT Article DE Cryptococcus neoformans; cryptococcal meningitis; cryptococcosis; opportunistic infection; HIV; fungal infection ID IMMUNE RECONSTITUTION SYNDROME; ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; ORGAN TRANSPLANT RECIPIENTS; IN-VITRO ACTIVITIES; B LIPID COMPLEX; PULMONARY CRYPTOCOCCOSIS; NEOFORMANS INFECTION; AMPHOTERICIN-B; PRACTICE GUIDELINES AB The incidence of cryptococcal infections in the HIV-infected. population has diminished because of the effectiveness of anti-retroviral therapy, whereas the incidence in non-HIV-infected hosts has grown. Despite improvements in antifungal therapy, successful outcomes in the management of cryptococcal meningitis are dependent on a high index of clinical suspicion, appropriate use of diagnostic assays, early and aggressive antifungal therapy, and recognition of complications such as increased intracranial pressure and immune reconstitution syndromes. Published guidelines for the care of patients with cryptococcal meningitis are available and may be adapted to individual patient requirements. Basic and clinical studies are needed to further define the components of immune protection, optimal therapy in special patient populations, and the recognition and treatment of complications of cryptococcal meningitis. C1 [Martin, Stanley I.] Ohio State Univ, Columbus, OH 43210 USA. [Fishman, Jay A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Fishman, Jay A.] Massachusetts Gen Hosp, Transplantat Ctr, Boston, MA 02114 USA. [Fishman, Jay A.] Massachusetts Gen Hosp, Transplant Infect Dis, Boston, MA 02114 USA. [Fishman, Jay A.] Massachusetts Gen Hosp, Compromised Host Program, Boston, MA 02114 USA. RP Martin, SI (reprint author), Ohio State Univ, Columbus, OH 43210 USA. RI Martin, Stanley/E-3600-2011 NR 51 TC 0 Z9 0 U1 1 U2 1 PU SCP COMMUNICATIONS INC PI NEW YORK PA 134 W 29TH ST, NEW YORK, NY 10001-5304 USA SN 0749-6524 J9 INFECT MED JI Infect. Med. PD JAN PY 2008 VL 25 IS 1 BP 11 EP + PG 8 WC Infectious Diseases SC Infectious Diseases GA 253MA UT WOS:000252521100001 ER PT J AU Siegel, C Levy, LC Mackenzie, TA Sands, BE AF Siegel, CoreyA. Levy, L. Campbell Mackenzie, Todd A. Sands, Bruce E. TI Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE infliximab; risks; benefits; CD; UC ID FISTULIZING CROHNS-DISEASE; MAINTENANCE THERAPY; HOSPITALIZATIONS; SURGERIES; COHORT AB Background: For a patient to make informed, preference based decisions, they must be able to balance the risks and benefits of treatment. The aim of this study was to determine patients' and parents' perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease (IBD). Methods: Adult patients with IBD and parents of patients attending IBD patient education symposiums were asked to complete a questionnaire regarding the risks and benefits of infliximab. Results: One hundred and sixty-five questionnaires were completed. A majority (59%) of respondents expected a remission rate greater than 50% at 1 year and 18% expected a remission rate greater than 70% at 1 year. More than one-third (37%) of respondents answered that infliximab is not associated with a risk of lymphoma and 67% responded that the lymphoma risk is no higher than twice that of the general population. When presented a scenario of a hypothetical new drug for IBD with risks mirroring those estimated for infliximab, 64% of respondents indicated that they would not take the medication, despite its described benefits. Thirty percent of these patients were either currently taking or had previously taken infliximab. Patients actively taking infliximab predicted the highest remission rates for the infliximab (P = 0.05), and parents of patients predicted the lowest (P = 0.01). Parents estimated a higher risk of lymphoma than patients (P = 0.003). Risk and benefit perception was independent of gender and age of patient respondents. Conclusions: Compared to published literature, patients and parents of patients overestimate the benefit of infliximab and underestimate its risks. We conclude that effective methods for communicating risks and benefits to patients need to be developed. C1 [Siegel, CoreyA.; Levy, L. Campbell] Dartmouth Hitchcock Med Ctr, Ctr Inflammatory Bowel Dis, Sect Gastroenterol & Hepatol, Lebanon, NH 03756 USA. [Mackenzie, Todd A.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA. [Sands, Bruce E.] Massachusetts Gen Hosp, Gastrointestinal Unit, MGH Crohns & Colitis Ctr, Boston, MA 02114 USA. [Sands, Bruce E.] Harvard Univ, Sch Med, Boston, MA USA. RP Siegel, C (reprint author), Dartmouth Hitchcock Med Ctr, Ctr Inflammatory Bowel Dis, Sect Gastroenterol & Hepatol, 1 Med Ctr Dr, Lebanon, NH 03756 USA. EM corey.a.siegel@hitcheock.org NR 16 TC 32 Z9 32 U1 1 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2008 VL 14 IS 1 BP 1 EP 6 DI 10.1002/ibd.20283 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 247RR UT WOS:000252097800001 PM 17924559 ER PT J AU Bordeianou, L AF Bordeianou, Liliana TI Bad news on glues: Fibrin glue success rates in the treatment of anal fistulas SO INFLAMMATORY BOWEL DISEASES LA English DT Editorial Material ID CROHNS-DISEASE; ANORECTAL FISTULAS; SURGICAL-TREATMENT C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA. RP Bordeianou, L (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA. NR 12 TC 1 Z9 1 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2008 VL 14 IS 1 BP 134 EP 135 DI 10.1002/ibd.20305 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 247RR UT WOS:000252097800020 PM 17941077 ER PT J AU Huett, A Xavier, R AF Huett, Alan Xavier, Rarnnik TI SNPping away at the pathogenesis of Crohn's disease SO INFLAMMATORY BOWEL DISEASES LA English DT Editorial Material ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY; INFECTION; LRG-47 C1 Massachusetts Gen Hosp, Gastrointestinal Unit, Richard B Simches Res Ctr, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Richard B Simches Res Ctr, Boston, MA 02114 USA. RP Huett, A (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, Richard B Simches Res Ctr, Boston, MA 02114 USA. NR 13 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2008 VL 14 IS 1 BP 136 EP 137 DI 10.1002/ibd.20306 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 247RR UT WOS:000252097800021 PM 17941076 ER PT J AU Gupta, N Heyman, M Bostrom, A Winter, H Baldassano, R Cohen, S Gold, B Cannon, R Ferry, G Kirschner, B AF Gupta, N. Heyman, M. Bostrom, A. Winter, H. Baldassano, R. Cohen, S. Gold, B. Cannon, R. Ferry, G. Kirschner, B. TI The development of fistulizing and fibrosing complications of Crohn's disease in a pediatric cohort SO INFLAMMATORY BOWEL DISEASES LA English DT Meeting Abstract CT CCFA National Research and Clinical Conference/6th Annual Advances in the Inflammatory Bowel Diseases CY DEC 06-09, 2007 CL Aventura, FL SP CCFA C1 [Gupta, N.; Heyman, M.; Bostrom, A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Winter, H.] MassGen Hosp Children, Boston, MA USA. [Baldassano, R.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Cohen, S.; Gold, B.] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Cannon, R.] Kaiser Permanente No Calif, Oakland, CA USA. [Ferry, G.] Baylor Coll Med, Houston, TX 77030 USA. [Kirschner, B.] Univ Chicago, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2008 VL 14 IS 1 SU S BP S9 EP S9 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 248IG UT WOS:000252145700030 ER PT J AU Korzenik, JR AF Korzenik, Joshua R. TI Flare Factor: Are There Any Triggering Factors Associated with Onset of Clinical Symptoms or Disease Relapse? SO INFLAMMATORY BOWEL DISEASES LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ULCERATIVE-COLITIS; CROHNS-DISEASE; CLOSTRIDIUM-DIFFICILE; SEASONAL-VARIATION; RISK; INFECTION C1 Massachusetts Gen Hosp, Gastrointestinal Unit, MGH Crohns & Colitis Ctr, Boston, MA 02114 USA. RP Korzenik, JR (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, MGH Crohns & Colitis Ctr, Boston, MA 02114 USA. NR 26 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PY 2008 VL 14 SU 2 BP S150 EP S151 DI 10.1002/ibd.20732 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 359QQ UT WOS:000260003600071 PM 18816722 ER PT J AU Maillard, M Nguyen, D Boden, E Snapper, S AF Maillard, M. Nguyen, D. Boden, E. Snapper, S. TI Regulatory T cell-based cellular therapy prevents colitis in WASP-deficient mice SO INFLAMMATORY BOWEL DISEASES LA English DT Meeting Abstract CT CCFA National Research and Clinical Conference/6th Annual Advances in the Inflammatory Bowel Diseases CY DEC 06-09, 2007 CL Aventura, FL SP CCFA C1 [Maillard, M.; Nguyen, D.; Boden, E.; Snapper, S.] Massachusetts Gen Hosp, Ctr Study Inflammat Bowel Dis, Gastrointestinal Unit, Boston, MA 02114 USA. [Maillard, M.; Nguyen, D.; Boden, E.; Snapper, S.] Harvard Med Sch, Boston, MA USA. [Maillard, M.] Univ Lausanne Hosp, Div Gastroenterol & Hepatol, Lausanne, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2008 VL 14 IS 1 SU S BP S7 EP S7 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 248IG UT WOS:000252145700022 ER PT J AU Sandborn Rutgeerts, P Feagan, B Reinisch, W Olson, A Johanns, J Lu, J Rachrnilewitz, D Hanauer, S Lichtenstein, G Devilliers, W Present, D Sands, B Colombel, J AF Sandborn Rutgeerts, P. Feagan, B. Reinisch, W. Olson, A. Johanns, J. Lu, J. Rachrnilewitz, D. Hanauer, S. Lichtenstein, G. deVilliers, W. Present, D. Sands, B. Colombel, J. TI Infliximab reduces colectomy in patients with moderate-to-severe ulcerative colitis: colectomy analysis from ACT 1 and ACT 2 SO INFLAMMATORY BOWEL DISEASES LA English DT Meeting Abstract CT CCFA National Research and Clinical Conference/6th Annual Advances in the Inflammatory Bowel Diseases CY DEC 06-09, 2007 CL Aventura, FL SP CCFA C1 [Sandborn] Mayo Clin, Rochester, NY USA. [Rutgeerts, P.] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium. [Feagan, B.] Univ Western Ontario, Robarts Res Inst, London, ON, Canada. [Reinisch, W.] Univ Hosp Vienna, Vienna, Austria. [Olson, A.; Johanns, J.; Lu, J.] Centocor Res & Dev Inc, Malvern, PA USA. [Rachrnilewitz, D.] Shaare Zedek Med Ctr, Jerusalem, Israel. [Hanauer, S.] Univ Chicago, Chicago, IL 60637 USA. [Lichtenstein, G.] Hosp Univ Penn, Ctr IBD, Philadelphia, PA 19104 USA. [deVilliers, W.] Univ Kentucky, Lexington, KY USA. [Present, D.] Mt Sinai Med Ctr, New York, NY 10029 USA. [Sands, B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Colombel, J.] Hop Claude Huriez, Lille, France. RI Feagan, Brian/M-4283-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2008 VL 14 IS 1 SU S BP S2 EP S2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 248IG UT WOS:000252145700007 ER PT J AU Houston, TK Ford, DE AF Houston, Tom K. Ford, Daniel E. TI A tailored Internet-delivered intervention for smoking cessation designed to encourage social support and treatment seeking: usability testing and user tracing SO INFORMATICS FOR HEALTH & SOCIAL CARE LA English DT Article DE Internet; smoking cessation; physician-patient relations; social support ID PROGRAM; WEB; EDUCATION; QUIT; INFORMATION; SMOKERS; SYSTEM; TRIAL; TOOL AB While Internet technologies show promise for changing behavior, new methods for engaging individuals are needed to maximize effectiveness. The aim of this study is to design and evaluate an Internet-delivered intervention for smoking cessation that encouraged seeking support from family and treatment from doctors. To evaluate different introductions to the Internet site. We conducted usability testing and analyzed server logs to trace user participation in the website. Two groups of users (current smokers) were recruited using Google advertisements. In Phase 1, 58% (75/ 126) of users accessed the selfmanagement strategies, but few users accessed the social support (28%) and treatment-seeking modules (33%). Then, a brief motivational introduction was added, stating the proven effectiveness of content in the unused modules, low use of these modules, and recommendations by two doctors to use all modules. Compared with Phase 1, in Phase 2 the mean time spent on the website per session increased (8 to 18 min, p 0.01) and use of the social support (50%) and treatment seeking modules (56%) increased (both p<0.01). At 1-month follow-up, reports of talking to family about smoking cessation also increased from 84% to 100% (p = 0.038). Changing the rationale and context of Web-based health information using a motivational introduction can change user behavior. C1 [Houston, Tom K.] Univ Alabama, Div Gen Internal Med, Birmingham, AL 35294 USA. [Houston, Tom K.] Birmingham VA Med Ctr, A HSR&D REAP, Deep S Ctr Effectiveness Res, Birmingham, AL USA. [Houston, Tom K.] Univ Alabama, Ctr Outcomes & Effectiveness Res, Birmingham, AL 35294 USA. [Ford, Daniel E.] Johns Hopkins Sch Med, Div Gen Internal Med, Baltimore, MD USA. [Ford, Daniel E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Houston, TK (reprint author), Univ Alabama, Div Gen Internal Med, 1530 3rd Ave S,FOT 720, Birmingham, AL 35294 USA. EM thouston@uab.edu RI Houston, Thomas/F-2469-2013 FU National Cancer Institute [1R21CA089011-01A1] FX The authors would like to acknowledge the efforts of Heather Coley, MPH in the editing of this manuscript. This work was supported by funding from the National Cancer Institute (1R21CA089011-01A1). NR 40 TC 25 Z9 25 U1 0 U2 11 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1753-8157 J9 INFORM HEALTH SOC CA JI Inform. Health Soc. Care PY 2008 VL 33 IS 1 BP 5 EP 19 DI 10.1080/14639230701842240 PG 15 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 352LN UT WOS:000259498800002 PM 18604759 ER PT J AU Cavallari, JM Fang, SC Eisen, EA Schwartz, J Hauser, R Herrick, RF Christiani, DC AF Cavallari, Jennifer M. Fang, Shona C. Eisen, Ellen A. Schwartz, Joel Hauser, Russ Herrick, Robert F. Christiani, David C. TI Time course of heart rate variability decline following particulate matter exposures in an occupational cohort SO INHALATION TOXICOLOGY LA English DT Article ID CONCENTRATED AMBIENT PARTICLES; SPONTANEOUSLY HYPERTENSIVE-RATS; TRANSITION-METALS; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; AIR-POLLUTION; FINE; HEALTHY; ASSOCIATION; POPULATION AB Although research suggests that particles influence cardiac autonomic response as evidenced by decreases in heart rate variability (HRV), the time course of the response remains unclear. Using a crossover panel study, we monitored 36 male boilermaker welders, occupationally exposed to metal-rich particulate matter (PM) to investigate the temporal trend of hourly HRV subsequent to PM exposure. Ambulatory electrocardiograms were collected over work (exposure) and non-work (control) periods and the mean of the standard deviations of all normal-to-normal intervals for all 5-min segments (SDNNi) was calculated hourly for up to 14-hrs post-work. The exposure-response relationship was examined with linear mixed effects regression models to account for participants monitored over multiple occasions. Models were adjusted for non-work HRV to control for diurnal fluctuations and individual predictors of HRV. The mean (SD) work PM2.5 concentration was 1.12 (0.76) mg/m(3). Hourly SDNNi was consistently lower post-work as compared to the same time period on a non-work day. HRV was inversely associated with work PM2.5 exposures in each of the 14-hrs post-work. The hourly associations suggested an early and later phase response, with the largest regression coefficients observed 2-3 hrs (beta = -6.86 (95% CI: -11.91, -1.81) msec/1 mg/m(3) at 3-hrs), and then 9-13 hrs (beta = -8.60 (95% CI: -17.45, 0.24) msec/1 mg/m(3) at 11-hrs), after adjusting for non-work HRV, smoking status, and age. This investigation demonstrates declines in HRV for up to 14 hours following PM exposure and a multiphase cardiovascular autonomic response with immediate (2 hrs) and delayed (9-13 hrs) responses. C1 [Cavallari, Jennifer M.; Fang, Shona C.; Eisen, Ellen A.; Schwartz, Joel; Hauser, Russ; Herrick, Robert F.; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Environm & Occupat Med & Epidemiol Program, Dept Environm Hlth, Boston, MA 02115 USA. [Christiani, David C.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Christiani, David C.] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Dept Med, Boston, MA 02114 USA. RP Cavallari, JM (reprint author), Harvard Univ, Sch Publ Hlth, Environm & Occupat Med & Epidemiol Program, Dept Environm Hlth, 665 Huntington Ave,SPH1-1420, Boston, MA 02115 USA. EM jcavalla@hsph.harvard.edu NR 38 TC 28 Z9 29 U1 0 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0895-8378 J9 INHAL TOXICOL JI Inhal. Toxicol. PY 2008 VL 20 IS 4 BP 415 EP 422 DI 10.1080/08958370801903800 PG 8 WC Toxicology SC Toxicology GA 269IN UT WOS:000253642800005 PM 18302049 ER PT J AU Wang, ZX Neuberg, D Su, L Kim, JY Chen, JC Christiani, DC AF Wang, Zhaoxi Neuberg, Donna Su, Li Kim, Jee Young Chen, Jiu-Chiuan Christiani, David C. TI Prospective Study of Metal Fume-Induced Responses of Global Gene Expression Profiling in Whole Blood SO INHALATION TOXICOLOGY LA English DT Article ID PARTICULATE AIR-POLLUTION; MONICA-AUGSBURG; RAINBOW-TROUT; ASSOCIATION; MARKERS; EXPOSURE; PROJECT; MEN AB Metal particulate inhalation causes pulmonary and cardiovascular diseases. Our previous results showed that systemic responses to short-term occupational welding-fume exposure could be assessed by microarray analyses in whole-blood total RNA sampled before and after exposure. To expand our understanding of the duration of particulate-induced gene expression changes, we conducted a study using a similar population 1 yr after the original study and extended our observations in the postexposure period. We recruited 15 individuals with welding fume exposure and 7 nonexposed individuals. Thirteen of the 22 individuals (9 in exposed group and 4 in nonexposed group) had been monitored in the previous study. Whole-blood total RNA was analyzed at 3 time points, including baseline, immediately following exposure (approximately 5 h after baseline), and 24 h after baseline, using cDNA microarray technology. We replicated the patterns of Gene Ontology (GO) terms associated with response to stimulus, cell death, phosphorus metabolism, localization, and regulation of biological processes significantly enriched with altered genes in the nonsmoking exposed group. Most of the identified genes had opposite expression changes between the exposure and postexposure periods in nonsmoking welders. In addition, we found dose-dependent patterns that were affected by smoking status. In conclusion, short-term occupational exposure to metal particulates causes systemic responses in the peripheral blood. Furthermore, the acute particulate-induced effects on gene expression profiling were transient in nonsmoking welders, with most effects diminishing within 19 h following exposure. C1 [Wang, Zhaoxi; Su, Li; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Neuberg, Donna] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Kim, Jee Young] US EPA, Natl Ctr Environm Assessment, Res Triangle Pk, NC 27711 USA. [Chen, Jiu-Chiuan] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA. [Christiani, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit,Dept Med, Boston, MA USA. RP Wang, ZX (reprint author), 665 Huntington Ave,I-1404B, Boston, MA 02115 USA. EM mikewang@hsph.harvard.edu RI Chen, JC/I-2261-2016 FU National Institute of Environmental Health Sciences [T32 ES07069]; National Institutes of Health [ES009860, ES00002] FX This work was supported by grant T32 ES07069 from the National Institute of Environmental Health Sciences, and by research grants ES009860 and ES00002 from the National Institutes of Health. NR 37 TC 7 Z9 7 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0895-8378 J9 INHAL TOXICOL JI Inhal. Toxicol. PY 2008 VL 20 IS 14 BP 1233 EP 1244 DI 10.1080/08958370802192874 PG 12 WC Toxicology SC Toxicology GA 387GH UT WOS:000261939200003 PM 18951227 ER PT B AU Draznin, B AF Draznin, Boris BE Zeitler, PS Nadeau, KJ TI Molecular Mechanisms of Insulin Resistance SO INSULIN RESISTANCE: CHILDHOOD PRECURSORS AND ADULT DISEASE SE Contemporary Endocrinology Series LA English DT Article; Book Chapter DE insulin resistance; insulin action; IRS-1; PI3-kinase ID P85 REGULATORY SUBUNIT; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE B; P70 S6 KINASE; PHOSPHOINOSITIDE 3-KINASE; SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR SUBSTRATE-1; MAMMALIAN TARGET; SIGNALING PATHWAYS C1 [Draznin, Boris] Denver VA Med Ctr, Res Serv, Denver, CO USA. [Draznin, Boris] Univ Colorado Denver, Dept Med, Aurora, CO USA. RP Draznin, B (reprint author), Denver VA Med Ctr, Res Serv, Denver, CO USA. NR 120 TC 0 Z9 0 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-875-1 J9 CONTEMP ENDOCRINOL S PY 2008 BP 95 EP 108 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BJR35 UT WOS:000267023100006 ER PT B AU Rosenthal, DS Doherty-Gilman, A Medeiros, C DeCristofaro, S Dean-Clower, E AF Rosenthal, David S. Doherty-Gilman, Anne Medeiros, Cynthia DeCristofaro, Susan Dean-Clower, Elizabeth BE Cohen, L Markman, M TI Integrative Oncology-Leonard P. Zakim Center The Dana-Farber Cancer Institute Experience SO INTEGRATIVE ONCOLOGY: INCORPORATING COMPLEMENTARY MEDICINE INTO CONVENTIONAL CANCER CARE SE Current Clinical Oncology Series LA English DT Article; Book Chapter DE Integrative oncology; integrative therapies; cancer care; complementary therapies; program development; quality of life; patient empowerment; Zakim Center; integration strategies; acupuncture; massage therapy; Reiki; nutrition; integrative oncology consultation; Qigong; staffing model; documentation; Dana-Farber ID COMPLEMENTARY/ALTERNATIVE MEDICINE; PROSTATE-CANCER; THERAPIES AB More and more frequently, hospitals are expanding their services to incorporate complementary therapies into their medical settings. One of the first successful models for a hospital-based integrative therapies center was developed in Boston, Massachusetts at Dana-Farber Cancer Institute, a Harvard University academic medical center and world-renowned cancer patient care and research institute. Driven by patient advocacy and a desire to provide the most safe and efficacious care possible, the Leonard P. Zakim Center for Integrative Therapies at Dana-Farber unites leading cancer experts with complementary therapy practitioners in order to offer patients a more holistic, comprehensive cancer care. The Zakim Center is an interdisciplinary program that uses a three-prong approach by offering complementary therapies including acupuncture, massage, nutrition, and others to enhance patients' quality of life and to help them with symptom management, while at the same time, educating staff and patients about these therapies and researching them in order to advance their scientific evidence base. Development of this Center and the concept of a new discipline, "integrative oncology,' required much communication, strategic planning, leadership commitment, and the diligence of many individuals. Through focused program and operational development, active institutional collaborations, and the concerted efforts of the whole Dana-Farber community, a premier comprehensive integrative therapies center that is affordable and accessible was established and continues to flourish and grow extensively today to meet the needs of patients, clinicians, and researchers at Dana-Farber Cancer Institute. C1 [Rosenthal, David S.] Harvard Univ, Hlth Serv, Cambridge, MA 02138 USA. [Rosenthal, David S.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Rosenthal, David S.] Dana Farber Canc Inst, Zakim Ctr Integrat Therapies, Cambridge, MA 02138 USA. [Medeiros, Cynthia] Dana Farber Canc Inst, Patient Care Serv Adm, Boston, MA 02115 USA. [Doherty-Gilman, Anne; DeCristofaro, Susan; Dean-Clower, Elizabeth] Dana Farber Canc Inst, Leonard P Zakim Ctr Integrat Therapies, Boston, MA 02115 USA. RP Rosenthal, DS (reprint author), Harvard Univ, Hlth Serv, 75 Mt Auburn St, Cambridge, MA 02138 USA. EM drose@uhs.harvard.edu NR 11 TC 1 Z9 1 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-869-0 J9 CURR CLIN ONCOL PY 2008 BP 79 EP 103 DI 10.1007/978-1-59745-183-3_7 D2 10.1007/978-1-59745-183-3 PG 25 WC Oncology; Hematology SC Oncology; Hematology GA BJZ78 UT WOS:000267544700007 ER PT B AU Lu, WD Dean-Clower, E Doherty-Gilman, A Rosenthal, DS AF Lu, Weidong Dean-Clower, Elizabeth Doherty-Gilman, Anne Rosenthal, David S. BE Cohen, L Markman, M TI Acupuncture in Cancer Care at Dana-Farber Cancer Institute An Integrative Medical Practice SO INTEGRATIVE ONCOLOGY: INCORPORATING COMPLEMENTARY MEDICINE INTO CONVENTIONAL CANCER CARE SE Current Clinical Oncology Series LA English DT Article; Book Chapter DE Acupuncture; research; oncology acupuncture; electroacupuncture; cancer symptom management; treatment side effects; non-pharmaceutical intervention ID CONTROLLED-TRIAL; AURICULAR ACUPUNCTURE; SKIN TEMPERATURE; XEROSTOMIA; ANXIETY; RADIOTHERAPY; ACUPRESSURE; HEAD AB Acupuncture, an ancient form of medical treatment and philosophy originating in China over several thousand years ago, has gained increasing usage and acceptance in the United States over the past decade, including its use as adjunct treatment for cancer patients. Acupuncture is a major clinical service and focus of clinical research studies at the Leonard P. Zakim Center for Integrative Therapies at Dana-Farber Cancer Institute, in Boston, Massachusetts. The Zakim Center provides acupuncture for patients with cancer and cancer survivors for symptom management or treatment-related side effects, including chemotherapy-induced nausea/vomiting, cancer pain, insomnia, fatigue, anxiety, and/or a sense of well-being, based on the patient's condition and evidence of safety and efficacy. Communication with allopathic clinicians and documentation in the medical record are standard procedures in the Zakim Center which are crucial to the acupuncturist and the oncology care team members benefit from each other's contributions to the patient's overall cancer care. The successful integration of acupuncture at Dana-Farber, a premier academic medical and research facility, underscores the need for oncology acupuncture protocols and for more acupuncturists with specialized clinical experience working with cancer patients. For this reason, oncology acupuncture is proposed as a new subspecialty in which acupuncturists possess clinical knowledge and skills in both acupuncture and oncology in order to optimize safety and efficacy, thereby providing a truly integrative approach for the cancer patient population. C1 [Rosenthal, David S.] Harvard Univ, Hlth Serv, Cambridge, MA 02138 USA. [Rosenthal, David S.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Rosenthal, David S.] Dana Farber Canc Inst, Zakim Ctr Integrat Therapies, Cambridge, MA 02138 USA. [Lu, Weidong; Dean-Clower, Elizabeth; Doherty-Gilman, Anne] Dana Farber Canc Inst, Leonard P Zakim Ctr Integrat Therapies, Boston, MA 02115 USA. RP Rosenthal, DS (reprint author), Harvard Univ, Hlth Serv, 75 Mt Auburn St, Cambridge, MA 02138 USA. EM drose@uhs.harvard.edu RI Lu, Weidong/C-3844-2008 OI Lu, Weidong/0000-0003-2838-6307 NR 14 TC 1 Z9 1 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-869-0 J9 CURR CLIN ONCOL PY 2008 BP 181 EP 199 DI 10.1007/978-1-59745-183-3_12 D2 10.1007/978-1-59745-183-3 PG 19 WC Oncology; Hematology SC Oncology; Hematology GA BJZ78 UT WOS:000267544700012 ER PT B AU Napadow, V Dhond, RP Kettner, NW AF Napadow, Vitaly Dhond, Rupali P. Kettner, Norman W. BE Audette, JF Bailey, A TI Neuroimaging for the Evaluation of CAM Mechanisms SO INTEGRATIVE PAIN MEDICINE: THE SCIENCE AND PRACTICE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE IN PAIN MANAGEMENT SE Contemporary Pain Medicine LA English DT Article; Book Chapter DE acupuncture; functional MRI, fMRI; PET; MEG; EEG; brain; neurophysiology ID CARPAL-TUNNEL-SYNDROME; SOMATOSENSORY CORTICAL PLASTICITY; ACUPUNCTURE STIMULATION; HUMAN BRAIN; SENSORY STIMULATION; FUNCTIONAL MRI; HEART-RATE; CONVERGENT NEURONS; SYMPATHETIC-NERVE; HEALTHY-SUBJECTS AB Complementary and alternative medicine (CAM) research is entering a new era where state-of-the-art neuroimaging modalities are able noninvasively to measure brain response in humans to both simple and complex CAM stimuli. While the neurophysiological mechanisms of action for many CAM treatments and pain are not well understood and controversy regarding their clinical efficacy remains, neuroimaging research can begin to decode any specific treatment-related mechanisms, if indeed they exist. This chapter will briefly outline the pain neuromatrix and modern neuroimaging techniques such as functional magnetic resonance imaging (fMRI), positron emission tomography (PET), electroencephalography (EEG), and magnetoencephalography (MEG). We will also summarize neuroimaging results for several CAM treatments, though the focus will be on acupuncture, which has been most extensively researched with neuroimaging. Acupuncture is an ancient healing modality that originated in China and has been in use for over 2000 years. Importantly, acupuncture needling often evokes complex somatosensory sensations and may modulate the cognitive/affective perception of pain, Suggesting that many effects are mediated by the brain and extending central nervous system (CNS) networks. Other CAM modalities evaluated with neuroimaging include meditation and biofeedback. We will also discuss future directions for CAM neuroimaging research, as this is a very dynamic and evolving field which may ultimately shed light on the mechanisms of action for several CAM treatments. C1 [Napadow, Vitaly; Dhond, Rupali P.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Kettner, Norman W.] Logan Coll Chiropract, Dept Radiol, Chesterfield, MO USA. RP Napadow, V (reprint author), Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. NR 95 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-786-0 J9 CONTEMP PAIN MED PY 2008 BP 85 EP 106 DI 10.1007/978-1-59745-344-8_4 D2 10.1007/978-1-59745-344-8 PG 22 WC Medicine, General & Internal SC General & Internal Medicine GA BKH64 UT WOS:000268129700004 ER PT B AU Bailey, A Stein, M AF Bailey, Allison Stein, Meryl BE Audette, JF Bailey, A TI Integrative Pain Medicine Models Women's Health Programs SO INTEGRATIVE PAIN MEDICINE: THE SCIENCE AND PRACTICE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE IN PAIN MANAGEMENT SE Contemporary Pain Medicine LA English DT Article; Book Chapter DE women's health; sex hormones; pelvic floor muscle dysfunction; pelvic pain; urinary incontinence; fibromyalgia; myofascial pain; osteoporosis; back pain; pregnancy; postpartum; sacroiliac joint dysfunction ID ANTERIOR CRUCIATE LIGAMENT; LOW-BACK-PAIN; RANDOMIZED CONTROLLED-TRIAL; HORMONE-REPLACEMENT THERAPY; ESTROGEN PLUS PROGESTIN; BONE-MINERAL DENSITY; SYMPATHETIC DYSTROPHY SYNDROME; COGNITIVE-BEHAVIORAL TREATMENT; PELVIC FLOOR DYSFUNCTION; CARPAL-TUNNEL-SYNDROME AB Recognition of the important biological differences between men and women When it comes to pain processing is key to providing optimum care to women with both subacute and chronic musculoskeletal and pain conditions. Pregnancy, labor, and delivery, hormonal fluctuations of the menstrual cycle and the decrease in gonadal hormones that accompany menopause may all affect the musculoskeletal and neurological systems in varied and complex ways that may result in painful conditions. The precise mechanisms by which these changes occur remain under investigation. Nevertheless, pain programs in Women's Health should be designed to address the needs of women with a variety of health issues including, but not limited to, pregnancy and postpartum-related musculoskeletal problems, pelvic pain and pelvic floor muscle dysfunction, fibromyalgia and myofascial pain, osteoporosis and its complications, and general musculoskeletal health and fitness. In addition, Women's Health programs should recognize the effects of the sex hormones on pain processing and attempt to address underlying issues of hormone imbalance. An integrative model of care that combines high-quality complementary and alternative medicine (CAM) services with those of conventional medicine when appropriate may be the optimal setting in which to treat women with such pain disorders. C1 [Bailey, Allison] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Spaulding, MA USA. [Bailey, Allison] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Stein, Meryl] S Jersey Sports & Spine Med, Voorhees, NJ USA. [Stein, Meryl] Univ Penn, Dept Phys Med & Rehabil, Philadelphia, PA USA. RP Bailey, A (reprint author), Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Spaulding, MA USA. NR 245 TC 1 Z9 1 U1 1 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-786-0 J9 CONTEMP PAIN MED PY 2008 BP 497 EP 545 DI 10.1007/978-1-59745-344-8_22 D2 10.1007/978-1-59745-344-8 PG 49 WC Medicine, General & Internal SC General & Internal Medicine GA BKH64 UT WOS:000268129700022 ER PT J AU Dellinger, RP Levy, MM Carlet, JM Bion, J Parker, MM Jaeschke, R Reinhart, K Angus, DC Brun-Buisson, C Beale, R Calandra, T Dhainaut, JF Gerlach, H Harvey, M Marini, JJ Marshall, J Ranieri, M Ramsay, G Sevransky, J Thompson, BT Townsend, S Vender, JS Zimmerman, JL Vincent, JL AF Dellinger, R. Phillip Levy, Mitchell M. Carlet, Jean M. Bion, Julian Parker, Margaret M. Jaeschke, Roman Reinhart, Konrad Angus, Derek C. Brun-Buisson, Christian Beale, Richard Calandra, Thierry Dhainaut, Jean-Francois Gerlach, Herwig Harvey, Maurene Marini, John J. Marshall, John Ranieri, Marco Ramsay, Graham Sevransky, Jonathan Thompson, B. Taylor Townsend, Sean Vender, Jeffrey S. Zimmerman, Janice L. Vincent, Jean-Louis TI Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 SO INTENSIVE CARE MEDICINE LA English DT Review DE sepsis; severe sepsis; Septic shock; Sepsis syndrome; Infection; GRADE; Guidelines; Evidence-based medicine; Surviving Sepsis Campaign; sepsis bundles ID RESPIRATORY-DISTRESS-SYNDROME; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; ACUTE-RENAL-FAILURE; RANDOMIZED CONTROLLED-TRIAL; ACUTE LUNG INJURY; MECHANICALLY VENTILATED PATIENTS; DEEP-VEIN THROMBOSIS; LOW-DOSE HEPARIN; STRESS-ULCER PROPHYLAXIS AB Objective: To provide an update to the original Surviving Sepsis Campaign clinical management guidelines, "Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock," published in 2004. Design: Modified Delphi method with a consensus conference of 55 international experts, several subsequent meetings of subgroups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee. This process was conducted independently of any industry funding. Methods: We used the GRADE system to guide assessment of quality of evidence from high (A) to very low (D) and to determine the strength of recommendations. A strong recommendation [1] indicates that an intervention's desirable effects clearly outweigh its undesirable effects (risk, burden, cost), or clearly do not. Weak recommendations [2] indicate that the tradeoff between desirable and undesirable effects is less clear. The grade of strong or weak is considered of greater clinical importance than a difference in letter level of quality of evidence. In areas without complete agreement, a formal process of resolution was developed and applied. Recommendations are grouped into those directly targeting severe sepsis, recommendations targeting general care of the critically ill patient that are considered high priority in severe sepsis, and pediatric considerations. Results: Key recommendations, listed by category, include: early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition (1C); blood cultures prior to antibiotic therapy (1C); imaging studies performed promptly to confirm potential source of infection (1C); administration of broad-spectrum antibiotic therapy within 1 hr of diagnosis of septic shock (1B) and severe sepsis without septic shock (1D); reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate (1C); a usual 7-10 days of antibiotic therapy guided by clinical response (1D); source control with attention to the balance of risks and benefits of the chosen method (1C); administration of either crystalloid or colloid fluid resuscitation (1B); fluid challenge to restore mean circulating filling pressure (1C); reduction in rate of fluid administration with rising filing pressures and no improvement in tissue perfusion (1D); vasopressor preference for norepinephrine or dopamine to maintain an initial target of mean arterial pressure >= 65 mm Hg (1C); dobutamine inotropic therapy when cardiac output remains low despite fluid resuscitation and combined inotropic/vasopressor therapy (1C); stress-dose steroid therapy given only in septic shock after blood pressure is identified to be poorly responsive to fluid and vasopressor therapy (2C); recombinant activated protein C in patients with severe sepsis and clinical assessment of high risk for death (2B except 2C for post-operative patients). In the absence of tissue hypoperfusion, coronary artery disease, or acute hemorrhage, target a hemoglobin of 7-9 g/dL (1B); a low tidal volume (1B) and limitation of inspiratory plateau pressure strategy (1C) for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS); application of at least a minimal amount of positive end-expiratory pressure in acute lung injury (1C); head of bed elevation in mechanically ventilated patients unless contraindicated (1B); avoiding routine use of pulmonary artery catheters in ALI/ARDS (1A); to decrease days of mechanical ventilation and ICU length of stay, a conservative fluid strategy for patints with established ALI/ARDS who are not in shock (1C); protocols for weaning and sedation/analgesia (1B); using either intermittent bolus sedation or continuous infusion sedation with daily interruptions or lightening (1B); avoidance of neuromuscular blockers, if at all possible (1B); institution of glycemic control (1B) targeting a blood glucose < 150 mg/dL after initial stabilization ( 2C ); equivalency of continuous veno-veno hemofiltration or intermittent hemodialysis (2B); prophylaxis for deep vein thrombosis (1A); use of stress ulcer prophylaxis to prevent upper GI bleeding using H2 blockers (1A) or proton pump inhibitors (1B); and consideration of limitation of support where appropriate (1D). Recommendations specific to pediatric severe sepsis include: greater use of physical examination therapeutic end points (2C); dopamine as the first drug of choice for hypotension (2C); steroids only in children with suspected or proven adrenal insufficiency (2C); a recommendation against the use of recombinant activated protein C in children (1B). Conclusion: There was strong agreement among a large cohort of international experts regarding many level 1 recommendations for the best current care of patients with severe sepsis. Evidenced-based recommendations regarding the acute management of sepsis and septic shock are the first step toward improved outcomes for this important group of critically ill patients. C1 [Dellinger, R. Phillip] Cooper Univ Hosp, Camden, NJ 08103 USA. [Levy, Mitchell M.; Townsend, Sean] Rhode Isl Hosp, Providence, RI USA. [Carlet, Jean M.] St Joseph Hosp, Paris, France. [Bion, Julian] Univ Birmingham, Birmingham, W Midlands, England. [Parker, Margaret M.] SUNY Stony Brook, Stony Brook, NY 11794 USA. [Jaeschke, Roman] McMaster Univ, Hamilton, ON, Canada. [Reinhart, Konrad] Univ Jena, Jena, Germany. [Angus, Derek C.] Univ Pittsburgh, Pittsburgh, PA USA. [Brun-Buisson, Christian] Hop Henri Mondor, F-94010 Creteil, France. [Beale, Richard] Guys & St Thomas Hosp Turst, London, England. [Calandra, Thierry] Univ Vaudois, Ctr Hosp, Lausanne, Switzerland. [Dhainaut, Jean-Francois] French Agcy Evaluat Res & Higher Educ, Paris, France. [Gerlach, Herwig] Vivantes Klinikum Neukoelln, Berlin, Germany. [Harvey, Maurene] Crit Care Inc, Glenbrook, NV USA. [Marini, John J.] Univ Minnesota, St Paul, MN 55108 USA. [Marshall, John] St Michaels Hosp, Toronto, ON M5B 1W8, Canada. [Ranieri, Marco] Univ Turin, Turin, Italy. [Ramsay, Graham] W Hertfordshire Hlth Trust, Hemel Hempstead, Herts, England. [Sevransky, Jonathan] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Thompson, B. Taylor] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Vender, Jeffrey S.] Evanston NW Healthcare, Evanston, IL USA. [Zimmerman, Janice L.] Methodist Hosp, Houston, TX 77030 USA. [Vincent, Jean-Louis] Erasme Univ Hosp, B-1070 Brussels, Belgium. RP Dellinger, RP (reprint author), Cooper Univ Hosp, 1 Cooper Pl,393 Dorrance, Camden, NJ 08103 USA. EM Dellinger-Phil@CooperHealth.edu RI Beale, Richard/J-7831-2013; Angus, Derek/E-9671-2012; Calandra, Thierry/D-9017-2015 OI Calandra, Thierry/0000-0003-3051-1285 FU NIGMS NIH HHS [K23 GM071399-03] NR 341 TC 822 Z9 985 U1 10 U2 89 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0342-4642 EI 1432-1238 J9 INTENS CARE MED JI Intensive Care Med. PD JAN PY 2008 VL 34 IS 1 BP 17 EP 60 DI 10.1007/s00134-007-0934-2 PG 44 WC Critical Care Medicine SC General & Internal Medicine GA 250JS UT WOS:000252296600004 PM 18058085 ER PT J AU Yamaoka, Y Kato, M Asaka, M AF Yamaoka, Yoshio Kato, Mototsugu Asaka, Masahiro TI Geographic Differences in Gastric Cancer Incidence Can be Explained by Differences between Helicobacter pylori Strains SO INTERNAL MEDICINE LA English DT Review DE Helicobacter pylori; genotypes; gastric cancer; cagA; vacA ID CAG PATHOGENICITY ISLAND; ANTIGEN-BINDING ADHESIN; OUTER-MEMBRANE PROTEINS; VACUOLATING CYTOTOXIN; EPITHELIAL-CELLS; VIRULENCE FACTORS; TYROSINE PHOSPHORYLATION; MOLECULAR EPIDEMIOLOGY; GASTRODUODENAL DISEASE; PROMOTER ACTIVATION AB Certain populations with high incidences of Helicobacter pylori infection, such as those in East Asian countries, have high incidences of gastric cancer, while other highly infected populations, such as those in Africa and South Asia, do not. The various rates of gastric cancer associated with different geographic areas can be explained, at least in part, by the differences in the genotypes of H. pylori cagA and vacA. Populations expressing a high incidence of gastric cancer are mostly identical with regions where East Asian type CagA is predominant. In contrast, incidence of gastric cancer is low in Africa, South Asia, and Europe, where strains typically possess Western type CagA. Within East Asia, strains from northern parts, where the incidence of gastric cancer is high, predominantly possess the vacA m1 genotype, whereas the m2 genotype is predominant in southern parts where the gastric cancer incidence is low. C1 [Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX USA. [Yamaoka, Yoshio] Baylor Coll Med, Houston, TX 77030 USA. [Kato, Mototsugu] Hokkaido Univ Hosp, Div Endoscopy, Sapporo, Hokkaido 060, Japan. [Asaka, Masahiro] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol, Sapporo, Hokkaido, Japan. RP Yamaoka, Y (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX USA. EM yyamaoka@bcm.tme.edu RI Asaka, Masahiro/A-5948-2012; Kato, Mototsugu/A-6736-2012 FU National Institutes of Health [DK62813] FX This work was supported in part by grants from the National Institutes of Health DK62813. NR 77 TC 111 Z9 126 U1 1 U2 4 PU JAPAN SOC INTERNAL MEDICINE PI TOKYO PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN SN 0918-2918 J9 INTERNAL MED JI Intern. Med. PY 2008 VL 47 IS 12 BP 1077 EP 1083 DI 10.2169/internalmedicine.47.0975 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 349RA UT WOS:000259297800001 PM 18552463 ER PT J AU Kenning, P Marci, C Calvert, G AF Kenning, Peter Marci, Carl Calvert, Gemma TI Advertising and the brain SO INTERNATIONAL JOURNAL OF ADVERTISING LA English DT Editorial Material C1 [Kenning, Peter] Zeppelin Univ, Friedrichshafen, Germany. [Marci, Carl] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. [Calvert, Gemma] Univ Warwick, Coventry CV4 7AL, W Midlands, England. RP Kenning, P (reprint author), Zeppelin Univ, Friedrichshafen, Germany. NR 4 TC 2 Z9 2 U1 2 U2 6 PU WORLD ADVERTISING RESEARCH CENTER PI OXON PA FARM RD, HENLEY-ON-THAMES, OXON, OXFORDSHIRE RG9 1EJ, ENGLAND SN 0265-0487 J9 INT J ADVERT JI Int. J. Advert. PY 2008 VL 27 IS 3 BP 355 EP 356 DI 10.2501/S0265048708080013 PG 2 WC Business; Communication SC Business & Economics; Communication GA 339BT UT WOS:000258553800001 ER PT J AU Siefert, C Gallent, J Jaeobs, D Levine, B Stipp, H Marci, C AF Siefert, Caleb Gallent, Janet Jaeobs, Devra Levine, Brian Stipp, Horst Marci, Carl TI Biometric and eye-tracking insights into the efficiency of information processing of television advertising during fast-forward viewing SO INTERNATIONAL JOURNAL OF ADVERTISING LA English DT Article ID AUTOMATICITY; NEUROSCIENCE; BEHAVIOR; MEMORY; STIMULI; RECALL; IMPACT AB Despite increased research focusing on the impact of digital video recorder (DVR) use, there continues to be a notable lack of data on viewers' direct experience of time-shifted television ads. The current study was designed to increase understanding of information processing among DVR users by directly examining viewers' biometric responses, eye-gaze patterns and memory for ads viewed entirely in fast-forward (FF) mode compared with viewers who watched the same ads in real time. The results indicate that, compared with a control group of viewers of real-time advertising, viewers recalled the same ads viewed in FF at significantly higher rates than expected given the speed with which they were viewed. Notably, prior exposure to an ad increased the likelihood of that ad being recalled in FF mode. Eye-tracking data show that viewers in the DVR group spent significantly more time with their eyes on screen, more time looking at the centre of the screen, and also showed a substantial amount of visual processing activity during FF viewing. Finally, there were significantly higher levels of biometric response, :in indicator of emotional processing, suggesting that viewers are in a 'hyper-alert' state during FF viewing. The biometric results, when combined with indications of visual processing and increased screen time, help explain the higher than expected next-day recall of ads in the DVR group. C1 [Siefert, Caleb; Marci, Carl] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Siefert, Caleb; Marci, Carl] Massachusetts Gen Hosp, Boston, MA 02115 USA. [Siefert, Caleb; Jaeobs, Devra; Levine, Brian; Marci, Carl] Innerscope Res LLC, Boston, MA 02115 USA. [Gallent, Janet; Stipp, Horst] NBC Universal, New York, NY 10112 USA. RP Siefert, C (reprint author), Harvard Univ, Sch Med, 427 Newbury St, Boston, MA 02115 USA. EM cmarci@innerscope.com NR 40 TC 9 Z9 9 U1 1 U2 18 PU WORLD ADVERTISING RESEARCH CENTER PI OXON PA FARM RD, HENLEY-ON-THAMES, OXON, OXFORDSHIRE RG9 1EJ, ENGLAND SN 0265-0487 J9 INT J ADVERT JI Int. J. Advert. PY 2008 VL 27 IS 3 BP 425 EP + DI 10.2501/S0265048708080050 PG 23 WC Business; Communication SC Business & Economics; Communication GA 339BT UT WOS:000258553800005 ER PT J AU Marci, CD AF Marci, Carl D. TI Minding the gap: the evolving relationships between affective neuroscience and advertising research SO INTERNATIONAL JOURNAL OF ADVERTISING LA English DT Editorial Material C1 [Marci, Carl D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. RP Marci, CD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. NR 7 TC 4 Z9 4 U1 0 U2 4 PU WORLD ADVERTISING RESEARCH CENTER PI OXON PA FARM RD, HENLEY-ON-THAMES, OXON, OXFORDSHIRE RG9 1EJ, ENGLAND SN 0265-0487 J9 INT J ADVERT JI Int. J. Advert. PY 2008 VL 27 IS 3 BP 473 EP 475 PG 3 WC Business; Communication SC Business & Economics; Communication GA 339BT UT WOS:000258553800009 ER PT J AU Kukluk, JP Holder, LB Cook, DJ AF Kukluk, Jacek P. Holder, Lawrence B. Cook, Diane J. TI Inferring graph grammars by detecting overlap in frequent subgraphs SO INTERNATIONAL JOURNAL OF APPLIED MATHEMATICS AND COMPUTER SCIENCE LA English DT Article DE grammar induction; graph grammars; graph mining; multi-relational data mining AB In this paper we study the inference of node and edge replacement graph grammars. We search for frequent subgraphs and then check for an overlap among the instances of the subgraphs in the input graph. If the subgraphs overlap by one node, we propose a node replacement graph grammar production. If the subgraphs overlap by two nodes or two nodes and an edge, we propose an edge replacement graph grammar production. We can also infer a hierarchy of productions by compressing portions of a graph described by a production and then inferring new productions on the compressed graph. We validate the approach in experiments where we generate graphs from known grammars and measure how well the approach infers the original grammar from the generated graph. We show graph grammars found in biological molecules, biological networks, and analyze learning curves of the algorithm. C1 [Kukluk, Jacek P.] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA. [Holder, Lawrence B.; Cook, Diane J.] Washington State Univ, Sch Elect Engn & Comp Sci, Pullman, WA 99164 USA. RP Kukluk, JP (reprint author), Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, 75 Francis St, Boston, MA 02115 USA. EM jkukluk@lroc.harvard.edu; holder@wsu.edu; cook@eecs.wsu.edu NR 17 TC 2 Z9 2 U1 0 U2 0 PU UNIV ZIELONA GORA PRESS PI ZIELONA GORA PA UL PODGORNA 50, ZIELONA GORA, 65-246, POLAND SN 1641-876X J9 INT J AP MAT COM-POL JI Int. J. Appl. Math. Comput. Sci. PY 2008 VL 18 IS 2 BP 241 EP 250 DI 10.2478/v10006-008-0022-y PG 10 WC Automation & Control Systems; Computer Science, Artificial Intelligence; Mathematics, Applied SC Automation & Control Systems; Computer Science; Mathematics GA 321TW UT WOS:000257330400013 ER PT J AU Adamala, K AF Adamala, Katarzyna TI How to close the door leaving it open? On the origin of membrane transport system SO INTERNATIONAL JOURNAL OF ASTROBIOLOGY LA English DT Meeting Abstract C1 [Adamala, Katarzyna] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. OI Adamala, Kate/0000-0003-1066-7207 NR 0 TC 0 Z9 0 U1 1 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1473-5504 J9 INT J ASTROBIOL JI Int. J. Astrobiol. PD JAN PY 2008 VL 7 IS 1 BP 74 EP 74 PG 1 WC Astronomy & Astrophysics; Biology; Geosciences, Multidisciplinary SC Astronomy & Astrophysics; Life Sciences & Biomedicine - Other Topics; Geology GA 541AK UT WOS:000273382800050 ER PT J AU Willey, CD Palanisamy, AP Johnston, RK Mani, SK Shiraishi, H Tuxworth, WJ Zile, MR Balasubramanian, S Kuppuswamy, D AF Willey, Christopher D. Palanisamy, Arun P. Johnston, Rebecca K. Mani, Santhosh K. Shiraishi, Hirokazu Tuxworth, William J. Zile, Michael R. Balasubramanian, Sundaravadivel Kuppuswamy, Dhandapani TI STAT3 activation in pressure-overloaded feline myocardium: Role for integrins and the tyrosine kinase BMX SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES LA English DT Article DE STAT3; BMX; integrin; pressure-overload; cardiac hypertrophy ID FOCAL COMPLEX-FORMATION; CARDIAC-HYPERTROPHY; SIGNAL TRANSDUCER; C-SRC; CONSTITUTIVE ACTIVATION; BIOMECHANICAL STRESS; GENE-EXPRESSION; CARCINOMA-CELLS; HEART-FAILURE; TEC FAMILY AB Growth, survival and cytoskeletal rearrangement of cardiomyocytes are critical for cardiac hypertrophy. Signal transducer and activator of transcription-3 (STAT3) activation is an important cardioprotective factor associated with cardiac hypertrophy. Although STAT3 activation has been reported via signaling through Janus Kinase 2 (JAK2) in several cardiac models of hypertrophy, the importance of other nonreceptor tyrosine kinases (NTKs) has not been explored. Utilizing an in vivo feline right ventricular pressure-overload (RVPO) model of hypertrophy, we demonstrate that in 48 h pressure-overload (PO) myocardium, STAT3 becomes phosphorylated and redistributed to detergent-insoluble fractions with no accompanying JAK2 activation. PO also caused increased levels of phosphorylated STAT3 in both cytoplasmic and nuclear fractions. To investigate the role of other NTKs, we used our established in vitro cell culture model of hypertrophy where adult feline cardiomyocytes are embedded three-dimensionally (3D) in type-I collagen and stimulated with an integrin binding peptide containing an Arg-Gly-Asp (RGD) motif that we have previously shown to recapitulate the focal adhesion complex (FAC) formation of 48 h RVPO. RGD stimulation of adult cardiomyocytes in vitro caused both STAT3 redistribution and activation that were accompanied by the activation and redistribution of c-Src and the TEC family kinase, BMX, but not JAK2. However, infection with dominant negative c-Src adenovirus was unable to block RGD-stimulated changes on either STAT3 or BMX. Further analysis in vivo in 48 h PO myocardium showed the presence of both STAT3 and BMX in the detergent-insoluble fraction with their complex formation and phosphorylation. Therefore, these studies indicate a novel mechanism of BMX-mediated STAT3 activation within a PO model of cardiac hypertrophy that might contribute to cardiomyocyte growth and survival. C1 [Willey, Christopher D.; Palanisamy, Arun P.; Johnston, Rebecca K.; Mani, Santhosh K.; Shiraishi, Hirokazu; Tuxworth, William J.; Zile, Michael R.; Balasubramanian, Sundaravadivel; Kuppuswamy, Dhandapani] Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, Charleston, SC 29425 USA. [Zile, Michael R.; Kuppuswamy, Dhandapani] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29425 USA. RP Kuppuswamy, D (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, 114 Doughty St, Charleston, SC 29425 USA. EM kuppusd@musc.edu RI Palanisamy, Arun/L-2019-2014; OI Palanisamy, Arun/0000-0002-7793-0682; Willey, Christopher/0000-0001-9953-0279 FU NHLBI NIH HHS [P01 HL048788, PPG HL-48788]; NIGMS NIH HHS [GM08716, T32 GM008716] NR 43 TC 17 Z9 18 U1 0 U2 2 PU IVYSPRING INT PUBL PI LAKE HAVEN PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA SN 1449-2288 J9 INT J BIOL SCI JI Int. J. Biol. Sci. PY 2008 VL 4 IS 3 BP 184 EP 199 PG 16 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA 331TF UT WOS:000258034800008 PM 18612371 ER PT J AU Waxman, S Khabbaz, K Connolly, R Tang, J Dabreo, A Egerhei, L Ishibashi, F Muller, JE Tearney, GM AF Waxman, Sergio Khabbaz, Kamal Connolly, Raymond Tang, Jing Dabreo, Alexandra Egerhei, Lara Ishibashi, Fumiyuki Muller, James E. Tearney, Guillermo M. TI Intravascular imaging of atherosclerotic human coronaries in a porcine model: a feasibility study SO INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING LA English DT Article DE imaging; atherosclerosis; plaque; myocardial infarction; catheters ID PLAQUE DISRUPTION; ANIMAL-MODELS; ULTRASOUND; ARTERIES; LESIONS; DEATH; VIVO AB Objectives To perform intravascular imaging of atherosclerotic human coronary conduits in an animal model under conditions of flow and cardiac motion that approximate those encountered in vivo. Background Given the lack of animal models of vulnerable plaque, a model which would allow imaging of human disease and simulate coronary motion and blood flow could advance the development of emerging technologies to detect vulnerable plaques. Methods Human coronary segments from adult cadaver hearts were prepared as xenografts. In anesthetized Yorkshire pigs (45-50 kg) the chest was opened and the exposed aorta and right atrium were cannulated and attached in an end-to-end fashion to the human coronary xenograft, forming an aorto-atrial conduit. The xenograft was fixed to the anterior wall of the heart to simulate motion. Angiography and intravascular ultrasound (IVUS) of each graft were performed. Results Twelve human coronary grafts (10 from right coronary segments) were prepared and implanted successfully in seven animals. All animals tolerated the procedure. The average graft length was 39 +/- 2.3 mm. Blood flow rates distal to the graft were > 100 ml/min in nine grafts. IVUS was performed in all 12 grafts and documented expansion of arterial (6.9%) and luminal (9.3%) dimensions during the cardiac cycle (P < 0.001 for both). There was a wide range of coronary atherosclerotic pathology within the grafts, including intimal thickening, fibrocalcific plaque, and deep lipid pools. Conclusion This human-to-porcine coronary xenograft model allows intravascular imaging of human coronary pathology under conditions of blood flow and motion, and may be used to develop technologies aimed at identifying high-risk plaques. C1 Lahey Clin Fdn, Burlington, MA 01805 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol,Wellman Ctr Photomed, Boston, MA USA. InfraReDx Inc, Cambridge, MA USA. Tufts Univ New England Med Ctr, Dept Surg, Boston, MA USA. Tufts Univ New England Med Ctr, Dept Med, Boston, MA USA. Tufts Univ New England Med Ctr, Ctr Translat Cardiovasc Res, Boston, MA USA. RP Waxman, S (reprint author), Lahey Clin Fdn, 41 Mall Rd, Burlington, MA 01805 USA. EM sergio.waxman@lahey.org NR 16 TC 2 Z9 2 U1 0 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1569-5794 J9 INT J CARDIOVAS IMAG JI Int. J. Cardiovasc. Imaging PD JAN PY 2008 VL 24 IS 1 BP 37 EP 44 DI 10.1007/s10554-007-9227-7 PG 8 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 238PE UT WOS:000251458900006 PM 17503218 ER PT J AU Diamond, SG Davis, OC Howe, RD AF Diamond, Solomon Gilbert Davis, Orin C. Howe, Robert D. TI Heart-rate variability as a quantitative measure of hypnotic depth SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL HYPNOSIS LA English DT Article ID NEAR-INFRARED SPECTROSCOPY; EEG ACTIVITY; HYPNOSIS; MEDITATION; EXPERIENCE; ANALGESIA; PAIN; HYPNOTIZABILITY; SUGGESTIBILITY; MODULATION AB The authors investigated whether heart-rate variability can serve as a device for real-time quantitative measurement of hypnotic depth. This study compared the continuous self-rated hypnotic depth (SRHD) of 10 volunteers with heart rate, amplitude, and frequency changes from a time-frequency analysis of heart-rate variability (HRV). The authors found significant linear relationships between SRHD and the high-frequency (HF) component of HRV. Specifically, SRHD was correlated negatively with the frequency of the HF component and positively with the amplitude of the HF component. Unexpectedly, the average temporal trend in SRHD fit well (R-2 = .99) to the step response of a first-order system with a 4-minute time constant. The findings suggest that the reactivity of the parasympathetic branch of the autonomic nervous system reflected in HRV could become part of a real-time, quantitative measure of hypnotic depth. C1 [Diamond, Solomon Gilbert; Howe, Robert D.] Harvard Univ, Cambridge, MA 02138 USA. [Davis, Orin C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Diamond, SG (reprint author), Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA. EM Solomon.G.Diamond@Dartmouth.edu OI Diamond, Solomon/0000-0002-7589-2942 NR 38 TC 9 Z9 10 U1 2 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0020-7144 J9 INT J CLIN EXP HYP JI Int. J. Clin. Exp. Hypn. PD JAN-MAR PY 2008 VL 56 IS 1 BP 1 EP 18 DI 10.1080/00207140701672961 PG 18 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 248JN UT WOS:000252149700001 PM 18058483 ER PT J AU Patel, AK Rogers, JT Huang, XD AF Patel, Ami K. Rogers, Jack T. Huang, Xudong TI Flavanols, Mild Cognitive Impairment, and Alzheimer's Dementia SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE LA English DT Review DE Brain vascular atrophy; mild cognitive impairment; Alzheimer's disease; flavanols; oxidative stress; antioxidants AB Alzheimer's disease (AD) is a dementing neurological disorder that results in progressive memory loss and cognitive decline thought to be associated with buildup of amyloid plaques and neurofibrillary tangles in the brain. Vascular Dementia (VaD) is another common dementing disorder characterized by decreased brain perfusion. Together, AD and VaD constitute mixed dementia, an extremely common type of dementia associated with aging. Neuroimaging research suggests that brain vascular atrophy results in mild cognitive impairment (MCI), a possible precursor for AD. Additionally, literature suggests that attention to cardiovascular risk factors such as hypertension could reduce or delay the incidence of mixed dementia. Furthermore, foods and beverages rich in natural antioxidant flavanoids (i.e. epicatechin and catechin) are currently being advocated as possible preventative agents for a number of pathological conditions ranging from coronary heart disease to dementia. Experimental evidence is mounting that oxidative stress is involved in the pathophysiology of AD, and numerous studies are indicating that polyphenolic antioxidants found in fruits and vegetables can be useful in countering this and blocking neuronal death. More specifically, several cocoa studies suggest that daily intake of cocoa flavanols leads to cardiovascular benefits including vasodilatation via a nitric oxide mechanism and increased brain perfusion. The following text will consider an important question that thus arises regarding the potential of flavanols as effective agents for the prevention and delay of the onset of brain vascular atrophy and subsequently MCI and AD. It will also review the molecular mechanisms through which flavanols operate to accomplish their protective effects. C1 [Patel, Ami K.; Huang, Xudong] Brigham & Womens Hosp, Dept Radiol, Conjugate & Med Chem Lab, Boston, MA 02115 USA. [Patel, Ami K.; Huang, Xudong] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Rogers, Jack T.; Huang, Xudong] Massachusetts Gen Hosp, Neurochem Lab, Dept Psychiat, Charlestown, MA 02129 USA. [Rogers, Jack T.; Huang, Xudong] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Huang, XD (reprint author), Brigham & Womens Hosp, Dept Radiol, Conjugate & Med Chem Lab, 75 Francis St, Boston, MA 02115 USA. EM xhuang3@partners.org FU George Washington University School of Medicine and Health Sciences; NIH/NIA [R21AG028850]; Alzheimer's Association FX The authors would like to thank Ms. Kimbly Lawson for her wonderful manuscript editing, and Dr. Norman Hollenberg for his valuable advice during the manuscript preparation. This work was supported by the Stone Summer Scholarship from the George Washington University School of Medicine and Health Sciences (to AKP) and NIH/NIA grant (R21AG028850) and Alzheimer's Association (to XH). NR 96 TC 18 Z9 18 U1 2 U2 19 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 1940-5901 J9 INT J CLIN EXP MED JI Int. J. Clin. Exp. Med. PY 2008 VL 1 IS 2 BP 181 EP 191 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA V28SI UT WOS:000208700100008 PM 19079672 ER PT J AU Dupin, MM Halliday, I Care, CM Munn, LL AF Dupin, M. M. Halliday, I. Care, C. M. Munn, L. L. TI Lattice Boltzmann modelling of blood cell dynamics SO INTERNATIONAL JOURNAL OF COMPUTATIONAL FLUID DYNAMICS LA English DT Article; Proceedings Paper CT 4th International Conference for Mesoscopic Methods in Engineering and Science CY JUL 16-20, 2007 CL Munich, GERMANY DE lattice Boltzmann; abnormal blood flow; red blood cells; blood rheology ID DEFORMABLE PARTICLES; BOUNDARY-CONDITION; OPTICAL TWEEZERS; 3 DIMENSIONS; SHEAR-FLOW; ERYTHROCYTE; AGGREGATION; SIMULATIONS; EQUATION AB Many diseases are a result of, or are associated with, abnormal blood flow. Usually, these abnormalities are caused by unhealthy red blood cells with modified shape which have difficulty traversing the microvessels. Unfortunately, experimental approaches to these problems are limited due to difficulties in isolating the critical determinants of flow in vivo or in vitro. Computer models overcome these problems, but most strive only to reproduce the macroscopic, continuum aspect of blood flow by making many simplifying assumptions. Unfortunately, these models cannot address the relationship between microscopic, cellular flow dynamics and macroscopic, bulk blood rheology. Here, we demonstrate the wide applicability of a novel, computational model for simulating blood flow that includes each blood cell explicitly. This fully 3D model accounts for cell membrane dynamics and reproduces rest shapes accurately. This model allows us to: (i) extract empirical relationships for use in macroscopic models and (ii) simulate various disease states to identify potential targets for therapy. We show here that the model accurately reproduces the well-documented flow relationships for healthy blood, and also predicts the abnormalities in blood rheology exhibited by malaria and sickle cell patients. C1 [Dupin, M. M.; Munn, L. L.] Massachusetts Gen Hosp, Steele Lab Canc Biol, Boston, MA 02114 USA. [Dupin, M. M.; Munn, L. L.] Harvard Univ, Sch Med, Boston, MA USA. [Halliday, I.; Care, C. M.] Sheffield Hallam Univ, Mat & Engn Res Inst, Sheffield S1 1WB, S Yorkshire, England. RP Munn, LL (reprint author), Massachusetts Gen Hosp, Steele Lab Canc Biol, Boston, MA 02114 USA. EM lance@steele.mgh.harvard.edu RI Munn, Lance/L-3950-2016; OI Munn, Lance/0000-0003-0698-7232; Care, Christopher/0000-0003-2592-5280 NR 41 TC 32 Z9 32 U1 1 U2 9 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1061-8562 J9 INT J COMPUT FLUID D JI Int. J. Comput. Fluid Dyn. PY 2008 VL 22 IS 7 BP 481 EP 492 DI 10.1080/10618560802238242 PG 12 WC Mechanics; Physics, Fluids & Plasmas SC Mechanics; Physics GA 329UA UT WOS:000257894900007 ER PT J AU Yang, JY Yang, MQ AF Yang, Jack Y. Yang, Mary Qu TI Identification of Intrinsically Unstructured Proteins using hierarchical classifier SO INTERNATIONAL JOURNAL OF DATA MINING AND BIOINFORMATICS LA English DT Article DE intrinsically unstructured regions and proteins; Recursive Maximum Contrast Tree; RMCT; IUP; machine learning; classification; data mining; bioinformatics ID SEQUENCES; DISORDER; MEMBRANE AB It is suggested, that protein functions only when folded into a particular 3-D structure. Recently, many protein regions and some entire proteins have been identified with no definite tertiary structure, but presenting instead as dynamic, disorder ensembles Under different physiochemical circimstances. These proteins and regions are known as Intrinsically Unstructured regions and Proteins (IUP). We constructcd a Recursive Maximum Contrast Tree (RMCT) based classifier to identify IUP. The classifier has been benchmarked against industrial standard PONDR VLXT on out-of-sample, clata byexternalrrial evaluators. The IUP predictor is a viable alternative software tool for identifying intrinsic unstructured regions and proteins. C1 [Yang, Jack Y.] Harvard Univ, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Yang, Jack Y.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Yang, Mary Qu] NHGRI, NIH, US Dept Hlth & Human Serv Bethesda, Rockville, MD 20852 USA. RP Yang, JY (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. EM yang@hadron.mgh.harvard.edu; yangma@mail.nih.gov NR 23 TC 3 Z9 4 U1 0 U2 0 PU INDERSCIENCE ENTERPRISES LTD PI GENEVA PA WORLD TRADE CENTER BLDG, 29 ROUTE DE PRE-BOIS, CASE POSTALE 856, CH-1215 GENEVA, SWITZERLAND SN 1748-5673 EI 1748-5681 J9 INT J DATA MIN BIOIN JI Int. J. Data Min. Bioinform. PY 2008 VL 2 IS 2 BP 121 EP 133 DI 10.1504/IJDMB.2008.019093 PG 13 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA 341TZ UT WOS:000258739300002 PM 18767350 ER PT J AU Ciemerych, MA Yu, QY Szczepanska, K Sicinski, P AF Ciemerych, Maria A. Yu, Qunyan Szczepanska, Katarzyna Sicinski, Piotr TI CDK4 activity in mouse embryos expressing a single D-type cyclin SO INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY LA English DT Article DE mouse; embyyogenesis; CDK4; cyclin D; p27kip1; retinoblastoma protein ID DEPENDENT KINASE INHIBITOR; CELL-CYCLE; TRANSCRIPTION FACTOR; D1-DEPENDENT KINASE; MURINE FIBROBLASTS; ESTROGEN-RECEPTOR; GENE-EXPRESSION; DENTATE GYRUS; P27(KIP1); MICE AB D-type cyclins (D1, D2, and D3) are components of the cell cycle machinery. Their association with cyclin-dependent kinase 4 (CDK4) and CDK6 causes activation of these protein kinases and leads to phosphorylation and inactivation of the retinoblastoma protein, pRb. Using embryos expressing single D-type cyclin ('cyclin D1-only','cyclin D2-only' and 'cyclin D3-only'), we tested whether each of D-type cyclin plays the same role in CDK activation and phosphorylation of pRb during mouse embryonic development. We found that the level of CDK4 activity was similar in wild-type embryos and those expressing only cyclin D3 or cyclin D2. However, we did not detect CDK4 activity in embryos expressing only cyclin D1, despite the fact that this cyclin was able to form complexes with CDK4 and p27(kip1) in wild-type as well as in mutant embryos. Analysis of the expression pattern of mRNA encoding cyclin D1 revealed that the expression of this RNA is regulated temporally during embryogenesis. These data and results from other laboratories indicate that cyclin D1-dependent CDK4 activity is dispensable for normal development of the mouse embryo. C1 [Ciemerych, Maria A.] Warsaw Univ, Inst Zool, Fac Biol, Dept Cytol, PL-02096 Warsaw, Poland. [Szczepanska, Katarzyna] Warsaw Univ, Fac Biol, Dept Embryol, PL-02096 Warsaw, Poland. [Yu, Qunyan; Sicinski, Piotr] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Ciemerych, MA (reprint author), Warsaw Univ, Inst Zool, Fac Biol, Dept Cytol, Ilji Miecznikowa 1, PL-02096 Warsaw, Poland. EM ciemerych@biol.uw.edu.pl NR 56 TC 4 Z9 4 U1 0 U2 0 PU U B C PRESS PI BILBAO PA UNIV BASQUE COUNTRY, EDITORIAL SERVICES, PO BOX 1397, E-48080 BILBAO, SPAIN SN 0214-6282 J9 INT J DEV BIOL JI Int. J. Dev. Biol. PY 2008 VL 52 IS 2-3 BP 299 EP 305 DI 10.1387/ijdb.072336mc PG 7 WC Developmental Biology SC Developmental Biology GA 287TK UT WOS:000254939200027 PM 18311721 ER PT J AU Gans, JS Gans, NF AF Gans, Jerome S. Gans, Nancy Freeman TI Wait, wait! ... do tell them and do it now! SO INTERNATIONAL JOURNAL OF GROUP PSYCHOTHERAPY LA English DT Editorial Material C1 [Gans, Jerome S.] Harvard Univ, Sch Med, Wellesley, MA 02481 USA. [Gans, Jerome S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Gans, JS (reprint author), Harvard Univ, Sch Med, 55 Cleveland Rd, Wellesley, MA 02481 USA. EM jsgans@comcast.net NR 1 TC 0 Z9 0 U1 0 U2 1 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0020-7284 J9 INT J GROUP PSYCHOTH JI Int. J. Group Psychother. PD JAN PY 2008 VL 58 IS 1 BP 119 EP 123 DI 10.1521/ijgp.2008.58.1.119 PG 5 WC Psychology, Clinical SC Psychology GA 248NX UT WOS:000252161600007 PM 18211217 ER PT J AU Jarboe, E Folkins, A Nucci, MR Kindelberger, D Drapkin, R Miron, A Lee, YH Crum, CP AF Jarboe, Elke Folkins, Ann Nucci, Marisa R. Kindelberger, David Drapkin, Ronny Miron, Alexander Lee, Yonghee Crum, Christopher P. TI Serous carcinogenesis in the fallopian tube: A descriptive classification SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY LA English DT Article DE serous carcinogenesis; intraepithelial carcinoma; fallopian tube neoplasms; BRCA; p53; fimbria ID PROPHYLACTIC OOPHORECTOMY SPECIMENS; PATHOLOGICAL FINDINGS; OVARIAN-CANCER; CARCINOMA; PRECURSOR; BRCA1; WOMEN; H2AX AB The fimbria is the most common site of early serous cancer (tubal intraepithelial carcinoma or STIC) in women with BRCA mutations (BRCA+). A candidate serous cancer precursor - the p53 signature - has been found in nonneoplastic secretory cells of the fimbria, suggesting serous carcinogenesis in the tube (SCAT). This study surveyed fallopian tubes from 3 populations to characterize the morphological and inummohistochemical correlates of SCAT. The SCAT sequence was defined by strong nuclear p53 staining and DNA damage (gamma-H2AX+) in secretory cells and subdivided morphologically by (1) degree of nuclear stratification, (2) proliferative index, and (3) degree of disorganized growth. Fallopian tubes from women without a current ovarian cancer, women with BRCA mutations, and women with a coexisting pelvic serous cancer were completely examined. p53 signatures exhibited cuboidal to pseudostratified, polarized p53+ epithelial segments with variable nuclear enlargement and a MiB1 index of 0% to 30%. Tubal intraepithelial carcinomas contained from single (uncommon) to multilayered, poorly polarized, uninterrupted neoplastic cell populations that completely displaced the normal mucosa; MiB1 index exceeded 45% and was usually more than 70%. An uncommon third category, p53-positive foci with features intermediate between p53 signatures and STICs, exhibited preserved epithelial polarity, pseudo stratification, incomplete replacement of the adjacent normal ciliated cells, and a MiB1 index between 40% and 75%. Transitions from I category to another were documented. Combined with recent reports associating STICs with pelvic serous cancer, this continuum of epithelial change validates the SCAT sequence and the fimbrial secretory cell as the site of origin for many serous carcinomas. C1 [Jarboe, Elke] Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, Boston, MA 02115 USA. Dana Farber Canc Res Inst, Dept Med Oncol, Boston, MA USA. Dana Farber Canc Res Inst, Dept Canc Biol, Boston, MA USA. RP Jarboe, E (reprint author), Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, 75 Francis St, Boston, MA 02115 USA. EM ejarboe@partners.org RI Drapkin, Ronny/E-9944-2016 OI Drapkin, Ronny/0000-0002-6912-6977 FU NCI NIH HHS [P50 CA10500, KO8 CA108748] NR 20 TC 133 Z9 150 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-1691 J9 INT J GYNECOL PATHOL JI Int. J. Gynecol. Pathol. PD JAN PY 2008 VL 27 IS 1 BP 1 EP 9 DI 10.1097/pgp.0b013e31814b191f PG 9 WC Obstetrics & Gynecology; Pathology SC Obstetrics & Gynecology; Pathology GA 248AT UT WOS:000252124400001 PM 18156967 ER PT J AU Mertyna, P Dewhirst, M Halpern, E Goldberg, W Goldberg, SN AF Mertyna, Pawel Dewhirst, Mark W. Halpern, Elkan Goldberg, Wallace Goldberg, S. Nahum TI Radiofrequency ablation: The effect of distance and baseline temperature on thermal dose required for coagulation SO INTERNATIONAL JOURNAL OF HYPERTHERMIA LA English DT Article DE Radiofrequency tumor ablation; thermal ablation; thermal dose; image-guided intervention; hyperthermia ID TUMOR ABLATION; HEPATOCELLULAR-CARCINOMA; ETHANOL INJECTION; BLOOD-FLOW; TISSUE; CANCER; CONDUCTIVITY; HYPERTHERMIA AB Purpose: To determine the effects of applied current, distance from an RF electrode and baseline tissue temperature upon thermal dosimetry requirements to induce coagulation in ex vivo bovine liver and in vivo porcine muscle models. Materials and methods: RF ablation was performed in ex vivo liver at varying baseline temperatures-19-21C (n = 114), 8-10C (n = 27), and 27-28C (n = 27)-using a 3-cm tip electrode and systematically varied current 400-1,300 mA, to achieve defined diameters of coagulation (20, 30 and 40 2 mm), and in in vivo muscle (n = 18) to achieve 35 mm 2 mm of coagulation. Thermal dose required for coagulation was calculated as the area under the curve and cumulative equivalent minutes at 43C. Results: Thermal dose correlated with current in a negative exponential fashion for all three diameters of coagulation in ex vivo experiments (p 0.001). The temperatures at the end of RF heating at the ablation margin were not reproducible, but varied 38C-74.7C, for 30 mm coagulation in ex vivo liver, and 59.8C-68.4C in the in vivo experiment. CEM43 correlated with current as a family of positive exponential functions (r2 = 0.76). However, a very wide range of CEM43 values (on the order of 1015) was noted. Although baseline temperatures in the ex vivo experiment did not change required thermal dose, the relationships between end temperature at the ablation margin and RF current were statistically different (p 0.001) as analysed at the 400 mA intercept. Conclusions: In both models, thermal dosimetry required to achieve coagulation was not constant, but current and distance dependent. Hence, other formulas for thermal dose equivalence may be needed to predict conditions for thermal ablation. C1 [Mertyna, Pawel; Goldberg, S. Nahum] Beth Israel Deaconess Med Ctr, Dept Radiol, Lab Minimally Invas Tumor Therapies, Boston, MA 02215 USA. [Dewhirst, Mark W.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA. [Halpern, Elkan] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Goldberg, Wallace] CUNY, Queens Coll, Dept Math, New York, NY 10021 USA. RP Goldberg, SN (reprint author), Beth Israel Deaconess Med Ctr, Dept Radiol, Lab Minimally Invas Tumor Therapies, 1 Deaconess Rd,WCC 308B, Boston, MA 02215 USA. EM sgoldber@caregroup.harvard.edu NR 26 TC 35 Z9 36 U1 0 U2 4 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0265-6736 J9 INT J HYPERTHER JI Int. J. Hyperthermia PY 2008 VL 24 IS 7 BP 550 EP 559 DI 10.1080/02656730802035662 PG 10 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 367SO UT WOS:000260573000003 PM 18608586 ER PT J AU Pienaar, R Fischl, B Caviness, V Makris, N Grant, PE AF Pienaar, R. Fischl, B. Caviness, V. Makris, N. Grant, P. E. TI A methodology for analyzing curvature in the developing brain from preterm to adult SO INTERNATIONAL JOURNAL OF IMAGING SYSTEMS AND TECHNOLOGY LA English DT Article DE MRI; gyral folding; brain development; principal curvature analysis; freesurfer; neonate; preterm; surface reconstruction; Gaussian curvature; bending energy ID HUMAN CEREBRAL-CORTEX; ANATOMICALLY SPECIFIED METHOD; CORTICAL FOLDING PATTERNS; SURFACE-BASED ANALYSIS; QUANTITATIVE-EVALUATION; SPHERICAL WAVELETS; VALUE IMAGES; MRI; PARCELLATION; MORPHOMETRY AB The character and timing of gyral development is one manifestation of the complex orchestration of human brain development. The ability to quantify these changes would not only allow for deeper understanding of cortical development but also conceivably allow for improved detection of pathologies. This article describes a FreeSurfer-based image-processing analysis "pipeline" or methodology that inputs an MRI volume, corrects possible contrast defects, creates surface reconstructions, and outputs various curvature-based function analyses. A technique of performing neonate reconstructions using FreeSurfer, which has not been possible previously because of inverted image contrast in premyelinated brains, is described. Once surfaces are reconstructed, the analysis component of the pipeline incorporates several surface-based curvature functions found in literature (principle curvatures, Gaussian, mean curvature, "curvedness," and Willmore Bending Energy). We consider the problem of analyzing curvatures from different sized brains by introducing a Gaussian-curvature based variable-radius filter. Segmented volume data are also analyzed for folding measures: a gyral folding index (gyrification-white index GWI) and a gray-white matter junction folding index (WMF). A very simple curvature-based classifier is proposed that has the potential to discriminate between certain classes of subjects. We also present preliminary results of this curvature analysis pipeline on nine neonate subjects (30.4 weeks through 40.3 weeks Corrected Gestational Age), three children (2, 3, and 7 years), and three adults (33, 37, and 39 years). Initial results demonstrate that curvature measures and functions across our subjects peaked at term, with a gradual decline through early childhood and further decline continuing through to adults. We can also discriminate older neonates, children, and adults based on curvature analysis. Using a variable radius Gaussian-curvature filter, we also observed that the per-unit bending energy of neonate brain surfaces was also much higher than the children and adults. (c) 2008 Wiley Periodicals, Inc. C1 [Pienaar, R.; Fischl, B.; Caviness, V.; Makris, N.; Grant, P. E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. RP Pienaar, R (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. EM rudolph@nmr.mgh.harvard.edu FU NCRR NIH HHS [R01 RR016594-01A1, P41 RR014075, R01 RR016594, U24 RR021382]; NIBIB NIH HHS [R01 EB001550, U54 EB005149]; NINDS NIH HHS [R01 NS052585] NR 64 TC 62 Z9 63 U1 0 U2 6 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0899-9457 J9 INT J IMAG SYST TECH JI Int. J. Imaging Syst. Technol. PY 2008 VL 18 IS 1 BP 42 EP 68 DI 10.1002/ima.20138 PG 27 WC Engineering, Electrical & Electronic; Optics; Imaging Science & Photographic Technology SC Engineering; Optics; Imaging Science & Photographic Technology GA 321JS UT WOS:000257301400006 PM 19936261 ER PT J AU Sharma, G Rege, K Budil, DE Yarmush, ML Mavroidis, C AF Sharma, Gaurav Rege, Kaushal Budil, David E. Yarmush, Martin L. Mavroidis, Constantinos TI Reversible pH-controlled DNA-binding peptide nanotweezers: An in-silico study SO INTERNATIONAL JOURNAL OF NANOMEDICINE LA English DT Article DE bionanotechnology; nanotweezers; coiled-coil; GCN4; leucine zipper; molecular dynamics; environmentally responsive peptides; transcription factor engineering ID MOLECULAR-DYNAMICS SIMULATIONS; GCN4 LEUCINE-ZIPPER; ARGININE-RICH PEPTIDES; COILED-COILS; ELECTROSTATIC INTERACTIONS; CRYSTAL-STRUCTURE; MEMBRANE-FUSION; PROTEIN; COMPLEX; DESIGN AB We describe the molecular dynamics (MD)-aided engineering design of mutant peptides based on the a-helical coiled-coil GCN4 leucine zipper peptide (GCN4-p1) in order to obtain environmentally-responsive nanotweezers. The actuation mechanism of the nanotweezers depends on the modi. cation of electrostatic charges on the residues along the length of the coiled coil. Modulating the solution pH between neutral and acidic values results in the reversible movement of helices toward and away from each other and creates a complete closed-open-closed transition cycle between the helices. Our results indicate that the mutants show a reversible opening of up to 15 angstrom (1.5 nm; approximately 150% of the initial separation) upon pH actuation. Investigation on the physicochemical phenomena that influence conformational properties, structural stability, and reversibility of the coiled-coil peptide-based nanotweezers revealed that a rationale-and design-based approach is needed to engineer stable peptide or macromolecules into stimuli-responsive devices. The efficacy of the mutant that demonstrated the most significant reversible actuation for environmentally responsive modulation of DNA-binding activity was also demonstrated. Our results have significant implications in bioseparations and in the engineering of novel transcription factors. C1 [Sharma, Gaurav; Mavroidis, Constantinos] Northeastern Univ, Dept Mech & Ind Engn, Boston, MA 02115 USA. [Budil, David E.] Northeastern Univ, Dept Chem & Biol Chem, Boston, MA 02115 USA. [Rege, Kaushal; Yarmush, Martin L.] Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA. [Rege, Kaushal; Yarmush, Martin L.] Harvard Univ, Sch Med, Boston, MA USA. [Rege, Kaushal] Arizona State Univ, Dept Chem Engn, Tempe, AZ USA. [Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08855 USA. RP Mavroidis, C (reprint author), Northeastern Univ, Dept Mech & Ind Engn, 360 Huntington Ave, Boston, MA 02115 USA. EM mavro@coe.neu.edu RI Budil, David/A-9931-2012 OI Budil, David/0000-0003-2384-7928 FU NASA Institute for Advanced Concepts (NIAC); National Science Foundation [DMI-0422724] FX The authors thank the NASA Institute for Advanced Concepts (NIAC) Phase II grant and the National Science Foundation (grant DMI-0422724) for the financial support of this research. The authors thank Prof. Alexei Aksimentiev at University of Illinois at Urbana-Champaign for providing the parameters of protonated adenosine nucleotide and Dr Zaki E Megeed and Dr Monica Casali at the Center for Engineering in Medicine (CEM) for helpful technical discussions. NR 64 TC 4 Z9 5 U1 1 U2 3 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1176-9114 J9 INT J NANOMED JI Int. J. Nanomed. PY 2008 VL 3 IS 4 BP 505 EP 521 PG 17 WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy SC Science & Technology - Other Topics; Pharmacology & Pharmacy GA 419AN UT WOS:000264191600012 PM 19337419 ER PT J AU Erakat, MS Chuang, SK Yoo, RH Weed, M Dodson, TB AF Erakat, Mohammed S. Chuang, Sung-Kiang Yoo, Roy H. Weed, Meghan Dodson, Thomas B. TI Immediate loading of splinted locking-taper implants: 1-year survival estimates and risk factors for failure SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS LA English DT Article DE dental implants; immediate loading; multivariate models; retrospective cohort study; risk factors ID SINGLE-TOOTH IMPLANTS; STRATEGY AB Purpose: The purpose of this study was to estimate the 1-year survival rate of immediate vertical-load splinted locking-taper implants and to identify risk factors for implant failure. Materials and Methods: To address the research aim, the investigators implemented a retrospective cohort study design and enrolled a sample derived from the population of patients who had received immediate vertical-load splinted implants (Bicon, Boston, MA). The predictor variables were the sets of exposures associated with implant failure and classified as demographic, health status, anatomic, implant specific, prosthetic, and surgical. The primary outcome variable was implant failure, which was defined as implant removal. Descriptive, univariate, and multivariate analyses using clustered marginal approach of the Cox proportional hazards models were computed. The level of statistical significance was set at P <.05. Results: The study cohort was composed of 209 patients who received 477 implants. The overall 1-year Kaplan-Meier survival estimate was 90.3% (95% Cl 86.9%, 93.7%). In the multivariate model, implant placement in a delayed manner versus implantation the same day as extraction (hazard ratio = 3.7, P =.002), uncoated implants versus coated implants (hazard ratio = 22.1, P <.001), and an increased per-unit number of pontics involved in the temporary prosthesis (hazard ratio = 1.8, P <.001) were statistically associated with an increased risk of implant failure. Conclusions: An overall 1-year survival estimate of 90.3% (95% CI: 86.9%, 93.7%) was calculated for immediately loaded splinted implants. After controlling for other variables, 3 variables-timing of implant placement relative to extraction (delayed implant placement after tooth extraction), coating of implant (uncoated), and increased number of pontics-were associated with an increased risk for implant failure. C1 [Chuang, Sung-Kiang; Dodson, Thomas B.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. [Erakat, Mohammed S.] Univ Med & Dent New Jersey, Dept Oral & Maxillofacial Surg, Newark, NJ 07103 USA. [Chuang, Sung-Kiang; Dodson, Thomas B.] Harvard Univ, Sch Dent Med, Dept Oral & Maxillofacial Surg, Boston, MA 02115 USA. [Weed, Meghan] Implant Dent Ctr, Boston, MA USA. [Dodson, Thomas B.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Ctr Appl Clin Invest, Boston, MA 02114 USA. RP Chuang, SK (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, 55 Fruit St,Warren 1201, Boston, MA 02114 USA. EM schuang@hsph.harvard.edu FU NIDCR NIH HHS [K24 DE000448] NR 16 TC 10 Z9 13 U1 0 U2 0 PU QUINTESSENCE PUBLISHING CO INC PI HANOVER PARK PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA SN 0882-2786 J9 INT J ORAL MAX IMPL JI Int. J. Oral Maxillofac. Implants PD JAN-FEB PY 2008 VL 23 IS 1 BP 105 EP 110 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 267EZ UT WOS:000253493600010 PM 18416418 ER PT J AU Scott, AR Chong, PST Randolph, GW Hartnick, CJ AF Scott, Andrew R. Chong, Peter Siao Tick Randolph, Gregory W. Hartnick, Christopher J. TI Intraoperative laryngeal electromyography in children with vocal fold immobility: A simplified technique SO INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY LA English DT Article DE vocal fold paralysis; laryngeal; electromyography; dysphonia; aspiration; stridor; children ID CORD PARALYSIS; MANAGEMENT AB Objectives: The primary objective of this study was to determine whether a simplified technique for intraoperative laryngeal electromyography was feasible using standard nerve integrity monitoring electrodes and audiovisual digital recording equipment. Our secondary objective was to determine if laryngeal electromyography data provided any additional information that significantly influenced patient management. Methods: Between February 2006 and February 2007, 10 children referred to our institution with vocal fold immobility underwent intraoperative laryngeal electromyography of the thyroarytenoid muscles. A retrospective chart review of these 10 patients was performed after institutional review board approval. Results: Standard nerve integrity monitoring electrodes can be used to perform intraoperative laryngeal electromyography of the thyroarytenoid muscles in children. In 5 of 10 cases reviewed, data from laryngeal electromyography recordings meaningfully influenced the care of children with vocal fold immobility and affected clinical decision-making, sometimes altering management strategies. In the remaining 5 children, data supported clinical impressions but did not alter treatment plans. Two children with idiopathic bilateral vocal fold paralysis initially presented with a lack of electrical activity on one or both sides but went on to develop motor unit action potentials that preceded recovery of motion in both vocal folds. Conclusions: Our findings suggest that standard nerve monitoring equipment can be used to perform intraoperative laryngeal electromyography and that electromyographic data can assist clinicians in the management of complex patients. Additionally, there may be a rote for the use of serial intraoperative measurements in predicting recovery from vocal fold paralysis in the pediatric age group. (C) 2007 Elsevier Ireland Ltd. All rights reserved. C1 [Scott, Andrew R.; Randolph, Gregory W.; Hartnick, Christopher J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. [Chong, Peter Siao Tick] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA. RP Hartnick, CJ (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, 243 Charles St, Boston, MA 02114 USA. EM christopher_hartnick@meei.harvard.edu NR 19 TC 8 Z9 8 U1 2 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-5876 J9 INT J PEDIATR OTORHI JI Int. J. Pediatr. Otorhinolaryngol. PD JAN PY 2008 VL 72 IS 1 BP 31 EP 40 DI 10.1016/j.ijporl.2007.09.011 PG 10 WC Otorhinolaryngology; Pediatrics SC Otorhinolaryngology; Pediatrics GA 260UE UT WOS:000253035100006 PM 18006083 ER PT J AU Kilzieh, N Rastam, S Maziak, W Ward, KD AF Kilzieh, Nael Rastam, Samar Maziak, Wasim Ward, Kenneth D. TI Comorbidity of depression with chronic diseases: A population-based study in Aleppo, Syria SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE depression; chronic disease; comorbidity; epidemiologic studies; Arab world ID QUALITY-OF-LIFE; MAJOR DEPRESSION; GENERAL-POPULATION; PSYCHIATRIC MORBIDITY; RHEUMATOID-ARTHRITIS; MENTAL-DISORDERS; RISK-FACTOR; SYMPTOMS; HEALTH; PREVALENCE AB Objective: To assess the comorbidity and correlates of depression in chronic diseases in the community in Aleppo, Syria. This has never been previously investigated in an Arab country. Method: We conducted a cross-sectional, population-based study in Aleppo on adults aged 18-65 (N = 2038). We collected data utilizing a structured inter-view questionnaire. Socio-demographics, general health information, and self-report of physician-diagnosed depression and chronic diseases active in the past year were obtained. We used logistic regression to estimate the odds of depression in chronic diseases and socio-demographic correlates of depression comorbid with chronic diseases. Results: Mean age (SD) was 35.3 (12.1) years, 55% were female. In women, predictors of depression were heart disease (OR = 3.95, 95% CI: 1.50-10.40), hypertension (OR = 2.92, 95% CI: 1.53-5.55), and kidney disease (OR = 2.96, 95% Cl: 1.64-5.32). Depression comorbidity with any chronic disease decreased in higher socio-economic status (middle vs. low: OR = 0.28, 95% CI: 0.12-0.65; high vs. low: OR = 0.20, 95% CI: 0.05-0.81). In men, predictors of depression were rheumatism (OR = 7.10, 95% CI: 2.58-19.60) and respiratory disease (OR = 3.77, 95% CI: 1.23-11.60). Depression comorbidity decreased in residence in formal zones (OR = 0.22, 95% CI: 0.06-0.80). Conclusion: Depression is associated with many chronic diseases in the community in Aleppo, a finding consistent with reports from other cultures., Potential gender-related risk factors were identified. Findings inform public mental health planning and support the delivery of depression treatment in primary care settings. C1 [Kilzieh, Nael] VA Puget Sound Hlth Care Syst, Amer Lake Div, Tacoma, WA 98493 USA. [Kilzieh, Nael] Univ Washington, Seattle, WA 98195 USA. [Rastam, Samar; Maziak, Wasim] Syrian Ctr Tobacco Studies, Aleppo, Syria. [Maziak, Wasim; Ward, Kenneth D.] Univ Memphis, Memphis, TN 38152 USA. RP Kilzieh, N (reprint author), VA Puget Sound Hlth Care Syst, Amer Lake Div, A-116, Tacoma, WA 98493 USA. EM nael.kilzieh@va.gov OI Rastam, Samer/0000-0002-4004-7773 FU FIC NIH HHS [R21 TW006545, R01 TW005962, R01 TW05962]; NIDA NIH HHS [R01 DA024876, R01 DA024876-01] NR 51 TC 14 Z9 15 U1 5 U2 9 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2008 VL 38 IS 2 BP 169 EP 184 DI 10.2190/PM.38.2.d PG 16 WC Psychiatry SC Psychiatry GA 336EZ UT WOS:000258348400004 PM 18724568 ER PT J AU Ara, G Watkins, BA Zhong, H Hawthorne, TR Karkaria, CE Sonis, ST LaRochelle, WJ AF Ara, Gulshan Watkins, Brynmor A. Zhong, Haihong Hawthorne, Thomas R. Karkaria, Cyrus E. Sonis, Stephen T. LaRochelle, William J. TI Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation SO INTERNATIONAL JOURNAL OF RADIATION BIOLOGY LA English DT Article DE FGF-20; velafermin; oral mucositis; fractionated radiation; inflammation ID INDUCED ORAL MUCOSITIS; KERATINOCYTE GROWTH-FACTOR; FACTOR-KAPPA-B; CYCLOOXYGENASE-2 COX-2 EXPRESSION; IONIZING-RADIATION; TRANSCRIPTION FACTOR; FACTOR PALIFERMIN; GENE-EXPRESSION; MUCOSAL INJURY; CANCER-THERAPY AB Purpose: Velafermin (recombinant human fibroblast growth factor-20, rhFGF-20) has been shown to reduce the severity and duration of mucositis in preclinical acute (single dose) radiation and chemotherapy/radiation models of oral mucositis. Our present study assessed the impact of velafermin on the severity and duration of oral mucositis that occurred as a consequence of fractionated radiation. Experimental design: Male Golden Syrian hamsters were exposed to eight doses of radiation (7.5 Gy/dose) to the cheek pouch on days 0, 1, 2, 3, 6, 7, 8 and 9 that resulted in severe mucositis. Velafermin (4 mg/kg intraperitoneally) was administered on days 3 and 9; days 2, 3, 8 and 9; days 3, 4, 9 and 10; or days 4, 5, 10 and 11. Results: Although all velafermin-treated groups showed some reduction in the degree of mucositis relative to the vehicle control, the most significant reduction (p<0.001) was observed in the groups treated on days 3 and 9 or on days 4, 5, 10 and 11. Further histological analysis of resected buccal mucosa revealed improvements in epithelial tissue degradation, connective tissue degradation and inflammation severity after velafermin treatment. Most notably, velafermin treatment reduced inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor (TNF) production possibly through nuclear factor-kappa B (NF-kappa B) mediation. The detection of increased NF-E2-related factor-2 (NRF-2) expression in the early onset stage of mucositis in the buccal mucosa suggested additional protective benefits from reactive oxygen species (ROS) generated as a consequence of fractionated radiation treatment. Conclusion: Thus, velafermin provided therapeutic benefit in a hamster model of oral mucositis induced by fractionated radiation therapy. C1 [Ara, Gulshan; Zhong, Haihong; Hawthorne, Thomas R.; Karkaria, Cyrus E.; LaRochelle, William J.] CuraGen Corp, Branford, CT 06405 USA. [Watkins, Brynmor A.] Biomodels, Watertown, MA USA. [Sonis, Stephen T.] Harvard Univ, Sch Dent Med, Brigham & Womens Hosp, Dept Oral Med Infect & Immun,Div Oral & Maxillofa, Boston, MA 02115 USA. [Sonis, Stephen T.] Harvard Univ, Sch Dent Med, Brigham & Womens Hosp, Dept Oral Med Infect & Immun,Div Oral Med, Boston, MA 02115 USA. [Sonis, Stephen T.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP LaRochelle, WJ (reprint author), CuraGen Corp, 322 E Main St, Branford, CT 06405 USA. EM wlarochelle@curagen.com NR 60 TC 16 Z9 16 U1 0 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0955-3002 J9 INT J RADIAT BIOL JI Int. J. Radiat. Biol. PY 2008 VL 84 IS 5 BP 401 EP 412 DI 10.1080/09553000802007601 PG 12 WC Biology; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Life Sciences & Biomedicine - Other Topics; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA 304BU UT WOS:000256085800005 PM 18464069 ER PT J AU Alexander, BM Glickman, J Wang, X Weaver, D D'Andrea, A Mamon, H AF Alexander, B. M. Glickman, J. Wang, X. Weaver, D. D'Andrea, A. Mamon, H. TI DNA repair biomarkers in rectal cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Alexander, B. M.] Harvard Radiat Oncol Program, Boston, MA USA. [Glickman, J.; Mamon, H.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Wang, X.; Weaver, D.] DNAR Inc, Boston, MA USA. [D'Andrea, A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S248 EP S248 DI 10.1016/j.ijrobp.2008.06.639 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805301030 ER PT J AU Allen, AM Sun, Y Caglar, HB Zygmanski, P Killoran, JH Albert, M AF Allen, A. M. Sun, Y. Caglar, H. B. Zygmanski, P. Killoran, J. H. Albert, M. TI Hyperpolarized helium MRI and the importance of ventilation tumor volumes (VTVs) before and after RT for non-small cell lung cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Allen, A. M.; Caglar, H. B.; Zygmanski, P.; Killoran, J. H.; Albert, M.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S626 EP S626 DI 10.1016/j.ijrobp.2008.06.274 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302303 ER PT J AU Balboni, TA Ng, A Block, SD Balboni, MJ Kachnic, L Stevenson, MA Hong, TS Wright, AA Trice, ED Prigerson, HG AF Balboni, T. A. Ng, A. Block, S. D. Balboni, M. J. Kachnic, L. Stevenson, M. A. Hong, T. S. Wright, A. A. Trice, E. D. Prigerson, H. G. TI Religious coping, quality of life and frequency of spiritual care among patients receiving palliative radiation therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Balboni, T. A.; Ng, A.; Block, S. D.; Balboni, M. J.; Wright, A. A.; Trice, E. D.; Prigerson, H. G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Balboni, T. A.; Ng, A.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Balboni, M. J.] Boston Univ, Boston, MA 02215 USA. [Kachnic, L.] Boston Med Ctr, Boston, MA USA. [Stevenson, M. A.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Hong, T. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S497 EP S497 DI 10.1016/j.ijrobp.2008.06.1455 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302020 ER PT J AU Caglar, HB Othus, M Allen, AM AF Caglar, H. B. Othus, M. Allen, A. M. TI Mean in-field esophagus dose predicts for esophagitis in lung cancer patients treated with 3D-CRT and concurrent chemotherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Caglar, H. B.; Othus, M.; Allen, A. M.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S427 EP S427 DI 10.1016/j.ijrobp.2008.06.1346 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805301431 ER PT J AU Chakravarti, A Wang, M Mischel, P Robins, HI Guha, A Machtay, M Curran, W Roach, M Mehta, M Dicker, A AF Chakravarti, A. Wang, M. Mischel, P. Robins, H. I. Guha, A. Machtay, M. Curran, W. Roach, M. Mehta, M. Dicker, A. TI An update on correlative molecular Endpoints from RTOG 0211: Phase I/II study of gefitinib plus radiation for newly diagnosed glioblastoma patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Chakravarti, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wang, M.] Amer Coll Radiol, Philadelphia, PA USA. [Mischel, P.] Univ Calif Los Angeles, Los Angeles, CA USA. [Robins, H. I.; Mehta, M.] Univ Wisconsin, Madison, WI USA. [Guha, A.] Univ Toronto, Toronto, ON, Canada. [Machtay, M.; Dicker, A.] Thomas Jefferson Med Coll, Philadelphia, PA USA. [Curran, W.] Emory Univ, Sch Med, Atlanta, GA USA. [Roach, M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S9 EP S10 DI 10.1016/j.ijrobp.2008.06.788 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300023 ER PT J AU Chan, AW Kamat, UR Truong, MT Holman, AS Goldsmith, TA AF Chan, A. W. Kamat, U. R. Truong, M. T. Holman, A. S. Goldsmith, T. A. TI Predictive factors of G-tube dependence after chemoradiation for oropharyngeal carcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Chan, A. W.; Kamat, U. R.; Truong, M. T.; Holman, A. S.; Goldsmith, T. A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S388 EP S388 DI 10.1016/j.ijrobp.2008.06.1255 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805301342 ER PT J AU Chen, AB Feng, Y Neuberg, D Recklitis, C Diller, L Mauch, P Ng, A AF Chen, A. B. Feng, Y. Neuberg, D. Recklitis, C. Diller, L. Mauch, P. Ng, A. TI Employment and insurance status in Hodgkin lymphoma survivors SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Chen, A. B.; Feng, Y.; Neuberg, D.; Recklitis, C.; Mauch, P.; Ng, A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Diller, L.] Childrens Hosp Boston, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S138 EP S138 DI 10.1016/j.ijrobp.2008.06.454 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300308 ER PT J AU Chen, RC Chin, MS Ng, AK Silver, B Mauch, PM AF Chen, R. C. Chin, M. S. Ng, A. K. Silver, B. Mauch, P. M. TI Lymphocyte-predominant Hodgkin lymphoma: Patient outcomes from a large single-institution series with long follow-up SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Chen, R. C.] Harvard Radiat Oncol Program, Boston, MA USA. [Chin, M. S.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Ng, A. K.; Silver, B.; Mauch, P. M.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S123 EP S124 DI 10.1016/j.ijrobp.2008.06.421 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300276 ER PT J AU Chen, WC Kim, J Kim, E Silverman, P Overmoyer, B Cooper, BW Anthony, S Shenk, R Leeming, R Lyons, J AF Chen, W. C. Kim, J. Kim, E. Silverman, P. Overmoyer, B. Cooper, B. W. Anthony, S. Shenk, R. Leeming, R. Lyons, J. TI Feasibility and outcomes of concurrent paclitaxel chemotherapy and radiotherapy for node-positive stage II-III breast cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Chen, W. C.; Silverman, P.; Cooper, B. W.; Anthony, S.; Shenk, R.; Leeming, R.; Lyons, J.] Univ Hosp Cleveland, Cleveland, OH 44106 USA. [Kim, J.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Kim, E.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Overmoyer, B.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S169 EP S169 DI 10.1016/j.ijrobp.2008.06.718 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300378 ER PT J AU Chen, Y Petit, J Fullerton, B Adams, J Grant, E Ebb, D AF Chen, Y. Petit, J. Fullerton, B. Adams, J. Grant, E. Ebb, D. TI 3D FIESTA MR cisternography for improved target volume definition in pediatric posterior fossa ependymomas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Chen, Y.; Petit, J.; Fullerton, B.; Adams, J.; Grant, E.; Ebb, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S78 EP S79 DI 10.1016/j.ijrobp.2008.06.944 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300176 ER PT J AU Chinnaiyan, P Wang, M Rojiani, AM Tofilon, PJ Chakravarti, A Ang, K Zhang, H Hammond, E Curran, W Mehta, MP AF Chinnaiyan, P. Wang, M. Rojiani, A. M. Tofilon, P. J. Chakravarti, A. Ang, K. Zhang, H. Hammond, E. Curran, W. Mehta, M. P. TI The prognostic value of nestin expression in newly diagnosed GBM: Report from the RTOG SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Chinnaiyan, P.; Rojiani, A. M.; Tofilon, P. J.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Wang, M.] Amer Coll Radiol, Philadelphia, PA USA. [Chakravarti, A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Ang, K.; Zhang, H.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Hammond, E.] LDS Hosp, Salt Lake City, UT USA. [Curran, W.] Emory Univ, Sch Med, Atlanta, GA USA. [Mehta, M. P.] Univ Wisconsin, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S206 EP S206 DI 10.1016/j.ijrobp.2008.06.1531 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300460 ER PT J AU Chun, TT Fischman, AJ Ancukiewicz, M Niemierko, A Fidias, PM Lynch, TJ Choi, NC AF Chun, T. T. Fischman, A. J. Ancukiewicz, M. Niemierko, A. Fidias, P. M. Lynch, T. J. Choi, N. C. TI Esophagitis identified in restaging FDG-PET after radiotherapy or chemo-radiotherapy in lung cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Chun, T. T.; Fischman, A. J.; Ancukiewicz, M.; Niemierko, A.; Fidias, P. M.; Lynch, T. J.; Choi, N. C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S453 EP S454 DI 10.1016/j.ijrobp.2008.06.1842 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805301489 ER PT J AU Chung, CS Keating, N Yock, T Tarbell, N AF Chung, C. S. Keating, N. Yock, T. Tarbell, N. TI Comparative analysis of second malignancy risk in patients treated with proton therapy versus conventional photon therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Chung, C. S.] Harvard Radiat Oncol Program, Boston, MA USA. [Keating, N.] Harvard Univ, Sch Med, Boston, MA USA. [Yock, T.; Tarbell, N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 29 Z9 29 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S8 EP S8 DI 10.1016/j.ijrobp.2008.06.785 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300020 ER PT J AU Court, LE Wagar, M Ionascu, D Berbeco, R Lingos, T AF Court, L. E. Wagar, M. Ionascu, D. Berbeco, R. Lingos, T. TI Development and experimental evaluation of guidelines for planning and treating moving tumors using dynamic IMRT SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Court, L. E.; Wagar, M.; Ionascu, D.; Berbeco, R.; Lingos, T.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S638 EP S638 DI 10.1016/j.ijrobp.2008.06.300 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302329 ER PT J AU Crowley, EM Kachnic, LA Mamon, HJ Adams, JA Choi, NC Hong, TS AF Crowley, E. M. Kachnic, L. A. Mamon, H. J. Adams, J. A. Choi, N. C. Hong, T. S. TI Optimizing the cardiac and pulmonary dose: A comparison of IMRT photon and 3-D proton treatment planning for distal esophageal cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Crowley, E. M.; Adams, J. A.; Choi, N. C.; Hong, T. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kachnic, L. A.] Boston Univ, Med Ctr, Boston, MA USA. [Mamon, H. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S539 EP S540 DI 10.1016/j.ijrobp.2008.06.082 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302115 ER PT J AU Dosoretz, AM Chen, MH Salenius, SA Ross, RH Dosoretz, DE Katin, MJ Nakfoor, BM D'Amico, AV AF Dosoretz, A. M. Chen, M. H. Salenius, S. A. Ross, R. H. Dosoretz, D. E. Katin, M. J. Nakfoor, B. M. D'Amico, A. V. TI Mortality in men age 70 or more with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormonal therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Dosoretz, A. M.] Harvard Radiat Oncol Program, Boston, MA USA. [Chen, M. H.] Univ Connecticut, Storrs, CT USA. [Salenius, S. A.; Ross, R. H.; Dosoretz, D. E.; Katin, M. J.; Nakfoor, B. M.] 21st Century Oncol Inc, Ft Myers, FL USA. [D'Amico, A. V.] Brigham & Womens Hosp, Boston, MA 02115 USA. [D'Amico, A. V.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S39 EP S39 DI 10.1016/j.ijrobp.2008.06.853 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300087 ER PT J AU El-Din, MAA Bellon, JR Strom, EA Bourgier, C Jagsi, R Niemierko, A Marsiglia, H Pierce, L Buchholz, TA Taghian, AG AF El-Din, M. A. Alm Bellon, J. R. Strom, E. A. Bourgier, C. Jagsi, R. Niemierko, A. Marsiglia, H. Pierce, L. Buchholz, T. A. Taghian, A. G. TI Radiation treatments may contribute to the development of cardiac dysfunction in breast cancer patients treated with chemotherapy and trastuzumab SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [El-Din, M. A. Alm; Niemierko, A.; Taghian, A. G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. [Bellon, J. R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Strom, E. A.; Buchholz, T. A.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA. [Bourgier, C.; Marsiglia, H.] Inst Gustave Roussy, Dept Radiat Oncol, Paris, France. [Jagsi, R.; Pierce, L.] Univ Michigan Hosp, Dept Radiat Oncol, Ann Arbor, MI 48109 USA. [Marsiglia, H.] Univ Florence, Florence, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S89 EP S90 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300202 ER PT J AU Gabeau-Lacet, D Mohapatra, G Betensky, R Barker, F Loeffler, J Louis, D AF Gabeau-Lacet, D. Mohapatra, G. Betensky, R. Barker, F. Loeffler, J. Louis, D. TI Bone involvement predicts poor outcome in atypical meningioma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Gabeau-Lacet, D.; Loeffler, J.] Harvard Radiat Oncol Program, Boston, MA USA. [Gabeau-Lacet, D.; Mohapatra, G.; Barker, F.; Loeffler, J.; Louis, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Betensky, R.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S207 EP S207 DI 10.1016/j.ijrobp.2008.06.1533 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300462 ER PT J AU Halasz, LM Bussiere, MR Niemierko, A Chapman, PH Loeffler, JS Shih, HA AF Halasz, L. M. Bussiere, M. R. Niemierko, A. Chapman, P. H. Loeffler, J. S. Shih, H. A. TI Outcornes of patients with benign meningiomas treated with proton stereotactic radiosurgery SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Halasz, L. M.] Harvard Radiat Oncol Program, Boston, MA USA. [Bussiere, M. R.; Niemierko, A.; Chapman, P. H.; Loeffler, J. S.; Shih, H. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S233 EP S233 DI 10.1016/j.ijrobp.2008.06.707 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300519 ER PT J AU Hoffman, KE McCarthy, EP Ng, AK AF Hoffman, K. E. McCarthy, E. P. Ng, A. K. TI Psychological distress in long-term survivors of adult-onset cancer: Results from a national survey SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Hoffman, K. E.] Harvard Univ, Sch Med, Harvard Radiat Oncol Program, Boston, MA USA. [McCarthy, E. P.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA. [Ng, A. K.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Ng, A. K.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S101 EP S102 DI 10.1016/j.ijrobp.2008.06.997 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300228 ER PT J AU Hong, TS Mamon, HJ Willett, CG Miyamoto, DT Choi, NC Ancukiewicz, M Clark, J Blaszkowsky, L Ryan, DP AF Hong, T. S. Mamon, H. J. Willett, C. G. Miyamoto, D. T. Choi, N. C. Ancukiewicz, M. Clark, J. Blaszkowsky, L. Ryan, D. P. TI Tolerability of chemoradiation for upper gastrointestinal malignancies in patients 75 years and older SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Hong, T. S.; Choi, N. C.; Ancukiewicz, M.; Clark, J.; Blaszkowsky, L.; Ryan, D. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mamon, H. J.] Brigham & Womens Hosp Dana Farber, Boston, MA USA. [Willett, C. G.] Duke Univ, Med Ctr, Durham, NC USA. [Miyamoto, D. T.] Harvard Radiat Oncol Program, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S265 EP S266 DI 10.1016/j.ijrobp.2008.06.1703 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805301069 ER PT J AU Hurwitz, M Zheng, H Nagaraja, GM Bausero, MA Manola, J Kaur, P Asea, A AF Hurwitz, M. Zheng, H. Nagaraja, G. M. Bausero, M. A. Manola, J. Kaur, P. Asea, A. TI Radiation therapy induces circulating serum heat shock proteins in prostate cancer patients: Clinical findings and laboratory correlates SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Hurwitz, M.; Manola, J.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Zheng, H.; Nagaraja, G. M.; Kaur, P.; Asea, A.] Texas A&M Hlth Sci Ctr, Scott & White Hosp & Clin, Temple, TX USA. [Bausero, M. A.] Inst Pasteur Montevideo, Montevideo, Uruguay. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S63 EP S63 DI 10.1016/j.ijrobp.2008.06.906 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300139 ER PT J AU Ionascu, D Park, S Mamede, M Killoran, J Gerbaudo, V Berbeco, R AF Ionascu, D. Park, S. Mamede, M. Killoran, J. Gerbaudo, V. Berbeco, R. TI Evaluation of target volume reconstruction from 4D-PET/CT imaging using a dynamic phantom and patient data SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Ionascu, D.; Park, S.; Killoran, J.; Berbeco, R.] Dana Farber Brigham & Womens Canc, Boston, MA USA. [Mamede, M.; Gerbaudo, V.] Brigham & Womens Hosp, Div Nucl Med, Dept Radiol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S605 EP S606 DI 10.1016/j.ijrobp.2008.06.229 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302259 ER PT J AU Kachnic, LA Tsai, HK Willins, J Kung, JH Feng, JK Shih, HA Hong, TS AF Kachnic, L. A. Tsai, H. K. Willins, J. Kung, J. H. Feng, J. K. Shih, H. A. Hong, T. S. TI Early clinical outcome in patients treated for anal canal cancer using dose-painted intensity modulated radiation therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Kachnic, L. A.; Willins, J.] Boston Med Ctr, Boston, MA USA. [Tsai, H. K.] Harvard Radiat Oncol Program, Boston, MA USA. [Kung, J. H.; Feng, J. K.; Shih, H. A.; Hong, T. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S260 EP S260 DI 10.1016/j.ijrobp.2008.06.1691 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805301057 ER PT J AU Katz, MS Efstathiou, JA Nguyen, PL Zietman, AL AF Katz, M. S. Efstathiou, J. A. Nguyen, P. L. Zietman, A. L. TI CaP calculator: An online decision support tool to improve evidence-based doctor-patient communication for clinically localized prostate cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Katz, M. S.] St Med Ctr, Lowell, MA USA. [Katz, M. S.] Radiat Oncol Associates PA, Manchester, NH USA. [Efstathiou, J. A.; Nguyen, P. L.] Harvard Radiat Oncol Program, Boston, MA USA. [Zietman, A. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S41 EP S41 DI 10.1016/j.ijrobp.2008.06.857 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300091 ER PT J AU Keefe, DM Elting, LS Sonis, ST Garden, A Spijkervet, F Barasch, A Jacquin, P Randolph, P Harari, P AF Keefe, D. M. Elting, L. S. Sonis, S. T. Garden, A. Spijkervet, F. Barasch, A. Jacquin, P. Randolph, P. Harari, P. TI Treatment for head and neck cancer and for lung cancer causes significant diarrhea SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Keefe, D. M.] Univ Adelaide, Adelaide, SA, Australia. [Elting, L. S.; Spijkervet, F.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Sonis, S. T.] Harvard Faber Canc Ctr, Boston, MA USA. [Barasch, A.] Univ Alabama, Birmingham, AL USA. [Jacquin, P.] Cookeville Reg Med Ctr, Cookeville, TN USA. [Randolph, P.] Washington Inst, Washington, DC USA. [Harari, P.] Univ Wisconsin, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S487 EP S487 DI 10.1016/j.ijrobp.2008.06.1432 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805301564 ER PT J AU Khor, L Bae, K Al-Saleem, T Hammond, EH Venketesan, V Byhardt, R Asbell, S Shipley, W Sandler, H Pollack, A AF Khor, L. Bae, K. Al-Saleem, T. Hammond, E. H. Venketesan, V. Byhardt, R. Asbell, S. Shipley, W. Sandler, H. Pollack, A. TI Protein kinase a RI-a overexpression is associated with prostate cancer outcome in men treated with androgen deprivation and radiotherapy: A secondary analysis of RTOG 92-02 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Khor, L.; Al-Saleem, T.; Pollack, A.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Bae, K.] Radiat Therapy Oncol Grp, Philadelphia, PA USA. [Hammond, E. H.] LDS Hosp, Salt Lake City, UT USA. [Venketesan, V.] Univ Western Ontario, London, ON, Canada. [Byhardt, R.] Zablocki Vet Adm Med Ctr, Milwaukee, WI 53295 USA. [Asbell, S.] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA. [Shipley, W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sandler, H.] Univ Michigan, Med Ctr, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S54 EP S55 DI 10.1016/j.ijrobp.2008.06.889 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300122 ER PT J AU Kleinberg, LR Powell, ME Forastiere, AA Keller, S Anne, R Benson, AB AF Kleinberg, L. R. Powell, M. E. Forastiere, A. A. Keller, S. Anne, R. Benson, A. B. TI Outcome of E1201: An eastern cooperative oncology group (ECOG) Randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/rt or irinotecan/cisplatin/rt in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Kleinberg, L. R.] Johns Hopkins Univ, Dept Radiat Oncol & Radiat Sci, Baltimore, MD USA. [Powell, M. E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Forastiere, A. A.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. [Keller, S.] Montefiore Hosp, Bronx, NY USA. [Anne, R.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Benson, A. B.] Northwestern Univ, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S72 EP S72 DI 10.1016/j.ijrobp.2008.06.930 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300162 ER PT J AU Kudo, S Noda, S Suzuki, Y Shirai, K Yoshida, Y Okamoto, M Al-Jahbari, W Mizui, T Shirao, T Takano, T AF Kudo, S. Noda, S. Suzuki, Y. Shirai, K. Yoshida, Y. Okamoto, M. Al-Jahbari, W. Mizui, T. Shirao, T. Takano, T. TI Investigation about the radiosensitivities of neural and glial cells derived from identical brain tissues SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Noda, S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kudo, S.; Suzuki, Y.; Shirai, K.; Yoshida, Y.; Okamoto, M.; Al-Jahbari, W.; Mizui, T.; Shirao, T.; Takano, T.] Gunma Univ, Maebashi, Gumma 371, Japan. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S225 EP S226 DI 10.1016/j.ijrobp.2008.06.691 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300503 ER PT J AU Lautenschlaeger, T Palanichamy, K Patel, D El-Jawahri, A Chakravarti, A AF Lautenschlaeger, T. Palanichamy, K. Patel, D. El-Jawahri, A. Chakravarti, A. TI Galectin-1 mediates resistance to radiotherapy through activation of the PI3K/Akt pathway SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Lautenschlaeger, T.; Palanichamy, K.; Patel, D.; El-Jawahri, A.; Chakravarti, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Palanichamy, Kamalakannan/E-3807-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S689 EP S689 DI 10.1016/j.ijrobp.2008.06.580 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302442 ER PT J AU Lee, LJ Macklin, EA Viswanatham, AN AF Lee, L. J. Macklin, E. A. Viswanatham, A. N. TI Clinical outcome following adjuvant radiotherapy for node-positive endometrial cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Lee, L. J.] Harvard Radiat Oncol Program, Boston, MA USA. [Macklin, E. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Viswanatham, A. N.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. RI Macklin, Eric/E-2955-2013 OI Macklin, Eric/0000-0003-1618-3502 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S368 EP S369 DI 10.1016/j.ijrobp.2008.06.1209 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805301297 ER PT J AU MacDonald, SM Harisinghani, MG Wolfgang, J Napolitano, B Katkar, A Taghian, AG AF MacDonald, S. M. Harisinghani, M. G. Wolfgang, J. Napolitano, B. Katkar, A. Taghian, A. G. TI Utilizing nanoparticle enhanced MRI for radiation treatment planning in patients with breast cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [MacDonald, S. M.; Harisinghani, M. G.; Wolfgang, J.; Napolitano, B.; Katkar, A.; Taghian, A. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S170 EP S171 DI 10.1016/j.ijrobp.2008.06.722 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300382 ER PT J AU Mak, RH Mamon, HJ Ryan, DP Miyamoto, DT Ancukiewicz, M Willeu, CG Choi, NC Blaszkowsky, LS Hong, TS AF Mak, R. H. Mamon, H. J. Ryan, D. P. Miyamoto, D. T. Ancukiewicz, M. Willeu, C. G. Choi, N. C. Blaszkowsky, L. S. Hong, T. S. TI Outcomes and tolerability of full dose chemoradiation for locally advanced esophageal cancer in patients age 75 or older SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Mak, R. H.; Miyamoto, D. T.] Harvard Radiat Oncol Residency Program, Boston, MA USA. [Mamon, H. J.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Mamon, H. J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Mamon, H. J.; Ryan, D. P.; Choi, N. C.; Blaszkowsky, L. S.; Hong, T. S.] Harvard Univ, Sch Med, Boston, MA USA. [Ryan, D. P.; Blaszkowsky, L. S.] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA. [Ancukiewicz, M.; Choi, N. C.; Hong, T. S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Willeu, C. G.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S271 EP S272 DI 10.1016/j.ijrobp.2008.06.1715 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805301081 ER PT J AU Martin, NE Nawaz, AO Schuller, B Kozak, KR Hong, TS Kachnic, LA AF Martin, N. E. Nawaz, A. O. Schuller, B. Kozak, K. R. Hong, T. S. Kachnic, L. A. TI Dosimetric comparison of radiation techniques to the prone pelvis for rectal cancer: 3-field based on bony landmarks (2D) vs. 3-dimensonal conformal (3D) vs. intensity modulated radiation therapy (IMRT) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Martin, N. E.; Kozak, K. R.] Harvard Radiat Oncol Program, Boston, MA USA. [Nawaz, A. O.; Schuller, B.; Kachnic, L. A.] Boston Med Ctr, Boston, MA USA. [Hong, T. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Martin, Neil/E-2193-2014 OI Martin, Neil/0000-0002-8164-8516 NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S548 EP S548 DI 10.1016/j.ijrobp.2008.06.100 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302133 ER PT J AU Miyamoto, DT Mamon, HJ Ryan, DP Willett, CG Ancukiewicz, M del Castillo, CF Blaszkowsky, L Hong, TS AF Miyamoto, D. T. Mamon, H. J. Ryan, D. P. Willett, C. G. Ancukiewicz, M. del Castillo, C. Fernandez Blaszkowsky, L. Hong, T. S. TI Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients 75 years or older SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Miyamoto, D. T.] Harvard Radiat Oncol Program, Boston, MA USA. [Mamon, H. J.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Ryan, D. P.; Ancukiewicz, M.; del Castillo, C. Fernandez; Blaszkowsky, L.; Hong, T. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Willett, C. G.] Duke Univ, Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S247 EP S247 DI 10.1016/j.ijrobp.2008.06.637 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805301028 ER PT J AU Mori, S Sharp, G Kumagai, M Hara, R Asakura, H Yamada, S Kishimoto, R Kato, H Kandatsu, S AF Mori, S. Sharp, G. Kumagai, M. Hara, R. Asakura, H. Yamada, S. Kishimoto, R. Kato, H. Kandatsu, S. TI Four-dimensional heavy charged particle ream radiotherapy in pancreatic cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Mori, S.; Kumagai, M.; Hara, R.; Asakura, H.; Yamada, S.; Kishimoto, R.; Kato, H.; Kandatsu, S.] NIRS, Chiba, Japan. [Sharp, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S541 EP S541 DI 10.1016/j.ijrobp.2008.06.086 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302119 ER PT J AU Munzenrider, JE Yeap, BY DeLaney, TF Marucci, L Filzek, MM Dean, SE Liebsch, NJ AF Munzenrider, J. E. Yeap, B. Y. DeLaney, T. F. Marucci, L. Filzek, M. M. Dean, S. E. Liebsch, N. J. TI Withdrawn SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Munzenrider, J. E.; Yeap, B. Y.; DeLaney, T. F.; Dean, S. E.; Liebsch, N. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Munzenrider, J. E.] Harvard Univ, Sch Med, Boston, MA USA. [Marucci, L.] Regina Elena Inst Canc Res, Rome, Italy. [Filzek, M. M.] Midwest Proton Therapy Ctr, Bloomington, IN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S104 EP S104 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300234 ER PT J AU Munzenrider, JE Yeap, BY DeLaney, TF Marucci, L Fitzek, MM Dean, SE Liebsch, NJ AF Munzenrider, J. E. Yeap, B. Y. DeLaney, T. F. Marucci, L. Fitzek, M. M. Dean, S. E. Liebsch, N. J. TI Long-term results of a dose searching trial in chordomas and chondrosarcomas of the skull base and cervical spine SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Munzenrider, J. E.; Yeap, B. Y.; DeLaney, T. F.; Dean, S. E.; Liebsch, N. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Munzenrider, J. E.] Harvard Univ, Sch Med, Boston, MA USA. [Marucci, L.] Regina Elena Inst Canc Res, Rome, Italy. [Fitzek, M. M.] Midwest Proton Therapy Ctr, Bloomington, IN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S104 EP S105 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300235 ER PT J AU Murphy, CD Russell, TA Specht, MC O'Toole, J Ancukiewicz, M Raad, RA Smith, BL Taghian, AG AF Murphy, C. D. Russell, T. A. Specht, M. C. O'Toole, J. Ancukiewicz, M. Raad, R. Abi Smith, B. L. Taghian, A. G. TI Prospective evaluation of early signs of lymphedema using the perometer: Impact of radiation and surgery in the treatment for breast SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Murphy, C. D.; Russell, T. A.; Specht, M. C.; O'Toole, J.; Ancukiewicz, M.; Raad, R. Abi; Smith, B. L.; Taghian, A. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S175 EP S176 DI 10.1016/j.ijrobp.2008.06.733 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300393 ER PT J AU Myerson, RJ Garofalo, M El Naqa, I Abrams, RA Das, P Gunderson, L Hong, T Kim, J Willett, CG Kachnic, LA AF Myerson, R. J. Garofalo, M. El Naqa, I. Abrams, R. A. Das, P. Gunderson, L. Hong, T. Kim, J. Willett, C. G. Kachnic, L. A. TI Elective clinical target volumes for conformal therapy in anorectal cancer: An RTOG consensus panel contouring atlas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Myerson, R. J.; El Naqa, I.] Washington Univ, Med Ctr, St Louis, MO USA. [Garofalo, M.] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA. [Abrams, R. A.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Das, P.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Gunderson, L.] Mayo Clin, Scottsdale, AZ USA. [Hong, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kim, J.] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada. [Willett, C. G.] Duke Univ, Med Ctr, Durham, NC USA. [Kachnic, L. A.] Boston Univ, Med Ctr, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S71 EP S71 DI 10.1016/j.ijrobp.2008.06.927 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300159 ER PT J AU Nanda, A Chen, M Renshaw, AA D'Amico, AV AF Nanda, A. Chen, M. Renshaw, A. A. D'Amico, A. V. TI PSA recurrence in men following definitive therapy for prostate cancer with gleason score 9/10, 8, and 7 with tertiary grade 5 disease SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Nanda, A.; D'Amico, A. V.] Brigham & Womens Hosp, Dana Farber Canc Inst, Harvard Radiat Oncol Program, Boston, MA 02115 USA. [Chen, M.] Univ Connecticut, Storrs, CT USA. [Renshaw, A. A.] Baptist Hosp Miami, Miami, FL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S40 EP S41 DI 10.1016/j.ijrobp.2008.06.856 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300090 ER PT J AU Nguyen, PL Chen, MH Hoffman, KE Katz, MS D'Amico, AV AF Nguyen, P. L. Chen, M. H. Hoffman, K. E. Katz, M. S. D'Amico, A. V. TI Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era: Implications for trial design SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Nguyen, P. L.; Hoffman, K. E.] Harvard Radiat Oncol Program, Boston, MA USA. [Chen, M. H.] Univ Connecticut, Storrs, CT USA. [Katz, M. S.] St Med Ctr, Lowell, MA USA. [D'Amico, A. V.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S39 EP S40 DI 10.1016/j.ijrobp.2008.06.854 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300088 ER PT J AU Noda, S Palanichamy, K Chakravarti, A AF Noda, S. Palanichamy, K. Chakravarti, A. TI GRP78 is a novel target for radiation therapy in malignant glioma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Noda, S.; Palanichamy, K.; Chakravarti, A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RI Palanichamy, Kamalakannan/E-3807-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S21 EP S21 DI 10.1016/j.ijrobp.2008.06.813 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300048 ER PT J AU Okamoto, M Suzuki, Y Shirai, K Mizui, T Yoshida, Y Noda, S Ali, AWS Shirao, T Nakano, T AF Okamoto, M. Suzuki, Y. Shirai, K. Mizui, T. Yoshida, Y. Noda, S. Ali, A. W. S. Shirao, T. Nakano, T. TI Effect of irradiation on the development of immature hippocampal neurons in vitro SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Okamoto, M.; Suzuki, Y.; Shirai, K.; Yoshida, Y.; Noda, S.; Ali, A. W. S.; Nakano, T.] Gunma Univ, Dept Radiat Oncol, Maebashi, Gumma 371, Japan. [Mizui, T.; Shirao, T.] Gunma Univ, Dept Neurobiol & Behav, Maebashi, Gumma 371, Japan. [Noda, S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S689 EP S690 DI 10.1016/j.ijrobp.2008.06.581 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302443 ER PT J AU Paganetti, H Jarlskog, CZ AF Paganetti, H. Jarlskog, C. Zacharatou TI The risk of developing a neutron-induced second malignancy for pediatric proton therapy patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Jarlskog, C. Zacharatou] Univ Copenhagen Hosp, DK-2100 Copenhagen, Denmark. [Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S67 EP S67 DI 10.1016/j.ijrobp.2008.06.918 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300151 ER PT J AU Palanichamy, K Erkkinen, M Noda, S Chakravarti, A AF Palanichamy, K. Erkkinen, M. Noda, S. Chakravarti, A. TI Novel models to investigate brain tumor stem cell biology SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English Estonian DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Palanichamy, K.; Erkkinen, M.; Noda, S.; Chakravarti, A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RI Palanichamy, Kamalakannan/E-3807-2011 NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S53 EP S54 DI 10.1016/j.ijrobp.2008.06.887 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300120 ER PT J AU Pollack, A Bae, K Khor, L Hammond, EH Chakravarti, A Dicker, A Brereton, HD Byhardt, R Venketesan, V Sandler, F AF Pollack, A. Bae, K. Khor, L. Hammond, E. H. Chakravarti, A. Dicker, A. Brereton, H. D. Byhardt, R. Venketesan, V. Sandler, F. TI A model for distant metastasis incorporating tissue biomarkers from prostate cancer patients in radiation therapy oncology group (RTOG) 92-02 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Pollack, A.; Khor, L.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Bae, K.] Radiat Therapy Oncol Grp, Philadelphia, PA USA. [Hammond, E. H.] Intermt Healthcare, LDS Hosp, Salt Lake City, UT USA. [Chakravarti, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Dicker, A.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. [Brereton, H. D.] NE Radiat Oncol Ctr, Dunmore, PA USA. [Byhardt, R.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Venketesan, V.] London Reg Canc Ctr, London, ON N6A 4L6, Canada. [Sandler, F.] Univ Michigan, Med Ctr, Ann Arbor, MI USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S58 EP S58 DI 10.1016/j.ijrobp.2008.06.896 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300129 ER PT J AU Racine, M Viswanathan, AN AF Racine, M. Viswanathan, A. N. TI Adjuvant high-close-rate brachytherapy alone for Stage I/II endometrial adenocarcinoma using a 4-gray versus 6-gray fractionation scheme SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Racine, M.; Viswanathan, A. N.] Brigham & Womens Hosp, DFCI, Boston, MA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S362 EP S362 DI 10.1016/j.ijrobp.2008.06.1195 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805301283 ER PT J AU Recht, A Ancukiewicz, M Lu, X Ei-Din, MA Martin, C MacDonald, S Katz, A Hirsch, A Kachnic, L Taghian, AG AF Recht, A. Ancukiewicz, M. Lu, X. Ei-Din, M. Alm Martin, C. MacDonald, S. Katz, A. Hirsch, A. Kachnic, L. Taghian, A. G. TI Lung dose-volume parameters and the risk of pneumonitis for patients treated with accelerated partial-breast irradiation (APBI) using 31) Conformal radiotherapy (3D-CRT) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Recht, A.; Lu, X.; Martin, C.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Ancukiewicz, M.; Ei-Din, M. Alm; MacDonald, S.; Katz, A.; Taghian, A. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hirsch, A.; Kachnic, L.] Boston Med Ctr, Boston, MA USA. NR 0 TC 8 Z9 8 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S4 EP S5 DI 10.1016/j.ijrobp.2008.06.777 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300012 ER PT J AU Rosenstein, BS Held, KD Williams, J Rockwell, S Zeman, EM AF Rosenstein, B. S. Held, K. D. Williams, J. Rockwell, S. Zeman, E. M. TI Survey of radiation biology educators in US and Canadian radiation oncology residency programs SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Rosenstein, B. S.] Mt Sinai Sch Med, New York, NY USA. [Rosenstein, B. S.] NYU, Sch Med, New York, NY USA. [Held, K. D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Williams, J.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA. [Rockwell, S.] Yale Univ, Sch Med, New Haven, CT USA. [Zeman, E. M.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. RI Rosenstein, Barry/A-7420-2009; Rockwell, Sara/B-8458-2009 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S717 EP S717 DI 10.1016/j.ijrobp.2008.06.557 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302507 ER PT J AU Safai, S MacDonald, S Lu, H Schwarz, M Trotimov, A Herrup, D Taghian, A Bortfeld, T AF Safai, S. MacDonald, S. Lu, H. Schwarz, M. Trotimov, A. Herrup, D. Taghian, A. Bortfeld, T. TI Feasibility study of pencil beam scanning in proton therapy for left-sided post-mastectomy chest wall irradiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Safai, S.; MacDonald, S.; Lu, H.; Schwarz, M.; Trotimov, A.; Herrup, D.; Taghian, A.; Bortfeld, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S520 EP S521 DI 10.1016/j.ijrobp.2008.06.039 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302072 ER PT J AU Sanghani, M Raad, RA Niemierko, A Taghian, A Wazer, D AF Sanghani, M. Raad, R. Abi Niemierko, A. Taghian, A. Wazer, D. TI Validation of a web-based predictive nomogram for ipsilateral breast tumor recurrence after breast conserving therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Sanghani, M.; Wazer, D.] Tufts Med Ctr, Boston, MA USA. [Sanghani, M.; Wazer, D.] Brown Univ, Rhode Isl Hosp, Providence, RI 02903 USA. [Raad, R. Abi; Niemierko, A.; Taghian, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S91 EP S91 DI 10.1016/j.ijrobp.2008.06.974 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300205 ER PT J AU Schwarz, M Herrup, D Safai, S Adams, J MacDonald, SM Kooy, HM Taghian, AM AF Schwarz, M. Herrup, D. Safai, S. Adams, J. MacDonald, S. M. Kooy, H. M. Taghian, A. M. TI Reduction of skin dose by pencil beam scanning and IMPT in partial breast irradiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Schwarz, M.] Agenzia Provinciale Protonterapia, Trento, Italy. [Schwarz, M.; Herrup, D.; Safai, S.; Adams, J.; MacDonald, S. M.; Kooy, H. M.; Taghian, A. M.] Massachusetts Gen Hosp, FH Burr Proton Therapy Ctr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S520 EP S520 DI 10.1016/j.ijrobp.2008.06.038 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302071 ER PT J AU Shih, HA Knopf, A Parodi, K Paganetti, H Bortfeld, T AF Shih, H. A. Knopf, A. Parodi, K. Paganetti, H. Bortfeld, T. TI PET/CT treatment verification after proton therapy in abdominopelvic tumor sites SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Shih, H. A.; Knopf, A.; Paganetti, H.; Bortfeld, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Parodi, K.] Heidelberg Ion Therapy Ctr, Heidelberg, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S642 EP S642 DI 10.1016/j.ijrobp.2008.06.309 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302337 ER PT J AU Siedow, M Zhang, M Saia, G Palanichamy, K Chakravarti, A AF Siedow, M. Zhang, M. Saia, G. Palanichamy, K. Chakravarti, A. TI Aurora kinases as targets for radiation therapy in prostate cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Siedow, M.; Zhang, M.; Saia, G.; Palanichamy, K.; Chakravarti, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Palanichamy, Kamalakannan/E-3807-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S708 EP S708 DI 10.1016/j.ijrobp.2008.06.536 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302486 ER PT J AU Smalley, S Rankin, C Benedetti, J Williamson, S Robertson, J Rich, T Martenson, J Benson, A Mayer, R Cripps, C AF Smalley, S. Rankin, C. Benedetti, J. Williamson, S. Robertson, J. Rich, T. Martenson, J. Benson, A. Mayer, R. Cripps, C. TI Pelvic failure analysis in INT 0144: Evaluation of chemotherapy regimen, risk group stratification, and nodal count SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Smalley, S.] Olathe Reg Oncol Ctr, Olathe, KS USA. [Rankin, C.; Benedetti, J.] SW Oncol Grp, Seattle, WA USA. [Williamson, S.] Univ Kansas, Kansas City, KS USA. [Rich, T.] Univ Virginia, Charlottesville, VA USA. [Martenson, J.] Mayo Clin, Rochester, MN USA. [Benson, A.] Northwestern Univ, Chicago, IL 60611 USA. [Mayer, R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Cripps, C.] Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S70 EP S70 DI 10.1016/j.ijrobp.2008.06.925 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300157 ER PT J AU Sonis, ST Jacquin, P Randolph-Jackson, P Harari, P Grunberg, S Liao, Z Bolek, T Elting, L Keefe, D AF Sonis, S. T. Jacquin, P. Randolph-Jackson, P. Harari, P. Grunberg, S. Liao, Z. Bolek, T. Elting, L. Keefe, D. TI Prevalence of mouth and throat soreness (MTS) in patients undergoing lung cancer treatment, with adverse impact on functional and quality of life outcomes SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Sonis, S. T.] Harvard Farber Canc Ctr, Boston, MA USA. [Jacquin, P.] Cookville Reg Med Ctr, Cookeville, TN USA. [Randolph-Jackson, P.] Washington Canc Inst, Washington, DC USA. [Harari, P.] Univ Wisconsin Hosp, Madison, WI USA. [Grunberg, S.] Vermont Reg Canc Ctr, Burlington, VT USA. [Liao, Z.; Elting, L.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Bolek, T.] Tallahassee Mem Hosp, Tallahassee, FL USA. [Keefe, D.] Univ Adelaide, Adelaide, SA, Australia. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S680 EP S680 DI 10.1016/j.ijrobp.2008.06.395 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302422 ER PT J AU Taghian, AG El-Din, MA Smith, BL Ancukiewicz, M MacDonald, SS Katz, A Specht, M Hirsch, A Powell, SN Recht, A AF Taghian, A. G. El-Din, M. Alm Smith, B. L. Ancukiewicz, M. MacDonald, S. S. Katz, A. Specht, M. Hirsch, A. Powell, S. N. Recht, A. TI Interim results of a phase I/II trial of 3D-conformal external beam accelerated partial breast irradiation in patients with early breast cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Taghian, A. G.; El-Din, M. Alm; Smith, B. L.; Ancukiewicz, M.; MacDonald, S. S.; Katz, A.; Specht, M.; Hirsch, A.; Powell, S. N.; Recht, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 19 Z9 19 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S4 EP S4 DI 10.1016/j.ijrobp.2008.06.776 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300011 ER PT J AU Truong, M Kamat, UR DeLaney, TF Chan, AW AF Truong, M. Kamat, U. R. DeLaney, T. F. Chan, A. W. TI Proton beam radiation therapy for soft tissue sarcomas of the paranasal sinus and nasal cavity SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Truong, M.; Kamat, U. R.; DeLaney, T. F.; Chan, A. W.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Truong, M.; Kamat, U. R.; DeLaney, T. F.; Chan, A. W.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S507 EP S507 DI 10.1016/j.ijrobp.2008.06.1477 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302042 ER PT J AU Viswanathan, AN Tanaka, C AF Viswanathan, A. N. Tanaka, C. TI The impact of positron emission tomography on the diagnosis and management of vulvar cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Viswanathan, A. N.; Tanaka, C.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S360 EP S361 DI 10.1016/j.ijrobp.2008.06.1191 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805301279 ER PT J AU Wagner, TD Kobayashi, W Dean, S Goldberg, SI Kirsch, DG Suit, HD Hornicek, FJ Springfield, DS Yoon, SS DeLaney, TF AF Wagner, T. D. Kobayashi, W. Dean, S. Goldberg, S. I. Kirsch, D. G. Suit, H. D. Hornicek, F. J. Springfield, D. S. Yoon, S. S. DeLaney, T. F. TI Combination short-course, preoperative irradiation, surgical resection and reduced-field, high-dose, postoperative irradiation in the treatment of tumors involving the bone SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Wagner, T. D.] Brooke Army Med Ctr, San Antonio, TX USA. [Kobayashi, W.; Dean, S.; Goldberg, S. I.; Suit, H. D.; Hornicek, F. J.; Springfield, D. S.; Yoon, S. S.; DeLaney, T. F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kirsch, D. G.] Duke Univ, Sch Med, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S503 EP S504 DI 10.1016/j.ijrobp.2008.06.1470 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302035 ER PT J AU Wang, AZ Guimaraes, A Zhang, L Gu, F Langer, R Weissleder, R Farokhzad, OC AF Wang, A. Z. Guimaraes, A. Zhang, L. Gu, F. Langer, R. Weissleder, R. Farokhzad, O. C. TI Development of novel multifunctional nanoparticles for combined imaging and targeted delivery of chemoradiotherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Wang, A. Z.] Harvard Radiat Oncol Program, Boston, MA USA. [Wang, A. Z.; Gu, F.; Farokhzad, O. C.] Harvard Univ, Brigham & Womens Hosp, Dept Anesthesia, Lab Nanomed & Biomat,Sch Med, Boston, MA 02115 USA. [Guimaraes, A.; Weissleder, R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Boston, MA USA. [Guimaraes, A.; Weissleder, R.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Zhang, L.; Langer, R.] Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RI Gu, Frank/G-8381-2011 OI Gu, Frank/0000-0001-8749-9075 NR 0 TC 0 Z9 0 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S707 EP S707 DI 10.1016/j.ijrobp.2008.06.534 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302484 ER PT J AU Winkfield, KM Linsenmeier, C Yeap, BY Tarbell, NJ Yock, TI AF Winkfield, K. M. Linsenmeier, C. Yeap, B. Y. Tarbell, N. J. Yock, T. I. TI Proton radiotherapy for childhood craniopharyngioma: Initial clinical outcomes SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Winkfield, K. M.] Harvard Univ, Sch Med, Harvard Radiat Oncol Program, Boston, MA USA. [Linsenmeier, C.; Tarbell, N. J.; Yock, T. I.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Yeap, B. Y.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S496 EP S496 DI 10.1016/j.ijrobp.2008.06.1453 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302018 ER PT J AU Wroe, AJ Clasie, B Kooy, H Flanz, J Schulte, RW Rosenfeld, AB AF Wroe, A. J. Clasie, B. Kooy, H. Flanz, J. Schulte, R. W. Rosenfeld, A. B. TI Out-of-field dose equivalents delivered by passively scattered therapeutic proton beams for clinically relevant field configurations SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Wroe, A. J.; Schulte, R. W.] Loma Linda Univ, Med Ctr, Dept Radiat Med, Loma Linda, CA USA. [Wroe, A. J.; Rosenfeld, A. B.] Univ Wollongong, Ctr Med Radiat Phys, Wollongong, NSW, Australia. [Clasie, B.; Kooy, H.; Flanz, J.] Harvard Univ, Sch Med, Boston, MA USA. [Clasie, B.; Kooy, H.; Flanz, J.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RI Rosenfeld, Anatoly/D-1989-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S644 EP S645 DI 10.1016/j.ijrobp.2008.06.315 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805302343 ER PT J AU Xiang, HF Kao, J Lo, Y Chin, LM Tishler, RB Court, LE Cormack, RA AF Xiang, H. F. Kao, J. Lo, Y. Chin, L. M. Tishler, R. B. Court, L. E. Cormack, R. A. TI Quantitative analysis of inter-fraction residual offsets of patient setup in head and neck IMRT by deformable registration of KV/MV projection images SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Xiang, H. F.; Kao, J.; Lo, Y.] Mt Sinai Med Ctr, New York, NY 10029 USA. [Xiang, H. F.; Kao, J.; Lo, Y.] Mt Sinai Sch Med, New York, NY USA. [Xiang, H. F.; Chin, L. M.; Tishler, R. B.; Court, L. E.; Cormack, R. A.] Harvard Univ, Sch Med, Dana Farber & Brigham Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S46 EP S46 DI 10.1016/j.ijrobp.2008.06.871 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300104 ER PT J AU Zhang, M Siedow, M Saia, G Palannichamy, K Lautenschlaeger, T Chakravarti, A AF Zhang, M. Siedow, M. Saia, G. Palannichamy, K. Lautenschlaeger, T. Chakravarti, A. TI Inhibition of p21-activated kinase 6 (PAK6) increases radiosensitivity of prostate cancer cells SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Zhang, M.; Siedow, M.; Saia, G.; Palannichamy, K.; Lautenschlaeger, T.; Chakravarti, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S22 EP S22 DI 10.1016/j.ijrobp.2008.06.815 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300050 ER PT J AU Zietman, AL Bae, K Coen, JJ Slater, JD Lunt, M Shipley, WU Rossi, C AF Zietman, A. L. Bae, K. Coen, J. J. Slater, J. D. Lunt, M. Shipley, W. U. Rossi, C. TI A prospective phase I/II study using proton beam radiation to deliver 82GyE, to men with localized prostate cancer: Preliminary results of ACR 0312 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY SEP 21-25, 2008 CL Boston, MA SP Amer Soc Therapeut Radiol & Oncol C1 [Zietman, A. L.; Coen, J. J.; Shipley, W. U.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bae, K.] Amer Coll Radiol, Philadelphia, PA USA. [Slater, J. D.; Lunt, M.; Rossi, C.] Loma Linda Univ, Med Ctr, Loma Linda, CA USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 72 IS 1 SU S BP S77 EP S77 DI 10.1016/j.ijrobp.2008.06.940 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 342TB UT WOS:000258805300172 ER PT J AU Cormack, RA AF Cormack, Robert A. TI Quality assurance issues for computed tomography-, ultrasound-, and magnetic resonance imaging-guided brachytherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE image guidance; brachytherapy; quality assurance ID PERMANENT PROSTATE BRACHYTHERAPY; RADIATION-THERAPY; INTRACAVITARY BRACHYTHERAPY; INTERSTITIAL-BRACHYTHERAPY; INTEROBSERVER VARIABILITY; AMERICAN-ASSOCIATION; CANCER; IMPLANTS; REGISTRATION; RADIOTHERAPY AB The requirements of quality assurance (QA) for both brachytherapy and imaging devices are well-defined, but image-guided brachytherapy has raised new issues. Image guidance in brachytherapy involves the transition from reference point dosimetry using films to volumetric imaging such as computed tomography, ultrasonography, and magnetic resonance imaging for treatment planning and guidance of applicator, needle, or seed placement. The QA of these devices might not reflect the conditions of use in brachytherapy or the requirements of brachytherapy treatment planning. Image interpretation becomes much more important with image-guided brachytherapy. The success of a procedure could depend on the interpretation of a single image in a calibration phase done under the time pressures of the operative setting. This change has implications at the level of treatment, the process, and the field of brachytherapy as a whole. The QA concerns arising from brachytherapy procedures using ultrasound, computed tomography, and magnetic resonance imaging guidance are discussed, as are the problems associated with using imaging in an interventional setting. This report was intended to indicate the QA concerns arising from the convergence of brachytherapy and imaging-highlighting areas in which technical improvements are needed. (c) 2008 Elsevier Inc. C1 Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA. RP Cormack, RA (reprint author), Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. EM rcormack@lroc.harvard.edu OI Cormack, Robert/0000-0001-5553-9984 NR 40 TC 8 Z9 8 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 71 IS 1 SU S BP S136 EP S141 DI 10.1016/j.ijrobp.2007.07.2389 PG 6 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 290WU UT WOS:000255154300029 PM 18406913 ER PT J AU Jiang, SB Wolfgang, JI Mageras, GS AF Jiang, Steve B. Wolfgang, John Mageras, Gig S. TI Quality assurance challenges for motion-adaptive radiation therapy: Gating, breath holding, and four-dimensional computed tomography SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE radiotherapy; quality assurance; respiratory gating; breath holding; 4D CT ID CELL LUNG-CANCER; DEEP INSPIRATION; CONTROL ABC; GATED RADIOTHERAPY; TECHNICAL ASPECTS; REPRODUCIBILITY; IMMOBILIZATION; TUMORS; REDUCTION AB Compared with conventional three-dimensional (3D) conformal radiation therapy and intensity-modulated radiation therapy treatments, quality assurance (QA) for motion-adaptive radiation therapy involves various challenges because of the added temporal dimension. Here we discuss those challenges for three specific techniques related to motion-adaptive therapy: namely respiratory gating, breath holding, and four-dimensional computed tomography. Similar to the introduction of any other new technologies in clinical practice, typical QA measures should be taken for these techniques also, including initial testing of equipment and clinical procedures, as well as frequent QA examinations during the early stage of implementation. Here, rather than covering every QA aspect in depth, we focus on some major QA challenges. The biggest QA challenge for gating and breath holding is how to ensure treatment accuracy when internal target position is predicted using external surrogates. Recommended QA measures for each component of treatment, including simulation, planning, patient positioning, and treatment delivery and verification, are discussed. For four-dimensional computed tomography, some major QA challenges have also been discussed. (C) 2008 Elsevier Inc. C1 [Jiang, Steve B.] Univ Calif San Diego, Dept Radiat Oncol, Morres Canc Ctr, La Jolla, CA 92093 USA. [Jiang, Steve B.; Wolfgang, John] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Jiang, Steve B.; Wolfgang, John] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Mageras, Gig S.] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA. RP Jiang, SB (reprint author), Univ Calif San Diego, Dept Radiat Oncol, Morres Canc Ctr, 3855 Hlth Sci Dr 0843, La Jolla, CA 92093 USA. EM sbjiang@ucsd.edu OI Mageras, Gikas/0000-0001-9851-4306 NR 24 TC 39 Z9 40 U1 1 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 71 IS 1 SU S BP S103 EP S107 DI 10.1016/j.ijrobp.2007.07.2386 PG 5 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 290WU UT WOS:000255154300022 PM 18406905 ER PT J AU John, SS Zietman, AL Shipley, WU Harisinghani, MG AF John, Subhash S. Zietman, Anthony L. Shipley, William U. Harisinghani, Mukesh G. TI Newer imaging modalities to assist with target localization in the radiation treatment of prostate cancer and possible lymph node metastases SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE prostate cancer; imaging; clinical target volume ID POSITRON-EMISSION-TOMOGRAPHY; MAGNETIC-RESONANCE-SPECTROSCOPY; DOMINANT INTRAPROSTATIC LESIONS; THERAPY ONCOLOGY GROUP-9413; RADICAL PROSTATECTOMY; PELVIC IRRADIATION; LOCAL RECURRENCE; WHOLE-PELVIS; 90 GY; RADIOTHERAPY AB Precise localization of prostate cancer and the drainage lymph nodes is mandatory to define an accurate clinical target volume for conformal radiotherapy. Better target definition and delineation on a daily basis is surely important in quality assurance for fractionated radiation therapy. This article reviews the evidence for major emerging techniques that show promise in better identifying the clinical target volume. Partial prostate boost by brachytherapy, intensity-modulated radiation therapy, or protons has become possible not only with standard imaging techniques but also with the availability of metabolic images obtained by magnetic resonance spectroscopy. Even though fluorine-18 fluorodeoxyglucose (F-18-FDG) positron emission tomography has not been found to be useful, novel radiolabeled tracers may eventually prove of value in the diagnosis and treatment planning of prostate cancer. For the metastatic lymph nodes, lymphotropic nanoparticle-enhanced magnetic resonance imaging using ultra-small superparamagnetic iron oxide particles has greater accuracy as compared with conventional techniques and has been instrumental in delineating the lymphatic drainage of the prostate gland. These novel investigational techniques could further help in optimizing conformal radiotherapy for patients with prostate cancer. The concepts of biologic target volume, real target volume, and multidimensional conformal radiotherapy are being explored. (C) 2008 Elsevier Inc. C1 [John, Subhash S.; Zietman, Anthony L.; Shipley, William U.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Harisinghani, Mukesh G.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Harisinghani, Mukesh G.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP John, SS (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Cox 3,100 Blossom St, Boston, MA 02114 USA. EM Subhashjohn@hotmail.com NR 39 TC 11 Z9 11 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2008 VL 71 IS 1 SU S BP S43 EP S47 DI 10.1016/j.ijrobp.2007.06.079 PG 5 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 290WU UT WOS:000255154300009 PM 18406936 ER PT J AU Mori, S Wolfgang, J Lu, HM Schneider, R Choi, NC Chen, GTY AF Mori, Shinichiro Wolfgang, John Lu, Hsiao-Ming Schneider, Robert Choi, Noah C. Chen, George T. Y. TI Quantitative assessment of range fluctuations in charged particle lung irradiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE charged particle radiotherapy; range variation; four-dimensional computed tomography; image-guided radiotherapy; lung cancer; radiotherapy planning ID BREATHING CONTROL ABC; DEEP INSPIRATION; HOLD TECHNIQUE; TUMOR MOTION; DEFORMABLE REGISTRATION; RESPIRATORY MOTION; RADIATION-THERAPY; ORGAN MOTION; CT-SCANNER; RADIOTHERAPY AB Purpose: Water equivalent path length (WEL) variations due to respiration can change the range of a charged particle beam and result in beam overshoot to critical organs or beam undershoot to tumor. We have studied range fluctuations by analyzing four-dimensional computed tomography data and quantitatively assessing potential beam overshoot. Methods and Materials: The maximal intensity volume is calculated by combining the gross tumor volume contours at each respiratory phase in the four-dimensional computed tomography study. The first target volume calculates the maximal intensity volume for the entire respiratory cycle (internal target volume [ITV] -radiotherapy [RT]), and the second target volume is the maximal intensity volume corresponding to gated RT (gated-RT, similar to 30% phase window around exhalation). A compensator at each respiratory phase is calculated. Two "composite" compensators for ITV-RT and gated-RT are then designed by selecting the minimal compensator depth at the respective respiratory phase. These compensators are then applied to the four-dimensional computed tomography data to estimate beam penetration. Analysis metrics; include range fluctuation and overshoot volume, both as a function of gantry angle. We compared WEL fluctuations observed in treating the ITV-RT versus gated-RT in 11 lung patients. Results: The WEL fluctuations were <21.8 mm-WEL and 9.5 mm-WEL for ITV-RT and gated-RT, respectively for all patients. Gated-RT reduced the beam overshoot volume by approximately a factor of four compared with ITV-RT. Such range fluctuations can affect the efficacy of treatment and result in an excessive dose to a distal critical organ. Conclusion: Time varying range fluctuation analysis provides information useful for determining appropriate patient-specific treatment parameters in charged particle RT. This analysis can also be useful for optimizing planning and delivery. (C) 2008 Elsevier Inc. C1 [Mori, Shinichiro; Wolfgang, John; Lu, Hsiao-Ming; Schneider, Robert; Choi, Noah C.; Chen, George T. Y.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. RP Mori, S (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,Cox 317, Boston, MA 02115 USA. EM shinshin@nirs.go.jp OI Mori, Shinichiro/0000-0002-0412-4399 FU NCI NIH HHS [P01 CA19138] NR 36 TC 33 Z9 34 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 2008 VL 70 IS 1 BP 253 EP 261 DI 10.1016/j.ijrobp.2007.08.049 PG 9 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 244LP UT WOS:000251867700034 PM 17967513 ER PT J AU Piwowarczyk, L Keane, TM Lincoln, A AF Piwowarczyk, Linda Keane, Terence M. Lincoln, Alisa TI Hunger: The silent epidemic among asylum seekers and resettled refugees SO INTERNATIONAL MIGRATION LA English DT Article; Proceedings Paper CT 19th Annual Conference of the International-Society-for-Traumatic-Stress-Studies CY OCT 29-NOV 01, 2003 CL Chicago, IL SP Int Soc Traumat Stress Studies ID MENTAL-HEALTH; TRAUMA; SYMPTOMS; EXILE; DEPRESSION; IMMIGRANTS; STRESSORS; DETENTION; ANXIETY; IMPACT AB Refugees and asylum seekers face challenges after arriving in a host country. They carry the trauma that they may have experienced in their countries of origin, during fight, and in countries of asylum. Other stressors impact on their adjustment after arriving in the United States including basic needs such as food, clothing, and shelter. This is a retrospective review of data collected as part of a needs assessment by a program, which serves survivors of torture and refugee trauma. Asylum seekers (n=65) and refugees were compared (n=30). Asylum seekers were more apt to be from Africa (p <.001), need family reunification (p=.027), speak more languages (p <.001), suffer from political persecution (p <.001), move from place to place due to not having a permanent place to live (p=.031), and be unable to contribute to the rent (p <.001). Unadjusted, asylum seekers were also more likely than refugees to have gone to bed hungry in the previous two weeks (p <.001) or since arriving in the United States (p <.001). Refugees were more likely to be eating more food now than before feeing, and asylum seekers the opposite (p <.001). Being an asylum seeker made one 3.7 times more likely to suffer from food insecurity than being a refugee, and 5.3 times more likely to not have work authorization. Among asylum seekers, adjusting for gender, age, education, lack of permanent housing, English fluency, and self-reported health status, not having work authorization made one 5.6 times more likely to suffer from hunger. Independently, being a torture survivor made one 10.4 times more likely to suffer from hunger. Asylum seekers must wait 150 days before applying for asylum in the United States. For humanitarian reasons, mandatory-waiting periods for work authorization for asylum seekers should be eliminated. C1 [Piwowarczyk, Linda] Boston Univ, Sch Med, Boston Ctr Refugee Hlth & Human Rights, Dept Psychiat,Boston Med Ctr, Boston, MA 02215 USA. [Keane, Terence M.] Boston Univ, Sch Med, Boston Ctr Refugee Hlth & Human Rights, Dept Psychiat,Natl Ctr PTSD, Boston, MA 02215 USA. [Lincoln, Alisa] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. RP Piwowarczyk, L (reprint author), Boston Univ, Sch Med, Boston Ctr Refugee Hlth & Human Rights, Dept Psychiat,Boston Med Ctr, Boston, MA 02215 USA. NR 36 TC 12 Z9 12 U1 1 U2 10 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0020-7985 J9 INT MIGR JI Int. Migr. PY 2008 VL 46 IS 1 BP 59 EP 77 DI 10.1111/j.1468-2435.2008.00436.x PG 19 WC Demography SC Demography GA 257PF UT WOS:000252810300003 ER PT S AU Heath, E Seco, J Wu, Z Sharp, GC Paganetti, H Seuntjens, J AF Heath, E. Seco, J. Wu, Z. Sharp, G. C. Paganetti, H. Seuntjens, J. BA Verhaegen, F Seuntjens, J BF Verhaegen, F Seuntjens, J TI A comparison of dose warping methods for 4D Monte Carlo dose calculations in lung SO INTERNATIONAL WORKSHOP ON MONTE CARLO TECHNIQUES IN RADIOTHERAPY DELIVERY AND VERIFICATION - THIRD MCGILL INTERNATIONAL WORKSHOP SE Journal of Physics Conference Series LA English DT Proceedings Paper CT International Workshop on Monte Carlo Techniques in Radiotherapy Delivery and Verification CY MAY 29-JUN 01, 2007 CL McGill Univ, Montreal, CANADA HO McGill Univ ID RADIOTHERAPY; TRACKING; ANATOMY; SEGMENTATION; REGISTRATION; SIMULATIONS; MOTION; BEAM AB Dose calculation methods which incorporate tissue motion are an important tool for evaluating the effect of respiratory motion on the delivered dose distribution. 4D dose calculation methods use a sum of remapped doses calculated on 4D CT images of the patient at different respiratory phases to determine the cumulative dose received over the entire respiratory cycle. A number of methods for remapping the dose to the reference phase have been proposed, including center-of-mass (COM) tracking and trilinear (TL) interpolation. In this work we compare calculations of dose distributions remapped between extreme breathing phases against a 4D Monte Carlo dose code defDOSXYZ for three planning scenarios. No clinically significant differences were noted between dose distributions calculated by the three methods with the exception of an extreme motion evaluation case where TL and COM remapping underestimated the 95% target dose coverage by up to 16%. The accuracy of these dose calculation methods is significantly affected by the continuity of the deformation fields from non-linear image registration. C1 [Heath, E.; Seuntjens, J.] McGill Univ, Montreal, PQ, Canada. [Seco, J.; Wu, Z.; Sharp, G. C.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA USA. RP Heath, E (reprint author), McGill Univ, Montreal, PQ, Canada. EM emily@medphys.mcgill.ca FU National Cancer Institute of Canada; Canadian Cancer Society; NIH [R01 CA 111590] FX The authors gratefully acknowledge the assistance of Dr. L. Dong who provided us with the 4D CT data for Patient 1. E. Heath is a research student of the Terry Fox Foundation through an award from the National Cancer Institute of Canada. J. Seuntjens is a Research Scientist of the NCIC appointed with funds provided by the Canadian Cancer Society. J. Seco, Z. Wu and H. Paganetti were fully or inpart supported by NIH grant R01 CA 111590. NR 16 TC 4 Z9 4 U1 0 U2 0 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 1742-6588 J9 J PHYS CONF SER PY 2008 VL 102 AR UNSP 012013 DI 10.1088/1742-6596/102/1/012013 PG 7 WC Biophysics; Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Biophysics; Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BSF47 UT WOS:000284328500013 ER PT S AU Roberts, DA Hansen, VN Seco, J Thompson, MG Evans, PM AF Roberts, D. A. Hansen, V. N. Seco, J. Thompson, M. G. Evans, P. M. BA Verhaegen, F Seuntjens, J BF Verhaegen, F Seuntjens, J TI A simple Monte Carlo based optimisation model to determine image contrast in an imaging system SO INTERNATIONAL WORKSHOP ON MONTE CARLO TECHNIQUES IN RADIOTHERAPY DELIVERY AND VERIFICATION - THIRD MCGILL INTERNATIONAL WORKSHOP SE Journal of Physics Conference Series LA English DT Proceedings Paper CT International Workshop on Monte Carlo Techniques in Radiotherapy Delivery and Verification CY MAY 29-JUN 01, 2007 CL McGill Univ, Montreal, CANADA HO McGill Univ ID BEAM; ACCELERATOR AB Whilst a radiotherapy imaging system can be modeled accurately using full Monte Carlo simulations a quicker method is required for system optimisation. Here we present a Monte Carlo based optimisation model that takes a radiation spectrum and detector response curve as inputs and predicts contrast for a particular imaging system. The model consists of two parts. The first part looks at the interaction of mono-energetic beams with phantoms of various bone and water compositions. In-particular the scatter and primary components emerging from the phantom are analysed. The second part models the response of a detector to various mono-energetic beams. Weighting of the phantom simulations with a linac spectrum results in the prediction of the scatter and primary components incident on an imaging device. Subsequent application of a detector response curve yields the scatter and primary signals in the imager. This technique has been applied to standard 6 and 4MV linac spectra as well as an experimental low atomic number (Z) target configuration to determine various imaging parameters. In particular it has been used to determine the contrast with various detector, phantom and linac spectra combinations. Use of the model shows significant benefits in using a detector with a reduced metal plate thickness for the low Z beam for thin, 5. 8cm phantoms that approximate the head and neck region. Whilst contrast can be doubled using the low Z beam and standard MV imager over the current 6MV system, a further improvement in contrast is predicted when using a detector without a metal plate C1 [Roberts, D. A.; Hansen, V. N.; Evans, P. M.] Inst Canc Res, Joint Dept Phys, Downs Rd, Sutton, Surrey, England. [Roberts, D. A.; Hansen, V. N.; Evans, P. M.] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England. [Seco, J.] Massachusetts Gen Hosp, Harvard Med, Boston, MA USA. [Thompson, M. G.] Elekta Ltd, Crawley, England. RP Roberts, DA (reprint author), Inst Canc Res, Joint Dept Phys, Downs Rd, Sutton, Surrey, England. EM david.roberts@icr.ac.uk RI Evans, Philip/A-6257-2009; Seco, Joao/J-4451-2012 FU Elekta Ltd; Institute of Cancer Research and Cancer Research UK FX Research supported by Elekta Ltd, The Institute of Cancer Research and Cancer Research UK. NR 7 TC 0 Z9 0 U1 0 U2 1 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 1742-6588 J9 J PHYS CONF SER PY 2008 VL 102 AR UNSP 012019 DI 10.1088/1742-6596/102/1/012019 PG 5 WC Biophysics; Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Biophysics; Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BSF47 UT WOS:000284328500019 ER PT J AU Pfefferbaum, RL Reissman, DB Pfefferbaum, B Wyche, KF Norris, FH Klomp, RW AF Pfefferbaum, Rose L. Reissman, Dori B. Pfefferbaum, Betty Wyche, Karen Fraser Norris, Fran H. Klomp, Richard W. BE Blumenfield, M Ursano, RJ TI Factors in the development of community resilience to disasters SO INTERVENTION AND RESILIENCE AFTER MASS TRAUMA LA English DT Article; Book Chapter ID CAPACITY C1 [Pfefferbaum, Rose L.] Phoenix Coll, Liberal Arts Dept, Phoenix, AZ USA. [Reissman, Dori B.] Ctr Dis Control & Prevent, CAPT, US Publ Hlth Serv, US Dept Hlth & Human Serv, Atlanta, GA USA. [Pfefferbaum, Betty; Wyche, Karen Fraser] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Psychiat & Behav Sci, Oklahoma City, OK 73190 USA. [Norris, Fran H.] US Dept Vet Affairs, Dept Psychiat, Dartmouth Med Sch, White River Jct, VT USA. [Norris, Fran H.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, White River Jct, VT USA. [Klomp, Richard W.] Ctr Dis Control & Prevent, Off Hlth & Safety, Off Chief Operating Officer, US Dept Hlth & Human Serv, Atlanta, GA USA. RP Pfefferbaum, RL (reprint author), Phoenix Coll, Liberal Arts Dept, Phoenix, AZ USA. NR 31 TC 6 Z9 6 U1 0 U2 2 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-88374-0 PY 2008 BP 49 EP 68 DI 10.1017/CBO9780511585975.004 D2 10.1017/CBO9780511585975 PG 20 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA BDP17 UT WOS:000314290100004 ER PT B AU Watson, PJ AF Watson, Patricia J. BE Blumenfield, M Ursano, RJ TI Psychological first aid SO INTERVENTION AND RESILIENCE AFTER MASS TRAUMA LA English DT Article; Book Chapter ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIOR THERAPY; COPING SELF-EFFICACY; SEPTEMBER-11 TERRORIST ATTACKS; RANDOMIZED CONTROLLED-TRIAL; NEW-YORK-CITY; REPRESENTATIVE SAMPLE; EARLY INTERVENTION; FUTURE-DIRECTIONS; TRAUMATIC EVENTS C1 US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, White River Jct, VT USA. RP Watson, PJ (reprint author), US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, White River Jct, VT USA. NR 70 TC 0 Z9 0 U1 2 U2 2 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-88374-0 PY 2008 BP 69 EP 84 DI 10.1017/CBO9780511585975.005 D2 10.1017/CBO9780511585975 PG 16 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA BDP17 UT WOS:000314290100005 ER PT J AU Friedman, MJ AF Friedman, Matthew J. BE Blumenfield, M Ursano, RJ TI The role of pharmacotherapy in early interventions SO INTERVENTION AND RESILIENCE AFTER MASS TRAUMA LA English DT Article; Book Chapter ID POSTTRAUMATIC-STRESS-DISORDER; WORKING-MEMORY PERFORMANCE; FEAR-POTENTIATED STARTLE; MEDIAL PREFRONTAL CORTEX; COMBAT-RELATED PTSD; HIPPOCAMPAL VOLUME; ADULT SURVIVORS; NMDA RECEPTORS; NEUROPEPTIDE-Y; DENTATE GYRUS C1 US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, White River Jct, VT USA. RP Friedman, MJ (reprint author), US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, White River Jct, VT USA. NR 84 TC 5 Z9 5 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-88374-0 PY 2008 BP 107 EP 125 DI 10.1017/CBO9780511585975.007 D2 10.1017/CBO9780511585975 PG 19 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA BDP17 UT WOS:000314290100007 ER PT J AU Saksena, MA Gervais, D Mueller, PR AF Saksena, Mansi A. Gervais, Debra Mueller, Peter R. BE Geschwind, JFH Soulen, MC TI PERCUTANEOUS RENAL ABLATION SO INTERVENTIONAL ONCOLOGY: PRINCIPLES AND PRACTICE LA English DT Article; Book Chapter ID RADIO-FREQUENCY ABLATION; GUIDED RADIOFREQUENCY ABLATION; PARENCHYMAL SPARING SURGERY; CELL CARCINOMA; THERMAL ABLATION; HEPATOCELLULAR-CARCINOMA; INITIAL-EXPERIENCE; IMAGING GUIDANCE; 100 TUMORS; CRYOABLATION C1 [Saksena, Mansi A.] Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging & Intervent, Boston, MA 02114 USA. RP Saksena, MA (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging & Intervent, Boston, MA 02114 USA. NR 69 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-86413-8 PY 2008 BP 400 EP 412 DI 10.1017/CBO9780511722226.034 D2 10.1017/CBO9780511722226 PG 13 WC Oncology SC Oncology GA BCY59 UT WOS:000312059500034 ER PT J AU Liu, CH Avinssh, KR Gervais, DA Sahani, DV AF Liu, Chang-Hsien Avinssh, Kambadakone R. Gervais, Debra A. Sahani, Dushyant V. BE Adam, A Mueller, PR TI Diagnostic imaging pre- and post-ablation SO INTERVENTIONAL RADIOLOGICAL TREATMENT OF LIVER TUMORS SE Contemporary Issues in Cancer Imaging LA English DT Article; Book Chapter ID POSITRON-EMISSION-TOMOGRAPHY; PERCUTANEOUS RADIOFREQUENCY ABLATION; SMALL HEPATOCELLULAR-CARCINOMA; FOCAL LIVER-LESIONS; HEPATIC-TUMORS; TISSUE ABLATION; FOLLOW-UP; F-18 FLUORODEOXYGLUCOSE; COLORECTAL-CANCER; HELICAL CT C1 [Liu, Chang-Hsien; Avinssh, Kambadakone R.; Gervais, Debra A.; Sahani, Dushyant V.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Liu, Chang-Hsien] Tri Serv Gen Hosp, Dept Radiol, Taipei, Taiwan. [Liu, Chang-Hsien] Natl Def Med Ctr, Taipei, Taiwan. RP Liu, CH (reprint author), Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 49 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-88687-1 J9 CONT ISS CANC IMAG PY 2008 BP 44 EP 73 DI 10.1017/CBO9780511575433.005 D2 10.1017/CBO9780511575433 PG 30 WC Oncology; Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging GA BCW56 UT WOS:000311687500005 ER PT J AU Farinha-Arcieri, LE Porchia, BM Carromeu, C Simabuco, FM Tamura, RE Ferreira, LCS Zerbini, LF Ventura, AM AF Farinha-Arcieri, Luis E. Porchia, Bruna M. Carromeu, Cassiano Simabuco, Fernando M. Tamura, Rodrigo E. Ferreira, Luis C. S. Zerbini, Luiz F. Ventura, Armando M. TI Expression and purification of a recombinant adenovirus fiber knob in a baculovirus system SO INTERVIROLOGY LA English DT Article DE adenovirus; fiber knob; baculovirus; Ni-NTA purification; Sf9 insect cells ID RECEPTOR-BINDING DOMAIN; HETEROLOGOUS PEPTIDES; IMMUNE-RESPONSES; SEROTYPE-2 FIBER; TYPE-2 FIBER; VECTORS; MICE; RESOLUTION; PROTEIN; VIRUS AB Objectives: To construct a recombinant baculovirus expressing the fiber knob domain of human adenovirus type 2 modified by the insertion of a foreign peptide, purify this protein after its production in insect cells, and to test its properties. Methods: Recombinant baculoviruses expressing the fiber knob were produced in Sf9 cells. The recombinant fiber knob was recovered from culture supernatants of infected cells and purified by a combination of Ni-NTA and ion-exchange chromatography. Results: Fiber knob was recovered from the culture media as a soluble protein. In the system used, the fiber knob is expressed fused with the V5 epitope and a histidine tag, which allowed purification by Ni-NTA chromatography. The protein was further purified by ion-exchange chromatography. We show that the recombinant fiber knob produced, with 31 extra amino acids in the C-terminus, can oligomerize and bind to the adenovirus receptor CAR, as it can block the infection of a recombinant type 5 adenovirus. Conclusions: The modified form of the fiber knob, produced in insect cells and purified by Ni-NTA and ion-exchange chromatography, retains the properties of oligomerization and binding to the fiber natural receptor, CAR. This construct has the potential to be a new adjuvant. Copyright (C) 2008 S. Karger AG, Basel. C1 [Farinha-Arcieri, Luis E.; Porchia, Bruna M.; Carromeu, Cassiano; Simabuco, Fernando M.; Tamura, Rodrigo E.; Ferreira, Luis C. S.; Ventura, Armando M.] Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, BR-05508900 Sao Paulo, Brazil. [Zerbini, Luiz F.] Harvard Inst Med, BIDMC, Boston, MA USA. RP Ventura, AM (reprint author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, Ave Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, Brazil. EM amventur@icb.usp.br RI tamura, rodrigo/C-3085-2012; Carromeu, Cassiano/B-1487-2014; Ferreira, Luis Carlos/M-3954-2014; tamura, rodrigo/O-9846-2014; Zerbini, Luiz /B-7720-2015 OI Ferreira, Luis Carlos/0000-0002-4883-1693; tamura, rodrigo/0000-0001-7767-0887; FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2003/02041-4, 06/59976-3]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq [479814/2004-0] FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; proc.No.2003/02041-4, 06/59976-3) and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq (proc. No. 479814/2004-0). L. E. F. A., F. M. S., C. C. and R. E. T. have doctoral degree fellowships from FAPESP. We are grateful to Joselma Siqueira and Fernanda Yeda for their expertise in handling insect cell culture, and to Camila Calderon and Rafael Ciro Marques Cavalcante for help with the protein purifications. We thank Dr. Carlos Menck (Sao Paulo University, Brazil) for DNA sequencing and fluorescence microscopy support. NR 18 TC 3 Z9 3 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0300-5526 J9 INTERVIROLOGY JI Intervirology PY 2008 VL 51 IS 3 BP 189 EP 195 DI 10.1159/000151532 PG 7 WC Virology SC Virology GA 350KS UT WOS:000259351900005 PM 18724066 ER PT J AU Konomi, K Chen, LL Tarko, RS Scally, A Schaumberg, DA Azar, D Dartt, DA AF Konomi, Keiko Chen, Li-Li Tarko, Rachel S. Scally, Amy Schaumberg, Debra A. Azar, Dimitri Dartt, Darlene A. TI Preoperative characteristics and a potential mechanism of chronic dry eye after LASIK SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID IN-SITU KERATOMILEUSIS; OCULAR SURFACE MANAGEMENT; CORNEAL SENSITIVITY; WORKSHOP 2007; TEAR FILM; PHOTOREFRACTIVE KERATECTOMY; MYOPIC LASIK; SUBCOMMITTEE; DISEASE; REINNERVATION AB PURPOSE. To determine whether measurable preoperative characteristics predispose patients to chronic dry eye after laser in situ keratomileusis (LASIK). METHODS. The study consisted of 24 eyes of 24 patients who underwent LASIK. Tear breakup time, Schirmer testing with and without anesthesia, rose bengal staining, central corneal sensitivity, nucleus-to-cytoplasmic ratio, and goblet cell density were evaluated 2 weeks before and 1 week, 3 months, and 9 months after surgery. Patients were classified into two outcome groups, the nondry-eye group (NDEG) and the chronic dry-eye group (CDEG), on the basis of dry eye status 9 months after surgery. The authors tested whether preoperative values of each parameter were associated with the development of chronic dry eye. RESULTS. All parameters, except rose bengal staining, deteriorated significantly after surgery but returned to preoperative levels within 3 to 9 months. The CDEG had significantly lower preoperative Schirmer test values with and without anesthesia and were delayed in recovery after surgery in goblet cell density, rose bengal staining, Schirmer test values without anesthesia, and tear breakup time. Results of preoperative Schirmer tests without anesthesia positively correlated with tear breakup time 9 months after surgery. CONCLUSIONS. Preoperative tear volume may affect recovery of the ocular surface after LASIK and may increase the risk for chronic dry eye. C1 [Konomi, Keiko; Chen, Li-Li; Tarko, Rachel S.; Schaumberg, Debra A.; Azar, Dimitri; Dartt, Darlene A.] Schepens Eye Res Inst, Boston, MA 02114 USA. [Konomi, Keiko; Chen, Li-Li; Schaumberg, Debra A.; Azar, Dimitri; Dartt, Darlene A.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Scally, Amy] Harvard Univ, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Schaumberg, Debra A.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA. RP Dartt, DA (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. EM darlene.dartt@schepens.harvard.edu NR 32 TC 35 Z9 37 U1 0 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JAN PY 2008 VL 49 IS 1 BP 168 EP 174 DI 10.1167/iovs.07-0337 PG 7 WC Ophthalmology SC Ophthalmology GA 256RJ UT WOS:000252747000023 PM 18172089 ER PT J AU Douglas, PS Weyman, AE Lindner, JR Wei, K AF Douglas, Pamela S. Weyman, Arthur E. Lindner, Jonathan R. Wei, Kevin TI Contrast Echocardiography: Past, Present, and ... Future? SO JACC-CARDIOVASCULAR IMAGING LA English DT Article AB THE FOOD AND DRUG ADMINISTRATION (FDA) has recently changed labelling requirements for ultrasound contrast agents, to include a 'Black Box' warning and the recommendation to monitor vital signs, electrocardiography, and pO(2) saturation for 30 min following administration. The warning was a result of an investigation of serious cardiopulmonary reactions, including fatalities, associated with ultrasound contrast administration. C1 [Douglas, Pamela S.] Duke Univ, Durham, NC 27706 USA. [Weyman, Arthur E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lindner, Jonathan R.; Wei, Kevin] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Douglas, PS (reprint author), Duke Univ, Durham, NC 27706 USA. NR 17 TC 11 Z9 11 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD JAN PY 2008 VL 1 IS 1 BP 107 EP 110 DI 10.1016/j.jcmg.2007.10.005 PG 4 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA V13EH UT WOS:000207649600016 PM 19356413 ER PT J AU Valerio, L Yazdanpanah, Y Poizot-Martin, I Rosenthal, E Marimoutou, C Gastaut, JA Tran, A Dellamonica, P Freedberg, KA Pradier, C AF Valerio, Laure Yazdanpanah, Yazdan Poizot-Martin, Isabelle Rosenthal, Eric Marimoutou, Catherine Gastaut, Jean-Albert Tran, Albert Dellamonica, Pierre Freedberg, Kenneth A. Pradier, Christian TI Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE antiviral agents; cohort studies; genotype; hepatitis C chronic; HIV infections ID HIV-INFECTED PATIENTS; HUMAN-IMMUNODEFICIENCY-VIRUS; CHRONIC HEPATITIS-C; ACTIVE ANTIRETROVIRAL THERAPY; MITOCHONDRIAL TOXICITY; COHORT; PROGRESSION; EVOLUTION; HCV AB Objective: When to start hepatitis C treatment in HIV/hepatitis C virus (HCV)-coinfected patients remains unresolved. Our objective was to determine if a baseline CD4 count >= 350 cells/mm(3) predicts a sustained HCV response to pegylated interferon plus ribavirin. Methods: We conducted a multicenter cohort study of HIV/HCV-coinfected patients treated for HIV in hospitals in Nice, Tourcoing, and Marseille (France). Sustained viral response (SVR) was defined as undetectable HCV RNA 24 weeks after treatment. The relation between CD4 cell count and SVR was examined separately for patients with HCV genotype 1 or non-1. Results: One hundred seventy-five patients were included. In patients with HCV genotype 1, the rate of SVR was 13% and was not related to baseline CD4 cell count (odds ratio [OR] = 1.0, 95% confidence interval [CI]: 0.1 to 9.3). In patients with HCV genotype non-1, the rate of SVR was 46% and was not significantly increased by a baseline CD4 count >= 350 cells/mm(3) (OR = 1.8, 95% CI: 0.6 to 5.9). Conclusions: Higher CD4 cell count at treatment initiation with pegylated interferon plus ribavirin did not improve treatment success probability, regardless of HCV genotype. C1 [Valerio, Laure] Hop Archet, CHU Nice, Dept Sante Publ, F-06202 Nice 3, France. [Valerio, Laure; Rosenthal, Eric; Tran, Albert; Dellamonica, Pierre; Pradier, Christian] Univ Nice Sophia Antipolis, Fac Med, Nice, France. [Yazdanpanah, Yazdan] Ctr Hosp Tourcoing, Serv Univ Malad Infect & Voyageur, Tourcoing, France. [Yazdanpanah, Yazdan] Fac Med Lille, EA 2694, F-59045 Lille, France. [Yazdanpanah, Yazdan] Inst Pasteur, Ctr Immunol & Biol Parasitaire, CNRS, Lab Rech Econ & Sociales,URA 362, F-59019 Lille, France. [Poizot-Martin, Isabelle; Marimoutou, Catherine; Gastaut, Jean-Albert] Hop St Marguerite, Ctr Informat & Soins Immunodeficience Humaine Sud, CHU Marseille, Marseille, France. [Poizot-Martin, Isabelle; Marimoutou, Catherine; Gastaut, Jean-Albert; Pradier, Christian] INSERM, U 379, F-13258 Marseille, France. [Rosenthal, Eric; Dellamonica, Pierre] CHU Nice, Pole Clin Univ Special Med, Nice, France. [Tran, Albert] CHU Nice, Pole Reference Hepatite C, Nice, France. [Freedberg, Kenneth A.] Massachusetts Gen Hosp, Gen Med & Infect Dis Div, Boston, MA 02114 USA. [Freedberg, Kenneth A.] Harvard Univ, Sch Med, Harvard Ctr AIDS Res, Program Epidemiol & Outcomes Res, Boston, MA USA. RP Valerio, L (reprint author), Hop Archet, CHU Nice, Dept Sante Publ, 1 ler Niveau,BP 3079, F-06202 Nice 3, France. EM valerio.l@chu-nice.fr FU NIAID NIH HHS [K24 AI062476, K24 AI062476-04, R01 AI042006, R01 AI042006-08, R01 AI42006, P30 AI060354, P30 AI060354-03] NR 27 TC 11 Z9 11 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JAN 1 PY 2008 VL 47 IS 1 BP 50 EP 55 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 245NG UT WOS:000251941500005 PM 18156991 ER PT J AU Reynolds, NR Testa, MA Su, M Chesney, MA Neidig, JL Frank, I Smith, S Ickovics, J Robbins, GK AF Reynolds, Nancy R. Testa, Marcia A. Su, Max Chesney, Margaret A. Neidig, Judith L. Frank, Ian Smith, Scott Ickovics, Jeannette Robbins, Gregory K. CA AIDS Clinical Trials Grp 731 TI Telephone support to improve antiretroviral medication adherence - A multisite, randomized controlled trial SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; adherence; randomized controlled trial; phone intervention ID CLINICAL-TRIALS; NONCOMPLIANCE; INTERVENTION; RESISTANCE; THERAPY; MODEL; HIV-1 AB Objective: To determine whether proactive telephone support improves adherence to antiretroviral therapy (ART) and clinical outcomes when compared to standard care. Methods: A multisite, randomized controlled trial (RCT) was conducted with 109 ART naive subjects coenrolled in AIDS Clinical Trials Group (ACTG) 384. Subjects received standard clinic-based patient education (SC) or SC plus structured proactive telephone calls. The customized calls were conducted from a central site over 16 weeks by trained registered nurses. Outcome measures (collected over 64 weeks) included an ACTG adherence questionnaire and 384 study endpoints. Results: For the primary endpoint, self-reported adherence, a significantly better overall treatment effect was observed in the telephone group (P = 0.023). In a post hoc analysis, composite adherence scores, taken as the first 2 factor scores from a principal components analysis, also found significant intervention benefit (P = 0.023 and 0.019 respectively). For the 384 primary study endpoint, time to regimen failure, the Kaplan-Meier survival curve for the telephone group remained above the SC group at weeks 20 to 64; a Cox proportional hazard model that controlled for baseline RNA stratification, CD4, gender, age, race/ethnicity, and randomized ART treatment arm suggested the telephone group tended to have a lower risk for failure (hazard ratio = 0.68; 95% confidence interval: 0.38 to 1.23). Conclusions: Findings indicate that customized, proactive telephone calls have good potential to improve long-term adherence behavior and clinical outcomes. C1 [Reynolds, Nancy R.; Neidig, Judith L.] Ohio State Univ, AIDS Clin Trials Unit, Off Responsible Res Practices, Columbus, OH 43210 USA. [Testa, Marcia A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Su, Max] Phase V Technol Inc, Boston, MA USA. [Chesney, Margaret A.] Univ Calif San Francisco, AIDS Clin Trials Unit, Natl Ctr Complementary & Alternat Med, NIH, Bethesda, MD USA. [Frank, Ian] Hosp Univ Penn, Div Infect Dis, Philadelphia, PA 19104 USA. [Smith, Scott] Univ N Carolina, Ctr Outcomes & Evidence Agcy Healthcare Res & Qua, AIDS Clin Trials Unit, Rockville, MD USA. [Ickovics, Jeannette] Yale Univ, New Haven, CT USA. [Robbins, Gregory K.] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA. RP Reynolds, NR (reprint author), Ohio State Univ, AIDS Clin Trials Unit, Off Responsible Res Practices, 1585 Neil Ave, Columbus, OH 43210 USA. EM reynolds.l@osu.edu RI Robbins, Gregory/F-7988-2011 FU NIAID NIH HHS [1K01AI062435, AI-45008, AI032783, AI068636, AI069419, AI069472, AI25868]; NINR NIH HHS [R01 NR05108] NR 25 TC 52 Z9 55 U1 2 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JAN 1 PY 2008 VL 47 IS 1 BP 62 EP 68 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 245NG UT WOS:000251941500007 PM 17891043 ER PT J AU Olson, CK Kutner, LA Warner, DE AF Olson, Cheryl K. Kutner, Lawrence A. Warner, Dorothy E. TI The role of violent video game content in adolescent development - Boys' perspectives SO JOURNAL OF ADOLESCENT RESEARCH LA English DT Article DE video games; focus groups; media violence; adolescence; gender; anger ID AGGRESSION; MEDIA; PLAY; CHILDREN; ADULTHOOD; APPEAL AB Numerous policies have been proposed at the local, state, and national level to restrict youth access to violent video and computer games. Although studies are cited to support policies, there is no published research on how children perceive the uses and influence of violent interactive games. The authors conduct focus groups with 42 boys ages 12 to 14. Boys use games to experience fantasies of power and fame, to explore and master what they perceive as exciting and realistic environments (but distinct from real life), to work through angry feelings or relieve stress, and as social tools. Boys did not believe they had been harmed by violent games but were concerned that younger children might imitate game behavior (especially swearing). C1 [Olson, Cheryl K.; Kutner, Lawrence A.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Mental Hlth & Media, Boston, MA 02114 USA. [Warner, Dorothy E.] Baker Childrens Ctr, Boston, MA USA. RP Olson, CK (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Ctr Mental Hlth & Media, Wang 812,Parkman St, Boston, MA 02114 USA. EM ckolson@partners.org NR 56 TC 31 Z9 32 U1 8 U2 30 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0743-5584 J9 J ADOLESCENT RES JI J. Adolesc. Res. PD JAN PY 2008 VL 23 IS 1 BP 55 EP 75 DI 10.1177/0743558407310713 PG 21 WC Psychology, Developmental SC Psychology GA 242NK UT WOS:000251732000003 ER PT J AU Kutner, LA Olson, CK Warner, DE Hertzog, SM AF Kutner, Lawrence A. Olson, Cheryl K. Warner, Dorothy E. Hertzog, Sarah M. TI Parents' and sons' perspectives on video game play - A qualitative study SO JOURNAL OF ADOLESCENT RESEARCH LA English DT Article DE video games; focus groups; media violence; adolescence; parenting ID ADOLESCENT DEVELOPMENT; TELEVISION-NEWS; MEDIA; VIOLENCE; CHILDREN; AGGRESSION; BEHAVIOR; FEAR AB Public policy efforts to restrict children's access to electronic games with violent or sexual content are often predicated on assumptions about parental concerns. As an initial step in determining whether those assumptions are accurate, the authors conduct focus groups of 21 adolescent boys and 21 of their parents or guardians to explore parents' concerns, compare parents' and children's perceptions, and see whether these are consistent with the focus of proposed legislation and other public policy efforts. Parents' primary concern is that games not interfere with their children's schoolwork, social skills, and exercise. They worry about exposure to violent content, but definitions of and opinions about what is harmful vary and may not match proposed public policies. C1 [Kutner, Lawrence A.; Olson, Cheryl K.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Mental Hlth & Media, Boston, MA 02114 USA. [Hertzog, Sarah M.] Baker Childrens Ctr, Boston, MA USA. RP Olson, CK (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Ctr Mental Hlth & Media, Wang 812,Parkman St, Boston, MA 02114 USA. EM colson@hms.harvard.edu NR 38 TC 18 Z9 18 U1 5 U2 17 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0743-5584 J9 J ADOLESCENT RES JI J. Adolesc. Res. PD JAN PY 2008 VL 23 IS 1 BP 76 EP 96 DI 10.1177/0743558407310721 PG 21 WC Psychology, Developmental SC Psychology GA 242NK UT WOS:000251732000004 ER PT J AU Goransson, KE Ehnfors, M Fonteyn, ME Ehrenberg, A AF Goransson, Katarina E. Ehnfors, Margareta Fonteyn, Marsha E. Ehrenberg, Anna TI Thinking strategies used by Registered Nurses during emergency department triage SO JOURNAL OF ADVANCED NURSING LA English DT Article DE decision-making; emergency department; Registered Nurses; think aloud method; thinking strategies; triage ID CLINICAL DECISION-MAKING; CARE AB Aim. This paper is a report of a study to describe and compare thinking strategies and cognitive processing in the emergency department triage process by Registered Nurses with high and low triage accuracy. Background. Sound clinical reasoning and accurate decision-making are integral parts of modern nursing practice and are of vital importance during triage in emergency departments. Although studies have shown that individual and contextual factors influence the decisions of Registered Nurses in the triage process, others have failed to explain the relationship between triage accuracy and clinical experience. Furthermore, no study has shown the relationship between Registered Nurses' thinking strategies and their triage accuracy. Method. Using the 'think aloud' method, data were collected in 2004-2005 from 16 RNs working in Swedish emergency departments who had previously participated in a study examining triage accuracy. Content analysis of the data was performed. Findings. The Registered Nurses used a variety of thinking strategies, ranging from searching for information, generating hypotheses to stating propositions. They structured the triage process in several ways, beginning by gathering data, generating hypotheses or allocating acuity ratings. Comparison of participants' use of thinking strategies and the structure of the triage process based on their previous triage accuracy revealed only slight differences. Conclusion. The wide range of thinking strategies used by Registered Nurses when performing triage indicates that triage decision-making is complex. Further research is needed to ascertain which skills are most important in triage decision-making. C1 [Goransson, Katarina E.; Ehnfors, Margareta; Ehrenberg, Anna] Univ Orebro, Dept Hlth Sci, Orebro, Sweden. [Goransson, Katarina E.] Karolinska Univ Hosp, Dept Emergency, Solna, Sweden. [Fonteyn, Marsha E.] Dana Farber Canc Ctr, Boston, MA USA. RP Goransson, KE (reprint author), Univ Orebro, Dept Hlth Sci, Orebro, Sweden. EM katarina.goransson@karolinska.se OI Goransson, Katarina/0000-0002-4062-4470 NR 33 TC 30 Z9 31 U1 1 U2 7 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0309-2402 J9 J ADV NURS JI J. Adv. Nurs. PD JAN PY 2008 VL 61 IS 2 BP 163 EP 172 PG 10 WC Nursing SC Nursing GA 247ZL UT WOS:000252121000006 PM 18186908 ER PT J AU Hammemess, P Harpold, T Petty, C Menard, C Zar-Kessler, C Biederman, J AF Hammemess, Paul Harpold, Theresa Petty, Carter Menard, Chantal Zar-Kessler, Claire Biederman, Joseph TI Characterizing non-OCD anxiety disorders in psychiatrically referred children and adolescents SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE anxiety disorders; psychiatrically referred; children ID COMORBIDITY SURVEY REPLICATION; SOCIAL PHOBIA; PANIC DISORDER; BIPOLAR DISORDER; DSM-IV; PREVALENCE; SYMPTOMS; ONSET; PSYCHOPATHOLOGY; COMMUNITY AB Background: To characterize childhood and adolescent anxiety disorders in a psychiatric clinic. Methods: Subjects were 1375 youth referred to a pediatric psychopharmacology program at a major academic center from 1991-2002. DSM-III-R diagnoses were obtained by Schedule for Affective Disorders and Schizophrenia for School-Age Children. Results: Of 1375 referred youth, 794 had at least one non-obsessive-compulsive anxiety disorder, and 581 psychiatric comparison subjects had at least one disruptive behavior disorder and no anxiety disorders. There were 367 (46%) youth with one anxiety disorder, 224 (28%) with two disorders. Most prevalent were separation anxiety (49%), and overanxious disorder (47%). Mean ages of onset ranged from simple phobia (4.1) to panic disorder (8.5). Risk analyses revealed anxiety disorders significantly increased risk for anxiety and mood disorders. Conclusions: The full complement of anxiety disorders occurs in youth. (C) 2007 Elsevier B.V. All rights reserved. C1 [Hammemess, Paul; Harpold, Theresa; Petty, Carter; Menard, Chantal; Zar-Kessler, Claire; Biederman, Joseph] Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Cambridge, MA 02138 USA. [Biederman, Joseph] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Hammemess, P (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, 185 Alewife Brook Pkwy,Suite 2000, Cambridge, MA 02138 USA. EM phammemess@partners.org NR 29 TC 12 Z9 12 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JAN PY 2008 VL 105 IS 1-3 BP 213 EP 219 DI 10.1016/j.jad.2007.05.012 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 258YB UT WOS:000252905200023 PM 17572506 ER PT J AU Bush, AI AF Bush, Ashley I. TI Drug Development Based on the Metals Hypothesis of Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Review DE Alzheimer's disease; amyloid-beta; clinical trials; copper; iron; metals; oligomer; oxidation; zinc ID AMYLOID-BETA-PEPTIDE; GROWTH-INHIBITORY FACTOR; P70 S6 KINASE; A-BETA; PRECURSOR-PROTEIN; TRANSGENIC MICE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; IN-VITRO; MOUSE-BRAIN AB The recent report of positive results from a Phase IIa clinical trial of PBT2, a novel drug that targets amyloid-beta-metal interactions, underscores the value of abnormal transition metal metabolism as a potential therapeutic target in Alzheimer's disease. The Metals Hypothesis of Alzheimer's disease is based upon observations of the precipitation of amyloid-beta by zinc and its radicalization by copper. Both metals are markedly enriched in plaques. The Hypothesis involves the perturbance of these endogenous brain metals, and it does not consider toxicological exposure part of pathogenesis. Recent descriptions of the release of ionic zinc and copper in the cortical glutamatergic synapse, modulating the response of the NMDA receptor, may explain the vulnerability of amyloid-beta to abnormal interaction with these metal ions in the synaptic region leading to aggregation and fostering toxicity. Increasingly sophisticated medicinal chemistry approaches are being tested which correct the abnormalities without causing systemic disturbance of these essential minerals. PBT2, clioquinol and related compounds are ionophores rather than chelators. PBT2 is a once per day, orally bioavailable, second generation 8-OH quinoline derivative of clioquinol. It has performed very satisfactorily in toxicology and Phase I clinical trials and is advancing as a disease-modifying candidate drug for Alzheimer's disease. C1 [Bush, Ashley I.] Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia. [Bush, Ashley I.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia. [Bush, Ashley I.] Massachusetts Gen Hosp, Genet & Aging Res Unit, Charlestown, MA USA. RP Bush, AI (reprint author), Mental Hlth Res Inst Victoria, 155 Oak St, Parkville, Vic 3052, Australia. EM abush@mhri.edu.au RI Bush, Ashley/A-1186-2007 OI Bush, Ashley/0000-0001-8259-9069 FU National Health and Medical Research Council of Australia; The Australian Research Council FX This work is supported with funds from the National Health and Medical Research Council of Australia, and The Australian Research Council. The author is a paid consultant for and/or shareholder in Prana Biotechnology Ltd. and Cogstate Ltd. NR 162 TC 148 Z9 153 U1 3 U2 37 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2008 VL 15 IS 2 BP 223 EP 240 PG 18 WC Neurosciences SC Neurosciences & Neurology GA 371UQ UT WOS:000260857300008 PM 18953111 ER PT J AU Vuletic, S Li, G Peskind, ER Kennedy, H Marcovina, SM Leverenz, JB Petrie, EC Lee, VMY Galasko, D Schellenberg, GD Albers, JJ AF Vuletic, Simona Li, Ge Peskind, Elaine R. Kennedy, Hal Marcovina, Santica M. Leverenz, James B. Petrie, Eric C. Lee, Virginia M-Y. Galasko, Douglas Schellenberg, Gerard D. Albers, John J. TI Apolipoprotein E Highly Correlates with A beta PP- and Tau-Related Markers in Human Cerebrospinal Fluid SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Amyloid-beta; amyloid-beta protein precursor protein; apolipoprotein E; cerebrospinal fluid; phospholipid transfer protein; tau ID PHOSPHOLIPID TRANSFER PROTEIN; CHOLESTEROL TRANSPORT PROTEIN; AMYLOID PRECURSOR PROTEIN; TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE; IN-VITRO; SYNAPTIC PROTEINS; EPSILON-4 ALLELE; FIBRIL FORMATION; LIPOPROTEINS AB We assessed cerebrospinal fluid (CSF) levels of apolipoprotein E (apoE), phospholipid transfer protein (PLTP) activity, cholesterol, secreted amyloid-beta protein precursor alpha and beta (sA beta PP alpha, sA beta PP beta), amyloid-beta peptides 1-40 (A beta(40)) and 1-42 (A beta(42)), total tau and tau phosphorylated at threonine 181 (pTau) in neurologically healthy, cognitively intact adults. ApoE significantly correlated with sA beta PP alpha (r = 0.679), sA beta PP beta (r = 0.634), A beta(40) (r = 0.609), total and pTau (r = 0.589 and r = 0.673, respectively, all p < 0.001), PLTP activity (r = 0.242, p = 0.002) and cholesterol (r = 0.194, p < 0.01). PLTP activity significantly correlated with sA beta PP alpha (r = 0.292), sA beta PP beta (r = 0.281), total and pTau (r = 0.265 and 0.258, respectively; all p <= 0.001). Using partial correlations of CSF biomarkers with apoE, PLTP activity, age and gender, apoE remained significantly correlated with sA beta PP alpha, sA beta PP beta, A beta(40), total and pTau (p < 0.001). The presence of apoE epsilon 2 was associated with lower levels of apoE, PLTP activity and A beta(42), while APOE epsilon 4 had no significant impact on any of the measured variables. Our data suggest that there is a significant physiological link between apoE and A beta PP, as well as between apoE and tau in neurologically healthy, cognitively intact individuals. C1 [Vuletic, Simona; Kennedy, Hal; Marcovina, Santica M.; Albers, John J.] Univ Washington, Sch Med, NW Lipid Metab & Diabet Res Labs, Seattle, WA 98109 USA. [Li, Ge; Peskind, Elaine R.; Leverenz, James B.; Petrie, Eric C.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98109 USA. [Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Lee, Virginia M-Y.] Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA. [Galasko, Douglas] Univ Calif San Diego, Dept Neurosci, ADRC, La Jolla, CA 92093 USA. [Schellenberg, Gerard D.] GRECC, Seattle, WA USA. [Schellenberg, Gerard D.] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. RP Albers, JJ (reprint author), Univ Washington, Sch Med, NW Lipid Metab & Diabet Res Labs, 401 Queen Anne Ave N, Seattle, WA 98109 USA. EM jja@u.washington.edu FU NIH [P01 HL030086]; NIA [P50 AG05136, K08 AG023670, K23 AG20020]; Department of Veterans Affairs FX Funding sources: NIH P01 HL030086; The Friends of Alzheimer's Research; NIA P50 AG05136; NIA K08 AG023670; NIA K23 AG20020; and the Department of Veterans Affairs. The funding sponsors were not involved in the study design and conduct, data collection, management, analyses or interpretation, nor in the preparation, review or approval of the manuscript. NR 50 TC 9 Z9 9 U1 1 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2008 VL 15 IS 3 BP 409 EP 417 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 371US UT WOS:000260857500007 PM 18997294 ER PT J AU Khurana, V AF Khurana, Vikram TI Modeling Tauopathy in the Fruit Fly Drosophila melanogaster SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Actin; Alzheimer's disease; cell cycle; Drosophila; dementia; fruit fly; neurodegeneration; oxidative Stress; tau; tauopathy ID TAU-INDUCED NEURODEGENERATION; PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE BRAIN; CELL-CYCLE ACTIVATION; NEUROFIBRILLARY PATHOLOGY; NEURONAL APOPTOSIS; OXIDATIVE STRESS; TRANSGENIC MICE; MOUSE MODEL; PHOSPHORYLATION AB The fruit fly Drosophila melanogaster has emerged as a powerful system in which to model human disease. This review focuses on the utility of the fly to model tau-dependent neurodegeneration, a hallmark of Alzheimer's disease and related neurodegenerative disorders. I provide a detailed description of fly tauopathy models and summarize a number of studies that demonstrate their ability to recapitulate both primary features of tauopathy, including tau-induced neurodegeneration and phosphorylation, and secondary features, including oxidative stress, cell-cycle activation and changes in the actin cytoskeleton. Important genetic and biochemical insights are discussed, and future directions proposed. C1 [Khurana, Vikram] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. [Khurana, Vikram] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Khurana, Vikram] Harvard Univ, Sch Med, Boston, MA USA. RP Khurana, V (reprint author), Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA. EM vkhurana@partners.org NR 71 TC 22 Z9 22 U1 2 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2008 VL 15 IS 4 BP 541 EP 553 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 391CE UT WOS:000262209800003 PM 19096155 ER PT J AU Begum, AN Yang, FS Teng, E Hu, SX Jones, MR Rosario, ER Beech, W Hudspeth, B Ubeda, OJ Cole, GM Frautschy, SA AF Begum, Aynun N. Yang, Fusheng Teng, Edmond Hu, Shuxin Jones, Mychica R. Rosario, Emily R. Beech, Walter Hudspeth, Beverly Ubeda, Oliver J. Cole, Greg M. Frautschy, Sally A. TI Use of Copper and Insulin-Resistance to Accelerate Cognitive Deficits and Synaptic Protein Loss in a Rat A beta-Infusion Alzheimer's Disease Model SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta; copper; cognitive deficit; high density lipoprotein; insulin resistance ID AMYLOID PRECURSOR PROTEIN; HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-E GENOTYPE; TRANSGENIC MICE; MEMORY DEFICITS; IN-VIVO; MOUSE MODEL; INTRACEREBROVENTRICULAR INFUSION; LEARNING-DEFICITS; OXIDATIVE STRESS AB The rat amyloid-beta (A beta) intracerebroventricular infusion can model aspects of Alzheimer's disease (AD) and has predicted efficacy of therapies such as ibuprofen and curcumin in transgenic mouse models. High density lipoprotein (HDL), a normal plasma carrier of A beta, is used to attenuate A beta aggregation within the pump, causing A beta-dependent toxicity and cognitive deficits within 3 months. Our goal was to identify factors that might accelerate onset of A beta-dependent deficits to improve efficiency and cost-effectiveness of model. We focused on: 1) optimizing HDL-A beta preparation for maximal toxicity; 2) evaluating the role of copper, a factor typically in water that can impact oligomer stability; and 3) determining impact of insulin resistance (type II diabetes), a risk factor for AD. In vitro studies were performed to determine doses of copper and methods of A beta-HDL preparation that maximized toxicity. These preparations when infused resulted in earlier onset of cognitive deficits within 6 weeks post-infusion. Induction of insulin resistance did not exacerbate A beta-dependent cognitive deficits, but did exacerbate synaptic protein loss. In summary, the newly described in vivo infusion model may be useful cost-effective method for screening for new therapeutic drugs for AD. C1 [Begum, Aynun N.; Yang, Fusheng; Hu, Shuxin; Jones, Mychica R.; Rosario, Emily R.; Beech, Walter; Hudspeth, Beverly; Ubeda, Oliver J.; Cole, Greg M.; Frautschy, Sally A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Teng, Edmond; Cole, Greg M.; Frautschy, Sally A.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Begum, Aynun N.; Yang, Fusheng; Hu, Shuxin; Jones, Mychica R.; Rosario, Emily R.; Beech, Walter; Hudspeth, Beverly; Ubeda, Oliver J.; Cole, Greg M.; Frautschy, Sally A.] GRECC, North Hills, CA USA. [Teng, Edmond] Greater Angeles Vet Affairs Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA. RP Frautschy, SA (reprint author), Sepulveda Ambulatory Care Ctr, Greater Los Angeles VA Healthcare Syst, Res 151,16111 Plummer St, North Hills, CA 91343 USA. EM frautsch@ucla.edu FU NIH [RO1AG685, AG21795] FX This work was supported by NIH grants RO1AG685 and AG21795. The authors state that there are no financial conflicts of interests. NR 79 TC 11 Z9 11 U1 0 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2008 VL 15 IS 4 BP 625 EP 640 PG 16 WC Neurosciences SC Neurosciences & Neurology GA 391CE UT WOS:000262209800009 PM 19096161 ER PT J AU Wang, W Shinto, L Connor, WE Quinn, JF AF Wang, Wei Shinto, Lynne Connor, William E. Quinn, Joseph F. TI Nutritional biomarkers in Alzheimer's disease: The association between carotenoids, n-3 fatty acids, and dementia severity SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; beta-carotene; carotenoids; dementia; docosahexaenoic acid; lutein ID MILD COGNITIVE IMPAIRMENT; NATIONAL-HEALTH; PLASMA ANTIOXIDANTS; SINGLET OXYGEN; RHESUS-MONKEYS; UNITED-STATES; CONSUMPTION; ZEAXANTHIN; LUTEIN; BRAIN AB Carotenoids are fat-soluble antioxidants that may protect polyunsaturated fatty acids, such as n-3 fatty acids from oxidation, and are potentially important for Alzheimer's disease (AD) prevention and treatment. Fasting plasma carotenoids were measured in 36 AD subjects and 10 control subjects by HPLC. Correlations between plasma carotenoid levels, red blood cell (RBC) n-3 fatty acids, and dementia severity were examined in AD patients. Moderately severe AD patients (MMSE = 16-19) had much lower plasma levels of two major carotenoids: lutein and beta-carotene, compared to mild AD patients (MMSE = 24-27) or controls. Among AD patients, variables (lutein, beta-carotene, RBC docosahexaenoic acid (DHA) and LDL-cholesterol) were significantly correlated with MMSE. A lower MMSE score was associated with lower lutein, beta-carotene and RBC DHA levels, and a higher LDL-cholesterol level. These variables explained the majority of variation in dementia severity (55% of variance in MMSE). Lutein, beta-carotene and beta-cryptoxanthin were positively correlated with RBC DHA in AD patients. The association between higher carotenoids levels and DHA and higher MMSE scores, supports a protective role of both types of nutrients in AD. These findings suggest targeting multiple specific nutrients, lutein, beta-carotene, and DHA in strategies to slow the rate of cognitive decline. C1 [Wang, Wei; Connor, William E.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. [Shinto, Lynne; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Dept Neurol, Portland, OR 97239 USA. RP Wang, W (reprint author), Oregon Hlth & Sci Univ, Dept Med, L465, Portland, OR 97239 USA. EM wangwe@ohsu.edu FU NCRR NIH HHS [5M01 RR 000334]; NIA NIH HHS [AG 08017, R21 AG 023805-01] NR 36 TC 47 Z9 49 U1 0 U2 16 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2008 VL 13 IS 1 BP 31 EP 38 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 278RG UT WOS:000254303400003 PM 18334754 ER PT J AU Carlsson, CM Gleason, CE Hess, TM Moreland, KA Blazel, HM Koscik, RL Schreiber, NTN Johnson, SC Atwood, CS Puglielli, L Hermann, BP McBride, PE Stein, JH Sager, MA Asthana, S AF Carlsson, Cynthia M. Gleason, Carey E. Hess, Timothy M. Moreland, Kimberly A. Blazel, Hanna M. Koscik, Rebecca L. Schreiber, Nathan T. N. Johnson, Sterling C. Atwood, Craig S. Puglielli, Luigi Hermann, Bruce P. McBride, Patrick E. Stein, James H. Sager, Mark A. Asthana, Sanjay TI Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid beta-protein; biological markers; cerebrospinal fluid; genetic predisposition to disease; hydroxymethylglutaryl-CoA reductase inhibitors; neuropsychological tests; simvastatin; tau proteins ID AMYLOID PRECURSOR PROTEIN; LIPID-LOWERING AGENTS; CLINICAL-DIAGNOSIS; INCIDENT DEMENTIA; EPSILON-4 ALLELE; TAU; BETA-AMYLOID(1-42); STATINS; HEALTH; TRIAL AB Background: Statins reduce amyloid-beta (A beta) levels in the brain and cerebrospinal fluid (CSF) in animals and may thereby favorably alter the pathobiology of AD. It is unclear if statins modify A beta metabolism or improve cognition in asymptomatic middle-aged adults at increased risk for AD. Methods: In a 4-month randomized, double-blind, controlled study, we evaluated the effects of simvastatin 40 mg daily vs. placebo on CSF A beta 42 levels and cognition in 57 asymptomatic middle-aged adult children of persons with AD. Results: Compared to placebo, individuals randomized to simvastatin for 4 months had similar changes in CSF A beta 42 (p = 0.344) and total tau levels (p = 0.226), yet greater improvements in some measures of verbal fluency (p = 0.024) and working memory (p = 0.015). APOE4 genotype, gender, and vascular risk factors were associated with CSF biomarker levels, but did not modify treatment effects. Conclusion: In asymptomatic middle-aged adults at increased risk for AD, simvastatin use improved selected measures of cognitive function without significantly changing CSF A beta 42 or total tau levels. Further studies are needed to clarify the impact of higher dose and/or longer duration statin therapy on not only A beta metabolism, but also other preclinical processes related to the development of AD. C1 [Carlsson, Cynthia M.; Gleason, Carey E.; Moreland, Kimberly A.; Blazel, Hanna M.; Schreiber, Nathan T. N.; Johnson, Sterling C.; Atwood, Craig S.; Puglielli, Luigi; Sager, Mark A.; Asthana, Sanjay] Univ Wisconsin, Sch Med & Publ Hlth,Dept Med, Sect Geriatr & Gerontol,GRECC, William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. [Hess, Timothy M.; Koscik, Rebecca L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. [Hermann, Bruce P.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, Madison, WI 53705 USA. [McBride, Patrick E.; Stein, James H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Cardiovasc Med, Madison, WI 53705 USA. [Carlsson, Cynthia M.; Gleason, Carey E.; Johnson, Sterling C.; Atwood, Craig S.; Puglielli, Luigi; Asthana, Sanjay] GRECC, Dept Vet Affairs, Madison, WI USA. RP Carlsson, CM (reprint author), Univ Wisconsin, Sch Med & Publ Hlth,Dept Med, Sect Geriatr & Gerontol,GRECC, William S Middleton Mem Vet Hosp, 11G,2500 Overlook Terrace, Madison, WI 53705 USA. EM cmc@medicine.wisc.edu NR 42 TC 58 Z9 64 U1 2 U2 6 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2008 VL 13 IS 2 BP 187 EP 197 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 278RH UT WOS:000254303500009 PM 18376061 ER PT J AU Mrakotsky, C Masek, B Biederman, J Raches, D Hsin, O Forbes, P de Moor, C DeMaso, DR Gonzalez-Heydrich, J AF Mrakotsky, Christine Masek, Bruce Biederman, Joseph Raches, Darcy Hsin, Olivia Forbes, Peter de Moor, Carl DeMaso, David Ray Gonzalez-Heydrich, Joseph TI Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE social anxiety disorder; pharmacological treatment; mirtazapine; children ID GENERALIZED ANXIETY DISORDER; MAJOR DEPRESSION; DOUBLE-BLIND; YOUNG-ADULTS; PLACEBO; RISK; TOLERABILITY; MULTICENTER; SERTRALINE; COMMUNITY AB Mirtazapine is indicated for major depression and used for anxiety in adults; however, little is known about its application in pediatric populations. This is an 8-week open-label pilot study of mirtazapine in children with social phobia age 8-17 years. Primary outcomes were symptom improvement based on clinician rating and self-report, as well as tolerability based on rates of discontinuation due to adverse effects. Fifty-six percent (10/18) responded to treatment, 17% (3/18) achieved full remission. Social phobia symptoms improved significantly during the first 2 weeks of treatment, as did comorbid symptoms of depression and anxiety. Eleven patients (61%) did not complete all 8 weeks of treatment, four patients (22%) discontinued due to adverse effects including fatigue and irritability. The others discontinued due to study burden (28%), insufficient response (6%), or to pursue herbal treatment (6%). Significant weight gain was observed. Larger controlled trials are needed to further evaluate efficacy and safety. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Mrakotsky, Christine; Raches, Darcy; Hsin, Olivia; DeMaso, David Ray; Gonzalez-Heydrich, Joseph] Childrens Hosp Boston, Dept Psychiat, Boston, MA 02115 USA. [Masek, Bruce; Biederman, Joseph] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Forbes, Peter; de Moor, Carl] Childrens Hosp Boston, Clin Res Program, Boston, MA 02115 USA. RP Gonzalez-Heydrich, J (reprint author), Childrens Hosp Boston, Dept Psychiat, 300 Longwood Ave,Fegan 8, Boston, MA 02115 USA. EM joseph.gonzalez-heydrich@tch.harvard.edu NR 43 TC 18 Z9 19 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PY 2008 VL 22 IS 1 BP 88 EP 97 DI 10.1016/j.janxdis.2007.01.005 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 257SV UT WOS:000252819700008 PM 17419001 ER PT J AU Court, LE Wolfsberger, L Allen, AM James, S Tishler, RB AF Court, Laurence E. Wolfsberger, Luciant Allen, Aaron M. James, Steven Tishler, Roy B. TI Clinical experience of the importance of daily portal imaging for head and neck IMRT treatments SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Article DE image-guided; localization; head and neck; IMRT ID INTENSITY-MODULATED RADIOTHERAPY; THERMOPLASTIC MASKS; SETUP UNCERTAINTIES; RADIATION-THERAPY; PATIENT MOTION; MARGINS; CANCER; IMMOBILIZATION; ACCURACY; PROBABILITY AB The purpose of this study was to evaluate patient setup in head and neck IMRT using daily portal imaging. At our institution, orthogonal digital portal images are taken daily to check patient positioning prior to head and neck IMRT treatment. Isocenter misalignments are corrected using a couch shift ( 3 mm action level). Therapists also compare the DRRs and portal images looking at points more distant from the isocenter, particularly in the supraclavicular region, and re-position the patient's shoulders in the mask if considered necessary. The daily isocenter shifts (C2 region) and frequency of patient repositioning were investigated by review of record-and-verify records for 15 patients. The magnitude of the shoulder repositioning was evaluated for 10 of these patients by comparing portal images and plan DRRs for a point 8 cm inferior of isocenter (T2-T4). For all patients, pretreatment isocenter discrepancies 3 mm or smaller were recorded for a median of 92.5% of fractions (range: 71.4-100%). Patients were repositioned in the immobilization mask before treatment for a median of 14% of fractions (3-34%). Thirty percent of these were for shoulder shifts of 1 cm or larger. Twenty percent of patients needed shoulder shifts of 1 cm or more for more than 7/35 fractions, meaning that without setup based on daily imaging, parts of the CTV would have received less than 95% of the prescribed dose. In conclusion, with our current immobilization, isocenter positioning accuracy is excellent, while correct shoulder position is more variable, particularly for a small subset of patients. Frequent imaging of head and neck IMRT patients is essential to accurate delivery of therapy, with shoulder position an important factor. C1 [Court, Laurence E.; Wolfsberger, Luciant; Allen, Aaron M.; James, Steven; Tishler, Roy B.] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA. RP Court, LE (reprint author), Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. EM lcourt@lroc.harvard.edu NR 19 TC 1 Z9 1 U1 0 U2 2 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2008 VL 9 IS 3 BP 26 EP 33 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 340IX UT WOS:000258640400004 ER PT J AU Court, LE Tishler, RB Allen, AM Xiang, H Makrigiorgos, M Chin, L AF Court, Laurence E. Tishler, Roy B. Allen, Aaron M. Xiang, Hong Makrigiorgos, Mike Chin, Lee TI Experimental evaluation of the accuracy of skin dose calculation for a commercial treatment planning system SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Article DE skin dose; dose calculations; MOSFET ID MODULATED RADIATION-THERAPY; RADIOTHERAPY; SURFACE; DOSIMETER; BUILDUP; MOSFET; HEAD AB The present work uses the Eclipse treatment planning system (TPS) to investigate the accuracy of skin dose calculations. Micro-MOSFETs (metal oxide semiconductor field effect transistors) were used to measure skin dose for a range of irradiation conditions (open fields, physical wedges, dynamic wedges, various source-to-surface distances) for 6-MV and 10-MV beams, and the results were compared with the calculated mean dose to a "skin" structure 2 mm thick for semi-cylindrical phantoms (representative of a neck or breast). Agreement between the calculated and measured skin dose values was better than +/- 20% for 95% of all measured points (6-MV and 10-MV X-ray spectra alike). For a fixed geometry, the TPS correctly calculated relative changes in dose, showing that minimization of skin dose in intensity-modulated radiation therapy will be effective in Eclipse. C1 [Court, Laurence E.; Tishler, Roy B.; Allen, Aaron M.; Xiang, Hong; Makrigiorgos, Mike; Chin, Lee] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA USA. RP Court, LE (reprint author), Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA USA. EM lcourt@lcroc.harvard.edu NR 15 TC 10 Z9 10 U1 0 U2 1 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2008 VL 9 IS 1 BP 29 EP 35 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 300XA UT WOS:000255857600003 ER PT J AU Sah, AP Scott, RD Iorio, R AF Sah, Alexander P. Scott, Richard D. Iorio, Richard TI Angled polyethylene insert exchange for sagittal tibial malalignment in total knee arthroplasty SO JOURNAL OF ARTHROPLASTY LA English DT Article DE angled; insert; exchange; sagittal; malalignment; knee arthroplasty AB Tibial component malposition in total knee arthroplasty can cause early failure and result in the need for revision surgery. Excessive posterior slope of the tibial component is an uncommon, but difficult problem to correct. Component revision risks additional loss of deficient posterior tibial bone stock. As an alternative, a custom-made angled insert can correct for component malalignment and possibly avoid prosthesis revision. In this report, we present the use of a custom-angled bearing for sagittal alignment correction with 6-year follow-up. The procedure is simple and has little risk, but the cost, potential limitations for correcting excessive deformity, and uncertainty of long-term results make the use of angled inserts a rare and selective procedure. However, when possible to use, an angled insert may be a useful alternative to complete prosthetic revision. C1 [Sah, Alexander P.] Massachusetts Gen Hosp, Dept Orthoped, Boston, MA 02114 USA. [Scott, Richard D.] Brigham & Womens Hosp, Dept Orthoped, Boston, MA 02115 USA. [Iorio, Richard] Lahey Clin Med Ctr, Dept Orthoped, Burlington, MA 01803 USA. RP Sah, AP (reprint author), Massachusetts Gen Hosp, Dept Orthoped, 55 Fruit St,GRB 624, Boston, MA 02114 USA. OI Iorio, Richard/0000-0001-8083-8687 NR 10 TC 4 Z9 4 U1 0 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 J9 J ARTHROPLASTY JI J. Arthroplast. PD JAN PY 2008 VL 23 IS 1 BP 141 EP 144 DI 10.1016/j.arth.2006.12.107 PG 4 WC Orthopedics SC Orthopedics GA 250VV UT WOS:000252330300024 PM 18165044 ER PT J AU Camargo, CA Reed, CR Ginde, AA Clark, S Emond, SD Radeos, MS AF Camargo, Carlos A., Jr. Reed, Caitlin R. Ginde, Adit A. Clark, Sunday Emond, Stephen D. Radeos, Mike S. TI A prospective multicenter study of written action plans among emergency department patients with acute asthma SO JOURNAL OF ASTHMA LA English DT Article DE asthma; action plans; emergency medicine; education; self-management ID SELF-MANAGEMENT; ORAL CORTICOSTEROIDS; HEALTH LITERACY; CARE; EXACERBATIONS; KNOWLEDGE; EDUCATION; CHILDREN; GUIDELINES; EXPERIENCE AB Background. The prevalence of written action plans (APs) among emergency department (ED) patients with acute asthma is unknown. Objective. To determine the prevalence of APs among ED patients, to describe the demographic and clinical profile of patients with and without APs, and to examine the appropriateness of response to an asthma exacerbation scenario. Methods. Using a standard protocol, 49 North American EDs performed a prospective cohort study involving interviews of 1,756 patients, ages 2-54, with acute asthma. Among children only, a random sample was contacted two years after the index ED visit to assess current AP status and parents' self-management knowledge. Results. The overall prevalence of APs was 32% (95% confidence interval [CI], 30%-34%), and was higher among children than adults (34% vs. 26%, respectively; p = 0.001). Patients with APs had worse measures of chronic asthma severity (p < 0.05) and were more likely to be hospitalized (multivariate odds ratio, 1.5; 95%CI, 1.1-2.1). After 2 years, most children with an AP at the index ED visit still had one but only 20% of those without an AP had obtained one; moreover, many of the APs appeared inadequate. Parents of children with a current AP performed slightly better on the asthma scenario, but both groups overestimated their asthma knowledge. Conclusion. The prevalence of APs among ED patients with acute asthma is unacceptably low, and many of these APs appear inadequate. Confounding by severity will complicate any non-randomized analysis of the potential impact of APs on asthma outcomes in ED patients. C1 [Camargo, Carlos A., Jr.; Reed, Caitlin R.; Clark, Sunday] Harvard Univ, Sch Med, Massachusetts Gen Hosp, EMNet Coordinating Ctr, Boston, MA 02114 USA. [Ginde, Adit A.] Univ Colorado, Denver Sch Med, Aurora, CO USA. [Emond, Stephen D.] Kaiser Santa Clara Med Ctr, Santa Clara, CA USA. [Emond, Stephen D.] Stanford Kaiser Emergency Med Residency Program, Palo Alto, CA USA. [Radeos, Mike S.] New York Hosp Queens, Flushing, NY USA. RP Camargo, CA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, EMNet Coordinating Ctr, 326 Cambridge St,Suite 410, Boston, MA 02114 USA. EM ccamargo@partners.org RI 段, 沛沛/C-9902-2010; Siry, Bonnie/D-7189-2017 FU NIAID NIH HHS [AI152338, R21 AI052338] NR 41 TC 9 Z9 9 U1 2 U2 6 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0277-0903 J9 J ASTHMA JI J. Asthma PY 2008 VL 45 IS 7 BP 532 EP 538 DI 10.1080/02770900801978573 PG 7 WC Allergy; Respiratory System SC Allergy; Respiratory System GA 344KD UT WOS:000258924700002 PM 18773321 ER PT J AU Bonci, CM Bonci, LJ Granger, LR Johnson, CL Malina, RM Milne, LW Ryan, RR Vanderbunt, EM AF Bonci, Christine M. Bonci, Leslie J. Granger, Lorita R. Johnson, Craig L. Malina, Robert M. Milne, Leslie W. Ryan, Randa R. Vanderbunt, Erin M. TI National athletic trainers' association position statement: Preventing, detecting, and managing disordered eating in athletes SO JOURNAL OF ATHLETIC TRAINING LA English DT Review DE eating disorders; anorexia nervosa; bulimia nervosa; subclinical eating disorders; pathogenic weight control behaviors; female athlete triad; body image ID BODY-MASS INDEX; ANOREXIA-NERVOSA; FEMALE ATHLETE; WEIGHT-LOSS; BULIMIA-NERVOSA; MENSTRUAL DYSFUNCTION; BONE-DENSITY; SELF-ESTEEM; ADOLESCENT GIRLS; YOUNG-WOMEN AB Objective: To present recommendations for the prevention, detection, and comprehensive management of disordered eating (DE) in athletes. Background: Athletes with DE rarely self-report their symptoms. They tend to deny the condition and are often resistant to referral and treatment. Thus, screenings and interventions must be handled skillfully by knowledgeable professionals to obtain desired outcomes. Certified athletic trainers have the capacity and responsibility to play active roles as integral members of the health care team. Their frequent daily interactions with athletes help to facilitate the level of medical surveillance necessary for early detection, timely referrals, treatment follow-through, and compliance. Recommendations: These recommendations are intended to provide certified athletic trainers and others participating in the health maintenance and performance enhancement of athletes with specific knowledge and problem-solving skills to better prevent, detect, and manage DE. The individual biological, psychological, sociocultural, and familial factors for each athlete with DE result in widely different responses to intervention strategies, challenging the best that athletics programs have to offer in terms of resources and expertise. The complexity, time intensiveness, and expense of managing DE necessitate an interdisciplinary approach representing medicine, nutrition, mental health, athletic training, and athletics administration in order to facilitate early detection and treatment, make it easier for symptomatic athletes to ask for help, enhance the potential for full recovery, and satisfy medicolegal requirements. Of equal importance is establishing educational initiatives for preventing DE. C1 [Bonci, Christine M.; Ryan, Randa R.] Univ Texas Austin, Austin, TX 78712 USA. [Bonci, Leslie J.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Granger, Lorita R.] Univ Calif Los Angeles, Los Angeles, CA USA. [Johnson, Craig L.] Laureate Psychiat Hosp, Tulsa, OK USA. [Malina, Robert M.] Tarleton State Univ, Stephenville, TX USA. [Milne, Leslie W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Vanderbunt, Erin M.] Paradise Valley Community Coll, Phoenix, AZ USA. RP Bonci, CM (reprint author), Natl Athlet Trainers Assoc, Dept Commun, 2952 Stemmons Freeway, Dallas, TX 75247 USA. NR 271 TC 73 Z9 80 U1 15 U2 34 PU NATL ATHLETIC TRAINERS ASSOC INC PI DALLAS PA 2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA SN 1062-6050 J9 J ATHL TRAINING JI J. Athl. Train. PD JAN-FEB PY 2008 VL 43 IS 1 BP 80 EP 108 DI 10.4085/1062-6050-43.1.80 PG 29 WC Sport Sciences SC Sport Sciences GA 292JE UT WOS:000255261500012 PM 18335017 ER PT J AU Spencer, TJ Sallee, FR Gilbert, DL Dunn, DW McCracken, JT Coffey, BJ Budman, CL Ricardi, RK Leonard, HL Allen, AJ Milton, DR Feldman, PD Kelsey, DK Geller, DA Linder, SL Lewis, DW Winner, PK Kurlan, RM Mintz, M AF Spencer, Thomas J. Sallee, F. Randy Gilbert, Donald L. Dunn, David W. McCracken, James T. Coffey, Barbara J. Budman, Cathy L. Ricardi, Randall K. Leonard, Henrietta L. Allen, Albert J. Milton, Denai R. Feldman, Peter D. Kelsey, Douglas K. Geller, Daniel A. Linder, Steven L. Lewis, Donald W. Winner, Paul K. Kurlan, Roger M. Mintz, Mark TI Atomoxetine Treatment of ADHD in Children With Comorbid Tourette Syndrome SO JOURNAL OF ATTENTION DISORDERS LA English DT Article DE atomoxetine; ADHD; tic disorders; Tourette syndrome AB Objective: This study examines changes in severity of tics and ADHD during atomoxetine treatment in ADHD patients with Tourette syndrome (TS). Method: Subjects (7-17 years old) with ADHD (Diagnostic and Statistical Manual of Mental Disorders, DSM-IV) and TS were randomly assigned to double-blind treatment with placebo (n = 56) or atomoxetine (0.5-1.5 mg/kg/day, n = 61) for approximately 18 weeks. Results: Atomoxetine subjects showed significantly greater improvement on ADHD symptom measures. Treatment was also associated with significantly greater reduction of tic severity on two of three measures. Significant increases were seen in mean pulse rate and rates of treatment-emergent nausea, decreased appetite, and decreased body weight. No other clinically relevant treatment differences were observed in any other vital sign, adverse event, laboratory parameter, or electrocardiographic measure. Conclusion: Atomoxetine is efficacious for treatment of ADHD and its use appears well tolerated in ADHD patients with comorbid TS. (J. of Att. Dis. 2008; 11(4) 470-481) C1 [Spencer, Thomas J.] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA. [Gilbert, Donald L.] Cincinnati Childrens Hosp, Med Ctr, Movement Disorders & Tourette Syndrome Clin, Cincinnati, OH USA. [Dunn, David W.] Indiana Univ, Sch Med, Dept Psychiat, Bloomington, IN 47405 USA. [Dunn, David W.] Indiana Univ, Sch Med, Dept Neurol, Bloomington, IN 47405 USA. [McCracken, James T.] Univ Calif Los Angeles, Inst Neuropsychiat, Joseph Campbell Div Child & Adolescent Psychiat, Los Angeles, CA 90024 USA. [Coffey, Barbara J.] NYU, Ctr Child Study, Tourette & Tic Inst, New York, NY 10003 USA. [Budman, Cathy L.] N Shore Univ Hosp, Long Isl Jewish Hlth Syst, Manhasset, NY USA. [Leonard, Henrietta L.] Brown Univ, Rhode Isl Hosp, Providence, RI 02912 USA. [Geller, Daniel A.] Harvard Univ, Sch Med, McLean Hosp, Dept Psychiat, Cambridge, MA 02138 USA. [Linder, Steven L.] Dallas Pediat Neurol Associates, Dallas, TX USA. [Kurlan, Roger M.] Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA. RP Spencer, TJ (reprint author), Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, 55 Fruit St, Boston, MA 02114 USA. EM tspencer@partners.org RI Gilbert, Donald/D-6443-2016 OI Gilbert, Donald/0000-0002-9245-6878 FU Eli Lilly and Company FX This study was sponsored by Eli Lilly and Company. The authors would like to dedicate this paper to the memory of our colleague and friend, Dr. Henrietta Leonard, who passed away on August 15, 2007. Address correspondence to Thomas J. Spencer, MD, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114-2696; e-mail: tspencer@partners.org. NR 43 TC 53 Z9 60 U1 2 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1087-0547 J9 J ATTEN DISORD JI J. Atten. Disord. PD JAN PY 2008 VL 11 IS 4 BP 470 EP 481 DI 10.1177/1087054707306109 PG 12 WC Psychology, Developmental; Psychiatry SC Psychology; Psychiatry GA V11EQ UT WOS:000207515300007 PM 17934184 ER PT J AU Mick, E Faraone, SV Spencer, T Zhang, HBF Biederman, J AF Mick, Eric Faraone, Stephen V. Spencer, Thomas Zhang, Huabin F. Biederman, Joseph TI Assessing the Validity of the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form in Adults With ADHD SO JOURNAL OF ATTENTION DISORDERS LA English DT Article DE ADHD; adult; quality of life; Q-LES-QSF AB Objective: The authors assessed the psychometric properties of the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-QSF) in adults with ADHD. Method: One hundred fifty ADHD and 134 non-ADHD adults from a case-control study and 173 adults randomized to placebo or methylphenidate were assessed with the Q-LES-QSF and the Social Adjustment Scale (SAS). Response to change was estimated by comparing change in Q-LES-QSF scores in responders and nonresponders in our randomized clinical trial. Results: Internal consistency of the Q-LES-QSF items was .88, and the correlation between the Q-LES-QSF total score and the SAS total T score was .72 in adults with ADHD. ADHD cases had statistically significantly poorer scores on the Q-LES-QSF than controls (76.5 +/- 10.9 vs. 59.2 +/- 17.3, p < .001), whereas ADHD responders showed Q-LES-QSF improvement compared to nonresponders (76.1 +/- 12.0 versus 67.9 +/- 14.5, p < .001). Conclusion: These results support the validity of the Q-LES-QSF as a measure of quality of life in adults with ADHD. (J. of Att. Dis. 2008; 11(4) 504-509) C1 [Mick, Eric] Massachusetts Gen Hosp, Pediat Psychopharmacol Res Unit, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA. [Mick, Eric; Spencer, Thomas; Biederman, Joseph] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Syracuse, NY USA. RP Mick, E (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol Res Unit, Clin & Res Program Pediat Psychopharmacol, Warren 705,55 Fruit St, Boston, MA 02114 USA. EM emick1@partners.org OI Mick, Eric/0000-0001-8505-8145; Faraone, Stephen/0000-0002-9217-3982 FU National Institutes of Health [KO1 MH065523, R01MH57934, R29MH57511]; McNeil Pediatrics FX This work was supported in part by National Institutes of Health grants to Eric Mick (KO1 MH065523), Stephen Faraone (R01MH57934), and Thomas Spencer (R29MH57511) and by grants from McNeil Pediatrics to Eric Mick and Joseph Biederman. We would also like to thank Jean Endicott, PhD, for her useful comments toward this article. Address correspondence to Eric Mick, ScD, Massachusetts General Hospital, Pediatric Psychopharmacology Research Unit, Warren 705, 55 Fruit St., Boston, MA 02114; e-mail: emick1@partners.org. NR 23 TC 34 Z9 34 U1 1 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1087-0547 J9 J ATTEN DISORD JI J. Atten. Disord. PD JAN PY 2008 VL 11 IS 4 BP 504 EP 509 DI 10.1177/1087054707308468 PG 6 WC Psychology, Developmental; Psychiatry SC Psychology; Psychiatry GA V11EQ UT WOS:000207515300010 PM 17934183 ER PT J AU Belmonte, MK Mazziotta, JC Minshew, NJ Evans, AC Courchesne, E Dager, SR Bookheimer, SY Aylward, EH Amaral, DG Cantor, RM Chugani, DC Dale, AM Davatzikos, C Gerig, G Herbert, MR Lainhart, JE Murphy, DG Piven, J Reiss, AL Schultz, RT Zeffiro, TA Levi-Pearl, S Lajonchere, C Colamarino, SA AF Belmonte, Matthew K. Mazziotta, John C. Minshew, Nancy J. Evans, Alan C. Courchesne, Eric Dager, Stephen R. Bookheimer, Susan Y. Aylward, Elizabeth H. Amaral, David G. Cantor, Rita M. Chugani, Diane C. Dale, Anders M. Davatzikos, Christos Gerig, Guido Herbert, Martha R. Lainhart, Janet E. Murphy, Declan G. Piven, Joseph Reiss, Allan L. Schultz, Robert T. Zeffiro, Thomas A. Levi-Pearl, Susan Lajonchere, Clara Colamarino, Sophia A. TI Offering to share: How to put heads together in autism neuroimaging SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE imaging; MRI; PET; morphometry; segmentation; data sharing ID DIAGNOSTIC INTERVIEW; CLINICAL-TRIALS; REVISED VERSION; SEX-DIFFERENCES; HUMAN BRAIN; MRI; RELIABILITY; DISORDERS; TISSUES; SCALE AB Data sharing in autism neuroimaging presents scientific, technical, and social obstacles. We outline the desiderata for a data-sharing scheme that combines imaging with other measures of phenotype and with genetics, defines requirements for comparability of derived data and recommendations for raw data, outlines a core protocol including multispectral structural and diffusion-tensor imaging and optional extensions, provides for the collection of prospective, confound-free normative data, and extends sharing and collaborative development not only to data but to the analytical tools and methods applied to these data. A theme in these requirements is the need to preserve creative approaches and risk-taking within individual laboratories at the same time as common standards are provided for these laboratories to build on. C1 [Belmonte, Matthew K.] Cornell Univ, Dept Human Dev, Ithaca, NY 14853 USA. [Mazziotta, John C.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Minshew, Nancy J.] Univ Pittsburgh, Dept Psychiat & Neurol, Pittsburgh, PA 15213 USA. [Evans, Alan C.] Montreal Neurol Inst, McConnel Brain Imaging Ctr, Montreal, PQ H3A 2B4, Canada. [Courchesne, Eric] Univ Calif San Diego, Dept Neurosci, Ctr Autism Res, La Jolla, CA 92037 USA. [Dager, Stephen R.] Univ Washington, Dept Radiol, Seattle, WA 98105 USA. [Bookheimer, Susan Y.] Univ Calif Los Angeles, Brain Mapping Ctr, Los Angeles, CA 90095 USA. [Aylward, Elizabeth H.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Amaral, David G.] Univ Calif Davis, MIND Inst, Sacramento, CA 95817 USA. [Cantor, Rita M.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA. [Chugani, Diane C.] Childrens Hosp, PET Ctr, Dept Pediat & Radiol, Detroit, MI 48201 USA. [Dale, Anders M.] Univ Calif San Diego, Dept Neurol, La Jolla, CA 92093 USA. [Davatzikos, Christos] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Gerig, Guido] Univ N Carolina, Dept Comp Sci, Chapel Hill, NC 27599 USA. [Herbert, Martha R.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02129 USA. [Lainhart, Janet E.] Univ Utah, Dept Psychiat, Salt Lake City, UT 84108 USA. [Murphy, Declan G.] Kings Coll London, Inst Psychiat, Dept Psychol Med, London SE5 8AF, England. [Piven, Joseph] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA. [Reiss, Allan L.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Schultz, Robert T.] Yale Univ, New Haven, CT 06520 USA. [Zeffiro, Thomas A.] Massachusetts Gen Hosp, Neural Syst Grp, Boston, MA 02129 USA. [Levi-Pearl, Susan] Tourette Syndrome Assoc, Bayside, NY 11361 USA. [Lajonchere, Clara] Autism Genet Resource Exchange, Los Angeles, CA 90036 USA. [Colamarino, Sophia A.] Cure Autism Now, Los Angeles, CA 90036 USA. RP Belmonte, MK (reprint author), Cornell Univ, Dept Human Dev, Martha Van Rensselaer Hall, Ithaca, NY 14853 USA. EM belmonte@mit.edu; mazz@loni.ucla.edu; MinshewNJ@upmc.edu; alan@bic.mni.mcgill.ca; ecourchesne@ucsd.edu; srd@u.washington.edu; sybook@ucla.edu; eaylward@u.washington.edu; christos.davatzikos@uphs.upenn.edu; gerig@cs.unc.edu; dchugani@pet.wayne.edu; amdale@ucsd.edu; christos.davatzikos@uphs.upenn.edu; gerig@cs.unc.edu; mherbert1@partners.org; janet.lainhart@hsc.utah.edu; D.Murphy@iop.kcl.ac.uk; joe_piven@med.unc.edu; reiss@stanford.edu; robert.schultz@yale.edu; zeffiro@nmr.mgh.harvard.edu; spearl@ix.netcom.com; clara@agre.org; scolamarino@cureautismnow.org RI Dale, Anders/A-5180-2010; OI Belmonte, Matthew/0000-0002-4633-9400; Gerig, Guido/0000-0002-9547-6233 FU NIA NIH HHS [R01 AG014971, R01 AG014971-08]; NICHD NIH HHS [P50 HD055784, P01 HD035465, P50 HD055784-02, R01 HD065280, R01 HD065280-01] NR 39 TC 12 Z9 13 U1 3 U2 6 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 EI 1573-3432 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD JAN PY 2008 VL 38 IS 1 BP 2 EP 13 DI 10.1007/s10803-006-0352-2 PG 12 WC Psychology, Developmental SC Psychology GA 248NQ UT WOS:000252160700001 PM 17347882 ER PT J AU Priel, A Ramos, AJ Tuszynski, JA Cantiello, HF AF Priel, Avner Ramos, Arnolt J. Tuszynski, Jack A. Cantiello, Horacio F. TI Effect of Calcium on Electrical Energy Transfer by Microtubules SO JOURNAL OF BIOLOGICAL PHYSICS LA English DT Article DE Cytoskeleton; Biomolecular transistors; Electrical connectivity; Microtubule dynamics; Electrical amplification ID FAST AXONAL-TRANSPORT; DEPOLYMERIZATION; DYNAMICS; POLARITY; NEURONS; SINGLE AB Microtubules (MTs) are important cytoskeletal superstructures implicated in neuronal morphology and function, which are involved in vesicle trafficking, neurite formation and differentiation and other morphological changes. The structural and functional properties of MTs depend on their high intrinsic charge density and functional regulation by the MT depolymerising properties of changes in Ca(2+) concentration. Recently, we reported on remarkable properties of isolated MTs, which behave as biomolecular transistors capable of amplifying electrical signals (Priel et al., Biophys J 90:4639-4643, 2006). Here, we demonstrate that MT-bathing (cytoplasmic) Ca(2+) concentrations modulate the electrodynamic properties of MTs. Electrical amplification by MTs was exponentially dependent on the Ca(2+) concentration between 10(-7) and 10(-2) M. However, the electrical connectivity (coupling) of MTs was optimal at a narrower window of Ca(2+) concentrations. We observed that while raising bathing Ca(2+) concentration increased electrical amplification by MTs, energy transfer was highest in the presence of ethylene glycol tetraacetic acid (lowest Ca(2+) concentration). Our data indicate that Ca(2+) is an important modulator of electrical amplification by MTs, supporting the hypothesis that this divalent cation, which adsorbs onto the polymer's surface, plays ail important role as a regulator of the electrical properties of MTs. The Ca(2+)-dependent ability of MTs to modulate and amplify electrical signals may provide a novel means of cell signaling, likely contributing to neuronal function. C1 [Ramos, Arnolt J.; Cantiello, Horacio F.] Massachusetts Gen Hosp, Nephrol Div & Electrophysiol Core, Boston, MA 02129 USA. [Ramos, Arnolt J.; Cantiello, Horacio F.] Harvard Univ, Sch Med, Boston, MA 02129 USA. [Priel, Avner; Tuszynski, Jack A.] Univ Alberta, Dept Phys, Edmonton, AB T6G 2J1, Canada. RP Cantiello, HF (reprint author), Massachusetts Gen Hosp, Nephrol Div & Electrophysiol Core, Boston, MA 02129 USA. EM cantiello@helix.mgh.harvard.edu FU NSERC (Canada); MITACS and Technology Innovations; LLC of Rochester, NY, USA; PKD Foundation FX Funding from NSERC (Canada), MITACS and Technology Innovations, LLC of Rochester, NY, USA supported this research (AP & JT). HC was partially funded by the PKD Foundation. AJR is the recipient of a PKD Foundation postdoctoral fellowship. NR 26 TC 7 Z9 7 U1 0 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0092-0606 J9 J BIOL PHYS JI J. Biol. Phys. PY 2008 VL 34 IS 5 BP 475 EP 485 DI 10.1007/s10867-008-9106-z PG 11 WC Biophysics SC Biophysics GA 399UJ UT WOS:000262824500002 PM 19669507 ER PT J AU Gelardi, M Del Giudice, AM Fiorella, ML Soleti, P Di Gioacchino, M Conti, CM Fulcheri, M Doyle, R Ciprandi, G AF Gelardi, M. Del Giudice, A. Maselli Fiorella, M. L. Soleti, P. Di Gioacchino, M. Conti, C. M. Fulcheri, M. Doyle, R. Ciprandi, G. TI Quality of life in non-allergic rhinitis depends on the predominant inflammatory cell type SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS LA English DT Article DE quality of inflammatory cells; non-allergic rhinitis; polyps; nasal resistances; nasal cytology ID ALLERGIC RHINITIS; EOSINOPHILIA SYNDROME; TNF-ALPHA; CYTOKINES AB Three main types of inflammatory Non-Allergic Rhinitis (NAR) have been defined: NAR infiltrated by eosinophils (NARES), by mast cells (NARMA), and by neutrophils (NARNE). In the absence of studies that investigated the Quality of Life (QoL) in NAR, the present work is aimed at evaluating the Quality of Life of patients with NARES, NARMA, and NARNE. One hundred thirty one (131) NAR patients were prospectively and consecutively evaluated: 54 patients with NARES, 38 with NARMA, and 39 with NARNE. Their history, nasal infiltration and rhinomanometry were characterized, and Quality of Life (using 2 instruments) was evaluated, and associated to clinical and histological features. Quality of Life was significantly different in the 3 groups (p<0.001); NARES patients had the worst Quality of Life. Nasal resistances were significantly higher in the NARES group. Significant associations were shown in NARES patients between Quality of Life and nasal function. This study provides the first evidence that Quality of Life is impaired in NAR as well as in allergic rhinitis. Furthermore, Quality of Life impairment differs among the various forms of NAR, and there is a correlation with the cellular infiltrating type. C1 [Di Gioacchino, M.] Univ G DAnnunzio, Allergy Related Dis Unit, Chieti, Italy. [Gelardi, M.; Del Giudice, A. Maselli; Fiorella, M. L.] Univ Bari, Dipartimento Oculistica & Otorinolaringoiatria, I-70121 Bari, Italy. [Soleti, P.] Univ Bari, Fac Econ, Dept Stat Sci, Bari, Italy. [Conti, C. M.; Fulcheri, M.] Univ G DAnnunzio, Dept Clin Psychol, Chieti, Italy. [Doyle, R.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Ciprandi, G.] Azienda Osped Univ San Martino, Dipartimento Med Interna, Genoa, Italy. RP Di Gioacchino, M (reprint author), Univ G DAnnunzio, Allergy Related Dis Unit, Chieti, Italy. EM m.digioacchino@unich.it OI Fulcheri, Mario/0000-0002-2389-9800 NR 43 TC 22 Z9 22 U1 0 U2 2 PU WICHTIG EDITORE PI MILAN PA 72/74 VIA FRIULI, 20135 MILAN, ITALY SN 0393-974X J9 J BIOL REG HOMEOS AG JI J. Biol. Regul. Homeost. Agents PD JAN-MAR PY 2008 VL 22 IS 1 BP 73 EP 81 PG 9 WC Endocrinology & Metabolism; Immunology; Medicine, Research & Experimental; Physiology SC Endocrinology & Metabolism; Immunology; Research & Experimental Medicine; Physiology GA 290FF UT WOS:000255108000009 PM 18394320 ER PT J AU Li, G Wan, L Kozanek, M AF Li, Guoan Wan, Lu Kozanek, Michal TI Determination of real-time in-vivo cartilage contact deformation in the ankle joint SO JOURNAL OF BIOMECHANICS LA English DT Article DE cartilage; in-vivo cartilage contact; in-vivo biomechanics; ankle; image ID HUMAN ARTICULAR-CARTILAGE; HUMAN HIP-JOINT; THICKNESS DISTRIBUTION; UNCONFINED COMPRESSION; GENDER-DIFFERENCES; KNEE JOINTS; MR-IMAGES; KINEMATICS; VOLUME; MODEL AB The knowledge of real-time in-vivo cartilage deformation is important for understanding of cartilage function and biomechanical factors that may relate to cartilage degeneration. This study investigated cartilage contact area and peak contact compressive strain of four healthy human ankle joints as a function of time using a combined magnetic resonance (MR) and dual-orthogonal fluoroscopic imaging technique. Each ankle was subjected to a different constant loading (between 700 and 820 N). The cartilage contact deformation,was obtained from the first second to 300 s after the load was applied. In all ankle joints studied in this paper, contact strains increased to 24-38% at first 20 s after loading. Beyond 20 s, the change of cartilage contact deformation was relatively small and varied in a rate close to zero beyond 50 s. These data indicated that the cartilage contact areas and contact strain could raise dramatically right after loading and reach a relatively stable condition within 1 min after constant loading. The history of cartilage deformation determined in this study may provide a real-time boundary condition for 3D finite element simulation of in vivo cartilage contact stress in the joint as a function of time. (c) 2007 Elsevier Ltd. All rights reserved. C1 [Li, Guoan; Wan, Lu; Kozanek, Michal] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Bioengn Lab, Boston, MA 02115 USA. [Wan, Lu] MIT, Dept Phys, Cambridge, MA 02139 USA. RP Li, G (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Bioengn Lab, Boston, MA 02115 USA. EM gli1@partners.ore NR 60 TC 34 Z9 36 U1 1 U2 10 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 J9 J BIOMECH JI J. Biomech. PY 2008 VL 41 IS 1 BP 128 EP 136 DI 10.1016/j.jbiomech.2007.07.006 PG 9 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 261EO UT WOS:000253062100017 PM 17697682 ER PT J AU Li, GA de Velde, SKV Bingham, JT AF Li, Guoan de Velde, Samuel K. Van Bingham, Jeffrey T. TI Validation of a non-invasive fluoroscopic imaging technique for the measurement of dynamic knee joint motion SO JOURNAL OF BIOMECHANICS LA English DT Article DE dual fluoroscopic imaging; dynamic kinematics; Roentgen stereophotogrammetric analysis (RSA) ID ANTERIOR CRUCIATE LIGAMENT; TREADMILL WALKING; 3-DIMENSIONAL KINEMATICS; VIVO MOTION; FLEXION; ARTHROPLASTY; DEFICIENCY AB The accurate measurement of the in vivo knee joint kinematics in six degrees- of-freedom (6DOF) remains a challenge in biomedical engineering. We have adapted a dual fluoroscopic imaging system (DFIS) to investigate the various in vivo dynamic knee joint motions. This paper presents a thorough validation of the accuracy and repeatability of the DFIS system when used to measure 6DOF dynamic knee kinematics. First, the validation utilized standard geometric spheres made from different materials to demonstrate the capability of the DFIS technique to determine the object positions under changing speeds. The translational pose of the spheres could be recreated to less than 0.15 +/- 0.09 mm for velocities below 300 mm/s. Next, tantalum beads were inserted into the femur and tibia of two fresh frozen cadaver knees to compare the dynamic kinematics measured by matching knee models to the kinematics from the tantalum bead matching-a technique similar to Roentgen stereophotogrammetric analysis (RSA). Each cadaveric knee was attached to the crosshead of a tensile testing machine and vertically translated at a rate of 16.66 mm/s while images were captured with the DFIS. Subsequently, the tibia was held fixed and the femur manually flexed from full extension to 90 degrees of flexion, as the DFIS acquired images. In vitro translation of the cadaver knee using the tensile testing machine deviated from predicted values by 0.08 +/- 0.14 mm for the matched knee models. The difference between matching the knee and tantalum bead models during the dynamic flexion-extension motion of the knee was 0.1 +/- 0.65 degrees/s in flexion speed; 0.24 +/- 0.16 mm in posterior femoral translation; and 0.16 +/- 0.6 V in internal-external tibial rotation. Finally, we applied the method to investigate the knee kinematics of a living subject during a step ascent and treadmill gait. High repeatability was demonstrated for the in vivo application. Thus, the DFIS provides an easy and powerful tool for accurately determining 6DOF positions of the knee when performing daily functional activities. (c) 2008 Elsevier Ltd. All rights reserved. C1 [Li, Guoan; de Velde, Samuel K. Van; Bingham, Jeffrey T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Bioengn Lab, Boston, MA 02114 USA. RP Li, G (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Bioengn Lab, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA. EM gli1@partners.org RI Bingham, Jeffrey/I-6901-2012 OI Bingham, Jeffrey/0000-0002-9590-8526 FU NIAMS NIH HHS [R21 AR 051078] NR 30 TC 95 Z9 97 U1 0 U2 17 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 J9 J BIOMECH JI J. Biomech. PY 2008 VL 41 IS 7 BP 1616 EP 1622 DI 10.1016/j.jbiomech.2008.01.034 PG 7 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 313VX UT WOS:000256769200028 PM 18394629 ER PT J AU Felton, SM Gaige, TA Benner, T Wang, R Reese, TG Wedeen, VJ Gilbert, RJ AF Felton, Samuel M. Gaige, Terry A. Benner, Thomas Wang, Ruopeng Reese, Timothy G. Wedeen, Van J. Gilbert, Richard J. TI Associating the mesoscale fiber organization of the tongue with local strain rate during swallowing SO JOURNAL OF BIOMECHANICS LA English DT Article DE MRI; phase contrast; DTI; tractography; muscle imaging; strain ID BOVINE TONGUE; 3-DIMENSIONAL MYOARCHITECTURE; IN-VIVO; DIFFUSION; DEFORMATION; MUSCLE; TRACTOGRAPHY; ARCHITECTURE; CONSISTENCY; MECHANICS AB The tongue is an intricately configured muscular organ that undergoes a stereotypical set of deformations during the course of normal human swallowing. In order to demonstrate quantitatively the relationship between 3D aligned lingual fiber organization and mechanics during swallowing, the tissue's myoarchitecture and strain rate were imaged before and during the propulsive phase of a 3.0 ml water bolus swallow. Mesoscale fiber organization was imaged with high-resolution diffusion tensor imaging (DTI) and multi-voxel myofiber tracts generated along maximum diffusion vectors. Tissue compression/expansion was obtained via lingual pressure-gated phase-contrast (PC) MRI, a method which determines local strain rate as a function of the phase shift occurring along an applied gradient vector. The co-alignment of myofiber tract direction and the localized principal strain rate vectors was obtained by translating the strain rate tenser into the reference frame with the primary axis parallel to the maximum diffusion vector using Mohr's circle, resulting in the generation of fiber-aligned strain rate (FASR). DTI tractography displayed the complete fiber anatomy of the tongue, consisting of a core region of orthogonally aligned fibers encased within a longitudinal sheath, which merge with the externally connected styloglossus, hyoglossus, and genioglossus fibers. FASR images obtained in the mid-sagittal plane demonstrated that bolus propulsion was associated with prominent compressive strain aligned with the genioglossus muscle combined with expansive strain aligned with the verticalis and geniohyoid muscles. These data demonstrate that lingual deformation during swallowing involves complex interactions involving intrinsic and extrinsic muscles, whose contractility is directed by the alignment of mesoscale fiber tracts. (C) 2008 Published by Elsevier Ltd. C1 [Felton, Samuel M.; Gaige, Terry A.; Benner, Thomas; Wang, Ruopeng; Reese, Timothy G.; Wedeen, Van J.; Gilbert, Richard J.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA. [Felton, Samuel M.; Gaige, Terry A.; Benner, Thomas; Wang, Ruopeng; Reese, Timothy G.; Wedeen, Van J.; Gilbert, Richard J.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. RP Gilbert, RJ (reprint author), MIT, Dept Mech Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM rgilbert@mit.edu NR 24 TC 10 Z9 10 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 J9 J BIOMECH JI J. Biomech. PY 2008 VL 41 IS 8 BP 1782 EP 1789 DI 10.1016/j.jbiomech.2008.01.030 PG 8 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 317GU UT WOS:000257008800020 PM 18456271 ER PT J AU Xu, XM Capito, RM Spector, M AF Xu, Ximing Capito, Ramille M. Spector, Myron TI Delivery of plasmid IGF-1 to chondrocytes via cationized gelatin nanoparticles SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A LA English DT Article DE gelatin; nanoparticles; IGF-1; chondrocytes ID GROWTH-FACTOR-I; PEPTIDE NUCLEIC-ACID; GENE DELIVERY; ARTICULAR CHONDROCYTES; TISSUE REGENERATION; MATRIX SYNTHESIS; ENHANCED REPAIR; CELLULAR UPTAKE; FACTOR RELEASE; DNA AB The objective of the present study was to investigate the use of gelatin and cationized-gelatin nanoparticles for the nonviral delivery of the plasmid DNA encoding for insulin-like growth factor (IGF)-1 to adult canine articular chondrocytes in vitro; plasmid for enhanced green fluorescence protein (EGFP) was used as a marker gene. The spherical cationized gelatin nanoparticles were on average 172 nm in diameter, compared with the often ellipsoid-shaped unmodified (noncationized) gelatin particles that generally appeared to be 10 pm to greater than 20 pm in length. The zeta potential of the positively charged cationized gelatin nanoparticles containing the plasmid was around 20 mV compared with about 2 mV for the unmodified gelatin particles. There was no noticeable fluorescence from the cells treated with the nanoparticles prepared with the original (noncationized) gelatin particles containing the pEGFP. In contrast, numerous cells in the group transfected with the cationized gelatin-pEGFP nanoparticles were found to fluoresce demonstrating the transfection of the cells. There was five-fold elevation in the amount of IGF-1 produced by the cells treated with the cationized gelatin nanoparticles containing the IGF-1 plasmid compared with the unmodified (noncationized) gelatin particles. There was a clear effect of varying the weight ratio of plasmid IGF-1 in the cationized gelatin nanoparticles on the IGF-1 in the medium of cells exposed to the nanoparticles for 5 h. A peak in the amount of released IGF-1 was detected at a gelatin:IGF-1 weight ratio of 250:1. (c) 2007 Wiley Periodicals, Inc. J Biomed Mater Res 84A: 73-83, 2008. C1 VA Boston Healthcare Syst, Tissue Engn, Boston, MA 02130 USA. Jiangsu Univ, Sch Pharm, Dept Pharmaceut, Zhenjiang 212001, Jiangsu, Peoples R China. Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Orthopaed Surg, Boston, MA 02115 USA. MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA. RP Spector, M (reprint author), VA Boston Healthcare Syst, Tissue Engn, Boston, MA 02130 USA. EM mspector@rics.bwh.harvard.edu RI Shah, Ramille/E-3737-2010 NR 52 TC 25 Z9 25 U1 2 U2 12 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1549-3296 J9 J BIOMED MATER RES A JI J. Biomed. Mater. Res. Part A PD JAN PY 2008 VL 84A IS 1 BP 73 EP 83 DI 10.1002/jbm.a.31372 PG 11 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA 239MF UT WOS:000251521700008 PM 17600330 ER PT J AU Goldberg, BD Iftimia, NV Bressner, JE Pitman, MB Halpern, E Bouma, BE Tearney, GJ AF Goldberg, Brian D. Iftimia, Nicusor V. Bressner, Jason E. Pitman, Martha B. Halpern, Elkan Bouma, Brett E. Tearney, Guillermo J. TI Automated algorithm for differentiation of human breast tissue using low coherence interferometry for fine needle aspiration biopsy guidance SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE breast cancer; low coherence interferometry; needle guidance; fine needles aspiration; breast biopsy; automated ID LESIONS; TOMOGRAPHY; ACCURACY; ADEQUACY; MASSES AB Fine needle aspiration biopsy (FNAB) is a rapid and cost-effective method for obtaining a first-line diagnosis of a palpable mass of the breast. However, because it can be difficult to manually discriminate between adipose tissue and the fibroglandular tissue more likely to harbor disease, this technique is plagued by a high number of nondiagnostic tissue draws. We have developed a portable, low coherence interferometry (LCI) instrument for FNAB guidance to combat this problem. The device contains an optical fiber probe inserted within the bore of the fine gauge needle and is capable of obtaining tissue structural information with a spatial resolution of 10 mu m over a depth of approximately 1.0 mm. For such a device to be effective clinically, algorithms that use the LCI data must be developed for classifying different tissue types. We present an automated algorithm for differentiating adipose tissue from fibroglandular human breast tissue based on three parameters computed from the LCI signal (slope, standard deviation, spatial frequency content ). A total of 260 breast tissue samples from 58 patients were collected from excised surgical specimens. A training set (N=72) was used to extract parameters for each tissue type and the parameters were fit to a multivariate normal density. The model was applied to a validation set (N=86) using likelihood ratios to classify groups. The overall accuracy of the model was 91.9% (84.0 to 96.7) with 98.1% (89.7 to 99.9) sensitivity and 82.4% (65.5 to 93.2) specificity where the numbers in parentheses represent the 95% confidence intervals. These results suggest that LCI can be used to determine tissue type and guide FNAB of the breast. c 2008 Society of Photo-Optical Instrumentation Engineers. C1 [Goldberg, Brian D.; Iftimia, Nicusor V.; Bressner, Jason E.; Halpern, Elkan; Bouma, Brett E.; Tearney, Guillermo J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Goldberg, Brian D.; Bouma, Brett E.] Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Pitman, Martha B.; Tearney, Guillermo J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Halpern, Elkan] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. RP Goldberg, BD (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 50 Blossom St,BAR 710, Boston, MA 02114 USA. EM bdg@mit.edu FU NIBIB NIH HHS [1 F31 EB005141-01A2] NR 25 TC 26 Z9 26 U1 0 U2 2 PU SPIE-SOC PHOTOPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2008 VL 13 IS 1 AR 014014 DI 10.1117/1.2837433 PG 8 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 283JK UT WOS:000254632300028 PM 18315372 ER PT J AU Jones, PB Rozkalne, A Meyer-Luehmann, M Spires-Jones, TL Makarova, A Kumar, ATN Berezovska, O Bacskai, BB Hyman, BT AF Jones, Phillip B. Rozkalne, Aneta Meyer-Luehmann, Melanie Spires-Jones, Tara L. Makarova, Alexandra Kumar, Anand T. N. Berezovska, Oksana Bacskai, Brian B. Hyman, Bradley T. TI Two postprocessing techniques for the elimination of background autofluorescence for fluorescence lifetime imaging microscopy SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE fluorescence lifetime imaging microscopy; fluorescence energy transfer; autofluorescence; data analysis; protein conformation ID AMYLOID PRECURSOR PROTEIN; MULTIPHOTON-FLIM; CELLS; PRESENILIN-1; SPECTRA; SYSTEM AB The analysis of fluorescence lifetime imaging microscopy (FLIM) data under complex biological conditions can be challenging. Particularly, the presence of short-lived autofluorescent aggregates can confound lifetime measurements in fluorescence energy transfer (FRET) experiments, where it can become confused with the signal from exogenous fluorophores. Here we report two techniques that can be used to discriminate the contribution of autofluorescence from exogenous fluorphores in FLIM. We apply the techniques to transgenic mice that natively express yellow fluorescence protein (YFP) in a subset of cortical neurons and to histological slices of aged human brain tissue, where we study the misfolding of intracellular tau protein in the form of neurofibrillary tangles. (C) 2008 Society of Photo-Optical Instrumentation Engineers. C1 [Jones, Phillip B.; Rozkalne, Aneta; Meyer-Luehmann, Melanie; Spires-Jones, Tara L.; Makarova, Alexandra; Berezovska, Oksana; Bacskai, Brian B.; Hyman, Bradley T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Disorders, Charlestown, MA 02129 USA. [Kumar, Anand T. N.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Hyman, BT (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Disorders, 114 16th St, Charlestown, MA 02129 USA. EM bhyman@partners.org OI Jones, Phillip/0000-0003-0525-6323; Spires-Jones, Tara/0000-0003-2530-0598; Meyer-Luehmann, Melanie/0000-0003-3661-2220 FU NIA NIH HHS [AG026240, AG026249, AG026593, AG08487, AG08487-16, AG12406]; NIAID NIH HHS [AI068871]; NIBIB NIH HHS [EB00768]; PHS HHS [NNS10828] NR 29 TC 8 Z9 8 U1 0 U2 5 PU SPIE-SOC PHOTOPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2008 VL 13 IS 1 AR 014008 DI 10.1117/1.2837169 PG 8 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 283JK UT WOS:000254632300022 PM 18315366 ER PT J AU Kim, P Puoris'haag, M Cote, D Lin, CP Yun, SH AF Kim, Pilhan Puoris'haag, Mehron Cote, Daniel Lin, Charles P. Yun, Seok H. TI In vivo confocal and multiphoton microendoscopy SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE endoscopy; imaging; fluorescence; microscopy; confocal optics; multiphoton processes ID ENDOSCOPY; MICROSCOPY AB The ability to conduct high-resolution fluorescence imaging in internal organs of small animal models in situ and over time can make a significant impact in biomedical research. Toward this goal, we developed a real-time confocal and multiphoton endoscopic imaging system. Using 1-mm-diameter endoscopes based on gradient index lenses, we demonstrate video-rate multicolor multimodal imaging with cellular resolution in live mice. (C) 2008 Society of Photo-Optical Instrumentation Engineers. C1 [Kim, Pilhan] Harvard Univ, Sch Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Kim, P (reprint author), Harvard Univ, Sch Med, 50 Blossom St,BAR 818, Boston, MA 02114 USA. EM syun@hms.harvard.edu RI Cote, Daniel/D-5185-2011; Kim, Pilhan/C-1836-2011 OI Kim, Pilhan/0000-0001-8388-1840 FU NIAID NIH HHS [R21 AI081010-01A1, R21 AI081010] NR 11 TC 56 Z9 57 U1 1 U2 9 PU SPIE-SOC PHOTOPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2008 VL 13 IS 1 AR 010501 DI 10.1117/1.2839043 PG 3 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 283JK UT WOS:000254632300001 PM 18315346 ER PT J AU Ntziachristos, V Culver, JP Rice, BW AF Ntziachristos, Vasilis Culver, Joseph P. Rice, Bradley W. TI Small-animal optical imaging SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Editorial Material C1 [Ntziachristos, Vasilis] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Culver, Joseph P.] Washington Univ, St Louis, MO 63130 USA. RP Ntziachristos, V (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 7 Z9 7 U1 0 U2 1 PU SPIE-SOC PHOTOPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2008 VL 13 IS 1 AR 011001 DI 10.1117/1.2890838 PG 1 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 283JK UT WOS:000254632300006 PM 18456953 ER PT J AU Willers, H Kachnic, LA Luo, CM Li, L Purschke, M Borgmann, K Held, KD Powell, SN AF Willers, Henning Kachnic, Lisa A. Luo, Chen-Mei Li, Li Purschke, Martin Borgmann, Kerstin Held, Kathryn D. Powell, Simon N. TI Biomarkers and mechanisms of FANCD2 function SO JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY LA English DT Article ID FANCONI-ANEMIA PROTEINS; DNA-REPAIR; OXIDATIVE STRESS; CELL-LINES; MONOUBIQUITINATED FANCD2; CANCER SUSCEPTIBILITY; HISTONE H2AX; NECK-CANCER; PATHWAY; DAMAGE AB Genetic or epigenetic inactivation of the pathway formed by the Fanconi anemia (FA) and BRCA1 proteins occurs in several cancer types, making the affected tumors potentially hypersensitive to DNA cross-linkers and other chemotherapeutic agents. It has been proposed that the inability of FA/BRCA-defective cells to form subnuclear foci of effector proteins, such as FANCD2, can be used as a biomarker to aid individualization of chemotherapy. We show that FANCD2 inactivation not only renders cells sensitive to cross-links, but also oxidative stress, a common effect of cancer therapeutics. Oxidative stress sensitivity does not correlate with FANCD2 or RAD51 foci formation, but associates with increased gamma H2AX foci levels and apoptosis. Therefore, FANCD2 may protect cells against cross-links and oxidative stress through distinct mechanisms, consistent with the growing notion that the pathway is not linear. Our data emphasize the need for multiple biomarkers, such as gamma H2AX, FANCD2, and RAD51, to capture all pathway activities. Copyright (c) 2008 Henning Willers et al. C1 [Willers, Henning; Kachnic, Lisa A.; Luo, Chen-Mei; Li, Li; Purschke, Martin; Held, Kathryn D.; Powell, Simon N.] Massachusetts Gen Hosp, Ctr Canc, Dept Radiat Oncol, Lab Cellular & Mol Radiat Oncol, Charlestown, MA 02129 USA. [Willers, Henning; Kachnic, Lisa A.; Luo, Chen-Mei; Li, Li; Purschke, Martin; Held, Kathryn D.; Powell, Simon N.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Borgmann, Kerstin] Univ Hamburg, Univ Hosp Eppendorf, Lab Radiobiol & Expt Radiat Oncol, D-20246 Hamburg, Germany. [Powell, Simon N.] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA. RP Willers, H (reprint author), Massachusetts Gen Hosp, Ctr Canc, Dept Radiat Oncol, Lab Cellular & Mol Radiat Oncol, Charlestown, MA 02129 USA. EM hwillers@partners.org NR 46 TC 17 Z9 17 U1 0 U2 2 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1110-7243 J9 J BIOMED BIOTECHNOL JI J. Biomed. Biotechnol. PY 2008 AR 821529 DI 10.1155/2008/821529 PG 8 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA 314DC UT WOS:000256788100001 ER PT J AU Radcliff, TA Henderson, WG Stoner, TJ Khuri, SF Dohm, M Hutt, E AF Radcliff, Tiffany A. Henderson, William G. Stoner, Tamara J. Khuri, Shukri F. Dohm, Michael Hutt, Evelyn TI Patient risk factors, operative care, and outcomes among older community-dwelling male veterans with hip fracture SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID SURGICAL CARE; MORTALITY; MORBIDITY; FIXATION; QUALITY; ARTHROPLASTY; VALIDATION; REDUCTION; AFFAIRS; MEN AB Background: Although more than 1200 hip fracture repairs are performed in United States Department of Veterans Affairs hospitals annually, little is known about the relationship between perioperative care and short-term outcomes for veterans with hip fracture. The purpose of the present study was to test whether perioperative care impacts thirty-day outcomes, with patient characteristics being taken into account. Methods: A national sample of 5683 community-dwelling male veterans with an age of sixty-five years or older who had been hospitalized for the operative treatment of a hip fracture at one of 108 Veterans Administration hospitals between 1998 and 2003 was identified from the National Surgical Quality Improvement Program data set. Operative care characteristics were assessed in relation to thirty-day outcomes (mortality, complications, and readmission to a Veterans Administration facility for inpatient care). Results: A surgical delay of four days or more after admission was associated with a higher adjusted mortality risk (odds ratio, 1.29; 95% confidence interval, 1.02 to 1.61) but a reduced risk of readmission (odds ratio, 0.70; 95% confidence interval, 0.54 to 0.91). Compared with spinal or epidural anesthesia, general anesthesia was related to a significantly higher risk of both mortality (odds ratio, 1.27; 95% confidence interval, 1.01 to 1.55) and complications (odds ratio, 1.33; 95% confidence interval, 1.15 to 1.53). The type of procedure was not significantly associated with outcome after controlling for other variables in the model. However, a higher American Society of Anesthesiologists Physical Status Classification (ASA class) was associated with worse thirty-day outcomes. Conclusions: In addition to recognizing the importance of patient-related factors, we identified operative factors that were related to thirty-day surgical outcomes. It will be important to investigate whether modifying operative factors, such as reducing surgical delays to less than four days, can directly improve the outcomes of hip fracture repair. Level of Evidence: Prognostic Level II. See Instructions to Authors for a complete description of levels of evidence. C1 [Radcliff, Tiffany A.; Henderson, William G.; Stoner, Tamara J.; Khuri, Shukri F.; Dohm, Michael; Hutt, Evelyn] Denver VA Med Ctr, Denver, CO USA. RP Radcliff, TA (reprint author), VA Eastern Colorado Hlth Care Syst, Colorado REAP Improve Care Coordinat, 1055 Clermont St MS 151, Denver, CO 80220 USA. EM Tiffany.Radcliff@uchsc.edu NR 32 TC 80 Z9 86 U1 0 U2 3 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD JAN PY 2008 VL 90A IS 1 BP 34 EP 42 DI 10.2106/JBJS.G.00065 PG 9 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 250PV UT WOS:000252313400005 PM 18171955 ER PT J AU Aryana, A Heist, EK D'Avila, A Holmvang, G Chevalier, J Ruskin, JN Mansour, MC AF Aryana, Arash Heist, E. Kevin D'Avila, Andre Holmvang, Godtfred Chevalier, Jianping Ruskin, Jeremy N. Mansour, Moussa C. TI Pain and anatomical locations of radiofrequency ablation as predictors of esophageal temperature rise during pulmonary vein isolation SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article DE ablation; atrial fibrillation; atrioesophageal fistula; esophageal temperature; pain; pulmonary vein isolation; thermal injury ID ATRIAL-FIBRILLATION; CATHETER ABLATION; INTRACARDIAC ECHOCARDIOGRAPHY; INJURY; FISTULA AB Pain and Esophageal Temperature. Introduction: Esophageal temperature rise (ETR) during ablation inside left atrium has been reported as a marker for esophageal thermal injury. We sought to investigate the possible relationships between chest pain and ETR during radiofrequency (RF) ablation, and ETR and locations of RF application, in patients undergoing pulmonary vein (PV) isolation under moderate sedation. Methods and Results: We analyzed anatomical locations of each RF application and its association with esophageal temperature and presence/absence of pain. Data from 40 consecutive patients (mean age: 56 +/- 10 years) were analyzed. There were a total of 4,071 RF applications resulting in 291 episodes of pain (7.1%) and 223 ETRs (5.5%). Thirty-five patients (87.5%) experienced at least one pain episode and 32 (80.0%) had at least one ETR. While 77.4% of posterior wall applications that caused pain also corresponded to an ETR (P < 0.0001), only 0.8% of pain-free posterior wall applications were associated with ETRs (P < 0.0001). The sensitivity and specificity of pain during ablation for ETR were 94% and 98%, respectively. No ETRs were observed during anterior wall applications. ETRs occurred more frequently during ablation on the left (86.1%) versus the right (13.9%), and in inferior (70.4%) versus superior (29.6%) segments. Conclusion: In patients undergoing PV isolation, ETR was encountered when ablating in the posterior left atrium with the distribution left > right and inferior > superior. Pain during ablation was associated with ETR, and lack of pain was strongly associated with absence of ETR. Pain during RF ablation may thus serve as a predictor of esophageal heating and potential injury. C1 [Aryana, Arash; Heist, E. Kevin; D'Avila, Andre; Chevalier, Jianping; Ruskin, Jeremy N.; Mansour, Moussa C.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Aryana, Arash; Heist, E. Kevin; D'Avila, Andre; Holmvang, Godtfred; Chevalier, Jianping; Ruskin, Jeremy N.; Mansour, Moussa C.] Harvard Univ, Sch Med, Boston, MA USA. [Holmvang, Godtfred] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. RP Mansour, MC (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, 55 Fruit St,GRB-109, Boston, MA 02114 USA. EM mmansour@partners.org RI d'Avila, Andre Luiz/F-8009-2010; d'Avila, Andre/A-7693-2009 OI d'Avila, Andre Luiz/0000-0001-8769-1411; NR 16 TC 18 Z9 19 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1045-3873 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD JAN PY 2008 VL 19 IS 1 BP 32 EP 38 DI 10.1111/j.1540-8167.2007.00975.x PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 244JJ UT WOS:000251861900007 PM 17900251 ER PT J AU Fiegel, HC Kaufmann, PM Bruns, H Kluth, D Horch, RE Vacanti, JP Kneser, U AF Fiegel, Henning C. Kaufmann, Peter M. Bruns, Helge Kluth, Dietrich Horch, Raymund E. Vacanti, Joseph P. Kneser, Ulrich TI Hepatic tissue engineering: from transplantation to customized cell-based liver directed therapies from the laboratory SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE LA English DT Review DE liver cell transplantation; hepatic tissue engineering ID MESENCHYMAL STEM-CELLS; ADULT-RAT HEPATOCYTES; BIOARTIFICIAL LIVER; IN-VITRO; PARENCHYMAL-CELLS; PHASE-I; 3-DIMENSIONAL MATRICES; EXTRACELLULAR-MATRIX; PANCREATIC-ISLETS; SUPPORT SYSTEM AB Today, liver transplantation is still the only curative treatment for liver failure due to end-stage liver diseases. Donor organ shortage, high cost and the need of immunosuppressive medications are still the major limitations in the field of liver transplantation. Thus, alternative innovative cell-based liver directed therapies, for example, liver tissue engineering, are under investigation with the aim that in future an artificial liver tissue could be created and be used for the replacement of the liver function in patients. Using cells instead of organs in this setting should permit (i) expansion of cells in an in vitro phase, (ii) genetic or immunological manipulation of cells for transplantation, (iii) tissue typing and cryopreservation in a cell bank and (iv) the ex vivo genetic modification of patient's own cells prior to re-implantation. Function and differentiation of liver cells are influenced by the three-dimensional organ architecture. The use of polymeric matrices permits the three-dimensional formation of a neo tissue and specific stimulation by adequate modification of the matrix surface, which might be essential for appropriate differentiation of transplanted cells. In addition, culturing hepatocytes on three-dimensional matrices permits culture in a flow bioreactor system with increased function and survival of the cultured cells. Based on bioreactor technology, bioartificial liver devices (BAL) are developed for extracorporeal liver support. Although BALs improved clinical and metabolic conditions, increased patient survival rates have not been proven yet. For intracorporeal liver replacement, a concept that combines tissue engineering using three-dimensional, highly porous matrices with cell transplantation could be useful. In such a concept, whole liver mass transplantation, long-term engraftment and function as well as correction of a metabolic defect in animal models could be achieved with a principally reversible procedure. Future studies have to investigate which environmental conditions and transplantation system would be most suitable for the development of artificial functional liver tissue including blood supply for a potential use in a clinical setting. C1 [Fiegel, Henning C.; Bruns, Helge; Kluth, Dietrich] Univ Leipzig, Dept Pediat Surg, D-04103 Leipzig, Germany. [Kaufmann, Peter M.] Leibniz Univ Hannover, Dept Urol, Hannover, Germany. [Horch, Raymund E.; Kneser, Ulrich] Univ Hosp Erlangen, Dept Plast & Hand Surg, Erlangen, Germany. [Vacanti, Joseph P.] Harvard Univ, Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02115 USA. RP Fiegel, HC (reprint author), Univ Leipzig, Dept Pediat Surg, Liebigstr 20A, D-04103 Leipzig, Germany. EM henning.fiegel@medizin.uni-leipzig.de RI Bruns, Helge/N-6013-2014 OI Bruns, Helge/0000-0003-1010-1043 NR 82 TC 62 Z9 73 U1 3 U2 19 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1582-1838 J9 J CELL MOL MED JI J. Cell. Mol. Med. PD JAN-FEB PY 2008 VL 12 IS 1 BP 56 EP 66 DI 10.1111/j.1582-4934.2007.00162.x PG 11 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 278HJ UT WOS:000254275500004 PM 18021311 ER PT J AU McMackin, RA Keane, TM Kline, PM AF McMackin, Robert A. Keane, Terence M. Kline, Paul M. TI Introduction to Special Issue on Betrayal and Recovery: Understanding the Trauma of Clergy Sexual Abuse INTRODUCTION SO JOURNAL OF CHILD SEXUAL ABUSE LA English DT Editorial Material DE Clergy sexual abuse; post-traumatic stress disorder; survivors; spirituality; restorative justice AB The sexual abuse of children can leave profound emotional and psychological scars that reverberate through the entire lifecycle. In this volume, the sexual abuse of children and adults perpetrated by clergy is considered. The editors have provided a cross section of authors to examine the unique aspect of this form of trauma, with particular emphasis on providing a voice for the survivors of such abuse. C1 [McMackin, Robert A.] Lemuel Shattuck Hosp, Jamaica Plain, MA 02130 USA. [McMackin, Robert A.] Massachusetts Dept Publ Hlth, Boston, MA USA. [McMackin, Robert A.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Keane, Terence M.] Natl Ctr PTSD, Behav Sci Div, Boston, MA USA. [Keane, Terence M.] VA Boston Healthcare Syst, Boston, MA USA. [Keane, Terence M.] Boston Univ, Sch Med, Div Psychiat, Boston, MA 02118 USA. [Kline, Paul M.] Boston Coll, Grad Sch Social Work, Chestnut Hill, MA 02167 USA. RP McMackin, RA (reprint author), Lemuel Shattuck Hosp, 170 Morton St, Jamaica Plain, MA 02130 USA. NR 1 TC 0 Z9 0 U1 1 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1053-8712 J9 J CHILD SEX ABUS JI J. Child Sex. Abus. PY 2008 VL 17 IS 3-4 BP 197 EP 200 DI 10.1080/10538710802330401 PG 4 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA V14BA UT WOS:000207708700001 PM 19042597 ER PT J AU Fogler, JM Shipherd, JC Rowe, E Jensen, J Clarke, S AF Fogler, Jason M. Shipherd, Jillian C. Rowe, Erin Jensen, Jennifer Clarke, Stephanie TI A Theoretical Foundation for Understanding Clergy-Perpetrated Sexual Abuse SO JOURNAL OF CHILD SEXUAL ABUSE LA English DT Article DE Sexual abuse; clergy; theory; trauma; terror management; community ID TERROR MANAGEMENT THEORY; FATHER-DAUGHTER INCEST; THEORY RELATING SELF; MORTALITY SALIENCE; OWN VOICES; CHILDHOOD; SHAME; CHILDREN; WOMEN; VICTIMIZATION AB Incorporating elements from broadband theories of psychological adaptation to extreme adversity, including Summit's (1983) Child Sexual Abuse Accommodation Syndrome, Finkelhor and Browne's (1986) Traumagenic Dynamics Model of sexual abuse, and Pyszczynski and colleagues' (1997) Terror Management Theory, this paper proposes a unified theoretical model of clergy-perpetrated sexual abuse for future research. The model conceptualizes clergy-perpetrated sexual abuse as the convergence of interactive processes between the clergy-perpetrator, the parishioner-survivor, and the religious community. C1 [Fogler, Jason M.] Brookline Community Mental Hlth Ctr, Brookline, MA USA. [Shipherd, Jillian C.; Jensen, Jennifer] Natl Ctr Posttraumat Stress Disorder, Womens Hlth Sci Div, Boston, MA USA. [Shipherd, Jillian C.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Rowe, Erin] Northeastern Univ, Inst Urban Hlth Res, Boston, MA 02115 USA. [Clarke, Stephanie] Univ Minnesota Twin Cities, Dev Psychopathol & Clin Sci Doctoral Program, Minneapolis, MN USA. RP Fogler, JM (reprint author), Brookline Ctr, 43 Garrison Rd, Brookline, MA 02445 USA. EM jfogler@bu.edu NR 88 TC 7 Z9 7 U1 2 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1053-8712 J9 J CHILD SEX ABUS JI J. Child Sex. Abus. PY 2008 VL 17 IS 3-4 BP 301 EP 328 DI 10.1080/10538710802329874 PG 28 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA V14BA UT WOS:000207708700008 PM 19042604 ER PT J AU Fogler, JM Shipherd, JC Clarke, S Jensen, J Rowe, E AF Fogler, Jason M. Shipherd, Jillian C. Clarke, Stephanie Jensen, Jennifer Rowe, Erin TI The Impact of Clergy-Perpetrated Sexual Abuse: The Role of Gender, Development, and Posttraumatic Stress SO JOURNAL OF CHILD SEXUAL ABUSE LA English DT Article DE Sexual abuse; clergy; gender; development; trauma; PTSD ID COGNITIVE-PROCESSING THERAPY; EXPOSURE THERAPY; ASSAULT VICTIMS; RAPE VICTIMS; CHRONIC PAIN; CHILDHOOD; DISORDER; SURVIVORS; PTSD; CHILDREN AB The literature on clergy-perpetrated sexual abuse suggests that there are two modal populations of survivors: boys and adult women. We review what is known about trauma and post-traumatic stress disorder following sexual abuse and explore the different treatment needs for these two survivor groups. For children, clergy-perpetrated sexual abuse can catastrophically alter the trajectory of psychosocial, sexual, and spiritual development. Depending on the age at which abuse occurred, adult clients may present with clinical issues that are more appropriate for a younger developmental stage. Additionally, the symptoms of traumatic stress may be misunderstood when clients conceptualize their abuse as an "affair" or "consensual" relationship. We discuss empirically supported treatments for post-traumatic stress disorder and potential adaptations for the needs of clergy-perpetrated sexual abuse survivors. C1 [Fogler, Jason M.] Brookline Community Mental Hlth Ctr, Brookline, MA USA. [Shipherd, Jillian C.; Jensen, Jennifer] Natl Ctr Posttraumat Stress Disorder, Womens Hlth Sci Div, Boston, MA USA. [Shipherd, Jillian C.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Clarke, Stephanie] Univ Minnesota Twin Cities, Dev Psychopathol & Clin Sci Doctoral Program, Minneapolis, MN USA. [Rowe, Erin] Northeastern Univ, Inst Urban Hlth Res, Boston, MA 02115 USA. RP Fogler, JM (reprint author), Brookline Ctr, 43 Garrison Rd, Brookline, MA 02445 USA. EM jfogler@bu.edu NR 120 TC 7 Z9 7 U1 5 U2 14 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1053-8712 J9 J CHILD SEX ABUS JI J. Child Sex. Abus. PY 2008 VL 17 IS 3-4 BP 329 EP 358 DI 10.1080/10538710802329940 PG 30 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA V14BA UT WOS:000207708700009 PM 19042605 ER PT J AU Levine, AJ Hardy, DJ Barclay, TR Reinhard, MJ Cole, MM Hinkin, CH AF Levine, Andrew J. Hardy, David J. Barclay, Terry R. Reinhard, Matthew J. Cole, Michael M. Hinkin, Charles H. TI Elements of attention in HIV-infected adults: Evaluation of an existing model SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article ID NEUROPSYCHOLOGICAL IMPAIRMENT; MEDICATION ADHERENCE; WORKING-MEMORY; PERFORMANCE; DEPRESSION; DISORDERS; NETWORKS; THERAPY AB Because of the multifactorial nature of neuropsychological tests, attention remains poorly defined from a neuropsychological perspective, and conclusions made regarding attention across studies may be limited due to the different nature of the measures used. Thus, a more definitive schema for this neurocognitive domain is needed. We assessed the applicability of Mirsky and Duncan's (2001) neuropsychological model of attention to a cohort of 104 HIV+ adults. Our analysis resulted in a five-factor structure similar to that of previous studies, which explained 74.5% of the variance. However, based on the psychometric characteristics of the measures comprising each factor, we offer an alternative interpretation of the factors. Findings also indicate that one factor, which is generally not assessed in clinical neuropsychology settings, may be more predictive of real-world behaviors (such as medication adherence) than those composed of traditional measures. Suggestions for further research in this important area are discussed. C1 [Levine, Andrew J.] Univ Calif Los Angeles, Natl Neurol AIDS Bank, Los Angeles, CA 90025 USA. [Hardy, David J.] Loyola Marymount Univ, Los Angeles, CA 90045 USA. [Hardy, David J.; Barclay, Terry R.; Reinhard, Matthew J.; Cole, Michael M.; Hinkin, Charles H.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90025 USA. [Hinkin, Charles H.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Levine, AJ (reprint author), Univ Calif Los Angeles, Natl Neurol AIDS Bank, 11645 Wilshire Blvd,Suite 770, Los Angeles, CA 90025 USA. EM ajlevine@mednet.ucla.edu FU NIDA NIH HHS [R01 DA013799, R01 DA013799-04, R01 DA13799]; NIMH NIH HHS [T32 MH019535]; NINDS NIH HHS [NS-38841, R24 NS038841] NR 56 TC 14 Z9 14 U1 1 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PY 2008 VL 30 IS 1 BP 53 EP 62 DI 10.1080/13803390601186684 PG 10 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 251AP UT WOS:000252343000006 PM 17852595 ER PT J AU Levine, AJ Hinkin, CH Ando, K Santangelo, G Martinez, M Valdes-Sueiras, M Saxton, EH Mathisen, G Commins, DL Moe, A Farthing, C Singer, EJ AF Levine, Andrew J. Hinkin, Charles H. Ando, Kazuhiro Santangelo, Gianni Martinez, Mariana Valdes-Sueiras, Miguel Saxton, Ernestina H. Mathisen, Glen Commins, Deborah L. Moe, Ardis Farthing, Charles Singer, Elyse J. TI An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article DE opportunistic infection; AIDS; neuropsychological functioning; toxoplasmosis encephalitis; progressive multifocal leukoencephalopathy; cryptococcal meningitis ID PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; HUMAN-IMMUNODEFICIENCY-VIRUS; PSYCHIATRIC RESEARCH INTERVIEW; CRYPTOCOCCAL MENINGITIS; CEREBRAL TOXOPLASMOSIS; ANTIRETROVIRAL THERAPY; AIDS PATIENTS; MENTAL-DISORDERS; DEMENTIA; ENCEPHALITIS AB Central nervous system opportunistic infections (CNS-OI) are a significant cause of morbidity and mortality in AIDS. While current interventions are increasingly successful in treating CNS-OI, little information exists regarding long-term behavioral outcomes among survivors. In this exploratory study we examined neurocognitive data among three groups of adults with different AIDS-related CNS-OI: 15 with past cryptococcal meningitis (CM), 8 with toxoplasmosis encephalitis (TE), and 8 with progressive multifocal leukoencephalopathy (PML). A group of 61 individuals with AIDS, but without CNS-OI, was used as a comparison group. A battery of standardized neuropsychological tests assessing a variety of cognitive domains was administered upon entry. Results indicate that individuals with a history of CNS-OI were most impaired on measures of cognitive and psychomotor speed relative to the HIV+ comparison group. Among the CNS-OI groups, individuals with history of TE had the most severe and varied deficits. The results are discussed in relation to what is known about the neuropathological consequences of the various CNS-OIs. While this is the first systematic group study of residual CNS-OI effects on neurocognitive function, future studies employing more participants, perhaps focusing on specific CNS-OIs, will further characterize the long-term outcomes in AIDS-related CNS-OI. C1 [Levine, Andrew J.; Hinkin, Charles H.; Ando, Kazuhiro; Santangelo, Gianni; Martinez, Mariana; Valdes-Sueiras, Miguel; Saxton, Ernestina H.; Mathisen, Glen; Commins, Deborah L.; Moe, Ardis; Farthing, Charles; Singer, Elyse J.] Univ Calif Los Angeles, Natl Neurol AIDS Bank, Los Angeles, CA 90025 USA. [Hinkin, Charles H.] Vet Adm Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Valdes-Sueiras, Miguel; Mathisen, Glen] Olive View UCLA Med Ctr, Dept Med, Sylmar, CA 91342 USA. [Valdes-Sueiras, Miguel; Farthing, Charles] AIDS Healthcare Fdn, Los Angeles, CA USA. [Mathisen, Glen; Moe, Ardis] Univ Calif Los Angeles, David Geffen Sch Med, Dept Internal Med, Los Angeles, CA 90025 USA. [Commins, Deborah L.] Univ So Calif, Dept Pathol, Univ Hosp, Los Angeles, CA 90089 USA. RP Levine, AJ (reprint author), Univ Calif Los Angeles, Natl Neurol AIDS Bank, 11645 Wilshire Blvd,Suite 770, Los Angeles, CA 90025 USA. EM ajlevine@mednet.ucla.edu FU National Neurological AIDS Bank [NS38841] FX This study was supported by Grant NS38841, National Neurological AIDS Bank. NR 34 TC 10 Z9 10 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PY 2008 VL 30 IS 7 BP 836 EP 843 DI 10.1080/13803390701819036 PG 8 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 345EH UT WOS:000258978400011 PM 18608693 ER PT J AU Collett-Solberg, PF Misra, M AF Collett-Solberg, Paulo F. Misra, Madhusmita CA Drug Therapeutics Comm TI The role of recombinant human insulin-like growth factor-I in treating children with short stature SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Review ID IDIOPATHIC SHORT STATURE; ACID-LABILE SUBUNIT; FACTOR BINDING-PROTEINS; HORMONE INSENSITIVITY SYNDROME; PLACEBO-CONTROLLED TRIAL; GH RECEPTOR DEFICIENCY; LONG-TERM TREATMENT; IGF-I; LARON-SYNDROME; CONSTITUTIONAL DELAY AB Context: Recombinant human (rh) IGF-I is now available to treat children with short stature resulting from severe primary IGF-I deficiency. This review from the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society discusses different aspects of rhIGF-I therapy, particularly with regard to potential advantages and disadvantages in comparison with the traditional use of rhGH for treatment of short stature. Evidence Acquisition: We used the Entrez-PubMed search engine to conduct a review of publications addressing IGF-I deficiency, the use of rhIGF-I, and treatment for short stature. Evidence Synthesis: rhIGF-I, as a twice-daily sc injection, is now approved for treatment of short stature in children with severe primary IGF-I deficiency, which may occur as a consequence of mutations in the GH receptor, defects in the post-GH receptor signaling pathway, and IGF-I gene defects. It is also approved for children with GH deficiency who develop neutralizing antibodies to GH. rhIGF-I significantly improves growth in these conditions. However, adult height may still be suboptimal, possibly due to lack of direct GH effects. Dosing regimens for rhIGF-I administration are under investigation, as are other indications for use of rhIGF-I. Conclusion: The use of rhIGF-I is justified in conditions approved by the Food and Drug Administration. Until more substantial data become available, the use of rhIGF-I outside Food and Drug Administration recommendations should only be investigational. C1 [Collett-Solberg, Paulo F.] Inst Estadual Diab & Endocrinol, Rio De Janeiro, Brazil. [Misra, Madhusmita] Massachusetts Gen Hosp, Pediat Endocrine & Neuroendocrine Units, Boston, MA 02114 USA. RP Collett-Solberg, PF (reprint author), Rua Saturnino Brito,190, BR-22470030 Rio De Janeiro, RJ, Brazil. EM paulosolberg@yahoo.com NR 81 TC 20 Z9 20 U1 0 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2008 VL 93 IS 1 BP 10 EP 18 DI 10.1210/jc.2007-1534 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 251GC UT WOS:000252359400004 PM 18165284 ER PT J AU Hartman, ML Weltman, A Zagar, A Qualy, RL Hoffman, AR Merriam, GR AF Hartman, Mark L. Weltman, Arthur Zagar, Anthony Qualy, Rebecca L. Hoffman, Andrew R. Merriam, George R. TI Growth hormone replacement therapy in adults with growth hormone deficiency improves maximal oxygen consumption independently of dosing regimen or physical activity SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID GH TREATMENT; LACTATE THRESHOLD; HYPOPITUITARY ADULTS; CHILDHOOD-ONSET; DOSE TITRATION; BLOOD LACTATE; EXERCISE; PERFORMANCE; MUSCLE; CAPACITY AB Context: Several studies have demonstrated an improvement in aerobic exercise capacity with 6 months of GH replacement in adults with GH deficiency (GHD). Objective: The objective of the study was to determine whether improvements in aerobic exercise capacity with GH treatment in adults with GHD are related to changes in physical activity or affected by the GH dosing regimen. Design: This was a randomized, two-arm, parallel, open-label study. Setting: The study was conducted at five academic medical centers with exercise physiology laboratories. Subjects: Study subjects were adults (n = 29) with GHD due to hypothalamic-pituitary disease. Interventions: The intervention was GH replacement therapy, administered either as a fixed body weight-based dosing regimen as an individualized dose titration regimen for 32 wk. Main Outcome Measures: Maximal oxygen consumption (VO2 max) and oxygen consumption (VO2) at the lactate threshold, ventilatory threshold using a cycle ergometry protocol, and weekly energy expenditure (physical activity questionnaire), assessed at baseline and end point, were measured. Results: In the group as a whole, VO2 max increased significantly (by 9%) from baseline (19.1 +/- 0.89 ml/ kg.min) to end point (21.6 +/- 1.23 ml/kg.min, P = 0.010). Compared with baseline, VO2 max also changed significantly within the individualized dose titration regimen group (+ 2.5 +/- 0.98 ml/kg.min, P =0.034) but not within the fixed body weight-based dosing regimen group (+ 1.2 +/- 0.78 ml/kg.min, P = 0.15), although these changes from baseline were not significantly different between the two groups. VO2 at lactate threshold, VO2 at ventilatory threshold, and weekly energy expenditure also did not change. Conclusions: GH replacement therapy in G H-deficient adults improved VO2 max similarly with both dosing regimens, without any influence of physical activity. There was no effect on submaximal exercise performance. C1 [Hartman, Mark L.; Zagar, Anthony; Qualy, Rebecca L.] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. [Weltman, Arthur] Univ Virginia, Dept Human Serv & Med, Charlottesville, VA 22908 USA. [Hoffman, Andrew R.] Vet Affairs Palo Alto Hlth Care Syst, Med Serv, Palo Alto, CA 94304 USA. [Hoffman, Andrew R.] Stanford Univ, Stanford, CA 94305 USA. [Merriam, George R.] Vet Affairs Puget Sound Hlth Care Syst, Med Res Serv, Tacoma, WA 98493 USA. [Merriam, George R.] Univ Washington, Sch Med, Seattle, WA 98195 USA. RP Merriam, GR (reprint author), Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, 9600 Vet Dr SW, Tacoma, WA 98493 USA. EM merriam@u.washington.edu OI Weltman, Arthur/0000-0002-0125-3769 NR 37 TC 10 Z9 10 U1 0 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2008 VL 93 IS 1 BP 125 EP 130 DI 10.1210/jc.2007-1430 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 251GC UT WOS:000252359400023 PM 17956953 ER PT J AU Basile, J AF Basile, Jan TI Shifting Paradigms in Defining and Treating Hypertension: Addressing Global Risk With Combination Therapy Introduction SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Editorial Material C1 [Basile, Jan] Ralph H Johnson VA Med Ctr, Primary Care Serv Line, Charleston, SC 29401 USA. [Basile, Jan] Med Univ S Carolina, Div Gen Internal Med Geriatr, Charleston, SC 29425 USA. RP Basile, J (reprint author), Ralph H Johnson VA Med Ctr, Primary Care Serv Line, 109 Bee St, Charleston, SC 29401 USA. EM jan.basile@med.va.gov NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD JAN PY 2008 VL 10 IS 1 BP 2 EP 3 DI 10.1111/j.1524-6175.2007.08026.x PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 378FO UT WOS:000261306800001 PM 18174777 ER PT J AU Palmas, W Pickering, T Teresi, J Schwartz, JE Eguchi, K Field, L Weinstock, RS Shea, S AF Palmas, Walter Pickering, Thomas Teresi, Jeanne Schwartz, Joseph E. Eguchi, Kazuo Field, Lesley Weinstock, Ruth S. Shea, Steven TI Nocturnal Blood Pressure Elevation Predicts Progression of Albuminuria in Elderly People With Type 2 Diabetes SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID AMBULATORY PULSE PRESSURE; CARDIOVASCULAR RISK; FOLLOW-UP; ESSENTIAL-HYPERTENSION; VASCULAR EVENTS; OLDER PATIENTS; MICROALBUMINURIA; EXCRETION; MORTALITY; POPULATION AB Ambulatory 24-hour pulse pressure predicts Progression of albuminuria in persons with diabetes mellitus. The authors assessed whether nocturnal blood pressure (BP) patterns added predictive information and examined the multivariate-adjusted association of nocturnal BP patterns with progression of urine albumin excretion during follow-up in a multiethnic cohort of older people (n=957) with type 2 diabetes mellitus who were free of macroalbuminuria. Albuminuria was assessed by spot urine measurement of albumin-to-creatinine ratio at baseline and annually for 3 years. Participants were categorized according to their sleep/wake systolic BP ratio as dippers (ratio <= 0.9; n=295), nondippers (flat nocturnal pattern, ratio >0.9 to 1; n=475), and nocturnal BP risers (ratio >1; n=187). The proportion exhibiting progression of albuminuria in dippers, nondippers, and risers was 17.6%, 22.9%, and 27.3%, respectively (P for linear trend =.01). A nocturnal BP rise was independently associated with progression of albuminuria (hazard ratio, 1.68; 95% confidence interval [CI], 1.09-2.60; P=.02), whereas office pulse pressure was not. When ambulatory 24-hour pulse pressure was added to the model, the nocturnal BP rise remained an independent Predictor of progression of albuminuria (hazard ratio, 1.58; 95% CI, 1.02-2.45; P=.04). Nocturnal nondipping (without BP increase) was not an independent predictor. In conclusion, nocturnal BP rise on ambulatory monitoring is superior to office BP to predict worsening of albuminuria in elderly individuals with type 2 diabetes and adds to the information provided by 24-hour pulse pressure. (J Clin Hypertens (Greenwich). 2008;10:12-20) (C) 2008 Le Jacq C1 [Palmas, Walter] Columbia Univ, Div Gen Med, Dept Med, New York, NY 10032 USA. [Pickering, Thomas; Eguchi, Kazuo] Columbia Univ, Behav Cardiovasc Hlth & Hypertens Program, New York, NY 10032 USA. [Shea, Steven] Columbia Univ, Joseph Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA. [Shea, Steven] Columbia Univ, Dept Biomed Informat, New York, NY 10032 USA. [Teresi, Jeanne] Columbia Univ, New York State Psychiat Inst, Stroud Ctr, New York, NY 10032 USA. [Teresi, Jeanne] Columbia Univ, Fac Med, New York, NY 10032 USA. [Teresi, Jeanne] Hebrew Home Aged, Div Res, Bronx, NY USA. [Schwartz, Joseph E.] SUNY Stony Brook, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA. [Weinstock, Ruth S.] SUNY Upstate Med Univ, Joslin Diabet Ctr, Syracuse, NY USA. [Weinstock, Ruth S.] SUNY Upstate Med Univ, Div Endocrinol Diabet & Metab, Syracuse, NY USA. [Weinstock, Ruth S.] VA Med Ctr, Dept Vet Affairs, Syracuse, NY USA. RP Palmas, W (reprint author), Columbia Univ, Div Gen Med, Dept Med, 622 W 168th St,PH 9-East, New York, NY 10032 USA. EM wp56@columbia.edu OI Eguchi, Kazuo/0000-0003-1841-6728 FU Centers for Medicare and Medicaid Services [95-C-90998] FX This research was supported by Cooperative Agreement 95-C-90998 from the Centers for Medicare and Medicaid Services. NR 45 TC 38 Z9 41 U1 0 U2 1 PU LE JACQ LTD PI DARIEN PA 3 PARKLANDS DRIVE, DARIEN, CT 06820 USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD JAN PY 2008 VL 10 IS 1 BP 12 EP 18 DI 10.1111/j.1524-6175.2007.07170.x PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 374OK UT WOS:000261053400002 PM 18174766 ER PT J AU Basile, J AF Basile, Jan TI The Importance of Prompt Blood Pressure Control SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Review ID FIXED-DOSE COMBINATION; PROSPECTIVELY-DESIGNED OVERVIEWS; RANDOMIZED CONTROLLED-TRIAL; HYPERTENSION TREATMENT; CARDIOVASCULAR EVENTS; ANTIHYPERTENSIVE THERAPY; SYSTOLIC HYPERTENSION; ACCOMPLISH TRIAL; LOWERING DRUGS; ELDERLY SCOPE AB Hypertension affects almost one-third of adults in the United States, but blood pressure is adequately controlled in only about 50% to 60% of persons with treated hypertension. Abundant clinical trial evidence has shown that antihypertensive therapy significantly reduces the risk of vascular events, and meta-analyses of observational and clinical trials have shown that greater reductions in blood pressure are associated with greater reductions in risk. Recent trials have also suggested that prompt control of blood pressure is beneficial in high-risk patients with hypertension. A post hoc analysis of a trial comparing an angiotensin If receptor blocker-based program with a calcium channel blocker-based treatment regimen found that the blood pressure response after 1 month (regardless of the drug used) predicted the risk of vascular events and survival. Therapy with >= 2 medications given separately or as a fixed combination is more likely than monotherapy to lower blood pressure to goal in part because drugs from different classes target different mechanisms that regulate blood pressure. Moreover, the likelihood of achieving blood pressure goals is greater if the time to achieve control is shortened, and prompt control of blood pressure is more likely with multiple-drug therapy than with monotherapy. (J Clin Hypertens (Greenwich). 2008;10(1 suppl 1):13-19) (C) 2008 Le Jacq C1 [Basile, Jan] Ralph H Johnson VA Med Ctr, Primary Care Serv Line, Charleston, SC 29403 USA. [Basile, Jan] Med Univ S Carolina, Div Gen Internal Med Geriatr, Charleston, SC 29425 USA. RP Basile, J (reprint author), Ralph H Johnson VA Med Ctr, Primary Care Serv Line, 109 Bee St, Charleston, SC 29403 USA. EM jan.basile@va.gov FU National Heart, Lung, and Blood Institute; Boehringer Ingelheim (ONTARGET); Novartis; Novartis Pharmaceuticals Corporation FX Dr Basile receives grant/research support from the National Heart, Lung, and Blood Institute, Boehringer Ingelheim (ONTARGET), and Novartis. He has served as a consultant for AstraZeneca, Merck, Novartis, and Daiichi Sankyo and has served on the Speakers' Bureau of Abbott, AstraZeneca, Boehringer Ingelheim, Forest, Merck, Novartis, Pfizer, and Daiichi Sankyo. The author acknowledges the assistance of Landmark Programs, Inc. in preparing this review article and styling the paper for journal submission. Editorial support was funded by Novartis Pharmaceuticals Corporation and the author received an honorarium for time and effort spent preparing this article. NR 42 TC 6 Z9 6 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD JAN PY 2008 VL 10 IS 1 BP 13 EP 19 DI 10.1111/j.1524-6175.2007.08027.x PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 378FO UT WOS:000261306800003 PM 18174779 ER PT J AU Jamerson, KA Basile, J AF Jamerson, Kenneth A. Basile, Jan TI Prompt, Aggressive BP Lowering in High-Risk Patients SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Review ID TYPE-2 DIABETES-MELLITUS; RANDOMIZED CONTROLLED-TRIAL; HIGH CARDIOVASCULAR RISK; BLOOD-PRESSURE CONTROL; ANGIOTENSIN RECEPTOR BLOCKER; END-POINT REDUCTION; HYPERTENSIVE PATIENTS; COMBINATION THERAPY; STAGE-2 HYPERTENSION; ACCOMPLISH TRIAL AB Various populations with hypertension have been singled out by current treatment guidelines as requiring more specific treatment. These include patients with stage 2 hypertension, black patients, and patients with coexistent diabetes mellitus and coronary heart disease. Hypertension in these groups is often associated with higher risk of cardiovascular morbidity and mortality. This article reviews current knowledge regarding hypertension in high-risk patient populations, with a particular focus on the importance of prompt, aggressive treatment to lower blood pressure and prevent cardiovascular disease progression. Such treatment includes the earl), use of multiple-drug therapy with agents that have complementary blood pressure-lowering mechanisms and provide protection from target, organ damage. While 2- or 3-drug antihypertensive therapy in these high-risk groups has typically included a diuretic, other combinations of agents may be indicated. Evidence suggests that therapy with a calcium channel blocker and an inhibitor of the renin-angiotensin system is one effective strategy for lowering blood pressure and improving outcomes in these populations. (J Clin Hypertens (Greenwich). 2008;10(1 suppl 1):40-48) (c) 2008 Le Jacq C1 [Jamerson, Kenneth A.] Univ Michigan Hlth Care Syst, Ann Arbor, MI USA. [Basile, Jan] Ralph H Johnson VA Med Ctr, Primary Care Serv Line, Charleston, SC USA. [Basile, Jan] Med Univ S Carolina, Div Gen Internal Med Geriatr, Charleston, SC USA. RP Jamerson, KA (reprint author), Univ Michigan Hlth Syst, Dept Internal Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA. EM jamerson@umich.edu FU National Heart, Lung, and Blood Institute; Boehringer Ingelheim (ONTARGET); Novartis; King Pharmaceuticals; National Institute of Diabetes and Digestive and Kidney Diseases; Speedel; Novartis Pharmaceuticals Corporation FX Dr Basile receives grant/research support from the National Heart, Lung, and Blood Institute, Boehringer Ingelheim (ONTARGET); and Novartis. He has served as a consultant for AstraZeneca, Merck, Novartis, and Daiichi Sankyo and has served on the Speakers' Bureau of Abbott, AstraZeneca, Boehringer Ingelheim, Forest, Merck, Novartis, Pfizer, and Daiichi Sankyo. Dr Jamerson has received grants/research support from King Pharmaceuticals; the National Heart, Lung, and Blood Institute; the National Institute of Diabetes and Digestive and Kidney Diseases; Novartis, and Speedel. He has served as a consultant for Merck, Novartis, Pfizer, Sanofi-Aventis, Sankyo, and Speedel and on the Speakers' Bureau for Abbott, GlaxoSmithKline, Merck, Nitromed, and Novartis. The authors acknowledge the assistance of Landmark Programs, Inc. in preparing this review article and styling the paper for journal submission. Editorial support was funded by Novartis Pharmaceuticals Corporation and the authors received an honorarium for time and effort spent preparing this article. NR 69 TC 11 Z9 11 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD JAN PY 2008 VL 10 IS 1 BP 40 EP 48 DI 10.1111/j.1524-6175.2007.08145.x PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 378FO UT WOS:000261306800007 PM 18174783 ER PT J AU Canellos, GP AF Canellos, George P. TI Clinical oncology: Onward and upward SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Editorial Material C1 Dana Farber Canc Inst, Boston, MA 02115 USA. RP Canellos, GP (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2008 VL 26 IS 1 BP 2 EP 2 DI 10.1200/JCO.2007.14.5144 PG 1 WC Oncology SC Oncology GA 276XK UT WOS:000254176800001 ER PT J AU Ramalingam, SS Dahlberg, SE Langer, CJ Gray, R Belani, CP Brahmer, JR Sandler, AB Schiller, JH Johnson, DH AF Ramalingam, Suresh S. Dahlberg, Suzanne E. Langer, Corey J. Gray, Robert Belani, Chandra P. Brahmer, Julie R. Sandler, Alan B. Schiller, Joan H. Johnson, David H. TI Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group trial 4599 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 43rd Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 01-05, 2007 CL Chicago, IL SP Amer Soc Clin Oncol ID QUALITY-OF-LIFE; RANDOMIZED-TRIAL; PHASE-III; CHEMOTHERAPY; VINORELBINE; CISPLATIN; SURVIVAL; AGE; EPIDEMIOLOGY; SURVEILLANCE AB Purpose Fit elderly patients with advanced non-small-cell lung cancer (NSCLC) benefit from platinumbased, two-drug chemotherapy. Bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) improves survival for advanced, nonsquamous NSCLC, as evidenced in Eastern Cooperative Oncology Group (ECOG) 4599. We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients. Patients and Methods ECOG 4599 randomly assigned patients with advanced nonsquamous NSCLC to PC or to PCB. We analyzed outcome in patients who were at least 70 years of age at the time of study entry. Patient characteristics, efficacy, and toxicity data were compared between PC and PCB for the elderly. Outcomes for elderly and younger patients (< 70 years) treated with PCB were also compared. Results Among elderly patients (n = 224; 26%), there was a trend towards higher response rate (29% v 17%; P = .067) and progression-free survival (5.9 v 4.9 months; P = .063) with PCB compared with PC, although overall survival ( PCB = 11.3 months; PC = 12.1 months; P = .4) was similar. Grade 3 to 5 toxicities occurred in 87% of elderly patients with PCB versus 61% with PC (P < .001), with seven treatment-related deaths in the PCB arm compared with two with PC. Elderly patients had higher incidence of grade 3 to 5 neutropenia, bleeding, and proteinuria with PCB compared with younger patients. Conclusion In elderly NSCLC patients, PCB was associated with a higher degree of toxicity, but no obvious improvement in survival compared with PC. Data from this unplanned, retrospective analysis justify prospective evaluation of the therapeutic index of PCB regimen in elderly patients. C1 Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RP Ramalingam, SS (reprint author), Emory Winship Canc Inst, 1365 Clifton Rd,Room C-5090, Atlanta, GA 30322 USA. EM suresh.ramalingam@emory.edu RI Johnson, David/A-7437-2009; OI Belani, Chandra/0000-0001-5049-5329 NR 28 TC 218 Z9 230 U1 1 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2008 VL 26 IS 1 BP 60 EP 65 DI 10.1200/JCO.2007.13.1144 PG 6 WC Oncology SC Oncology GA 276XK UT WOS:000254176800015 PM 18165641 ER PT J AU Choueiri, TK Plantade, A Elson, P Negrier, S Ravaud, A Oudard, S Zhou, M Rini, BI Bukowski, RM AF Choueiri, Toni K. Plantade, Anne Elson, Paul Negrier, Sylvie Ravaud, Alain Oudard, Stephane Zhou, Ming Rini, Brian I. Bukowski, Ronald M. TI Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 43rd Annual Meeting of the American-Society-of-Clinical-Oncology CY JUN 01-05, 2007 CL Chicago, IL SP Amer Soc Clin Oncol ID SURVIVAL; TUMORS; CLASSIFICATION; THERAPY AB Purpose Sunitinib and sorafenib are novel tyrosine kinase inhibitors (TKIs) that have shown significant clinical activity in metastatic clear cell renal cell carcinoma (RCC). The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated. Patients and Methods Clinical features at study entry and treatment outcomes were evaluated in patients with metastatic papillary RCC (PRCC) and chromophobe RCC (ChRCC) who received either sunitinib or sorafenib as their initial TKI treatment in five US and French institutions. Response rate and survival were documented. Fisher's exact test was used for categoric variables, and the Kaplan-Meier method was used to estimate survival. Results Fifty-three patients were included. The number of patients with papillary and chromophobe histologies was 41 (77%) and 12 (23%), respectively. Response rate, progression-free survival (PFS) time, and overall survival time for the entire cohort were 10%, 8.6 months, and 19.6 months, respectively. Three (25%) of 12 ChRCC patients achieved a response (two patients treated with sorafenib and one treated with sunitinib), and PFS was 10.6 months. Two (4.8%) of 41 PRCC patients achieved a response (both patients were treated with sunitinib). PFS for the whole cohort was 7.6 months. Sunitinib-treated PRCC patients had a PFS of 11.9 months compared with 5.1 months for sorafenib-treated patients (P < .001). Conclusion Patients with PRCC and ChRCC may have prolonged PFS from sunitinib and sorafenib, although clinical responses remain overall low in PRCC. Additional prospective trials with these agents in non-clear cell RCC will further clarify their use in the future. C1 [Choueiri, Toni K.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Cleveland Clin Taussig Canc Ctr, Cleveland, OH USA. Inst Gustave Roussy, Villejuif, France. Ctr Leon Berard, F-69373 Lyon, France. Univ Bordeaux, Ctr Hosp, Bordeaux, France. Hop Europeen Georges Pompidou, Paris, France. RP Choueiri, TK (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St,DANA 1230, Boston, MA 02115 USA. EM Toni_Choueiri@dfci.harvard.edu NR 22 TC 242 Z9 258 U1 1 U2 7 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2008 VL 26 IS 1 BP 127 EP 131 DI 10.1200/JCO.2007.13.3223 PG 5 WC Oncology SC Oncology GA 276XK UT WOS:000254176800024 PM 18165647 ER PT J AU McSwain, CS Benza, R Shapiro, S Hill, N Schilz, R Elliott, CG Zwicke, DL Oudiz, RJ Staszewski, JR Arneson, CR Wade, M Zaccardelli, D McLaughlin, V AF McSwain, C. Shane Benza, Ray Shapiro, Shelley Hill, Nicholas Schilz, Robert Elliott, C. Gregory Zwicke, Dianne L. Oudiz, Ronald J. Staszewski, James R. Arneson, Carl R. Wade, Michael Zaccardelli, David McLaughlin, Vallerie TI Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion SO JOURNAL OF CLINICAL PHARMACOLOGY LA English DT Article DE treprostinil; prostacyclin; pharmacokinetic; pulmonary arterial hypertension (PAH) ID PULMONARY-ARTERIAL-HYPERTENSION; CONTROLLED-TRIAL; PROSTACYCLIN; EPOPROSTENOL; PHARMACOKINETICS; EFFICACY; SAFETY; ANALOG AB This study assessed the relationship between dose and plasma concentration following administration of treprostinil sodium infusion therapy in pulmonary arterial hypertension patients. This was a multicenter, open-label, multiple-cohort, steady-state, pharmacokinetic study in subjects with pulmonary arterial hypertension receiving treprostinil by continuous intravenous or subcutaneous infusion at doses between 10 and 125 ng/kg/min. A blood sample was obtained from each patient at steady state and analyzed via a liquid chromatogrophy/tandem mass spectrometry method. Forty-nine subjects receiving treprostinil were enrolled. Treprostinil doses ranged from 12.1 to 125 ng/kg/min; treprostinil plasma concentrations ranged from 14.9 to 18 248 pg/mL. Linear regression analysis revealed a correlation between treprostinil dose and treprostinil plasma concentration with an R 2 value of 0.561. Using a power model to assess dose proportionality, the estimated nonproportionality parameter was 0.641 (95% confidence interval: 0.083-1.199), reflecting consistency with dose proportionality. Subset linear regression analysis, which excluded 2 subjects with anomalous treprostinil plasma concentrations, increased the R 2 value to 0.796. Using a power model to assess dose proportionality of this subset, the estimated nonproportionality parameter was 0.941 (95% confidence interval: 0.809-1.073). This study supports previous findings of linearity at lower doses up to 15 ng/kg/min and demonstrates linearity at treprostinil doses up to 125 ng/kg/min. C1 [McSwain, C. Shane; Staszewski, James R.; Arneson, Carl R.; Wade, Michael; Zaccardelli, David] United Therapeut Corp, Clin Affairs, Res Triangle Pk, NC 27709 USA. [Benza, Ray] Univ Alabama, Birmingham, AL USA. [Shapiro, Shelley] W Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Hill, Nicholas] Tufts Univ New England Med Ctr, Boston, MA USA. [Schilz, Robert] Univ Hosp Cleveland, Cleveland, OH 44106 USA. [Elliott, C. Gregory] LDS Hosp, Salt Lake City, UT USA. [Elliott, C. Gregory] Univ Utah, Salt Lake City, UT USA. [Zwicke, Dianne L.] St Lukes Hosp, Milwaukee, WI USA. [Oudiz, Ronald J.] Univ Calif Los Angeles, Harbor Med Ctr, LA Biomed Res Inst, Torrance, CA 90509 USA. [McLaughlin, Vallerie] Univ Michigan, Med Ctr, Ann Arbor, MI 48109 USA. RP McSwain, CS (reprint author), United Therapeut Corp, Clin Affairs, 1 Pk Dr,4th Floor, Res Triangle Pk, NC 27709 USA. EM csmcswain@unither.com NR 13 TC 27 Z9 28 U1 2 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0091-2700 J9 J CLIN PHARMACOL JI J. Clin. Pharmacol. PD JAN PY 2008 VL 48 IS 1 BP 19 EP 25 DI 10.1177/0091270007309708 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 248JS UT WOS:000252150200004 PM 18094217 ER PT J AU Nierenberg, AA AF Nierenberg, Andrew A. TI An Analysis of the Efficacy of Treatments for Bipolar Depression SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID COMORBIDITY SURVEY REPLICATION; TREATMENT ENHANCEMENT PROGRAM; WEEKLY SYMPTOMATIC STATUS; DOUBLE-BLIND; MOOD DISORDERS; MAINTENANCE TREATMENT; CONTROLLED-TRIALS; NATURAL-HISTORY; I DEPRESSION; PLACEBO AB Individuals with bipolar disorder are euthymic approximately half of the time, but recurring mood episodes are common, and time spent ill is predominated by depressive symptoms. Despite the prevalence of depression in bipolar disorder, evidence suggests that antidepressants are not likely to benefit most patients. Lithium, long considered a first-line treatment for bipolar disorder, is not the most effective agent for preventing bipolar depression. This article reviews multiple pharmacologic options that should be considered by clinicians treating bipolar disorder in both acute and maintenance phases. C1 [Nierenberg, Andrew A.] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. [Nierenberg, Andrew A.] Massachusetts Gen Hosp, Bipolar Res Program, Boston, MA 02114 USA. [Nierenberg, Andrew A.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Nierenberg, AA (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, 15 Parkman St,WACC 812, Boston, MA 02114 USA. EM anierenberg@partners.org FU Eli Lilly and Company FX This article is derived from the planning teleconference series "Easing the Burden of Bipolar Disorder: From Urgent Situations to Remission," which was held in February and March 2008 and supported by an educational grant from Eli Lilly and Company. NR 41 TC 5 Z9 5 U1 0 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2008 VL 69 SU 5 BP 4 EP 8 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 373PH UT WOS:000260983700001 PM 19265634 ER PT J AU Perlis, RH AF Perlis, Roy H. TI Clinical Decision Making in the Treatment of Mania SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID RELEASE CARBAMAZEPINE CAPSULES; PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIALS; BIPOLAR-I-DISORDER; DOUBLE-BLIND; WEIGHT-GAIN; PHARMACOLOGICAL-TREATMENT; ATYPICAL ANTIPSYCHOTICS; TREATMENT GUIDELINES; DIVALPROEX SODIUM AB Nine agents are now Food and Drug Administration-approved for acute treatment of bipolar mania, and several other agents are being studied for efficacy. With multiple treatment options available. clinicians face the challenge of selecting among agents. Although clinicians may consult the American Psychiatric Association's Practice Guideline for the Treatment of Patients With BiPolar Disorder, Second Edition, when selecting a treatment for bipolar mania, decisions about many aspects of treatment, such as choosing among agents, comparing combination therapy versus monotherapy. and individualizing treatments, remain complex. Considering data from recent clinical studies that have compared the efficacy, safety, and tolerability of medications for bipolar mania both between and within classes may facilitate such treatment decisions. C1 [Perlis, Roy H.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Perlis, Roy H.] Massachusetts Gen Hosp, Bipolar Clin & Res Program, Boston, MA 02114 USA. RP Perlis, RH (reprint author), 55 Fruit St,Psychiat S-50-4, Boston, MA 02114 USA. EM rperlis@partners.org NR 49 TC 1 Z9 1 U1 3 U2 4 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2008 VL 69 SU 5 BP 16 EP 21 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 373PH UT WOS:000260983700003 PM 19265636 ER PT J AU Thase, ME AF Thase, Michael E. TI Selecting Appropriate Treatments for Maintenance Therapy for Bipolar Disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID TREATMENT ENHANCEMENT PROGRAM; WEEKLY SYMPTOMATIC STATUS; I-DISORDER; LITHIUM MAINTENANCE; NATURAL-HISTORY; CLINICAL-TRIAL; DOUBLE-BLIND; STEP-BD; DIVALPROEX; PLACEBO AB Long-term management of bipolar disorder is a crucial component of treatment because the recurrence of the illness negatively affects patients' daily lives and increases their risks for poor health and suicide. An ideal maintenance treatment for bipolar disorder is relatively simple to take, prevents recurrence of both manic and depressive episodes, and is well-tolerated over the long term. Although many different types of medications are used for maintenance therapy of bipolar disorder, none can be considered ideal for a majority of people with bipolar disorder, and each specific form of therapy has different strengths and limitations. Clinicians need to be aware of unique efficacy and side effect factors when choosing long-term therapy and consider treatment components, goals, and individual patient characteristics, which are essential to the successful long-term management of bipolar disorder. Additionally, several forms of psychotherapy specifically tailored to the needs of people with bipolar disorder should be considered as an adjunct to medication. C1 [Thase, Michael E.] Univ Penn, Dept Psychiat, Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. RP Thase, ME (reprint author), Univ Penn, Dept Psychiat, Sch Med, 3535 Market St,Suite 670, Philadelphia, PA 19104 USA. EM thase@mail.med.upenn.edu NR 47 TC 5 Z9 5 U1 1 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2008 VL 69 SU 5 BP 28 EP 35 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 373PH UT WOS:000260983700005 PM 19265638 ER PT J AU Henderson, DC Doraiswamy, PM AF Henderson, David C. Doraiswamy, P. Murali TI Prolactin-related and metabolic adverse effects of atypical antipsychotic agents SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Satellite Broadcast on Endocrine Adverse Effects of Atypical Antipsychotic Agents CY JUN 05, 2007 CL ELECTR NETWORK ID EXTENDED-RELEASE TABLETS; PLACEBO-CONTROLLED TRIAL; WEIGHT CHANGE; DOUBLE-BLIND; INDUCED HYPERPROLACTINEMIA; 9-HYDROXY METABOLITE; PLATELET ACTIVATION; BREAST-CANCER; SCHIZOPHRENIA; ARIPIPRAZOLE AB While there are many effective antipsychotics available to clinicians for treating schizophrenia or bipolar mania, the onset of antipsychotic-associated prolactin-related and metabolic adverse effects can diminish the effectiveness of treatment. Increased levels of prolactin (hyperprolactinemia) associated with some antipsychotics raises the risk of sexual side effects. The increased appetite and/or sedation (reduced activity levels) induced by other antipsychotics can lead to weight gain, dyslipidemia, and high blood pressure and, if unchecked, ultimately to cardiovascular disease, diabetes, and metabolic syndrome. Clinicians should take steps to help their patients avoid unnecessary risks associated with antipsychotic use. These steps include monitoring risk factors for developing these illnesses by taking careful patient histories and baseline measurements of patients' weight and blood chemistry. Patients should be made aware of potential metabolic and prolactin-related side effects, and periodic checks should also be made to watch for changes in weight, body mass index, waist size, blood pressure, fasting glucose, or lipid levels that could be harmful and may increase risk for cardiovascular disease. C1 [Henderson, David C.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02138 USA. [Henderson, David C.] Harvard Univ, Massachusetts Gen Hosp, Schizophrenia Diabet & Weight Red Res Program, Boston, MA 02114 USA. [Doraiswamy, P. Murali] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Div Biol Psychiat, Durham, NC USA. RP Henderson, DC (reprint author), 25 Staniford St,2nd Floor, Boston, MA 02114 USA. EM dchenderson@partners.ory NR 56 TC 32 Z9 37 U1 4 U2 7 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2008 VL 69 SU 1 BP 32 EP 44 PG 13 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 270AI UT WOS:000253691700005 PM 18484806 ER PT J AU Perahia, DGS Quail, D Desaiah, D Corruble, E Fava, M AF Perahia, David G. S. Quail, Deborah Desaiah, Durisala Corruble, Emmanuelle Fava, Maurizio TI Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: A multicenter trial comparing 2 switching techniques SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID MAJOR DEPRESSIVE DISORDER; DOUBLE-BLIND; CLINICAL-TRIALS; OPEN-LABEL; FLUOXETINE; PAROXETINE; PLACEBO; SERTRALINE; EFFICACY; SAFETY AB Objective: To compare 2 methods of switching selective serotonin reuptake inhibitor (SSRI) non-responders or partial responders to duloxetine. Method: Adult outpatients with DSM-IV major depressive disorder, a Hamilton Rating Scale for Depression (HAM-D-17) total score of >= 15, and a Clinical Global Impressions-Severity of Illness score of >= 3 despite at least 6 weeks of SSRI treatment were randomly assigned to either abrupt discontinuation of SSRI immediately followed by initiation of duloxetine (direct switch [DS]; N = 183) or tapered discontinuation of SSRI over 2 weeks and simultaneous administration of duloxetine (start-taper switch [STS]; N = 185). Efficacy, safety, and tolerability outcomes associated with these 2 switch methods were compared following switch and after 10 weeks of duloxetine treatment. The study was conducted from August 2004 to March 2006. Results: There was a significant improvement in depressive symptom severity in both switch groups as measured by mean change in HAM-D,7 total score (p <= .001), but no difference between the switch groups (-10.23 DS vs. -10.49 STS). Criteria for noninferiority of the DS group to the STS group, which was the primary objective of the study, were met. Response rates (54.4% DS vs. 59.6% STS), remission rates (35.7% DS vs. 37.2% STS), and other secondary outcome measures were similar for both switch groups. Few patients discontinued the study due to adverse events (6.6% DS vs. 3.8% STS). Headache, dry mouth, and nausea were the most frequently reported adverse events in both switch groups. Conclusions: Switch to duloxetine was associated with significant improvements in both emotional and painful physical symptoms of depression and was well tolerated and safe, regardless of which of the switch methods was used. Trial Registration: clinicaltrials.gov Identifier: NCT00191932. C1 [Perahia, David G. S.; Quail, Deborah] Lilly Res Ctr Ltd, Windlesham GU20 6PH, Surrey, England. [Perahia, David G. S.] Gordon Hosp, London, England. [Desaiah, Durisala] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Corruble, Emmanuelle] Univ Paris Sud, Bicetre Hosp, Paris, France. [Fava, Maurizio] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Perahia, DGS (reprint author), Lilly Res Ctr Ltd, EMC Bldg,Erl Wood Manor,Sunninghill Rd, Windlesham GU20 6PH, Surrey, England. EM dperahia@lilly.com NR 41 TC 19 Z9 20 U1 3 U2 6 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2008 VL 69 IS 1 BP 95 EP 105 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 258ZH UT WOS:000252908400012 PM 18312043 ER PT J AU Strom, BL Faich, GA Reynolds, RF Eng, SM D'Agostino, RB Ruskin, JN Kane, JM AF Strom, Brian L. Faich, Gerald A. Reynolds, Robert F. Eng, Sybil M. D'Agostino, Ralph B. Ruskin, Jeremy N. Kane, John M. TI The ziprasidone observational study of cardiac outcomes (ZODIAC): Design and baseline subject characteristics SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID PLACEBO-CONTROLLED TRIAL; ACUTE BIPOLAR MANIA; DOUBLE-BLIND; SCHIZOAFFECTIVE DISORDER; CHRONIC-SCHIZOPHRENIA; ANTIPSYCHOTIC-DRUGS; ACUTE EXACERBATION; 160 MG/DAY; MULTICENTER; OLANZAPINE AB Background: Ziprasidone has been used to treat schizophrenia since 2000. It is unknown whether its modest QTc-prolonging effect increases cardiovascular event risk. Purpose: To describe the study design of the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Method: The study was conducted between February 2002 and February 2006. One-year follow-up for the primary endpoint of nonsuicide death ended in April 2007. ZODIAC is an open-label, randomized, postmarketing study enrolling patients with schizophrenia in naturalistic practice in 18 countries. The primary outcome measure was the rate of nonsuicide mortality in the year after initial recommendation for therapy. Subjects were randomly assigned to either ziprasidone or olanzapine, after which follow-up was conducted by investigators aware of the assigned exposure. A physician-administered questionnaire collected baseline information on patients' demographics, medical and psychiatric history, and concomitant medication use. Data were self-reported by patients or reported by enrolling physicians. Results: ZODIAC enrolled 18,240 patients with schizophrenia. Most (73.0%) were from the United States or Brazil. Patients' baseline mean age was 41.6 years, 55.1% were male, and 60.0% were white. At baseline, approximately 18% had hypertension, 14.8% had hyperlipidemia, 46.5% currently smoked, 28.9% had a body mass index >= 30 kg/m(2), and 7.7% had diabetes. Mean time from schizophrenia diagnosis to study enrollment was 10.4 years and mean Clinical Global Impressions scale score was 5.2 (range: 1-8). Nearly one third of patients had ever attempted suicide. Seventy-one percent were using antipsychotics at baseline. Almost 80% were using concomitant medications, with 29.5% using antidepressants, 25.4% using anxiolytics, and 19.0% using mood stabilizers. Less than 3% were using antihypertensives or statins. Conclusions: ZODIAC is a uniquely designed study with an initial randomization to ziprasidone or olanzapine and follow-up largely consistent with usual practice (i.e., many characteristics of a nonexperimental study). Baseline data suggest this study population has a substantial prevalence of cardiovascular risk factors. Concomitant medications were used frequently, although hyperlipidemia and hypertension may be undertreated. Trial Registration: clinicaltrials.gov Identifier: NCT00174447. C1 [Strom, Brian L.; Faich, Gerald A.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat,Ctr Educ & Res Thera, Philadelphia, PA 19104 USA. [Faich, Gerald A.] United BioSource Corp, Dept Epidemiol, Blue Bell, PA USA. [Reynolds, Robert F.; Eng, Sybil M.] Pfizer Inc, Dept Epidemiol Safety & Risk Management, New York, NY USA. [Reynolds, Robert F.] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA. [D'Agostino, Ralph B.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA. [Ruskin, Jeremy N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kane, John M.] Zucker Hillside Hosp, Dept Psychiat, Glen Oaks, NY USA. RP Strom, BL (reprint author), Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat,Ctr Educ & Res Thera, 824 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM bstrom@mail.med.upenn.edu NR 25 TC 22 Z9 23 U1 0 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2008 VL 69 IS 1 BP 114 EP 121 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 258ZH UT WOS:000252908400014 PM 18312045 ER PT J AU Osman, A Barrios, FX Gutierrez, PM Williams, JE Bailey, J AF Osman, Augustine Barrios, Francisco X. Gutierrez, Peter M. Williams, John E. Bailey, Jennifer TI Psychometric properties of the beek depression inventory-II in nonclinical adolescent samples SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE depression severity; factor analyses; nonclinical adolescents; psychometrics ID IDEATION PANSI INVENTORY; PSYCHIATRIC-INPATIENTS; LIVING INVENTORY; PRELIMINARY VALIDATION; NEGATIVE AFFECTIVITY; RISK-FACTORS; SELF-HARM; BECK; DISORDER; VALIDITY AB This study examined the factor structure and psychometric properties of the Beck Depression Inventory-II (BDI-II; A. T. Beck, Steer, & Brown, 1996) in samples of high-school adolescents (N=414; 210 boys and 204 girls, ages 14-18 years). Confirmatory factor analyses provided satisfactory fit estimates for the two- and three-factor oblique solutions reported frequently in the extant literature. The solution to a general factor with domain-specific somatic and cognitive-affective factors was examined as an alternative model to previously established models for the current high-school sample data. Results provided stronger support for the general factor model. Estimates of internal consistency for scores on this instrument were high (coefficient alpha =.92, average interitern correlation =.35). The mean BDI-II total score for the nonclinical samples (M= 12.50, SD = 10.50) was compared with the mean scores reported for various adolescent normative samples in the extant literature. The BDI-11 total score correlated moderately and significantly with scores on self-report measures of hopelessness (r=.63), anxiety (r=.53), and suicide-related behaviors (r=.57), providing support of adequate correlates for the BDI-11. Estimates of known-groups validity were evaluated using data from a small sample of 167 clinical adolescent inpatients. Specific study findings, limitations, and recommendations are discussed. (c) 2007 Wiley Periodicals, Inc. C1 [Osman, Augustine] Univ Texas San Antonio, Dept Psychol, San Antonio, TX 78249 USA. [Barrios, Francisco X.] Texas State Univ, San Marcos, TX USA. [Gutierrez, Peter M.] Denver VA Med Ctr, Denver, CO USA. [Williams, John E.; Bailey, Jennifer] Univ No Iowa, Cedar Falls, IA 50614 USA. RP Osman, A (reprint author), Univ Texas San Antonio, Dept Psychol, UTSA Circle 1, San Antonio, TX 78249 USA. EM augustine.osman@gmail.com NR 68 TC 65 Z9 68 U1 6 U2 21 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9762 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD JAN PY 2008 VL 64 IS 1 BP 83 EP 102 DI 10.1002/jclp.20433 PG 20 WC Psychology, Clinical SC Psychology GA 249AE UT WOS:000252197900007 PM 18161034 ER PT J AU Shah, ZK Uppot, RN Wargo, JA Hahn, PF Sahani, DV AF Shah, Zarine K. Uppot, Raul N. Wargo, Jennifer A. Hahn, Peter F. Sahani, Dushyant V. TI Small bowel obstruction: The value of coronal reformatted images from 16-multidetector computed tomography - A clinicoradiological perspective SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LA English DT Article DE small bowel obstruction; MDCT; coronal reformations ID MULTIDETECTOR-ROW CT; INTESTINAL-OBSTRUCTION; DIAGNOSIS; STRANGULATION AB Objectives: To assess performance of 16-multidetector computed tomography for small bowel. obstruction with surgery as standard of reference. To assess the impact of coronal reformats on reader confidence, and to address management perspective and surgeon's assessment of coronal images. Materials and Methods: 16-Multidetector computed tomography scans of 30 patients presenting with clinical features of small bowel obstruction were reviewed. Five-millimeter axial images and 2.5-mm coronal images were available for interpretation. All patients had subsequent surgery. Two blinded readers independently reviewed axial and then coronal and axial (combination) images for transition site; etiology, and complications. Reader confidence was scored on a 3-point scale. A single surgeon evaluated studies for adequacy of scans and usefulness of coronal images. Results: Results showed that the recorded accuracies were slightly higher for etiology, transition site, and complications using the combination data set; this reached statistical significance for etiology only (P = 0.08). There was no significant increase in scan evaluation time with addition of coronal images. Surgeon considered the coronal images more informative as compared with the axial images in 76.6% of cases. Conclusions: Coronal images generated at the scanner console are complementary to axials and improve reader confidence. Surgeons find coronal images more helpful than axial images for management. C1 [Shah, Zarine K.; Uppot, Raul N.; Hahn, Peter F.; Sahani, Dushyant V.] Massachusetts Gen Hosp, Dept Abdominal Imaging & Intervent, Boston, MA 02114 USA. [Shah, Zarine K.; Uppot, Raul N.; Hahn, Peter F.; Sahani, Dushyant V.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Wargo, Jennifer A.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Sahani, DV (reprint author), Massachusetts Gen Hosp, Dept Abdominal Imaging & Intervent, Boston, MA 02114 USA. EM dsahani@partners.org RI Shah, Zarine/E-4064-2011 OI Shah, Zarine/0000-0002-0354-9678 NR 25 TC 5 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0363-8715 J9 J COMPUT ASSIST TOMO JI J. Comput. Assist. Tomogr. PD JAN-FEB PY 2008 VL 32 IS 1 BP 23 EP 31 DI 10.1097/RCT.0b013e318063c66d PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 258KE UT WOS:000252866000005 PM 18303284 ER PT J AU Izikson, L AF Izikson, Leonid TI Laser photorejuvenation of Asian and ethnic skin SO JOURNAL OF COSMETIC AND LASER THERAPY LA English DT Review DE Ablative; Asian skin; chronological aging; ethnic skin; fractional; laser; non-ablative; photoaging; rejuvenation; resurfacing ID INTENSE PULSED-LIGHT; FRACTIONAL PHOTOTHERMOLYSIS; FACIAL LENTIGINES; YAG LASER; REJUVENATION; COMPRESSION; RESPONSES; FRECKLES; IV AB Laser therapy of Asian and ethnic skin has been relatively poorly studied in the literature. Owing to particular physiologic aspects of darker skin, the physical properties of currently available lasers, and the nature of laser-tissue interactions, the use of lasers to treat chronological and photodamage in such patients may be challenging and fraught with complications. Nevertheless, both ablative and non-ablative technologies have been used successfully to address various cosmetic concerns. This article is a review of skin physiology and laser-tissue interactions in Asian and ethnic skin, particular aesthetic concerns and medical pre- and postoperative considerations in such patients, and a summary of the past 20 years of experience with ablative and non-ablative technologies for effective and safe photorejuvenation. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. RP Izikson, L (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Dermatol, BHX-630,Bartlett Hall, Boston, MA 02114 USA. EM lizikson@partners.org NR 31 TC 1 Z9 1 U1 0 U2 0 PU INFORMA HEALTHCARE-SWEDEN PI STOCKHOLM PA PO BOX 3255, STOCKHOLM, SE-10365, SWEDEN SN 1476-4172 J9 J COSMET LASER THER JI J. Cosmet. Laser Ther. PY 2008 VL 10 IS 3 BP 161 EP 166 DI 10.1080/14764170802308427 PG 6 WC Dermatology; Surgery SC Dermatology; Surgery GA 387CX UT WOS:000261930400006 PM 18788034 ER PT J AU Izikson, L Avram, M Tannous, Z AF Izikson, Leonid Avram, Mathew Tannous, Zeina TI Treatment of port wine stains with pulsed dye laser in patients with systemic lupus erythematosus: Practical considerations and complications SO JOURNAL OF COSMETIC AND LASER THERAPY LA English DT Article DE Complication; hydroxychloroquine; lupus; port wine stain; pulsed dye laser; treatment ID COLLAGEN; THERAPY; VII AB There is a paucity of clinical information on the treatment of port wine stains (PWS) with pulse dye lasers (PDL) in patients with connective tissue diseases. Systemic lupus (SLE) is characterized by increased skin fragility and the potential for pigmentary alterations. Additionally, medications used to treat SLE may alter patient responses to laser therapy. We describe two complications, tense blisters and hypopigmentation, after PDL treatment of PWS in SLE, and discuss the current knowledge on the use of PDL in patients with lupus. C1 [Izikson, Leonid] Massachusetts Gen Hosp, MGH Laser & Cosmet Dermatol Ctr, Boston, MA 02114 USA. Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Izikson, L (reprint author), Massachusetts Gen Hosp, MGH Laser & Cosmet Dermatol Ctr, BHX 630,Bartlett Hall, Boston, MA 02114 USA. EM lizikson@partners.org NR 10 TC 2 Z9 2 U1 0 U2 0 PU INFORMA HEALTHCARE-SWEDEN PI STOCKHOLM PA PO BOX 3255, STOCKHOLM, SE-10365, SWEDEN SN 1476-4172 J9 J COSMET LASER THER JI J. Cosmet. Laser Ther. PY 2008 VL 10 IS 4 BP 223 EP 225 DI 10.1080/14764170802307965 PG 3 WC Dermatology; Surgery SC Dermatology; Surgery GA 387DA UT WOS:000261930700009 PM 18830867 ER PT J AU Flotte, TJ AF Flotte, Thomas J. TI Transverse sectioning of the scalp (Headington technique) in the 19th century SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Editorial Material AB A review of the history of microscopy shows a period of intense amateur as well as professional interest in light microscopy in the 19th century. In order to accommodate these activities, there developed a group of people who prepared high quality microscopic slides. These slides covered a range of specimens including diatoms, insects, plants, rocks as well as animal and human tissues. Two slides of human scalp that were prepared in the latter half of the 19th century recently became available. They were processed to show both vertically and transversely sectioned skin. The slide of transversely sectioned skin contained two levels, one in the subcutis and the other in the mid-dermis. These slides are very similar to the slides that are prepared today for the evaluation of alopecia. It is interesting that slide preparers of the 19th century were using methods similar to those that were pioneered by Dr Headington but not for the evaluation of hair diseases. Rather they came to a similar method of preparation to maximally display the normal morphology of the hair of the scalp. C1 Massachusetts Gen Hosp, Harvard Med Sch, Dept Dermatol, Boston, MA 02114 USA. [Flotte, Thomas J.] Massachusetts Gen Hosp, Harvard Med Sch, Dept Pathol, Boston, MA 02114 USA. RP Flotte, TJ (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Dept Dermatol, Boston, MA 02114 USA. EM tflotte@partners.org NR 6 TC 7 Z9 8 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2008 VL 35 IS 1 BP 82 EP 85 DI 10.1111/j.1600-0560.2007.00772.x PG 4 WC Dermatology; Pathology SC Dermatology; Pathology GA 239XQ UT WOS:000251552000015 PM 18096001 ER PT J AU Mukherjee, S Muzikansky, A Duncan, L AF Mukherjee, S. Muzikansky, A. Duncan, L. TI Melastatin expression and prognosis in melanoma: A follow-up study SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [Mukherjee, S.] Harvard Med Sch, Boston, MA USA. [Muzikansky, A.; Duncan, L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2008 VL 35 IS 1 BP 94 EP 94 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 239XQ UT WOS:000251552000031 ER PT J AU Baran, J Nazarian, R Duncan, L AF Baran, J. Nazarian, R. Duncan, L. TI Diagnosis of rocky mountain spotted fever diagnosed after three months SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [Baran, J.; Nazarian, R.; Duncan, L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2008 VL 35 IS 1 BP 101 EP 101 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 239XQ UT WOS:000251552000057 ER PT J AU Mandal, R Zembowicz, A AF Mandal, R. Zembowicz, A. TI Sebaceous carcinoma of the eyelid: The great masquerader SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [Mandal, R.; Zembowicz, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2008 VL 35 IS 1 BP 109 EP 109 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 239XQ UT WOS:000251552000088 ER PT J AU Sepehr, A Burnett, M AF Sepehr, A. Burnett, M. TI Bullous acrodermatitis enteropathica SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [Sepehr, A.; Burnett, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2008 VL 35 IS 1 BP 120 EP 120 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 239XQ UT WOS:000251552000132 ER PT J AU Johnson, M Duncan, L Sepehr, A Dadras, S Nielsen, G AF Johnson, M. Duncan, L. Sepehr, A. Dadras, S. Nielsen, G. TI D2-40 and LYVE-1 expression in angiosarcoma SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [Johnson, M.; Duncan, L.; Sepehr, A.; Nielsen, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Dadras, S.] Stanford Univ, Stanford, CA 94305 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2008 VL 35 IS 1 BP 125 EP 125 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 239XQ UT WOS:000251552000151 ER PT J AU Zembowicz, A Duncan, L AF Zembowicz, A. Duncan, L. TI A case of warfarin-induced skin necrosis SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [Zembowicz, A.; Duncan, L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0303-6987 EI 1600-0560 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2008 VL 35 IS 1 BP 134 EP 134 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 239XQ UT WOS:000251552000187 ER PT J AU Johnson, M Thiagalingam, S Colby, K Zembowicz, A AF Johnson, M. Thiagalingam, S. Colby, K. Zembowicz, A. TI Juvenile conjunctival nevus: Clinicopathological analysis of 33 cases SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [Johnson, M.; Zembowicz, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Thiagalingam, S.; Colby, K.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2008 VL 35 IS 1 BP 147 EP 148 PG 2 WC Dermatology; Pathology SC Dermatology; Pathology GA 239XQ UT WOS:000251552000241 ER PT J AU Kolman, O Duncan, L AF Kolman, O. Duncan, L. TI Pigmented lesion specimen processing and margin assessment practices SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [Kolman, O.; Duncan, L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2008 VL 35 IS 1 BP 147 EP 147 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 239XQ UT WOS:000251552000238 ER PT J AU Papagerakis, P Lin, HK Lee, KY Hu, Y Simmer, JP Bartlett, JD Hu, JCC AF Papagerakis, P. Lin, H. -K. Lee, K. Y. Hu, Y. Simmer, J. P. Bartlett, J. D. Hu, J. C. -C. TI Premature stop codon in MMP20 causing amelogenesis imperfecta SO JOURNAL OF DENTAL RESEARCH LA English DT Article DE enamelysin; MMP20; enamel; tooth; amelogenesis imperfecta ID ENAMEL PROTEINASES; TOOTH AGENESIS; MUTATION; EXPRESSION; MMP-20; MATRIX; AMELOBLASTIN; MATURATION; CLONING; DIFFERENTIATION AB Proteolytic enzymes are necessary for the mineralization of dental enamel during development, and mutations in the kallikrein 4 (KLK4) and enamelysin (MMP20) genes cause autosomal-recessive amelogenesis imperfecta (ARAI). So far, only one KLK4 and two MMP20 mutations have been reported. We have identified an ARAI-causing point mutation ( c. 102G > A, g. 102G > A, and p. W34X) in exon 1 of MMP20 in a proband with autosomal-recessive hypoplastic-hypomaturation amelogenesis imperfecta. The G to A transition changes the tryptophan ( W) codon (TGG) at amino acid position 34 into a translation termination (X) codon (TGA). No disease-causing sequence variations were detected in KLK4. The affected enamel is thin, with mild spacing in the anterior dentition. The enamel layer is hypomineralized, does not contrast with dentin on radiographs, and tends to chip away from the underlying dentin. An intrinsic yellowish pigmentation is evident, even during eruption. The phenotype supports current ideas concerning the function of enamelysin. C1 [Papagerakis, P.; Simmer, J. P.] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA. [Lin, H. -K.] Taipei Med Univ Hosp, Dept Prosthodont, Taipei 11049, Taiwan. [Lee, K. Y.] Taipei Med Univ Hosp, Dept Pediat Dent, Taipei 11049, Taiwan. [Hu, Y.; Hu, J. C. -C.] Univ Michigan, Sch Dent, Dept Orthodont & Pediat Dent, Ann Arbor, MI 48109 USA. [Bartlett, J. D.] Forsyth Inst, Dept Cytokine, Boston, MA 02115 USA. RP Hu, JCC (reprint author), Univ Michigan, Dent Res Lab, 1210 Eisenhower Pl, Ann Arbor, MI 48108 USA. EM janhu@umich.edu FU NIDCR NIH HHS [R56 DE016276, R01 DE016276-03, R01 DE016276, R01 DE015846-05, R01 DE015846, DE016276, DE15846] NR 35 TC 49 Z9 50 U1 0 U2 1 PU INT AMER ASSOC DENTAL RESEARCHI A D R/A A D R PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314-3406 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PD JAN PY 2008 VL 87 IS 1 BP 56 EP 59 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 243LL UT WOS:000251798200010 PM 18096894 ER PT J AU Gulliver, SB Kamholz, BW Helstrom, AW Morissette, SB Kahler, CW AF Gulliver, Suzy Bird Kamholz, Barbara W. Helstrom, Amy W. Morissette, Sandra B. Kahler, Christopher W. TI A Preliminary Evaluation of Adjuncts to Motivational Interviewing for Psychiatrically Complex Smokers SO JOURNAL OF DUAL DIAGNOSIS LA English DT Article DE Motivational interviewing; smoking; tobacco; spirometry AB Two hundred eight psychiatrically complex military veterans (97% male; n = 201) were recruited as part of a study investigating the differential efficacy of three brief (one-session) motivational interviewing (MI) interventions to yield changes in smoking behavior. Participants were randomly assigned to one of three MI interventions: MI alone, MI plus breathing instruction, or MI plus incentive spirometry (a tool for feedback about lung function and an inexpensive form of biofeedback. Results suggested that smoking behavior, measured by self-reported number of cigarettes per day and confirmed by expired carbon monoxide levels, decreased across groups over time. However, there were no differences among treatment conditions on cigarettes per day or measures of tobacco dependence. Implications for harm reduction in this challenging population are discussed. C1 [Gulliver, Suzy Bird] Ctr Excellence Res Returning War Vet, Waco, TX USA. [Kamholz, Barbara W.; Helstrom, Amy W.; Morissette, Sandra B.] VA Boston Healthcare Syst, Boston, MA USA. [Gulliver, Suzy Bird; Kamholz, Barbara W.; Helstrom, Amy W.; Morissette, Sandra B.] Boston Univ, Boston, MA 02215 USA. [Kahler, Christopher W.] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. RP Gulliver, SB (reprint author), CTXVHCS, VISN Ctr Excellence Res Returning War Vet 17, Waco Campus,Bldg 7,4800 Mem Dr, Waco, TX 76711 USA. EM suzy.gulliver2@va.gov NR 45 TC 2 Z9 2 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1550-4263 J9 J DUAL DIAGN JI J. Dual Diagn. PY 2008 VL 4 IS 4 BP 394 EP 413 DI 10.1080/15504260802086149 PG 20 WC Psychology, Clinical; Substance Abuse; Psychiatry SC Psychology; Substance Abuse; Psychiatry GA V14AU UT WOS:000207708100006 ER PT J AU Nelson, SW Brown, DFM Nadel, ES AF Nelson, Sara W. Brown, David F. M. Nadel, Eric S. TI Pediatric fever and leg pain SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID CHILDREN; HIP C1 [Brown, David F. M.; Nadel, Eric S.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Nelson, Sara W.; Brown, David F. M.; Nadel, Eric S.] Harvard Univ, Sch Med, Div Emergency Med, Boston, MA USA. [Nadel, Eric S.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. RP Brown, DFM (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 55 Fruit St,Founders 114, Boston, MA 02114 USA. NR 16 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD JAN PY 2008 VL 34 IS 1 BP 79 EP 81 DI 10.1016/j.jemermed.2007.10.016 PG 3 WC Emergency Medicine SC Emergency Medicine GA 256HV UT WOS:000252720100017 PM 18065184 ER PT J AU Lisi, S Botta, R Pinchera, A Collins, AB Marcocci, C Marino, M AF Lisi, S. Botta, R. Pinchera, A. Collins, A. Bernard Marcocci, C. Marino, M. TI Kidney abnormalities in low density lipoprotein receptor associated protein knockout mice SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION LA English DT Article ID THYROID-HORMONE RELEASE; SPECIALIZED CHAPERONE; ENDOCYTIC RECEPTORS; THYROGLOBULIN TG; MEGALIN GP330; RAP; TRANSCYTOSIS; CELLS; PATHWAY; MEMBERS AB Mice lacking the LDL receptor associated protein (RAP) have a severe defect of thyroglobulin secretion into the colloid, associated with moderately increased serum TSH levels and histological features of early goiter. RAP is expressed also in renal proximal tubule cells, where it functions as a molecular chaperone for the endocytic receptor megalin, which is responsible for reabsorption of low molecular weight proteins from the glomerular filtrate. Here we investigated whether the thyroid phenotype in RAP knockout (KO) mice is associated with kidney alterations. By immunohistochemistry, we found that in RAP KO mice megalin expression on the apical membrane of renal proximal tubule cells was markedly reduced, with intracellular retention of the receptor. The reduced expression of megalin was associated with its impaired function. Thus, urinary protein concentrations and urinary protein excretion in 24 h were higher in RAP KO than in wild-type mice. Coomassie staining of urine samples revealed an increased intensity of low molecular mass bands in the urine of RAP KO mice, indicating that they had low molecular weight proteinuria. Therefore, we concluded that disruption of the RAP gene determines not only thyroid abnormalities, but also a severe defect of megalin expression and function in the kidney. C1 [Lisi, S.; Botta, R.; Pinchera, A.; Marcocci, C.; Marino, M.] Univ Pisa, Dept Endocrinol, I-56124 Pisa, Italy. [Collins, A. Bernard] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA. RP Marino, M (reprint author), Univ Pisa, Dept Endocrinol, Via Paradisa 2, I-56124 Pisa, Italy. EM m.marino@endoc.med.unipi.it NR 16 TC 1 Z9 1 U1 0 U2 0 PU EDITRICE KURTIS S R L PI MILAN PA VIA LUIGI ZOJA 30, 20153 MILAN, ITALY SN 0391-4097 J9 J ENDOCRINOL INVEST JI J. Endocrinol. Invest. PD JAN PY 2008 VL 31 IS 1 BP 57 EP 61 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 270NF UT WOS:000253726800009 PM 18296906 ER PT J AU Nareika, A Im, YB Game, BA Slate, EH Sanders, JJ London, SD Lopes-Virella, MF Huang, Y AF Nareika, Alena Im, Yeong-Bin Game, Bryan A. Slate, Elizabeth H. Sanders, John J. London, Steven D. Lopes-Virella, Maria F. Huang, Yan TI High glucose enhances lipopolysaccharide-stimulated CD14 expression in U937 mononuclear cells by increasing nuclear factor kappa B and AP-1 activities SO JOURNAL OF ENDOCRINOLOGY LA English DT Article; Proceedings Paper CT 66th Annual Meeting of the American-Diabetes-Association CY JUN 09-13, 2006 CL Washington, DC SP Amer Diabet Assoc ID SOLUBLE CD14; DIABETES-MELLITUS; GENE-EXPRESSION; MESSENGER-RNA; MEMBRANE CD14; RECEPTOR; DISEASE; ACTIVATION; PROTEIN; LPS AB We have demonstrated recently that high glucose augments lipopolysaccharide (LPS)-stimulated matrix metalloproteinase (MMP) and cytokine expression by U937 mononuclear cells and human mono cyte-derived macrophages. Since CD14 is a receptor for LPS, one potential underlying mechanism is that high glucose enhances CD14 expression. In the present study, we determined the effect of high glucose on CD14 expression by U937 mononuclear cells. After being chronically exposed to normal or high glucose for 2 weeks or longer, cells were treated with LPS for 24 h. Real-time PCR showed that although high glucose by itself did not increase CD14 expression significantly, it augmented LPS-stimulated CD14 expression by 15-fold. Immunoassay showed a marked enhancement of both membrane-associated and soluble CD14 protein levels by high glucose. Further investigations using transcription factor activity assays and gel shift assays revealed that high glucose augmented LPS-stimulated CD14 expression by enhancing transcription factor nuclear factor kappa B (NF kappa B) and activator protein-1 (AP-1) activities. Finally, studies using anti-CD14 neutralizing antibody showed that CD14 expression is essential for the enhancement of LPS-stimulated MMP-1 expression by high glucose. Taken together, this study has demonstrated a robust augmentation by high glucose of LPS-stimulated CD 14 expression through AP-1 and NF kappa B transcriptional activity enhancement, elucidating a new mechanism by which hyperglycemia boosts LPS-elicited gene expression involved in inflammation and tissue destruction. C1 [Game, Bryan A.; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Nareika, Alena; Im, Yeong-Bin; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29401 USA. [Slate, Elizabeth H.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29401 USA. [Sanders, John J.; London, Steven D.] Med Univ S Carolina, Coll Dent Med, Charleston, SC 29401 USA. RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29401 USA. EM huangyan@musc.edu FU NCRR NIH HHS [P20 RR017696]; NIDCR NIH HHS [DE16353] NR 39 TC 28 Z9 30 U1 0 U2 3 PU SOC ENDOCRINOLOGY PI BRISTOL PA 22 APEX COURT, WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 0022-0795 J9 J ENDOCRINOL JI J. Endocrinol. PD JAN PY 2008 VL 196 IS 1 BP 45 EP 55 DI 10.1677/JOE-07-0145 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 257MK UT WOS:000252803000005 PM 18180316 ER PT J AU Sheesley, RJ Schauer, JJ Smith, TJ Garshick, E Laden, F Marr, LC Molina, LT AF Sheesley, Rebecca J. Schauer, James J. Smith, Thomas J. Garshick, Eric Laden, Francine Marr, Linsey C. Molina, Luisa T. TI Assessment of diesel particulate matter exposure in the workplace: freight terminals SO JOURNAL OF ENVIRONMENTAL MONITORING LA English DT Article ID AIR-POLLUTION SOURCES; FINE ORGANIC AEROSOL; MOTOR-VEHICLE EMISSIONS; US TRUCKING INDUSTRY; SOURCE APPORTIONMENT; LUNG-CANCER; RAILROAD WORKERS; RETROSPECTIVE COHORT; ELEMENTAL CARBON; EXHAUST EXPOSURE AB A large study has been undertaken to assess the exposure to diesel exhaust within diesel trucking terminals. A critical component of this assessment is an analysis of the variation in carbonaceous particulate matter (PM) across trucking terminal locations; consistency in the primary sources can be effectively tracked by analyzing trends in elemental carbon (EC) and organic molecular marker concentrations. Ambient samples were collected at yard, dock and repair shop work stations in 7 terminals in the USA and 1 in Mexico. Concentrations of EC ranged from 0.2 to 12 mu g m(-3) among the terminals, which corresponds to the range seen in the concentration of summed hopanes (0.5 to 20.5 ng m(-3)). However, when chemical mass balance (CMB) source apportionment results were presented as percent contribution to organic carbon (OC) concentrations, the contribution of mobile sources to OC are similar among the terminals in different cities. The average mobile source percent contribution to OC was 75.3 +/- 17.1% for truck repair shops, 65.4 +/- 20.4% for the docks and 38.4 +/- 9.5% for the terminal yard samples. A relatively consistent mobile source impact was present at all the terminals only when considering percentage of total OC concentrations, not in terms of absolute concentrations. C1 [Sheesley, Rebecca J.; Schauer, James J.] Univ Wisconsin, Environm Chem & Technol Program, Madison, WI 53706 USA. [Smith, Thomas J.; Laden, Francine] Harvard Univ, Sch Publ Hlth, Epidemiol & Risk Program, Dept Environm Hlth, Boston, MA 02115 USA. [Garshick, Eric] VA Boston Hlthcare Syst, Pulm & Crit Care Med Sect, Med Serv, Boston, MA USA. [Garshick, Eric; Laden, Francine] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab,Dept Med, Boston, MA 02115 USA. [Marr, Linsey C.; Molina, Luisa T.] MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA. [Marr, Linsey C.] Virginia Polytech & State Univ, Dept Civil & Environm Engn, Blacksburg, VA USA. [Molina, Luisa T.] Molina Ctr Energy & Environm, La Jolla, CA USA. RP Schauer, JJ (reprint author), Univ Wisconsin, Environm Chem & Technol Program, 660 N Pk St, Madison, WI 53706 USA. EM jjschauer@wisc.edu RI Marr, Linsey/C-9698-2010; Lucas, Elizabeth/E-2733-2010; Sheesley, Rebecca/I-6655-2015; OI Marr, Linsey/0000-0003-3628-6891; Sheesley, Rebecca/0000-0002-8187-0571 FU NCI NIH HHS [R01 CA090792, R01 CA090792-05, R01 CA90792] NR 47 TC 11 Z9 11 U1 3 U2 10 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1464-0325 J9 J ENVIRON MONITOR JI J. Environ. Monit. PY 2008 VL 10 IS 3 BP 305 EP 314 DI 10.1039/b715429a PG 10 WC Chemistry, Analytical; Environmental Sciences SC Chemistry; Environmental Sciences & Ecology GA 273CU UT WOS:000253908800004 PM 18392272 ER PT J AU Peden-Adams, MM Eudaly, JG Lee, AM Miller, J Keil, DE Gilkeson, GS AF Peden-Adams, Margie M. Eudaly, Jackie G. Lee, A. Michelle Miller, Julie Keil, Deborah E. Gilkeson, Gary S. TI Lifetime exposure to trichloroethylene (TCE) does not accelerate autoimmune disease in MRL+/+ mice SO JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART A-TOXIC/HAZARDOUS SUBSTANCES & ENVIRONMENTAL ENGINEERING LA English DT Article DE TCE; trichloroethylene; immune; developmental; autoimmune; MRL plus / ID SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTI-DNA ANTIBODIES; TRICHLOROACETIC-ACID; BACTERIAL-DNA; NZB/NZW MICE; AUTOANTIBODIES; WATER; IMMUNOTOXICITY; IMMUNIZATION; ASSOCIATION AB A genetically-prone murine lupus model was used to assess the developmental effects of trichloroethylene (TCE) exposure on disease symptom onset (e.g., autoantibody production and proteinuria), lymphocyte proliferation, splenic B-cell populations, and thymic and splenic T-cell populations. MRL +/+ mice were exposed to TCE (0, 1,400 or 14,000 ppb) via drinking water beginning on gestation day (GD) 0 and continuing until 12 months of age. With the exception of splenic CD4-/CD8-cells in female mice only, no alterations were observed in splenic T-cell populations, numbers of splenic B220+ cells, or in lymphocyte proliferation at 12 months of age. Furthermore, populations of all thymic T-cell subpopulations were decreased in male but not female mice following exposure to 14,000 ppb TCE. Autoantibody levels (anti-dsDNA and anti-GA) were assessed periodically from 4 to 12 months of age. Over this period, no increase in autoantibody levels as compared to control was detected, suggesting that TCE did not contribute to or accelerate the development of autoimmune disease markers following lifetime exposure. Not only does this study offer encouraging results, but it is the first study to approach the development of autoimmunity in a novel lifetime exposure paradigm, using an autoimmune prone model, at environmentally relevant exposure levels. C1 [Peden-Adams, Margie M.] Med Univ S Carolina, MBES, Dept Pediat, Charleston, SC 29412 USA. [Peden-Adams, Margie M.; Eudaly, Jackie G.; Miller, Julie; Gilkeson, Gary S.] Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29412 USA. [Peden-Adams, Margie M.; Eudaly, Jackie G.; Lee, A. Michelle; Gilkeson, Gary S.] Med Univ S Carolina, Marine Biomed & Environm Sci Ctr, Charleston, SC 29412 USA. [Keil, Deborah E.] Univ Nevada, Clin Sci Lab, Las Vegas, NV 89154 USA. [Gilkeson, Gary S.] Ralph Johnson VAMC, Med Res Serv, Charleston, SC USA. RP Peden-Adams, MM (reprint author), Med Univ S Carolina, MBES, Dept Pediat, 221 Ft Johnson Rd, Charleston, SC 29412 USA. EM pedenada@musc.edu FU Medical Research Service, Ralph H. Johnson VAMC; Department of Energy to the MUSC Environmental Biosciences Program [DE-FC09-02CH11109] FX The authors would like to thank Raymond Kivi and Jennifer Berger-Ritchie for assistance with manuscript preparation. This research was supported by the Medical Research Service, Ralph H. Johnson VAMC and by Contract DE-FC09-02CH11109 from the Department of Energy to the MUSC Environmental Biosciences Program. NR 32 TC 4 Z9 4 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1093-4529 J9 J ENVIRON SCI HEAL A JI J. Environ. Sci. Health Part A-Toxic/Hazard. Subst. Environ. Eng. PY 2008 VL 43 IS 12 BP 1402 EP 1409 DI 10.1080/10934520802232063 PG 8 WC Engineering, Environmental; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA 348QZ UT WOS:000259226300008 PM 18780217 ER EF